

INTERROGATORY CELL-BASED ASSAYS AND USES THEREOF

Related Applications

This application claims priority to Provisional Patent Application Serial No. 61/619326, filed on April 2, 2012; Provisional Patent Application Serial No. 61/668617, filed on July 6, 2012; Provisional Patent Application Serial No. 61/620305, filed on April 4, 2012; Provisional Patent Application Serial No. 61/665631, filed on June 28, 2012; Provisional Patent Application Serial No. 61/678596, filed on August 1, 2012; and Provisional Patent Application Serial No. 61/678590, filed on August 1, 2012, the entire contents of each of which are expressly incorporated herein by reference.

Background of the Invention

New drug development has been enhanced greatly since the discovery of DNA in 1964 by James Watson and Francis Crick, pioneers of what we refer today as molecular biology. The tools and products of molecular biology allow for rapid, detailed, and precise measurement of gene regulation at both the DNA and RNA level. The next three decades following the paradigm-shifting discovery would see the genesis of knock-out animal models, key enzyme-linked reactions, and novel understanding of disease mechanisms and pathophysiology from the aforementioned platforms. In spring 2000, when Craig Venter and Francis Collins announced the initial sequencing of the human genome, the scientific world entered a new wave of medicine.

The mapping of the genome immediately sparked hopes of, for example, being able to control disease even before it was initiated, of using gene therapy to reverse the degenerative brain processes that causes Alzheimer's or Parkinson's Disease, and of a construct that could be introduced to a tumor site and cause eradication of disease while restoring the normal tissue architecture and physiology. Others took controversial twists and proposed the notion of creating desired offspring with respect to eye or hair color, height, etc. Ten years later, however, we are still waiting with no particular path in sight for sustained success of gene therapy, or even elementary control of the genetic process.

Thus, one apparent reality is that genetics, at least independent of supporting constructs, does not drive the end-point of physiology. Indeed, many processes such as post-transcriptional modifications, mutations, single-nucleotide polymorphisms (SNP's), and translational modifications could alter the providence of a gene and/or its encoded complementary protein, and thereby contribute to the disease process.

Summary of the Invention

The information age and creation of the internet has allowed for an information overload, while also facilitating international collaboration and critique. Ironically, the aforementioned realities may also be the cause of the scientific community overlooking a few simple points, including that communication of signal cascades and cross-talk within and between cells and/or tissues allows for homeostasis and messaging for corrective mechanisms to occur when something goes awry.

A case on point relates to cardiovascular disease (CVD), which remains the leading cause of death in the United States and much of the developed world, accounting for 1 of every 2.8 deaths in the U.S. alone. In addition, CVD serves as an underlying pathology that contributes to associated complications such as Chronic Kidney Disease (~ 19 million US cases), chronic fatigue syndrome, and a key factor in metabolic syndrome. Significant advances in technology related to diagnostics, minimally invasive surgical techniques, drug eluting stents and effective clinical surveillance has contributed to an unparalleled period of growth in the field of interventional cardiology, and has allowed for more effective management of CVD. However, disease etiology related to CVD and associated co-morbidities such as diabetes and peripheral vascular disease are yet to be fully elucidated.

New approaches to explore the mechanisms and pathways involved in a biological process, such as the etiology of disease conditions (e.g., CVD), and to identify key regulatory pathways and/or target molecules (e.g., “drugable targets”) and/or markers for better disease diagnosis, management, and/or treatment, are still lacking.

The invention described herein is based, at least in part, on a novel, collaborative utilization of network biology, genomic, proteomic, metabolomic, transcriptomic, and bioinformatics tools and methodologies, which, when combined, may be used to study any biological system of interest, such as selected disease conditions including cancer,

diabetes, obesity, cardiovascular disease, and angiogenesis, using a systems biology approach. In a first step, cellular modeling systems are developed to probe various biological systems, such as a disease process, comprising disease-related cells subjected to various disease-relevant environment stimuli (e.g., hyperglycemia, hypoxia, immunostress, and lipid peroxidation, cell density, angiogenic agonists and antagonists). In some embodiments, the cellular modeling system involves cellular cross-talk mechanisms between various interacting cell types (such as aortic smooth muscle cells (HASMC), proximal tubule kidney cells (HK-2), aortic, endothelial cells (HAEC), and dermal fibroblasts (HDFa)). High throughput biological readouts from the cell model system are obtained by using a combination of techniques, including, for example, cutting edge mass spectrometry (LC/MSMS), flow cytometry, cell-based assays, and functional assays. The high throughput biological readouts are then subjected to a bioinformatic analysis to study congruent data trends by *in vitro*, *in vivo*, and *in silico* modeling. The resulting matrices allow for cross-related data mining where linear and non-linear regression analysis were developed to reach conclusive pressure points (or “hubs”). These “hubs,” as presented herein, are candidates for drug discovery. In particular, these hubs represent potential drug targets and/or disease markers.

The molecular signatures of the differentials allow for insight into the mechanisms that dictate the alterations in the tissue microenvironment that lead to disease onset and progression. Taken together, the combination of the aforementioned technology platforms with strategic cellular modeling allows for robust intelligence that can be employed to further establish disease understanding while creating biomarker libraries and drug candidates that may clinically augment standard of care.

Moreover, this approach is not only useful for disease diagnosis or intervention, but also has general applicability to virtually all pathological or non-pathological conditions in biological systems, such as biological systems where two or more cell systems interact. For example, this approach is useful for obtaining insight into the mechanisms associated with or causal for drug toxicity. The invention therefore provides a framework for an interrogative biological assessment that can be generally applied in a broad spectrum of settings.

A significant feature of the platform of the invention is that the AI-based system is based on the data sets obtained from the cell model system, without resorting to or taking into consideration any existing knowledge in the art, such as known biological

relationships (i.e., no data points are artificial), concerning the biological process. Accordingly, the resulting statistical models generated from the platform are unbiased. Another significant feature of the platform of the invention and its components, e.g., the cell model systems and data sets obtained therefrom, is that it allows for continual building on the cell models over time (e.g., by the introduction of new cells and/or conditions), such that an initial, “first generation” consensus causal relationship network generated from a cell model for a biological system or process can evolve along with the evolution of the cell model itself to a multiple generation causal relationship network (and delta or delta-delta networks obtained therefrom). In this way, both the cell models, the data sets from the cell models, and the causal relationship networks generated from the cell models by using the Platform Technology methods can constantly evolve and build upon previous knowledge obtained from the Platform Technology.

The invention provides methods for identifying a modulator of a biological system, the methods comprising:

establishing a model for the biological system, using cells associated with the biological system, to represents a characteristic aspect of the biological system;

obtaining a first data set from the model, wherein the first data set represents global proteomic changes in the cells associated with the biological system;

obtaining a second data set from the model, wherein the second data set represents one or more functional activities or cellular responses of the cells associated with the biological system, wherein said one or more functional activities or cellular responses of the cells comprises global enzymatic activity and/or an effect of the global enzyme activity on the enzyme metabolites or substrates in the cells associated with the biological system;

generating a consensus causal relationship network among the global proteomic changes and the one or more functional activities or cellular responses based solely on the first and second data sets using a programmed computing device, wherein the generation of the consensus causal relationship network is not based on any known biological relationships other than the first and second data sets; and

identifying, from the consensus causal relationship network, a causal relationship unique in the biological system, wherein at least one enzyme associated with the unique causal relationship is identified as a modulator of the biological system.

In certain embodiments, the first data set is a single proteomic data set. In certain embodiments, the second data set represents a single functional activity or cellular response of the cells associated with the biological system. In certain embodiments, the first data set further represents lipidomic data characterizing the cells associated with the biological system. In certain embodiments, the consensus causal relationship network is generated among the global proteomic changes, lipidomic data, and the one or more functional activities or cellular responses of the cells, wherein said one or more functional activities or cellular responses of the cells comprises global enzymatic activity.

In certain embodiments, the first data set further represents one or more of lipidomic, metabolomic, transcriptomic, genomic and SNP data characterizing the cells associated with the biological system. In certain embodiments, the first data set further represents two or more of lipidomic, metabolomic, transcriptomic, genomic and SNP data characterizing the cells associated with the biological system. In certain embodiments, the consensus causal relationship network is generated among the global proteomic changes, the one or more of lipidomic, metabolomic, transcriptomic, genomic, and SNP data, and the one or more functional activities or cellular responses of the cells, wherein said one or more functional activities or cellular responses of the cells comprises global enzymatic activity and/or the effect of the global enzymatic activity on at least one enzyme metabolite or substrate.

In certain embodiments, the global enzyme activity comprises global kinase activity. In certain embodiments, the effect of the global enzyme activity on the enzyme metabolites or substrates comprises the phospho proteome of the cells.

In certain embodiments, the second data set representing one or more functional activities or cellular responses of the cell further comprises one or more of bioenergetics, cell proliferation, apoptosis, organellar function, cell migration, tube formation, chemotaxis, extracellular matrix degradation, sprouting, and a genotype-phenotype associate actualized by functional models selected from ATP, ROS, OXPHOS, and

Seahorse assays. In certain embodiments, the consensus causal relationship network is generated among the global proteomic changes, the one or more of lipidomic, metabolomic, transcriptomic, genomic, and SNP data, and the one or more functional activities or cellular responses of the cells, wherein said one or more functional activities or cellular responses of the cells comprises global enzymatic activity and/or the effect of the global enzymatic activity on at least one enzyme metabolite or substrate and further comprises one or more of bioenergetics, cell proliferation, apoptosis, organellar function, cell migration, tube formation, chemotaxis, extracellular matrix degradation, sprouting, and a genotype-phenotype associate actualized by functional models selected from ATP, ROS, OXPHOS, and Seahorse assays.

In certain embodiments of the invention, the model of the biological system comprises an *in vitro* culture of cells associated with the biological system. In certain embodiments of the invention, the model of the biological system optionally further comprising a matching *in vitro* culture of control cells.

In certain embodiments of the invention, the model of the biological system the *in vitro* culture of the cells is subject to an environmental perturbation, and the *in vitro* culture of the matching control cells is identical cells not subject to the environmental perturbation. In certain embodiments, the model of the biological system the environmental perturbation comprises one or more of contact with a bioactive agent, a change in culture condition, introduction of a genetic modification / mutation, and introduction of a vehicle that causes a genetic modification / mutation. In certain embodiments, the model of the biological system the environmental perturbation comprises contacting the cells with an enzymatic activity inhibitor. In certain embodiments, in the model of the biological system the enzymatic activity inhibitor is a kinase inhibitor. In certain embodiments, the environmental perturbation comprises contacting the cells with CoQ10. In certain embodiments, the environmental perturbation comprises further contacting the cells with CoQ10.

In certain embodiments of the invention, the generating step is carried out by an artificial intelligence (AI) -based informatics platform. In certain embodiments, the AI-based informatics platform receives all data input from the first and second data sets without applying a statistical cut-off point. In certain embodiments of the invention, the consensus causal relationship network established in the generating step is further

refined to a simulation causal relationship network, before the identifying step, by *in silico* simulation based on input data, to provide a confidence level of prediction for one or more causal relationships within the consensus causal relationship network.

In certain embodiments of the invention, the unique causal relationship is identified as part of a differential causal relationship network that is uniquely present in cells associated with the biological system, and absent in the matching control cells. In certain embodiments, the unique causal relationship is identified as part of a differential causal relationship network that is uniquely present in cells associated with the biological system, and absent in the matching control cells.

In certain embodiments of the invention, the unique causal relationship identified is a relationship between at least one pair selected from the group consisting of expression of a gene and level of a lipid; expression of a gene and level of a transcript; expression of a gene and level of a metabolite; expression of a first gene and expression of a second gene; expression of a gene and presence of a SNP; expression of a gene and a functional activity; level of a lipid and level of a transcript; level of a lipid and level of a metabolite; level of a first lipid and level of a second lipid; level of a lipid and presence of a SNP; level of a lipid and a functional activity; level of a first transcript and level of a second transcript; level of a transcript and level of a metabolite; level of a transcript and presence of a SNP; level of a first transcript and level of a functional activity; level of a first metabolite and level of a second metabolite; level of a metabolite and presence of a SNP; level of a metabolite and a functional activity; presence of a first SNP and presence of a second SNP; and presence of a SNP and a functional activity. In certain embodiments, the unique causal relationship identified is a relationship between at least a level of a lipid, expression of a gene, and one or more functional activities wherein the functional activity is a kinase activity.

The invention provides methods for identifying a modulator of a disease process, the method comprising:

establishing a model for the disease process, using disease related cells, to represents a characteristic aspect of the disease process;

obtaining a first data set from the model, wherein the first data set represents global proteomic changes in the disease related cells;

obtaining a second data set from the model, wherein the second data set represents one or more functional activities or cellular responses of the cells associated with the biological system, wherein said one or more functional activities or cellular responses of the cells comprises global enzyme activity and/or an effect of the global enzyme activity on the enzyme metabolites or substrates in the disease related cells;

generating a consensus causal relationship network among the global proteomic changes and the one or more functional activities or cellular responses of the cells based solely on the first and second data sets using a programmed computing device, wherein the generation of the consensus causal relationship network is not based on any known biological relationships other than the first and second data sets; and

identifying, from the consensus causal relationship network, a causal relationship unique in the disease process, wherein at least one enzyme associated with the unique causal relationship is identified as a modulator of the disease process.

In certain embodiments, the first data set is a single proteomic data set. In certain embodiments, the second data set represents a single functional activity or cellular response of the cells associated with the biological system. In certain embodiments, the first data set further represents lipidomic data characterizing the cells associated with the biological system. In certain embodiments, the consensus causal relationship network is generated among the global proteomic changes, lipidomic data, and the one or more functional activities or cellular responses of the cells, wherein said one or more functional activities or cellular responses of the cells comprises global enzymatic activity. In certain embodiments, the first data set further represents one or more of lipidomic, metabolomic, transcriptomic, genomic and SNP data characterizing the cells associated with the biological system. In certain embodiments, the first data set further represents two or more of lipidomic, metabolomic, transcriptomic, genomic and SNP data characterizing the cells associated with the biological system. In certain embodiments, the consensus causal relationship network is generated among the global proteomic changes, the one or more of lipidomic, metabolomic, transcriptomic, genomic and SNP data, and the one or more functional activities or cellular responses of the cells,

wherein said one or more functional activities or cellular responses of the cells comprises global enzymatic activity and/or the effect of the global enzymatic activity on at least one enzyme metabolite or substrate.

In certain embodiments of the invention, the global enzyme activity comprises global kinase activity, and wherein the effect of the global enzyme activity on the enzyme metabolites or substrates comprises the phospho proteome of the cells. In certain embodiments, the second data set representing one or more functional activities or cellular responses of the cell further comprises one or more of bioenergetics, cell proliferation, apoptosis, organellar function, cell migration, tube formation, chemotaxis, extracellular matrix degradation, sprouting, and a genotype-phenotype associate actualized by functional models selected from ATP, ROS, OXPHOS, and Seahorse assays. In certain embodiments, the consensus causal relationship network is generated among the global proteomic changes, the one or more of lipidomic, metabolomic, transcriptomic, genomic and SNP data, and the one or more functional activities or cellular responses of the cells, wherein said one or more functional activities or cellular responses of the cells comprises one or more of bioenergetics, cell proliferation, apoptosis, organellar function, cell migration, tube formation, chemotaxis, extracellular matrix degradation, sprouting, and a genotype-phenotype associate actualized by functional models selected from ATP, ROS, OXPHOS, and Seahorse assays.

In certain embodiments of the invention, the disease process is cancer, diabetes, obesity, cardiovascular disease, age related macular degeneration, diabetic retinopathy, inflammatory disease. In certain embodiments, the disease process comprises angiogenesis. In certain embodiments, the disease process comprises hepatocellular carcinoma, lung cancer, breast cancer, prostate cancer, melanoma, carcinoma, sarcoma, lymphoma, leukemia, squamous cell carcinoma, colorectal cancer, pancreatic cancer, thyroid cancer, endometrial cancer, bladder cancer, kidney cancer, a solid tumor, leukemia, non-Hodgkin lymphoma, or a drug-resistant cancer.

In certain embodiments of the invention, the disease model comprises an *in vitro* culture of disease cells, optionally further comprising a matching *in vitro* culture of control or normal cells. In certain embodiments, the *in vitro* culture of the disease cells is subject to an environmental perturbation, and the *in vitro* culture of the matching control cells is identical disease cells not subject to the environmental perturbation. In

certain embodiments, the environmental perturbation comprises one or more of contact with a bioactive agent, a change in culture condition, introduction of a genetic modification / mutation, and introduction of a vehicle that causes a genetic modification / mutation. In certain embodiments, the environmental perturbation comprises contacting the cells with an enzymatic activity inhibitor. In certain embodiments, the enzymatic activity inhibitor is a kinase inhibitor. In certain embodiments, the environmental perturbation further comprises contacting the cells with CoQ10. In certain embodiments, the environmental perturbation comprises contacting the cells with CoQ10.

In certain embodiments, the characteristic aspect of the disease process comprises a hypoxia condition, a hyperglycemic condition, a lactic acid rich culture condition, or combinations thereof. In certain embodiments, the generating step is carried out by an artificial intelligence (AI) -based informatics platform. In certain embodiments, the AI-based informatics platform receives all data input from the first and second data sets without applying a statistical cut-off point.

In certain embodiments, the consensus causal relationship network established in the generating step is further refined to a simulation causal relationship network, before the identifying step, by *in silico* simulation based on input data, to provide a confidence level of prediction for one or more causal relationships within the consensus causal relationship network. In certain embodiments, the unique causal relationship is identified as part of a differential causal relationship network that is uniquely present in model of disease cells, and absent in the matching control cells. In certain embodiments, the unique causal relationship is identified as part of a differential causal relationship network that is uniquely present in cells subject to environmental perturbation, and absent in the matching control cells.

The invention provides methods for identifying modulators of a biological system, the methods comprising:

establishing a model for the biological system, using cells associated with the biological system, to represent a characteristic aspect of the biological system ;

obtaining a first data set from the model, wherein the first data set represents global proteomic changes in the cells and one or more of lipidomic, metabolomic, transcriptomic, genomic, and SNP data characterizing the cells associated with the biological system;

obtaining a second data set from the model, wherein the second data set represents one or more functional activities or cellular responses of the cells associated with the biological system, wherein said one or more functional activities or cellular responses of the cells comprises global kinase activity and an effect of the global kinase activity on the kinase metabolites or substrates in the cells associated with the biological system;

generating a consensus causal relationship network among the global proteomic changes, the one or more of lipidomic, metabolomic, transcriptomic, genomic, and SNP data, and the one or more functional activities or cellular responses based solely on the first and second data sets using a programmed computing device, wherein the generation of the consensus causal relationship network is not based on any known biological relationships other than the first and second data sets; and

identifying, from the consensus causal relationship network, a causal relationship unique in the biological system, wherein at least one kinase associated with the unique causal relationship is identified as a modulator of the biological system.

The invention provides methods for treating, alleviating a symptom of, inhibiting progression of, preventing, diagnosing, or prognosing a disease in a mammalian subject, the methods comprising:

administering to the mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a biologically active substance that affects the modulator identified by any of the methods provided herein, thereby treating, alleviating a symptom of, inhibiting progression of, preventing, diagnosing, or prognosing the disease.

The invention provides methods of diagnosing or prognosing a disease in a mammalian subject, the method comprising:

determining an expression or activity level, in a biological sample obtained from the subject, of one or more modulators identified by any of the methods provided herein; and

comparing the level in the subject with the level of expression or activity of the one or more modulators in a control sample,

wherein a difference between the level in the subject and the level of expression or activity of the one or more modulators in the control sample is an indication that the subject is afflicted with a disease, or predisposed to developing a disease, or responding favorably to a therapy for a disease, thereby diagnosing or prognosing the disease in the mammalian subject.

The invention provides methods of identifying a therapeutic compound for treating, alleviating a symptom of, inhibiting progression of, or preventing a disease in a mammalian subject, the methods comprising:

contacting a biological sample from a mammalian subject with a test compound;

determining the level of expression, in the biological sample, of one or more modulators identified by any of the methods provided herein;

comparing the level of expression of the one or more modulators in the biological sample with a control sample not contacted by the test compound; and

selecting the test compound that modulates the level of expression of the one or more modulators in the biological sample,

thereby identifying a therapeutic compound for treating, alleviating a symptom of, inhibiting progression of, or preventing a disease in a mammalian subject.

The invention provides methods for treating, alleviating a symptom of, inhibiting progression of, or preventing a disease in a mammalian subject, the methods comprising:

administering to the mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising the therapeutic compound identified using

any of the methods provided herein, thereby treating, alleviating a symptom of, inhibiting progression of, or preventing the disease.

The invention provides methods for treating, alleviating a symptom of, inhibiting progression of, or preventing a disease in a mammalian subject, the methods comprising:

administering to the mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a biologically active substance that affects expression or activity of any one or more of TCOF1, TOP2A, CAMK2A, CDK1, CLTCL1, EIF4G1, ENO1, FBL, GSK3B, HDLBP, HIST1H2BA, HMGB2, HNRNPK, HNRPDL, HSPA9, MAP2K2, LDHA, MAP4, MAPK1, MARCKS, NME1, NME2, PGK1, PGK2, RAB7A, RPL17, RPL28, RPS5, RPS6, SLTM, TMED4, TNRCBA, TUBB, and UBE21,

thereby treating, alleviating a symptom of, inhibiting progression of, or preventing the disease. In certain embodiments, the disease is hepatocellular carcinoma.

The invention provides methods of diagnosing or prognosing diseases in a mammalian subject, the methods comprising:

determining an expression or activity level, in a biological sample obtained from the subject, of any one or more proteins of TCOF1, TOP2A, CAMK2A, CDK1, CLTCL1, EIF4G1, ENO1, FBL, GSK3B, HDLBP, HIST1H2BA, HMGB2, HNRNPK, HNRPDL, HSPA9, MAP2K2, LDHA, MAP4, MAPK1, MARCKS, NME1, NME2, PGK1, PGK2, RAB7A, RPL17, RPL28, RPS5, RPS6, SLTM, TMED4, TNRCBA, TUBB, and UBE21; and

comparing the level in the subject with the level of expression or activity of the one or more proteins in a control sample,

wherein a difference between the level in the subject and the level of expression or activity of the one or more proteins in the control sample is an indication that the subject is afflicted with a disease, or predisposed to developing a disease, or responding favorably to a therapy for a disease, thereby diagnosing or prognosing the disease in the mammalian subject. In certain embodiments, the disease is hepatocellular carcinoma.

The invention provides methods of identifying therapeutic compounds for treating, alleviating a symptom of, inhibiting progression of, or preventing a diseases in a mammalian subject, the methods comprising:

contacting a biological sample from a mammalian subject with a test compound;

determining the level of expression, in the biological sample, of any one or more proteins of TCOF1, TOP2A, CAMK2A, CDK1, CLTCL1, EIF4G1, ENO1, FBL, GSK3B, HDLBP, HIST1H2BA, HMGB2, HNRNPK, HNRPDL, HSPA9, MAP2K2, LDHA, MAP4, MAPK1, MARCKS, NME1, NME2, PGK1, PGK2, RAB7A, RPL17, RPL28, RPS5, RPS6, SLTM, TMED4, TNRCBA, TUBB, and UBE21;

comparing the level of expression of the one or more proteins in the biological sample with a control sample not contacted by the test compound; and

selecting the test compound that modulates the level of expression of the one or more proteins in the biological sample,

thereby identifying a therapeutic compound for treating, alleviating a symptom of, inhibiting progression of, or preventing a disease in a mammalian subject. In certain embodiments, the disease is hepatocellular carcinoma.

The invention provides methods for treating, alleviating a symptom of, inhibiting progression of, or preventing a diseases in a mammalian subject, the methods comprising:

administering to the mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising the therapeutic compound identified by any of the methods provided herein, thereby treating, alleviating a symptom of, inhibiting progression of, or preventing the disease.

The invention provides methods for identifying a modulator of angiogenesis, said methods comprising:

(1) establishing a model for angiogenesis, using cells associated with angiogenesis, to represents a characteristic aspect of angiogenesis;

(2) obtaining a first data set from the model for angiogenesis, wherein the

first data set represents one or more of genomic data, lipidomic data, proteomic data, metabolomic data, transcriptomic data, and single nucleotide polymorphism (SNP) data characterizing the cells associated with angiogenesis;

(3) obtaining a second data set from the model for angiogenesis, wherein the second data set represents one or more functional activities or a cellular responses of the cells associated with angiogenesis;

(4) generating a consensus causal relationship network among the one or more of genomic data, lipidomic data, proteomic data, metabolic data, transcriptomic data, and single nucleotide polymorphism (SNP) data characterizing the cells associated with angiogenesis, and the one or more functional activities or cellular responses of the cells associated with angiogenesis based solely on the first data set and the second data set using a programmed computing device, wherein the generation of the consensus causal relationship network is not based on any known biological relationships other than the first data set and the second data set;

(5) identifying, from the consensus causal relationship network, a causal relationship unique in angiogenesis, wherein a gene, lipid, protein, metabolite, transcript, or SNP associated with the unique causal relationship is identified as a modulator of angiogenesis.

The invention provides methods for identifying a modulator of angiogenesis, said methods comprising:

(1) establishing a model for angiogenesis, using cells associated with angiogenesis, to represents a characteristic aspect of angiogenesis;

(2) obtaining a first data set from the model for angiogenesis, wherein the first data set represents lipidomic data;

(3) obtaining a second data set from the model for angiogenesis, wherein the second data set represents one or more functional activities or a cellular responses of the cells associated with angiogenesis;

(4) generating a consensus causal relationship network among the lipidomics data and the functional activity or cellular response based solely on the first data set and

the second data set using a programmed computing device, wherein the generation of the consensus causal relationship network is not based on any known biological relationships other than the first data set and the second data set;

(5) identifying, from the consensus causal relationship network, a causal relationship unique in angiogenesis, wherein a lipid associated with the unique causal relationship is identified as a modulator of angiogenesis.

In certain embodiments, the second data set representing one or more functional activities or cellular responses of the cells associated with angiogenesis comprises global enzymatic activity and an effect of the global enzymatic activity on the enzyme metabolites or substrates in the cells associated with angiogenesis.

The invention provides methods for identifying modulators of angiogenesis, said methods comprising:

(1) establishing a model for angiogenesis, using cells associated with angiogenesis, to represents a characteristic aspect of angiogenesis;

(2) obtaining a first data set from the model for angiogenesis, wherein the first data set represents one or more of genomic data, lipidomic data, proteomic data, metabolic data, transcriptomic data, and single nucleotide polymorphism (SNP) data characterizing the cells associated with angiogenesis;

(3) obtaining a second data set from the model for angiogenesis, wherein the second data set represents one or more functional activities or cellular responses kinase activity of the cells associated with angiogenesis, wherein the one or more functional activities or cellular responses comprises global enzymatic activity and/or an effect of the global enzymatic activity on the enzyme metabolites or substrates in the cells associated with angiogenesis;

(4) generating a consensus causal relationship network among the one or more of genomic data, lipidomic data, proteomic data, metabolic data, transcriptomic data, and single nucleotide polymorphism (SNP) data characterizing the cells associated with angiogenesis and the one or more functional activities or cellular responses of the cells associated with angiogenesis based solely on the first data set and the second data

set using a programmed computing device, wherein the generation of the consensus causal relationship network is not based on any known biological relationships other than the first data set and the second data set;

(5) identifying, from the consensus causal relationship network, a causal relationship unique in angiogenesis, wherein an enzyme associated with the unique causal relationship is identified as a modulator of angiogenesis.

In certain embodiments of the invention, the global enzyme activity comprises global kinase activity and an effect of the global enzymatic activity on the enzyme metabolites or substrates in the cells associated with angiogenesis comprises the phosphoproteome of the cell. In certain embodiments, the global enzyme activity comprises global protease activity.

In certain embodiments of the invention, the modulator stimulates or promotes angiogenesis. In certain embodiments of the invention, the modulator inhibits angiogenesis.

In certain embodiments, the model for angiogenesis comprising cells associated with angiogenesis is selected from the group consisting of an *in vitro* cell culture angiogenesis model, rat aorta microvessel model, newborn mouse retina model, chick chorioallantoic membrane (CAM) model, corneal angiogenic growth factor pocket model, subcutaneous sponge angiogenic growth factor implantation model, MATRIGEL® angiogenic growth factor implantation model, and tumor implantation model; and wherein the model of angiogenesis optionally further comprises a matching control model of angiogenesis comprising control cells. In certain embodiments, the *in vitro* culture angiogenesis model is selected from the group consisting of MATRIGEL® tube formation assay, migration assay, Boyden chamber assay, scratch assay.

In certain embodiments, the cells associated with angiogenesis in the *in vitro* culture model are human endothelial vessel cells (HUVEC). In certain embodiments, the angiogenic growth factor in the corneal angiogenic growth factor pocket model, subcutaneous sponge angiogenic growth factor implantation model, or MATRIGEL® angiogenic growth factor implantation model is selected from the group consisting of FGF-2 and VEGF.

In certain embodiments of the invention, the cells in the model of angiogenesis are subject to an environmental perturbation, and the cells in the matching model of angiogenesis are identical cells not subject to the environmental perturbation. In certain embodiments, the environmental perturbation comprises one or more of a contact with an agent, a change in culture condition, an introduced genetic modification or mutation, a vehicle that causes a genetic modification or mutation, and induction of ischemia.

In certain embodiments, the agent is a pro-angiogenic agent or an anti-angiogenic agent. In certain embodiments, the pro-angiogenic agent is selected from the group consisting of FGF-2 and VEGF. In certain embodiments, the anti-angiogenic agent is selected from the group consisting of VEGF inhibitors, integrin antagonists, angiostatin, endostatin, tumstatin, Avastin, sorafenib, sunitinib, pazopanib, and everolimus, soluble VEGF-receptor, angiopoietin 2, thrombospondin1, thrombospondin 2, vasostatin, calreticulin, prothrombin (kringle domain-2), antithrombin III fragment, vascular endothelial growth inhibitor (VEGI), Secreted Protein Acidic and Rich in Cysteine (SPARC) and a SPARC peptide corresponding to the follistatin domain of the protein (FS-E), and coenzyme Q10.

In any of the embodiments, the agent is an enzymatic activity inhibitor. In any of the embodiments, the agent is a kinase activity inhibitor.

In any of the embodiments of the invention, the first data set comprises protein and/or mRNA expression levels of a plurality of genes in the genomic data set. In certain embodiments of the invention, the first data set comprises two or more of genomic data, lipidomic data, proteomic data, metabolic data, transcriptomic data, and single nucleotide polymorphism (SNP) data. In certain embodiments of the invention, the first data set comprises three or more of genomic data, lipidomic data, proteomic data, metabolic data, transcriptomic data, and single nucleotide polymorphism (SNP) data.

In any of the embodiments of the invention, the second data set representing one or more functional activities or a cellular responses of the cells associated with angiogenesis comprising one or more of bioenergetics, cell proliferation, apoptosis, organellar function, cell migration, tube formation, enzyme activity, chemotaxis,

extracellular matrix degradation, sprouting, and a genotype-phenotype association actualized by functional models selected from ATP, ROS, OXPHOS, and Seahorse assays.

In any of the embodiments of the invention, the first data set can be a single data set such as one of genomic data, lipidomic data, proteomic data, metabolic data, transcriptomic data, and single nucleotide polymorphism (SNP) data. In any of the embodiment, the first data set can be a two data sets. In any of the embodiment, the first data set is three data sets. In any of the embodiment, the first data set can be four data sets. In any of the embodiment, the first data set can be five data sets. In any of the embodiment, the first data set can be six data sets.

In any of the embodiments of the invention, the second data set is a single data set such as one of one or more functional activities or a cellular responses of the cells associated with angiogenesis comprising one or more of bioenergetics, cell proliferation, apoptosis, organellar function, cell migration, tube formation, enzyme activity, chemotaxis, extracellular matrix degradation, sprouting, and a genotype-phenotype association actualized by functional models selected from ATP, ROS, OXPHOS, and Seahorse assay data. In any of the embodiment, the second data set can be two data sets. In any of the embodiment, the second data set can be three data sets. In certain embodiments, the second data set can be four data sets. In any of the embodiment, the second data set can be five data sets. In any of the embodiment, the second data set can be six data sets. In any of the embodiment, the second data set can be seven data sets. In any of the embodiment, the second data set can be eight data sets. In any of the embodiment, the second data set can be nine data sets. In certain embodiments, the second data set can be ten data sets.

In any of the embodiments of the invention, the enzyme activity can be a kinase activity. In any of the embodiments of the invention, the enzyme activity can be a protease activity.

In certain of the embodiments of the invention, step (4) is carried out by an artificial intelligence (AI) -based informatics platform. In certain embodiments, the AI-based informatics platform comprises REFS(TM). In certain embodiments, the AI-based informatics platform receives all data input from the first data set and the second

data set without applying a statistical cut-off point. In certain embodiments, the consensus causal relationship network established in step (4) is further refined to a simulation causal relationship network, before step (5), by *in silico* simulation based on input data, to provide a confidence level of prediction for one or more causal relationships within the consensus causal relationship network.

In certain embodiments of the invention, the unique causal relationship is identified as part of a differential causal relationship network that is uniquely present in cells, and absent in the matching control cells.

In the invention, the unique causal relationship identified is a relationship between at least one pair selected from the group consisting of expression of a gene and level of a lipid; expression of a gene and level of a transcript; expression of a gene and level of a metabolite; expression of a first gene and expression of a second gene; expression of a gene and presence of a SNP; expression of a gene and a functional activity; level of a lipid and level of a transcript; level of a lipid and level of a metabolite; level of a first lipid and level of a second lipid; level of a lipid and presence of a SNP; level of a lipid and a functional activity; level of a first transcript and level of a second transcript; level of a transcript and level of a metabolite; level of a transcript and presence of a SNP; level of a first transcript and level of a functional activity; level of a first metabolite and level of a second metabolite; level of a metabolite and presence of a SNP; level of a metabolite and a functional activity; presence of a first SNP and presence of a second SNP; and presence of a SNP and a functional activity.

In certain embodiments, the functional activity is selected from the group consisting of bioenergetics, cell proliferation, apoptosis, organellar function, cell migration, tube formation, enzyme activity, chemotaxis, extracellular matrix degradation, and sprouting, , and a genotype-phenotype association actualized by functional models selected from ATP, ROS, OXPHOS, and Seahorse assays. In certain embodiments, the functional activity is kinase activity. In certain embodiments, the functional activity is protease activity.

In certain embodiments of the invention, the unique causal relationship identified is a relationship between at least a level of a lipid, expression of a gene, and one or more functional activities wherein the functional activity is a kinase activity.

In the invention, the methods can further comprise validating the identified unique causal relationship in angiogenesis.

The invention provides methods for providing a model for angiogenesis for use in a platform methods, comprising:

establishing a model for angiogenesis, using cells associated with angiogenesis, to represent a characteristic aspect of angiogenesis, wherein the model for angiogenesis is useful for generating data sets used in the platform method;

thereby providing a model for angiogenesis for use in a platform method.

The invention provides methods for obtaining a first data set and second data set from a model for angiogenesis for use in a platform method, comprising:

(1) obtaining a first data set from the model for angiogenesis for use in a platform method, wherein the model for angiogenesis comprises cells associated with angiogenesis, and wherein the first data set represents one or more of genomic data, lipidomic data, proteomic data, metabolic data, transcriptomic data, and single nucleotide polymorphism (SNP) data characterizing the cells associated with angiogenesis;

(2) obtaining a second data set from the model for angiogenesis for use in the platform method, wherein the second data set represents one or more functional activities or cellular responses of the cells associated with angiogenesis;

thereby obtaining a first data set and second data set from the model for angiogenesis for use in a platform method.

The invention provides methods for identifying a modulator of angiogenesis, said method comprising:

(1) generating a consensus causal relationship network among a first data set and second data set obtained from a model for angiogenesis, wherein the model comprises cells associated with angiogenesis, and wherein the first data set represents one or more of genomic data, lipidomic data, proteomic data, metabolic data, transcriptomic data, and single nucleotide polymorphism (SNP) data characterizing the

cells associated with angiogenesis; and the second data set represents one or more functional activities or cellular responses of the cells associated with angiogenesis, using a programmed computing device, wherein the generation of the consensus causal relationship network is not based on any known biological relationships other than the first data set and the second data set;

(2) identifying, from the consensus causal relationship network, a causal relationship unique in angiogenesis, wherein at least one of a gene, a lipid, a protein, a metabolite, a transcript, or a SNP associated with the unique causal relationship is identified as a modulator of angiogenesis;

thereby identifying a modulator of angiogenesis.

The invention provides methods for identifying a modulator of angiogenesis, said method comprising:

(1) providing a consensus causal relationship network generated from a model for angiogenesis;

(2) identifying, from the consensus causal relationship network, a causal relationship unique in angiogenesis, wherein at least one of a gene, a lipid, a protein, a metabolite, a transcript, or a SNP associated with the unique causal relationship is identified as a modulator of angiogenesis;

thereby identifying a modulator of angiogenesis.

In certain embodiments, the consensus causal relationship network is generated among a first data set and second data set obtained from the model for angiogenesis, wherein the model comprises cells associated with angiogenesis, and wherein the first data set represents one or more of genomic data, lipidomic data, proteomic data, metabolic data, transcriptomic data, and single nucleotide polymorphism (SNP) data characterizing the cells associated with angiogenesis; and

the second data set represents one or more functional activities or cellular responses of the cells associated with angiogenesis, using a programmed computing device, wherein the generation of the consensus causal relationship network is not based on any known biological relationships other than the first data set and the second data

set.

In certain embodiments, the model for angiogenesis is selected from the group consisting of *in vitro* cell culture angiogenesis model, rat aorta microvessel model, newborn mouse retina model, chick chorioallantoic membrane (CAM) model, corneal angiogenic growth factor pocket model, subcutaneous sponge angiogenic growth factor implantation model, MATRIGEL® angiogenic growth factor implantation model, and tumor implantation model; and wherein the model of angiogenesis optionally further comprises a matching control model of angiogenesis comprising control cells.

In certain embodiments, the first data set comprises lipidomics data. In certain embodiments, the first data set comprises only lipidomics data.

In certain embodiments, the second data set represents one or more functional activities or cellular responses of the cells associated with angiogenesis comprising global enzymatic activity, and an effect of the global enzymatic activity on the enzyme metabolites or substrates in the cells associated with angiogenesis.

In certain embodiments, the second data set comprises kinase activity or protease activity. In certain embodiments, the second data set comprises only kinase activity or protease activity.

In certain embodiments, the second data set represents one or more functional activities or cellular responses of the cells associated with angiogenesis comprises one or more of bioenergetics profiling, cell proliferation, apoptosis, organellar function, cell migration, tube formation, kinase activity, and protease activity; and a genotype-phenotype association actualized by functional models selected from ATP, ROS, OXPHOS, and Seahorse assays.

In certain embodiments of the invention, the angiogenesis is related to a disease state.

The invention provides methods for modulating angiogenesis in a mammalian subject, the methods comprising:

administering to the mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a biologically active substance that affects

the modulator identified by any one of the methods provided herein, thereby modulating angiogenesis.

The invention provides method of detecting modulated angiogenesis in a mammalian subject, the method comprising:

determining a level, activity, or presence, in a biological sample obtained from the subject, of one or more modulators identified by any one of the methods provided herein; and

comparing the level, activity, or presence in the subject with the level, activity, or presence of the one or more modulators in a control sample,

wherein a difference between the level, activity, or presence in the subject and the level, activity, or presence of the one or more modulators in the control sample is an indication that angiogenesis is modulated in the mammalian subject.

The invention provides methods of identifying a therapeutic compound for modulating angiogenesis in a mammalian subject, the methods comprising:

contacting a biological sample from a mammalian subject with a test compound;

determining the level of expression, in the biological sample, of one or more modulators identified by any one of the methods provided herein;

comparing the level, activity, or presence of the one or more modulators in the biological sample with a control sample not contacted by the test compound; and

selecting the test compound that modulates the level, activity, or presence of the one or more modulators in the biological sample,

thereby identifying a therapeutic compound for modulating angiogenesis in a mammalian subject.

The invention provides methods for modulating angiogenesis in a mammalian subject, the methods comprising:

administering to the mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising the therapeutic compound identified by any of the methods provided herein, thereby treating, alleviating a symptom of, inhibiting progression of, preventing, diagnosing, or prognosing the disease.

In certain embodiments, the “environmental perturbation”, also referred to herein as “external stimulus component”, is a therapeutic agent. In certain embodiments, the external stimulus component is a small molecule (*e.g.*, a small molecule of no more than 5 kDa, 4 kDa, 3 kDa, 2 kDa, 1 kDa, 500 Dalton, or 250 Dalton). In certain embodiments, the external stimulus component is a biologic. In certain embodiments, the external stimulus component is a chemical. In certain embodiments, the external stimulus component is endogenous or exogenous to cells. In certain embodiments, the external stimulus component is a MIM or epishifter. In certain embodiments, the external stimulus component is a stress factor for the cell system, such as hypoxia, hyperglycemia, hyperlipidemia, hyperinsulinemia, and/or lactic acid rich conditions.

In certain embodiments, the external stimulus component may include a therapeutic agent or a candidate therapeutic agent for treating a disease condition, including chemotherapeutic agent, protein-based biological drugs, antibodies, fusion proteins, small molecule drugs, lipids, polysaccharides, nucleic acids, *etc.*

In certain embodiments, the external stimulus component may be one or more stress factors, such as those typically encountered *in vivo* under the various disease conditions, including hypoxia, hyperglycemic conditions, acidic environment (that may be mimicked by lactic acid treatment), *etc.*

In other embodiments, the external stimulus component may include one or more MIMs and/or epishifters, as defined herein below. Exemplary MIMs include Coenzyme Q10 (also referred to herein as CoQ10) and compounds in the Vitamin B family, or nucleosides, mononucleotides or dinucleotides that comprise a compound in the Vitamin B family. In certain embodiments, the external stimulus is not CoQ10. In certain embodiments, the external stimulus is not Vitamin B or a compound in the Vitamin B family.

In making cellular output measurements (such as protein expression, lipid level), either absolute amount (*e.g.*, expression or total amount) or relative level (*e.g.*, relative expression level or amount) may be used. In one embodiment, absolute amounts (*e.g.*, expression or total amounts) are used. In one embodiment, relative levels or amounts

(e.g., relative expression levels or amounts) are used. For example, to determine the relative protein expression level of a cell system, the amount of any given protein in the cell system, with or without the external stimulus to the cell system, may be compared to a suitable control cell line or mixture of cell lines (such as all cells used in the same experiment) and given a fold-increase or fold-decrease value. The skilled person will appreciate that absolute amounts or relative amounts can be employed in any cellular output measurement, such as gene and/or RNA transcription level, level of lipid, or any functional output, *e.g.*, level of apoptosis, level of toxicity, or ECAR or OCR as described herein. A pre-determined threshold level for a fold-increase (*e.g.*, at least 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 75 or 100 or more fold increase) or fold-decrease (*e.g.*, at least a decrease to 0.9, 0.8, 0.75, 0.7, 0.6, 0.5, 0.45, 0.4, 0.35, 0.3, 0.25, 0.2, 0.15, 0.1 or 0.05 fold, or a decrease to 90%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10% or 5% or less) may be used to select significant differentials, and the cellular output data for the significant differentials may then be included in the data sets (*e.g.*, first and second data sets) utilized in the platform technology methods of the invention. All values presented in the foregoing list can also be the upper or lower limit of ranges, *e.g.*, between 1.5 and 5 fold, 5 and 10 fold, 2 and 5 fold, or between 0.9 and 0.7, 0.9 and 0.5, or 0.7 and 0.3 fold, are intended to be a part of this invention.

Throughout the present application, all values presented in a list, *e.g.*, such as those above, can also be the upper or lower limit of ranges that are intended to be a part of this invention.

In one embodiment of the methods of the invention, not every observed causal relationship in a causal relationship network may be of biological significance. With respect to any given biological system for which the subject interrogative biological assessment is applied, some (or maybe all) of the causal relationships (and the genes associated therewith) may be “determinative” with respect to the specific biological problem at issue, *e.g.*, either responsible for causing a disease condition (a potential target for therapeutic intervention) or is a biomarker for the disease condition (a potential diagnostic or prognostic factor). In one embodiment, an observed causal relationship unique in the biological system is determinative with respect to the specific biological problem at issue. In one embodiment, not every observed causal relationship

unique in the biological system is determinative with respect to the specific problem at issue.

Such determinative causal relationships may be selected by an end user of the subject method, or it may be selected by a bioinformatics software program, such as REFS, DAVID-enabled comparative pathway analysis program, or the KEGG pathway analysis program. In certain embodiments, more than one bioinformatics software program is used, and consensus results from two or more bioinformatics software programs are preferred.

As used herein, “differentials” of cellular outputs include differences (*e.g.*, increased or decreased levels) in any one or more parameters of the cellular outputs. In certain embodiments, the differentials are each independently selected from the group consisting of differentials in mRNA transcription, protein expression, protein activity, metabolite / intermediate level, and/or ligand-target interaction. For example, in terms of protein expression level, differentials between two cellular outputs, such as the outputs associated with a cell system before and after the treatment by an external stimulus component, can be measured and quantitated by using art-recognized technologies, such as mass-spectrometry based assays (*e.g.*, iTRAQ, 2D-LC-MSMS, *etc.*).

In one aspect, the cell model for a biological system comprises a cellular cross-talking system, wherein a first cell system having a first cellular environment with an external stimulus component generates a first modified cellular environment; such that a cross-talking cell system is established by exposing a second cell system having a second cellular environment to the first modified cellular environment.

In one embodiment, at least one significant cellular cross-talking differential from the cross-talking cell system is generated; and at least one determinative cellular cross-talking differential is identified such that an interrogative biological assessment occurs. In certain embodiments, the at least one significant cellular cross-talking differential is a plurality of differentials.

In certain embodiments, the at least one determinative cellular cross-talking differential is selected by the end user. Alternatively, in another embodiment, the at least one determinative cellular cross-talking differential is selected by a bioinformatics software program (such as, *e.g.*, REFS, KEGG pathway analysis or DAVID-enabled comparative pathway analysis) based on the quantitative proteomics data.

In certain embodiments, the method further comprises generating a significant cellular output differential for the first cell system.

In certain embodiments, the differentials are each independently selected from the group consisting of differentials in mRNA transcription, protein expression, protein activity, metabolite / intermediate level, and/or ligand-target interaction.

In certain embodiments, the first cell system and the second cell system are independently selected from: a homogeneous population of primary cells, a cancer cell line, or a normal cell line.

In certain embodiments, the first modified cellular environment comprises factors secreted by the first cell system into the first cellular environment, as a result of contacting the first cell system with the external stimulus component. The factors may comprise secreted proteins or other signaling molecules. In certain embodiments, the first modified cellular environment is substantially free of the original external stimulus component.

In certain embodiments, the cross-talking cell system comprises a transwell having an insert compartment and a well compartment separated by a membrane. For example, the first cell system may grow in the insert compartment (or the well compartment), and the second cell system may grow in the well compartment (or the insert compartment).

In certain embodiments, the cross-talking cell system comprises a first culture for growing the first cell system, and a second culture for growing the second cell system. In this case, the first modified cellular environment may be a conditioned medium from the first cell system.

In certain embodiments, the first cellular environment and the second cellular environment can be identical. In certain embodiments, the first cellular environment and the second cellular environment can be different.

In certain embodiments, the cross-talking cell system comprises a co-culture of the first cell system and the second cell system.

The methods of the invention may be used for, or applied to, any number of “interrogative biological assessments.” Application of the methods of the invention to an interrogative biological assessment allows for the identification of one or more

modulators of a biological system or determinative cellular process “drivers” of a biological system or process.

The methods of the invention may be used to carry out a broad range of interrogative biological assessments. In certain embodiments, the interrogative biological assessment is the diagnosis of a disease state. In certain embodiments, the interrogative biological assessment is the determination of the efficacy of a drug. In certain embodiments, the interrogative biological assessment is the determination of the toxicity of a drug. In certain embodiments, the interrogative biological assessment is the staging of a disease state. In certain embodiments, the interrogative biological assessment identifies targets for anti-aging cosmetics.

As used herein, an “interrogative biological assessment” may include the identification of one or more modulators of a biological system, e.g., determinative cellular process “drivers,” (*e.g.*, an increase or decrease in activity of a biological pathway, or key members of the pathway, or key regulators to members of the pathway) associated with the environmental perturbation or external stimulus component, or a unique causal relationship unique in a biological system or process. It may further include additional steps designed to test or verify whether the identified determinative cellular process drivers are necessary and/or sufficient for the downstream events associated with the environmental perturbation or external stimulus component, including *in vivo* animal models and/or *in vitro* tissue culture experiments.

In certain embodiments, the interrogative biological assessment is the diagnosis or staging of a disease state, wherein the identified modulators of a biological system, e.g., determinative cellular process drivers (e.g., cross-talk differentials or causal relationships unique in a biological system or process) represent either disease markers or therapeutic targets that can be subject to therapeutic intervention. The subject interrogative biological assessment is suitable for any disease condition in theory, but may found particularly useful in areas such as oncology / cancer biology, diabetes, obesity, cardiovascular disease, and neurological conditions (especially neuro-degenerative diseases, such as, without limitation, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Amyotrophic lateral sclerosis (ALS), and aging related neurodegeneration), and conditions associated with angiogenesis.

In certain embodiments, the interrogative biological assessment is the determination of the efficacy of a drug, wherein the identified modulators of a biological

system, e.g., determinative cellular process driver (e.g., cross-talk differentials or causal relationships unique in a biological system or process) may be the hallmarks of a successful drug, and may in turn be used to identify additional agents, such as MIMs or epishifters, for treating the same disease condition.

In certain embodiments, the interrogative biological assessment is the identification of drug targets for preventing or treating infection, wherein the identified determinative cellular process driver (e.g., cellular cross-talk differentials or causal relationships unique in a biological system or process) may be markers/indicators or key biological molecules causative of the infective state, and may in turn be used to identify anti-infective agents.

In certain embodiments, the interrogative biological assessment is the assessment of a molecular effect of an agent, *e.g.*, a drug, on a given disease profile, wherein the identified modulators of a biological system, e.g., determinative cellular process driver (e.g., cellular cross-talk differentials or causal relationships unique in a biological system or process) may be an increase or decrease in activity of one or more biological pathways, or key members of the pathway(s), or key regulators to members of the pathway(s), and may in turn be used, *e.g.*, to predict the therapeutic efficacy of the agent for the given disease.

In certain embodiments, the interrogative biological assessment is the assessment of the toxicological profile of an agent, *e.g.*, a drug, on a cell, tissue, organ or organism, wherein the identified modulators of a biological system, e.g., determinative cellular process driver (e.g., cellular cross-talk differentials or causal relationships unique in a biological system or process) may be indicators of toxicity, *e.g.*, cytotoxicity, and may in turn be used to predict or identify the toxicological profile of the agent. In one embodiment, the identified modulators of a biological system, e.g., determinative cellular process driver (e.g., cellular cross-talk differentials or causal relationships unique in a biological system or process) is an indicator of cardiotoxicity of a drug or drug candidate, and may in turn be used to predict or identify the cardiotoxicological profile of the drug or drug candidate.

In certain embodiments, the interrogative biological assessment is the identification of drug targets for preventing or treating a disease or disorder caused by biological weapons, such as disease-causing protozoa, fungi, bacteria, protests, viruses, or toxins, wherein the identified modulators of a biological system, e.g., determinative

cellular process driver (e.g., cellular cross-talk differentials or causal relationships unique in a biological system or process) may be markers/indicators or key biological molecules causative of said disease or disorder, and may in turn be used to identify biodefense agents.

In certain embodiments, the interrogative biological assessment is the identification of targets for anti-aging agents, such as anti-aging cosmetics, wherein the identified modulators of a biological system, e.g., determinative cellular process driver (e.g., cellular cross-talk differentials or causal relationships unique in a biological system or process) may be markers or indicators of the aging process, particularly the aging process in skin, and may in turn be used to identify anti-aging agents.

In one exemplary cell model for aging that is used in the methods of the invention to identify targets for anti-aging cosmetics, the cell model comprises an aging epithelial cell that is, for example, treated with UV light (an environmental perturbation or external stimulus component), and/or neonatal cells, which are also optionally treated with UV light. In one embodiment, a cell model for aging comprises a cellular cross-talk system. In one exemplary two-cell cross-talk system established to identify targets for anti-aging cosmetics, an aging epithelial cell (first cell system) may be treated with UV light (an external stimulus component), and changes, e.g., proteomic changes and/or functional changes, in a neonatal cell (second cell system) resulting from contacting the neonatal cells with conditioned medium of the treated aging epithelial cell may be measured, e.g., proteome changes may be measured using conventional quantitative mass spectrometry, or a causal relationship unique in aging may be identified from a causal relationship network generated from the data.

In another aspect, the invention provides a kit for conducting an interrogative biological assessment using a discovery Platform Technology, comprising one or more reagents for detecting the presence of, and/or for quantitating the amount of, an analyte that is the subject of a causal relationship network generated from the methods of the invention. In one embodiment, said analyte is the subject of a unique causal relationship in the biological system, e.g., a gene associated with a unique causal relationship in the biological system. In certain embodiments, the analyte is a protein, and the reagents comprise an antibody against the protein, a label for the protein, and/or one or more agents for preparing the protein for high throughput analysis (e.g., mass spectrometry based sequencing).

In yet another aspect, the technology provides a method for treating, alleviating a symptom of, inhibiting progression of, preventing, diagnosing, or prognosing a disease in a mammalian subject. The method includes administering to the mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a biologically active substance that affects expression or activity of any one or more of TCOF1, TOP2A, CAMK2A, CDK1, CLTCL1, EIF4G1, ENO1, FBL, GSK3B, HDLBP, HIST1H2BA, HMGB2, HNRNPK, HNRPDL, HSPA9, MAP2K2, LDHA, MAP4, MAPK1, MARCKS, NME1, NME2, PGK1, PGK2, RAB7A, RPL17, RPL28, RPS5, RPS6, SLTM, TMED4, TNRCBA, TUBB, and UBE21, thereby treating, alleviating a symptom of, inhibiting progression of, preventing, diagnosing, or prognosing the disease. In some embodiments, the disease is a cancer, for example hepatocellular carcinoma. In various embodiments, the method can use 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, or 34 of the kinases. In one embodiment, the composition increases expression and/or activity of one or more of the kinases. In another embodiment, the composition decreases expression and/or activity of one or more of the kinases.

In still yet another aspect, the technology provides a method of diagnosing a disease in a mammalian subject. The method includes (i) determining an expression or activity level, in a biological sample obtained from the subject, of any one or more of TCOF1, TOP2A, CAMK2A, CDK1, CLTCL1, EIF4G1, ENO1, FBL, GSK3B, HDLBP, HIST1H2BA, HMGB2, HNRNPK, HNRPDL, HSPA9, MAP2K2, LDHA, MAP4, MAPK1, MARCKS, NME1, NME2, PGK1, PGK2, RAB7A, RPL17, RPL28, RPS5, RPS6, SLTM, TMED4, TNRCBA, TUBB, and UBE21, and (ii) comparing the level in the subject with the level of expression or activity of the one or more proteins in a control sample, wherein a difference between the level in the subject and the level of expression or activity of the one or more proteins in the control sample is an indication that the subject is afflicted with a disease, or predisposed to developing a disease, or responding favorably to a therapy for a disease, thereby diagnosing the disease in the mammalian subject. In some embodiments, the disease is a cancer, for example hepatocellular carcinoma. In various embodiments, the method can use 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, or 34 of the kinases. In one embodiment, the difference is an increase in

expression and/or activity of one or more of the kinases. In another embodiment, the difference is a decrease in expression and/or activity of one or more of the kinases.

In yet another aspect, the technology provides a method of identifying a therapeutic compound for treating, alleviating a symptom of, inhibiting progression of, preventing, diagnosing, or prognosing a disease in a mammalian subject. The method includes (i) contacting a biological sample from a mammalian subject with a test compound, (ii) determining the level of expression, in the biological sample, of any one or more of TCOF1, TOP2A, CAMK2A, CDK1, CLTCL1, EIF4G1, ENO1, FBL, GSK3B, HDLBP, HIST1H2BA, HMGB2, HNRNPK, HNRPDL, HSPA9, MAP2K2, LDHA, MAP4, MAPK1, MARCKS, NME1, NME2, PGK1, PGK2, RAB7A, RPL17, RPL28, RPS5, RPS6, SLTM, TMED4, TNRCBA, TUBB, and UBE21, (iii) comparing the level of expression of the one or more proteins in the biological sample with a control sample not contacted by the test compound, and (iv) selecting the test compound that modulates the level of expression of the one or more proteins in the biological sample, thereby identifying a therapeutic compound for treating, alleviating a symptom of, inhibiting progression of, preventing, diagnosing, or prognosing a disease in a mammalian subject. In some embodiments, the disease is a cancer, for example hepatocellular carcinoma. In various embodiments, the method can use 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, or 34 of the kinases. In one embodiment, the compound increases expression and/or activity of one or more of the kinases. In another embodiment, the compound decreases expression and/or activity of one or more of the kinases.

In still yet another aspect, the technology provides a method for treating, alleviating a symptom of, inhibiting progression of, preventing, diagnosing, or prognosing a disease in a mammalian subject. The method comprising administering to the mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising the therapeutic compound identified by the aspect above (i.e., utilizing any one or more of TCOF1, TOP2A, CAMK2A, CDK1, CLTCL1, EIF4G1, ENO1, FBL, GSK3B, HDLBP, HIST1H2BA, HMGB2, HNRNPK, HNRPDL, HSPA9, MAP2K2, LDHA, MAP4, MAPK1, MARCKS, NME1, NME2, PGK1, PGK2, RAB7A, RPL17, RPL28, RPS5, RPS6, SLTM, TMED4, TNRCBA, TUBB, and UBE21), thereby treating, alleviating a symptom of, inhibiting progression of, preventing, diagnosing, or prognosing the disease. In some embodiments, the disease is a cancer, for example

hepatocellular carcinoma. In various embodiments, the method can use 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, or 34 of the kinases.

It should be understood that all embodiments described herein, including those described only in examples, are parts of the general description of the invention, and can be combined with any other embodiments of the invention unless explicitly disclaimed or inapplicable.

Brief Description of the Drawings

Various embodiments of the present disclosure will be described herein below with reference to the figures wherein:

Figure 1: Illustration of approach to identify therapeutics.

Figure 2: Illustration of systems biology of cancer and consequence of integrated multi-physiological interactive output regulation.

Figure 3: Illustration of systematic interrogation of biological relevance using MIMS.

Figure 4: Illustration of modeling cancer network to enable interrogative biological query.

Figure 5: Illustration of the interrogative biology platform technology.

Figure 6: Illustration of technologies employed in the platform technology.

Figure 7: Schematic representation of the components of the platform including data collection, data integration, and data mining.

Figure 8: Schematic representation of the systematic interrogation using MIMS and collection of response data from the “omics” cascade.

Figure 9: Sketch of the components employed to build the *In vitro* models representing normal and diabetic states.

Figure 10: Schematic representation of the informatics platform REFS™ used to generate causal networks of the protein as they relate to disease pathophysiology.

Figure 11: Schematic representation of the approach towards generation of differential network in diabetic versus normal states and diabetic nodes that are restored to normal states by treatment with MIMS.

Figure 12: A representative differential network in diabetic versus normal states.

Figure 13: A schematic representation of a node and associated edges of interest (Node1 in the center). The cellular functionality associated with each edge is represented.

Figure 14: High level flow chart of an exemplary method, in accordance with some embodiments.

Figure 15A-15D: High level schematic illustration of the components and process for an AI-based informatics system that may be used with exemplary embodiments.

Figure 16: Flow chart of process in AI-based informatics system that may be used with some exemplary embodiments.

Figure 17: Schematically depicts an exemplary computing environment suitable for practicing exemplary embodiments taught herein.

Figure 18: Illustration of case study design described in Example 1.

Figure 19: Effect of CoQ10 treatments on downstream nodes.

Figure 20: CoQ10 treatment decreases expression of LDHA in cancer cell line HepG2.

Figure 21: Exemplary protein interaction consensus network at 70% fragment frequency based on data from Paca2, HepG2 and THLE2 cell lines.

Figure 22: Proteins responsive to LDHA expression simulation in two cancer cell lines were identified using the platform technology.

Figure 23: Ingenuity Pathway Assist® analysis of LDHA – PARK7 network identifies TP53 as upstream hub.

Figure 24: Effect of CoQ10 treatment on TP53 expression levels in SKMEL28 cancer cell line.

Figure 25: Activation of TP53 associated with altered expression of BCL-2 proteins effectuating apoptosis in SKMEL28 cancer cell line and effect of CoQ10 treatment on Bcl-2, Bax and Caspase3 expression levels in SKMEL28.

Figure 26: Illustration of the mathematical approach towards generation of delta-delta networks.

Figure 27: Cancer- Healthy differential (delta-delta) network that drive ECAR and OCR. Each driver has differential effects on the end point as represented by the thickness of the edge. The thickness of the edge in cytoscape represents the strength of the fold change.

Figure 28: Mapping PARK7 and associated nodes from the interrogative platform technology outputs using IPA: The gray shapes include all the nodes associated with PARK7 from the interrogative biology outputs that were imported into IPA. The unfilled shapes (with names) are new connections incorporated by IPA to create a complete map.

Figure 29: The interrogative platform technology of the invention, demonstrating novel associations of nodes associated with PARK7. Edges shown in dashed lines are connections between two nodes in the simulations that have intermediate nodes, but do not have intermediate nodes in IPA. Edges shown in dotted lines are connections between two nodes in the simulations that have intermediate nodes, but have different intermediate nodes in IPA.

Figure 30: Illustration of the mathematical approach towards generation of delta-delta networks. Compare unique edges from NG in the $NG \cap HG$ delta network with unique edges of HGT1 in the $HG \cap HGT1$ delta network. Edges in the intersection of NG and HGT1 are HG edges that are restored to NG with T1.

Figure 31: Delta-delta network of diabetic edges restored to normal with Coenzyme Q10 treatment superimposed on the $NG \cap HG$ delta network.

Figure 32: Delta-delta network of hyperlipidemic edges restored to normal with Coenzyme Q10 treatment superimposed on the normal lipidemia $\cap$ Hyper lipidemia delta network.

Figure 33: A Schematic representing the altered fate of fatty acid in disease and drug treatment. A balance between utilization of free fatty acid (FFA) for generation of ATP and membrane remodeling in response to disruption of membrane biology has been implicated in drug induced cardiotoxicity.

Figure 34: A Schematic representing experimental design and modeling parameters used to study drug induced toxicity in diabetic cardiomyocytes.

Figure 35: Dysregulation of transcriptional network and expression of human mitochondrial energy metabolism genes in diabetic cardiomyocytes by drug treatment (T): rescue molecule (R) normalizes gene expression.

Figure 36: A. Drug treatment (T) induced expression of GPAT1 and TAZ in mitochondria from cardiomyocytes conditioned in hyperglycemia. In combination with the rescue molecule (T+R) the levels of GPAT1 and TAZ were normalized. B. Synthesis of TAG from G3P.

Figure 37: A. Drug treatment (T) decreases mitochondrial OCR (oxygen consumption rate) in cardiomyocytes conditioned in hyperglycemia. The rescue molecule (T+R) normalizes OCR. B. Drug treatment (T) represses mitochondrial ATP synthesis in cardiomyocytes conditioned in hyperglycemia.

Figure 38: GO Annotation of proteins down regulated by drug treatment. Proteins involved in mitochondrial energy metabolism were down regulated with drug treatment.

Figure 39: Illustration of the mathematical approach towards generation of delta networks. Compare unique edges from T versus UT both the models being in diabetic environment.

Figure 40: A schematic representing potential protein hubs and networks that drive pathophysiology of drug induced toxicity.

Figure 41 illustrates a method for identifying a modulator of a biological system or disease process.

Figure 42 illustrates a significant decrease in ENO1 activity not protein expression in HepG2 treated with Sorafenib.

Figure 43 illustrates a significant decrease in PGK1 activity and not protein expression in HepG2 treated with Sorafenib.

Figure 44 illustrates a Significant decrease in LDHA activity in HepG2 treated with Sorafenib.

Figure 45 illustrates a causal molecular interaction network that can be produced by analyzing the dataset using the AI based REFS™ system.

Figure 46 illustrates how integration of multiomics data employing bayesian network inference algorithms can lead to improved understanding of signaling pathways in hepatocellular carcinoma. Yellow squares represent post transcriptional

modification (Phospho) data, blue triangles represent activity based (Kinase) data, and green circles represent proteomics data.

Figure 47 illustrates how autoregulation and reverse feed back regulation in hepatocellular carcinoma signaling pathways can be inferred by the Platform. Squares represent post transcriptional modification (Phospho) data (grey/dark = Kinase, yellow/light – No Kinase Activity), squares represent activity based (Kinase) + Proteomics data (grey/dark = Kinase, yellow/light – No Kinase Activity).

Figures 48-51 illustrate examples of causal association in signaling pathways inferred by the Platform. Kinase isoforms are indicated on representative squares and circles, with causal associations indicated by connectors.

Figures 52A-B show human umbilical vein endothelial cells (HUVECs) grown in (A) confluent or (B) subconfluent cultures were treated for 24 hours with a range of concentrations of CoQ10 as indicated. Confluent cells closely resemble ‘normal’ cells whereas to sub-confluent cells more closely represent the angiogenic phenotype of proliferating cells. In confluent cultures, addition of increasing concentrations of CoQ10 led to closer association, elongation and alignment of ECs. 5000 μ M led to a subtle increase in rounded cells.

Figures 53A-C show confluent (A) and subconfluent (B) cultures of HUVEC cells were treated for 24 hours with 100 or 1500 μ M CoQ10 and assayed for propidium iodide positive apoptotic cells. CoQ10 was protective to ECs treated at confluence, whereas sub-confluent cells were sensitive to CoQ10 and displayed increased apoptosis at 1500 μ M CoQ10. (C) Representative histograms of sub-confluent control ECs (left), 100 μ M CoQ10 (middle) and 1500 μ M CoQ10 (right).

Figures 54A-C show subconfluent cultures of HUVEC cells were treated for 72 hours with 100 or 1500 μ M CoQ10 and assayed for both cell numbers (A) and proliferation (B) using a propidium iodide incorporation assay (detects G2/M phase DNA). High concentrations of CoQ10 led to a significant decrease in cell numbers and had a dose-dependent effect on EC proliferation. Representative histograms of cell proliferation gating for cells in the G2/M phase of the cell cycle [control ECs (left), 100 μ M CoQ10 (middle) and 1500 μ M CoQ10 (right)] are shown in (C).

Figure 55 shows HUVEC cells were grown to confluence tested for migration

using the 'scratch' assay. 100 or 1500 μ M CoQ10 was applied at the time of scratching and closure of the cleared area was monitored over 48 hours. 100 μ M CoQ10 delayed endothelial closure compared to control. Addition of 1500 μ M CoQ10 prevented closure, even up to 48 hours (data not shown).

Figure 56 shows endothelial cells growing in 3-D matrigel form tubes over time. Differential effects of 100 μ M and 1500 μ M CoQ10 on tube formation were observed. Impaired cell to cell association and breakdown of early tube structure was significant at 1500 μ M CoQ10. Images shown were taken at 72 hours.

Figures 57A-B show endothelial cells were grown in subconfluent and confluent cultures were grown in the presence or absence of CoQ10 under both normal and hypoxic conditions. Generation of nitric oxide (NO) (A) and reactive oxygen species (ROS) (B) in response to CoQ10 and hypoxia were assessed.

Figures 58A-D show endothelial cells were grown in subconfluent or confluent cultures in the presence or absence of CoQ10 to assess mitochondrial oxygen consumption under the indicated growth conditions. Assessment of Total OCR (A); Mitochondrial OCR(B); ATP production (C); ECAR (D) are shown.

Figures 59A-C show results from the interrogative biology platform used to identify key biological functional nodes through modulating endothelial cell function by CoQ10. These nodes are represented by a full multi-omic network (A), a hub of a protein enriched network (B), and a hub of a kinase, lipidomic, and functional endpoint network (C). Figures 59B and 59C are exploded portions of Figure 59A.

Detailed Description of the Invention

I. Overview

Exemplary embodiments of the present invention incorporate methods that may be performed using an interrogative biology platform ("the Platform") that is a tool for understanding a wide variety of biological processes, such as disease pathophysiology or angiogenesis, and the key molecular drivers underlying such biological processes, including factors that enable a disease process. Some exemplary embodiments include

systems that may incorporate at least a portion of, or all of, the Platform. Some exemplary methods may employ at least some of, or all of the Platform. Goals and objectives of some exemplary embodiments involving the platform are generally outlined below for illustrative purposes:

- i) to create specific molecular signatures as drivers of critical components of the biological process (e.g., disease process, angiogenesis) as they relate to the overall biological process;
- ii) to generate molecular signatures or differential maps pertaining to the biological process, which may help to identify differential molecular signatures that distinguishes one biological state (e.g., a disease state, angiogenic state) versus a different biological stage (e.g., a normal state), and develop understanding of signatures or molecular entities as they arbitrate mechanisms of change between the two biological states (e.g., from normal to disease state or angiogenic state); and,
- iii) to investigate the role of “hubs” of molecular activity as potential intervention targets for external control of the biological process (e.g., to use the hub as a potential therapeutic target or target for the modulation of angiogenesis), or as potential bio-markers for the biological process in question (e.g., disease specific biomarkers and angiogenic specific markers, in prognostic and/or theranostics uses).

Some exemplary methods involving the Platform may include one or more of the following features:

- 1) modeling the biological process (e.g., disease process, angiogenic process) and/or components of the biological process (e.g., disease physiology and pathophysiology, physiology of angiogenesis) in one or more models, preferably in vitro models or laboratory models (e.g., CAM models, corneal pocket models, MATRIGEL® models), using cells associated with the biological process. For example, the cells may be human derived cells which normally participate in the biological process in question. The model may include various cellular cues / conditions / perturbations that are specific to the biological process (e.g., disease, angiogenesis). Ideally, the model represents various (disease, angiogenesis) states and flux components, instead of a static assessment of the biological (disease, angiogenesis) condition.
- 2) profiling mRNA and/or protein signatures using any art-recognized means. For example, quantitative polymerase chain reaction (qPCR) and proteomics

analysis tools such as Mass Spectrometry (MS). Such mRNA and protein data sets represent biological reaction to environment / perturbation. Where applicable and possible, lipidomics, metabolomics, and transcriptomics data may also be integrated as supplemental or alternative measures for the biological process in question. SNP analysis is another component that may be used at times in the process. It may be helpful for investigating, for example, whether the SNP or a specific mutation has any effect on the biological process. These variables may be used to describe the biological process, either as a static “snapshot,” or as a representation of a dynamic process.

3) assaying for one or more cellular responses to cues and perturbations, including but not limited to bioenergetics profiling, cell proliferation, apoptosis, and organellar function. True genotype-phenotype association is actualized by employment of functional models, such as ATP, ROS, OXPHOS, Seahorse assays, caspase assays, migration assays, chemotaxis assays, tube formation assays, etc. Such cellular responses represent the reaction of the cells in the biological process (or models thereof) in response to the corresponding state(s) of the mRNA / protein expression, and any other related states in 2) above.

4) integrating functional assay data thus obtained in 3) with proteomics and other data obtained in 2), and determining protein associations as driven by causality, by employing artificial intelligence based (AI-based) informatics system or platform. Such an AI-based system is based on, and preferably based only on, the data sets obtained in 2) and/or 3), without resorting to existing knowledge concerning the biological process. Preferably, no data points are statistically or artificially cut-off. Instead, all obtained data is fed into the AI-system for determining protein associations. One goal or output of the integration process is one or more differential networks (otherwise may be referred to herein as “delta networks,” or, in some cases, “delta-delta networks” as the case may be) between the different biological states (e.g., disease vs. normal states).

5) profiling the outputs from the AI-based informatics platform to explore each hub of activity as a potential therapeutic target and/or biomarker. Such profiling can be done entirely *in silico* based on the obtained data sets, without resorting to any actual wet-lab experiments.

6) validating hub of activity by employing molecular and cellular techniques. Such post-informatic validation of output with wet-lab cell-based experiments may be optional, but they help to create a full-circle of interrogation.

Any or all of the approaches outlined above may be used in any specific application concerning any biological process, depending, at least in part, on the nature of the specific application. That is, one or more approaches outlined above may be omitted or modified, and one or more additional approaches may be employed, depending on specific application.

Various schematics illustrating the platform are provided. In particular, an illustration of an exemplary approach to identify therapeutics using the platform is depicted in Figure 1. An illustration of systems biology of cancer and the consequence of integrated multi-physiological interactive output regulation is depicted in Figure 2. An illustration of a systematic interrogation of biological relevance using MIMS is depicted in Figure 3. An illustration of modeling a cancer network to enable an interrogative biological query is depicted in Figure 4. Illustrations of the interrogative biology platform and technologies employed in the platform are depicted in Figures 5 and 6. A schematic representation of the components of the platform including data collection, data integration, and data mining is depicted in Figure 7. A schematic representation of a systematic interrogation using MIMS and collection of response data from the “omics” cascade is depicted in Figure 8.

Figure 14 is a high level flow chart of an exemplary method 10, in which components of an exemplary system that may be used to perform the exemplary method are indicated. Initially, a model (e.g., an in vitro model) is established for a biological process (e.g., a disease process) and/or components of the biological process (e.g., disease physiology and pathophysiology) using cells normally associated with the biological process (step 12). For example, the cells may be human-derived cells that normally participate in the biological process (e.g., disease). The cell model may include various cellular cues, conditions, and/or perturbations that are specific to the biological process (e.g., disease). Ideally, the cell model represents various (disease) states and flux components of the biological process (e.g., disease), instead of a static assessment of the biological process. The comparison cell model may include control cells or normal (e.g., non-diseased) cells. Additional description of the cell models appears below in sections III.A and IV.

A first data set is obtained from the cell model for the biological process, which includes information representing expression levels of a plurality of genes (e.g., mRNA and/or protein signatures) (step 16) using any known process or system (e.g.,

quantitative polymerase chain reaction (qPCR) and proteomics analysis tools such as Mass Spectrometry (MS)).

A third data set is obtained from the comparison cell model for the biological process (step 18). The third data set includes information representing expression levels of a plurality of genes in the comparison cells from the comparison cell model.

In certain embodiments of the methods of the invention, these first and third data sets are collectively referred to herein as a “first data set” that represents expression levels of a plurality of genes in the cells (all cells including comparison cells) associated with the biological system.

The first data set and third data set may be obtained from one or more mRNA and/or Protein Signature Analysis System(s). The mRNA and protein data in the first and third data sets may represent biological reactions to environment and/or perturbation. Where applicable and possible, lipidomics, metabolomics, and transcriptomics data may also be integrated as supplemental or alternative measures for the biological process. The SNP analysis is another component that may be used at times in the process. It may be helpful for investigating, for example, whether a single-nucleotide polymorphism (SNP) or a specific mutation has any effect on the biological process. The data variables may be used to describe the biological process, either as a static “snapshot,” or as a representation of a dynamic process. Additional description regarding obtaining information representing expression levels of a plurality of genes in cells appears below in section III.B.

A second data set is obtained from the cell model for the biological process, which includes information representing a functional activity or response of cells (step 20). Similarly, a fourth data set is obtained from the comparison cell model for the biological process, which includes information representing a functional activity or response of the comparison cells (step 22).

In certain embodiments of the methods of the invention, these second and fourth data sets are collectively referred to herein as a “second data set” that represents a functional activity or a cellular response of the cells (all cells including comparison cells) associated with the biological system.

One or more functional assay systems may be used to obtain information regarding the functional activity or response of cells or of comparison cells. The

information regarding functional cellular responses to cues and perturbations may include, but is not limited to, bioenergetics profiling, cell proliferation, apoptosis, and organellar function. Functional models for processes and pathways (e.g., adenosine triphosphate (ATP), reactive oxygen species (ROS), oxidative phosphorylation (OXPHOS), Seahorse assays, caspase assay, migration assay, chemotaxis assay, tube formation assay, etc.,) may be employed to obtain true genotype-phenotype association. The functional activity or cellular responses represent the reaction of the cells in the biological process (or models thereof) in response to the corresponding state(s) of the mRNA / protein expression, and any other related applied conditions or perturbations. Additional information regarding obtaining information representing functional activity or response of cells is provided below in section III.B.

The method also includes generating computer-implemented models of the biological processes in the cells and in the control cells. For example, one or more (e.g., an ensemble of) Bayesian networks of causal relationships between the expression level of the plurality of genes and the functional activity or cellular response may be generated for the cell model (the “generated cell model networks”) from the first data set and the second data set (step 24). The generated cell model networks, individually or collectively, include quantitative probabilistic directional information regarding relationships. The generated cell model networks are not based on known biological relationships between gene expression and/or functional activity or cellular response, other than information from the first data set and second data set. The one or more generated cell model networks may collectively be referred to as a consensus cell model network.

One or more (e.g., an ensemble of) Bayesian networks of causal relationships between the expression level of the plurality of genes and the functional activity or cellular response may be generated for the comparison cell model (the “generated comparison cell model networks”) from the first data set and the second data set (step 26). The generated comparison cell model networks, individually or collectively, include quantitative probabilistic directional information regarding relationships. The generated cell networks are not based on known biological relationships between gene expression and/or functional activity or cellular response, other than the information in the first data set and the second data set. The one or more generated comparison model networks may collectively be referred to as a consensus cell model network.

The generated cell model networks and the generated comparison cell model networks may be created using an artificial intelligence based (AI-based) informatics platform. Further details regarding the creation of the generated cell model networks, the creation of the generated comparison cell model networks and the AI-based informatics system appear below in section III.C and in the description of Figures 2A-3.

It should be noted that many different AI-based platforms or systems may be employed to generate the Bayesian networks of causal relationships including quantitative probabilistic directional information. Although certain examples described herein employ one specific commercially available system, i.e., REFSTM (Reverse Engineering/Forward Simulation) from GNS (Cambridge, MA), embodiments are not limited. AI-Based Systems or Platforms suitable to implement some embodiments employ mathematical algorithms to establish causal relationships among the input variables (e.g., the first and second data sets), based only on the input data without taking into consideration prior existing knowledge about any potential, established, and/or verified biological relationships.

For example, the REFSTM AI-based informatics platform utilizes experimentally derived raw (original) or minimally processed input biological data (e.g., genetic, genomic, epigenetic, proteomic, metabolomic, and clinical data), and rapidly performs trillions of calculations to determine how molecules interact with one another in a complete system. The REFSTM AI-based informatics platform performs a reverse engineering process aimed at creating an *in silico* computer-implemented cell model (e.g., generated cell model networks), based on the input data, that quantitatively represents the underlying biological system. Further, hypotheses about the underlying biological system can be developed and rapidly simulated based on the computer-implemented cell model, in order to obtain predictions, accompanied by associated confidence levels, regarding the hypotheses.

With this approach, biological systems are represented by quantitative computer-implemented cell models in which “interventions” are simulated to learn detailed mechanisms of the biological system (e.g., disease), effective intervention strategies, and/or clinical biomarkers that determine which patients will respond to a given treatment regimen. Conventional bioinformatics and statistical approaches, as well as approaches based on the modeling of known biology, are typically unable to provide these types of insights.

After the generated cell model networks and the generated comparison cell model networks are created, they are compared. One or more causal relationships present in at least some of the generated cell model networks, and absent from, or having at least one significantly different parameter in, the generated comparison cell model networks are identified (step 28). Such a comparison may result in the creation of a differential network. The comparison, identification, and/or differential (delta) network creation may be conducted using a differential network creation module, which is described in further detail below in section III.D and with respect to the description of Figure 26.

In some embodiments, input data sets are from one cell type and one comparison cell type, which creates an ensemble of cell model networks based on the one cell type and another ensemble of comparison cell model networks based on the one comparison control cell type. A differential may be performed between the ensemble of networks of the one cell type and the ensemble of networks of the comparison cell type(s).

In other embodiments, input data sets are from multiple cell types (e.g., two or more cancer cell types, two or more cell types in different angiogenic states e.g., induced by different pro-angiogenic stimuli) and multiple comparison cell types (e.g., two or more normal, non-cancerous cell types, two or more non-angiogenic and angiogenic cell types). An ensemble of cell model networks may be generated for each cell types and each comparison cell type individually, and/or data from the multiple cell types and the multiple comparison cell types may be combined into respective composite data sets. The composite data sets produce an ensemble of networks corresponding to the multiple cell types (composite data) and another ensemble of networks corresponding to the multiple comparison cell types (comparison composite data). A differential may be performed on the ensemble of networks for the composite data as compared to the ensemble of networks for the comparison composite data.

In some embodiments, a differential may be performed between two different differential networks. This output may be referred to as a delta-delta network, and is described below with respect to Figure 26.

Quantitative relationship information may be identified for each relationship in the generated cell model networks (step 30). Similarly, quantitative relationship information for each relationship in the generated comparison cell model networks may be identified (step 32). The quantitative information regarding the relationship may

include a direction indicating causality, a measure of the statistical uncertainty regarding the relationship (e.g., an Area Under the Curve (AUC) statistical measurement), and/or an expression of the quantitative magnitude of the strength of the relationship (e.g., a fold). The various relationships in the generated cell model networks may be profiled using the quantitative relationship information to explore each hub of activity in the networks as a potential therapeutic target and/or biomarker. Such profiling can be done entirely *in silico* based on the results from the generated cell model networks, without resorting to any actual wet-lab experiments.

In some embodiments, a hub of activity in the networks may be validated by employing molecular and cellular techniques. Such post-informatic validation of output with wet-lab cell based experiments need not be performed, but it may help to create a full-circle of interrogation. Figure 15 schematically depicts a simplified high level representation of the functionality of an exemplary AI-based informatics system (e.g., REFS™ AI-based informatics system) and interactions between the AI-based system and other elements or portions of an interrogative biology platform (“the Platform”). In Figure 15A, various data sets obtained from a model for a biological process (e.g., a disease model), such as drug dosage, treatment dosage, protein expression, mRNA expression, and any of many associated functional measures (such as OCR, ECAR) are fed into an AI-based system. As shown in Figure 15B, from the input data sets, the AI-system creates a library of “network fragments” that includes variables (proteins, lipids and metabolites) that drive molecular mechanisms in the biological process (e.g., disease), in a process referred to as Bayesian Fragment Enumeration (Figure 15B).

In Figure 15C, the AI-based system selects a subset of the network fragments in the library and constructs an initial trial network from the fragments. The AI-based system also selects a different subset of the network fragments in the library to construct another initial trial network. Eventually an ensemble of initial trial networks are created (e.g., 1000 networks) from different subsets of network fragments in the library. This process may be termed parallel ensemble sampling. Each trial network in the ensemble is evolved or optimized by adding, subtracting and/or substitution additional network fragments from the library. If additional data is obtained, the additional data may be incorporated into the network fragments in the library and may be incorporated into the ensemble of trial networks through the evolution of each trial network. After

completion of the optimization/evolution process, the ensemble of trial networks may be described as the generated cell model networks.

As shown in Figure 15D, the ensemble of generated cell model networks may be used to simulate the behavior of the biological system. The simulation may be used to predict behavior of the biological system to changes in conditions, which may be experimentally verified using wet-lab cell-based, or animal-based, experiments. Also, quantitative parameters of relationships in the generated cell model networks may be extracted using the simulation functionality by applying simulated perturbations to each node individually while observing the effects on the other nodes in the generated cell model networks. Further detail is provided below in section III.C.

The automated reverse engineering process of the AI-based informatics system, which is depicted in Figures 2A-2D, creates an ensemble of generated cell model networks that is an unbiased and systematic computer-based model of the cells.

The reverse engineering determines the probabilistic directional network connections between the molecular measurements in the data, and the phenotypic outcomes of interest. The variation in the molecular measurements enables learning of the probabilistic cause and effect relationships between these entities and changes in endpoints. The machine learning nature of the platform also enables cross training and predictions based on a data set that is constantly evolving.

The network connections between the molecular measurements in the data are “probabilistic,” partly because the connection may be based on correlations between the observed data sets “learned” by the computer algorithm. For example, if the expression level of protein X and that of protein Y are positively or negatively correlated, based on statistical analysis of the data set, a causal relationship may be assigned to establish a network connection between proteins X and Y. The reliability of such a putative causal relationship may be further defined by a likelihood of the connection, which can be measured by p-value (e.g., $p < 0.1$, 0.05, 0.01, etc).

The network connections between the molecular measurements in the data are “directional,” partly because the network connections between the molecular measurements, as determined by the reverse-engineering process, reflects the cause and effect of the relationship between the connected gene / protein, such that raising the

expression level of one protein may cause the expression level of the other to rise or fall, depending on whether the connection is stimulatory or inhibitory.

The network connections between the molecular measurements in the data are “quantitative,” partly because the network connections between the molecular measurements, as determined by the process, may be simulated *in silico*, based on the existing data set and the probabilistic measures associated therewith. For example, in the established network connections between the molecular measurements, it may be possible to theoretically increase or decrease (e.g., by 1, 2, 3, 5, 10, 20, 30, 50, 100-fold or more) the expression level of a given protein (or a “node” in the network), and quantitatively simulate its effects on other connected proteins in the network.

The network connections between the molecular measurements in the data are “unbiased,” at least partly because no data points are statistically or artificially cut-off, and partly because the network connections are based on input data alone, without referring to pre-existing knowledge about the biological process in question.

The network connections between the molecular measurements in the data are “systemic” and (unbiased), partly because all potential connections among all input variables have been systemically explored, for example, in a pair-wise fashion. The reliance on computing power to execute such systemic probing exponentially increases as the number of input variables increases.

In general, an ensemble of ~1,000 networks is usually sufficient to predict probabilistic causal quantitative relationships among all of the measured entities. The ensemble of networks captures uncertainty in the data and enables the calculation of confidence metrics for each model prediction. Predictions generated using the ensemble of networks together, where differences in the predictions from individual networks in the ensemble represent the degree of uncertainty in the prediction. This feature enables the assignment of confidence metrics for predictions of clinical response generated from the model.

Once the models are reverse-engineered, further simulation queries may be conducted on the ensemble of models to determine key molecular drivers for the biological process in question, such as a disease condition.

Sketch of components employed to build exemplary *In vitro* models representing normal and diabetic states is depicted in Figure 9. Schematic representation of an

exemplary informatics platform REFSTM used to generate causal networks of the protein as they relate to disease pathophysiology is depicted in Figure 10. Schematic representation of exemplary approach towards generation of differential network in diabetic versus normal states and diabetic nodes that are restored to normal states by treatment with MIMS is depicted in Figure 11. A representative differential network in diabetic versus normal states is depicted in Figure 12. A schematic representation of a node and associated edges of interest (Node1 in the center) and the cellular functionality associated with each edge is depicted in Figure 13.

The invention having been generally described above, the sections below provide more detailed description for various aspects or elements of the general invention, in conjunction with one or more specific biological systems that can be analyzed using the methods herein. It should be noted, however, the specific biological systems used for illustration purpose below are not limiting. To the contrary, it is intended that other distinct biological systems, including any alternatives, modifications, and equivalents thereof, may be analyzed similarly using the subject Platform technology.

II. Definitions

As used herein, certain terms intended to be specifically defined, but are not already defined in other sections of the specification, are defined herein.

The articles “a” and “an” are used herein to refer to one or to more than one (*i.e.*, to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.

The term “including” is used herein to mean, and is used interchangeably with, the phrase “including but not limited to.”

The term “or” is used herein to mean, and is used interchangeably with, the term “and/or,” unless context clearly indicates otherwise.

The term “such as” is used herein to mean, and is used interchangeably, with the phrase “such as but not limited to.”

“Metabolic pathway” refers to a sequence of enzyme-mediated reactions that transform one compound to another and provide intermediates and energy for cellular functions. The metabolic pathway can be linear or cyclic or branched.

“Metabolic state” refers to the molecular content of a particular cellular, multicellular or tissue environment at a given point in time as measured by various chemical and biological indicators as they relate to a state of health or disease.

“Angiogenesis” refers to is the physiological process involving the growth of new blood vessels from pre-existing vessels. Angiogenesis includes at least the proliferation of vascular endothelial cells, the migration of vascular endothelial cells typically in response to chemotactic agents, the degradation of extracellular matrix typically by matrix metalloprotease production, matrix metalloproteinase production, tube formation, vessel lumen formation, vessel sprouting, adhesion molecule expression typically integrin expression, and differentiation. Depending on the culture system (e.g., one dimensional vs. three dimensional) and the cell type, various aspects of angiogenesis can be observed in cells grown in vitro as well as in vivo. Angiogenic cells or cells exhibiting at least one characteristic of an angiogenic cell exhibit 1, 2, 3, 4, 5, 6, 7, 8, 9, or more characteristics set forth above. Modulators of angiogenesis increase or decrease at least one of the characteristics provided above. Angiogenesis is distinct from vasculogenesis which is the spontaneous formation of blood vessels or intussusception is the term for the formation of new blood vessels by the splitting of existing ones.

The term “microarray” refers to an array of distinct polynucleotides, oligonucleotides, polypeptides (e.g., antibodies) or peptides synthesized on a substrate, such as paper, nylon or other type of membrane, filter, chip, glass slide, or any other suitable solid support.

The terms “disorders” and “diseases” are used inclusively and refer to any deviation from the normal structure or function of any part, organ or system of the body (or any combination thereof). A specific disease is manifested by characteristic symptoms and signs, including biological, chemical and physical changes, and is often associated with a variety of other factors including, but not limited to, demographic, environmental, employment, genetic and medically historical factors. Certain characteristic signs, symptoms, and related factors can be quantitated through a variety of methods to yield important diagnostic information.

The term “expression” includes the process by which a polypeptide is produced from polynucleotides, such as DNA. The process may involves the transcription of a gene into mRNA and the translation of this mRNA into a polypeptide. Depending on

the context in which it is used, “expression” may refer to the production of RNA, protein or both.

The terms “level of expression of a gene” or “gene expression level” refer to the level of mRNA, as well as pre-mRNA nascent transcript(s), transcript processing intermediates, mature mRNA(s) and degradation products, or the level of protein, encoded by the gene in the cell.

The term “modulation” refers to upregulation (i.e., activation or stimulation), downregulation (i.e., inhibition or suppression) of a response, or the two in combination or apart. A “modulator” is a compound or molecule that modulates, and may be, e.g., an agonist, antagonist, activator, stimulator, suppressor, or inhibitor.

The phrase “affects the modulator” is understood as altering the expression of, altering the level of, or altering the activity of the modulator.

The term “Trolamine,” as used herein, refers to Trolamine NF, Triethanolamine, TEALAN[®], TEAlan 99%, Triethanolamine, 99%, Triethanolamine, NF or Triethanolamine, 99%, NF. These terms may be used interchangeably herein.

The term “genome” refers to the entirety of a biological entity’s (cell, tissue, organ, system, organism) genetic information. It is encoded either in DNA or RNA (in certain viruses, for example). The genome includes both the genes and the non-coding sequences of the DNA.

The term “proteome” refers to the entire set of proteins expressed by a genome, a cell, a tissue, or an organism at a given time. More specifically, it may refer to the entire set of expressed proteins in a given type of cells or an organism at a given time under defined conditions. Proteome may include protein variants due to, for example, alternative splicing of genes and/or post-translational modifications (such as glycosylation or phosphorylation).

The term “transcriptome” refers to the entire set of transcribed RNA molecules, including mRNA, rRNA, tRNA, microRNA, dicer substrate RNAs, and other non-coding RNA produced in one or a population of cells at a given time. The term can be applied to the total set of transcripts in a given organism, or to the specific subset of transcripts present in a particular cell type. Unlike the genome, which is roughly fixed for a given cell line (excluding mutations), the transcriptome can vary with external environmental conditions. Because it includes all mRNA transcripts in the cell, the

transcriptome reflects the genes that are being actively expressed at any given time, with the exception of mRNA degradation phenomena such as transcriptional attenuation.

The study of transcriptomics, also referred to as expression profiling, examines the expression level of mRNAs in a given cell population, often using high-throughput techniques based on DNA microarray technology.

The term “metabolome” refers to the complete set of small-molecule metabolites (such as metabolic intermediates, hormones and other signalling molecules, and secondary metabolites) to be found within a biological sample, such as a single organism, at a given time under a given condition. The metabolome is dynamic, and may change from second to second.

The term “lipidome” refers to the complete set of lipids to be found within a biological sample, such as a single organism, at a given time under a given condition. The lipidome is dynamic, and may change from second to second.

The term “interactome” refers to the whole set of molecular interactions in a biological system under study (*e.g.*, cells). It can be displayed as a directed graph. Molecular interactions can occur between molecules belonging to different biochemical families (proteins, nucleic acids, lipids, carbohydrates, *etc.*) and also within a given family. When spoken in terms of proteomics, interactome refers to protein-protein interaction network (PPI), or protein interaction network (PIN). Another extensively studied type of interactome is the protein-DNA interactome (network formed by transcription factors (and DNA or chromatin regulatory proteins) and their target genes).

The term “cellular output” includes a collection of parameters, preferably measurable parameters, relating to cellular status, including (without limiting): level of transcription for one or more genes (*e.g.*, measurable by RT-PCR, qPCR, microarray, *etc.*), level of expression for one or more proteins (*e.g.*, measurable by mass spectrometry or Western blot), absolute activity (*e.g.*, measurable as substrate conversion rates) or relative activity (*e.g.*, measurable as a % value compared to maximum activity) of one or more enzymes or proteins, level of one or more metabolites or intermediates, level of oxidative phosphorylation (*e.g.*, measurable by Oxygen Consumption Rate or OCR), level of glycolysis (*e.g.*, measurable by Extra Cellular Acidification Rate or ECAR), extent of ligand-target binding or interaction, activity of extracellular secreted molecules, *etc.* The cellular output may include data for a pre-determined number of target genes or proteins, *etc.*, or may include a global assessment

for all detectable genes or proteins. For example, mass spectrometry may be used to identify and/or quantitate all detectable proteins expressed in a given sample or cell population, without prior knowledge as to whether any specific protein may be expressed in the sample or cell population.

As used herein, a “cell system” includes a population of homogeneous or heterogeneous cells. The cells within the system may be growing *in vivo*, under the natural or physiological environment, or may be growing *in vitro* in, for example, controlled tissue culture environments. The cells within the system may be relatively homogeneous (*e.g.*, no less than 70%, 80%, 90%, 95%, 99%, 99.5%, 99.9% homogeneous), or may contain two or more cell types, such as cell types usually found to grow in close proximity *in vivo*, or cell types that may interact with one another *in vivo* through, *e.g.*, paracrine or other long distance inter-cellular communication. The cells within the cell system may be derived from established cell lines, including cancer cell lines, immortal cell lines, or normal cell lines, or may be primary cells or cells freshly isolated from live tissues or organs.

Cells in the cell system are typically in contact with a “cellular environment” that may provide nutrients, gases (oxygen or CO₂, *etc.*), chemicals, or proteinaceous / non-proteinaceous stimulants that may define the conditions that affect cellular behavior. The cellular environment may be a chemical media with defined chemical components and/or less well-defined tissue extracts or serum components, and may include a specific pH, CO₂ content, pressure, and temperature under which the cells grow. Alternatively, the cellular environment may be the natural or physiological environment found *in vivo* for the specific cell system.

In certain embodiments, a cell environment comprises conditions that simulate an aspect of a biological system or process, *e.g.*, simulate a disease state, process, or environment. Such culture conditions include, for example, hyperglycemia, hypoxia, or lactic-rich conditions. Numerous other such conditions are described herein.

In certain embodiments, a cellular environment for a specific cell system also include certain cell surface features of the cell system, such as the types of receptors or ligands on the cell surface and their respective activities, the structure of carbohydrate or lipid molecules, membrane polarity or fluidity, status of clustering of certain membrane proteins, *etc.* These cell surface features may affect the function of nearby cells, such as cells belonging to a different cell system. In certain other embodiments, however, the

cellular environment of a cell system does not include cell surface features of the cell system.

The cellular environment may be altered to become a “modified cellular environment.” Alterations may include changes (*e.g.*, increase or decrease) in any one or more component found in the cellular environment, including addition of one or more “external stimulus component” to the cellular environment. The environmental perturbation or external stimulus component may be endogenous to the cellular environment (*e.g.*, the cellular environment contains some levels of the stimulant, and more of the same is added to increase its level), or may be exogenous to the cellular environment (*e.g.*, the stimulant is largely absent from the cellular environment prior to the alteration). The cellular environment may further be altered by secondary changes resulting from adding the external stimulus component, since the external stimulus component may change the cellular output of the cell system, including molecules secreted into the cellular environment by the cell system.

As used herein, “external stimulus component”, also referred to herein as “environmental perturbation”, include any external physical and/or chemical stimulus that may affect cellular function. This may include any large or small organic or inorganic molecules, natural or synthetic chemicals, temperature shift, pH change, radiation, light (UVA, UVB *etc.*), microwave, sonic wave, electrical current, modulated or unmodulated magnetic fields, *etc.*

The term “**Multidimensional Intracellular Molecule (MIM)**”, is an isolated version or synthetically produced version of an endogenous molecule that is naturally produced by the body and/or is present in at least one cell of a human. A MIM is capable of entering a cell and the entry into the cell includes complete or partial entry into the cell as long as the biologically active portion of the molecule wholly enters the cell. MIMs are capable of inducing a signal transduction and/or gene expression mechanism within a cell. MIMs are multidimensional because the molecules have both a therapeutic and a carrier, *e.g.*, drug delivery, effect. MIMs also are multidimensional because the molecules act one way in a disease state and a different way in a normal state. For example, in the case of CoQ-10, administration of CoQ-10 to a melanoma cell in the presence of VEGF leads to a decreased level of Bcl2 which, in turn, leads to a decreased oncogenic potential for the melanoma cell. In contrast, in a normal fibroblast, co-administration of CoQ-10 and VEGF has no effect on the levels of Bcl2.

In one embodiment, a MIM is also an epi-shifter. In another embodiment, a MIM is not an epi-shifter. In another embodiment, a MIM is characterized by one or more of the foregoing functions. In another embodiment, a MIM is characterized by two or more of the foregoing functions. In a further embodiment, a MIM is characterized by three or more of the foregoing functions. In yet another embodiment, a MIM is characterized by all of the foregoing functions. The skilled artisan will appreciate that a MIM of the invention is also intended to encompass a mixture of two or more endogenous molecules, wherein the mixture is characterized by one or more of the foregoing functions. The endogenous molecules in the mixture are present at a ratio such that the mixture functions as a MIM.

MIMs can be lipid based or non-lipid based molecules. Examples of MIMs include, but are not limited to, CoQ10, acetyl Co-A, palmitoyl Co-A, L-carnitine, amino acids such as, for example, tyrosine, phenylalanine, and cysteine. In one embodiment, the MIM is a small molecule. In one embodiment of the invention, the MIM is not CoQ10. MIMs can be routinely identified by one of skill in the art using any of the assays described in detail herein. MIMs are described in further detail in US 12/777,902 (US 2011-0110914), the entire contents of which are expressly incorporated herein by reference.

As used herein, an “epimetabolic shifter” (epi-shifter) is a molecule that modulates the metabolic shift from a healthy (or normal) state to a disease state and vice versa, thereby maintaining or reestablishing cellular, tissue, organ, system and/or host health in a human. Epi-shifters are capable of effectuating normalization in a tissue microenvironment. For example, an epi-shifter includes any molecule which is capable, when added to or depleted from a cell, of affecting the microenvironment (*e.g.*, the metabolic state) of a cell. The skilled artisan will appreciate that an epi-shifter of the invention is also intended to encompass a mixture of two or more molecules, wherein the mixture is characterized by one or more of the foregoing functions. The molecules in the mixture are present at a ratio such that the mixture functions as an epi-shifter. Examples of epi-shifters include, but are not limited to, CoQ-10; vitamin D3; ECM components such as fibronectin; immunomodulators, such as TNF α or any of the interleukins, *e.g.*, IL-5, IL-12, IL-23; angiogenic factors; and apoptotic factors.

In one embodiment, the epi-shifter also is a MIM. In one embodiment, the epi-shifter is not CoQ10. Epi-shifters can be routinely identified by one of skill in the art

using any of the assays described in detail herein. Epi-shifters are described in further detail in US 12/777,902 (US 2011-0110914), the entire contents of which are expressly incorporated herein by reference.

Other terms not explicitly defined in the instant application have meaning as would have been understood by one of ordinary skill in the art.

III. Exemplary Steps and Components of the Platform Technology

For illustration purpose only, the following steps of the subject Platform Technology may be described herein below as an exemplary utility for integrating data obtained from a custom built cancer model, and for identifying novel proteins / pathways driving the pathogenesis of cancer. Relational maps resulting from this analysis provides cancer treatment targets, as well as diagnostic / prognostic markers associated with cancer. However, the subject Platform Technology has general applicability for any biological system or process, and is not limited to any particular cancer or other specific disease models.

In addition, although the description below is presented in some portions as discrete steps, it is for illustration purpose and simplicity, and thus, in reality, it does not imply such a rigid order and/or demarcation of steps. Moreover, the steps of the invention may be performed separately, and the invention provided herein is intended to encompass each of the individual steps separately, as well as combinations of one or more (e.g., any one, two, three, four, five, six or all seven steps) steps of the subject Platform Technology, which may be carried out independently of the remaining steps.

The invention also is intended to include all aspects of the Platform Technology as separate components and embodiments of the invention. For example, the generated data sets are intended to be embodiments of the invention. As further examples, the generated causal relationship networks, generated consensus causal relationship networks, and/or generated simulated causal relationship networks, are also intended to be embodiments of the invention. The causal relationships identified as being unique in the biological system are intended to be embodiments of the invention. Further, the custom built models for a particular biological system are also intended to be embodiments of the invention. For example, custom built models for a disease state or

process, such as, e.g., models for angiogenesis, cell models for cancer, obesity/diabetes/cardiovascular disease, or a custom built model for toxicity (e.g., cardiotoxicity) of a drug, are also intended to be embodiments of the invention.

A. Custom Model Building

The first step in the Platform Technology is the establishment of a model for a biological system or process.

1. Angiogenesis models

Both in vitro and in vivo models of angiogenesis are known. For example, an in vitro model using human umbilical cord vascular endothelial cells (HUVECs) is provided in detail in the Examples. Briefly, when HUVECs are grown in sub-confluent cultures, they exhibit characteristics of angiogenic cells. When HUVECs are grown in confluent cultures, they do not exhibit characteristics of angiogenic cells. Most steps in the angiogenic cascade can be analyzed in vitro, including endothelial cell proliferation, migration and differentiation. The proliferation studies are based on cell counting, thymidine incorporation, or immuno histochemical staining for cell proliferation (by measurement of PCNA) or cell death (by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling or Tunel assay). Chemotaxis can be examined in a Boyden chamber, which consists of an upper and lower well separated by a membrane filter. Chemotactic solutions are placed in the lower well, cells are added to the top well, and after a period of incubation the cells that have migrated toward the chemotactic stimulus are counted on the lower surface of the membrane. Cell migration can also be studied using the “scratch” assay provided in the Examples below. Differentiation can be induced in vitro by culturing endothelial cells in different ECM components, including two- and three-dimensional fibrin clots, collagen gels and matrigel. Microvessels have also been shown to grow from rings of rat aorta embedded in a three dimensional fibrin gel. Matrix metalloprotease expression can be assayed by zymogen assay.

Retinal vasculature is not fully formed in mice at the time of birth. Vascular growth and angiogenesis have been studied in detail in this model. Staged retina can be used to analyze angiogenesis as a normal biological process.

The chick chorioallantoic membrane (CAM) assay is well known in the art. The early chick embryo lacks a mature immune system and is therefore used to study tumor-induced angiogenesis. Tissue grafts are placed on the CAM through a window made in the eggshell. This caused a typical radial rearrangement of vessels towards, and a clear increase of vessels around the graft within four days after implantation. Blood vessels entering the graft are counted under a stereomicroscope. To assess the anti-angiogenic or angiogenic activity of test substances, the compounds are either prepared in slow release polymer pellets, absorbed by gelatin sponges or air-dried on plastic discs and then implanted onto the CAM. Several variants of the CAM assay including culturing of shell-less embryos in Petri dishes, and different quantification methods (i.e. measuring the rate of basement membrane biosynthesis using radio-labeled proline, counting the number of vessels under a microscope or image analysis) have been described.

The cornea presents an in vivo avascular site. Therefore, any vessels penetrating from the limbus into the corneal stroma can be identified as newly formed. To induce an angiogenic response, slow release polymer pellets [i.e. poly-2-hydroxyethyl-methacrylate (hydron) or ethylene-vinyl acetate copolymer (ELVAX)], containing an angiogenic substance (i.e. FGF-2 or VEGF) are implanted in "pockets" created in the corneal stroma of a rabbit. Also, a wide variety of tissues, cells, cell extracts and conditioned media have been examined for their effect on angiogenesis in the cornea. The vascular response can be quantified by computer image analysis after perfusion of the cornea with India ink. Cornea can be harvested and analyzed using the platform methods provided herein.

MATRIGEL® is a matrix of a mouse basement membrane neoplasm known as Engelbreth-Holm-Swarm murine sarcoma. It is a complex mixture of basement membrane proteins including laminin, collagen type IV, heparan sulfate, fibrin and growth factors, including EGF, TGF- β , PDGF and IGF-1. It was originally developed to study endothelial cell differentiation in vitro. However, MATRIGEL®-containing FGF-2 can be injected subcutaneously in mice. MATRIGEL® is liquid at 4°C but forms a solid gel at 37°C that traps the growth factor to allow its slow release. Typically, after 10 days, the MATRIGEL® plugs are removed and angiogenesis is quantified histologically or morphometrically in plug sections. MATRIGEL® plugs can be harvested and analyzed using the platform methods provided herein.

2. In vitro disease models

An example of a biological system or process is cancer. As any other complicated biological process or system, cancer is a complicated pathological condition characterized by multiple unique aspects. For example, due to its high growth rate, many cancer cells are adapted to grow in hypoxia conditions, have up-regulated glycolysis and reduced oxidative phosphorylation metabolic pathways. As a result, cancer cells may react differently to an environmental perturbation, such as treatment by a potential drug, as compared to the reaction by a normal cell in response to the same treatment. Thus, it would be of interest to decipher cancer's unique responses to drug treatment as compared to the responses of normal cells. To this end, a custom cancer model may be established to simulate the environment of a cancer cell, e.g., within a tumor *in vivo*, by creating cell culture conditions closely approximating the conditions of a cancer cell in a tumor *in vivo*, or to mimic various aspects of cancer growth, by isolating different growth conditions of the cancer cells.

One such cancer "environment", or growth stress condition, is hypoxia, a condition typically found within a solid tumor. Hypoxia can be induced in cells in cells using art-recognized methods. For example, hypoxia can be induced by placing cell systems in a Modular Incubator Chamber (MIC-101, Billups-Rothenberg Inc. Del Mar, CA), which can be flooded with an industrial gas mix containing 5% CO₂, 2% O₂ and 93% nitrogen. Effects can be measured after a pre-determined period, e.g., at 24 hours after hypoxia treatment, with and without additional external stimulus components (e.g., CoQ10 at 0, 50, or 100 μ M).

Likewise, lactic acid treatment of cells mimics a cellular environment where glycolysis activity is high, as exists in the tumor environment *in vivo*. Lactic acid induced stress can be investigated at a final lactic acid concentration of about 12.5 mM at a pre-determined time, e.g., at 24 hours, with or without additional external stimulus components (e.g., CoQ10 at 0, 50, or 100 μ M).

Hyperglycemia is normally a condition found in diabetes; however, hyperglycemia also to some extent mimics one aspect of cancer growth because many cancer cells rely on glucose as their primary source of energy. Exposing subject cells to

a typical hyperglycemic condition may include adding 10% culture grade glucose to suitable media, such that the final concentration of glucose in the media is about 22 mM.

Individual conditions reflecting different aspects of cancer growth may be investigated separately in the custom built cancer model, and/or may be combined together. In one embodiment, combinations of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50 or more conditions reflecting or simulating different aspects of cancer growth / conditions are investigated in the custom built cancer model. In one embodiment, individual conditions and, in addition, combinations of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50 or more of the conditions reflecting or simulating different aspects of cancer growth / conditions are investigated in the custom built cancer model. All values presented in the foregoing list can also be the upper or lower limit of ranges, that are intended to be a part of this invention, *e.g.*, between 1 and 5, 1 and 10, 1 and 20, 1 and 30, 2 and 5, 2 and 10, 5 and 10, 1 and 20, 5 and 20, 10 and 20, 10 and 25, 10 and 30 or 10 and 50 different conditions.

Listed herein below are a few exemplary combinations of conditions that can be used to treat cells. Other combinations can be readily formulated depending on the specific interrogative biological assessment that is being conducted.

1. Media only
2. 50 μ M CTL Coenzyme Q10 (CoQ10)
3. 100 μ M CTL Coenzyme Q10
4. 12.5 mM Lactic Acid
5. 12.5 mM Lactic Acid + 50 μ M CTL Coenzyme Q10
6. 12.5 mM Lactic Acid + 100 μ M CTL Coenzyme Q10
7. Hypoxia
8. Hypoxia + 50 μ M CTL Coenzyme Q10
9. Hypoxia + 100 μ M CTL Coenzyme Q10
10. Hypoxia + 12.5 mM Lactic Acid
11. Hypoxia + 12.5 mM Lactic Acid + 50 μ M CTL Coenzyme Q10
12. Hypoxia + 12.5 mM Lactic Acid + 100 μ M CTL Coenzyme Q10
13. Media + 22 mM Glucose
14. 50 μ M CTL Coenzyme Q10 + 22 mM Glucose
15. 100 μ M CTL Coenzyme Q10 + 22 mM Glucose

16. 12.5 mM Lactic Acid + 22 mM Glucose
17. 12.5 mM Lactic Acid + 22 mM Glucose + 50 μ M CTL Coenzyme Q10
18. 12.5 mM Lactic Acid + 22 mM Glucose +100 μ M CTL Coenzyme Q10
19. Hypoxia + 22 mM Glucose
20. Hypoxia + 22 mM Glucose + 50 μ M CTL Coenzyme Q10
21. Hypoxia + 22 mM Glucose + 100 μ M CTL Coenzyme Q10
22. Hypoxia +12.5 mM Lactic Acid + 22 mM Glucose
23. Hypoxia +12.5 mM Lactic Acid + 22 mM Glucose + 50 μ M CTL Coenzyme Q10
24. Hypoxia + 12.5 mM Lactic Acid + 22 mM Glucose +100 μ M CTL Coenzyme Q10

As a control one or more normal cell lines (e.g., THLE2 and HDFa) are cultured under similar conditions in order to identify cancer unique proteins or pathways (see below). The control may be the comparison cell model described above.

Multiple cancer cells of the same or different origin (for example, cancer lines PaCa2, HepG2, PC3 and MCF7), as opposed to a single cancer cell type, may be included in the cancer model. In certain situations, cross talk or ECS experiments between different cancer cells (e.g., HepG2 and PaCa2) may be conducted for several inter-related purposes.

In some embodiments that involve cross talk, experiments conducted on the cell models are designed to determine modulation of cellular state or function of one cell system or population (e.g., Hepatocarcinoma cell HepG2) by another cell system or population (e.g., Pancreatic cancer PaCa2) under defined treatment conditions (e.g., hyperglycemia, hypoxia (ischemia)). According to a typical setting, a first cell system / population is contacted by an external stimulus components, such as a candidate molecule (e.g., a small drug molecule, a protein) or a candidate condition (e.g., hypoxia, high glucose environment). In response, the first cell system / population changes its transcriptome, proteome, metabolome, and/or interactome, leading to changes that can be readily detected both inside and outside the cell. For example, changes in transcriptome can be measured by the transcription level of a plurality of target mRNAs; changes in proteome can be measured by the expression level of a plurality of target

proteins; and changes in metabolome can be measured by the level of a plurality of target metabolites by assays designed specifically for given metabolites. Alternatively, the above referenced changes in metabolome and/or proteome, at least with respect to certain secreted metabolites or proteins, can also be measured by their effects on the second cell system / population, including the modulation of the transcriptome, proteome, metabolome, and interactome of the second cell system / population. Therefore, the experiments can be used to identify the effects of the molecule(s) of interest secreted by the first cell system / population on a second cell system / population under different treatment conditions. The experiments can also be used to identify any proteins that are modulated as a result of signaling from the first cell system (in response to the external stimulus component treatment) to another cell system, by, for example, differential screening of proteomics. The same experimental setting can also be adapted for a reverse setting, such that reciprocal effects between the two cell systems can also be assessed. In general, for this type of experiment, the choice of cell line pairs is largely based on the factors such as origin, disease state and cellular function.

Although two-cell systems are typically involved in this type of experimental setting, similar experiments can also be designed for more than two cell systems by, for example, immobilizing each distinct cell system on a separate solid support.

Once the custom model is built, one or more “perturbations” may be applied to the system, such as genetic variation from patient to patient, or with / without treatment by certain drugs or pro-drugs. *See* Figure 15D. The effects of such perturbations to the system, including the effect on disease related cancer cells, and disease related normal control cells, can be measured using various art-recognized or proprietary means, as described in section III.B below.

In an exemplary experiment, cancer lines PaCa2, HepG2, PC3 and MCF7, and normal cell lines THLE2 and HDFa, are conditioned in each of hyperglycemia, hypoxia, and lactic acid-rich conditions, as well as in all combinations of two or three of these conditions, and in addition with or without an environmental perturbation, specifically treatment by CoenzymeQ10.

The custom built cell model may be established and used throughout the steps of the Platform Technology of the invention to ultimately identify a causal relationship unique in the biological system, by carrying out the steps described herein. It will be understood by the skilled artisan, however, that a custom built cell model that is used to

generate an initial, “first generation” consensus causal relationship network for a biological process can continually evolve or expand over time, e.g., by the introduction of additional cancer or normal cell lines and/or additional cancer conditions. Additional data from the evolved cell model, i.e., data from the newly added portion(s) of the cell model, can be collected. The new data collected from an expanded or evolved cell model, i.e., from newly added portion(s) of the cell model, can then be introduced to the data sets previously used to generate the “first generation” consensus causal relationship network in order to generate a more robust “second generation” consensus causal relationship network. New causal relationships unique to the biological system can then be identified from the “second generation” consensus causal relationship network. In this way, the evolution of the cell model provides an evolution of the consensus causal relationship networks, thereby providing new and/or more reliable insights into the modulators of the biological system.

Additional examples of custom built cell models are described in detail herein.

B. Data Collection

In general, two types of data may be collected from any custom built model systems. One type of data (e.g., the first set of data, the third set of data) usually relates to the level of certain macromolecules, such as DNA, RNA, protein, lipid, etc. An exemplary data set in this category is proteomic data (e.g., qualitative and quantitative data concerning the expression of all or substantially all measurable proteins from a sample). The other type of data is generally functional data (e.g., the second set of data, the fourth set of data) that reflects the phenotypic changes resulting from the changes in the first type of data..

With respect to the first type of data, in some example embodiments, quantitative polymerase chain reaction (qPCR) and proteomics are performed to profile changes in cellular mRNA and protein expression by quantitative polymerase chain reaction (qPCR) and proteomics. Total RNA can be isolated using a commercial RNA isolation kit. Following cDNA synthesis, specific commercially available qPCR arrays (e.g., those from SA Biosciences) for disease area or cellular processes such as angiogenesis, apoptosis, and diabetes, may be employed to profile a predetermined set of genes by following a manufacturer’s instructions. For example, the Biorad cfx-384 amplification

system can be used for all transcriptional profiling experiments. Following data collection (Ct), the final fold change over control can be determined using the δ Ct method as outlined in manufacturer's protocol. Proteomic sample analysis can be performed as described in subsequent sections.

The subject method may employ large-scale high-throughput quantitative proteomic analysis of hundreds of samples of similar character, and provides the data necessary for identifying the cellular output differentials.

There are numerous art-recognized technologies suitable for this purpose. An exemplary technique, iTRAQ analysis in combination with mass spectrometry, is briefly described below.

The quantitative proteomics approach is based on stable isotope labeling with the 8-plex iTRAQ reagent and 2D-LC MALDI MS/MS for peptide identification and quantification. Quantification with this technique is relative: peptides and proteins are assigned abundance ratios relative to a reference sample. Common reference samples in multiple iTRAQ experiments facilitate the comparison of samples across multiple iTRAQ experiments.

For example, to implement this analysis scheme, six primary samples and two control pool samples can be combined into one 8-plex iTRAQ mix according to the manufacturer's suggestions. This mixture of eight samples then can be fractionated by two-dimensional liquid chromatography; strong cation exchange (SCX) in the first dimension, and reversed-phase HPLC in the second dimension, then can be subjected to mass spectrometric analysis.

A brief overview of exemplary laboratory procedures that can be employed is provided herein.

Protein extraction: Cells can be lysed with 8 M urea lysis buffer with protease inhibitors (Thermo Scientific Halt Protease inhibitor EDTA-free) and incubate on ice for 30 minutes with vortex for 5 seconds every 10 minutes. Lysis can be completed by ultrasonication in 5 seconds pulse. Cell lysates can be centrifuged at 14000 x g for 15 minutes (4 °C) to remove cellular debris. Bradford assay can be performed to determine the protein concentration. 100ug protein from each samples can be reduced (10mM Dithiothreitol (DTT), 55 °C, 1 h), alkylated (25 mM iodoacetamide, room temperature,

30 minutes) and digested with Trypsin (1:25 w/w, 200 mM triethylammonium bicarbonate (TEAB), 37 °C, 16 h).

Secretome sample preparation: 1) In one embodiment, the cells can be cultured in serum free medium: Conditioned media can be concentrated by freeze dryer, reduced (10mM Dithiothreitol (DTT), 55 °C, 1 h), alkylated (25 mM iodoacetamide, at room temperature, incubate for 30 minutes), and then desalted by acetone precipitation. Equal amount of proteins from the concentrated conditioned media can be digested with Trypsin (1:25 w/w, 200 mM triethylammonium bicarbonate (TEAB), 37 °C, 16 h).

In one embodiment, the cells can be cultured in serum containing medium: The volume of the medium can be reduced using 3k MWCO Vivaspins columns (GE Healthcare Life Sciences), then can be reconstituted with 1xPBS (Invitrogen). Serum albumin can be depleted from all samples using AlbuVoid column (Biotech Support Group, LLC) following the manufacturer's instructions with the modifications of buffer-exchange to optimize for condition medium application.

iTRAQ 8 Plex Labeling: Aliquot from each tryptic digest in each experimental set can be pooled together to create the pooled control sample. Equal aliquots from each sample and the pooled control sample can be labeled by iTRAQ 8 Plex reagents according to the manufacturer's protocols (AB Sciex). The reactions can be combined, vacuumed to dryness, re-suspended by adding 0.1% formic acid, and analyzed by LC-MS/MS.

2D-NanoLC-MS/MS: All labeled peptides mixtures can be separated by online 2D-nanoLC and analysed by electrospray tandem mass spectrometry. The experiments can be carried out on an Eksigent 2D NanoLC Ultra system connected to an LTQ Orbitrap Velos mass spectrometer equipped with a nanoelectrospray ion source (Thermo Electron, Bremen, Germany).

The peptides mixtures can be injected into a 5 cm SCX column (300µm ID, 5µm, PolySULFOETHYL Aspartamide column from PolyLC, Columbia, MD) with a flow of 4 µL / min and eluted in 10 ion exchange elution segments into a C18 trap column (2.5 cm, 100µm ID, 5µm, 300 Å ProteoPep II from New Objective, Woburn, MA) and washed for 5 min with H₂O/0.1%FA. The separation then can be further carried out at 300 nL/min using a gradient of 2-45% B (H₂O /0.1%FA (solvent A) and ACN /0.1%FA (solvent B)) for 120 minutes on a 15 cm fused silica column (75µm ID, 5µm, 300 Å ProteoPep II from New Objective, Woburn, MA).

Full scan MS spectra (m/z 300-2000) can be acquired in the Orbitrap with resolution of 30,000. The most intense ions (up to 10) can be sequentially isolated for fragmentation using High energy C-trap Dissociation (HCD) and dynamically exclude for 30 seconds. HCD can be conducted with an isolation width of 1.2 Da. The resulting fragment ions can be scanned in the orbitrap with resolution of 7500. The LTQ Orbitrap Velos can be controlled by Xcalibur 2.1 with foundation 1.0.1.

Peptides/proteins identification and quantification: Peptides and proteins can be identified by automated database searching using Proteome Discoverer software (Thermo Electron) with Mascot search engine against SwissProt database. Search parameters can include 10 ppm for MS tolerance, 0.02 Da for MS2 tolerance, and full trypsin digestion allowing for up to 2 missed cleavages. Carbamidomethylation (C) can be set as the fixed modification. Oxidation (M), TMT6, and deamidation (NQ) can be set as dynamic modifications. Peptides and protein identifications can be filtered with Mascot Significant Threshold ($p < 0.05$). The filters can be allowed a 99% confidence level of protein identification (1% FDA).

The Proteome Discoverer software can apply correction factors on the reporter ions, and can reject all quantitation values if not all quantitation channels are present. Relative protein quantitation can be achieved by normalization at the mean intensity.

With respect to the second type of data, in some exemplary embodiments, bioenergetics profiling of cancer and normal models may employ the Seahorse™ XF24 analyzer to enable the understanding of glycolysis and oxidative phosphorylation components.

Specifically, cells can be plated on Seahorse culture plates at optimal densities. These cells can be plated in 100 μ l of media or treatment and left in a 37°C incubator with 5% CO₂. Two hours later, when the cells are adhered to the 24 well plate, an additional 150 μ l of either media or treatment solution can be added and the plates can be left in the culture incubator overnight. This two step seeding procedure allows for even distribution of cells in the culture plate. Seahorse cartridges that contain the oxygen and pH sensor can be hydrated overnight in the calibrating fluid in a non-CO₂ incubator at 37°C. Three mitochondrial drugs are typically loaded onto three ports in the cartridge. Oligomycin, a complex III inhibitor, FCCP, an uncoupler and Rotenone, a complex I inhibitor can be loaded into ports A, B and C respectively of the cartridge. All stock drugs can be prepared at a 10x concentration in an unbuffered DMEM media.

The cartridges can be first incubated with the mitochondrial compounds in a non-CO₂ incubator for about 15 minutes prior to the assay. Seahorse culture plates can be washed in DMEM based unbuffered media that contains glucose at a concentration found in the normal growth media. The cells can be layered with 630 ul of the unbuffered media and can be equilibrated in a non-CO₂ incubator before placing in the Seahorse instrument with a precalibrated cartridge. The instrument can be run for three-four loops with a mix, wait and measure cycle for get a baseline, before injection of drugs through the port is initiated. There can be two loops before the next drug is introduced.

OCR (Oxygen consumption rate) and ECAR (Extracellular Acidification Rate) can be recorded by the electrodes in a 7 µl chamber and can be created with the cartridge pushing against the seahorse culture plate.

C. Data Integration and *in silico* Model Generation

Once relevant data sets have been obtained, integration of data sets and generation of computer-implemented statistical models may be performed using an AI-based informatics system or platform (e.g, the REFSTM platform). For example, an exemplary AI-based system may produce simulation-based networks of protein associations as key drivers of metabolic end points (ECAR/OCR). *See* Figure 15. Some background details regarding the REFSTM system may be found in Xing et al., “Causal Modeling Using Network Ensemble Simulations of Genetic and Gene Expression Data Predicts Genes Involved in Rheumatoid Arthritis,” *PLoS Computational Biology*, vol. 7, issue. 3, 1-19 (March 2011) (e100105) and U.S. Patent 7,512,497 to Periwai, the entire contents of each of which is expressly incorporated herein by reference in its entirety. In essence, as described earlier, the REFSTM system is an AI-based system that employs mathematical algorithms to establish causal relationships among the input variables (e.g., protein expression levels, mRNA expression levels, and the corresponding functional data, such as the OCR / ECAR values measured on Seahorse culture plates). This process is based only on the input data alone, without taking into consideration prior existing knowledge about any potential, established, and/or verified biological relationships.

In particular, a significant advantage of the platform of the invention is that the AI-based system is based on the data sets obtained from the cell model, without

resorting to or taking into consideration any existing knowledge in the art concerning the biological process. Further, preferably, no data points are statistically or artificially cut-off and, instead, all obtained data is fed into the AI-system for determining protein associations. Accordingly, the resulting statistical models generated from the platform are unbiased, since they do not take into consideration any known biological relationships.

Specifically, data from the proteomics and ECAR/OCR can be input into the AI-based information system, which builds statistical models based on data associations, as described above. Simulation-based networks of protein associations are then derived for each disease versus normal scenario, including treatments and conditions using the following methods.

A detailed description of an exemplary process for building the generated (e.g., optimized or evolved) networks appears below with respect to Figure 16. As described above, data from the proteomics and functional cell data is input into the AI-based system (step 210). The input data, which may be raw data or minimally processed data, is pre-processed, which may include normalization (e.g., using a quantile function or internal standards) (step 212). The pre-processing may also include imputing missing data values (e.g., by using the K-nearest neighbor (K-NN) algorithm) (step 212).

The pre-processed data is used to construct a network fragment library (step 214). The network fragments define quantitative, continuous relationships among all possible small sets (e.g., 2-3 member sets or 2-4 member sets) of measured variables (input data). The relationships between the variables in a fragment may be linear, logistic, multinomial, dominant or recessive homozygous, etc. The relationship in each fragment is assigned a Bayesian probabilistic score that reflect how likely the candidate relationship is given the input data, and also penalizes the relationship for its mathematical complexity. By scoring all of the possible pairwise and three-way relationships (and in some embodiments also four-way relationships) inferred from the input data, the most likely fragments in the library can be identified (the likely fragments). Quantitative parameters of the relationship are also computed based on the input data and stored for each fragment. Various model types may be used in fragment enumeration including but not limited to linear regression, logistic regression, (Analysis of Variance) ANOVA models, (Analysis of Covariance) ANCOVA models, non-linear/polynomial regression models and even non-parametric regression. The prior

assumptions on model parameters may assume Gull distributions or Bayesian Information Criterion (BIC) penalties related to the number of parameters used in the model. In a network inference process, each network in an ensemble of initial trial networks is constructed from a subset of fragments in the fragment library. Each initial trial network in the ensemble of initial trial networks is constructed with a different subset of the fragments from the fragment library (step 216).

An overview of the mathematical representations underlying the Bayesian networks and network fragments, which is based on Xing et al., “Causal Modeling Using Network Ensemble Simulations of Genetic and Gene Expression Data Predicts Genes Involved in Rheumatoid Arthritis,” *PLoS Computational Biology*, vol. 7, issue. 3, 1-19 (March 2011) (e100105), is presented below.

A multivariate system with random variables $X_1, \dots, X_n$ may be characterized by a multivariate probability distribution function $P(X_1, \dots, X_n; \Theta)$, that includes a large number of parameters Θ . The multivariate probability distribution function may be factorized and represented by a product of local conditional probability distributions:

$$P(X_1, \dots, X_n; \Theta) = \prod_{i=1}^n P_i(X_i | Y_{j_1}, \dots, Y_{j_{K_i}}; \Theta_i)$$

in which each variable X_i is independent from its non-descendent variables given its K_i parent variables, which are $Y_{j_1}, \dots, Y_{j_{K_i}}$. After factorization, each local probability distribution has its own parameters Θ_i .

The multivariate probability distribution function may be factorized in different ways with each particular factorization and corresponding parameters being a distinct probabilistic model. Each particular factorization (model) can be represented by a Directed Acyclic Graph (DAG) having a vertex for each variable X_i and directed edges between vertices representing dependences between variables in the local conditional distributions $P_i(X_i | Y_{j_1}, \dots, Y_{j_{K_i}})$. Subgraphs of a DAG, each including a vertex and associated directed edges are network fragments.

A model is evolved or optimized by determining the most likely factorization and the most likely parameters given the input data. This may be described as “learning

a Bayesian network,” or, in other words, given a training set of input data, finding a network that best matches the input data. This is accomplished by using a scoring function that evaluates each network with respect to the input data.

A Bayesian framework is used to determine the likelihood of a factorization given the input data. Bayes Law states that the posterior probability, $P(D|M)$, of a model M , given data D is proportional to the product of the posterior probability of the data given the model assumptions, $P(D|M)$, multiplied by the prior probability of the model, $P(M)$, assuming that the probability of the data, $P(D)$, is constant across models. This is expressed in the following equation:

$$P(M|D) = \frac{P(D|M) * P(M)}{P(D)}.$$

The posterior probability of the data assuming the model is the integral of the data likelihood over the prior distribution of parameters:

$$P(D|M) = \int P(D|M(\Theta))P(\Theta|M)d\Theta.$$

Assuming all models are equally likely (i.e., that $P(M)$ is a constant), the posterior probability of model M given the data D may be factored into the product of integrals over parameters for each local network fragment M_i as follows:

$$P(M|D) = \prod_{i=1}^n \int P_i(X_i | Y_{j_1}, \dots, Y_{j_{K_i}}; \Theta_i).$$

Note that in the equation above, a leading constant term has been omitted. In some embodiments, a Bayesian Information Criterion (BIC), which takes a negative logarithm of the posterior probability of the model $P(D|M)$ may be used to “Score” each model as follows:

$$S_{tot}(M) = -\log P(M|D) = \sum_{i=1}^n S(M_i),$$

where the total score S_{tot} for a model M is a sum of the local scores S_i for each local network fragment. The BIC further gives an expression for determining a score each individual network fragment:

$$S(M_i) \approx S_{BIC}(M_i) = S_{MLE}(M_i) + \frac{\kappa(M_i)}{2} \log N$$

where $\kappa(M_i)$ is the number of fitting parameter in model M_i and N is the number of samples (data points). $S_{MLE}(M_i)$ is the negative logarithm of the likelihood function for a network fragment, which may be calculated from the functional relationships used for each network fragment. For a BIC score, the lower the score, the more likely a model fits the input data.

The ensemble of trial networks is globally optimized, which may be described as optimizing or evolving the networks (step 218). For example, the trial networks may be evolved and optimized according to a Metropolis Monte Carlo Sampling algorithm. Simulated annealing may be used to optimize or evolve each trial network in the ensemble through local transformations. In an example simulated annealing processes, each trial network is changed by adding a network fragment from the library, by deleted a network fragment from the trial network, by substituting a network fragment or by otherwise changing network topology, and then a new score for the network is calculated. Generally speaking, if the score improves, the change is kept and if the score worsens the change is rejected. A “temperature” parameter allows some local changes which worsen the score to be kept, which aids the optimization process in avoiding some local minima. The “temperature” parameter is decreased over time to allow the optimization/evolution process to converge.

All or part of the network inference process may be conducted in parallel for the trial different networks. Each network may be optimized in parallel on a separate processor and/or on a separate computing device. In some embodiments, the optimization process may be conducted on a supercomputer incorporating hundreds to thousands of processors which operate in parallel. Information may be shared among the optimization processes conducted on parallel processors.

The optimization process may include a network filter that drops any networks from the ensemble that fail to meet a threshold standard for overall score. The dropped network may be replaced by a new initial network. Further any networks that are not “scale free” may be dropped from the ensemble. After the ensemble of networks has been optimized or evolved, the result may be termed an ensemble of generated cell

model networks, which may be collectively referred to as the generated consensus network.

D. Simulation to Extract Quantitative Relationship Information and for Prediction

Simulation may be used to extract quantitative parameter information regarding each relationship in the generated cell model networks (step 220). For example, the simulation for quantitative information extraction may involve perturbing (increasing or decreasing) each node in the network by 10 fold and calculating the posterior distributions for the other nodes (e.g., proteins) in the models. The endpoints are compared by t-test with the assumption of 100 samples per group and the 0.01 significance cut-off. The t-test statistic is the median of 100 t-tests. Through use of this simulation technique, an AUC (area under the curve) representing the strength of prediction and fold change representing the *in silico* magnitude of a node driving an end point are generated for each relationship in the ensemble of networks.

A relationship quantification module of a local computer system may be employed to direct the AI-based system to perform the perturbations and to extract the AUC information and fold information. The extracted quantitative information may include fold change and AUC for each edge connecting a parent node to a child node. In some embodiments, a custom-built R program may be used to extract the quantitative information.

In some embodiments, the ensemble of generated cell model networks can be used through simulation to predict responses to changes in conditions, which may be later verified through wet-lab cell-based, or animal-based, experiments.

The output of the AI-based system may be quantitative relationship parameters and/or other simulation predictions (222).

E. Generation of Differential (Delta) Networks

A differential network creation module may be used to generate differential (delta) networks between generated cell model networks and generated comparison cell model networks. As described above, in some embodiments, the differential network compares all of the quantitative parameters of the relationships in the generated cell model networks and the generated comparison cell model network. The quantitative parameters for each relationship in the differential network are based on the comparison. In some embodiments, a differential may be performed between various differential networks, which may be termed a delta-delta network. An example of a delta-delta network is described below with respect to Figure 26 in the Examples section. The differential network creation module may be a program or script written in PERL.

F. Visualization of Networks

The relationship values for the ensemble of networks and for the differential networks may be visualized using a network visualization program (e.g., Cytoscape open source platform for complex network analysis and visualization from the Cytoscape consortium). In the visual depictions of the networks, the thickness of each edge (e.g., each line connecting the proteins) represents the strength of fold change. The edges are also directional indicating causality, and each edge has an associated prediction confidence level.

G. Exemplary Computer System

Figure 17 schematically depicts an exemplary computer system/environment that may be employed in some embodiments for communicating with the AI-based informatics system, for generating differential networks, for visualizing networks, for saving and storing data, and/or for interacting with a user. As explained above, calculations for an AI-based informatics system may be performed on a separate supercomputer with hundreds or thousands of parallel processors that interacts, directly or indirectly, with the exemplary computer system. The environment includes a

computing device 100 with associated peripheral devices. Computing device 100 is programmable to implement executable code 150 for performing various methods, or portions of methods, taught herein. Computing device 100 includes a storage device 116, such as a hard-drive, CD-ROM, or other non-transitory computer readable media. Storage device 116 may store an operating system 118 and other related software. Computing device 100 may further include memory 106. Memory 106 may comprise a computer system memory or random access memory, such as DRAM, SRAM, EDO RAM, etc. Memory 106 may comprise other types of memory as well, or combinations thereof. Computing device 100 may store, in storage device 116 and/or memory 106, instructions for implementing and processing each portion of the executable code 150.

The executable code 150 may include code for communicating with the AI-based informatics system 190, for generating differential networks (e.g., a differential network creation module), for extracting quantitative relationship information from the AI-based informatics system (e.g., a relationship quantification module) and for visualizing networks (e.g., Cytoscape).

In some embodiments, the computing device 100 may communicate directly or indirectly with the AI-based informatics system 190 (e.g., a system for executing REFS). For example, the computing device 100 may communicate with the AI-based informatics system 190 by transferring data files (e.g., data frames) to the AI-based informatics system 190 through a network. Further, the computing device 100 may have executable code 150 that provides an interface and instructions to the AI-based informatics system 190.

In some embodiments, the computing device 100 may communicate directly or indirectly with one or more experimental systems 180 that provide data for the input data set. Experimental systems 180 for generating data may include systems for mass spectrometry based proteomics, microarray gene expression, qPCR gene expression, mass spectrometry based metabolomics, and mass spectrometry based lipidomics, SNP microarrays, a panel of functional assays, and other in-vitro biology platforms and technologies.

Computing device 100 also includes processor 102, and may include one or more additional processor(s) 102', for executing software stored in the memory 106 and other programs for controlling system hardware, peripheral devices and/or peripheral

hardware. Processor 102 and processor(s) 102' each can be a single core processor or multiple core (104 and 104') processor. Virtualization may be employed in computing device 100 so that infrastructure and resources in the computing device can be shared dynamically. Virtualized processors may also be used with executable code 150 and other software in storage device 116. A virtual machine 114 may be provided to handle a process running on multiple processors so that the process appears to be using only one computing resource rather than multiple. Multiple virtual machines can also be used with one processor.

A user may interact with computing device 100 through a visual display device 122, such as a computer monitor, which may display a user interface 124 or any other interface. The user interface 124 of the display device 122 may be used to display raw data, visual representations of networks, etc. The visual display device 122 may also display other aspects or elements of exemplary embodiments (e.g., an icon for storage device 116). Computing device 100 may include other I/O devices such a keyboard or a multi-point touch interface (e.g., a touchscreen) 108 and a pointing device 110, (e.g., a mouse, trackball and/or trackpad) for receiving input from a user. The keyboard 108 and the pointing device 110 may be connected to the visual display device 122 and/or to the computing device 100 via a wired and/or a wireless connection.

Computing device 100 may include a network interface 112 to interface with a network device 126 via a Local Area Network (LAN), Wide Area Network (WAN) or the Internet through a variety of connections including, but not limited to, standard telephone lines, LAN or WAN links (e.g., 802.11, T1, T3, 56kb, X.25), broadband connections (e.g., ISDN, Frame Relay, ATM), wireless connections, controller area network (CAN), or some combination of any or all of the above. The network interface 112 may comprise a built-in network adapter, network interface card, PCMCIA network card, card bus network adapter, wireless network adapter, USB network adapter, modem or any other device suitable for enabling computing device 100 to interface with any type of network capable of communication and performing the operations described herein.

Moreover, computing device 100 may be any computer system such as a workstation, desktop computer, server, laptop, handheld computer or other form of computing or telecommunications device that is capable of communication and that has

sufficient processor power and memory capacity to perform the operations described herein.

Computing device 100 can be running any operating system 118 such as any of the versions of the MICROSOFT WINDOWS operating systems, the different releases of the Unix and Linux operating systems, any version of the MACOS for Macintosh computers, any embedded operating system, any real-time operating system, any open source operating system, any proprietary operating system, any operating systems for mobile computing devices, or any other operating system capable of running on the computing device and performing the operations described herein. The operating system may be running in native mode or emulated mode.

IV. Models for a Biological System and Uses Therefor

A. Establishing a Model for a Biological System

Virtually all biological systems or processes involve complicated interactions among different cell types and/or organ systems. Perturbation of critical functions in one cell type or organ may lead to secondary effects on other interacting cells types and organs, and such downstream changes may in turn feedback to the initial changes and cause further complications. Therefore, it is beneficial to dissect a given biological system or process to its components, such as interaction between pairs of cell types or organs, and systemically probe the interactions between these components in order to gain a more complete, global view of the biological system or process.

Accordingly, the present invention provides cell models for biological systems. To this end, Applicants have built cell models for several exemplary biological systems which have been employed in the subject discovery Platform Technology. Applicants have conducted experiments with the cell models using the subject discovery Platform Technology to generate consensus causal relationship networks, including causal relationships unique in the biological system, and thereby identify “modulators” or critical molecular “drivers” important for the particular biological systems or processes.

One significant advantage of the Platform Technology and its components, e.g., the custom built cell models and data sets obtained from the cell models, is that an initial, “first generation” consensus causal relationship network generated for a biological system or process can continually evolve or expand over time, e.g., by the introduction of additional cell lines/types and/or additional conditions. Additional data from the evolved cell model, i.e., data from the newly added portion(s) of the cell model, can be collected. The new data collected from an expanded or evolved cell model, i.e., from newly added portion(s) of the cell model, can then be introduced to the data sets previously used to generate the “first generation” consensus causal relationship network in order to generate a more robust “second generation” consensus causal relationship network. New causal relationships unique to the biological system can then be identified from the “second generation” consensus causal relationship network. In this way, the evolution of the cell model provides an evolution of the consensus causal relationship networks, thereby providing new and/or more reliable insights into the modulators of the biological system. In this way, both the cell models, the data sets from the cell models, and the causal relationship networks generated from the cell models by using the Platform Technology methods can constantly evolve and build upon previous knowledge obtained from the Platform Technology.

Accordingly, the invention provides consensus causal relationship networks generated from the cell models employed in the Platform Technology. These consensus causal relationship networks may be first generation consensus causal relationship networks, or may be multiple generation consensus causal relationship networks, e.g., 2nd, 3rd, 4th, 5th, 6th, 7th, 8th, 9th, 10th, 11th, 12th, 13th, 14th, 15th, 16th, 17th, 18th, 19th, 20th or greater generation consensus causal relationship networks. Further, the invention provides simulated consensus causal relationship networks generated from the cell models employed in the Platform Technology. These simulated consensus causal relationship networks may be first generation simulated consensus causal relationship networks, or may be multiple generation simulated consensus causal relationship networks, e.g., 2nd, 3rd, 4th, 5th, 6th, 7th, 8th, 9th, 10th, 11th, 12th, 13th, 14th, 15th, 16th, 17th, 18th, 19th, 20th or greater simulated generation consensus causal relationship networks. The invention further provides delta networks and delta-delta networks generated from any of the consensus causal relationship networks of the invention.

A custom built cell model for a biological system or process comprises one or more cells associated with the biological system. The model for a biological system/process may be established to simulate an environment of biological system, e.g., environment of a cancer cell *in vivo*, by creating conditions (e.g., cell culture conditions) that mimic a characteristic aspect of the biological system or process.

Multiple cells of the same or different origin, as opposed to a single cell type, may be included in the cell model. In one embodiment, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 50 or more different cell lines or cell types are included in the cell model. In one embodiment, the cells are all of the same type, e.g., all breast cancer cells or plant cells, but are different established cell lines, e.g., different established cell lines of breast cancer cells or plant cells. All values presented in the foregoing list can also be the upper or lower limit of ranges, that are intended to be a part of this invention, e.g., between 1 and 5, 1 and 10, 2 and 5, or 5 and 15 different cell lines or cell types.

Examples of cell types that may be included in the cell models of the invention include, without limitation, human cells, animal cells, mammalian cells, plant cells, yeast, bacteria, or fungi. In one embodiment, cells of the cell model can include diseased cells, such as cancer cells or bacterially or virally infected cells. In one embodiment, cells of the cell model can include disease-associated cells, such as cells involved in diabetes, obesity or cardiovascular disease state, e.g., aortic smooth muscle cells or hepatocytes. The skilled person would recognize those cells that are involved in or associated with a particular biological state/process, e.g., disease state/process, and any such cells may be included in a cell model of the invention.

Cell models of the invention may include one or more “control cells.” In one embodiment, a control cell may be an untreated or unperturbed cell. In another embodiment, a “control cell” may be a normal, e.g., non-diseased, cell. In one embodiment, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50 or more different control cells are included in the cell model. All values presented in the foregoing list can also be the upper or lower limit of ranges, that are intended to be a part of this invention, e.g., between 1 and 5, 1 and 10, 2 and 5, or 5 and 15 different control cell lines or control cell types. In one embodiment, the control cells are all of the same type but are different established cell lines of that cell type. In

one embodiment, as a control, one or more normal, e.g., non-diseased, cell lines are cultured under similar conditions, and/or are exposed to the same perturbation, as the primary cells of the cell model in order to identify proteins or pathways unique to the biological state or process.

A custom cell model of the invention may also comprise conditions that mimic a characteristic aspect of the biological state or process. For example, cell culture conditions may be selected that closely approximating the conditions of a cancer cell in a tumor environment *in vivo*, or of an aortic smooth muscle cell of a patient suffering from cardiovascular disease. In some instances, the conditions are stress conditions. Various conditions / stressors may be employed in the cell models of the invention. In one embodiment, these stressors / conditions may constitute the “perturbation”, e.g., external stimulus, for the cell systems. One exemplary stress condition is hypoxia, a condition typically found, for example, within solid tumors. Hypoxia can be induced using art-recognized methods. For example, hypoxia can be induced by placing cell systems in a Modular Incubator Chamber (MIC-101, Billups-Rothenberg Inc. Del Mar, CA), which can be flooded with an industrial gas mix containing 5% CO₂, 2% O₂ and 93% nitrogen. Effects can be measured after a pre-determined period, e.g., at 24 hours after hypoxia treatment, with and without additional external stimulus components (e.g., CoQ10 at 0, 50, or 100 μM). Likewise, lactic acid treatment mimics a cellular environment where glycolysis activity is high. Lactic acid induced stress can be investigated at a final lactic acid concentration of about 12.5 mM at a pre-determined time, e.g., at 24 hours, with or without additional external stimulus components (e.g., CoQ10 at 0, 50, or 100 μM). Hyperglycemia is a condition found in diabetes as well as in cancer. A typical hyperglycemic condition that can be used to treat the subject cells include 10% culture grade glucose added to suitable media to bring up the final concentration of glucose in the media to about 22 mM. Hyperlipidemia is a condition found, for example, in obesity and cardiovascular disease. The hyperlipidemic conditions can be provided by culturing cells in media containing 0.15 mM sodium palmitate. Hyperinsulinemia is a condition found, for example, in diabetes. The hyperinsulinemic conditions may be induced by culturing the cells in media containing 1000 nM insulin.

Individual conditions may be investigated separately in the custom built cell models of the invention, and/or may be combined together. In one embodiment, a combination of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50 or more conditions reflecting or simulating different characteristic aspects of the biological system are investigated in the custom built cell model. In one embodiment, individual conditions and, in addition, combinations of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50 or more of the conditions reflecting or simulating different characteristic aspects of the biological system are investigated in the custom built cell model. All values presented in the foregoing list can also be the upper or lower limit of ranges, that are intended to be a part of this invention, *e.g.*, between 1 and 5, 1 and 10, 1 and 20, 1 and 30, 2 and 5, 2 and 10, 5 and 10, 1 and 20, 5 and 20, 10 and 20, 10 and 25, 10 and 30 or 10 and 50 different conditions.

Once the custom cell model is built, one or more “perturbations” may be applied to the system, such as genetic variation from patient to patient, or with / without treatment by certain drugs or pro-drugs. *See* Figure 15D. The effects of such perturbations to the cell model system can be measured using various art-recognized or proprietary means, as described in section III.B below.

The custom built cell model may be exposed to a perturbation, *e.g.*, an “environmental perturbation” or “external stimulus component”. The “environmental perturbation” or “external stimulus component” may be endogenous to the cellular environment (*e.g.*, the cellular environment contains some levels of the stimulant, and more of the same is added to increase its level), or may be exogenous to the cellular environment (*e.g.*, the stimulant/perturbation is largely absent from the cellular environment prior to the alteration). The cellular environment may further be altered by secondary changes resulting from adding the environmental perturbation or external stimulus component, since the external stimulus component may change the cellular output of the cell system, including molecules secreted into the cellular environment by the cell system. The environmental perturbation or external stimulus component may include any external physical and/or chemical stimulus that may affect cellular function. This may include any large or small organic or inorganic molecules, natural or synthetic chemicals, temperature shift, pH change, radiation, light (UVA, UVB *etc.*), microwave, sonic wave, electrical current, modulated or unmodulated magnetic fields, *etc.* The

environmental perturbation or external stimulus component may also include an introduced genetic modification or mutation or a vehicle (e.g., vector) that causes a genetic modification / mutation.

(i) Cross-talk cell systems

In certain situations, where interaction between two or more cell systems are desired to be investigated, a “cross-talking cell system” may be formed by, for example, bringing the modified cellular environment of a first cell system into contact with a second cell system to affect the cellular output of the second cell system.

As used herein, “cross-talk cell system” comprises two or more cell systems, in which the cellular environment of at least one cell system comes into contact with a second cell system, such that at least one cellular output in the second cell system is changed or affected. In certain embodiments, the cell systems within the cross-talk cell system may be in direct contact with one another. In other embodiments, none of the cell systems are in direct contact with one another.

For example, in certain embodiments, the cross-talk cell system may be in the form of a transwell, in which a first cell system is growing in an insert and a second cell system is growing in a corresponding well compartment. The two cell systems may be in contact with the same or different media, and may exchange some or all of the media components. External stimulus component added to one cell system may be substantially absorbed by one cell system and/or degraded before it has a chance to diffuse to the other cell system. Alternatively, the external stimulus component may eventually approach or reach an equilibrium within the two cell systems.

In certain embodiments, the cross-talk cell system may adopt the form of separately cultured cell systems, where each cell system may have its own medium and/or culture conditions (temperature, CO₂ content, pH, *etc.*), or similar or identical culture conditions. The two cell systems may come into contact by, for example, taking the conditioned medium from one cell system and bringing it into contact with another cell system. Direct cell-cell contacts between the two cell systems can also be effected if desired. For example, the cells of the two cell systems may be co-cultured at any point if desired, and the co-cultured cell systems can later be separated by, for example,

FACS sorting when cells in at least one cell system have a sortable marker or label (such as a stably expressed fluorescent marker protein GFP).

Similarly, in certain embodiments, the cross-talk cell system may simply be a co-culture. Selective treatment of cells in one cell system can be effected by first treating the cells in that cell system, before culturing the treated cells in co-culture with cells in another cell system. The co-culture cross-talk cell system setting may be helpful when it is desired to study, for example, effects on a second cell system caused by cell surface changes in a first cell system, after stimulation of the first cell system by an external stimulus component.

The cross-talk cell system of the invention is particularly suitable for exploring the effect of certain pre-determined external stimulus component on the cellular output of one or both cell systems. The primary effect of such a stimulus on the first cell system (with which the stimulus directly contact) may be determined by comparing cellular outputs (*e.g.*, protein expression level) before and after the first cell system's contact with the external stimulus, which, as used herein, may be referred to as "(significant) cellular output differentials." The secondary effect of such a stimulus on the second cell system, which is mediated through the modified cellular environment of the first cell system (such as its secretome), can also be similarly measured. There, a comparison in, for example, proteome of the second cell system can be made between the proteome of the second cell system *with* the external stimulus treatment on the first cell system, and the proteome of the second cell system *without* the external stimulus treatment on the first cell system. Any significant changes observed (in proteome or any other cellular outputs of interest) may be referred to as a "significant cellular cross-talk differential."

In making cellular output measurements (such as protein expression), either absolute expression amount or relative expression level may be used. For example, to determine the relative protein expression level of a second cell system, the amount of any given protein in the second cell system, with or without the external stimulus to the first cell system, may be compared to a suitable control cell line and mixture of cell lines and given a fold-increase or fold-decrease value. A pre-determined threshold level for such fold-increase (*e.g.*, at least 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 75 or 100 or more fold increase) or fold-

decrease (*e.g.*, at least a decrease to 0.95, 0.9, 0.8, 0.75, 0.7, 0.6, 0.5, 0.45, 0.4, 0.35, 0.3, 0.25, 0.2, 0.15, 0.1 or 0.05 fold, or 90%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10% or 5% or less) may be used to select significant cellular cross-talk differentials. All values presented in the foregoing list can also be the upper or lower limit of ranges, *e.g.*, between 1.5 and 5 fold, between 2 and 10 fold, between 1 and 2 fold, or between 0.9 and 0.7 fold, that are intended to be a part of this invention.

Throughout the present application, all values presented in a list, *e.g.*, such as those above, can also be the upper or lower limit of ranges that are intended to be a part of this invention.

To illustrate, in one exemplary two-cell system established to imitate aspects of a cardiovascular disease model, a heart smooth muscle cell line (first cell system) may be treated with a hypoxia condition (an external stimulus component), and proteome changes in a kidney cell line (second cell system) resulting from contacting the kidney cells with conditioned medium of the heart smooth muscle may be measured using conventional quantitative mass spectrometry. Significant cellular cross-talking differentials in these kidney cells may be determined, based on comparison with a proper control (*e.g.*, similarly cultured kidney cells contacted with conditioned medium from similarly cultured heart smooth muscle cells not treated with hypoxia conditions).

Not every observed significant cellular cross-talking differentials may be of biological significance. With respect to any given biological system for which the subject interrogative biological assessment is applied, some (or maybe all) of the significant cellular cross-talking differentials may be “determinative” with respect to the specific biological problem at issue, *e.g.*, either responsible for causing a disease condition (a potential target for therapeutic intervention) or is a biomarker for the disease condition (a potential diagnostic or prognostic factor).

Such determinative cross-talking differentials may be selected by an end user of the subject method, or it may be selected by a bioinformatics software program, such as DAVID-enabled comparative pathway analysis program, or the KEGG pathway analysis program. In certain embodiments, more than one bioinformatics software program is

used, and consensus results from two or more bioinformatics software programs are preferred.

As used herein, “differentials” of cellular outputs include differences (*e.g.*, increased or decreased levels) in any one or more parameters of the cellular outputs. For example, in terms of protein expression level, differentials between two cellular outputs, such as the outputs associated with a cell system before and after the treatment by an external stimulus component, can be measured and quantitated by using art-recognized technologies, such as mass-spectrometry based assays (*e.g.*, iTRAQ, 2D-LC-MSMS, *etc.*).

(ii) Cancer Specific Models

An example of a biological system or process is cancer. As any other complicated biological process or system, cancer is a complicated pathological condition characterized by multiple unique aspects. For example, due to its high growth rate, many cancer cells are adapted to grow in hypoxia conditions, have up-regulated glycolysis and reduced oxidative phosphorylation metabolic pathways. As a result, cancer cells may react differently to an environmental perturbation, such as treatment by a potential drug, as compared to the reaction by a normal cell in response to the same treatment. Thus, it would be of interest to decipher cancer’s unique responses to drug treatment as compared to the responses of normal cells. To this end, a custom cancer model may be established to simulate the environment of a cancer cell, *e.g.*, within a tumor *in vivo*, by choosing appropriate cancer cell lines and creating cell culture conditions that mimic a characteristic aspect of the disease state or process. For example, cell culture conditions may be selected that closely approximating the conditions of a cancer cell in a tumor *in vivo*, or to mimic various aspects of cancer growth, by isolating different growth conditions of the cancer cells.

Multiple cancer cells of the same or different origin (for example, cancer lines PaCa2, HepG2, PC3 and MCF7), as opposed to a single cancer cell type, may be included in the cancer model. In one embodiment, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50 or more different cancer cell lines or cancer cell types are included in the cancer model. All values presented in the foregoing list can also be the upper or lower limit of ranges, that are intended to be a part

of this invention, *e.g.*, between 1 and 5, 1 and 10, 2 and 5, or 5 and 15 different cancer cell lines or cell types.

In one embodiment, the cancer cells are all of the same type, *e.g.*, all breast cancer cells, but are different established cell lines, *e.g.*, different established cell lines of breast cancer.

Examples of cancer cell types that may be included in the cancer model include, without limitation, lung cancer, breast cancer, prostate cancer, melanoma, squamous cell carcinoma, colorectal cancer, pancreatic cancer, thyroid cancer, endometrial cancer, bladder cancer, kidney cancer, solid tumor, leukemia, non-Hodgkin lymphoma. In one embodiment, a drug-resistant cancer cell may be included in the cancer model. Specific examples of cell lines that may be included in a cancer model include, without limitation, PaCa2, HepG2, PC3 and MCF7 cells. Numerous cancer cell lines are known in the art, and any such cancer cell line may be included in a cancer model of the invention.

Cell models of the invention may include one or more “control cells.” In one embodiment, a control cell may be an untreated or unperturbed cancer cell. In another embodiment, a “control cell” may be a normal, non-cancerous cell. Any one of numerous normal, non-cancerous cell lines may be included in the cell model. In one embodiment, the normal cells are one or more of THLE2 and HDFa cells. In one embodiment, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50 or more different normal cell types are included in the cancer model. All values presented in the foregoing list can also be the upper or lower limit of ranges, that are intended to be a part of this invention, *e.g.*, between 1 and 5, 1 and 10, 2 and 5, or 5 and 15 different normal cell lines or cell types. In one embodiment, the normal cells are all of the same type, *e.g.*, all healthy epithelial or breast cells, but are different established cell lines, *e.g.*, different established cell lines of epithelial or breast cells. In one embodiment, as a control, one or more normal non-cancerous cell lines (*e.g.*, THLE2 and HDFa) are cultured under similar conditions, and/or are exposed to the same perturbation, as the cancer cells of the cell model in order to identify cancer unique proteins or pathways.

A custom cancer model may also comprise cell culture conditions that mimic a characteristic aspect of the cancerous state or process. For example, cell culture conditions may be selected that closely approximating the conditions of a cancer cell in a tumor environment *in vivo*, or to mimic various aspects of cancer growth, by isolating different growth conditions of the cancer cells. In some instances the cell culture conditions are stress conditions.

One such cancer “environment”, or stress condition, is hypoxia, a condition typically found within a solid tumor. Hypoxia can be induced in cells in cells using art-recognized methods. For example, hypoxia can be induced by placing cell systems in a Modular Incubator Chamber (MIC-101, Billups-Rothenberg Inc. Del Mar, CA), which can be flooded with an industrial gas mix containing 5% CO₂, 2% O₂ and 93% nitrogen. Effects can be measured after a pre-determined period, *e.g.*, at 24 hours after hypoxia treatment, with and without additional external stimulus components (*e.g.*, CoQ10 at 0, 50, or 100 μM).

Likewise, lactic acid treatment of cells mimics a cellular environment where glycolysis activity is high, as exists in the tumor environment *in vivo*. Lactic acid induced stress can be investigated at a final lactic acid concentration of about 12.5 mM at a pre-determined time, *e.g.*, at 24 hours, with or without additional external stimulus components (*e.g.*, CoQ10 at 0, 50, or 100 μM).

Hyperglycemia is normally a condition found in diabetes; however, hyperglycemia also to some extent mimics one aspect of cancer growth because many cancer cells rely on glucose as their primary source of energy. Exposing subject cells to a typical hyperglycemic condition may include adding 10% culture grade glucose to suitable media, such that the final concentration of glucose in the media is about 22 mM.

Individual conditions reflecting different aspects of cancer growth may be investigated separately in the custom built cancer model, and/or may be combined together. In one embodiment, combinations of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50 or more conditions reflecting or simulating different aspects of cancer growth / conditions are investigated in the custom built cancer model. In one embodiment, individual conditions and, in addition, combinations of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50 or more of the conditions reflecting or simulating

different aspects of cancer growth / conditions are investigated in the custom built cancer model. All values presented in the foregoing list can also be the upper or lower limit of ranges, that are intended to be a part of this invention, *e.g.*, between 1 and 5, 1 and 10, 1 and 20, 1 and 30, 2 and 5, 2 and 10, 5 and 10, 1 and 20, 5 and 20, 10 and 20, 10 and 25, 10 and 30 or 10 and 50 different conditions.

Once the custom cell model is built, one or more “perturbations” may be applied to the system, such as genetic variation from patient to patient, or with / without treatment by certain drugs or pro-drugs. *See* Figure 15D. The effects of such perturbations to the system, including the effect on disease related cancer cells, and disease related normal control cells, can be measured using various art-recognized or proprietary means, as described in section III.B below.

In an exemplary experiment, cancer lines PaCa2, HepG2, PC3 and MCF7, and normal cell lines THLE2 and HDFa, are conditioned in each of hyperglycemia, hypoxia, and lactic acid-rich conditions, as well as in all combinations of two or three of these conditions, and in addition with or without an environmental perturbation, specifically treatment by Coenzyme Q10. Listed herein below are such exemplary combinations of conditions, with or without a perturbation, Coenzyme Q10 treatment, that can be used to treat the cancer cells and/or control (*e.g.*, normal) cells of the cancer cell model. Other combinations can be readily formulated depending on the specific interrogative biological assessment that is being conducted.

1. Media only
2. 50 μ M CTL Coenzyme Q10
3. 100 μ M CTL Coenzyme Q10
4. 12.5 mM Lactic Acid
5. 12.5 mM Lactic Acid + 50 μ M CTL Coenzyme Q10
6. 12.5 mM Lactic Acid + 100 μ M CTL Coenzyme Q10
7. Hypoxia

8. Hypoxia + 50 μ M CTL Coenzyme Q10
9. Hypoxia + 100 μ M CTL Coenzyme Q10
10. Hypoxia + 12.5 mM Lactic Acid
11. Hypoxia + 12.5 mM Lactic Acid + 50 μ M CTL Coenzyme Q10
12. Hypoxia + 12.5 mM Lactic Acid + 100 μ M CTL Coenzyme Q10
13. Media + 22 mM Glucose
14. 50 μ M CTL Coenzyme Q10 + 22 mM Glucose
15. 100 μ M CTL Coenzyme Q10 + 22 mM Glucose
16. 12.5 mM Lactic Acid + 22 mM Glucose
17. 12.5 mM Lactic Acid + 22 mM Glucose + 50 μ M CTL Coenzyme Q10
18. 12.5 mM Lactic Acid + 22 mM Glucose + 100 μ M CTL Coenzyme Q10
19. Hypoxia + 22 mM Glucose
20. Hypoxia + 22 mM Glucose + 50 μ M CTL Coenzyme Q10
21. Hypoxia + 22 mM Glucose + 100 μ M CTL Coenzyme Q10
22. Hypoxia + 12.5 mM Lactic Acid + 22 mM Glucose
23. Hypoxia + 12.5 mM Lactic Acid + 22 mM Glucose + 50 μ M CTL Coenzyme Q10
24. Hypoxia + 12.5 mM Lactic Acid + 22 mM Glucose + 100 μ M CTL Coenzyme Q10

In certain situations, cross talk or ECS experiments between different cancer cells (e.g., HepG2 and PaCa2) may be conducted for several inter-related purposes. In some embodiments that involve cross talk, experiments conducted on the cell models are

designed to determine modulation of cellular state or function of one cell system or population (*e.g.*, Hepatocarcinoma cell HepG2) by another cell system or population (*e.g.*, Pancreatic cancer PaCa2) under defined treatment conditions (*e.g.*, hyperglycemia, hypoxia (ischemia)). According to a typical setting, a first cell system / population is contacted by an external stimulus components, such as a candidate molecule (*e.g.*, a small drug molecule, a protein) or a candidate condition (*e.g.*, hypoxia, high glucose environment). In response, the first cell system / population changes its transcriptome, proteome, metabolome, and/or interactome, leading to changes that can be readily detected both inside and outside the cell. For example, changes in transcriptome can be measured by the transcription level of a plurality of target mRNAs; changes in proteome can be measured by the expression level of a plurality of target proteins; and changes in metabolome can be measured by the level of a plurality of target metabolites by assays designed specifically for given metabolites. Alternatively, the above referenced changes in metabolome and/or proteome, at least with respect to certain secreted metabolites or proteins, can also be measured by their effects on the second cell system / population, including the modulation of the transcriptome, proteome, metabolome, and interactome of the second cell system / population. Therefore, the experiments can be used to identify the effects of the molecule(s) of interest secreted by the first cell system / population on a second cell system / population under different treatment conditions. The experiments can also be used to identify any proteins that are modulated as a result of signaling from the first cell system (in response to the external stimulus component treatment) to another cell system, by, for example, differential screening of proteomics. The same experimental setting can also be adapted for a reverse setting, such that reciprocal effects between the two cell systems can also be assessed. In general, for this type of experiment, the choice of cell line pairs is largely based on the factors such as origin, disease state and cellular function.

Although two-cell systems are typically involved in this type of experimental setting, similar experiments can also be designed for more than two cell systems by, for example, immobilizing each distinct cell system on a separate solid support.

The custom built cancer model may be established and used throughout the steps of the Platform Technology of the invention to ultimately identify a causal relationship unique in the biological system, by carrying out the steps described herein. It will be

understood by the skilled artisan, however, that a custom built cancer model that is used to generate an initial, “first generation” consensus causal relationship network can continually evolve or expand over time, e.g., by the introduction of additional cancer or normal cell lines and/or additional cancer conditions. Additional data from the evolved cancer model, i.e., data from the newly added portion(s) of the cancer model, can be collected. The new data collected from an expanded or evolved cancer model, i.e., from newly added portion(s) of the cancer model, can then be introduced to the data sets previously used to generate the “first generation” consensus causal relationship network in order to generate a more robust “second generation” consensus causal relationship network. New causal relationships unique to the cancer state (or unique to the response of the cancer state to a perturbation) can then be identified from the “second generation” consensus causal relationship network. In this way, the evolution of the cancer model provides an evolution of the consensus causal relationship networks, thereby providing new and/or more reliable insights into the determinative drivers (or modulators) of the cancer state.

(iii) Diabetes/Obesity/Cardiovascular Disease Cell Models

Other examples of a biological system or process are diabetes, obesity and cardiovascular disease. As with cancer, the related disease states of diabetes, obesity and cardiovascular disease are complicated pathological conditions characterized by multiple unique aspects. It would be of interest to identify the proteins/pathways driving the pathogenesis of diabetes/obesity/ cardiovascular disease. It would also be of interest to decipher the unique response of cells associated with diabetes/obesity/cardiovascular disease to drug treatment as compared to the responses of normal cells. To this end, a custom diabetes/obesity/cardiovascular model may be established to simulate an environment experienced by disease-relevant cells, by choosing appropriate cell lines and creating cell culture conditions that mimic a characteristic aspect of the disease state or process. For example, cell culture conditions may be selected that closely approximate hyperglycemia, hyperlipidemia, hyperinsulinemia, hypoxia or lactic-acid rich conditions.

Any cells relevant to diabetes/obesity/cardiovascular disease may be included in the diabetes/obesity/cardiovascular disease model. Examples of cells relevant to

diabetes/obesity/cardiovascular disease include, for example, adipocytes, myotubes, hepatocytes, aortic smooth muscle cells (HASMC) and proximal tubular cells (e.g., HK2). Multiple cell types of the same or different origin, as opposed to a single cell type, may be included in the diabetes/obesity/cardiovascular disease model. In one embodiment, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50 or more different cell types are included in the diabetes/obesity/cardiovascular disease model. All values presented in the foregoing list can also be the upper or lower limit of ranges, that are intended to be a part of this invention, *e.g.*, between 1 and 5, 1 and 10, 2 and 5, or 5 and 15 different cell cell types. In one embodiment, the cells are all of the same type, *e.g.*, all adipocytes, but are different established cell lines, *e.g.*, different established adipocyte cell lines. Numerous other cell types that are involved in the diabetes/obesity/cardiovascular disease state are known in the art, and any such cells may be included in a diabetes/obesity/cardiovascular disease model of the invention.

Diabetes/obesity/cardiovascular disease cell models of the invention may include one or more “control cells.” In one embodiment, a control cell may be an untreated or unperturbed disease-relevant cell, *e.g.*, a cell that is not exposed to a hyperlipidemic or hyperinsulinemic condition. In another embodiment, a “control cell” may be a non-disease relevant cell, such as an epithelial cell. Any one of numerous non-disease relevant cells may be included in the cell model. In one embodiment, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50 or more different non-disease relevant cell types are included in the cell model. All values presented in the foregoing list can also be the upper or lower limit of ranges, that are intended to be a part of this invention, *e.g.*, between 1 and 5, 1 and 10, 2 and 5, or 5 and 15 different non-disease relevant cell lines or cell types. In one embodiment, the non-disease relevant cells are all of the same type, *e.g.*, all healthy epithelial or breast cells, but are different established cell lines, *e.g.*, different established cell lines of epithelial or breast cells. In one embodiment, as a control, one or more non-disease relevant cell lines are cultured under similar conditions, and/or are exposed to the same perturbation, as the disease relevant cells of the cell model in order to identify proteins or pathways unique to diabetes/obesity/cardiovascular disease.

A custom diabetes/obesity/cardiovascular disease model may also comprise cell culture conditions that mimic a characteristic aspect of (represent the pathophysiology of) the diabetes/obesity/cardiovascular disease state or process. For example, cell culture conditions may be selected that closely approximate the conditions of a cell relevant to diabetes/obesity/cardiovascular disease in its environment *in vivo*, or to mimic various aspects of diabetes/obesity/cardiovascular disease. In some instances the cell culture conditions are stress conditions.

Exemplary conditions that represent the pathophysiology of diabetes/ obesity/ cardiovascular disease include, for example, any one or more of hypoxia, lactic acid rich conditions, hyperglycemia, hyperlipidemia and hyperinsulinemia. Hypoxia can be induced in cells in cells using art-recognized methods. For example, hypoxia can be induced by placing cell systems in a Modular Incubator Chamber (MIC-101, Billups-Rothenberg Inc. Del Mar, CA), which can be flooded with an industrial gas mix containing 5% CO₂, 2% O₂ and 93% nitrogen. Effects can be measured after a pre-determined period, *e.g.*, at 24 hours after hypoxia treatment, with and without additional external stimulus components (*e.g.*, CoQ10 at 0, 50, or 100 µM).

Likewise, lactic acid treatment of cells mimics a cellular environment where glycolysis activity is high. Lactic acid induced stress can be investigated at a final lactic acid concentration of about 12.5 mM at a pre-determined time, *e.g.*, at 24 hours, with or without additional external stimulus components (*e.g.*, CoQ10 at 0, 50, or 100 µM). Hyperglycemia is a condition found in diabetes. Exposing subject cells to a typical hyperglycemic condition may include adding 10% culture grade glucose to suitable media, such that the final concentration of glucose in the media is about 22 mM. Hyperlipidemia is a condition found in obesity and cardiovascular disease. The hyperlipidemic conditions can be provided by culturing cells in media containing 0.15 mM sodium palmitate. Hyperinsulinemia is a condition found in diabetes. The hyperinsulinemic conditions may be induced by culturing the cells in media containing 1000 nM insulin.

Additional conditions that represent the pathophysiology of diabetes/ obesity/ cardiovascular disease include, for example, any one or more of inflammation, endoplasmic reticulum stress, mitochondrial stress and peroxisomal stress. Methods for

creating an inflammatory-like condition in cells are known in the art. For example, an inflammatory condition may be simulated by culturing cells in the presence of TNF α and or IL-6. Methods for creating conditions simulating endoplasmic reticulum stress are also known in the art. For example, a conditions simulating endoplasmic reticulum stress may be created by culturing cells in the presence of thapsigargin and/or tunicamycin. Methods for creating conditions simulating mitochondrial stress are also known in the art. For example, a conditions simulating mitochondrial stress may be created by culturing cells in the presence of rapamycin and/or galactose. Methods for creating conditions simulating peroxisomal stress are also known in the art. For example, a conditions simulating peroxisomal stress may be created by culturing cells in the presence of abscisic acid.

Individual conditions reflecting different aspects of diabetes/obesity/cardiovascular disease may be investigated separately in the custom built diabetes/obesity/cardiovascular disease model, and/or may be combined together. In one embodiment, combinations of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50 or more conditions reflecting or simulating different aspects of diabetes/obesity/cardiovascular disease are investigated in the custom built diabetes/obesity/cardiovascular disease model. In one embodiment, individual conditions and, in addition, combinations of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50 or more of the conditions reflecting or simulating different aspects of diabetes/obesity/cardiovascular disease are investigated in the custom built diabetes/obesity/cardiovascular disease model. All values presented in the foregoing list can also be the upper or lower limit of ranges, that are intended to be a part of this invention, *e.g.*, between 1 and 5, 1 and 10, 1 and 20, 1 and 30, 2 and 5, 2 and 10, 5 and 10, 1 and 20, 5 and 20, 10 and 20, 10 and 25, 10 and 30 or 10 and 50 different conditions.

Once the custom cell model is built, one or more “perturbations” may be applied to the system, such as genetic variation from patient to patient, or with / without treatment by certain drugs or pro-drugs. *See* Figure 15D. The effects of such perturbations to the system, including the effect on diabetes/obesity/cardiovascular disease related cells, can be measured using various art-recognized or proprietary means, as described in section III.B below.

In an exemplary experiment, each of adipocytes, myotubes, hepatocytes, aortic smooth muscle cells (HASMC) and proximal tubular cells (HK2), are conditioned in each of hyperglycemia, hypoxia, hyperlipidemia, hyperinsulinemia, and lactic acid-rich conditions, as well as in all combinations of two, three, four and all five conditions, and in addition with or without an environmental perturbation, specifically treatment by Coenzyme Q10. In addition to exemplary combinations of conditions described above in the context of the cancer model, listed herein below are some additional exemplary combinations of conditions, with or without a perturbation, e.g., Coenzyme Q10 treatment, which can be used to treat the diabetes/obesity/cardiovascular disease relevant cells (and/or control cells) of the diabetes/obesity/cardiovascular disease cell model. These are merely intended to be exemplary, and the skilled artisan will appreciate that any individual and/or combination of the above-mentioned conditions that represent the pathophysiology of diabetes/ obesity/ cardiovascular disease may be employed in the cell model to produce output data sets. Other combinations can be readily formulated depending on the specific interrogative biological assessment that is being conducted.

1. Media only
2. 50 μ M CTL Coenzyme Q10
3. 100 μ M CTL Coenzyme Q10
4. 0.15 mM sodium palmitate
5. 0.15 mM sodium palmitate + 50 μ M CTL Coenzyme Q10
6. 0.15 mM sodium palmitate + 100 μ M CTL Coenzyme Q10
7. 1000 nM insulin
8. 1000 nM insulin + 50 μ M CTL Coenzyme Q10
9. 1000 nM insulin + 100 μ M CTL Coenzyme Q10
10. 1000 nM insulin + 0.15 mM sodium palmitate

11. 1000 nM insulin + 0.15 mM sodium palmitate + 50 μ M CTL
Coenzyme Q10

12. 1000 nM insulin + 0.15 mM sodium palmitate + 100 μ M CTL
Coenzyme Q10

In certain situations, cross talk or ECS experiments between different disease-relevant cells (e.g., HASMC and HK2 cells, or liver cells and adipocytes) may be conducted for several inter-related purposes. In some embodiments that involve cross talk, experiments conducted on the cell models are designed to determine modulation of cellular state or function of one cell system or population (e.g., liver cells) by another cell system or population (e.g., adipocytes) under defined treatment conditions (e.g., hyperglycemia, hypoxia, hyperlipidemia, hyperinsulinemia). According to a typical setting, a first cell system / population is contacted by an external stimulus components, such as a candidate molecule (e.g., a small drug molecule, a protein) or a candidate condition (e.g., hypoxia, high glucose environment). In response, the first cell system / population changes its transcriptome, proteome, metabolome, and/or interactome, leading to changes that can be readily detected both inside and outside the cell. For example, changes in transcriptome can be measured by the transcription level of a plurality of target mRNAs; changes in proteome can be measured by the expression level of a plurality of target proteins; and changes in metabolome can be measured by the level of a plurality of target metabolites by assays designed specifically for given metabolites. Alternatively, the above referenced changes in metabolome and/or proteome, at least with respect to certain secreted metabolites or proteins, can also be measured by their effects on the second cell system / population, including the modulation of the transcriptome, proteome, metabolome, and interactome of the second cell system / population. Therefore, the experiments can be used to identify the effects of the molecule(s) of interest secreted by the first cell system / population on a second cell system / population under different treatment conditions. The experiments can also be used to identify any proteins that are modulated as a result of signaling from the first cell system (in response to the external stimulus component treatment) to another cell system, by, for example, differential screening of proteomics. The same experimental

setting can also be adapted for a reverse setting, such that reciprocal effects between the two cell systems can also be assessed. In general, for this type of experiment, the choice of cell line pairs is largely based on the factors such as origin, disease state and cellular function.

Although two-cell systems are typically involved in this type of experimental setting, similar experiments can also be designed for more than two cell systems by, for example, immobilizing each distinct cell system on a separate solid support.

The custom built diabetes/obesity/cardiovascular disease model may be established and used throughout the steps of the Platform Technology of the invention to ultimately identify a causal relationship unique to the diabetes/obesity/cardiovascular disease state, by carrying out the steps described herein. It will be understood by the skilled artisan, however, that just as with a cancer model, a custom built diabetes/obesity/cardiovascular disease model that is used to generate an initial, “first generation” consensus causal relationship network can continually evolve or expand over time, e.g., by the introduction of additional disease-relevant cell lines and/or additional disease-relevant conditions. Additional data from the evolved diabetes/obesity/cardiovascular disease model, i.e., data from the newly added portion(s) of the cancer model, can be collected. The new data collected from an expanded or evolved model, i.e., from newly added portion(s) of the model, can then be introduced to the data sets previously used to generate the “first generation” consensus causal relationship network in order to generate a more robust “second generation” consensus causal relationship network. New causal relationships unique to the diabetes/obesity/cardiovascular disease state (or unique to the response of the diabetes/obesity/cardiovascular disease state to a perturbation) can then be identified from the “second generation” consensus causal relationship network. In this way, the evolution of the diabetes/obesity/cardiovascular disease model provides an evolution of the consensus causal relationship networks, thereby providing new and/or more reliable insights into the determinative drivers (or modulators) of the diabetes/obesity/cardiovascular disease state.

B. Use of Cell Models for Interrogative Biological Assessments

The methods and cell models provided in the present invention may be used for, or applied to, any number of “interrogative biological assessments.” Use of the methods of the invention for an interrogative biological assessment facilitates the identification of “modulators” or determinative cellular process “drivers” of a biological system.

As used herein, an “interrogative biological assessment” may include the identification of one or more modulators of a biological system, e.g., determinative cellular process “drivers,” (e.g., an increase or decrease in activity of a biological pathway, or key members of the pathway, or key regulators to members of the pathway) associated with the environmental perturbation or external stimulus component, or a unique causal relationship unique in a biological system or process. It may further include additional steps designed to test or verify whether the identified determinative cellular process drivers are necessary and/or sufficient for the downstream events associated with the environmental perturbation or external stimulus component, including in vivo animal models and/or in vitro tissue culture experiments.

In certain embodiments, the interrogative biological assessment is the diagnosis or staging of a disease state, wherein the identified modulators of a biological system, e.g., determinative cellular process drivers (e.g., cross-talk differentials or causal relationships unique in a biological system or process) represent either disease markers or therapeutic targets that can be subject to therapeutic intervention. The subject interrogative biological assessment is suitable for any disease condition in theory, but may found particularly useful in areas such as oncology / cancer biology, diabetes, obesity, cardiovascular disease, and neurological conditions (especially neurodegenerative diseases, such as, without limitation, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Amyotrophic lateral sclerosis (ALS), and aging related neurodegeneration).

In certain embodiments, the interrogative biological assessment is the determination of the efficacy of a drug, wherein the identified modulators of a biological system, e.g., determinative cellular process driver (e.g., cross-talk differentials or causal relationships unique in a biological system or process) may be the hallmarks of a successful drug, and may in turn be used to identify additional agents, such as MIMs or epishifters, for treating the same disease condition.

In certain embodiments, the interrogative biological assessment is the identification of drug targets for preventing or treating infection (e.g., bacterial or viral infection), wherein the identified determinative cellular process driver (e.g., cellular cross-talk differentials or causal relationships unique in a biological system or process) may be markers/indicators or key biological molecules causative of the infective state, and may in turn be used to identify anti-infective agents.

In certain embodiments, the interrogative biological assessment is the assessment of a molecular effect of an agent, e.g., a drug, on a given disease profile, wherein the identified modulators of a biological system, e.g., determinative cellular process driver (e.g., cellular cross-talk differentials or causal relationships unique in a biological system or process) may be an increase or decrease in activity of one or more biological pathways, or key members of the pathway(s), or key regulators to members of the pathway(s), and may in turn be used, e.g., to predict the therapeutic efficacy of the agent for the given disease.

In certain embodiments, the interrogative biological assessment is the assessment of the toxicological profile of an agent, e.g., a drug, on a cell, tissue, organ or organism, wherein the identified modulators of a biological system, e.g., determinative cellular process driver (e.g., cellular cross-talk differentials or causal relationships unique in a biological system or process) may be indicators of toxicity, e.g., cytotoxicity, and may in turn be used to predict or identify the toxicological profile of the agent. In one embodiment, the identified modulators of a biological system, e.g., determinative cellular process driver (e.g., cellular cross-talk differentials or causal relationships unique in a biological system or process) is an indicator of cardiotoxicity of a drug or drug candidate, and may in turn be used to predict or identify the cardiotoxicological profile of the drug or drug candidate.

In certain embodiments, the interrogative biological assessment is the identification of drug targets for preventing or treating a disease or disorder caused by biological weapons, such as disease-causing protozoa, fungi, bacteria, protests, viruses, or toxins, wherein the identified modulators of a biological system, e.g., determinative cellular process driver (e.g., cellular cross-talk differentials or causal relationships unique in a biological system or process) may be markers/indicators or key biological

molecules causative of said disease or disorder, and may in turn be used to identify biodefense agents.

In certain embodiments, the interrogative biological assessment is the identification of targets for anti-aging agents, such as anti-aging cosmetics, wherein the identified modulators of a biological system, e.g., determinative cellular process driver (e.g., cellular cross-talk differentials or causal relationships unique in a biological system or process) may be markers or indicators of the aging process, particularly the aging process in skin, and may in turn be used to identify anti-aging agents.

In one exemplary cell model for aging that is used in the methods of the invention to identify targets for anti-aging cosmetics, the cell model comprises an aging epithelial cell that is, for example, treated with UV light (an environmental perturbation or external stimulus component), and/or neonatal cells, which are also optionally treated with UV light. In one embodiment, a cell model for aging comprises a cellular cross-talk system. In one exemplary two-cell cross-talk system established to identify targets for anti-aging cosmetics, an aging epithelial cell (first cell system) may be treated with UV light (an external stimulus component), and changes, e.g., proteomic changes and/or functional changes, in a neonatal cell (second cell system) resulting from contacting the neonatal cells with conditioned medium of the treated aging epithelial cell may be measured, e.g., proteome changes may be measured using conventional quantitative mass spectrometry, or a causal relationship unique in aging may be identified from a causal relationship network generated from the data.

V. Proteomic Sample Analysis

In certain embodiments, the subject method employs large-scale high-throughput quantitative proteomic analysis of hundreds of samples of similar character, and provides the data necessary for identifying the cellular output differentials.

There are numerous art-recognized technologies suitable for this purpose. An exemplary technique, iTRAQ analysis in combination with mass spectrometry, is briefly described below.

To provide reference samples for relative quantification with the iTRAQ technique, multiple QC pools are created. Two separate QC pools, consisting of aliquots

of each sample, were generated from the Cell #1 and Cell #2 samples - these samples are denoted as QCS1 and QCS2, and QCP1 and QCP2 for supernatants and pellets, respectively. In order to allow for protein concentration comparison across the two cell lines, cell pellet *aliquots* from the QC pools described above are combined in equal volumes to generate reference samples (QCP).

The quantitative proteomics approach is based on stable isotope labeling with the 8-plex iTRAQ reagent and 2D-LC MALDI MS/MS for peptide identification and quantification. Quantification with this technique is relative: peptides and proteins are assigned abundance ratios relative to a reference sample. Common reference samples in multiple iTRAQ experiments facilitate the comparison of samples across multiple iTRAQ experiments.

To implement this analysis scheme, six primary samples and two control pool samples are combined into one 8-plex iTRAQ mix, with the control pool samples labeled with 113 and 117 reagents according to the manufacturer's suggestions. This mixture of eight samples is then fractionated by two-dimensional liquid chromatography; strong cation exchange (SCX) in the first dimension, and reversed-phase HPLC in the second dimension. The HPLC eluent is directly fractionated onto MALDI plates, and the plates are analyzed on an MDS SCIEX/AB 4800 MALDI TOF/TOF mass spectrometer.

In the absence of additional information, it is assumed that the most important changes in protein expression are those within the same cell types under different treatment conditions. For this reason, primary samples from Cell#1 and Cell#2 are analyzed in separate iTRAQ mixes. To facilitate comparison of protein expression in Cell#1 vs. Cell#2 samples, universal QCP samples are analyzed in the available "iTRAQ slots" not occupied by primary or cell line specific QC samples (QC1 and QC2).

A brief overview of the laboratory procedures employed is provided herein.

A. Protein Extraction From Cell Supernatant Samples

For cell supernatant samples (CSN), proteins from the culture medium are present in a large excess over proteins secreted by the cultured cells. In an attempt to reduce this background, upfront abundant protein depletion was implemented. As

specific affinity columns are not available for bovine or horse serum proteins, an anti-human IgY14 column was used. While the antibodies are directed against human proteins, the broad specificity provided by the polyclonal nature of the antibodies was anticipated to accomplish depletion of both bovine and equine proteins present in the cell culture media that was used.

A 200- μ L aliquot of the CSN QC material is loaded on a 10-mL IgY14 depletion column before the start of the study to determine the total protein concentration (Bicinchoninic acid (BCA) assay) in the flow-through material. The loading volume is then selected to achieve a depleted fraction containing approximately 40 μ g total protein.

B. Protein Extraction From Cell Pellets

An aliquot of Cell #1 and Cell #2 is lysed in the “standard” lysis buffer used for the analysis of tissue samples at BGM, and total protein content is determined by the BCA assay. Having established the protein content of these representative cell lysates, all cell pellet samples (including QC samples described in Section 1.1) were processed to cell lysates. Lysate amounts of approximately 40 μ g of total protein were carried forward in the processing workflow.

C. Sample Preparation for Mass Spectrometry

Sample preparation follows standard operating procedures and constitute of the following:

- Reduction and alkylation of proteins
- Protein clean-up on reversed-phase column (cell pellets only)
- Digestion with trypsin
- iTRAQ labeling
- Strong cation exchange chromatography – collection of six fractions (Agilent 1200 system)

- HPLC fractionation and spotting to MALDI plates (Dionex Ultimate3000/Probot system)

D. MALDI MS and MS/MS

HPLC-MS generally employs online ESI MS/MS strategies. BG Medicine uses an off-line LC-MALDI MS/MS platform that results in better concordance of observed protein sets across the primary samples without the need of injecting the same sample multiple times. Following first pass data collection across all iTRAQ mixes, since the peptide fractions are retained on the MALDI target plates, the samples can be analyzed a second time using a targeted MS/MS acquisition pattern derived from knowledge gained during the first acquisition. In this manner, maximum observation frequency for all of the identified proteins is accomplished (ideally, every protein should be measured in every iTRAQ mix).

E. Data Processing

The data processing process within the BGM Proteomics workflow can be separated into those procedures such as preliminary peptide identification and quantification that are completed for each iTRAQ mix individually (Section 1.5.1) and those processes (Section 1.5.2) such as final assignment of peptides to proteins and final quantification of proteins, which are not completed until data acquisition is completed for the project.

The main data processing steps within the BGM Proteomics workflow are:

- Peptide identification using the Mascot (Matrix Sciences) database search engine
- Automated in house validation of Mascot IDs
- Quantification of peptides and preliminary quantification of proteins
- Expert curation of final dataset

- Final assignment of peptides from each mix into a common set of proteins using the automated PVT tool
- Outlier elimination and final quantification of proteins

(i) Data Processing of Individual iTRAQ Mixes

As each iTRAQ mix is processed through the workflow the MS/MS spectra are analyzed using proprietary BGM software tools for peptide and protein identifications, as well as initial assessment of quantification information. Based on the results of this preliminary analysis, the quality of the workflow for each primary sample in the mix is judged against a set of BGM performance metrics. If a given sample (or mix) does not pass the specified minimal performance metrics, and additional material is available, that sample is repeated in its entirety and it is data from this second implementation of the workflow that is incorporated in the final dataset.

(ii) Peptide Identification

MS/MS spectra was searched against the Uniprot protein sequence database containing human, bovine, and horse sequences augmented by common contaminant sequences such as porcine trypsin. The details of the Mascot search parameters, including the complete list of modifications, are given in Table 3.

Table 3: Mascot Search Parameters

Precursor mass tolerance	100 ppm
Fragment mass tolerance	0.4 Da
Variable modifications	N-term iTRAQ8 Lysine iTRAQ8 Cys carbamidomethyl Pyro-Glu (N-term) Pyro-Carbamidomethyl Cys (N-term) Deamidation (N only)

	Oxidation (M)
Enzyme specificity	Fully Tryptic
Number of missed tryptic sites allowed	2
Peptide rank considered	1

After the Mascot search is complete, an auto-validation procedure is used to promote (*i.e.*, validate) specific Mascot peptide matches. Differentiation between valid and invalid matches is based on the attained Mascot score relative to the expected Mascot score and the difference between the Rank 1 peptides and Rank 2 peptide Mascot scores. The criteria required for validation are somewhat relaxed if the peptide is one of several matched to a single protein in the iTRAQ mix or if the peptide is present in a catalogue of previously validated peptides.

(iii) Peptide and Protein Quantification

The set of validated peptides for each mix is utilized to calculate preliminary protein quantification metrics for each mix. Peptide ratios are calculated by dividing the peak area from the iTRAQ label (*i.e.*, m/z 114, 115, 116, 118, 119, or 121) for each validated peptide by the best representation of the peak area of the reference pool (QC1 or QC2). This peak area is the average of the 113 and 117 peaks provided both samples pass QC acceptance criteria. Preliminary protein ratios are determined by calculating the median ratio of all “useful” validated peptides matching to that protein. “Useful” peptides are fully iTRAQ labeled (all N-terminal are labeled with either Lysine or PyroGlu) and fully Cysteine labeled (*i.e.*, all Cys residues are alkylated with Carbamidomethyl or N-terminal Pyro-cmc).

(iv) Post-acquisition Processing

Once all passes of MS/MS data acquisition are complete for every mix in the project, the data is collated using the three steps discussed below which are aimed at enabling the results from each primary sample to be simply and meaningfully compared to that of another.

(v) Global Assignment of Peptide Sequences to Proteins

Final assignment of peptide sequences to protein accession numbers is carried out through the proprietary Protein Validation Tool (PVT). The PVT procedure

determines the best, minimum non-redundant protein set to describe the entire collection of peptides identified in the project. This is an automated procedure that has been optimized to handle data from a homogeneous taxonomy.

Protein assignments for the supernatant experiments were manually curated in order to deal with the complexities of mixed taxonomies in the database. Since the automated paradigm is not valid for cell cultures grown in bovine and horse serum supplemented media, extensive manual curation is necessary to minimize the ambiguity of the source of any given protein.

(vi) Normalization of Peptide Ratios

The peptide ratios for each sample are normalized based on the method of Vandesompele *et al. Genome Biology*, **2002**, 3(7), research 0034.1-11. This procedure is applied to the cell pellet measurements only. For the supernatant samples, quantitative data are not normalized considering the largest contribution to peptide identifications coming from the media.

(vii) Final Calculation of Protein Ratios

A standard statistical outlier elimination procedure is used to remove outliers from around each protein median ratio, beyond the 1.96σ level in the log-transformed data set. Following this elimination process, the final set of protein ratios are (re-)calculated.

VI. Markers of the Invention and Uses Thereof

The present invention is based, at least in part, on the identification of novel biomarkers that are associated with a biological system, such as a disease process, or response of a biological system to a perturbation, such as a therapeutic agent.

In particular, the invention relates to markers (hereinafter “markers” or “markers of the invention”), which are described in the examples. The invention provides nucleic acids and proteins that are encoded by or correspond to the markers (hereinafter “marker nucleic acids” and “marker proteins,” respectively). These markers are particularly useful in diagnosing disease states; prognosing disease states; developing drug targets

for varies disease states; screening for the presence of toxicity, preferably drug-induced toxicity, e.g., cardiotoxicity; identifying an agent that cause or is at risk for causing toxicity; identifying an agent that can reduce or prevent drug-induced toxicity; alleviating, reducing or preventing drug-induced cardiotoxicity; and identifying markers predictive of drug-induced cardiotoxicity.

A "marker" is a gene whose altered level of expression in a tissue or cell from its expression level in normal or healthy tissue or cell is associated with a disease state such as cancer, diabetes, obesity, cardiovascular disease, or a toxicity state, such as a drug-induced toxicity, e.g., cardiotoxicity. A "marker nucleic acid" is a nucleic acid (*e.g.*, mRNA, cDNA) encoded by or corresponding to a marker of the invention. Such marker nucleic acids include DNA (*e.g.*, cDNA) comprising the entire or a partial sequence of any of the genes that are markers of the invention or the complement of such a sequence. Such sequences are known to the one of skill in the art and can be found for example, on the NIH government pubmed website. The marker nucleic acids also include RNA comprising the entire or a partial sequence of any of the gene markers of the invention or the complement of such a sequence, wherein all thymidine residues are replaced with uridine residues. A "marker protein" is a protein encoded by or corresponding to a marker of the invention. A marker protein comprises the entire or a partial sequence of any of the marker proteins of the invention. Such sequences are known to the one of skill in the art and can be found for example, on the NIH government pubmed website. The terms "protein" and "polypeptide" are used interchangeably.

A "disease state or toxic state associated" body fluid is a fluid which, when in the body of a patient, contacts or passes through sarcoma cells or into which cells or proteins shed from sarcoma cells are capable of passing. Exemplary disease state or toxic state associated body fluids include blood fluids (*e.g.* whole blood, blood serum, blood having platelets removed therefrom), and are described in more detail below. Disease state or toxic state associated body fluids are not limited to, whole blood, blood having platelets removed therefrom, lymph, prostatic fluid, urine and semen.

The "normal" level of expression of a marker is the level of expression of the marker in cells of a human subject or patient not afflicted with a disease state or a toxicity state.

An "over-expression" or "higher level of expression" of a marker refers to an expression level in a test sample that is greater than the standard error of the assay employed to assess expression, and is preferably at least twice, and more preferably three, four, five, six, seven, eight, nine or ten times the expression level of the marker in a control sample (*e.g.*, sample from a healthy subject not having the marker associated a disease state or a toxicity state, *e.g.*, cancer, diabetes, obesity, cardiovascular disease, and cardiotoxicity) and preferably, the average expression level of the marker in several control samples.

A "lower level of expression" of a marker refers to an expression level in a test sample that is at least twice, and more preferably three, four, five, six, seven, eight, nine or ten times lower than the expression level of the marker in a control sample (*e.g.*, sample from a healthy subjects not having the marker associated a disease state or a toxicity state, *e.g.*, cancer, diabetes, obesity, cardiovascular disease, and cardiotoxicity) and preferably, the average expression level of the marker in several control samples.

A "transcribed polynucleotide" or "nucleotide transcript" is a polynucleotide (*e.g.* an mRNA, hnRNA, a cDNA, or an analog of such RNA or cDNA) which is complementary to or homologous with all or a portion of a mature mRNA made by transcription of a marker of the invention and normal post-transcriptional processing (*e.g.* splicing), if any, of the RNA transcript, and reverse transcription of the RNA transcript.

"Complementary" refers to the broad concept of sequence complementarity between regions of two nucleic acid strands or between two regions of the same nucleic acid strand. It is known that an adenine residue of a first nucleic acid region is capable of forming specific hydrogen bonds ("base pairing") with a residue of a second nucleic acid region which is antiparallel to the first region if the residue is thymine or uracil. Similarly, it is known that a cytosine residue of a first nucleic acid strand is capable of base pairing with a residue of a second nucleic acid strand which is antiparallel to the first strand if the residue is guanine. A first region of a nucleic acid is complementary to a second region of the same or a different nucleic acid if, when the two regions are arranged in an antiparallel fashion, at least one nucleotide residue of the first region is capable of base pairing with a residue of the second region. Preferably, the first region comprises a first portion and the second region comprises a second portion, whereby,

when the first and second portions are arranged in an antiparallel fashion, at least about 50%, and preferably at least about 75%, at least about 90%, or at least about 95% of the nucleotide residues of the first portion are capable of base pairing with nucleotide residues in the second portion. More preferably, all nucleotide residues of the first portion are capable of base pairing with nucleotide residues in the second portion.

"Homologous" as used herein, refers to nucleotide sequence similarity between two regions of the same nucleic acid strand or between regions of two different nucleic acid strands. When a nucleotide residue position in both regions is occupied by the same nucleotide residue, then the regions are homologous at that position. A first region is homologous to a second region if at least one nucleotide residue position of each region is occupied by the same residue. Homology between two regions is expressed in terms of the proportion of nucleotide residue positions of the two regions that are occupied by the same nucleotide residue. By way of example, a region having the nucleotide sequence 5'-ATTGCC-3' and a region having the nucleotide sequence 5'-TATGGC-3' share 50% homology. Preferably, the first region comprises a first portion and the second region comprises a second portion, whereby, at least about 50%, and preferably at least about 75%, at least about 90%, or at least about 95% of the nucleotide residue positions of each of the portions are occupied by the same nucleotide residue. More preferably, all nucleotide residue positions of each of the portions are occupied by the same nucleotide residue.

"Proteins of the invention" encompass marker proteins and their fragments; variant marker proteins and their fragments; peptides and polypeptides comprising an at least 15 amino acid segment of a marker or variant marker protein; and fusion proteins comprising a marker or variant marker protein, or an at least 15 amino acid segment of a marker or variant marker protein.

The invention further provides antibodies, antibody derivatives and antibody fragments which specifically bind with the marker proteins and fragments of the marker proteins of the present invention. Unless otherwise specified herewithin, the terms "antibody" and "antibodies" broadly encompass naturally-occurring forms of antibodies (*e.g.*, IgG, IgA, IgM, IgE) and recombinant antibodies such as single-chain antibodies, chimeric and humanized antibodies and multi-specific antibodies, as well as fragments and derivatives of all of the foregoing, which fragments and derivatives have at least an

antigenic binding site. Antibody derivatives may comprise a protein or chemical moiety conjugated to an antibody.

In certain embodiments, the markers of the invention include one or more genes (or proteins) selected from the group consisting of HSPA8, FLNB, PARK7, HSPA1A/HSPA1B, ST13, TUBB3, MIF, KARS, NARS, LGALS1, DDX17, EIF5A, HSPA5, DHX9, HNRNPC, CKAP4, HSPA9, PARP1, HADHA, PHB2, ATP5A1, CANX, GRP78, GRP75, TIMP1, PTX3, HSP76, PDIA4, PDIA1, CA2D1, GPAT1 and TAZ. In some embodiments, the markers are a combination of at least two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-five, thirty, or more of the foregoing genes (or proteins). All values presented in the foregoing list can also be the upper or lower limit of ranges, that are intended to be a part of this invention, *e.g.*, between 1 and 5, 1 and 10, 1 and 20, 1 and 30, 2 and 5, 2 and 10, 5 and 10, 1 and 20, 5 and 20, 10 and 20, 10 and 25, 10 and 30 of the foregoing genes (or proteins).

In one embodiment, the markers of the invention are genes or proteins associated with or involved in cancer. Such genes or proteins involved in cancer include, for example, HSPA8, FLNB, PARK7, HSPA1A/HSPA1B, ST13, TUBB3, MIF, KARS, NARS, LGALS1, DDX17, EIF5A, HSPA5, DHX9, HNRNPC, CKAP4, HSPA9, PARP1, HADHA, PHB2, ATP5A1, and/or CANX. In some embodiments, the markers of the invention are a combination of at least two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty or more of the foregoing genes (or proteins). All values presented in the foregoing list can also be the upper or lower limit of ranges, that are intended to be a part of this invention, *e.g.*, between 1 and 5, 1 and 10, 1 and 20, 1 and 30, 2 and 5, 2 and 10, 5 and 10, 1 and 20, 5 and 20, 10 and 20, 10 and 25, 10 and 30 of the foregoing genes (or proteins).

In one embodiment, the markers of the invention are genes or proteins associated with or involved in drug-induced toxicity. Such genes or proteins involved in drug-induced toxicity include, for example, GRP78, GRP75, TIMP1, PTX3, HSP76, PDIA4, PDIA1, CA2D1, GPAT1 and/or TAZ. In some embodiments, the markers of the invention are a combination of at least two, three, four, five, six, seven, eight, nine, ten of the foregoing genes (or proteins). All values presented in the foregoing list can also

be the upper or lower limit of ranges, that are intended to be a part of this invention, *e.g.*, between 1 and 5, 1 and 10, 1 and 20, 1 and 30, 2 and 5, 2 and 10, 5 and 10, 1 and 20, 5 and 20, 10 and 20, 10 and 25, 10 and 30 of the foregoing genes (or proteins).

A. Cardiotoxicity Associated Markers

The present invention is based, at least in part, on the identification of novel biomarkers that are associated with drug-induced cardiotoxicity. The invention is further based, at least in part, on the discovery that Coenzyme Q10 is capable of reducing or preventing drug-induced cardiotoxicity.

Accordingly, the invention provides methods for identifying an agent that causes or is at risk for causing toxicity. In one embodiment, the agent is a drug or drug candidate. In one embodiment, the toxicity is drug-induced toxicity, *e.g.*, cardiotoxicity. In one embodiment, the agent is a drug or drug candidate for treating diabetes, obesity or a cardiovascular disorder. In these methods, the amount of one or more biomarkers/proteins in a pair of samples (a first sample not subject to the drug treatment, and a second sample subjected to the drug treatment) is assessed. A modulation in the level of expression of the one or more biomarkers in the second sample as compared to the first sample is an indication that the drug causes or is at risk for causing drug-induced toxicity, *e.g.*, cardiotoxicity. In one embodiment, the one or more biomarkers is selected from the group consisting of GRP78, GRP75, TIMP1, PTX3, HSP76, PDIA4, PDIA1, CA2D1, GPAT1 and TAZ. The methods of the present invention can be practiced in conjunction with any other method used by the skilled practitioner to identify a drug at risk for causing drug-induced cardiotoxicity.

Accordingly, in one aspect, the invention provides a method for identifying a drug that causes or is at risk for causing drug-induced toxicity (*e.g.*, cardiotoxicity), comprising: comparing (i) the level of expression of one or more biomarkers present in a first cell sample obtained prior to the treatment with the drug; with (ii) the level of expression of the one or more biomarkers present in a second cell sample obtained following the treatment with the drug; wherein the one or more biomarkers is selected from the group consisting of GRP78, GRP75, TIMP1, PTX3, HSP76, PDIA4, PDIA1, CA2D1, GPAT1 and TAZ; wherein a modulation in the level of expression of the one or

more biomarkers in the second sample as compared to the first sample is an indication that the drug causes or is at risk for causing drug-induced toxicity (e.g., cardiotoxicity).

In one embodiment, the drug-induced toxicity is drug-induced cardiotoxicity. In one embodiment, the cells are cells of the cardiovascular system, e.g., cardiomyocytes. In one embodiment, the cells are diabetic cardiomyocytes. In one embodiment, the drug is a drug or candidate drug for treating diabetes, obesity or cardiovascular disease.

In one embodiment, a modulation (e.g., an increase or a decrease) in the level of expression of one, two, three, four, five, six, seven, eight, nine or all ten of the biomarkers selected from the group consisting of GRP78, GRP75, TIMP1, PTX3, HSP76, PDIA4, PDIA1, CA2D1, GPAT1 and TAZ in the second sample as compared to the first sample is an indication that the drug causes or is at risk for causing drug-induced toxicity.

Methods for identifying an agent that can reduce or prevent drug-induced toxicity are also provided by the invention. In one embodiment, the drug-induced toxicity is cardiotoxicity. In one embodiment, the drug is a drug or drug candidate for treating diabetes, obesity or a cardiovascular disorder. In these methods, the amount of one or more biomarkers in three samples (a first sample not subjected to the drug treatment, a second sample subjected to the drug treatment, and a third sample subjected both to the drug treatment and the agent) is assessed. Approximately the same level of expression of the one or more biomarkers in the third sample as compared to the first sample is an indication that the agent can reduce or prevent drug-induced toxicity, e.g., drug-induced cardiotoxicity. In one embodiment, the one or more biomarkers is selected from the group consisting of GRP78, GRP75, TIMP1, PTX3, HSP76, PDIA4, PDIA1, CA2D1, GPAT1 and TAZ.

Using the methods described herein, a variety of molecules, particularly including molecules sufficiently small to be able to cross the cell membrane, may be screened in order to identify molecules which modulate, *e.g.*, increase or decrease the expression and/or activity of a marker of the invention. Compounds so identified can be provided to a subject in order to reduce, alleviate or prevent drug-induced toxicity in the subject.

Accordingly, in another aspect, the invention provides a method for identifying an agent that can reduce or prevent drug-induced toxicity comprising: (i) determining

the level of expression of one or more biomarkers present in a first cell sample obtained prior to the treatment with a toxicity inducing drug; (ii) determining the level of expression of the one or more biomarkers present in a second cell sample obtained following the treatment with the toxicity inducing drug; (iii) determining the level of expression of the one or more biomarkers present in a third cell sample obtained following the treatment with the toxicity inducing drug and the agent; and (iv) comparing the level of expression of the one or more biomarkers present in the third sample with the first sample; wherein the one or more biomarkers is selected from the group consisting of GRP78, GRP75, TIMP1, PTX3, HSP76, PDIA4, PDIA1, CA2D1, GPAT1 and TAZ; and wherein about the same level of expression of the one or more biomarkers in the third sample as compared to the first sample is an indication that the agent can reduce or prevent drug-induced toxicity.

In one embodiment, the drug-induced toxicity is drug-induced cardiotoxicity. In one embodiment, the cells are cells of the cardiovascular system, e.g., cardiomyocytes. In one embodiment, the cells are diabetic cardiomyocytes. In one embodiment, the drug is a drug or candidate drug for treating diabetes, obesity or cardiovascular disease.

In one embodiment, about the same level of expression of one, two, three, four, five, six, seven, eight, nine or all ten of the biomarkers selected from the group consisting of GRP78, GRP75, TIMP1, PTX3, HSP76, PDIA4, PDIA1, CA2D1, GPAT1 and TAZ in the third sample as compared to the first sample is an indication that the agent can reduce or prevent drug-induced toxicity.

The invention further provides methods for alleviating, reducing or preventing drug-induced cardiotoxicity in a subject in need thereof, comprising administering to a subject (e.g., a mammal, a human, or a non-human animal) an agent identified by the screening methods provided herein, thereby reducing or preventing drug-induced cardiotoxicity in the subject. In one embodiment, the agent is administered to a subject that has already been treated with a cardiotoxicity-inducing drug. In one embodiment, the agent is administered to a subject at the same time as treatment of the subject with a cardiotoxicity-inducing drug. In one embodiment, the agent is administered to a subject prior to treatment of the subject with a cardiotoxicity-inducing drug.

The invention further provides methods for alleviating, reducing or preventing drug-induced cardiotoxicity in a subject in need thereof, comprising administering

Coenzyme Q10 to the subject (e.g., a mammal, a human, or a non-human animal), thereby reducing or preventing drug-induced cardiotoxicity in the subject. In one embodiment, the Coenzyme Q10 is administered to a subject that has already been treated with a cardiotoxicity-inducing drug. In one embodiment, the Coenzyme Q10 is administered to a subject at the same time as treatment of the subject with a cardiotoxicity-inducing drug. In one embodiment, the Coenzyme Q10 is administered to a subject prior to treatment of the subject with a cardiotoxicity-inducing drug. In one embodiment, the drug-induced cardiotoxicity is associated with modulation of expression of one, two, three, four, five, six, seven, eight, nine or all ten of the biomarkers selected from the group consisting of GRP78, GRP75, TIMP1, PTX3, HSP76, PDIA4, PDIA1, CA2D1, GPAT1 and TAZ. All values presented in the foregoing list can also be the upper or lower limit of ranges, that are intended to be a part of this invention, *e.g.*, between 1 and 5, 1 and 10, 2 and 5, 2 and 10, or 5 and 10 of the foregoing genes (or proteins).

The invention further provides biomarkers (e.g, genes and/or proteins) that are useful as predictive markers for cardiotoxicity, *e.g.*, drug-induced cardiotoxicity. These biomarkers include GRP78, GRP75, TIMP1, PTX3, HSP76, PDIA4, PDIA1, CA2D1, GPAT1 and TAZ. The ordinary skilled artisan would, however, be able to identify additional biomarkers predictive of drug-induced cardiotoxicity by employing the methods described herein, *e.g.*, by carrying out the methods described in Example 3 but by using a different drug known to induce cardiotoxicity. Exemplary drug-induced cardiotoxicity biomarkers of the invention are further described below.

GRP78 and GRP75 are also referred to as glucose response proteins. These proteins are associated with endo/sarcoplasmic reticulum stress (ER stress) of cardiomyocytes. SERCA, or sarcoendoplasmic reticulum calcium ATPase, regulates Ca²⁺ homeostasis in cardiac cells. Any disruption of these ATPase can lead to cardiac dysfunction and heart failure. Based upon the data provided herein, GRP75 and GRP78 and the edges around them are novel predictors of drug induced cardiotoxicity.

TIMP1, also referred to as TIMP metalloprotease inhibitor 1, is involved with remodeling of extra cellular matrix in association with MMPs. TIMP1 expression is correlated with fibrosis of the heart, and hypoxia of vascular endothelial cells also

induces TIMP1 expression. Based upon the data provided herein, TIMP1 is a novel predictor of drug induced cardiotoxicity

PTX3, also referred to as Pentraxin 3, belongs to the family of C Reactive Proteins (CRP) and is a good marker of an inflammatory condition of the heart. However, plasma PTX3 could also be representative of systemic inflammatory response due to sepsis or other medical conditions. Based upon the data provided herein, PTX3 may be a novel marker of cardiac function or cardiotoxicity. Additionally, the edges associated with PTX 3 in the network could form a novel panel of biomarkers.

HSP76, also referred to as HSPA6, is only known to be expressed in endothelial cells and B lymphocytes. There is no known role for this protein in cardiac function. Based upon the data provided herein, HSP76 may be a novel predictor of drug induced cardiotoxicity

PDIA4, PDIA1, also referred to as protein disulphide isomerase family A proteins, are associated with ER stress response, like GRPs. There is no known role for these proteins in cardiac function. Based upon the data provided herein, these proteins may be novel predictors of drug induced cardiotoxicity.

CA2D1 is also referred to as calcium channel, voltage-dependent, alpha 2/delta subunit. The alpha-2/delta subunit of voltage-dependent calcium channel regulates calcium current density and activation/inactivation kinetics of the calcium channel. CA2D1 plays an important role in excitation-contraction coupling in the heart. There is no known role for this protein in cardiac function. Based upon the data provided herein, CA2D1 is a novel predictor of drug induced cardiotoxicity

GPAT1 is one of four known glycerol-3-phosphate acyltransferase isoforms, and is located on the mitochondrial outer membrane, allowing reciprocal regulation with carnitine palmitoyltransferase-1. GPAT1 is upregulated transcriptionally by insulin and SREBP-1c and downregulated acutely by AMP-activated protein kinase, consistent with a role in triacylglycerol synthesis. Based upon the data provided herein, GPAT1 is a novel predictor of drug induced cardiotoxicity.

TAZ, also referred to as Tafazzin, is highly expressed in cardiac and skeletal muscle. TAZ is involved in the metabolism of cardiolipin and functions as a phospholipid-lysophospholipid transacylase. Tafazzin is responsible for remodeling of a phospholipid cardiolipin (CL), the signature lipid of the mitochondrial inner membrane.

Based upon the data provided herein, TAZ is a novel predictor of drug induced cardiotoxicity

B. Cancer Associated Markers

The present invention is based, at least in part, on the identification of novel biomarkers that are associated with cancer. Such markers associated in cancer include, for example, HSPA8, FLNB, PARK7, HSPA1A/HSPA1B, ST13, TUBB3, MIF, KARS, NARS, LGALS1, DDX17, EIF5A, HSPA5, DHX9, HNRNPC, CKAP4, HSPA9, PARP1, HADHA, PHB2, ATP5A1, and/or CANX. In some embodiments, the markers of the invention are a combination of at least two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty or more of the foregoing markers.

Accordingly, the invention provides methods for identifying an agent that causes or is at risk for causing cancer. In one embodiment, the agent is a drug or drug candidate. In these methods, the amount of one or more biomarkers/proteins in a pair of samples (a first sample not subject to the drug treatment, and a second sample subjected to the drug treatment) is assessed. A modulation in the level of expression of the one or more biomarkers in the second sample as compared to the first sample is an indication that the drug causes or is at risk for causing cancer. In one embodiment, the one or more biomarkers is selected from the group consisting of HSPA8, FLNB, PARK7, HSPA1A/HSPA1B, ST13, TUBB3, MIF, KARS, NARS, LGALS1, DDX17, EIF5A, HSPA5, DHX9, HNRNPC, CKAP4, HSPA9, PARP1, HADHA, PHB2, ATP5A1, and CANX. The methods of the present invention can be practiced in conjunction with any other method used by the skilled practitioner to identify a drug at risk for causing the cancer.

In one aspect, the invention provides methods for assessing the efficacy of a therapy for treating a cancer in a subject, the method comprising: comparing the level of expression of one or more markers present in a first sample obtained from the subject prior to administering at least a portion of the treatment regimen to the subject, wherein the one or more markers is selected from the group consisting of HSPA8, FLNB, PARK7, HSPA1A/HSPA1B, ST13, TUBB3, MIF, KARS, NARS, LGALS1, DDX17, EIF5A, HSPA5, DHX9, HNRNPC, CKAP4, HSPA9, PARP1, HADHA, PHB2,

ATP5A1, and CANX; and the level of expression of the one or more markers present in a second sample obtained from the subject following administration of at least a portion of the treatment regimen, wherein a modulation in the level of expression of the one or more markers in the second sample as compared to the first sample is an indication that the therapy is efficacious for treating the cancer in the subject.

In one embodiment, the sample comprises a fluid obtained from the subject. In one embodiment, the fluid is selected from the group consisting of blood fluids, vomit, saliva, lymph, cystic fluid, urine, fluids collected by bronchial lavage, fluids collected by peritoneal rinsing, and gynecological fluids. In one embodiment, the sample is a blood sample or a component thereof.

In another embodiment, the sample comprises a tissue or component thereof obtained from the subject. In one embodiment, the tissue is selected from the group consisting of bone, connective tissue, cartilage, lung, liver, kidney, muscle tissue, heart, pancreas, and skin.

In one embodiment, the subject is a human.

In one embodiment, the level of expression of the one or more markers in the biological sample is determined by assaying a transcribed polynucleotide or a portion thereof in the sample. In one embodiment, wherein assaying the transcribed polynucleotide comprises amplifying the transcribed polynucleotide.

In one embodiment, the level of expression of the marker in the subject sample is determined by assaying a protein or a portion thereof in the sample. In one embodiment, the protein is assayed using a reagent which specifically binds with the protein.

In one embodiment, the level of expression of the one or more markers in the sample is determined using a technique selected from the group consisting of polymerase chain reaction (PCR) amplification reaction, reverse-transcriptase PCR analysis, single-strand conformation polymorphism analysis (SSCP), mismatch cleavage detection, heteroduplex analysis, Southern blot analysis, Northern blot analysis, Western blot analysis, in situ hybridization, array analysis, deoxyribonucleic acid sequencing, restriction fragment length polymorphism analysis, and combinations or sub-combinations thereof, of said sample.

In one embodiment, the level of expression of the marker in the sample is determined using a technique selected from the group consisting of

immunohistochemistry, immunocytochemistry, flow cytometry, ELISA and mass spectrometry.

In one embodiment, the level of expression of a plurality of markers is determined.

In one embodiment, the subject is being treated with a therapy selected from the group consisting of an environmental influencer compound, surgery, radiation, hormone therapy, antibody therapy, therapy with growth factors, cytokines, chemotherapy, allogenic stem cell therapy. In one embodiment, the environmental influencer compound is a Coenzyme Q10 molecule.

The invention further provides methods of assessing whether a subject is afflicted with a cancer, the method comprising: determining the level of expression of one or more markers present in a biological sample obtained from the subject, wherein the one or more markers is selected from the group consisting of HSPA8, FLNB, PARK7, HSPA1A/HSPA1B, ST13, TUBB3, MIF, KARS, NARS, LGALS1, DDX17, EIF5A, HSPA5, DHX9, HNRNPC, CKAP4, HSPA9, PARP1, HADHA, PHB2, ATP5A1, and CANX; and comparing the level of expression of the one or more markers present in the biological sample obtained from the subject with the level of expression of the one or more markers present in a control sample, wherein a modulation in the level of expression of the one or more markers in the biological sample obtained from the subject relative to the level of expression of the one or more markers in the control sample is an indication that the subject is afflicted with cancer, thereby assessing whether the subject is afflicted with the cancer.

In one embodiment, the sample comprises a fluid obtained from the subject. In one embodiment, the fluid is selected from the group consisting of blood fluids, vomit, saliva, lymph, cystic fluid, urine, fluids collected by bronchial lavage, fluids collected by peritoneal rinsing, and gynecological fluids. In one embodiment, the sample is a blood sample or a component thereof.

In another embodiment, the sample comprises a tissue or component thereof obtained from the subject. In one embodiment, the tissue is selected from the group consisting of bone, connective tissue, cartilage, lung, liver, kidney, muscle tissue, heart, pancreas, and skin.

In one embodiment, the subject is a human.

In one embodiment, the level of expression of the one or more markers in the biological sample is determined by assaying a transcribed polynucleotide or a portion thereof in the sample. In one embodiment, wherein assaying the transcribed polynucleotide comprises amplifying the transcribed polynucleotide.

In one embodiment, the level of expression of the marker in the subject sample is determined by assaying a protein or a portion thereof in the sample. In one embodiment, the protein is assayed using a reagent which specifically binds with the protein.

In one embodiment, the level of expression of the one or more markers in the sample is determined using a technique selected from the group consisting of polymerase chain reaction (PCR) amplification reaction, reverse-transcriptase PCR analysis, single-strand conformation polymorphism analysis (SSCP), mismatch cleavage detection, heteroduplex analysis, Southern blot analysis, Northern blot analysis, Western blot analysis, in situ hybridization, array analysis, deoxyribonucleic acid sequencing, restriction fragment length polymorphism analysis, and combinations or sub-combinations thereof, of said sample.

In one embodiment, the level of expression of the marker in the sample is determined using a technique selected from the group consisting of immunohistochemistry, immunocytochemistry, flow cytometry, ELISA and mass spectrometry.

In one embodiment, the level of expression of a plurality of markers is determined.

In one embodiment, the subject is being treated with a therapy selected from the group consisting of an environmental influencer compound, surgery, radiation, hormone therapy, antibody therapy, therapy with growth factors, cytokines, chemotherapy, allogenic stem cell therapy. In one embodiment, the environmental influencer compound is a Coenzyme Q10 molecule.

The invention further provides methods of prognosing whether a subject is predisposed to developing a cancer, the method comprising: determining the level of expression of one or more markers present in a biological sample obtained from the subject, wherein the one or more markers is selected from the group consisting of HSPA8, FLNB, PARK7, HSPA1A/HSPA1B, ST13, TUBB3, MIF, KARS, NARS, LGALS1, DDX17, EIF5A, HSPA5, DHX9, HNRNPC, CKAP4, HSPA9, PARP1,

HADHA, PHB2, ATP5A1, and CANX; and comparing the level of expression of the one or more markers present in the biological sample obtained from the subject with the level of expression of the one or more markers present in a control sample, wherein a modulation in the level of expression of the one or more markers in the biological sample obtained from the subject relative to the level of expression of the one or more markers in the control sample is an indication that the subject is predisposed to developing cancer, thereby prognosing whether the subject is predisposed to developing the cancer.

In one embodiment, the sample comprises a fluid obtained from the subject. In one embodiment, the fluid is selected from the group consisting of blood fluids, vomit, saliva, lymph, cystic fluid, urine, fluids collected by bronchial lavage, fluids collected by peritoneal rinsing, and gynecological fluids. In one embodiment, the sample is a blood sample or a component thereof.

In another embodiment, the sample comprises a tissue or component thereof obtained from the subject. In one embodiment, the tissue is selected from the group consisting of bone, connective tissue, cartilage, lung, liver, kidney, muscle tissue, heart, pancreas, and skin.

In one embodiment, the subject is a human.

In one embodiment, the level of expression of the one or more markers in the biological sample is determined by assaying a transcribed polynucleotide or a portion thereof in the sample. In one embodiment, wherein assaying the transcribed polynucleotide comprises amplifying the transcribed polynucleotide.

In one embodiment, the level of expression of the marker in the subject sample is determined by assaying a protein or a portion thereof in the sample. In one embodiment, the protein is assayed using a reagent which specifically binds with the protein.

In one embodiment, the level of expression of the one or more markers in the sample is determined using a technique selected from the group consisting of polymerase chain reaction (PCR) amplification reaction, reverse-transcriptase PCR analysis, single-strand conformation polymorphism analysis (SSCP), mismatch cleavage detection, heteroduplex analysis, Southern blot analysis, Northern blot analysis, Western blot analysis, in situ hybridization, array analysis, deoxyribonucleic acid sequencing,

restriction fragment length polymorphism analysis, and combinations or sub-combinations thereof, of said sample.

In one embodiment, the level of expression of the marker in the sample is determined using a technique selected from the group consisting of immunohistochemistry, immunocytochemistry, flow cytometry, ELISA and mass spectrometry.

In one embodiment, the level of expression of a plurality of markers is determined.

In one embodiment, the subject is being treated with a therapy selected from the group consisting of an environmental influencer compound, surgery, radiation, hormone therapy, antibody therapy, therapy with growth factors, cytokines, chemotherapy, allogenic stem cell therapy. In one embodiment, the environmental influencer compound is a Coenzyme Q10 molecule.

The invention further provides methods of prognosing the recurrence of a cancer in a subject, the method comprising: determining the level of expression of one or more markers present in a biological sample obtained from the subject, wherein the one or more markers is selected from the group consisting of HSPA8, FLNB, PARK7, HSPA1A/HSPA1B, ST13, TUBB3, MIF, KARS, NARS, LGALS1, DDX17, EIF5A, HSPA5, DHX9, HNRNPC, CKAP4, HSPA9, PARP1, HADHA, PHB2, ATP5A1, and CANX; and comparing the level of expression of the one or more markers present in the biological sample obtained from the subject with the level of expression of the one or more markers present in a control sample, wherein a modulation in the level of expression of the one or more markers in the biological sample obtained from the subject relative to the level of expression of the one or more markers in the control sample is an indication of the recurrence of cancer, thereby prognosing the recurrence of the cancer in the subject.

In one embodiment, the sample comprises a fluid obtained from the subject. In one embodiment, the fluid is selected from the group consisting of blood fluids, vomit, saliva, lymph, cystic fluid, urine, fluids collected by bronchial lavage, fluids collected by peritoneal rinsing, and gynecological fluids. In one embodiment, the sample is a blood sample or a component thereof.

In another embodiment, the sample comprises a tissue or component thereof obtained from the subject. In one embodiment, the tissue is selected from the group consisting of bone, connective tissue, cartilage, lung, liver, kidney, muscle tissue, heart, pancreas, and skin.

In one embodiment, the subject is a human.

In one embodiment, the level of expression of the one or more markers in the biological sample is determined by assaying a transcribed polynucleotide or a portion thereof in the sample. In one embodiment, wherein assaying the transcribed polynucleotide comprises amplifying the transcribed polynucleotide.

In one embodiment, the level of expression of the marker in the subject sample is determined by assaying a protein or a portion thereof in the sample. In one embodiment, the protein is assayed using a reagent which specifically binds with the protein.

In one embodiment, the level of expression of the one or more markers in the sample is determined using a technique selected from the group consisting of polymerase chain reaction (PCR) amplification reaction, reverse-transcriptase PCR analysis, single-strand conformation polymorphism analysis (SSCP), mismatch cleavage detection, heteroduplex analysis, Southern blot analysis, Northern blot analysis, Western blot analysis, in situ hybridization, array analysis, deoxyribonucleic acid sequencing, restriction fragment length polymorphism analysis, and combinations or sub-combinations thereof, of said sample.

In one embodiment, the level of expression of the marker in the sample is determined using a technique selected from the group consisting of immunohistochemistry, immunocytochemistry, flow cytometry, ELISA and mass spectrometry.

In one embodiment, the level of expression of a plurality of markers is determined.

In one embodiment, the subject is being treated with a therapy selected from the group consisting of an environmental influencer compound, surgery, radiation, hormone therapy, antibody therapy, therapy with growth factors, cytokines, chemotherapy, allogenic stem cell therapy. In one embodiment, the environmental influencer compound is a Coenzyme Q10 molecule.

The invention further provides methods of prognosing the survival of a subject with a cancer, the method comprising: determining the level of expression of one or more markers present in a biological sample obtained from the subject, wherein the one or more markers is selected from the group consisting of HSPA8, FLNB, PARK7, HSPA1A/HSPA1B, ST13, TUBB3, MIF, KARS, NARS, LGALS1, DDX17, EIF5A, HSPA5, DHX9, HNRNPC, CKAP4, HSPA9, PARP1, HADHA, PHB2, ATP5A1, and CANX; and comparing the level of expression of the one or more markers present in the biological sample obtained from the subject with the level of expression of the one or more markers present in a control sample, wherein a modulation in the level of expression of the one or more markers in the biological sample obtained from the subject relative to the level of expression of the one or more markers in the control sample is an indication of survival of the subject, thereby prognosing survival of the subject with the cancer.

In one embodiment, the sample comprises a fluid obtained from the subject. In one embodiment, the fluid is selected from the group consisting of blood fluids, vomit, saliva, lymph, cystic fluid, urine, fluids collected by bronchial lavage, fluids collected by peritoneal rinsing, and gynecological fluids. In one embodiment, the sample is a blood sample or a component thereof.

In another embodiment, the sample comprises a tissue or component thereof obtained from the subject. In one embodiment, the tissue is selected from the group consisting of bone, connective tissue, cartilage, lung, liver, kidney, muscle tissue, heart, pancreas, and skin.

In one embodiment, the subject is a human.

In one embodiment, the level of expression of the one or more markers in the biological sample is determined by assaying a transcribed polynucleotide or a portion thereof in the sample. In one embodiment, wherein assaying the transcribed polynucleotide comprises amplifying the transcribed polynucleotide.

In one embodiment, the level of expression of the marker in the subject sample is determined by assaying a protein or a portion thereof in the sample. In one embodiment, the protein is assayed using a reagent which specifically binds with the protein.

In one embodiment, the level of expression of the one or more markers in the sample is determined using a technique selected from the group consisting of

polymerase chain reaction (PCR) amplification reaction, reverse-transcriptase PCR analysis, single-strand conformation polymorphism analysis (SSCP), mismatch cleavage detection, heteroduplex analysis, Southern blot analysis, Northern blot analysis, Western blot analysis, in situ hybridization, array analysis, deoxyribonucleic acid sequencing, restriction fragment length polymorphism analysis, and combinations or sub-combinations thereof, of said sample.

In one embodiment, the level of expression of the marker in the sample is determined using a technique selected from the group consisting of immunohistochemistry, immunocytochemistry, flow cytometry, ELISA and mass spectrometry.

In one embodiment, the level of expression of a plurality of markers is determined.

In one embodiment, the subject is being treated with a therapy selected from the group consisting of an environmental influencer compound, surgery, radiation, hormone therapy, antibody therapy, therapy with growth factors, cytokines, chemotherapy, allogenic stem cell therapy. In one embodiment, the environmental influencer compound is a Coenzyme Q10 molecule.

The invention further provides methods of monitoring the progression of a cancer in a subject, the method comprising: comparing, the level of expression of one or more markers present in a first sample obtained from the subject prior to administering at least a portion of a treatment regimen to the subject and the level of expression of the one or more markers present in a second sample obtained from the subject following administration of at least a portion of the treatment regimen, wherein the one or more markers is selected from the group consisting of HSPA8, FLNB, PARK7, HSPA1A/HSPA1B, ST13, TUBB3, MIF, KARS, NARS, LGALS1, DDX17, EIF5A, HSPA5, DHX9, HNRNPC, CKAP4, HSPA9, PARP1, HADHA, PHB2, ATP5A1, and CANX, thereby monitoring the progression of the cancer in the subject.

In one embodiment, the sample comprises a fluid obtained from the subject. In one embodiment, the fluid is selected from the group consisting of blood fluids, vomit, saliva, lymph, cystic fluid, urine, fluids collected by bronchial lavage, fluids collected by peritoneal rinsing, and gynecological fluids. In one embodiment, the sample is a blood sample or a component thereof.

In another embodiment, the sample comprises a tissue or component thereof obtained from the subject. In one embodiment, the tissue is selected from the group consisting of bone, connective tissue, cartilage, lung, liver, kidney, muscle tissue, heart, pancreas, and skin.

In one embodiment, the subject is a human.

In one embodiment, the level of expression of the one or more markers in the biological sample is determined by assaying a transcribed polynucleotide or a portion thereof in the sample. In one embodiment, wherein assaying the transcribed polynucleotide comprises amplifying the transcribed polynucleotide.

In one embodiment, the level of expression of the marker in the subject sample is determined by assaying a protein or a portion thereof in the sample. In one embodiment, the protein is assayed using a reagent which specifically binds with the protein.

In one embodiment, the level of expression of the one or more markers in the sample is determined using a technique selected from the group consisting of polymerase chain reaction (PCR) amplification reaction, reverse-transcriptase PCR analysis, single-strand conformation polymorphism analysis (SSCP), mismatch cleavage detection, heteroduplex analysis, Southern blot analysis, Northern blot analysis, Western blot analysis, in situ hybridization, array analysis, deoxyribonucleic acid sequencing, restriction fragment length polymorphism analysis, and combinations or sub-combinations thereof, of said sample.

In one embodiment, the level of expression of the marker in the sample is determined using a technique selected from the group consisting of immunohistochemistry, immunocytochemistry, flow cytometry, ELISA and mass spectrometry.

In one embodiment, the level of expression of a plurality of markers is determined.

In one embodiment, the subject is being treated with a therapy selected from the group consisting of an environmental influencer compound, surgery, radiation, hormone therapy, antibody therapy, therapy with growth factors, cytokines, chemotherapy, allogenic stem cell therapy. In one embodiment, the environmental influencer compound is a Coenzyme Q10 molecule.

The invention further provides methods of identifying a compound for treating a cancer in a subject, the method comprising: obtaining a biological sample from the subject; contacting the biological sample with a test compound; determining the level of expression of one or more markers present in the biological sample obtained from the subject, wherein the one or more markers is selected from the group consisting of HSPA8, FLNB, PARK7, HSPA1A/HSPA1B, ST13, TUBB3, MIF, KARS, NARS, LGALS1, DDX17, EIF5A, HSPA5, DHX9, HNRNPC, CKAP4, HSPA9, PARP1, HADHA, PHB2, ATP5A1, and CANX with a positive fold change and/or with a negative fold change; comparing the level of expression of the one of more markers in the biological sample with an appropriate control; and selecting a test compound that decreases the level of expression of the one or more markers with a negative fold change present in the biological sample and/or increases the level of expression of the one or more markers with a positive fold change present in the biological sample, thereby identifying a compound for treating the cancer in a subject.

In one embodiment, the sample comprises a fluid obtained from the subject. In one embodiment, the fluid is selected from the group consisting of blood fluids, vomit, saliva, lymph, cystic fluid, urine, fluids collected by bronchial lavage, fluids collected by peritoneal rinsing, and gynecological fluids. In one embodiment, the sample is a blood sample or a component thereof.

In another embodiment, the sample comprises a tissue or component thereof obtained from the subject. In one embodiment, the tissue is selected from the group consisting of bone, connective tissue, cartilage, lung, liver, kidney, muscle tissue, heart, pancreas, and skin.

In one embodiment, the subject is a human.

In one embodiment, the level of expression of the one or more markers in the biological sample is determined by assaying a transcribed polynucleotide or a portion thereof in the sample. In one embodiment, wherein assaying the transcribed polynucleotide comprises amplifying the transcribed polynucleotide.

In one embodiment, the level of expression of the marker in the subject sample is determined by assaying a protein or a portion thereof in the sample. In one embodiment, the protein is assayed using a reagent which specifically binds with the protein.

In one embodiment, the level of expression of the one or more markers in the sample is determined using a technique selected from the group consisting of polymerase chain reaction (PCR) amplification reaction, reverse-transcriptase PCR analysis, single-strand conformation polymorphism analysis (SSCP), mismatch cleavage detection, heteroduplex analysis, Southern blot analysis, Northern blot analysis, Western blot analysis, in situ hybridization, array analysis, deoxyribonucleic acid sequencing, restriction fragment length polymorphism analysis, and combinations or sub-combinations thereof, of said sample.

In one embodiment, the level of expression of the marker in the sample is determined using a technique selected from the group consisting of immunohistochemistry, immunocytochemistry, flow cytometry, ELISA and mass spectrometry.

In one embodiment, the level of expression of a plurality of markers is determined.

In one embodiment, the subject is being treated with a therapy selected from the group consisting of an environmental influencer compound, surgery, radiation, hormone therapy, antibody therapy, therapy with growth factors, cytokines, chemotherapy, allogenic stem cell therapy. In one embodiment, the environmental influencer compound is a Coenzyme Q10 molecule.

The invention further provides a kit for assessing the efficacy of a therapy for treating a cancer, the kit comprising reagents for determining the level of expression of at least one marker selected from the group consisting of HSPA8, FLNB, PARK7, HSPA1A/HSPA1B, ST13, TUBB3, MIF, KARS, NARS, LGALS1, DDX17, EIF5A, HSPA5, DHX9, HNRNPC, CKAP4, HSPA9, PARP1, HADHA, PHB2, ATP5A1, and CANX and instructions for use of the kit to assess the efficacy of the therapy for treating the cancer.

The invention further provides a kit for assessing whether a subject is afflicted with a cancer, the kit comprising reagents for determining the level of expression of at least one marker selected from the group consisting of HSPA8, FLNB, PARK7, HSPA1A/HSPA1B, ST13, TUBB3, MIF, KARS, NARS, LGALS1, DDX17, EIF5A, HSPA5, DHX9, HNRNPC, CKAP4, HSPA9, PARP1, HADHA, PHB2, ATP5A1, and

CANX and instructions for use of the kit to assess whether the subject is afflicted with the cancer.

The invention further provides a kit for prognosing whether a subject is predisposed to developing a cancer, the kit comprising reagents for determining the level of expression of at least one marker selected from the group consisting of HSPA8, FLNB, PARK7, HSPA1A/HSPA1B, ST13, TUBB3, MIF, KARS, NARS, LGALS1, DDX17, EIF5A, HSPA5, DHX9, HNRNPC, CKAP4, HSPA9, PARP1, HADHA, PHB2, ATP5A1, and CANX and instructions for use of the kit to prognose whether the subject is predisposed to developing the cancer.

The invention further provides a kit for prognosing the recurrence of a cancer in a subject, the kit comprising reagents for assessing the level of expression of at least one marker selected from the group consisting of HSPA8, FLNB, PARK7, HSPA1A/HSPA1B, ST13, TUBB3, MIF, KARS, NARS, LGALS1, DDX17, EIF5A, HSPA5, DHX9, HNRNPC, CKAP4, HSPA9, PARP1, HADHA, PHB2, ATP5A1, and CANX and instructions for use of the kit to prognose the recurrence of the cancer.

The invention further provides a kit for prognosing the recurrence of a cancer, the kit comprising reagents for determining the level of expression of at least one marker selected from the group consisting of HSPA8, FLNB, PARK7, HSPA1A/HSPA1B, ST13, TUBB3, MIF, KARS, NARS, LGALS1, DDX17, EIF5A, HSPA5, DHX9, HNRNPC, CKAP4, HSPA9, PARP1, HADHA, PHB2, ATP5A1, and CANX and instructions for use of the kit to prognose the recurrence of the cancer.

The invention further provides a kit for prognosing the survival of a subject with a cancer, the kit comprising reagents for determining the level of expression of at least one marker selected from the group consisting of HSPA8, FLNB, PARK7, HSPA1A/HSPA1B, ST13, TUBB3, MIF, KARS, NARS, LGALS1, DDX17, EIF5A, HSPA5, DHX9, HNRNPC, CKAP4, HSPA9, PARP1, HADHA, PHB2, ATP5A1, and CANX and instructions for use of the kit to prognose the survival of the subject with the cancer.

The invention further provides a kit for monitoring the progression of a cancer in a subject, the kit comprising reagents for determining the level of expression of at least one marker selected from the group consisting of HSPA8, FLNB, PARK7, HSPA1A/HSPA1B, ST13, TUBB3, MIF, KARS, NARS, LGALS1, DDX17, EIF5A,

HSPA5, DHX9, HNRNPC, CKAP4, HSPA9, PARP1, HADHA, PHB2, ATP5A1, and CANX and instructions for use of the kit to prognose the progression of the cancer in a subject.

The kits of the invention may further comprising means for obtaining a biological sample from a subject, a control sample, and/or an environmental influencer compound

The means for determining the level of expression of at least one marker may comprises means for assaying a transcribed polynucleotide or a portion thereof in the sample and/or means for assaying a protein or a portion thereof in the sample.

In one embodiment, the kits comprises reagents for determining the level of expression of a plurality of markers. Various aspects of the invention are described in further detail in the following subsections.

C. Isolated Nucleic Acid Molecules

One aspect of the invention pertains to isolated nucleic acid molecules, including nucleic acids which encode a marker protein or a portion thereof. Isolated nucleic acids of the invention also include nucleic acid molecules sufficient for use as hybridization probes to identify marker nucleic acid molecules, and fragments of marker nucleic acid molecules, *e.g.*, those suitable for use as PCR primers for the amplification or mutation of marker nucleic acid molecules. As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (*e.g.*, cDNA or genomic DNA) and RNA molecules (*e.g.*, mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.

An "isolated" nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid molecule. In one embodiment, an "isolated" nucleic acid molecule is free of sequences (preferably protein-encoding sequences) which naturally flank the nucleic acid (*i.e.*, sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated nucleic acid molecule can contain less than about 5 kB, 4 kB, 3 kB, 2 kB, 1 kB,

0.5 kB or 0.1 kB of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. In another embodiment, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. A nucleic acid molecule that is substantially free of cellular material includes preparations having less than about 30%, 20%, 10%, or 5% of heterologous nucleic acid (also referred to herein as a "contaminating nucleic acid").

A nucleic acid molecule of the present invention can be isolated using standard molecular biology techniques and the sequence information in the database records described herein. Using all or a portion of such nucleic acid sequences, nucleic acid molecules of the invention can be isolated using standard hybridization and cloning techniques (*e.g.*, as described in Sambrook *et al.*, ed., *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

A nucleic acid molecule of the invention can be amplified using cDNA, mRNA, or genomic DNA as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, nucleotides corresponding to all or a portion of a nucleic acid molecule of the invention can be prepared by standard synthetic techniques, *e.g.*, using an automated DNA synthesizer.

In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which has a nucleotide sequence complementary to the nucleotide sequence of a marker nucleic acid or to the nucleotide sequence of a nucleic acid encoding a marker protein. A nucleic acid molecule which is complementary to a given nucleotide sequence is one which is sufficiently complementary to the given nucleotide sequence that it can hybridize to the given nucleotide sequence thereby forming a stable duplex.

Moreover, a nucleic acid molecule of the invention can comprise only a portion of a nucleic acid sequence, wherein the full length nucleic acid sequence comprises a marker nucleic acid or which encodes a marker protein. Such nucleic acids can be used,

for example, as a probe or primer. The probe/primer typically is used as one or more substantially purified oligonucleotides. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 7, preferably about 15, more preferably about 25, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, or 400 or more consecutive nucleotides of a nucleic acid of the invention.

Probes based on the sequence of a nucleic acid molecule of the invention can be used to detect transcripts or genomic sequences corresponding to one or more markers of the invention. The probe comprises a label group attached thereto, *e.g.*, a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as part of a diagnostic test kit for identifying cells or tissues which mis-express the protein, such as by measuring levels of a nucleic acid molecule encoding the protein in a sample of cells from a subject, *e.g.*, detecting mRNA levels or determining whether a gene encoding the protein has been mutated or deleted.

The invention further encompasses nucleic acid molecules that differ, due to degeneracy of the genetic code, from the nucleotide sequence of nucleic acids encoding a marker protein, and thus encode the same protein.

It will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequence can exist within a population (*e.g.*, the human population). Such genetic polymorphisms can exist among individuals within a population due to natural allelic variation. An allele is one of a group of genes which occur alternatively at a given genetic locus. In addition, it will be appreciated that DNA polymorphisms that affect RNA expression levels can also exist that may affect the overall expression level of that gene (*e.g.*, by affecting regulation or degradation).

As used herein, the phrase "allelic variant" refers to a nucleotide sequence which occurs at a given locus or to a polypeptide encoded by the nucleotide sequence.

As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame encoding a polypeptide corresponding to a marker of the invention. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of a given gene. Alternative alleles can be identified by sequencing the gene of interest in a number of different individuals. This can be readily carried out by using hybridization probes to identify the same genetic locus in a

variety of individuals. Any and all such nucleotide variations and resulting amino acid polymorphisms or variations that are the result of natural allelic variation and that do not alter the functional activity are intended to be within the scope of the invention.

In another embodiment, an isolated nucleic acid molecule of the invention is at least 7, 15, 20, 25, 30, 40, 60, 80, 100, 150, 200, 250, 300, 350, 400, 450, 550, 650, 700, 800, 900, 1000, 1200, 1400, 1600, 1800, 2000, 2200, 2400, 2600, 2800, 3000, 3500, 4000, 4500, or more nucleotides in length and hybridizes under stringent conditions to a marker nucleic acid or to a nucleic acid encoding a marker protein. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% (65%, 70%, preferably 75%) identical to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in sections 6.3.1-6.3.6 of *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989). A preferred, non-limiting example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 50-65°C.

In addition to naturally-occurring allelic variants of a nucleic acid molecule of the invention that can exist in the population, the skilled artisan will further appreciate that sequence changes can be introduced by mutation thereby leading to changes in the amino acid sequence of the encoded protein, without altering the biological activity of the protein encoded thereby. For example, one can make nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence without altering the biological activity, whereas an "essential" amino acid residue is required for biological activity. For example, amino acid residues that are not conserved or only semi-conserved among homologs of various species may be non-essential for activity and thus would be likely targets for alteration. Alternatively, amino acid residues that are conserved among the homologs of various species (*e.g.*, murine and human) may be essential for activity and thus would not be likely targets for alteration.

Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding a variant marker protein that contain changes in amino acid residues that are not essential for activity. Such variant marker proteins differ in amino acid sequence

from the naturally-occurring marker proteins, yet retain biological activity. In one embodiment, such a variant marker protein has an amino acid sequence that is at least about 40% identical, 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of a marker protein.

An isolated nucleic acid molecule encoding a variant marker protein can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of marker nucleic acids, such that one or more amino acid residue substitutions, additions, or deletions are introduced into the encoded protein. Mutations can be introduced by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (*e.g.*, lysine, arginine, histidine), acidic side chains (*e.g.*, aspartic acid, glutamic acid), uncharged polar side chains (*e.g.*, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (*e.g.*, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (*e.g.*, threonine, valine, isoleucine) and aromatic side chains (*e.g.*, tyrosine, phenylalanine, tryptophan, histidine). Alternatively, mutations can be introduced randomly along all or part of the coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for biological activity to identify mutants that retain activity. Following mutagenesis, the encoded protein can be expressed recombinantly and the activity of the protein can be determined.

The present invention encompasses antisense nucleic acid molecules, *i.e.*, molecules which are complementary to a sense nucleic acid of the invention, *e.g.*, complementary to the coding strand of a double-stranded marker cDNA molecule or complementary to a marker mRNA sequence. Accordingly, an antisense nucleic acid of the invention can hydrogen bond to (*i.e.* anneal with) a sense nucleic acid of the invention. The antisense nucleic acid can be complementary to an entire coding strand, or to only a portion thereof, *e.g.*, all or part of the protein coding region (or open reading frame). An antisense nucleic acid molecule can also be antisense to all or part of a non-

coding region of the coding strand of a nucleotide sequence encoding a marker protein. The non-coding regions ("5' and 3' untranslated regions") are the 5' and 3' sequences which flank the coding region and are not translated into amino acids.

An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 or more nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (*e.g.*, an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, *e.g.*, phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been sub-cloned in an antisense orientation (*i.e.*, RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

As used herein, a "nucleic acid" inhibitor is any nucleic acid based inhibitor that causes a decrease in the expression of the target by hybridizing with at least a portion of the RNA transcript from the target gene to result in a decrease in the expression of

target. Nucleic acid inhibitors include, for example, single stranded nucleic acid molecules, e.g., antisense nucleic acids, and double stranded nucleic acids such as siRNA, shRNA, dsRNA (see, e.g., US Patent publication 20070104688). As used herein, double stranded nucleic acid molecules are designed to be double stranded over at least 12, preferably at least 15 nucleotides. Double stranded nucleic acid molecules can be a single nucleic acid strand designed to hybridize to itself, e.g., an shRNA. It is understood that a nucleic acid inhibitor of target can be administered as an isolated nucleic acid. Alternatively, the nucleic acid inhibitor can be administered as an expression construct to produce the inhibitor in the cell. In certain embodiments, the nucleic acid inhibitor includes one or more chemical modifications to improve the activity and/or stability of the nucleic acid inhibitor. Such modifications are well known in the art. The specific modifications to be used will depend, for example, on the type of nucleic acid inhibitor.

Antisense nucleic acid therapeutic agent single stranded nucleic acid therapeutics, typically about 16 to 30 nucleotides in length and are complementary to a target nucleic acid sequence in the target cell, either in culture or in an organism.

Patents directed to antisense nucleic acids, chemical modifications, and therapeutic uses are provided, for example, in U.S. Patent No. 5,898,031 related to chemically modified RNA-containing therapeutic compounds, and U.S. Patent No. 6,107,094 related methods of using these compounds as therapeutic agent. U.S. Patent No. 7,432,250 related to methods of treating patients by administering single-stranded chemically modified RNA-like compounds; and U.S. Patent No. 7,432,249 related to pharmaceutical compositions containing single-stranded chemically modified RNA-like compounds. U.S. Patent No. 7,629,321 is related to methods of cleaving target mRNA using a single-stranded oligonucleotide having a plurality RNA nucleosides and at least one chemical modification. Each of the patents listed in the paragraph are incorporated herein by reference.

In many embodiments, the duplex region is 15-30 nucleotide pairs in length. In some embodiments, the duplex region is 17-23 nucleotide pairs in length, 17-25 nucleotide pairs in length, 23-27 nucleotide pairs in length, 19-21 nucleotide pairs in length, or 21-23 nucleotide pairs in length.

In certain embodiments, each strand has 15-30 nucleotides.

The RNAi agents that can be used in the methods of the invention include agents with chemical modifications as disclosed, for example, in U.S. Provisional Application No. 61/561,710, filed on November 18, 2011, International Application No. PCT/US2011/051597, filed on September 15, 2010, and PCT Publication WO 2009/073809, the entire contents of each of which are incorporated herein by reference.

An “RNAi agent,” “double stranded RNAi agent,” double-stranded RNA (dsRNA) molecule, also referred to as “dsRNA agent,” “dsRNA”, “siRNA”, “iRNA agent,” as used interchangeably herein, refers to a complex of ribonucleic acid molecules, having a duplex structure comprising two anti-parallel and substantially complementary, as defined below, nucleic acid strands. As used herein, an RNAi agent can also include dsRNA (see, e.g., US Patent publication 20070104688, incorporated herein by reference). In general, the majority of nucleotides of each strand are ribonucleotides, but as described herein, each or both strands can also include one or more non-ribonucleotides, e.g., a deoxyribonucleotide and/or a modified nucleotide. In addition, as used in this specification, an “RNAi agent” may include ribonucleotides with chemical modifications; an RNAi agent may include substantial modifications at multiple nucleotides. Such modifications may include all types of modifications disclosed herein or known in the art. Any such modifications, as used in a siRNA type molecule, are encompassed by “RNAi agent” for the purposes of this specification and claims.

The two strands forming the duplex structure may be different portions of one larger RNA molecule, or they may be separate RNA molecules. Where the two strands are part of one larger molecule, and therefore are connected by an uninterrupted chain of nucleotides between the 3'-end of one strand and the 5'-end of the respective other strand forming the duplex structure, the connecting RNA chain is referred to as a “hairpin loop.” Where the two strands are connected covalently by means other than an uninterrupted chain of nucleotides between the 3'-end of one strand and the 5'-end of the respective other strand forming the duplex structure, the connecting structure is referred to as a “linker.” The RNA strands may have the same or a different number of nucleotides. The maximum number of base pairs is the number of nucleotides in the shortest strand of the dsRNA minus any overhangs that are present in the duplex. In addition to the duplex structure, an RNAi agent may comprise one or more nucleotide

overhangs. The term “siRNA” is also used herein to refer to an RNAi agent as described above.

In another aspect, the agent is a single-stranded antisense RNA molecule. An antisense RNA molecule is complementary to a sequence within the target mRNA. Antisense RNA can inhibit translation in a stoichiometric manner by base pairing to the mRNA and physically obstructing the translation machinery, see Dias, N. et al., (2002) *Mol Cancer Ther* 1:347-355. The antisense RNA molecule may have about 15-30 nucleotides that are complementary to the target mRNA. For example, the antisense RNA molecule may have a sequence of at least 15, 16, 17, 18, 19, 20 or more contiguous nucleotides from one of the antisense sequences of Table 1.

The term “antisense strand” refers to the strand of a double stranded RNAi agent which includes a region that is substantially complementary to a target sequence. As used herein, the term “region complementary to part of an mRNA encoding” a protein of interest refers to a region on the antisense strand that is substantially complementary to part of a target mRNA sequence encoding the protein. Where the region of complementarity is not fully complementary to the target sequence, the mismatches are most tolerated in the terminal regions and, if present, are generally in a terminal region or regions, e.g., within 6, 5, 4, 3, or 2 nucleotides of the 5' and/or 3' terminus.

The term “sense strand,” as used herein, refers to the strand of a dsRNA that includes a region that is substantially complementary to a region of the antisense strand.

In various embodiments, the nucleic acid molecules of the invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids (see Hyrup *et al.*, 1996, *Bioorganic & Medicinal Chemistry* 4(1): 5-23). As used herein, the terms “peptide nucleic acids” or “PNAs” refer to nucleic acid mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup

et al. (1996), *supra*; Perry-O'Keefe *et al.* (1996) *Proc. Natl. Acad. Sci. USA* 93:14670-675.

PNAs can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, *e.g.*, inducing transcription or translation arrest or inhibiting replication. PNAs can also be used, *e.g.*, in the analysis of single base pair mutations in a gene by, *e.g.*, PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, *e.g.*, S1 nucleases (Hyrup (1996), *supra*; or as probes or primers for DNA sequence and hybridization (Hyrup, 1996, *supra*; Perry-O'Keefe *et al.*, 1996, *Proc. Natl. Acad. Sci. USA* 93:14670-675).

In another embodiment, PNAs can be modified, *e.g.*, to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras can be generated which can combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes, *e.g.*, RNase H and DNA polymerases, to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup, 1996, *supra*). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup (1996), *supra*, and Finn *et al.* (1996) *Nucleic Acids Res.* 24(17):3357-63. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry and modified nucleoside analogs. Compounds such as 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite can be used as a link between the PNA and the 5' end of DNA (Mag *et al.*, 1989, *Nucleic Acids Res.* 17:5973-88). PNA monomers are then coupled in a step-wise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment (Finn *et al.*, 1996, *Nucleic Acids Res.* 24(17):3357-63). Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment (Peterser *et al.*, 1975, *Bioorganic Med. Chem. Lett.* 5:1119-11124).

In other embodiments, the oligonucleotide can include other appended groups such as peptides (*e.g.*, for targeting host cell receptors *in vivo*), or agents facilitating

transport across the cell membrane (see, *e.g.*, Letsinger *et al.*, 1989, *Proc. Natl. Acad. Sci. USA* 86:6553-6556; Lemaitre *et al.*, 1987, *Proc. Natl. Acad. Sci. USA* 84:648-652; PCT Publication No. WO 88/09810) or the blood-brain barrier (see, *e.g.*, PCT Publication No. WO 89/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (see, *e.g.*, Krol *et al.*, 1988, *Bio/Techniques* 6:958-976) or intercalating agents (see, *e.g.*, Zon, 1988, *Pharm. Res.* 5:539-549). To this end, the oligonucleotide can be conjugated to another molecule, *e.g.*, a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

The invention also includes molecular beacon nucleic acids having at least one region which is complementary to a nucleic acid of the invention, such that the molecular beacon is useful for quantitating the presence of the nucleic acid of the invention in a sample. A "molecular beacon" nucleic acid is a nucleic acid comprising a pair of complementary regions and having a fluorophore and a fluorescent quencher associated therewith. The fluorophore and quencher are associated with different portions of the nucleic acid in such an orientation that when the complementary regions are annealed with one another, fluorescence of the fluorophore is quenched by the quencher. When the complementary regions of the nucleic acid are not annealed with one another, fluorescence of the fluorophore is quenched to a lesser degree. Molecular beacon nucleic acids are described, for example, in U.S. Patent 5,876,930.

D. Isolated Proteins and Antibodies

One aspect of the invention pertains to isolated marker proteins and biologically active portions thereof, as well as polypeptide fragments suitable for use as immunogens to raise antibodies directed against a marker protein or a fragment thereof. In one embodiment, the native marker protein can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, a protein or peptide comprising the whole or a segment of the marker protein is produced by recombinant DNA techniques. Alternative to recombinant expression, such protein or peptide can be synthesized chemically using standard peptide synthesis techniques.

An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the protein is derived, or substantially free of chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of protein in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly produced. Thus, protein that is substantially free of cellular material includes preparations of protein having less than about 30%, 20%, 10%, or 5% (by dry weight) of heterologous protein (also referred to herein as a "contaminating protein"). When the protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, *i.e.*, culture medium represents less than about 20%, 10%, or 5% of the volume of the protein preparation. When the protein is produced by chemical synthesis, it is preferably substantially free of chemical precursors or other chemicals, *i.e.*, it is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. Accordingly such preparations of the protein have less than about 30%, 20%, 10%, 5% (by dry weight) of chemical precursors or compounds other than the polypeptide of interest.

Biologically active portions of a marker protein include polypeptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence of the marker protein, which include fewer amino acids than the full length protein, and exhibit at least one activity of the corresponding full-length protein. Typically, biologically active portions comprise a domain or motif with at least one activity of the corresponding full-length protein. A biologically active portion of a marker protein of the invention can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acids in length. Moreover, other biologically active portions, in which other regions of the marker protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of the native form of the marker protein.

Preferred marker proteins are encoded by nucleotide sequences comprising the sequences encoding any of the genes described in the examples. Other useful proteins are substantially identical (*e.g.*, at least about 40%, preferably 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) to one of these sequences

and retain the functional activity of the corresponding naturally-occurring marker protein yet differ in amino acid sequence due to natural allelic variation or mutagenesis.

To determine the percent identity of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (*e.g.*, gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. Preferably, the percent identity between the two sequences is calculated using a global alignment. Alternatively, the percent identity between the two sequences is calculated using a local alignment. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (*i.e.*, % identity = # of identical positions/total # of positions (*e.g.*, overlapping positions) x100). In one embodiment the two sequences are the same length. In another embodiment, the two sequences are not the same length.

The determination of percent identity between two sequences can be accomplished using a mathematical algorithm. A preferred, non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul (1990) *Proc. Natl. Acad. Sci. USA* 87:2264-2268, modified as in Karlin and Altschul (1993) *Proc. Natl. Acad. Sci. USA* 90:5873-5877. Such an algorithm is incorporated into the BLASTN and BLASTX programs of Altschul, *et al.* (1990) *J. Mol. Biol.* 215:403-410. BLAST nucleotide searches can be performed with the BLASTN program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to a nucleic acid molecules of the invention. BLAST protein searches can be performed with the BLASTP program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to a protein molecules of the invention. To obtain gapped alignments for comparison purposes, a newer version of the BLAST algorithm called Gapped BLAST can be utilized as described in Altschul *et al.* (1997) *Nucleic Acids Res.* 25:3389-3402, which is able to perform gapped local alignments for the programs BLASTN, BLASTP and BLASTX. Alternatively, PSI-Blast can be used to perform an iterated search which detects distant relationships between molecules. When utilizing

BLAST, Gapped BLAST, and PSI-Blast programs, the default parameters of the respective programs (*e.g.*, BLASTX and BLASTN) can be used. See <http://www.ncbi.nlm.nih.gov>. Another preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, (1988) *CABIOS* 4:11-17. Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used. Yet another useful algorithm for identifying regions of local sequence similarity and alignment is the FASTA algorithm as described in Pearson and Lipman (1988) *Proc. Natl. Acad. Sci. USA* 85:2444-2448. When using the FASTA algorithm for comparing nucleotide or amino acid sequences, a PAM120 weight residue table can, for example, be used with a *k*-tuple value of 2.

The percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating percent identity, only exact matches are counted.

The invention also provides chimeric or fusion proteins comprising a marker protein or a segment thereof. As used herein, a "chimeric protein" or "fusion protein" comprises all or part (preferably a biologically active part) of a marker protein operably linked to a heterologous polypeptide (*i.e.*, a polypeptide other than the marker protein). Within the fusion protein, the term "operably linked" is intended to indicate that the marker protein or segment thereof and the heterologous polypeptide are fused in-frame to each other. The heterologous polypeptide can be fused to the amino-terminus or the carboxyl-terminus of the marker protein or segment.

One useful fusion protein is a GST fusion protein in which a marker protein or segment is fused to the carboxyl terminus of GST sequences. Such fusion proteins can facilitate the purification of a recombinant polypeptide of the invention.

In another embodiment, the fusion protein contains a heterologous signal sequence at its amino terminus. For example, the native signal sequence of a marker protein can be removed and replaced with a signal sequence from another protein. For example, the gp67 secretory sequence of the baculovirus envelope protein can be used as a heterologous signal sequence (Ausubel *et al.*, ed., *Current Protocols in Molecular*

Biology, John Wiley & Sons, NY, 1992). Other examples of eukaryotic heterologous signal sequences include the secretory sequences of melittin and human placental alkaline phosphatase (Stratagene; La Jolla, California). In yet another example, useful prokaryotic heterologous signal sequences include the *phoA* secretory signal (Sambrook *et al.*, *supra*) and the protein A secretory signal (Pharmacia Biotech; Piscataway, New Jersey).

In yet another embodiment, the fusion protein is an immunoglobulin fusion protein in which all or part of a marker protein is fused to sequences derived from a member of the immunoglobulin protein family. The immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a ligand (soluble or membrane-bound) and a protein on the surface of a cell (receptor), to thereby suppress signal transduction *in vivo*. The immunoglobulin fusion protein can be used to affect the bioavailability of a cognate ligand of a marker protein. Inhibition of ligand/receptor interaction can be useful therapeutically, both for treating proliferative and differentiative disorders and for modulating (*e.g.* promoting or inhibiting) cell survival. Moreover, the immunoglobulin fusion proteins of the invention can be used as immunogens to produce antibodies directed against a marker protein in a subject, to purify ligands and in screening assays to identify molecules which inhibit the interaction of the marker protein with ligands.

Chimeric and fusion proteins of the invention can be produced by standard recombinant DNA techniques. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and re-amplified to generate a chimeric gene sequence (see, *e.g.*, Ausubel *et al.*, *supra*). Moreover, many expression vectors are commercially available that already encode a fusion moiety (*e.g.*, a GST polypeptide). A nucleic acid encoding a polypeptide of the invention can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the polypeptide of the invention.

A signal sequence can be used to facilitate secretion and isolation of marker proteins. Signal sequences are typically characterized by a core of hydrophobic amino

acids which are generally cleaved from the mature protein during secretion in one or more cleavage events. Such signal peptides contain processing sites that allow cleavage of the signal sequence from the mature proteins as they pass through the secretory pathway. Thus, the invention pertains to marker proteins, fusion proteins or segments thereof having a signal sequence, as well as to such proteins from which the signal sequence has been proteolytically cleaved (*i.e.*, the cleavage products). In one embodiment, a nucleic acid sequence encoding a signal sequence can be operably linked in an expression vector to a protein of interest, such as a marker protein or a segment thereof. The signal sequence directs secretion of the protein, such as from a eukaryotic host into which the expression vector is transformed, and the signal sequence is subsequently or concurrently cleaved. The protein can then be readily purified from the extracellular medium by art recognized methods. Alternatively, the signal sequence can be linked to the protein of interest using a sequence which facilitates purification, such as with a GST domain.

The present invention also pertains to variants of the marker proteins. Such variants have an altered amino acid sequence which can function as either agonists (mimetics) or as antagonists. Variants can be generated by mutagenesis, *e.g.*, discrete point mutation or truncation. An agonist can retain substantially the same, or a subset, of the biological activities of the naturally occurring form of the protein. An antagonist of a protein can inhibit one or more of the activities of the naturally occurring form of the protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the protein of interest. Thus, specific biological effects can be elicited by treatment with a variant of limited function. Treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein can have fewer side effects in a subject relative to treatment with the naturally occurring form of the protein.

Variants of a marker protein which function as either agonists (mimetics) or as antagonists can be identified by screening combinatorial libraries of mutants, *e.g.*, truncation mutants, of the protein of the invention for agonist or antagonist activity. In one embodiment, a variegated library of variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of variants can be produced by, for example, enzymatically ligating a

mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential protein sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (*e.g.*, for phage display). There are a variety of methods which can be used to produce libraries of potential variants of the marker proteins from a degenerate oligonucleotide sequence. Methods for synthesizing degenerate oligonucleotides are known in the art (see, *e.g.*, Narang, 1983, *Tetrahedron* 39:3; Itakura *et al.*, 1984, *Annu. Rev. Biochem.* 53:323; Itakura *et al.*, 1984, *Science* 198:1056; Ike *et al.*, 1983 *Nucleic Acid Res.* 11:477).

In addition, libraries of segments of a marker protein can be used to generate a variegated population of polypeptides for screening and subsequent selection of variant marker proteins or segments thereof. For example, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of the coding sequence of interest with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes amino terminal and internal fragments of various sizes of the protein of interest.

Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. The most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify variants of a protein of the invention (Arkin and Yourvan, 1992, *Proc. Natl. Acad. Sci. USA* 89:7811-7815; Delgrave *et al.*, 1993, *Protein Engineering* 6(3):327- 331).

Another aspect of the invention pertains to antibodies directed against a protein of the invention. In preferred embodiments, the antibodies specifically bind a marker protein or a fragment thereof. The terms "antibody" and "antibodies" as used interchangeably herein refer to immunoglobulin molecules as well as fragments and derivatives thereof that comprise an immunologically active portion of an immunoglobulin molecule, (*i.e.*, such a portion contains an antigen binding site which specifically binds an antigen, such as a marker protein, *e.g.*, an epitope of a marker protein). An antibody which specifically binds to a protein of the invention is an antibody which binds the protein, but does not substantially bind other molecules in a sample, *e.g.*, a biological sample, which naturally contains the protein. Examples of an immunologically active portion of an immunoglobulin molecule include, but are not limited to, single-chain antibodies (scAb), F(ab) and F(ab')₂ fragments.

An isolated protein of the invention or a fragment thereof can be used as an immunogen to generate antibodies. The full-length protein can be used or, alternatively, the invention provides antigenic peptide fragments for use as immunogens. The antigenic peptide of a protein of the invention comprises at least 8 (preferably 10, 15, 20, or 30 or more) amino acid residues of the amino acid sequence of one of the proteins of the invention, and encompasses at least one epitope of the protein such that an antibody raised against the peptide forms a specific immune complex with the protein. Preferred epitopes encompassed by the antigenic peptide are regions that are located on the surface of the protein, *e.g.*, hydrophilic regions. Hydrophobicity sequence analysis, hydrophilicity sequence analysis, or similar analyses can be used to identify hydrophilic regions. In preferred embodiments, an isolated marker protein or fragment thereof is used as an immunogen.

An immunogen typically is used to prepare antibodies by immunizing a suitable (*i.e.* immunocompetent) subject such as a rabbit, goat, mouse, or other mammal or vertebrate. An appropriate immunogenic preparation can contain, for example, recombinantly-expressed or chemically-synthesized protein or peptide. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or a similar immunostimulatory agent. Preferred immunogen compositions are those that contain no other human proteins such as, for example, immunogen compositions made using a non-human host cell for recombinant expression of a protein of the invention. In

such a manner, the resulting antibody compositions have reduced or no binding of human proteins other than a protein of the invention.

The invention provides polyclonal and monoclonal antibodies. The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope. Preferred polyclonal and monoclonal antibody compositions are ones that have been selected for antibodies directed against a protein of the invention. Particularly preferred polyclonal and monoclonal antibody preparations are ones that contain only antibodies directed against a marker protein or fragment thereof.

Polyclonal antibodies can be prepared by immunizing a suitable subject with a protein of the invention as an immunogen. The antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized polypeptide. At an appropriate time after immunization, *e.g.*, when the specific antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies (mAb) by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975) *Nature* 256:495-497, the human B cell hybridoma technique (see Kozbor *et al.*, 1983, *Immunol. Today* 4:72), the EBV-hybridoma technique (see Cole *et al.*, pp. 77-96 In *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., 1985) or trioma techniques. The technology for producing hybridomas is well known (see generally *Current Protocols in Immunology*, Coligan *et al.* ed., John Wiley & Sons, New York, 1994). Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the hybridoma culture supernatants for antibodies that bind the polypeptide of interest, *e.g.*, using a standard ELISA assay.

Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal antibody directed against a protein of the invention can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (*e.g.*, an antibody phage display library) with the polypeptide of interest. Kits for generating and screening phage display libraries are commercially available (*e.g.*, the Pharmacia *Recombinant Phage Antibody System*, Catalog No. 27-9400-01; and the Stratagene

SurfZAP Phage Display Kit, Catalog No. 240612). Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, U.S. Patent No. 5,223,409; PCT Publication No. WO 92/18619; PCT Publication No. WO 91/17271; PCT Publication No. WO 92/20791; PCT Publication No. WO 92/15679; PCT Publication No. WO 93/01288; PCT Publication No. WO 92/01047; PCT Publication No. WO 92/09690; PCT Publication No. WO 90/02809; Fuchs *et al.* (1991) *Bio/Technology* 9:1370-1372; Hay *et al.* (1992) *Hum. Antibod. Hybridomas* 3:81-85; Huse *et al.* (1989) *Science* 246:1275- 1281; Griffiths *et al.* (1993) *EMBO J.* 12:725-734.

The invention also provides recombinant antibodies that specifically bind a protein of the invention. In preferred embodiments, the recombinant antibodies specifically binds a marker protein or fragment thereof. Recombinant antibodies include, but are not limited to, chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, single-chain antibodies and multi-specific antibodies. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region. (See, *e.g.*, Cabilly *et al.*, U.S. Patent No. 4,816,567; and Boss *et al.*, U.S. Patent No. 4,816,397, which are incorporated herein by reference in their entirety.) Single-chain antibodies have an antigen binding site and consist of a single polypeptide. They can be produced by techniques known in the art, for example using methods described in Ladner *et. al* U.S. Pat. No. 4,946,778 (which is incorporated herein by reference in its entirety); Bird *et al.*, (1988) *Science* 242:423-426; Whitlow *et al.*, (1991) *Methods in Enzymology* 2:1-9; Whitlow *et al.*, (1991) *Methods in Enzymology* 2:97-105; and Huston *et al.*, (1991) *Methods in Enzymology Molecular Design and Modeling: Concepts and Applications* 203:46-88. Multi-specific antibodies are antibody molecules having at least two antigen-binding sites that specifically bind different antigens. Such molecules can be produced by techniques known in the art, for example using methods described in Segal, U.S. Patent No. 4,676,980 (the disclosure of which is incorporated herein by reference in its entirety); Holliger *et al.*, (1993) *Proc. Natl. Acad. Sci. USA* 90:6444-6448; Whitlow *et al.*, (1994) *Protein Eng.* 7:1017-1026 and U.S. Pat. No. 6,121,424.

Humanized antibodies are antibody molecules from non-human species having one or more complementarity determining regions (CDRs) from the non-human species and a framework region from a human immunoglobulin molecule. (See, *e.g.*, Queen, U.S. Patent No. 5,585,089, which is incorporated herein by reference in its entirety.) Humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in PCT Publication No. WO 87/02671; European Patent Application 184,187; European Patent Application 171,496; European Patent Application 173,494; PCT Publication No. WO 86/01533; U.S. Patent No. 4,816,567; European Patent Application 125,023; Better *et al.* (1988) *Science* 240:1041-1043; Liu *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:3439-3443; Liu *et al.* (1987) *J. Immunol.* 139:3521- 3526; Sun *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:214-218; Nishimura *et al.* (1987) *Cancer Res.* 47:999-1005; Wood *et al.* (1985) *Nature* 314:446-449; and Shaw *et al.* (1988) *J. Natl. Cancer Inst.* 80:1553-1559); Morrison (1985) *Science* 229:1202-1207; Oi *et al.* (1986) *Bio/Techniques* 4:214; U.S. Patent 5,225,539; Jones *et al.* (1986) *Nature* 321:552-525; Verhoeyan *et al.* (1988) *Science* 239:1534; and Beidler *et al.* (1988) *J. Immunol.* 141:4053-4060.

More particularly, humanized antibodies can be produced, for example, using transgenic mice which are incapable of expressing endogenous immunoglobulin heavy and light chains genes, but which can express human heavy and light chain genes. The transgenic mice are immunized in the normal fashion with a selected antigen, *e.g.*, all or a portion of a polypeptide corresponding to a marker of the invention. Monoclonal antibodies directed against the antigen can be obtained using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar (1995) *Int. Rev. Immunol.* 13:65-93). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, *e.g.*, U.S. Patent 5,625,126; U.S. Patent 5,633,425; U.S. Patent 5,569,825; U.S. Patent 5,661,016; and U.S. Patent 5,545,806. In addition, companies such as Abgenix, Inc. (Freemont,

CA), can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, *e.g.*, a murine antibody, is used to guide the selection of a completely human antibody recognizing the same epitope (Jespers *et al.*, 1994, *Bio/technology* 12:899-903).

The antibodies of the invention can be isolated after production (*e.g.*, from the blood or serum of the subject) or synthesis and further purified by well-known techniques. For example, IgG antibodies can be purified using protein A chromatography. Antibodies specific for a protein of the invention can be selected or (*e.g.*, partially purified) or purified by, *e.g.*, affinity chromatography. For example, a recombinantly expressed and purified (or partially purified) protein of the invention is produced as described herein, and covalently or non-covalently coupled to a solid support such as, for example, a chromatography column. The column can then be used to affinity purify antibodies specific for the proteins of the invention from a sample containing antibodies directed against a large number of different epitopes, thereby generating a substantially purified antibody composition, *i.e.*, one that is substantially free of contaminating antibodies. By a substantially purified antibody composition is meant, in this context, that the antibody sample contains at most only 30% (by dry weight) of contaminating antibodies directed against epitopes other than those of the desired protein of the invention, and preferably at most 20%, yet more preferably at most 10%, and most preferably at most 5% (by dry weight) of the sample is contaminating antibodies. A purified antibody composition means that at least 99% of the antibodies in the composition are directed against the desired protein of the invention.

In a preferred embodiment, the substantially purified antibodies of the invention may specifically bind to a signal peptide, a secreted sequence, an extracellular domain, a transmembrane or a cytoplasmic domain or cytoplasmic membrane of a protein of the invention. In a particularly preferred embodiment, the substantially purified antibodies of the invention specifically bind to a secreted sequence or an extracellular domain of the amino acid sequences of a protein of the invention. In a more preferred embodiment,

the substantially purified antibodies of the invention specifically bind to a secreted sequence or an extracellular domain of the amino acid sequences of a marker protein.

An antibody directed against a protein of the invention can be used to isolate the protein by standard techniques, such as affinity chromatography or immunoprecipitation. Moreover, such an antibody can be used to detect the marker protein or fragment thereof (*e.g.*, in a cellular lysate or cell supernatant) in order to evaluate the level and pattern of expression of the marker. The antibodies can also be used diagnostically to monitor protein levels in tissues or body fluids (*e.g.* in disease state or toxicity state associated body fluid) as part of a clinical testing procedure, *e.g.*, to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by the use of an antibody derivative, which comprises an antibody of the invention coupled to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ¹²⁵I, ¹³¹I, ³⁵S or ³H.

Antibodies of the invention may also be used as therapeutic agents in treating cancers. In a preferred embodiment, completely human antibodies of the invention are used for therapeutic treatment of human cancer patients, particularly those having a cancer. In another preferred embodiment, antibodies that bind specifically to a marker protein or fragment thereof are used for therapeutic treatment. Further, such therapeutic antibody may be an antibody derivative or immunotoxin comprising an antibody conjugated to a therapeutic moiety such as a cytotoxin, a therapeutic agent or a radioactive metal ion. A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin,

doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (*e.g.*, methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (*e.g.*, mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (*e.g.*, daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (*e.g.*, dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (*e.g.*, vincristine and vinblastine).

The conjugated antibodies of the invention can be used for modifying a given biological response, for the drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as ribosome-inhibiting protein (see Better et al., U.S. Patent No. 6,146,631, the disclosure of which is incorporated herein in its entirety), abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor, α -interferon, β -interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

Techniques for conjugating such therapeutic moiety to antibodies are well known, see, *e.g.*, Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in *Monoclonal Antibodies And Cancer Therapy*, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery", in *Controlled Drug Delivery* (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in *Monoclonal Antibodies '84: Biological And Clinical Applications*, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in

Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", Immunol. Rev., 62:119-58 (1982).

Accordingly, in one aspect, the invention provides substantially purified antibodies, antibody fragments and derivatives, all of which specifically bind to a protein of the invention and preferably, a marker protein. In various embodiments, the substantially purified antibodies of the invention, or fragments or derivatives thereof, can be human, non-human, chimeric and/or humanized antibodies. In another aspect, the invention provides non-human antibodies, antibody fragments and derivatives, all of which specifically bind to a protein of the invention and preferably, a marker protein. Such non-human antibodies can be goat, mouse, sheep, horse, chicken, rabbit, or rat antibodies. Alternatively, the non-human antibodies of the invention can be chimeric and/or humanized antibodies. In addition, the non-human antibodies of the invention can be polyclonal antibodies or monoclonal antibodies. In still a further aspect, the invention provides monoclonal antibodies, antibody fragments and derivatives, all of which specifically bind to a protein of the invention and preferably, a marker protein. The monoclonal antibodies can be human, humanized, chimeric and/or non-human antibodies.

The invention also provides a kit containing an antibody of the invention conjugated to a detectable substance, and instructions for use. Still another aspect of the invention is a pharmaceutical composition comprising an antibody of the invention. In one embodiment, the pharmaceutical composition comprises an antibody of the invention and a pharmaceutically acceptable carrier.

E. Predictive Medicine

The present invention pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the present invention relates to diagnostic assays for determining the level of expression of one or more marker proteins or nucleic acids, in order to determine whether an individual is at risk of developing certain disease

or drug-induced toxicity. Such assays can be used for prognostic or predictive purposes to thereby prophylactically treat an individual prior to the onset of the disorder.

Yet another aspect of the invention pertains to monitoring the influence of agents (*e.g.*, drugs or other compounds administered either to inhibit or to treat or prevent a disorder or drug-induced toxicity {*i.e.* in order to understand any drug-induced toxic effects that such treatment may have}) on the expression or activity of a marker of the invention in clinical trials. These and other agents are described in further detail in the following sections.

F. Diagnostic Assays

An exemplary method for detecting the presence or absence of a marker protein or nucleic acid in a biological sample involves obtaining a biological sample (*e.g.* toxicity-associated body fluid or tissue sample) from a test subject and contacting the biological sample with a compound or an agent capable of detecting the polypeptide or nucleic acid (*e.g.*, mRNA, genomic DNA, or cDNA). The detection methods of the invention can thus be used to detect mRNA, protein, cDNA, or genomic DNA, for example, in a biological sample *in vitro* as well as *in vivo*. For example, *in vitro* techniques for detection of mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detection of a marker protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. *In vitro* techniques for detection of genomic DNA include Southern hybridizations. *In vivo* techniques for detection of mRNA include polymerase chain reaction (PCR), Northern hybridizations and *in situ* hybridizations. Furthermore, *in vivo* techniques for detection of a marker protein include introducing into a subject a labeled antibody directed against the protein or fragment thereof. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

A general principle of such diagnostic and prognostic assays involves preparing a sample or reaction mixture that may contain a marker, and a probe, under appropriate conditions and for a time sufficient to allow the marker and probe to interact and bind, thus forming a complex that can be removed and/or detected in the reaction mixture.

These assays can be conducted in a variety of ways.

For example, one method to conduct such an assay would involve anchoring the marker or probe onto a solid phase support, also referred to as a substrate, and detecting target marker/probe complexes anchored on the solid phase at the end of the reaction. In one embodiment of such a method, a sample from a subject, which is to be assayed for presence and/or concentration of marker, can be anchored onto a carrier or solid phase support. In another embodiment, the reverse situation is possible, in which the probe can be anchored to a solid phase and a sample from a subject can be allowed to react as an unanchored component of the assay.

There are many established methods for anchoring assay components to a solid phase. These include, without limitation, marker or probe molecules which are immobilized through conjugation of biotin and streptavidin. Such biotinylated assay components can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques known in the art (*e.g.*, biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). In certain embodiments, the surfaces with immobilized assay components can be prepared in advance and stored.

Other suitable carriers or solid phase supports for such assays include any material capable of binding the class of molecule to which the marker or probe belongs. Well-known supports or carriers include, but are not limited to, glass, polystyrene, nylon, polypropylene, nylon, polyethylene, dextran, amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite.

In order to conduct assays with the above mentioned approaches, the non-immobilized component is added to the solid phase upon which the second component is anchored. After the reaction is complete, uncomplexed components may be removed (*e.g.*, by washing) under conditions such that any complexes formed will remain immobilized upon the solid phase. The detection of marker/probe complexes anchored to the solid phase can be accomplished in a number of methods outlined herein.

In a preferred embodiment, the probe, when it is the unanchored assay component, can be labeled for the purpose of detection and readout of the assay, either directly or indirectly, with detectable labels discussed herein and which are well-known to one skilled in the art.

It is also possible to directly detect marker/probe complex formation without further manipulation or labeling of either component (marker or probe), for example by utilizing the technique of fluorescence energy transfer (see, for example, Lakowicz *et al.*, U.S. Patent No. 5,631,169; Stavrianopoulos, *et al.*, U.S. Patent No. 4,868,103). A fluorophore label on the first, 'donor' molecule is selected such that, upon excitation with incident light of appropriate wavelength, its emitted fluorescent energy will be absorbed by a fluorescent label on a second 'acceptor' molecule, which in turn is able to fluoresce due to the absorbed energy. Alternately, the 'donor' protein molecule may simply utilize the natural fluorescent energy of tryptophan residues. Labels are chosen that emit different wavelengths of light, such that the 'acceptor' molecule label may be differentiated from that of the 'donor'. Since the efficiency of energy transfer between the labels is related to the distance separating the molecules, spatial relationships between the molecules can be assessed. In a situation in which binding occurs between the molecules, the fluorescent emission of the 'acceptor' molecule label in the assay should be maximal. An FET binding event can be conveniently measured through standard fluorometric detection means well known in the art (*e.g.*, using a fluorimeter).

In another embodiment, determination of the ability of a probe to recognize a marker can be accomplished without labeling either assay component (probe or marker) by utilizing a technology such as real-time Biomolecular Interaction Analysis (BIA) (see, *e.g.*, Sjolander, S. and Urbaniczky, C., 1991, *Anal. Chem.* 63:2338-2345 and Szabo *et al.*, 1995, *Curr. Opin. Struct. Biol.* 5:699-705). As used herein, "BIA" or "surface plasmon resonance" is a technology for studying biospecific interactions in real time, without labeling any of the interactants (*e.g.*, BIAcore). Changes in the mass at the binding surface (indicative of a binding event) result in alterations of the refractive index of light near the surface (the optical phenomenon of surface plasmon resonance (SPR)), resulting in a detectable signal which can be used as an indication of real-time reactions between biological molecules.

Alternatively, in another embodiment, analogous diagnostic and prognostic assays can be conducted with marker and probe as solutes in a liquid phase. In such an assay, the complexed marker and probe are separated from uncomplexed components by any of a number of standard techniques, including but not limited to: differential centrifugation, chromatography, electrophoresis and immunoprecipitation. In

differential centrifugation, marker/probe complexes may be separated from uncomplexed assay components through a series of centrifugal steps, due to the different sedimentation equilibria of complexes based on their different sizes and densities (see, for example, Rivas, G., and Minton, A.P., 1993, *Trends Biochem Sci.* 18(8):284-7). Standard chromatographic techniques may also be utilized to separate complexed molecules from uncomplexed ones. For example, gel filtration chromatography separates molecules based on size, and through the utilization of an appropriate gel filtration resin in a column format, for example, the relatively larger complex may be separated from the relatively smaller uncomplexed components. Similarly, the relatively different charge properties of the marker/probe complex as compared to the uncomplexed components may be exploited to differentiate the complex from uncomplexed components, for example through the utilization of ion-exchange chromatography resins. Such resins and chromatographic techniques are well known to one skilled in the art (see, *e.g.*, Heegaard, N.H., 1998, *J. Mol. Recognit.* Winter 11(1-6):141-8; Hage, D.S., and Tweed, S.A. *J Chromatogr B Biomed Sci Appl* 1997 Oct 10;699(1-2):499-525). Gel electrophoresis may also be employed to separate complexed assay components from unbound components (see, *e.g.*, Ausubel *et al.*, ed., *Current Protocols in Molecular Biology*, John Wiley & Sons, New York, 1987-1999). In this technique, protein or nucleic acid complexes are separated based on size or charge, for example. In order to maintain the binding interaction during the electrophoretic process, non-denaturing gel matrix materials and conditions in the absence of reducing agent are typically preferred. Appropriate conditions to the particular assay and components thereof will be well known to one skilled in the art.

In a particular embodiment, the level of marker mRNA can be determined both by *in situ* and by *in vitro* formats in a biological sample using methods known in the art. The term "biological sample" is intended to include tissues, cells, biological fluids and isolates thereof, isolated from a subject, as well as tissues, cells and fluids present within a subject. Many expression detection methods use isolated RNA. For *in vitro* methods, any RNA isolation technique that does not select against the isolation of mRNA can be utilized for the purification of RNA from cells (see, *e.g.*, Ausubel *et al.*, ed., *Current Protocols in Molecular Biology*, John Wiley & Sons, New York 1987-1999). Additionally, large numbers of tissue samples can readily be processed using techniques

well known to those of skill in the art, such as, for example, the single-step RNA isolation process of Chomczynski (1989, U.S. Patent No. 4,843,155).

The isolated mRNA can be used in hybridization or amplification assays that include, but are not limited to, Southern or Northern analyses, polymerase chain reaction analyses and probe arrays. One preferred diagnostic method for the detection of mRNA levels involves contacting the isolated mRNA with a nucleic acid molecule (probe) that can hybridize to the mRNA encoded by the gene being detected. The nucleic acid probe can be, for example, a full-length cDNA, or a portion thereof, such as an oligonucleotide of at least 7, 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to a mRNA or genomic DNA encoding a marker of the present invention. Other suitable probes for use in the diagnostic assays of the invention are described herein. Hybridization of an mRNA with the probe indicates that the marker in question is being expressed.

In one format, the mRNA is immobilized on a solid surface and contacted with a probe, for example by running the isolated mRNA on an agarose gel and transferring the mRNA from the gel to a membrane, such as nitrocellulose. In an alternative format, the probe(s) are immobilized on a solid surface and the mRNA is contacted with the probe(s), for example, in an Affymetrix gene chip array. A skilled artisan can readily adapt known mRNA detection methods for use in detecting the level of mRNA encoded by the markers of the present invention.

An alternative method for determining the level of mRNA marker in a sample involves the process of nucleic acid amplification, *e.g.*, by RT-PCR (the experimental embodiment set forth in Mullis, 1987, U.S. Patent No. 4,683,202), ligase chain reaction (Barany, 1991, *Proc. Natl. Acad. Sci. USA*, 88:189-193), self sustained sequence replication (Guatelli *et al.*, 1990, *Proc. Natl. Acad. Sci. USA* 87:1874-1878), transcriptional amplification system (Kwoh *et al.*, 1989, *Proc. Natl. Acad. Sci. USA* 86:1173-1177), Q-Beta Replicase (Lizardi *et al.*, 1988, *Bio/Technology* 6:1197), rolling circle replication (Lizardi *et al.*, U.S. Patent No. 5,854,033) or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers. As used herein, amplification primers are defined as being

a pair of nucleic acid molecules that can anneal to 5' or 3' regions of a gene (plus and minus strands, respectively, or vice-versa) and contain a short region in between. In general, amplification primers are from about 10 to 30 nucleotides in length and flank a region from about 50 to 200 nucleotides in length. Under appropriate conditions and with appropriate reagents, such primers permit the amplification of a nucleic acid molecule comprising the nucleotide sequence flanked by the primers.

For *in situ* methods, mRNA does not need to be isolated from the prior to detection. In such methods, a cell or tissue sample is prepared/processed using known histological methods. The sample is then immobilized on a support, typically a glass slide, and then contacted with a probe that can hybridize to mRNA that encodes the marker.

As an alternative to making determinations based on the absolute expression level of the marker, determinations may be based on the normalized expression level of the marker. Expression levels are normalized by correcting the absolute expression level of a marker by comparing its expression to the expression of a gene that is not a marker, *e.g.*, a housekeeping gene that is constitutively expressed. Suitable genes for normalization include housekeeping genes such as the actin gene, or epithelial cell-specific genes. This normalization allows the comparison of the expression level in one sample, *e.g.*, a patient sample, to another sample, *e.g.*, a non-disease or non-toxic sample, or between samples from different sources.

Alternatively, the expression level can be provided as a relative expression level. To determine a relative expression level of a marker, the level of expression of the marker is determined for 10 or more samples of normal versus disease or toxic cell isolates, preferably 50 or more samples, prior to the determination of the expression level for the sample in question. The mean expression level of each of the genes assayed in the larger number of samples is determined and this is used as a baseline expression level for the marker. The expression level of the marker determined for the test sample (absolute level of expression) is then divided by the mean expression value obtained for that marker. This provides a relative expression level.

Preferably, the samples used in the baseline determination will be from non-disease or non-toxic cells. The choice of the cell source is dependent on the use of the relative expression level. Using expression found in normal tissues as a mean expression

score aids in validating whether the marker assayed is disease or toxicity specific (versus normal cells). In addition, as more data is accumulated, the mean expression value can be revised, providing improved relative expression values based on accumulated data. Expression data from disease cells or toxic cells provides a means for grading the severity of the disease or toxic state.

In another embodiment of the present invention, a marker protein is detected. A preferred agent for detecting marker protein of the invention is an antibody capable of binding to such a protein or a fragment thereof, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment or derivative thereof (*e.g.*, Fab or F(ab')²) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (*i.e.*, physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin.

Proteins from cells can be isolated using techniques that are well known to those of skill in the art. The protein isolation methods employed can, for example, be such as those described in Harlow and Lane (Harlow and Lane, 1988, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York).

A variety of formats can be employed to determine whether a sample contains a protein that binds to a given antibody. Examples of such formats include, but are not limited to, enzyme immunoassay (EIA), radioimmunoassay (RIA), Western blot analysis and enzyme linked immunoabsorbant assay (ELISA). A skilled artisan can readily adapt known protein/antibody detection methods for use in determining whether cells express a marker of the present invention.

In one format, antibodies, or antibody fragments or derivatives, can be used in methods such as Western blots or immunofluorescence techniques to detect the expressed proteins. In such uses, it is generally preferable to immobilize either the antibody or proteins on a solid support. Suitable solid phase supports or carriers include any support capable of binding an antigen or an antibody. Well-known supports or

carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite.

One skilled in the art will know many other suitable carriers for binding antibody or antigen, and will be able to adapt such support for use with the present invention. For example, protein isolated from disease or toxic cells can be run on a polyacrylamide gel electrophoresis and immobilized onto a solid phase support such as nitrocellulose. The support can then be washed with suitable buffers followed by treatment with the detectably labeled antibody. The solid phase support can then be washed with the buffer a second time to remove unbound antibody. The amount of bound label on the solid support can then be detected by conventional means.

The invention also encompasses kits for detecting the presence of a marker protein or nucleic acid in a biological sample. Such kits can be used to determine if a subject is suffering from or is at increased risk of developing certain diseases or drug-induced toxicity. For example, the kit can comprise a labeled compound or agent capable of detecting a marker protein or nucleic acid in a biological sample and means for determining the amount of the protein or mRNA in the sample (*e.g.*, an antibody which binds the protein or a fragment thereof, or an oligonucleotide probe which binds to DNA or mRNA encoding the protein). Kits can also include instructions for interpreting the results obtained using the kit.

For antibody-based kits, the kit can comprise, for example: (1) a first antibody (*e.g.*, attached to a solid support) which binds to a marker protein; and, optionally, (2) a second, different antibody which binds to either the protein or the first antibody and is conjugated to a detectable label.

For oligonucleotide-based kits, the kit can comprise, for example: (1) an oligonucleotide, *e.g.*, a detectably labeled oligonucleotide, which hybridizes to a nucleic acid sequence encoding a marker protein or (2) a pair of primers useful for amplifying a marker nucleic acid molecule. The kit can also comprise, *e.g.*, a buffering agent, a preservative, or a protein stabilizing agent. The kit can further comprise components necessary for detecting the detectable label (*e.g.*, an enzyme or a substrate). The kit can also contain a control sample or a series of control samples which can be assayed and compared to the test sample. Each component of the kit can be enclosed within an

individual container and all of the various containers can be within a single package, along with instructions for interpreting the results of the assays performed using the kit.

G. Pharmacogenomics

The markers of the invention are also useful as pharmacogenomic markers. As used herein, a “pharmacogenomic marker” is an objective biochemical marker whose expression level correlates with a specific clinical drug response or susceptibility in a patient (see, e.g., McLeod *et al.* (1999) *Eur. J. Cancer* 35(12): 1650-1652). The presence or quantity of the pharmacogenomic marker expression is related to the predicted response of the patient and more particularly the patient’s diseased or toxic cells to therapy with a specific drug or class of drugs. By assessing the presence or quantity of the expression of one or more pharmacogenomic markers in a patient, a drug therapy which is most appropriate for the patient, or which is predicted to have a greater degree of success, may be selected. For example, based on the presence or quantity of RNA or protein encoded by specific tumor markers in a patient, a drug or course of treatment may be selected that is optimized for the treatment of the specific tumor likely to be present in the patient. The use of pharmacogenomic markers therefore permits selecting or designing the most appropriate treatment for each cancer patient without trying different drugs or regimes.

Another aspect of pharmacogenomics deals with genetic conditions that alters the way the body acts on drugs. These pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main clinical complication is hemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (*e.g.*, N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive

metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, a PM will show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. The other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.

Thus, the level of expression of a marker of the invention in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the identification of an individual's drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with a modulator of expression of a marker of the invention.

H. Monitoring Clinical Trials

Monitoring the influence of agents (*e.g.*, drug compounds) on the level of expression of a marker of the invention can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent to affect marker expression can be monitored in clinical trials of subjects receiving treatment for certain diseases, such as cancer, diabetes, obesity, cardiovascular disease, and cardiotoxicity, or drug-induced toxicity. In a preferred embodiment, the present invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (*e.g.*, an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of one or more selected markers of the invention in the pre-administration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the

level of expression of the marker(s) in the post-administration samples; (v) comparing the level of expression of the marker(s) in the pre-administration sample with the level of expression of the marker(s) in the post-administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased expression of the marker gene(s) during the course of treatment may indicate ineffective dosage and the desirability of increasing the dosage. Conversely, decreased expression of the marker gene(s) may indicate efficacious treatment and no need to change dosage.

H. Arrays

The invention also includes an array comprising a marker of the present invention. The array can be used to assay expression of one or more genes in the array. In one embodiment, the array can be used to assay gene expression in a tissue to ascertain tissue specificity of genes in the array. In this manner, up to about 7600 genes can be simultaneously assayed for expression. This allows a profile to be developed showing a battery of genes specifically expressed in one or more tissues.

In addition to such qualitative determination, the invention allows the quantitation of gene expression. Thus, not only tissue specificity, but also the level of expression of a battery of genes in the tissue is ascertainable. Thus, genes can be grouped on the basis of their tissue expression *per se* and level of expression in that tissue. This is useful, for example, in ascertaining the relationship of gene expression between or among tissues. Thus, one tissue can be perturbed and the effect on gene expression in a second tissue can be determined. In this context, the effect of one cell type on another cell type in response to a biological stimulus can be determined. Such a determination is useful, for example, to know the effect of cell-cell interaction at the level of gene expression. If an agent is administered therapeutically to treat one cell type but has an undesirable effect on another cell type, the invention provides an assay to determine the molecular basis of the undesirable effect and thus provides the opportunity to co-administer a counteracting agent or otherwise treat the undesired effect. Similarly, even within a single cell type, undesirable biological effects can be determined at the molecular level. Thus, the effects of an agent on expression of other than the target gene can be ascertained and counteracted.

In another embodiment, the array can be used to monitor the time course of expression of one or more genes in the array. This can occur in various biological contexts, as disclosed herein, for example development of drug-induced toxicity, progression of drug-induced toxicity, and processes, such a cellular transformation associated with drug-induced toxicity.

The array is also useful for ascertaining the effect of the expression of a gene on the expression of other genes in the same cell or in different cells. This provides, for example, for a selection of alternate molecular targets for therapeutic intervention if the ultimate or downstream target cannot be regulated.

The array is also useful for ascertaining differential expression patterns of one or more genes in normal and abnormal cells. This provides a battery of genes that could serve as a molecular target for diagnosis or therapeutic intervention.

VII. Methods for Obtaining Samples

Samples useful in the methods of the invention include any tissue, cell, biopsy, or bodily fluid sample that expresses a marker of the invention. In one embodiment, a sample may be a tissue, a cell, whole blood, serum, plasma, buccal scrape, saliva, cerebrospinal fluid, urine, stool, or bronchoalveolar lavage. In preferred embodiments, the tissue sample is a disease state or toxicity state sample. In more preferred embodiments, the tissue sample is a cancer sample, a diabetes sample, an obesity sample, a cardiovascular sample or a drug-induced toxicity sample.

Body samples may be obtained from a subject by a variety of techniques known in the art including, for example, by the use of a biopsy or by scraping or swabbing an area or by using a needle to aspirate bodily fluids. Methods for collecting various body samples are well known in the art.

Tissue samples suitable for detecting and quantitating a marker of the invention may be fresh, frozen, or fixed according to methods known to one of skill in the art. Suitable tissue samples are preferably sectioned and placed on a microscope slide for further analyses. Alternatively, solid samples, *i.e.*, tissue samples, may be solubilized and/or homogenized and subsequently analyzed as soluble extracts.

In one embodiment, a freshly obtained biopsy sample is frozen using, for example, liquid nitrogen or difluorodichloromethane. The frozen sample is mounted for sectioning using, for example, OCT, and serially sectioned in a cryostat. The serial sections are collected on a glass microscope slide. For immunohistochemical staining the slides may be coated with, for example, chrome-alum, gelatine or poly-L-lysine to ensure that the sections stick to the slides. In another embodiment, samples are fixed and embedded prior to sectioning. For example, a tissue sample may be fixed in, for example, formalin, serially dehydrated and embedded in, for example, paraffin.

Once the sample is obtained any method known in the art to be suitable for detecting and quantitating a marker of the invention may be used (either at the nucleic acid or at the protein level). Such methods are well known in the art and include but are not limited to western blots, northern blots, southern blots, immunohistochemistry, ELISA, *e.g.*, amplified ELISA, immunoprecipitation, immunofluorescence, flow cytometry, immunocytochemistry, mass spectrometric analyses, *e.g.*, MALDI-TOF and SELDI-TOF, nucleic acid hybridization techniques, nucleic acid reverse transcription methods, and nucleic acid amplification methods. In particular embodiments, the expression of a marker of the invention is detected on a protein level using, for example, antibodies that specifically bind these proteins.

Samples may need to be modified in order to make a marker of the invention accessible to antibody binding. In a particular aspect of the immunocytochemistry or immunohistochemistry methods, slides may be transferred to a pretreatment buffer and optionally heated to increase antigen accessibility. Heating of the sample in the pretreatment buffer rapidly disrupts the lipid bi-layer of the cells and makes the antigens (may be the case in fresh specimens, but not typically what occurs in fixed specimens) more accessible for antibody binding. The terms "pretreatment buffer" and "preparation buffer" are used interchangeably herein to refer to a buffer that is used to prepare cytology or histology samples for immunostaining, particularly by increasing the accessibility of a marker of the invention for antibody binding. The pretreatment buffer may comprise a pH-specific salt solution, a polymer, a detergent, or a nonionic or anionic surfactant such as, for example, an ethyloxylated anionic or nonionic surfactant, an alkanoate or an alkoxylate or even blends of these surfactants or even the use of a bile salt. The pretreatment buffer may, for example, be a solution of 0.1% to 1% of

deoxycholic acid, sodium salt, or a solution of sodium laureth-13-carboxylate (*e.g.*, Sandopan LS) or and ethoxylated anionic complex. In some embodiments, the pretreatment buffer may also be used as a slide storage buffer.

Any method for making marker proteins of the invention more accessible for antibody binding may be used in the practice of the invention, including the antigen retrieval methods known in the art. See, for example, Bibbo, *et al.* (2002) *Acta. Cytol.* 46:25-29; Saqi, *et al.* (2003) *Diagn. Cytopathol.* 27:365-370; Bibbo, *et al.* (2003) *Anal. Quant. Cytol. Histol.* 25:8-11, the entire contents of each of which are incorporated herein by reference.

Following pretreatment to increase marker protein accessibility, samples may be blocked using an appropriate blocking agent, *e.g.*, a peroxidase blocking reagent such as hydrogen peroxide. In some embodiments, the samples may be blocked using a protein blocking reagent to prevent non-specific binding of the antibody. The protein blocking reagent may comprise, for example, purified casein. An antibody, particularly a monoclonal or polyclonal antibody that specifically binds to a marker of the invention is then incubated with the sample. One of skill in the art will appreciate that a more accurate prognosis or diagnosis may be obtained in some cases by detecting multiple epitopes on a marker protein of the invention in a patient sample. Therefore, in particular embodiments, at least two antibodies directed to different epitopes of a marker of the invention are used. Where more than one antibody is used, these antibodies may be added to a single sample sequentially as individual antibody reagents or simultaneously as an antibody cocktail. Alternatively, each individual antibody may be added to a separate sample from the same patient, and the resulting data pooled.

Techniques for detecting antibody binding are well known in the art. Antibody binding to a marker of the invention may be detected through the use of chemical reagents that generate a detectable signal that corresponds to the level of antibody binding and, accordingly, to the level of marker protein expression. In one of the immunohistochemistry or immunocytochemistry methods of the invention, antibody binding is detected through the use of a secondary antibody that is conjugated to a labeled polymer. Examples of labeled polymers include but are not limited to polymer-enzyme conjugates. The enzymes in these complexes are typically used to catalyze the deposition of a chromogen at the antigen-antibody binding site, thereby resulting in cell

staining that corresponds to expression level of the biomarker of interest. Enzymes of particular interest include, but are not limited to, horseradish peroxidase (HRP) and alkaline phosphatase (AP).

In one particular immunohistochemistry or immunocytochemistry method of the invention, antibody binding to a marker of the invention is detected through the use of an HRP-labeled polymer that is conjugated to a secondary antibody. Antibody binding can also be detected through the use of a species-specific probe reagent, which binds to monoclonal or polyclonal antibodies, and a polymer conjugated to HRP, which binds to the species specific probe reagent. Slides are stained for antibody binding using any chromagen, *e.g.*, the chromagen 3,3-diaminobenzidine (DAB), and then counterstained with hematoxylin and, optionally, a bluing agent such as ammonium hydroxide or TBS/Tween-20. Other suitable chromagens include, for example, 3-amino-9-ethylcarbazole (AEC). In some aspects of the invention, slides are reviewed microscopically by a cytotechnologist and/or a pathologist to assess cell staining, *e.g.*, fluorescent staining (*i.e.*, marker expression). Alternatively, samples may be reviewed *via* automated microscopy or by personnel with the assistance of computer software that facilitates the identification of positive staining cells.

Detection of antibody binding can be facilitated by coupling the anti-marker antibodies to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S , ^{14}C , or ^3H .

In one embodiment of the invention frozen samples are prepared as described above and subsequently stained with antibodies against a marker of the invention diluted to an appropriate concentration using, for example, Tris-buffered saline (TBS). Primary antibodies can be detected by incubating the slides in biotinylated anti-immunoglobulin.

This signal can optionally be amplified and visualized using diaminobenzidine precipitation of the antigen. Furthermore, slides can be optionally counterstained with, for example, hematoxylin, to visualize the cells.

In another embodiment, fixed and embedded samples are stained with antibodies against a marker of the invention and counterstained as described above for frozen sections. In addition, samples may be optionally treated with agents to amplify the signal in order to visualize antibody staining. For example, a peroxidase-catalyzed deposition of biotinyl-tyramide, which in turn is reacted with peroxidase-conjugated streptavidin (Catalyzed Signal Amplification (CSA) System, DAKO, Carpinteria, CA) may be used.

Tissue-based assays (*i.e.*, immunohistochemistry) are the preferred methods of detecting and quantitating a marker of the invention. In one embodiment, the presence or absence of a marker of the invention may be determined by immunohistochemistry. In one embodiment, the immunohistochemical analysis uses low concentrations of an anti-marker antibody such that cells lacking the marker do not stain. In another embodiment, the presence or absence of a marker of the invention is determined using an immunohistochemical method that uses high concentrations of an anti-marker antibody such that cells lacking the marker protein stain heavily. Cells that do not stain contain either mutated marker and fail to produce antigenically recognizable marker protein, or are cells in which the pathways that regulate marker levels are dysregulated, resulting in steady state expression of negligible marker protein.

One of skill in the art will recognize that the concentration of a particular antibody used to practice the methods of the invention will vary depending on such factors as time for binding, level of specificity of the antibody for a marker of the invention, and method of sample preparation. Moreover, when multiple antibodies are used, the required concentration may be affected by the order in which the antibodies are applied to the sample, *e.g.*, simultaneously as a cocktail or sequentially as individual antibody reagents. Furthermore, the detection chemistry used to visualize antibody binding to a marker of the invention must also be optimized to produce the desired signal to noise ratio.

In one embodiment of the invention, proteomic methods, *e.g.*, mass spectrometry, are used for detecting and quantitating the marker proteins of the

invention. For example, matrix-associated laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) or surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) which involves the application of a biological sample, such as serum, to a protein-binding chip (Wright, G.L., Jr., *et al.* (2002) *Expert Rev Mol Diagn* 2:549; Li, J., *et al.* (2002) *Clin Chem* 48:1296; Laronga, C., *et al.* (2003) *Dis Markers* 19:229; Petricoin, E.F., *et al.* (2002) 359:572; Adam, B.L., *et al.* (2002) *Cancer Res* 62:3609; Tolson, J., *et al.* (2004) *Lab Invest* 84:845; Xiao, Z., *et al.* (2001) *Cancer Res* 61:6029) can be used to detect and quantitate the PY-Shc and/or p66-Shc proteins. Mass spectrometric methods are described in, for example, U.S. Patent Nos. 5,622,824, 5,605,798 and 5,547,835, the entire contents of each of which are incorporated herein by reference.

In other embodiments, the expression of a marker of the invention is detected at the nucleic acid level. Nucleic acid-based techniques for assessing expression are well known in the art and include, for example, determining the level of marker mRNA in a sample from a subject. Many expression detection methods use isolated RNA. Any RNA isolation technique that does not select against the isolation of mRNA can be utilized for the purification of RNA from cells that express a marker of the invention (see, *e.g.*, Ausubel *et al.*, ed., (1987-1999) *Current Protocols in Molecular Biology* (John Wiley & Sons, New York). Additionally, large numbers of tissue samples can readily be processed using techniques well known to those of skill in the art, such as, for example, the single-step RNA isolation process of Chomczynski (1989, U.S. Pat. No. 4,843,155).

The term "probe" refers to any molecule that is capable of selectively binding to a marker of the invention, for example, a nucleotide transcript and/or protein. Probes can be synthesized by one of skill in the art, or derived from appropriate biological preparations. Probes may be specifically designed to be labeled. Examples of molecules that can be utilized as probes include, but are not limited to, RNA, DNA, proteins, antibodies, and organic molecules.

Isolated mRNA can be used in hybridization or amplification assays that include, but are not limited to, Southern or Northern analyses, polymerase chain reaction analyses and probe arrays. One method for the detection of mRNA levels involves contacting the isolated mRNA with a nucleic acid molecule (probe) that can hybridize to the marker mRNA. The nucleic acid probe can be, for example, a full-length cDNA, or a

portion thereof, such as an oligonucleotide of at least 7, 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to marker genomic DNA.

In one embodiment, the mRNA is immobilized on a solid surface and contacted with a probe, for example by running the isolated mRNA on an agarose gel and transferring the mRNA from the gel to a membrane, such as nitrocellulose. In an alternative embodiment, the probe(s) are immobilized on a solid surface and the mRNA is contacted with the probe(s), for example, in an Affymetrix gene chip array. A skilled artisan can readily adapt known mRNA detection methods for use in detecting the level of marker mRNA.

An alternative method for determining the level of marker mRNA in a sample involves the process of nucleic acid amplification, *e.g.*, by RT-PCR (the experimental embodiment set forth in Mullis, 1987, U.S. Pat. No. 4,683,202), ligase chain reaction (Barany (1991) *Proc. Natl. Acad. Sci. USA* 88:189-193), self sustained sequence replication (Guatelli et al. (1990) *Proc. Natl. Acad. Sci. USA* 87:1874-1878), transcriptional amplification system (Kwoh *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86:1173-1177), Q-Beta Replicase (Lizardi *et al.* (1988) *Bio/Technology* 6:1197), rolling circle replication (Lizardi et al., U.S. Pat. No. 5,854,033) or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers. In particular aspects of the invention, marker expression is assessed by quantitative fluorogenic RT-PCR (*i.e.*, the TaqManTM System). Such methods typically utilize pairs of oligonucleotide primers that are specific for a marker of the invention. Methods for designing oligonucleotide primers specific for a known sequence are well known in the art.

The expression levels of a marker of the invention may be monitored using a membrane blot (such as used in hybridization analysis such as Northern, Southern, dot, and the like), or microwells, sample tubes, gels, beads or fibers (or any solid support comprising bound nucleic acids). See U.S. Pat. Nos. 5,770,722, 5,874,219, 5,744,305, 5,677,195 and 5,445,934, which are incorporated herein by reference. The detection of marker expression may also comprise using nucleic acid probes in solution.

In one embodiment of the invention, microarrays are used to detect the expression of a marker of the invention. Microarrays are particularly well suited for this purpose because of the reproducibility between different experiments. DNA microarrays provide one method for the simultaneous measurement of the expression levels of large numbers of genes. Each array consists of a reproducible pattern of capture probes attached to a solid support. Labeled RNA or DNA is hybridized to complementary probes on the array and then detected by laser scanning. Hybridization intensities for each probe on the array are determined and converted to a quantitative value representing relative gene expression levels. See, U.S. Pat. Nos. 6,040,138, 5,800,992 and 6,020,135, 6,033,860, and 6,344,316, which are incorporated herein by reference. High-density oligonucleotide arrays are particularly useful for determining the gene expression profile for a large number of RNA's in a sample.

The amounts of marker, and/or a mathematical relationship of the amounts of a marker of the invention may be used to calculate the risk of recurrence of a disease state, e.g. cancer, diabetes, obesity, cardiovascular disease, or a toxicity state, e.g., a drug-induced toxicity or cardiotoxicity, in a subject being treated for a disease state or toxicity state, the survival of a subject being treated for a disease state or a toxicity state, whether a disease state or toxicity state is aggressive, the efficacy of a treatment regimen for treating a disease state or toxicity state, and the like, using the methods of the invention, which may include methods of regression analysis known to one of skill in the art. For example, suitable regression models include, but are not limited to CART (*e.g.*, Hill, T, and Lewicki, P. (2006) "STATISTICS Methods and Applications" StatSoft, Tulsa, OK), Cox (*e.g.*, www.evidence-based-medicine.co.uk), exponential, normal and log normal (*e.g.*, www.obgyn.cam.ac.uk/mrg/statsbook/stsurvan.html), logistic (*e.g.*, www.en.wikipedia.org/wiki/Logistic_regression), parametric, non-parametric, semi-parametric (*e.g.*, www.socserv.mcmaster.ca/jfox/Books/Companion), linear (*e.g.*, www.en.wikipedia.org/wiki/Linear_regression), or additive (*e.g.*, www.en.wikipedia.org/wiki/Generalized_additive_model).

In one embodiment, a regression analysis includes the amounts of marker. In another embodiment, a regression analysis includes a marker mathematical relationship. In yet another embodiment, a regression analysis of the amounts of marker, and/or a marker mathematical relationship may include additional clinical and/or molecular co-

variates. Such clinical co-variates include, but are not limited to, nodal status, tumor stage, tumor grade, tumor size, treatment regime, *e.g.*, chemotherapy and/or radiation therapy, clinical outcome (*e.g.*, relapse, disease-specific survival, therapy failure), and/or clinical outcome as a function of time after diagnosis, time after initiation of therapy, and/or time after completion of treatment.

VIII. Kits

The invention also provides compositions and kits for prognosing a disease state, *e.g.* cancer, diabetes, obesity, cardiovascular disease, or a toxicity state, *e.g.*, a drug-induced toxicity or cardiotoxicity, recurrence of a disease state or a toxicity state, or survival of a subject being treated for a disease state or a toxicity state. These kits include one or more of the following: a detectable antibody that specifically binds to a marker of the invention, a detectable antibody that specifically binds to a marker of the invention, reagents for obtaining and/or preparing subject tissue samples for staining, and instructions for use.

The kits of the invention may optionally comprise additional components useful for performing the methods of the invention. By way of example, the kits may comprise fluids (*e.g.*, SSC buffer) suitable for annealing complementary nucleic acids or for binding an antibody with a protein with which it specifically binds, one or more sample compartments, an instructional material which describes performance of a method of the invention and tissue specific controls/standards.

IX. Screening Assays

Targets of the invention include, but are not limited to, the genes and/or proteins listed herein. Based on the results of experiments described by Applicants herein, the key proteins modulated in a disease state or a toxicity state are associated with or can be classified into different pathways or groups of molecules, including cytoskeletal components, transcription factors, apoptotic response, pentose phosphate pathway, biosynthetic pathway, oxidative stress (pro-oxidant), membrane alterations, and oxidative phosphorylation metabolism. Accordingly, in one embodiment of the invention, a marker may include one or more genes (or proteins) selected from the group consisting of HSPA8, FLNB, PARK7, HSPA1A/HSPA1B, ST13, TUBB3, MIF, KARS,

NARS, LGALS1, DDX17, EIF5A, HSPA5, DHX9, HNRNPC, CKAP4, HSPA9, PARP1, HADHA, PHB2, ATP5A1, CANX, GRP78, GRP75, TIMP1, PTX3, HSP76, PDIA4, PDIA1, CA2D1, GPAT1 and TAZ. In one embodiment, a marker may include one or more genes (or proteins) selected from the group consisting of GRP78, GRP75, TIMP1, PTX3, HSP76, PDIA4, PDIA1, CA2D1, GPAT1 and TAZ. In some embodiments, the markers are a combination of at least two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-five, thirty, or more of the foregoing genes (or proteins).

Screening assays useful for identifying modulators of identified markers are described below.

The invention also provides methods (also referred to herein as "screening assays") for identifying modulators, *i.e.*, candidate or test compounds or agents (*e.g.*, proteins, peptides, peptidomimetics, peptoids, small molecules or other drugs), which are useful for treating or preventing a disease state or a toxicity state by modulating the expression and/or activity of a marker of the invention. Such assays typically comprise a reaction between a marker of the invention and one or more assay components. The other components may be either the test compound itself, or a combination of test compounds and a natural binding partner of a marker of the invention. Compounds identified *via* assays such as those described herein may be useful, for example, for modulating, *e.g.*, inhibiting, ameliorating, treating, or preventing aggressiveness of a disease state or toxicity state.

The test compounds used in the screening assays of the present invention may be obtained from any available source, including systematic libraries of natural and/or synthetic compounds. Test compounds may also be obtained by any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; peptoid libraries (libraries of molecules having the functionalities of peptides, but with a novel, non-peptide backbone which are resistant to enzymatic degradation but which nevertheless remain bioactive; see, *e.g.*, Zuckermann *et al.*, 1994, *J. Med. Chem.* 37:2678-85); spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the 'one-bead one-compound' library method; and synthetic library methods using affinity chromatography selection. The biological library and peptoid library approaches are limited to peptide libraries, while

the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, 1997, *Anticancer Drug Des.* 12:145).

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt *et al.* (1993) *Proc. Natl. Acad. Sci. U.S.A.* 90:6909; Erb *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:11422; Zuckermann *et al.* (1994). *J. Med. Chem.* 37:2678; Cho *et al.* (1993) *Science* 261:1303; Carrell *et al.* (1994) *Angew. Chem. Int. Ed. Engl.* 33:2059; Carell *et al.* (1994) *Angew. Chem. Int. Ed. Engl.* 33:2061; and in Gallop *et al.* (1994) *J. Med. Chem.* 37:1233.

Libraries of compounds may be presented in solution (*e.g.*, Houghten, 1992, *Biotechniques* 13:412-421), or on beads (Lam, 1991, *Nature* 354:82-84), chips (Fodor, 1993, *Nature* 364:555-556), bacteria and/or spores, (Ladner, USP 5,223,409), plasmids (Cull *et al.*, 1992, *Proc Natl Acad Sci USA* 89:1865-1869) or on phage (Scott and Smith, 1990, *Science* 249:386-390; Devlin, 1990, *Science* 249:404-406; Cwirla *et al.*, 1990, *Proc. Natl. Acad. Sci.* 87:6378-6382; Felici, 1991, *J. Mol. Biol.* 222:301-310; Ladner, *supra.*).

The screening methods of the invention comprise contacting a disease state cell or a toxicity state cell with a test compound and determining the ability of the test compound to modulate the expression and/or activity of a marker of the invention in the cell. The expression and/or activity of a marker of the invention can be determined as described herein.

In another embodiment, the invention provides assays for screening candidate or test compounds which are substrates of a marker of the invention or biologically active portions thereof. In yet another embodiment, the invention provides assays for screening candidate or test compounds which bind to a marker of the invention or biologically active portions thereof. Determining the ability of the test compound to directly bind to a marker can be accomplished, for example, by coupling the compound with a radioisotope or enzymatic label such that binding of the compound to the marker can be determined by detecting the labeled marker compound in a complex. For example, compounds (*e.g.*, marker substrates) can be labeled with ¹³¹I, ¹²⁵I, ³⁵S, ¹⁴C, or ³H, either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting. Alternatively, assay components can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase,

or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product.

This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an agent capable of modulating the expression and/or activity of a marker of the invention identified as described herein can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatment as described above.

*Exemplification of the Invention***EXAMPLE 1: Employing Platform Technology to Build a Cancer Consensus and Simulation Networks**

In this example, the platform technology described in detail above was employed to integrate data obtained from a custom built *in vitro* cancer model, and thereby identify novel proteins/pathways driving the pathogenesis of cancer. Relational maps resulting from this analysis have provided cancer treatment targets, as well as diagnostic/prognostic markers associated with cancer.

The study design is depicted in Figure 18. Briefly, two cancer cell lines (PaCa2, HepG2) and one normal cell line (THLE2) were subjected to one of seven conditions simulating an environment experienced by cancer cells *in vivo*. Specifically, cells were exposed to hyperglycemic condition, hypoxia condition, lactic acid condition, hyperglycemic + hypoxia combination condition, hyperglycemic + lactic acid combination condition, hypoxia + lactic acid combination condition, or hyperglycemic + hypoxia + lactic acid combination condition. Different conditions were created as the following:

- Hyperglycemic condition was created by culturing the cells in media containing 22 mM glucose.
- Hypoxia condition was induced by placing the cells in a Modular Incubator Chamber (MIC-101, Billups-Rothenberg Inc. Del Mar, CA), which was flooded with an industrial gas mix containing 5% CO₂, 2% O₂ and 93% nitrogen.
- Lactic acid condition was created by culturing the cells in media containing 12.5 mM lactic acid.
- Hyperglycemic + hypoxia combination condition was created by culturing the cells in media containing 22 mM glucose and the cells were placed in a Modular Incubator Chamber flooded with an industrial gas mix containing 5% CO₂, 2% O₂ and 93% nitrogen.

--Hyperglycemic + lactic acid combination condition was created by culturing the cells in media containing 22 mM glucose and 12.5 mM lactic acid.

--Hypoxia + lactic acid combination condition was created by culturing the cells in media containing 12.5 mM lactic acid and the cells were placed in a Modular Incubator Chamber flooded with an industrial gas mix containing 5% CO₂, 2% O₂ and 93% nitrogen.

--Hyperglycemic + hypoxia + lactic acid combination condition was created by culturing the cells in media containing 22 mM glucose and 12.5 mM lactic acid, and the cells were placed in a Modular Incubator Chamber flooded with an industrial gas mix containing 5% CO₂, 2% O₂ and 93% nitrogen.

The cell model comprising the above-mentioned cells, wherein the cells were exposed to each condition described above, was additionally interrogated by exposing the cells to an environmental perturbation by treating with Coenzyme Q10. Specifically, the cells were treated with Coenzyme Q10 at 0, 50μM, or 100μM.

Cell samples as well as media samples for each cell line with each condition and each Coenzyme Q10 treatment were collected at various times following treatment, including after 24 hours and 48 hours of treatment.

In addition, cross talk experiments between two different cancer cells, PaCa2 and HepG2 cells, were carried out in which PaCa2 and HepG2 cells were co-cultured. This co-culturing approach is referred to as an extracellular secretome (ECS) experiment. The first cell system (PaCa2) was first seeded in the inserts of the wells of a transwell type growth chamber. Six well plates were used to enable better statistical analysis. At the time of seeding with the first cell system in the inserts, the inserts were placed in a separate 6-well plate. The second cell system (HepG2) was seeded on the primary tray. The insert tray containing the first cell system and the primary tray containing the second cell system were incubated at 37°C overnight. Each of the cell systems was grown in the specific cell specific media (wherein alternatively, each of the cell systems could be grown in a medium adapted to support the growth of both cell types). On the second day, the pre-determined treatment was given by media exchange. Specifically, the inserts containing the first cell system were placed into the primary tray containing the second cell system. The tray was then incubated for a pre-determined time period,

e.g., 24 hour or 48 hours. Duplicate wells were set up with the same conditions, and cells were pooled to yield sufficient material for 2D analysis. The media (1 ml aliquot), the cells from the inserts and the cells from the wells of the primary tray were harvested as separate samples. The experiments were conducted in triplicate in order to provide better statistical analysis power.

Cross-talk experiments were also conducted by “media swap” experiments. Specifically, a cultured media or “secretome” from the first cell system (PaCa2) was collected after 24 hrs or 48 hrs following perturbation or conditioning as described above and then added to the second cell system (HepG2) for 24-48 hrs. The final cultured media or “secretome” from the second cell system was then collected. All final secretomes were subjected to proteomic analysis.

iProfiling of changes in total cellular protein expression by quantitative proteomics was performed for cell and media samples collected for each cell line at each condition and with each “environmental perturbation”, i.e, Coenzyme Q10 treatment, using the techniques described above in the detailed description. iProfiling of changes in total cellular protein expression by quantitative proteomics was similarly performed for cell and media samples collected for each co-cultured cell line at each condition with each treatment.

Further, bioenergetics profiling of the cancer, normal cells and cells in cross-talk experiments exposed to each condition and with or without Coenzyme Q10 perturbation were generated by employing the Seahorse analyzer essentially as recommended by the manufacturer. OCR (Oxygen consumption rate) and ECAR (Extracellular Acidification Rate) were recorded by the electrodes in a 7 μ l chamber created with the cartridge pushing against the seahorse culture plate.

Proteomics data collected for each cell line (including cells in cross-talk experiments) at each condition and with each perturbation, and bioenergetics profiling data collected for each cell line at each condition and with each perturbation, were all inputted and processed by the REFSTM system. Raw data for Paca2, HepG2, THLE2 and cross-talk experiments were then combined using a standardized nomenclature. Genes with more than 15% of the proteomics data missing were filtered out. Data imputation strategy was developed. For example, a within replicates error model was

used to impute data from experimental conditions with replicates. A K-NN algorithm based on 10 neighbors was used to impute data with no replicates. Different REFS™ models were built for three biological systems together, for just the Paca2 system, or for just the HepG2 system linked to the phenotypic data.

The area under the curve and fold changes for each edge connecting a parent node to a child node in the simulation networks were extracted by a custom-built program using the R programming language, where the R programming language is an open source software environment for statistical computing and graphics.

Output from the R program were inputted into Cytoscape, an open source program, to generate a visual representation of the consensus network.

Among all the models built, an exemplary protein interaction REFS consensus network at 70% fragment frequency is shown in figure 21.

Each node in the consensus network shown in figure 21 was simulated by increasing or decreasing expression of LDHA by 4-fold to generate a simulation network using REFS™, as described in detail above in the detailed description.

The effect of simulated LDHA expression change on PARK7 and proteins in notes associated with PARK7 at high level in the exemplary consensus network shown in figure 21 were investigated. Proteins responsive to the LDHA simulation in two cancer cell lines, i.e., Paca2 and HepG2, were identified using REFS™ (see figure 22). The numbers represent particular protein expression level fold changes.

To validate the protein connections identified using the above method, markers identified to be in immediate proximity to LDHA in the simulation network were inputted to IPA, a software program that utilizes neural networks to determine molecular linkage between experimental outputs to networks based on *previously published literature*. Output of the IPA program is shown in figure 23, wherein the markers in grey shapes were identified to be in immediate proximity to LDHA in the simulation network generated by the platform and the markers in unfilled shapes are connections identified by IPA based on known knowledge in previously published literature.

Markers identified in the output from the Interrogative Biology platform technology (shown in Figure 21), i.e. DHX9, HNRNPC, CKAP4, HSPA9, PARP1, HADHA, PHB2, ATP5A1 and CANX were observed to be connected to well-known

cancer markers such as TP53 and PARK7 within the IPA generated network (shown in Figure 23). The fact that the factors identified by the use of the Interrogative Biology platform share connectivity with known factors published in the scientific literatures validated the accuracy of the network created by the use of the Interrogative Biology Platform. In addition, the network association within the LDHA sub-network created by the use of the Interrogative Biology platform outputs demonstrated the presence of directional influence of each factor, in contrast to the IPA network wherein the linkage between molecular entities does not provide functional directionality between the interacting nodes. Thus, by employing an unbiased approach to data generation, integration and reverse engineering to create a computational model followed by simulation and differential network analysis, the Interrogative Biology discovery platform enables the understanding of hitherto unknown mechanisms in cancer pathophysiology that are in congruence with well-established scientific understandings of disease pathophysiology.

Figure 19 shows effect of CoQ10 treatment on downstream nodes (pubmed protein accession numbers are listed in Figure 19) based on the protein expression data from iProfiling. Protein accession number P00338 is LDHA. Wet lab validation of proteomics data were performed for LDHA expression in HepG2 cells (see Figure 20). As shown in Figure 20, LDHA expression levels were decreased when HepG2 were treated with 50 uM CoQ10 or 100 uM CoQ10 for 24 or 48 hours.

For the well know cancer markers TP53, Bcl-2, Bax and Caspase3 , wet lab validation of effects of CoQ10 treatment on these markers' expression level in SKMEL 28 cells were performed (see Figure 24 and Figure 25).

EXAMPLE 2: Employing Platform Technology to Build a Cancer Delta-Delta Network

In this example, the platform technology described in detail above was employed to integrate data obtained from a custom built *in vitro* cancer model, and thereby identity novel proteins/pathways driving the pathogenesis of cancer. Relational maps resulting

from this analysis have provided cancer treatment targets, as well as diagnostic/prognostic markers associated with cancer.

Briefly, four cancer lines (PaCa2, HepG2, PC3 and MCF7) and two normal cells lines (THLE2 and HDFa) were subject to various conditions simulating an environment experienced by cancer cells *in vivo*. Specifically, cells were exposed separately to each of hyperglycemic conditions, hypoxic conditions and treatment with lactic acid. For example, a hyperglycemic condition was created by culturing the cells in media containing 22 mM glucose. A hypoxic condition was induced by placing the cells in a Modular Incubator Chamber (MIC-101, Billups-Rothenberg Inc. Del Mar, CA), which was flooded with an industrial gas mix containing 5% CO₂, 2% O₂ and 93% nitrogen. For lactic acid treatment, each cell line was treated with 0 or 12.5 mM lactic acid. In addition to exposing the cells to each of the three foregoing conditions separately, cells were also exposed to combinations of two or all three of the conditions (i.e., hyperglycemic and hypoxic conditions; hyperglycemic condition and lactic acid; hypoxic condition and lactic acid; and, hyperglycemic and hypoxic conditions and lactic acid).

The cell model comprising the above-mentioned cells, wherein each type of cell was exposed to each condition described above, was additionally interrogated by exposing the cells to an environmental perturbation by treating with Coenzyme Q10. Specifically, the cells were treated with Coenzyme Q10 at 0, 50 μ M or 100 μ M.

Cell samples, as well as media samples containing the secretome from the cells, for each cell line exposed to each condition (or combination of conditions), with and without Coenzyme Q10 treatment, were collected at various times following treatment, including after 24 hours and 48 hours of treatment.

In addition, cross talk experiments between two different cancer cells, PaCa2 and HepG2 cells, were carried out in which PaCa2 and HepG2 cells were co-cultured. This co-culturing approach is referred to as an extracellular secretome (ECS) experiment. The first cell system (PaCa2) was seeded in the inserts of the wells of a transwell type growth chamber. Six well plates were generally used in order to enable better statistical analysis. At the time of seeding of the first cell system in the inserts, the inserts were placed in a separate 6-well plate. The second cell system (HepG2) was seeded in the

primary tray. The 6-well plate containing the inserts, which contained the first cell system, and the primary tray containing the second cell system were incubated at 37°C overnight. Each of the cell systems was grown in its respective cell specific media (wherein alternatively, each of the cell systems could be grown in a medium adapted to support the growth of both cell types). On the second day, the pre-determined treatment was given by media exchange. Specifically, the inserts containing the first cell system and the first cell system's respective media were placed into the primary tray containing the second cell system and the second cell system's respective media. In all cases of co-culture, however, co-cultured cells had been exposed to the same "cancer condition" (e.g., hyperglycemia, hypoxia, lactic acid, or combinations thereof), albeit separately, during the first day prior to co-culturing. That is, the first cell system in the inserts and the second cell system in the trays were exposed to the same condition before being moved to a "coculture" arrangement. The tray was then incubated for a pre-determined time period, *e.g.*, 24 hour or 48 hours. Duplicate wells were set up with the same conditions, and cells were pooled to yield sufficient material for subsequent proteomic analysis. The media containing the secretome (1 ml aliquot), the cells from the inserts and the cells from the wells of the primary tray were harvested as separate samples. The experiments were conducted in triplicate in order to provide better statistical power.

Cross-talk experiments were also conducted by "media swap" experiments. Specifically, a cultured media or "secretome" from the first cell system (PaCa2) was collected after 24 hrs or 48 hrs following perturbation and/or conditioning and then added to the second cell system for 24-48 hrs. The final cultured media or "secretome" from the second cell system was then collected. All final secretomes were subjected to proteomic analysis.

Following the exposure of the cell system to the "cancer conditions" described above, the perturbation (i.e., Coenzyme Q10 treatment), and/or the conditions produced in the secretome of a paired cell from a co-culture experiment, the response of the cells was then analyzed by analysis of various readouts from the cell system. The readouts included proteomic data, specifically intracellular protein expression as well as proteins secreted into cell culture media, and functional data, specifically cellular bioenergetics.

iProfiling of changes in total cellular protein expression by quantitative proteomics was performed for cell and media samples collected for each cell line

(normal and cancer cell lines) exposed to each condition (or combination of conditions), with or without the “environmental perturbation”, i.e., Coenzyme Q10 treatment, using the techniques described above in the detailed description.

Further, bioenergetics profiling of each cell line (normal and cancer cell lines) exposed to each condition (or combination of conditions), with or without the “environmental perturbation”, i.e., Coenzyme Q10 treatment, were generated by employing the Seahorse analyzer essentially as recommended by the manufacturer. Oxygen consumption rate (OCR) and Extracellular Acidification Rate (ECAR) were recorded by the electrodes in a 7 μ l chamber created with the cartridge pushing against the seahorse culture plate.

Proteomics data collected for each cell line at each condition(s) and with/without each perturbation, and bioenergetics profiling data collected for each cell line at each condition(s) and with/without each perturbation, were then processed by the REFS™ system. A “composite cancer perturbed network” was generated from combined data obtained from all of the cancer cell lines, each having been exposed to each specific condition (and combination of conditions), and further exposed to perturbation (CoQ10). A “composite cancer unperturbed network” was generated from combined data obtained from all of the cancer cell lines, each having been exposed to each specific condition (and combination of conditions), without perturbation (without CoQ10). Similarly, a “composite normal perturbed network” was generated from combined data obtained from all of the normal cell lines, each having been exposed to each specific condition (and combination of conditions), and additionally exposed to perturbation (CoQ10). A “composite normal unperturbed network” was generated from combined data obtained from all of the normal cell lines, each having been exposed to each specific condition (and combination of conditions), without perturbation (without CoQ10).

Next, “simulation composite networks” (also referred to herein as “simulation networks”) were generated for each of the four composite networks described above using REFS™. To accomplish this, each node in the given consensus composite network was simulated (by increasing or decreasing by 10-fold) to generate simulation networks using REFS™, as described in detail above in the detailed description.

The area under the curve and fold changes for each edge connecting a parent node to a child node in the simulation networks were extracted by a custom-built program using the R programming language, where the R programming language is an open source software environment for statistical computing and graphics.

Finally, delta networks were generated, where the delta networks represent the differential between two simulation composite networks. The delta networks were generated from the simulation composite networks. To generate a cancer vs. normal differential network in response to Coenzyme Q10 (delta-delta network), consecutive comparison steps were performed as illustrated in Figure 26, by a custom built program using the PERL programming language.

First, cancer untreated (T0) and cancer treated (T1) networks were compared using the R program, and the unique Cancer treated T1 networks were separated (see the crescent shape in dark grey in Figure 26). This represents the Cancer T1 $\cap$ (intersection) Cancer T0 “delta” network. Protein interaction / associations within this delta network can be viewed as representing the unique cancer response to Coenzyme Q10 treatment.

Similarly, normal untreated (T0) and normal treated (T1) networks were compared using the R program, and the unique normal treated T1 networks were separated (see the crescent shape in light grey in Figure 26). This represents the Normal T1 $\cap$ Normal T0 “delta” network. Protein interactions / associations within this delta network can be viewed as representing the unique normal cell response to Coenzyme Q10 treatment.

Finally, unique Cancer T1 networks (see the crescent shape in dark grey in Figure 26) and unique normal T1 networks (see the crescent shape in light grey in Figure 26) were compared using the R program, and networks that are unique to cancer alone, and not present in normal cells, in response to Coenzyme Q10 were generated (see Figure 26). This collection of protein interactions / associations represents the unique pathways within cancer cells that are not present in normal cells upon Coenzyme Q10 treatment. This collection of protein interactions/associations is called a “delta-delta network,” since it is a differential map produced from a comparison of a differential map from cancer cells and a differential map from normal control cells.

Output from the PERL and R programs were input into Cytoscape, an open source program, to generate a visual representation of the Delta-Delta network.

The delta-delta networks identified using the method described herein are highly useful for identifying targets for cancer treatment. For example, according to the delta-delta network presented in Figure 27, Protein A inhibits OCR3 (a measurement for oxydative phosphorylation) and enhances ECAR3 (a measurement for glycolysis). Since this interaction is unique in cancer cells (because the delta-delta network has subtracted any interactions that are commonly present in normal cells upon Coenzyme Q10 treatment), inhibiting the expression of protein A is expected to reduce glycolysis-based energy metabolism, which is a hallmark of the cancer metabolic pathway, and shift the cells towards an oxidative phosphorylation-based energy metabolism, which is a phenotype more closely associated with normal cells. Thus, a combination therapy using Coenzyme Q10 and protein A inhibitor is expected to be effective to treat cancer, at least in part by shifting the energy metabolism profile of the cancer cell to that which resembles a normal cell.

The advantage of the Interrogative Biology platform technology of the invention is further illustrated by the use of a substantive example wherein a sub-network derived from causal networks was compared to molecular network using IPA, a software program that utilizes neural networks to determine molecular linkage between experimental outputs to networks based on *previously published literature*. The causal sub-network containing PARK7 generated using the Interrogative Biology platform (shown in Figure 29) is used as a substantive example. All molecular signatures of the PARK7 network from the Interrogative Biology platform were incorporated into IPA to generate a network based on known/existing literature evidence. The network outputs between the Interrogative Biology output and that generated by the use of IPA was then compared.

Six markers identified by the output from the Interrogative Biology platform technology (shown in Figure 29), i.e. A, B, C, X, Y and Z in Figures 27-29, were observed to be connected to TP53 within the IPA generated network (Figure 28). Among the six markers, A, B and C have been reported in the literature to be associated with cancer, as well as HSPA1A/HSPA1B. X, Y and Z were identified as “hubs” or key drivers of the cancer state, and are therefore identified as novel cancer markers. Further,

MIF1 and KARS were also identified as “hubs” or key drivers of the cancer state, and are therefore identified as novel cancer markers. The fact that the factors identified by the use of the Interrogative Biology platform share connectivity with known factors published in the scientific literatures validated the accuracy of the network created by the use of the Interrogative Biology Platform. In addition, the network association within the PARK7 sub-network created by the use of the Interrogative Biology platform outputs (shown in Figure 29) demonstrated the presence of directional influence of each factor, in contrast to the IPA network (shown in Figure 28) wherein the linkage between molecular entities does not provide functional directionality between the interacting nodes. Furthermore, outputs from the Interrogative Biology platform (shown as dotted lines in Figure 29) demonstrated the association of these components leading to a potential mechanism through PARK7. Protein C, Protein A and other nodes of PARK7 were observed to be key drivers of cancer metabolism (Figure 27).

As evidenced by the present example, by employing an unbiased approach to data generation, integration and reverse engineering to create a computational model followed by simulation and differential network analysis, the Interrogative Biology discovery platform enables the understanding of hitherto unknown mechanisms in cancer pathophysiology that are in congruence with well-established scientific understandings of disease pathophysiology.

**EXAMPLE 3: Employing Platform Technology to Build a Diabetes/Obesity/
Cardiovascular Disease Delta-Delta Network**

In this example, the platform technology described in detail above in the detailed description was employed to integrate data obtained from a custom built diabetes/obesity/cardiovascular disease (CVD) model, and to identify novel proteins/pathways driving the pathogenesis of diabetes/obesity/CVD. Relational maps resulting from this analysis have provided diabetes/obesity/CVD treatment targets, as well as diagnostic/prognostic markers associated with diabetes/obesity/CVD.

Five primary human cell lines, namely adipocytes, myotubes, hepatocytes, aortic smooth muscle cells (HASMC), and proximal tubular cells (HK2) were subject to one of five conditions simulating an environment experienced by these disease-relevant cells *in*

vivo. Specifically, each of the five cell lines were exposed separately to each of the following conditions: hyperglycemic conditions, hyperlipidemic conditions, hyperinsulinemic conditions, hypoxic conditions and exposure to lactic acid. The hyperglycemic condition was induced by culturing cells in media containing 22 mM glucose. The hyperlipidemic condition was induced by culturing the cells in media containing 0.15 mM sodium palmitate. The hyperinsulinemic condition was induced by culturing the cells in media containing 1000 nM insulin. The hypoxic condition was induced by placing the cells in a Modular Incubator Chamber (MIC-101, Billups-Rothenberg Inc. Del Mar, CA), which was flooded with an industrial gas mix containing 5% CO₂, 2% O₂ and 93% nitrogen. Each cell line was also treated with 0 or 12.5 mM lactic acid.

In addition, cross talk experiments between two different pairs of cells, HASMC (cell system 1) and HK2 cells (cell system 2) or liver cells (cell system 1) and adipocytes (cell system 2) were carried out in which the paired cells were co-cultured. This co-culturing approach is referred to as an extracellular secretome (ECS) experiment. The first cell system (e.g., HASMC) was first seeded in the inserts of the wells of a transwell type growth chamber. Six well plates were used to enable better statistical analysis. At the time of seeding with the first cell system in the inserts, the inserts were placed in a separate 6-well plate. The second cell system (e.g., HK2) was seeded on the primary tray. The insert tray containing the first cell system and the primary tray containing the second cell system were incubated at 37°C overnight. Each of the cell systems was grown in the specific cell specific media (wherein alternatively, each of the cell systems could be grown in a medium adapted to support the growth of both cell types). On the second day, the pre-determined treatment was given by media exchange. Specifically, the inserts containing the first cell system were placed into the primary tray containing the second cell system. The tray was then incubated for a pre-determined time period, e.g., 24 hour or 48 hours. Duplicate wells were set up with the same conditions, and cells were pooled to yield sufficient material for 2D analysis. The media (1 ml aliquot), the cells from the inserts and the cells from the wells of the primary tray were harvested as separate samples. The experiments were conducted in triplicate in order to provide better statistical analysis power.

Cross-talk experiments were also conducted by “media swap” experiments. Specifically, a cultured media or “secretome” from the first cell system, HASMC was collected after 24 hrs or 48 hrs following perturbation or conditioning and then added to the second cell system, Adipocytes, for 24-48 hrs. The final cultured media or “secretome” from the second cell system was then collected. All final secretomes were subjected to proteomic analysis.

The cell model comprising the above-mentioned cells, wherein the cells were exposed to each condition described above, was additionally “interrogated” by exposing the cells to an “environmental perturbation” by treating with Coenzyme Q10. Specifically, the cells were treated with Coenzyme Q10 at 0, 50 μ M, or 100 μ M.

Cell samples for each cell line, condition and Coenzyme Q10 treatment were collected at various times following treatment, including after 24 hours and 48 hours of treatment. For certain cells and under certain conditions, media samples were also collected and analyzed.

iProfiling of changes in total cellular protein expression by quantitative proteomics was performed for cell and media samples collected for each cell line at each condition and with each “environmental perturbation”, i.e, Coenzyme Q10 treatment, using the techniques described above in the detailed description.

Proteomics data collected for each cell line listed above at each condition and with each perturbation, and bioenergetics profiling data collected for each cell line at each condition and with each perturbation, were then processed by the REFS™ system. A composite perturbed network was generated from combined data obtained from all the cell lines for one specific condition (e.g., hyperglycemia) exposed to perturbation (CoQ10). A composite unperturbed network was generated from combined data obtained from all of the cell lines for the same one specific condition (e.g., hyperglycemia), without perturbation (without CoQ10). Similarly, a composite perturbed network was generated from combined data obtained from all of the cell lines for a second, control condition (e.g., normal glycemia) exposed to perturbation (CoQ10). A composite unperturbed network was generated from combined data obtained from all of the cell lines for the same second, control condition (e.g., normal glycemia), without perturbation (without CoQ10).

Each node in the consensus composite networks described above was simulated (by increasing or decreasing by 10-fold) to generate simulation networks using REFS™, as described in detail above in the detailed description.

The area under the curve and fold changes for each edge connecting a parent node to a child node in the simulation networks were extracted by a custom-built program using the R programming language, where the R programming language is an open source software environment for statistical computing and graphics.

Delta networks were generated from the simulated composite networks. To generate a Diabetes/Obesity/Cardiovascular disease condition vs. normal condition differential network in response to Coenzyme Q10 (delta-delta network), steps of comparison were performed as illustrated in Figure 30, by a custom built program using the PERL programming language.

Specifically, as shown in Figure 30, Treatment T1 refers to Coenzyme Q10 treatment and NG and HG refer to normal and hyperglycemia as conditions. Unique edges from NG in the $NG \cap HG$ delta network was compared with unique edges of HGT1 in the $HG \cap HGT1$ delta network. Edges in the intersection of NG and HGT1 are HG edges that are restored to NG with T1. HG edges restored to NG with T1 were superimposed on the $NG \cap HG$ delta network (shown in darker colored circles in Figure 31)

-

Specifically, a simulated composite map of normal glycemia (NG) condition and a simulated composite map of hyperglycemia (HG) condition were compared using a custom-made Perl program to generate unique edges of the normal glycemia condition. A simulated composite map of hyperglycemia condition without Coenzyme Q10 treatment (HG) and a simulated map of hyperglycemia condition with Coenzyme Q10 treatment (HGT1) were compared using a custom-made Perl program to generate unique edges of the hyperglycemia condition with Coenzyme Q10 treatment (HGT1). Edges in the intersection of the unique edges from normal glycemia condition (NG) and the unique edges from hyperglycemia condition with Coenzyme Q10 treatment (HGT1)

were identified using the Perl program. These edges represent factors/networks that are restored to normal glycemia condition from hyperglycemia condition by the treatment of Coenzyme Q10. The delta-delta network of hyperglycemic edges restored to normal with Coenzyme Q10 treatment was superimposed on the normal glycemia $\cap$ Hyperglycemia delta network. A sample of the superimposed networks is shown in Figure 31. Figure 31 is an exemplary diabetes/obesity/cardiovascular disease condition vs. normal condition differential network in response to Coenzyme Q10 (delta-delta network). Darker colored circles in Figure 31 are identified edges which were restored to a normal glycemia condition from a hyperglycemia condition by the treatment of Coenzyme Q10. Lighter colored circles in Figure 31 are identified unique normal hypercemia edges.

Output from the PERL and R programs were input into Cytoscape, an open source program, to generate a visual representation of the Delta-Delta network.

Similarly to the experiments described above for hyperglycemia vs. normal glycemie condition, a simulated composite network of hyperlipidemia condition (combining data from all diabetes/obesity/cardiovascular-related cells described above) without Coenzyme Q10 treatment and a simulated composite network of hyperlipidemia condition (combining data from all diabetes/obesity/cardiovascular-related cells, described above) with Coenzyme Q10 treatment were compared using the Perl program to generate unique edges of the hyperlipidemia condition with Coenzyme Q10 treatment. Edges in the intersection of the unique edges from normal lipidemia condition and the unique edges from hyperlipidemic condition with Coenzyme Q10 treatment were identified using the Perl program. These edges represent factors/networks that are restored to a normal lipidemia condition from a hyperlipidemia condition by the treatment of Coenzyme Q10. A delta-delta network of hyperlipidemic edges restored to normal with Coenzyme Q10 treatment was superimposed on the normal lipidemia $\cap$ Hyperlipidemia delta network. A sample of the superimposed networks is shown in Figure 32. Darker colored circles in Figure 32 are identified edges which were restored to a normal lipidemia condition from a hyperlipidemia condition by the treatment of Coenzyme Q10. Lighter colored circles in Figure 32 are identified unique normal lipidemia edges. FASN was identified as one important factor of a signaling pathway

which modulates Coenzyme Q10's effect of restoring hyperlipidemia to a normal lipidemia condition.

Fatty acid synthase- fatty acid synthesis enzymes such as FASN have been implicated in almost all aspects of human metabolic alterations such as obesity, insulin resistance or dyslipidemia. FASN inhibitors have been proposed as lead molecules for treatment of obesity, although molecular mechanisms are unknown (Mobbs *et al* 2002). Cerulenin and synthetic compound C75- FASN inhibitors have been shown to have an effect in reducing food intake and effectuate weight loss (Loftus *et al* 2000).

The fact that FASN was identified by the platform technology described herein as one important factor in the signaling pathway which modulates Coenzyme Q10's effect of restoring a diabetic to a normal state, as shown in Figure 32, validated the accuracy of this delta-delta network. Therefore, other novel-factors identified in this delta-delta network will be potential therapeutic factors or drug targets for further investigation.

EXAMPLE 4: Employing Platform Technology to Build Models of Drug Induced Cardiotoxicity

In this example, the platform technology described in detail above in the detailed description was employed to integrate data obtained from a custom built cardiotoxicity model, and to identify novel proteins/pathways driving the pathogenesis/ toxicity of drugs. Relational maps resulting from this analysis have provided toxicity biomarkers.

In the healthy heart contractile function depends on a balance of fatty acid and carbohydrate oxidation. Chronic imbalance in uptake, utilization, organellar biogenesis and secretion in non-adipose tissue (heart and liver) is thought to be at the center of mitochondrial damage and dysfunction and a key player in drug induced cardiotoxicity. Here Applicants describe a systems approach combining protein and lipid signatures with functional end point assays specifically looking at cellular bioenergetics and mitochondrial membrane function. *In vitro* models comprising diabetic and normal cardiomyocytes supplemented with excessive fatty acid and hyperglycemia were treated with a panel of drugs to create signatures and potential mechanisms of toxicity. Applicants demonstrated the varied effects of drugs in destabilizing the mitochondria by disrupting the energy metabolism component at various levels including (i)

Dysregulation of transcriptional networks that controls expression of mitochondrial energy metabolism genes; (ii) Induction of GPAT1 and tafazzin in diabetic cardiomyocytes thereby initiating de novo phospholipid synthesis and remodeling in the mitochondrial membrane; and (iii) Altered fate of fatty acid in diabetic cardiomyocytes, influencing uptake, fatty acid oxidation and ATP synthesis. Further, Applicants combined the power of wet lab biology and AI based data mining platform to generate causal network based on bayesian models. Networks of proteins and lipids that are causal for loss of normal cell function were used to discern mechanisms of drug induced toxicity from cellular protective mechanisms. This novel approach will serve as a powerful new tool to understand mechanism of toxicity while allowing for development of safer therapeutics that correct an altered phenotype.

Human cardiomyocytes were subject to conditions simulating an diabetic environment experienced by the disease-relevant cells *in vivo*. Specifically, the cells were exposed to hyperglycemic conditions and hyperlipidemia conditions. The hyperglycemic condition was induced by culturing cells in media containing 22 mM glucose. The hyperlipidemia condition was induced by culturing the cells in media containing 1mM L-carnitine, 0.7mM Oleic acid and 0.7mM Linoleic acid.

The cell model comprising the above-mentioned cells, wherein the cells were exposed to each condition described above, was additionally “interrogated” by exposing the cells to an “environmental perturbation” by treating with a diabetic drug (T) which is known to cause cardiotoxicity, a rescue molecule (R) or both the diabetic drug and the rescue molecule (T+R). Specifically, the cells were treated with diabetic drug; or treated with rescue molecule Coenzyme Q10 at 0, 50μM, or 100μM; or treated with both of the diabetic drug and the rescue molecule Coenzyme Q10.

Cell samples from each condition with each perturbation treatment were collected at various times following treatment, including after 6 hours of treatment. For certain conditions, media samples were also collected and analyzed.

iProfiling of changes in total cellular protein expression by quantitative proteomics was performed for cell and media samples collected for each condition and with each “environmental perturbation”, i.e, diabetic drug treatment, Coenzyme Q10 treatment or both, using the techniques described above in the detailed description.

Transcriptional profiling experiments were carried out using the Biorad cfx-384 amplification system. Following data collection (Ct), the final fold change over control was determined using the δ Ct method as outlined in manufacturer's protocol.

Lipidomics experiments were carried out using mass spectrometry. Functional assays such as Oxygen consumption rate OCR were measured by employing the Seahorse analyzer essentially as recommended by the manufacturer. OCR was recorded by the electrodes in a 7 μ l chamber created with the cartridge pushing against the seahorse culture plate.

As shown in Figure 35, transcriptional network and expression of human mitochondrial energy metabolism genes in diabetic cardiomyocytes (cardiomyocytes conditioned in hyperglycemic and hyperlipidemia) were compared between perturbed and unperturbed treatments. Specifically, data of transcriptional network and expression of human mitochondrial energy metabolism genes were compared between diabetic cardiomyocytes treated with diabetic drug (T) and untreated diabetic cardiomyocytes samples (UT). Data of Transcriptional network and expression of human mitochondrial energy metabolism genes were compared between diabetic cardiomyocytes treated with both diabetic drug and rescue molecule Coenzyme Q10 (T+R) and untreated diabetic cardiomyocytes samples (UT). Comparing to data from untreated diabetic cardiomyocytes, certain genes expression and transcription were altered when diabetic cardiomyocytes were treated with diabetic drug. Rescue molecule Coenzyme Q10 was demonstrated to reverse the toxic effect of diabetic drug and normalize gene expression and transcription.

As shown in Figure 36A, cardiomyocytes were cultured either in normoglycemia (NG) or hyperglycemia (HG) condition and treated with either diabetic drug alone (T) or with both diabetic drug and rescue molecule Coenzyme Q10 (T+R). Protein expression levels of GPAT1 and TAZ for each condition and each treatment were tested with western blotting. Both GPAT1 and TAZ were upregulated in hyperglycemia conditioned and diabetic drug treated cardiomyocytes. When hyperglycemia conditioned cardiomyocytes were treated with both diabetic drug and rescue molecule Coenzyme Q10, the upregulated protein expression level of GPAT1 and TAZ were normalized.

As shown in Figure 37A, mitochondrial oxygen consumption rate (%) experiments were carried out for hyperglycemia conditioned cardiomyocytes samples. Hyperglycemia conditioned cardiomyocytes were either untreated (UT), treated with diabetic drug T1 which is known to cause cardiotoxicity, treated with diabetic drug T2 which is known to cause cardiotoxicity, treated with both diabetic drug T1 and rescue molecule Coenzyme Q10 (T1+R), or treated with both diabetic drug T2 and rescue molecule Coenzyme Q10 (T2+R). Comparing to untreated control samples, mitochondrial OCR was decreased when hyperglycemia conditioned cardiomyocytes were treated with diabetic drug T1 or T2. However, mitochondrial OCR was normalized when hyperglycemia conditioned cardiomyocytes were treated with both diabetic drug and rescue molecule Coenzyme Q10 (T1 + R, or T2 + R).

As shown in Figure 37B, mitochondria ATP synthesis experiments were carried out for hyperglycemia conditioned cardiomyocytes samples. Hyperglycemia conditioned cardiomyocytes were either untreated (UT), treated with a diabetic drug (T), or treated with both diabetic drug and rescue molecule Coenzyme Q10 (T+R). Comparing to untreated control samples, mitochondrial ATP synthesis was repressed when hyperglycemia conditioned cardiomyocytes were treated with diabetic drug (T).

As shown in Figure 38, based on the collected proteomic data, proteins down regulated by drug treatment were annotated with GO terms. Proteins involved in mitochondrial energy metabolism were down regulated when hyperglycemia conditioned cardiomyocytes were treated with a diabetic drug which is known to cause cardiotoxicity.

Proteomics, lipidomics, transcriptional profiling, functional assays, and western blotting data collected for each condition and with each perturbation, were then processed by the REFSTM system. Composite perturbed networks were generated from combined data obtained from one specific condition (e.g., hyperglycemia, or hyperlipidemia) exposed to each perturbation (e.g., diabetic drug, CoQ10, or both). Composite unperturbed networks were generated from combined data obtained from the same one specific condition (e.g., hyperglycemia, or hyperlipidemia), without perturbation (untreated). Similarly, composite perturbed networks were generated from combined data obtained for a second, control condition (e.g., normal glycemia) exposed to each perturbation (e.g., diabetic drug, CoQ10, or both). Composite unperturbed

networks were generated from combined data obtained from the same second, control condition (e.g., normal glycemia), without perturbation (untreated).

Each node in the consensus composite networks described above was simulated (by increasing or decreasing by 10-fold) to generate simulation networks using REFSTM, as described in detail above in the detailed description.

The area under the curve and fold changes for each edge connecting a parent node to a child node in the simulation networks were extracted by a custom-built program using the R programming language, where the R programming language is an open source software environment for statistical computing and graphics.

Delta networks were generated from the simulated composite networks. To generate a drug induced toxicity condition vs. normal condition differential network in response to the diabetic drug (delt network), steps of comparison were performed as illustrated in Figure 39, by a custom built program using the PERL programming language.

Specifically, as shown in Figure 39, UT refers to protein expression networks of untreated control cardiomyocytes in hyperglycemia condition. Treatment T refers to protein expression networks of diabetic drug treated cardiomyocytes in hyperglycemia condition. Unique edges from T in the $UT \cap T$ delta network are presented in Figure 40.

Specifically, a simulated composite map of untreated cardiomyocytes in hyperglycemia condition and a simulated composite map of diabetic drug treated cardiomyocytes in hyperglycemia condition were compared using a custom-made Perl program to generate unique edges of the diabetic drug treated cardiomyocytes in hyperglycemia condition. Output from the PERL and R programs were input into Cytoscape, an open source program, to generate a visual representation of the delta network. As shown in figure 40, the network represents delta networks that are driven by the diabetic drug versus untreated in cardiomyocytes/ cardiotox models in hyperglycemia condition.

From the drug induced toxicity condition vs. normal condition differential network shown in Figure 40, proteins were identified which drive pathophysiology of drug induced cardiotoxicity, such as GRP78, GRP75, TIMP1, PTX3, HSP76, PDIA4, PDIA1, CA2D1. These proteins can function as biomarkers for identification of other

cardiotoxicity inducing drugs. These proteins can also function as biomarkers for identification of agents which can alleviate cardiotoxicity.

The experiments described in this Example demonstrate that perturbed membrane biology and altered fate of free fatty acid in diabetic cardiomyocytes exposed to drug treatment represent the center piece of drug induced toxicity. Data integration and network biology have allowed for an enhanced understanding of cardiotoxicity, and identification of novel biomarkers predictive for cardiotoxicity.

**EXAMPLE 5: Employing Platform Technology to Implement Multi
Proteomics**

Models for Elucidating Enzymatic Activity.

In general, the platform technology described in Example 1-4 above can be adapted to implement further methods for identifying a modulator of a biological system or disease process. The methods employ a model for the biological system, using cells associated with the biological system, to represents a characteristic aspect of the biological system. The model is used to obtain at least three levels of data, namely (i) a first data set representing global enzyme activity in the cells associated with the biological system, (ii) a second data set representing an effect of the global enzyme activity on the enzyme metabolites or substrates in the cells associated with the biological system, and (iii) a third data set representing global proteomic changes in the cells associated with the biological system. The data is used to generate a consensus causal relationship network among the global enzyme activity, the effect of the global enzyme activity, and the global proteomic changes. The consensus causal relationship network is based solely on the first, second, and third data sets using a programmed computing device (i.e., not based on any other known biological relationship). The consensus causal relationship network is then used to identify a causal relationship unique to the biological system, where at least one gene or protein associated with the unique causal relationship is identified as a modulator of the biological system or disease process.

In this example, the platform technology was adapted to implement multi proteomics techniques for measuring enzyme activity and the direct effects of that activity on the proteome, thereby, provide a system that can be used to understand causal relationships between enzymes and their metabolites/substrates in the context of global changes in the cellular proteome. Such techniques can provide valuable insight because, as demonstrated in this example, enzyme activity can be orthogonal to enzyme expression (e.g., activity down regulated and expression unregulated). Relational maps resulting from such an analysis can provide disease treatment targets, as well as diagnostic/prognostic markers associated with disease. Such targets and markers can provide for therapeutic compositions and methods. Techniques for establishing models, obtaining data sets, generating consensus causal relationship networks, and identifying causal relationship unique to the biological system are discussed in the summary, detailed description, and examples above. Further techniques for establishing models and obtaining data sets representing global enzyme activity and the effect of the global enzyme activity on the enzyme metabolites or substrates are provided below.

FIG. 41A illustrates a method for identifying a modulator of a biological system or disease process, which employs multi proteomic techniques for elucidating enzyme (e.g., kinase) activity. First, a model is established in accordance with the platform technology wherein cell lines are subjected to conditions simulating a disease and interrogated by exposure to an environmental perturbation (e.g., exposure to Sorafenib in the specific example of hepatocellular carcinoma provided below). A control is provided for comparison. Second, enzyme activity and its downstream effects are tracked in the context of global proteomic changes by analyzing (i) global enzymatic activity, (ii) the specific effect of the enzymatic activity on the proteome (e.g., the metabolites/substrates of the enzymatic activity), and (iii) the global effect on the cellular proteome. Third, the datasets are analyzed in accordance with the platform technology to identify modulators of interest. For example, a cancer model can be interrogated by a known anti-cancer drug kinase inhibitor; the effects of this perturbation to the system on the global kinase activity can be analyzed, along with the resulting effects on the phospho proteome and whole proteome; and the dataset can be analyzed by the AI based REFS™ system.

In this example, hepatocellular carcinoma (HCC) was selected to provide an illustrative implementation of the platform technology. HCC is one of the leading causes of cancer-related death worldwide, ranked as the third most fatal cancer after lung and stomach carcinomas. The diverse etiology, high morbidity/mortality, lack of diagnostic markers for early diagnosis and the highly variable clinical course of HCC have hindered advances in diagnosis and treatment. After years of studying the HCC, the understanding of molecular mechanism operational in HCC remains incomplete. The genomic, transcriptomic, and comparative proteomic profiles have yielded some important insights for HCC research. However, many studies focused on single aspect of the cellular changes associated with HCC, hindering the full understanding of biological systems in their true complexity and dynamics.

This illustrative example combines the power of (i) cell biology, (ii) integrated proteomics platforms and an informatics platform that generates causal protein networks to delineate the role of post-translation modification, e.g., phosphorylation, and enzymes that participate in such mechanisms, e.g., kinases, in the pathophysiology of HCC. In particular, this approach incorporates activity based proteomics employing ATP binding domain enrichment probes and phospho-proteome mapping of total proteins in HCC cellular models.

Multikinase inhibitor Sorafenib, a first line chemotherapeutic agent for the advanced HCC patients, was used to probe the role of global kinase activity and protein phosphorylation changes associated with this treatment. The HepG2 (ATCC Ascension No. HB-8065) cell line was selected to model HCC cells and the THLE2 (ATCC Ascension No. CRL-10149) cell line was selected to model normal hepatic cells.

FIG. 41B illustrates a method for global enzyme (e.g., kinase) enrichment profiling. First, a cell lysate including the targeted enzyme (e.g., kinase) is prepared. The second step is probe binding (e.g., an ATP probe in the case of kinase). Then the enzyme is digested and probe-bound fragments are captured. These fragments can be analyzed (e.g., by LC-MS/MS) and the corresponding protein thus identified (e.g., via a database search of the LC-MS/MS data).

THERMO SCIENTIFIC© PIERCE® Kinase Enrichment Kits and ACTIVX© probes (instructions available from THERMO SCIENTIFIC© and PIERCE® Biotechnology www.thermoscientific.com/pierce) were used for global enzyme activity analysis. Briefly, these and similar kits enable selective labeling and enrichment of ATPases including kinases, chaperones and metabolic enzymes. ATP and ADP Probes are generally nucleotide derivatives, which covalently modify the active site of enzymes with conserved lysine residues in the nucleotide-binding site. For example, the structure of desthiobiotin-ATP and -ADP consists of a modified biotin attached to the nucleotide by a labile acyl-phosphate bond. Depending on the position of the lysine within the enzyme active site, either desthiobiotin-ATP or -ADP can be preferred for labeling specific ATPases.

Both desthiobiotin-ATP and -ADP can selectively enrich, identify and profile target enzyme classes in samples or assess the specificity and affinity of enzyme inhibitors. Many ATPases and other nucleotide-binding proteins bind nucleotides or inhibitors even when they are enzymatically inactive; these reagents bind both inactive and active enzymes in a complex sample. Preincubation of samples with small-molecule inhibitors that compete for active-site probes can be used to determine inhibitor binding affinity and target specificity.

Assessment of active-site labeling can be accomplished by either Western blot or mass spectrometry (MS). For the Western blot workflow, desthiobiotin-labeled proteins are enriched for SDS-PAGE analysis and subsequent detection with specific antibodies. For the MS workflow, desthiobiotin-labeled proteins are reduced, alkylated and enzymatically digested to peptides. Only the desthiobiotin-labeled, active-site peptides are enriched for analysis by LC-MS/MS. Both workflows can be used for determining inhibitor target binding, but only the MS workflow can identify global inhibitor targets and off-targets.

THERMO SCIENTIFIC© PIERCE® TiO₂ Phosphopeptide Enrichment and Clean-up Kit (instructions available from THERMO SCIENTIFIC© and PIERCE® Biotechnology www.thermoscientific.com/pierce) were used for the phospho proteome analysis. Briefly, these and similar kits can enable efficient isolation of phosphorylated

peptides from complex and fractionated protein digests for analysis by mass spectrometry (MS). Spherical porous titanium dioxide (TiO₂) combined with optimized buffers provide enhanced enrichment and identification of phosphopeptides with minimal nonspecific binding. The spin-column format is fast and easy to use and can enrich up to 100µg of phosphopeptides from 300-1000µg of digested protein sample. The kit's optimized protocol, buffer components and graphite spin columns result in a high yield of clean phosphopeptide samples ready for MS analysis.

Phosphorylation is a protein modification essential to biological functions such as cell signaling, growth, differentiation and division, and programmed cell death. However, phosphopeptides have high hydrophilicity and are low in abundance, resulting in poor chromatography, ionization and fragmentation. Phosphopeptide enrichment is therefore essential to successful MS analysis. Phosphopeptide enrichment and clean-up kit can be compatible with lysis, reduction, alkylation, digestion and graphite spin columns to provide a complete workflow for phosphopeptide enrichment and identification.

Comparative proteomics, phospho proteome and enzyme activity data are integrated into the AI based REFSTM informatics platform. Causal networks of protein interaction specifically from a functional stand point namely kinase/enzyme activity and potential targets that kinases can phosphorylate are then generated. In addition, using cellular functional read out, enzymes/ kinases that modulate phosphorylation of targets and mechanistically drive pathophysiological cellular behavior are determined. The illustrative implementation outlined herein facilitates global characterization of cellular responses, insights into mechanisms of chemo sensitivity and potential targets/biomarkers for clinical management of HCC.

Materials and Methods

The cells were cultured according to the following protocol. Day 1: HepG2/Hep3B – seed 3.2×10^6 cells in T-75 culture flasks; 7.4×10^6 cells in T-175 culture flasks; or 9.5×10^6 cells in T-225 culture flasks. THLE-2 – seed 1.3×10^6 cells in T-75 culture flasks. Day 2: 16-24 hours later, at 50-70% confluence – add treatment. Control: DMSO at final concentration of 0.01%. EGF: 500 ng/mL in 10 mM acetic

acid. Sorafenib: 1 μ M at 0.1% volume in DMSO. Day 3: 24 hours after treatment, harvest cells by trypsinization. Wash pellets 2X with PBS before freezing.

The global enzyme activity analysis was conducted according to the following protocol.

Cell Lysis:

Fresh-made Lysis buffer – 5 M urea, 50 mM Tris-HCL pH 8.4, 0.1% SDS, 1% Protease Inhibitor Cocktail, 1% Phosphatase Inhibitor Cocktail

- 1) Pellet cells in 1.5-2 mL Eppendorf microtubes by centrifuging at 2000 g for 5 minutes and remove supernatant.
- 2) Wash cells by resuspending pellet in PBS. Repeat wash once more.
- 3) Add an appropriate amount of lysis buffer to each sample and vortex.
- 4) Incubate on ice for 10 minutes with periodic mixing
- 5) Sonicate each sample until lysis is complete
- 6) Centrifuge at top speed for 15 minutes
- 7) Transfer lysate (supernatant) to new tube

Lysis Buffer-Exchange:

Used Pierce's pre-made Reaction Buffer.

Reaction buffer – 20 mM HEPES pH 7.4, 150 mM NaCl, 0.1% TritonX-100

- 1) Twist off Zeba Spin Desalting Column's bottom closure and loosen cap
- 2) Put in 15 mL conical tube
- 3) Centrifuge column at room temperature at 1000 g for 2 minutes to remove storage solution

- 4) Add 3 mL of *Reaction Buffer* to column. Centrifuge at 1000 g for 2 minutes to remove buffer. Repeat 2 more times, discarding buffer
 - a. Centrifuge additional 1000 g for 2-3 minutes if there is excess buffer on last wash
- 5) Transfer column to new conical tube
- 6) SLOWLY apply entire lysate to center of resin bed
- 7) Centrifuge at 1000 g for 2 minutes to collect sample. Discard column
- 8) Add 1:100 protease/phosphatase inhibitor cocktail to sample and place on ice
 - a. Samples may be frozen in -80° C freezer

Stopping point

Sample Labeling with Probe:

Used pre-made 1 M MgCl₂ from Pierce.

Made fresh 1 M MnCl₂.

- 1) Determine protein concentration using Bradford Assay
- 2) Dilute lysate with water to 2 mg/mL (2 µg/µL) if possible
- 3) Transfer 2 mg to new microcentrifuge tube
- 4) Add 20 µL of 1 M MgCl₂ to each sample, mix, incubate for 1 min at room temperature.

Note: Final concentration is 0.02 M MgCl₂

- 5) Add 10 µL of 1 M MgCl₂ to each sample, mix, incubate for 1 min at room temperature

Note: Final concentration is 10 mM MgCl₂.

- 6) Equilibrate ATP/ADP reagent to room temperature with desiccant. Store remainder at -80° C
- 7) For 20 μ M reaction – add 10 μ L of ultrapure water to reagent to make 1 mM stock solution
- 8) Add 20 μ L of ATP/ADP stock to each sample and incubate for 1 hour at room temperature.

Labeled Protein Reduction and Alkylation:

Prepare fresh 10 M Urea/50 mM Tris-HCL pH 8.4

- 1) Add 1 mL of 10 M Urea/50 mM Tris-HCL to each reaction
- 2) Add 100 μ L of 200 mM TCEP to each sample. Incubate at 55° C for 1 hr
- 3) Add 100 μ L of 375 mM iodoacetamide to each sample. Incubate at room temperature for 30 minutes in the dark

Buffer Exchange:

Prepare fresh Digest Buffer – 2 M urea, 200 mM Tris-HCL pH 8.4

- 1) Twist off Zeba Spin Desalting Column's bottom closure and loosen cap
- 2) Put in 15 mL conical tube
- 3) Centrifuge column at room temperature at 1000 g for 2 minutes to remove storage solution
- 4) Add 3 mL of Digest Buffer to column. Centrifuge at 1000 g for 2 minutes to remove buffer. Repeat 2 more times, discarding buffer
 - a. Centrifuge additional 1000 g for 2-3 minutes if there is excess buffer on last wash
- 5) Transfer column to new conical tube

- 6) SLOWLY apply entire sample to center of resin bed
- 7) Centrifuge at 1000 g for 2 minutes to collect sample. Discard column

Labeled Protein Digest:

- 1) Add trypsin in 1:50 ratio (trypsin:protein)
- 2) Incubate at 37° C with shaking for overnight

Labeled Peptide Capture and Elution:

Prepare fresh Elution Buffer (50% ACN; 0.1% formic acid)

- 1) Add 50 µL of slurry to each digested sample. Incubate for 1.5 hours at room temperature with constant mixing
- 2) Transfer sample to Pierce Spin column. Centrifuge at 1000 g for 1 minute. Collect flow-through and save.
- 3) At 1000 g for 1 minute per wash:
 - a. Wash resin 3X with 500 µL of 4 M urea/50 mM Tris-HCl pH 8.4
 - b. Wash resin 4X with 500 µL of PBS
 - c. Wash resin 4X with 500 µL of water
- 4) Elute peptides with 75 µL of Elution Buffer and incubate for 3 minutes. Repeat 2 more times, combining eluate fractions
- 5) Lyophilize samples in vacuum concentrator.

Label-free, 1-D separation for LCMSMS analysis

- 1) Once samples are dried by lyophilizing, resuspend each sample in 25 µL of 0.1% formic acid

- 2) Transfer 10 μ L into vials for LCMSMS

iTRAQ Labeling

- 1) The remaining 15 μ L samples were dried completely
- 2) Resuspend samples in 30 μ L of 200 mM TEAB
- 3) 15 μ L of sample was labeled with 30 μ L of iTRAQ reagent and incubated for 2 hours at room temperature
 - a. 6 μ L per sample was pooled for the QCP
- 4) After labeling, 8 μ L of 5% hydroxamine was added for quenching for 15 minutes at 4° C
- 5) All MP's were pooled together, dried, desalted, and resuspended in 20 μ L of 0.1% formic acid.

Eksigent/LTQ Orbitrap instrument was having problems so MP's were dried and resuspended in 18 μ L of 20 mM ammonium formate.

Leftovers per sample:

- 9 μ L of eluate in 200 mM TEAB in -80° C
- MP's in 20 mM ammonium formate on instrument

The phospho protein analysis was conducted according to the following protocol.

Sample prep protocol:

1. Cell lysis

- a. Lysis buffer – 5 M urea, 50 mM Tris-HCL, 0.1% SDS, 1% Protease Inhibitor Cocktail, 1% Phosphatase Inhibitor Cocktail
 - b. Suspend pellet in the appropriate amount of lysis buffer
 - c. Vortex and incubate for 10 minutes on ice. Repeat.
 - d. Sonicate and incubate for 10 minutes on ice.
 - e. Centrifuge at top speed for 15 minutes
 - f. Resonicate if lysate is still viscous/sticky.
 - g. Transfer lysate to new tube
2. Perform Bradford assay to determine protein concentration
 3. Transfer 700 µg of protein (400 µg for THLE-2) to new microtube with 45 µL of 200 mM TEAB
 4. Reduced with 200 mM TCEP at 5 µL TCEP : 100 µL volume for 1 hour at 55° C
 5. Alkylate with 375 mM iodoacetamide at 5 µL iodo:100 µL volume at room temperature for 30 minutes in the dark
 6. Acetone precipitation at 7X the volume overnight in -20° C
 7. Resuspend protein in 200 mM TEAB at 50 µg/µL. Digest with trypsin at 1:40 (trypsin:protein) at 37° C overnight

During column preparation, resuspend peptide sample in 150 µL of Buffer B.

Column Preparation:

1. Place Centrifuge Column Adaptor in collection tube and insert TiO₂ Spin Tip into adaptor.
2. Add 20 µL of Buffer A. Centrifuge at 3000 g for 2 minutes. Discard FT.

3. Add 20 μ L of Buffer B. Centrifuge at 3000 g for 2 minutes. Discard FT.

Phosphopeptide Binding:

1. Transfer spin tip to a clean microtube.
2. Apply suspended sample to spin tip. Centrifuge at 1000 g for 10 minutes
3. Reapply sample to spin tip and centrifuge 1000 g for 10 minutes. Save FT.
4. Transfer spin tip to a new microtube.
5. Wash column by adding 20 μ L of Buffer B. Centrifuge at 3000 g for 2 minutes.
6. Wash column by adding 20 μ L of Buffer A. Centrifuge at 3000 g for 2 minutes.
Repeat once more.

Elution:

1. Place spin tip in new collection tube. Add 50 μ L of Elution Buffer 1. Centrifuge at 1000 g for 5 minutes
2. Using same collection tube, add 50 μ L of Elution Buffer 2 to spin tip.
Centrifuge for 1000 g for 5 minutes
3. Acidify elution fraction by adding 100 μ L of 2.5% Formic Acid.

Graphite Clean-up of Phosphopeptides

**Replace TFA with Formic Acid since this is the final clean-up before
LC/MS/MS analysis

Column Preparation:

1. Remove top and bottom cap from graphite spin column. Place column in 1.5 mL microtube. Centrifuge at 2000 g for 1 minute to remove storage buffer.

2. Add 100 μ L of 1 M NH_4OH . Centrifuge at 2000 g for 1 minute. Discard FT.
Repeat once more.
3. Activate graphite by adding 100 μ L of acetonitrile. Centrifuge at 2000 g for 1 minute. Discard FT.
4. Add 100 μ L of 1% Formic Acid. Centrifuge at 2000 g for 1 minute. Discard FT.
Repeat once more.

Sample Binding and Elution:

Elution = 0.1% FA + 50% ACN

1. Place column into new collection tube. Apply sample on top of resin bed. Allow binding for 10 minutes with periodic vortex mixing
2. Centrifuge at 1000 g for 3 minutes. Discard FT.
3. Place column into new collection tube. Wash column by adding 200 μ L of 1% FA. Centrifuge at 2000 g for 1 minute. Discard FT. Repeat once more.
4. Place column into new collection tube. Add 100 μ L of 0.1% FA/50% ACN to elute sample. Centrifuge at 2000 g for 1 minute. Repeat 3 more times for total elution of 400 μ L.
5. Dry samples in vacuum evaporator (SpeedVac)

HepG2 and Hep3B:

- Start with 700 μ g of protein
- After TiO_2 enrichment and graphite clean-up, phosphopeptides were eluted in 400 μ L of 0.1% formic acid/50% ACN.
- A ratio of $(400/700) \times 400$ μ L aliquot was taken from eluent and dried completely. It was resuspended in 20 μ L of 200 mM TEAB for iTRAQ labeling.

- After labeling, samples were desalted, dried, and resuspended in 20 μ L of 0.1% formic acid.
- Remaining aliquot was dried completely and resuspended in 20 μ L of 0.1% formic acid.
- 10 μ L was transferred to vials for label-free LCMSMS analysis.

THLE-2:

- Only 400 μ g of protein was harvested.
- All of the protein was enriched with TiO_2 columns and cleaned with graphite columns
- The elutes were dried, resuspended in 20 μ L of 200 mM TEAB for iTRAQ labeling
- After labeling, samples were desalted, dried, and resuspended in 20 μ L of 0.1% formic acid.

Leftover samples:

iTRAQ samples – on instrument in 20 mM ammonium formate

Label-free HepG2/Hep3B – 10 μ L in 0.1% formic acid in -80°C ; 10 μ L in 0.1% formic acid on instrument

Results

FIG. 42 illustrates a significant decrease in ENO1 activity but not ENO1 expression in HepG2 treated with Sorafenib. FIG. 43 illustrates a significant decrease in PGK1 activity but not in PGK1 protein expression in HepG2 treated with Sorafenib. FIG. 44 illustrates a significant decrease in LDHA activity in HepG2 treated with Sorafenib. In each case, ENO1 expression was measured in units relative to a QC

sample and the ENO1 activity change was measured in units relative to the control, untreated sample.

The data in FIGS. 42-44 show that for ENO1, LDHA, and PGK1 in the HCC disease model, treatment of cells with Sorafenib results in upregulation of protein expression while concomitantly downregulating the protein's enzymatic activity. Thus, the phospho proteome affords an additional layer of information that can be used for elucidating the complex relationship between the effect of an extracellular signal (e.g., drug molecule) on kinase activity and total cellular protein, thereby facilitating the identification of disease treatment targets, as well as diagnostic/prognostic markers associated with disease.

FIG. 45 illustrates (see left frame) a causal molecular interaction network that can be produced by analyzing a resulting dataset using the AI based REFS™ system. The network can be used, for example, to identify networks of interest that are differentially regulated in normal and cancer cells (see middle and right frames, respectively). Such information can be used to provide HCC treatment targets, as well as diagnostic/prognostic markers associated with HCC.

FIGS. 46-51 illustrate how a two dimensional chemical interrogation of oncogenic systems and multi-omics integration of signatures can reveal novel signaling pathways involved in the pathophysiology of cancer, thereby identifying therapeutic targets, relevant biomarkers, and/or therapeutics. In particular, FIGS. 46-51 illustrate the implementation of the general methodology shown in FIG. 41 and in accordance with the various methods described herein. As shown in FIG. 41, the approach is powered by “two dimensional chemical interrogation” where *in vitro* cancer and control models were interrogated by a kinase inhibitor (Sorafenib) in a first dimension. Overall changes in kinase activity were captured by a second dimension of chemical interrogation employing activity based kinase enrichment probes. Kinases were identified by LC-MS. In addition, changes in the phospho proteome in response to exposure to the kinase inhibitor were captured using a phospho protein enrichment method followed by LC-MS for identification of proteins. Finally, quantitative changes in total protein expression were obtained. The resulting multi-omics data was integrated

using AI-based informatics, leading to the generation of data-driven causal networks representing differential kinase activity driving phosphorylation of proteins that are operational in a cancer model but not in a “normal” model. Integration of these complementary analysis is shown in the inferred pathways of FIGS. 46 and 47. The technology led to the discovery of novel kinases and relationships that are mechanistically relevant to pathophysiology of cancer (e.g., FIGS. 48-50).

FIG. 46 illustrates how the integration of multiomics data employing bayesian network inference algorithms can lead to improved understanding of signaling pathways in hepatocellular carcinoma. Yellow squares represent post transcriptional modification (Phospho) data, blue triangles represent activity based (Kinase) data, and green circles represent proteomics data. FIG. 47 illustrates how autoregulation and reverse feed back regulation in hepatocellular carcinoma signaling pathways can be inferred by the Platform. Squares represent PMT (Phospho) data (grey/dark = Kinase, yellow/light – No Kinase Activity), squares represent activity based (Kinase) + Proteomics data (grey/dark = Kinase, yellow/light – No Kinase Activity). These analyses were carried out using the three-layered multi-proteomics methodology described above and summarized in FIG. 41. Results of these analyses are shown in FIGS. 48-51 and discussed in further detail below.

FIGS. 48-50 illustrate examples of causal association in signaling pathways inferred by the Platform. Kinase names are indicated on representative squares and circles, with causal associates indicated by connectors. FIG. 48 identifies the CLTCL1, MAPK1, NME1, HIST1H2BA, RPS5, TMED4, and MAP4 kinase isoforms and shows an inferred relationship therebetween. FIG. 49 identifies the HNRPD, HNRNP, RAB7A, RPL28, HSPA9, MAP2K2, RPS6, FBL, TCOF1, PGK1, SLTM, TUBB, PGK2, CDK1, MARCKS, HDLBP, and GSK3B kinase isoforms and shows an inferred relationship therebetween. FIG. 50 identifies the RPS5, TNRC18, CLTCL1, NME1, MAPK1, RPL17, CAMK2A, NME2, UBE21, CLTCL1, HMGB2, and NME2 kinase isoforms and shows an inferred relationship therebetween. These kinase isoforms present potential therapeutic targets, markers, and therapeutics.

FIG. 51 illustrates a causal association derived by the Platform. In particular, FIG. 51 identifies the EIF4G1, MAPK1, and TOP2A kinase isoforms and shows an inferred relationship therebetween. This relationship provides validation for the model and method because it comports with the published relationship between EIF, MAPK, and TOP kinases.

In conclusion, multiomics based analysis of enzyme (e.g., kinase) activity represents a useful method for the determination of downstream causal relationships between metabolites and substrates as a function of cell behavior. Likewise, activity based proteome monitoring of changes in global enzyme activity in response to therapeutic treatment can provide critical insight into cellular signaling dynamics as compared to monitoring only the overall cellular expression of proteins (e.g., enzymes). Furthermore, it has been shown that the Platform can robustly infer signaling pathways and reverse feed back regulation in oncogenic versus normal environments and, therefore, identify novel causal associations in oncogenic signaling pathways. Accordingly, the technology provides identification of novel kinases and deciphering mechanism of action of kinase inhibitors.

EXAMPLE 6: In Vitro Model of Angiogenesis and Modulation by CoQ10

Introduction: Progression of tumor size greater than 2-5mm in size requires induction of angiogenesis to supply the tumor with oxygen and nutrients. Angiogenesis occurs due to intratumoral cell release of endothelial mitogenic factors in response to hypoxia or genetic mutation, and there are currently numerous endogenous proteins in clinical development as therapeutic antiangiogenesis targets e.g. VEGF and PlGF. Herein, we have investigated Coenzyme Q10 (CoQ10) *in vitro*, which is currently under investigation in human studies of cancer progression.

Methods: Human umbilical vein endothelial cell (HUVEC) fate decisions that modulate the angiogenic phenotype were examined in the presence of 100 or 1500 μ M CoQ10 or excipient and compared to untreated control cells. Endothelial cell fate assays for apoptosis, proliferation, migration and 3-D tube formation within MATRIGEL® were performed.

Results: Morphological and flow cytometric analysis of annexin V/propidium iodide positive cells revealed an increase in HUVEC apoptosis in the presence of 1500 μ M CoQ10, compared to excipient or control cells. Concomitant with increased cell death due to CoQ10, HUVEC cell counts were significantly decreased in the presence of 1500 μ M CoQ10. To assess the potential effects of CoQ10 on endothelial migration, HUVEC migration was examined 5 hours post-cell clearance, in an endothelial scratch assay. Both CoQ10 and excipient significantly impaired HUVEC migration at both 100 and 1500 μ M concentration, demonstrating antimigratory activity of both the excipient and CoQ10. In order to determine if the CoQ10 anti-tumor activity is due to effects on endothelial sprouting angiogenesis, we examined endothelial tube formation in 3-D MATRIGEL® cultures over time. Addition of excipient in both the gel and overlying media impaired tube formation compared to control. Moreover, addition of 1500 μ M CoQ10 further impaired HUVEC tube formation compared to both excipient and control untreated cells. These effects were noted as early as 24 hours after seeding and up to 96 hours in culture. Taken together, these studies demonstrate that CoQ10 effect is likely, at least in part, due to inhibition of tumor recruitment of local blood supply for neo-vessel formation.

Effect of CoQ10 on endothelial morphology: Human umbilical vein endothelial cells (HUVEC cells) were treated for 24 hours with a range of concentrations of CoQ10. Drug was applied to confluent cells that closely resemble 'normal' cells and also to sub-confluent cells that more closely represent the angiogenic phenotype of proliferating cells. In confluent cultures, addition of increasing concentrations of CoQ10 led to closer association, elongation and alignment of ECs. 5000 μ M led to a subtle increase in rounded cells (Figure 52A). The response of sub-confluent endothelial cells to CoQ10 diverged from the confluent cell response (Figure 52B). Endothelial were visibly unhealthy at 1000 μ M CoQ10 and above. Increased cell death was visible with increasing concentrations of CoQ10.

CoQ10 has divergent effects on endothelial cell survival: Confluent and sub-confluent cultures of HUVEC cells were treated for 24 hours with 100 or 1500 μ M CoQ10 and assayed for propidium iodide positive apoptotic cells. The results are shown in Figures 53A and 53B, respectively. CoQ10 was protective to ECs treated at confluence, whereas sub-confluent cells were sensitive to CoQ10 and displayed

increased apoptosis at 1500 μ M CoQ10. Representative histograms of sub-confluent control ECs (left), 100 μ M CoQ10 (middle) and 1500 μ M CoQ10 (right) demonstrating increasing levels of apoptosis with increasing concentrations of CoQ10 are shown in Figure 53C.

CoQ10 decreases endothelial cell numbers and proliferation: Sub-confluent cultures of HUVEC cells were treated for 72 hours with 100 or 1500 μ M CoQ10 and assayed for both cell numbers (Figure 54A) and proliferation (Figure 54B) using a propidium iodide incorporation assay (detects G2/M phase DNA). High concentrations of CoQ10 led to a significant decrease in cell numbers and had a dose-dependent effect on EC proliferation. Representative histograms of cell proliferation gating for cells in the G2/M phase of the cell cycle demonstrating decreased cell proliferation with increasing concentrations of CoQ10 [Figure 54C, control ECs (left), 100 μ M CoQ10 (middle) and 1500 μ M CoQ10 (right)].

CoQ10 decreases endothelial cell migration: HUVEC cells were grown to confluence tested for migration using the 'scratch' assay. 100 or 1500 μ M CoQ10 was applied at the time of scratching and closure of the cleared area was monitored over 48 hours. 100 μ M CoQ10 delayed endothelial closure compared to control. Representative images at 0, 12, 24, and 36 hours are provided in Figure 55. Addition of 1500 μ M CoQ10 prevented closure, even up to 48 hours (data not shown).

CoQ10 impairs endothelial tube formation: Endothelial cells growing in 3-D matrigel form tubes over time. Differential effects of 100 μ M and 1500 μ M CoQ10 on tube formation were observed. Impaired cell to cell association and breakdown of early tube structure was significant at 1500 μ M CoQ10. Interestingly, tube formation did commence in the presence of 1500 μ M CoQ10, however the process was impaired 48 hours into tube growth and formation. Images shown in Figure 56 were taken at 72 hours.

Results and Conclusion:

We investigated the potential angiogenesis modulating effects of CoQ10. CoQ10 is an anti-cancer agent currently under investigation in human solid tumor studies that modulates the cellular energy metabolism.

CoQ10 at low doses was protective to confluent endothelial cells, whereas addition of CoQ10 to sub-confluent cells led to increased apoptosis, decreased cell numbers and was a potent inhibitor of endothelial proliferation. We demonstrate divergent effects on confluent and subconfluent cells that would protect the 'normal' vasculature.

Functional assessment of the endothelial ability to migrate in 2-D scratch assays revealed a potent inhibition of endothelial migration. Time-lapse photography revealed a dynamic endothelial 'front' that fails to close the cleared zone over a 2 day culture/treatment.

Suspension of endothelial cells in 3-D matrigel leads to formation of tubes over time. Using this well-characterized assay that recapitulates many of the factors at play in tumor angiogenesis, we examined the effect of CoQ10 on endothelial tube formation. Addition of 100 μ M CoQ10 had a modest effect of tube formation, however addition of 1500 μ M CoQ10 led to a dramatic disruption of endothelial tube formation.

In summary, these results demonstrate the effect of CoQ10 on endothelial sprouting, migration and proliferation and selectively induces cell death in angiogenic endothelial cells.

EXAMPLE 7: Coenzyme Q10 Differentially Modulated Functional Responses in Confluent and Subconfluent HUVEC Cells

Having demonstrated a differential effect of CoQ10 on cell proliferation and migration in HUVEC cells grown under confluent and subconfluent conditions, the effects of CoQ10 on the biochemical pathways of HUVEC cells was investigated.

The response of HUVEC cells to normoxia and hypoxia in the presence of absence of CoQ10 was assessed. Specifically, HUVEC cells were grown in subconfluent and confluent cultures under normoxic or hypoxic conditions as described herein. The cells were also exposed to 0, 100, or 1500 μ M CoQ10. Nitric oxide (NO) and reactive oxygen species (ROS) levels were determined using methods provided

herein. As shown in Figure 57, the HUVEC cells demonstrated a differential dose dependent generation of nitric oxide (NO) and reactive oxygen species (ROS) in response to CoQ10 and hypoxia.

The bioenergetics of HUVEC cells were assessed in the presence of various concentrations of CoQ10. Specifically, HUVEC cells were grown in subconfluent or confluent conditions in the absence or presence of CoQ10 (10, 100, 1500 μ M). Oxygen consumption rates (OCR), both total and mitochondrial, ATP production, and Extra Cellular Acidification Rate (ECAR) were assessed using Seahorse assays. HUVEC cells growing in sub-confluent cultures limit mitochondrial oxygen consumption when compared to confluent cultures as shown in Figure 58A-D ((A) Total OCR; (B) Mitochondrial OCR; (C) ATP; (D) ECAR). Addition of CoQ10 to sub-confluent cultures reverts mitochondrial OCR to confluent level OCR (Figure 58B).

EXAMPLE 8: Application of Functional Proteomics and Lipidomics to Elucidate Anti-angiogenic Mechanism of CoQ10

Angiogenesis is a key enabling feature of tumor progression that provides oxygen and nutrients that are required for tumor cell growth. We have investigated the anti-angiogenic properties of CoQ10, an anti-tumor drug that is currently under investigation in human studies of cancer progression. CoQ10 impairs endothelial migration in 'scratch' assays and tube formation in 3-D MATRIGEL® tube formation assays. Addition of CoQ10 also impairs endothelial proliferation, as detected by G2/M phase cells and proliferating cell nuclear antigen (pCNA) protein. CoQ10 induces activation of caspase 3 and increases apoptosis of angiogenic/proliferating endothelial cells, whereas cell death of non-proliferating confluent endothelial cell cultures is decreased compared to controls.

In order to determine the intracellular proteomic profile of angiogenic proliferating endothelial cells and non-proliferating endothelial cells, we used a proteomic, lipidomic, and functional proteomic approach. Proteomic and shotgun lipidomic analysis were performed on a LTQ-OrbiTrap-Velos and Vantage-QqQ, respectively. The functional proteomics approach employed activity-based probes in combination with comparative proteomics. Kinases and other ATPases were specifically labeled with ATP-binding domain enrichment probes that interact with the

active sites of enzymes in their native conformation. Enrichment was carried out through immunoprecipitation with streptavidin resin.

Using integrated lipidomics and proteomic platforms, and an AI based Bayesian informatics platform that generates causal lipid/ protein/ functional proteomics networks, novel proteins, lipids, and enzymes that modulate angiogenesis were identified. CoQ10 treated cells and comparison of normal and angiogenic endothelial cells were used to probe the global kinase activity. Comparative proteomics and enzyme activity data were integrated into the AI based Bayesian informatics platform to investigate causal networks of functional protein-protein interactions in order to elucidate the complexity and dynamics of angiogenesis. A causal interactive network is shown in Figure 59A-C. Specifically, Figure 59A is a full multiomic causal interaction network of lipids, proteins, and kinases. Figure 59B shows a hub of a protein enriched network, and Figure 59C shows a hub of a kinase, lipidomic, and functional endpoint network. In the networks, proteins are indicated by circles, kinases are indicated by squares, lipids are indicated by diamonds, and functional activity or cellular response are indicated by octagons. Some protein and kinase names are provided. The outputs from the platform confirmed known protein interactions.

In summary, using the platform technology, the anti-angiogenic mechanism of CoQ10 and the unique characteristics of proliferating endothelial cells by applying integrated functional proteomic assays to determine global changes in enzymatic activity have been investigated. Interrogative “omic” based platform robustly infers cellular intelligence. The AI-based network engineering approach to data mining to infer causality results in actionable biological intelligence. Moreover, the discovery platform allows for enhanced understanding of the pathophysiology of endothelial cells in response to environmental challenge, alteration in metabolic status, and production of adaptive molecules to mitigate physiologic perturbations.

EXAMPLE 9: Employing Platform Technology to Build Models of Angiogenesis

In this example, the platform technology described in detail above in the detailed description is employed to integrate data obtained from a custom built angiogenesis

model, and to identify novel proteins/pathways driving angiogenesis. Relational maps resulting from this analysis provide angiogenesis biomarkers.

Angiogenesis is a result of a complex series of signaling pathways that are not fully understood. Angiogenesis plays a role in a number of pathological conditions including, but not limited to, cancer. A systems approach combining protein and lipid signatures with functional end point assays specifically looking at cellular bioenergetics and mitochondrial membrane function is provided herein. As demonstrated above, sub-confluent HUVEC cells can be used to mimic an angiogenic state, whereas confluent HUVEC cells can be used to mimic a non-angiogenic, i.e., normal, state.

In an *in vitro* model, HUVEC cells are grown under conditions of contact inhibition (e.g., confluent cultures) or under conditions lacking contact inhibition (e.g., sub-confluent cultures, e.g., less than about 60% confluent, less than about 70% confluent, less than about 80% confluent, less than about 90% confluent; three-dimensional cultures; or cultures in which a patch of cells is removed by “scratching” the culture), in the presence or absence of an environmental influencer, such as an angiogenesis inhibitor, e.g., CoQ10, to create signatures and elucidate potential mechanisms of angiogenesis. The proteomic and lipidomic signatures are analyzed using the platform methods provided herein. Biomarkers of angiogenesis are further confirmed using wet lab methods. This approach serves as a powerful tool to understand mechanism of angiogenesis, allowing for the identification of new angiogenic biomarkers and the development and testing of agents that modulate angiogenesis.

Human umbilical vein endothelial cells are subject to conditions simulating an angiogenic environment experienced by the disease-relevant cells *in vivo*. Specifically, the cells are grown under conditions wherein growth is inhibited due to contact inhibition (i.e., normal cells) or under conditions wherein, in at least a portion of the culture, growth is not inhibited due to contact inhibition (i.e., angiogenic cells). For the sake of simplicity, such cells grown under conditions wherein, in at least a portion of the culture, growth is not inhibited due to contact inhibition will be referred to as non-confluent cultures.

The cell model comprising the above-mentioned cells, wherein the cells are grown in confluent or non-confluent cultures, is additionally “interrogated” by exposing the cells to an “environmental perturbation” by treating with an agent that modulates angiogenesis, e.g., an agent that inhibits angiogenesis. For example, the cells are treated

with Coenzyme Q10 at various concentrations, for example, one or more of, 0, 50 μ M, 100 μ M, 250 μ M, 500 μ M, 750 μ M, 1000 μ M, 1250 μ M, or 1500 μ M. As provided herein, perturbation can include mechanical disruption of the cells, e.g., by “scratching” the culture or subculturing the cells at a lower density.

Cell samples from each condition with each perturbation treatment are collected at various times following treatment, for example, after 6, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, or 120 hours, or some time point therebetween, of treatment. For certain conditions, media samples are also collected and analyzed. Samples can then be analyzed for one or more of level of protein expression or activity, gene expression, and lipid levels.

iProfiling of changes in total cellular protein expression by quantitative proteomics is performed for cell and media samples collected for each condition and with each “environmental perturbation”, i.e, Coenzyme Q10 treatment, using the techniques described above in the detailed description. Transcriptional profiling experiments are carried out, for example, using the Biorad® CFX-384 amplification system. Following data collection (Ct), the final fold change over control is determined using, for example, the δ Ct method as outlined in manufacturer’s protocol. Lipidomics experiments are carried out using mass spectrometry. Functional assays such as Oxygen Consumption Rate (OCR) are measured, for example, by employing the Seahorse analyzer essentially as recommended by the manufacturer. OCR can be recorded by the electrodes in a 7 μ l chamber created with the cartridge pushing against the seahorse culture plate.

In summary, morphological, enzymatic, and flow cytometric analysis revealed dramatic changes in apoptosis, migration, nitric oxide and ROS generation, and bioenergetic capacity in response to CoQ10 treatment. Lipidomic analysis revealed novel changes in lipid pathways mitigated by altering mitochondrial function and cell density. Proteomic integration utilizing the Platform methods revealed uncharacterized association of intracellular adaption and signaling directed by mitochondrial modulation. Taken together, these studies reveal that CoQ10 alters endothelial migration, proliferation, apoptosis, nitric oxide, ROS, and protein/lipid architecture. A novel mechanism is presented herein where anti-tumor activity of CoQ10 is due to metabolic cross-talk of angiogenic and apoptotic factors to inhibit tumor recruitment of local blood supply for neo-vessel formation. Additionally, proteomic and lipidomic adaption was

associated with interactive networks which support the physiological requirements of endothelial cells in response to environmental stimuli. These data provide hallmark insight into the selective adaptation of tumor angiogenesis due to dysregulated mitochondrial metabolic control elements.

EXAMPLE 10: Employing Platform Technology to Implement Multi Proteomics

Models for Elucidating Enzymatic Activity.

In general, the enzymatic platform technology described in Example 5 above can be adapted to implement further methods for identifying a modulator of a biological system or disease process such as angiogenesis. The methods employ a model for angiogenesis, comprising cells associated with angiogenesis, to represents a characteristic aspect of angiogenesis. The model is used to obtain at least three levels of data, namely (i) a first data set representing global enzyme activity in the cells associated with angiogenesis, (ii) a second data set representing an effect of the global enzyme activity on the enzyme metabolites or substrates in the cells associated with angiogenesis, and (iii) a third data set representing global proteomic changes in the cells associated with angiogenesis. Additional data sets such as lipidomic, transcriptomic, metabolomics, and SNP data. The data is used to generate a consensus causal relationship network among the global enzyme activity, the effect of the global enzyme activity, and the global proteomic changes. The consensus causal relationship network is based solely on the first, second, and third data sets using a programmed computing device (i.e., not based on any other known biological relationship). The consensus causal relationship network is then used to identify a causal relationship unique to angiogenesis, where at least one gene or protein associated with the unique causal relationship is identified as a modulator of angiogenesis.

In this example, the platform technology was adapted to implement multi proteomics techniques for measuring enzyme activity related to angiogenesis and the direct effects of that activity on the proteome; and thereby, provide a system that can be used to understand causal relationships between enzymes (e.g., kinases and/or proteases) and their metabolites/substrates in the context of global changes in the cellular proteome during angiogenesis. Such techniques can provide valuable insight because enzyme

activity can be orthogonal to enzyme expression (e.g., activity down regulated and expression unregulated). Relational maps resulting from such an analysis can provide disease treatment targets by modulating angiogenesis, as well as diagnostic/prognostic markers associated with angiogenesis. Such targets and markers can provide for therapeutic compositions and methods. Techniques for establishing models, obtaining data sets, generating consensus causal relationship networks, and identifying causal relationships unique to angiogenesis are discussed in the summary, detailed description, and examples above. Further techniques for establishing models and obtaining data sets representing global enzyme activity and the effect of the global enzyme activity on the enzyme metabolites or substrates are provided below.

First, a model is established in accordance with the platform technology wherein, for example, cell lines are subjected to conditions simulating a disease and interrogated by exposure to an environmental perturbation (e.g., exposure to a modulator of angiogenesis, e.g., CoQ10, Avastin, a VEGF inhibitor, angiostatin, bevacizumab, change of confluency of HUVEC cells). A control is provided for comparison. Second, enzyme activity and its downstream effects are tracked in the context of global proteomic changes by analyzing (i) global enzymatic activity, (ii) the specific effect of the enzymatic activity on the proteome (e.g., the metabolites/substrates of the enzymatic activity), and (iii) the global effect on the cellular proteome. Third, the datasets are analyzed in accordance with the platform technology to identify modulators of interest. For example, an angiogenic model can be interrogated by a known modulator of angiogenesis; the effects of this perturbation to the system on the global kinase activity can be analyzed, along with the resulting effects on the phospho proteome and whole proteome; and the dataset can be analyzed by the AI based REFS™ system.

For example, HUVEC cells grown under various conditions can be used to simulate angiogenic and normal (e.g., non-angiogenic) states. As angiogenesis does not occur in adults except under specific circumstances, e.g., pregnancy, wound healing, etc. the presence of angiogenic markers identified by using this approach may be useful as markers indicative of a disease state, e.g., cancer, rheumatoid arthritis, age related macular degeneration, or diabetic retinopathy.

This illustrative example combines the power of (i) cell biology, (ii) integrated proteomics platforms and an informatics platform that generates causal protein networks

to delineate the role of post-translation modification, e.g., phosphorylation, and enzymes that partake in such mechanisms, e.g., kinases, in the angiogenesis. In particular, this approach incorporates activity based proteomics employing ATP binding domain enrichment probes and phospho-proteome mapping of total proteins in angiogenesis models.

Comparative proteomics, phospho proteome and enzyme activity data are integrated into the AI based REFSTM informatics platform. Causal networks of protein interaction specifically from a functional stand point namely kinase/enzyme activity and potential targets that kinases can phosphorylate are then generated. In addition, using cellular functional read out, enzymes/ kinases that modulate phosphorylation of targets and mechanistically drive pathophysiological cellular behavior are determined. The illustrative implementation outlined herein facilitates global characterization of cellular responses, insights into mechanisms of angiogenesis and potential targets/biomarkers for clinical management of angiogenesis.

As an illustrative example, cells representing normal cells and angiogenic cells are selected for comparison. As demonstrated herein, HUVEC cells when grown in sub-confluent cultures show characteristics of angiogenesis, whereas confluent HUVEC cells do not. Treatment of sub-confluent cultures of HUVEC cells with CoQ10 shifts the HUVEC cells to non-angiogenic state as demonstrated herein. As with the proteomics methods provided above, methods for analysis of enzymatic activity can include pairwise analysis of HUVEC cells grown under any conditions, and optionally further analysis of the results from the pairwise comparison with results from a third data set.

As an exemplary embodiment, equivalent numbers of HUVEC cells cultured in confluent and non-confluent cultures are harvested and the cells are enriched for the presence of peptides of interest, e.g., phosphopeptides. A comparative analysis is performed as in Example 5 to detect changes in enzymatic activity associated with angiogenesis.

Incorporation by Reference

The contents of all cited references (including literature references, patents, patent applications, GenBank Numbers in the version available on the date of filing the instant application, and websites) that maybe cited throughout this application are hereby expressly incorporated by reference in their entirety, as are the references cited therein. The practice of the present invention will employ, unless otherwise indicated, conventional techniques of protein formulation, which are well known in the art.

Equivalents

The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting of the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes that come within the meaning and range of equivalency of the claims are therefore intended to be embraced herein.

Appendix A: Amino acid and cDNA sequences for relevant proteins

1. TCOF1: Treacher Collins-Franceschetti syndrome 1
 LOCUS NM_000356
 AA: MAEARKRRELLPLIYHHLLRAGYVRAAREVKEQSGQKCFLAQPV
 TLLDIYTHWQQTSELGRKRKAEEDAALQAKKTRVSDPISTSESESESESESEAEETAKAT
 PRLASTNSSVLGADLPSSMKEKAKAETEKAGKTGNSMPHPATGKTVANLLSGKSPRKS
 AEPSANTTLVSETEEEGSPAFGAAAKPGMVSAQADSSSEDTSSSSDETDEVEVKASE
 KILQVRAASAPAKGTPGKGATPAPPGKAGAVASQTKAGKPEEDSESSSEESSDSEET
 PAAKALLQAKASGKTSQVGAASAPAKESPRKGAAPAPPGKTGPAVAKAQAGKREEDSQ
 SSSEESDSEEEAPQAKPSGKAPQVRAASAPAKESPRKGAAPAPPRKTGPAAQVQVG
 KQEEDSRSSSEESDSDREALAAMNAAQVKPLGKSPQVKPASTMGMGPLGKGAGVPVPG
 KVGPAATPSAQVGKWEEDSESSSEESSDSDGEVPTAVAPAQEKSLGNILQAKPTSSPA
 KGPPQKAGPVAQVKA EKPMDNSESEESSDSDADSEEAPAAMTAAQAKPALKIPQTKA
 CPKKTNTTASAKVAPVRVGTQAPRKAGTATSPAGSSPAVAGGTQRPADSSSSEESDS
 EEEKTGLAVTVGQAKSVGKGLQVKAASVPVKGSLGQGTAPVLPKGTGPTVTQVKA EKQ
 EDSESESEESDSEEEAASPAQVKTSVKKTQAKANPAAARAPSAKGTISAPGKVVTAAA
 QAKQRSPSKVKPPVRNPQNSTVLARGPASVPSVGKAVATAAQATGPEEDSGSSEES
 DSEEEAETLAQVKPSGKTHQIRAAALAPAKESPRKGAAPTTPGKTGPSAAQAGKQDDSG
 SSSEESDSDGEAPAAVTSQVVIKPLIFVDPNRSFAGPAATPAQAQAASSTPRKARASE
 STARSSSSSESEDEDVIPATQCLTPGIRTNVVTMPAHPRIAPKASMGAGSSSKESSRI
 SDGKKQEGPATQVSKKNPASLPLTQAALKVLAQKASEAQPFPVARTQPSSGVDASVGT
 PATSPQSTSVQAKGTNKLRLKPKLPEVQQATKAPESSDDSEDSSSSSGSEEDGEGPQG
 AKSAHTLGPTPSRTETLVEETAESSEDDVAPSQSLLSGYMTPLTPANSQASKATP
 KLDSSPSVSVSTLAAKDDPDGKQEAQKPPQAAGMLSPKTTGGKEAASGTTTPQKSRKPKKGA
 GNPQASTLALQSNITQCLLGQPWPLNEAQVQASVVKVLTELLEQERKKVVDTTKESSR
 KGWESRRKRLSGDQPAARTPRSKKKKKL GAGEGGEASVSPEKTSTTSKGKAKRDKASG
 DVKEKKKGKSLGSGQAKDEPEEELQKGMGTVEGGDQSNPKSKKEKKKSDKRKKDKKEK
 EKKKKAKKASTKDESPSQKKKKKKKTAEQTV

cDNA: 1 gaaagaggag ccggaagtgt ggcgcgcgag gtctaagggc gcgagggaag
 tggcggggcgg
 61 ggactaaggc ggggcgtgca ggtagccggc cgcccgggg tgcgggtat
 ggccgaggcc
 121 aggaagcggc gggagctact tcccctgata taccaccata tgctgcgggc
 tggtatgtg
 181 cgtgcggcgc gggaagtga ggagcagagc ggccagaagt gtttctgtgc
 tcagcccgt
 241 acccttctgg acatctatac acactggcaa caaacctcag agcttggtcg
 gaagcggaag
 301 gcagaggaag atgcggcact gcaagctaag aaaaccctg tgtcagaccc
 catcagcacc
 361 tcggagagct cggaagagga ggaagaagca gaagccgaaa ccgccaagc
 caccccaaga
 421 ctagcatcta ccaactctc agtctctggg gcggacttgc catcaagcat
 gaaagaaaa
 481 gccaaaggcag agacagagaa agctggcaag actgggaatt ccatgccaca
 ccctgccact
 541 gggaagacgg tggccaacct tctttctggg aagtctccca ggaagtcagc
 agagccctca
 601 gcaatacta cgttggtctc agaaactgag gaggagggca gcgtcccggc
 ctttgagct
 661 gctgccaagc ctgggatggt gtcagcgggc caggccgaca gctccagcga
 ggacacctcc
 721 agctccagt atgagacaga cgtggaggta aaggcctctg aaaaaattct
 ccaggtcaga
 781 gctgcctcag cccctgccaa ggggacctt gggaaagggg ctacccagc
 accccctggg
 841 aaggcagggg ctgtagctc ccagaccaag gcagggaagc cagaggagga
 ctcagagagc
 901 agcagcgagg agtcatctga cagtgaggag gagacgccag ctgccaaggc

```

cctgcttcag
  961 gcgaaggcct caggaaaaac ctctcaggtc ggagctgcct cagcccctgc
caaggagtcc
 1021 cccaggaaag gagctgcccc agcgccccct gggaagacag ggcttgcaat
tgccaaggcc
 1081 caggcgggga agcgggagga ggactcgcag agcagcagcg aggaatcgga
cagtgaggag
 1141 gaggcgcctg ctccaggcga gccttcaggg aaggcccccc aggtcagagc
cgccctggcc
 1201 cctgccaagg agtccccccag gaaaggggct gccccagcac ctcttaggaa
aacagggcct
 1261 gcagccgccc aggtccaggt ggggaagcag gaggaggact caagaagcag
cagcgaggag
 1321 tcagacagtg acagagagga actggcagcc atgaatgcag ctccagtgaa
gcccttgggg
 1381 aaaagcccc aggtgaaacc tgcctctacc atgggcatgg ggcccttggg
gaaaggcgcc
 1441 ggcccagtgc caccgggga ggtggggcct gcaacccct cagcccaggt
ggggaagtgg
 1501 gaggaggact cagagagcag tagtgaggag tcattcagaca gcagtgatgg
agaggtgccc
 1561 acagctgtgg ccccggtcca ggaaaagtcc ttggggaaca tcctccaggc
caaaccacc
 1621 tccagtcctg ccaaggggccc ccctcagaag gcagggcctg tagccgtcca
ggtaaggt
 1681 gaaaagccca tggacaactc ggagagcagc gaggagtcat cggacagtgc
ggacagtgag
 1741 gaggcaccag cagccatgac tgcagctcag gcaaaaccag ctctgaaaat
tcctcagacc
 1801 aaggcctgcc caaagaaaaac caataccact gcattctgcca aggtcgcccc
tgtgcgagtg
 1861 ggcacccaag cccccggaa agcaggaact gcgacttctc cagcaggctc
atccccagct
 1921 gtggctgggg gcacccagag accagcagag gattcttcaa gcagtgagga
atcagatagt
 1981 gaggaagaga agacaggtct tgcagtaacc gtgggacagg caaagtctgt
ggggaaggc
 2041 ctccaggtga aagcagcctc agtgccctgtc aaggggtcct tggggcaagg
gactgctcca
 2101 gtactccctg ggaagacggg gcctacagtc acccaggtga aagctgaaaa
gcaggaagac
 2161 tctgagagca gtgaggagga atcagacagt gaggaagcag ctgcatctcc
agcacagggtg
 2221 aaaacctcag taaagaaaaac ccaggccaaa gccaaccag ctgccgccag
agcaccttca
 2281 gcaaaaggga caatttcagc ccctggaaaa gttgtcactg cagctgctca
agccaagcag
 2341 aggtctccat ccaaggtgaa gccaccagtg agaaaccccc agaacagtac
cgtcttggcg
 2401 aggggcccag catctgtgcc atctgtgggg aaggccgtgg ctacagcagc
tcaggcccag
 2461 acagggccag aggaggactc agggagcagt gaggaggagt cagacagtga
ggaggaggcg
 2521 gagacgtggt ctccagtgaa gccttcaggg aagaccacc agatcagagc
tgcttggct
 2581 cctgccaagg agtccccccag gaaaggggct gccccaacac ctctgggaa
gacagggcct
 2641 tcggctgccc aggcagggaa gcaggatgac tcaggagca gcagcgagga
atcagacagt
 2701 gatggggagg caccggcagc tgtgacctct gccaggtga ttaaaccccc
tctgattttt

```

2761 gtcgacccta atcgtagtcc agctggccca gctgctacac ccgcacaagc
 ccaggctgca
 2821 agcacccega ggaaggcccg agcctcggag agcacagcca ggagctcctc
 ctccgagagc
 2881 gaggatgagg acgtgatccc cgctacacag tgcttgactc ctggcatcag
 aaccaatgtg
 2941 gtgaccatgc ccaactgccca cccaagaata gccccaaaag ccagcatggc
 tggggccagc
 3001 agcagcaagg agtccagtcg gatatcagat ggcaagaaac aggagggacc
 agccactcag
 3061 gtgtcaaaga agaaccacgc ttccctccca ctgaccagg ctgccctgaa
 ggtcctcgcc
 3121 cagaaagcca gtgaggtcca gcctcctgtt gccaggacc agccttcaag
 tggggttgac
 3181 agtgctgtgg gaacactccc tgcaacaagt cccagagca cctccgtcca
 ggccaaaggg
 3241 accaacaagc tcagaaaacc taagcttcct gaggtccagc aggccaccaa
 agccccctgag
 3301 agctcagatg acagtgagga cagcagcgac agttcttcag ggagtgagga
 agatggtgaa
 3361 gggccccagg gggccaagtc agcccacacg ctgggtccca cccctccag
 gacagagacc
 3421 ctggtggagg agaccgcagc agagtccagc gaggatgatg tgggtggcgc
 atcccagtct
 3481 ctctctcag gttatatgac ccctggacta accccagcca attcccaggc
 ctcaaaagcc
 3541 actcccaagc tagactccag cccctcagtt tcctctactc tggccgcca
 agatgacca
 3601 gatggcaagc aggaggcaaa gcccacaacag gcagcaggca tgttgtcccc
 taaaacaggt
 3661 ggaaaagagg ctgcttcagg caccacacct cagaagtccc ggaagcccaa
 gaaaggggct
 3721 gggaaccccc aagcctcaac cctggcgctg caaagcaaca tcaccagtg
 cctcctgggc
 3781 caaccctggc ccctgaatga ggcccagggt caggcctcag tggatgaagg
 cctgactgag
 3841 ctgctggaac aggaaagaaa gaaggtggtg gacaccacca aggagagcag
 caggaagggc
 3901 tgggagagcc gcaagcggaa gctatcggga gaccagccag ctgccaggac
 cccaggagc
 3961 aagaagaaga agaagctggg ggccggggaa ggtggggagg cctctgtttc
 ccagaaaaag
 4021 acctccacga cttccaaggg gaaagcaaa agagacaaa caagtgggtga
 tgtcaaggag
 4081 aagaaaggga aggggtctct tggctcccaa ggggccaagg acgagccaga
 agaggagctt
 4141 cagaagggga tggggacggt tgaaggtgga gatcaaagca acccaaagag
 caagaaggag
 4201 aagaagaaat ccgacaagag aaaaaaagac aaagaaaaaa aagaaaagaa
 gaagaaagca
 4261 aaaaaggcct caaccaaaga ttctgagtca ccgtcccaga agaaaaagaa
 gaaaaagaag
 4321 aagacagcag agcagactgt atgacgagca ccagcaccag gcacagggat
 ttctagccg
 4381 agcagtggcc atccccatgc ctctgacctc caccgacctc tgcccaccat
 gggttggaac
 4441 taaactgtta ccttccctcg ctccacagaa gaagacagcc agcttcaggg
 gtccctgtgc
 4501 tggccaagcc agtgagcctg cggggaggct ggtccaagga gaaagtggac
 cagctccat
 4561 gacctcacc cactccccc acacaggacg cttcatatag atgtgtacag

tatatgtatt
 4621 tttttaagtg acctcctctc cttccacaga cccacatgc ccaaaggcct
 cgggacttcc
 4681 caccaccttg ctccacagat ccagctaggc ctgacctgtg cctcatcccg
 tgccgctcgg
 4741 tctctggctg atccccgagc tttgtcttcc tctcgtcagt tcttttggtt
 gtgttttttg
 4801 tttttttttt aataactcaa aaaaaaata aaagacttgg aggaagggtg
 caagctccca
 4861 gtgcaaaaaa aaaaaaaaaa aa
 //

2. TOP2A: Homo sapiens topoisomerase
 LOCUS NM_001067
 AA translation="MEVSPLQPVNENMQVNKIKKNEDAKKRLSVERIYQKKTQLEHIL
 LRPDTYIGSVELVTQQMWVYDEDVGINYREVTFVPGLYKIFDEILVNAADNKQRDPKM
 SCIRVTIDPENNLISIWNNKGKIPVVEHKVEKMYVPALIFGQLLTSSNYDDDEKKVTG
 GRNGYGAKLCNIFSTKFTVETASREYKKMFQWTMDNMGRAGEMELKPFNGEDYTCIT
 FQPDLSKFKMQSLDKDIVALMVRRAYDIAGSTKDVKVFLNGNKLVPKGRFSYVDMYLK
 DKLDETGNSLKVIEHQVNRHWEVCLTMSEKGFQQISFVNSIATSKGGRHVDYVADQIV
 TKLVDDVKKKNGGVAVKAHQVKNHMIWFVNALIENPTFDSQTKENMTLQPKSFGSTC
 QLSEKFIKAAIGCGIVESILNWVKFKAQVQLNKKCSAVKHNRIKGIPLKDDANDAGGR
 NSTECTLILTEGDSAKTLAVSGLGVVGRDKYGVFPLRGKILNVREASHKQIMENAEIN
 NIIKIVGLQYKKNYEDEDLSKTLRYGKIMIMTDQDQDGSNIKGLLINF IHHNWPSLLR
 HRFLEEFITPIVKVSKNKQEMAFYSLPEFEFEWKSSTPNHKKWKVKYKGLGTSTKEA
 KEYFADMKRHRHQFYKSGPEDDAISLAFSKKQIDDRKEWLTNFMEDRRQRKLLGLPE
 DYLYGQTTTTYLTYNDFINKELILFSNSDNEERSIPSMVDGLKPGQRKVLFCTCFKRNDR
 EVKVAQLAGSVAEMSSYHHGEMSLMNTIINLAQNFVGSNNLNLQPIGQFGRHLHGGK
 DSASPRYIFTMLSSLARLLFPKDDHTLKFLYDDNQVPEWYIPIIPMVLINGAEGI
 GTGWSCKIPNFDVREIVNNIRRLMDGEEPLPMLPSYKNFKGTIEELAPNQYVISGEVA
 ILNSTTIEISELPVRTWTQTYKEQVLEPMLNGTEKTPPLITDYREYHTDITTVKFVVKM
 TEEKLAAEERVGLHKVFKLQTSLTCSNMFVDFHVGCLKKYDITVLDILRDFELRLKYY
 GLRKEWLLGMLGAESAKLNNQARFILEKIDGKII IENKPKKELIKVLIQRGYSDFPVK
 AWKEAQKVPDEEENEESDNEKETEKSDSVTDSGPTFNYYLLDMPLWYLTKEKKDELCL
 LRNEKEQELDTLKRKSPSDLWKEDLATFIEELEAVEAKEKQDEQVGLPGKGGKAKGKK
 TQMAEVLPSPRGQRVIPRITIEKAEAEKKNKKKIKNENTEGSPQEDGVELEGLKQRL
 EKKQKREPGTKTKQTTLAFKPIKKGKKRNPWSDSESDRSSDESDFVPPRETEPRRA
 ATKTKFTMDLDSDEDFSDFDEKTDDEDFVPSDASPPKTKTSPKLSNKELKPKQSVVSD
 LEADDVKGSVPLSSSPPATHFPDETEITNPVPKKNVTVKKTAAKSQSSTSTTGAKKRA
 APKGTKRDPALNSGVSQKPDPAKTKNRRKRKPSTSDSDSNFEKIVSKAVTSKSKSGE
 SDDFHMDFDSAVAPRAKSVRAKKPIKYLEESEDDEDLF

cDNA: 1 gattggctgg tctgcttcgg gcgggctaaa ggaagggtca agtggagctc
 tcctaaccga
 61 cgcgcgtctg tggagaagcg gcttggtcgg ggggtggtctc gtgggggtcct
 gcctgttttag
 121 tcgctttcag ggttctttgag ccccttcacg accgtcacca tggaagtgtc
 accattgcag
 181 cctgtaaatg aaaatatgca agtcaacaaa ataaagaaaa atgaagatgc
 taagaaaaga
 241 ctgtctgttg aaagaatcta tcaaaagaaa acacaattgg aacatatattt
 gtcgcgcca
 301 gacacctaca ttggttctgt ggaattagt acccagcaaa tgtgggttta
 cgatgaagat
 361 gttggcatta actataggga agtcactttt gttcctgggt tgtacaaaat
 ctttgatgag
 421 attctagtta atgctgcgga caacaaacaa agggacccaa aaatgtcttg
 tattagagtc
 481 acaattgatc cggaaaacaa ttttaattagt atatggaata atggaaaagg
 tattcctggt
 541 gttgaacaca aagttgaaaa gatgtatgtc ccagctctca tatttgagaca

gctcctaact
 601 tctagtaact atgatgatga tgaaaagaaa gtgacaggtg gtcgaaatgg
 ctatggagcc
 661 aaattgtgta acatattcag taccaaattt actgtggaaa cagccagtag
 agaatacaag
 721 aaaatgttca aacagacatg gatggataat atgggaagag ctggtgagat
 ggaactcaag
 781 cccttcaatg gagaagatta tacatgtatc acctttcagc ctgatttgtc
 taagttttaa
 841 atgcaaagcc tggacaaaga tattgttgca ctaatgggtca gaagagcata
 tgatattgct
 901 ggatccacca aagatgtcaa agtctttctt aatggaaata aactgccagt
 aaaaggattt
 961 cgtagttatg tggacatgta tttgaaggac aagttggatg aaactggtaa
 ctccttgaaa
 1021 gtaatacatg aacaagtaaa ccacaggtgg gaagtgtggt taactatgag
 tgaaaaaggc
 1081 tttcagcaaa ttagctttgt caacagcatt gctacatcca aggggtggcag
 acatgttgat
 1141 tatgtagctg atcagattgt gactaaactt gttgatgttg tgaagaagaa
 gaacaaggg
 1201 ggtgttgtag taaaagcaca tcaggtgaaa aatcacatgt ggatttttgt
 aaatgcctta
 1261 attgaaaacc caacctttga ctctcagaca aaagaaaaca tgactttaca
 acccaagagc
 1321 tttggatcaa catgccattt gagtgaataa tttatcaaag ctgccattgg
 ctgtggtatt
 1381 gtagaaagca tactaaactg ggtgaagttt aaggcccaag tccagttaaa
 caagaagtgt
 1441 tcagctgtaa aacataatag aatcaaggga attoccaaac tcgatgatgc
 caatgatgca
 1501 gggggccgaa actccactga gtgtacgctt atcctgactg agggagattc
 agccaaaact
 1561 ttggctgttt caggccttgg tgtggttggg agagacaaat atggggtttt
 ccctcttaga
 1621 ggaaaaatac tcaatgttcg agaagcttct cataagcaga tcatggaaaa
 tgctgagatt
 1681 aacaatatca tcaagattgt gggctctcag tacaagaaaa actatgaaga
 tgaagattca
 1741 ttgaagacgc ttcgttatgg gaagataatg attatgacag atcaggacca
 agatggttcc
 1801 cacatcaaag gcttgtgat taattttatc catcacaact ggccctctct
 tctgcgacat
 1861 cgttttctgg aggaatttat cactcccatg gtaaaggatc ctaaaaacaa
 gcaagaaatg
 1921 gcattttaca gccttctcga atttgaagag tggaagagtt ctactccaaa
 tcataaaaaa
 1981 tggaaagtca aatattacaa aggtttgggc accagcacat caaaggaagc
 taaagaatac
 2041 tttgcagata tgaaaagaca tcgtatccag ttcaaatact ctggtcctga
 agatgatgct
 2101 gctatcagcc tggcctttag caaaaaacag atagatgatc gaaaggaatg
 gttaactaat
 2161 ttcatggagg atagaagaca acgaaagtta cttgggcttc ctgaggatta
 cttgtatgga
 2221 caaactacca catatctgac atataatgac ttcatcaaca aggaacttat
 cttgttctca
 2281 aattctgata acgagagatc tatcccttct atgggtggatg gtttgaaacc
 aggtcagaga
 2341 aaggttttgt ttacttgctt caaacggaat gacaagcgag aagtaaagg
 tgcccaatta

2401 gctggatcag tggctgaaat gtcttcttat catcatggtg agatgtcact
 aatgatgacc
 2461 attatcaatt tggctcagaa ttttgtgggt agcaataatc taaacctctt
 gcagcccatt
 2521 ggtcagtttg gtaccaggct acatggtggc aaggattctg ctagtccacg
 atacatcttt
 2581 acaatgctca gctctttggc tcgattgtta tttccaccaa aagatgatca
 cacgttgaag
 2641 tttttatatg atgacaacca gcgtgttgag cctgaatggt acattcctat
 tattcccatg
 2701 gtgctgataa atggtgctga aggaatcggc actgggtggc cctgcaaaat
 ccccaacttt
 2761 gatgtgctg aaattgtaaa taacatcagg cgtttgatgg atggagaaga
 acctttgcc
 2821 atgcttccaa gttacaagaa cttcaagggt actattgaag aactggctcc
 aatcaatat
 2881 gtgattagt gtgaagtagc tattcttaat tctacaacca ttgaaatctc
 agagcttccc
 2941 gtcagaacat ggaccagac atacaaagaa caagttctag aacctatggt
 gaatggcacc
 3001 gagaagacac ctctctcat aacagactat agggaatacc atacagatac
 cactgtgaaa
 3061 tttgttgtga agatgactga agaaaaactg gcagaggcag agagagttgg
 actacacaaa
 3121 gtcttcaaac tccaaactag tctcacatgc aactctatgg tgctttttga
 ccacgtaggc
 3181 tgttttaaaga aatatgacac ggtgttggtg attctaagag acttttttga
 actcagactt
 3241 aaatattatg gattaagaaa agaattggctc ctaggaatgc ttggtgctga
 atctgctaaa
 3301 ctgaataatc aggcctcgctt tatcttagag aaaatagatg gcaaaataat
 cattgaaaat
 3361 aagcctaaga aagaattaat taaagttctg attcagaggg gatatgattc
 ggatcctgtg
 3421 aaggcctgga aagaagccca gcaaaagggt ccagatgaag aagaaaatga
 agagagtga
 3481 aacgaaaagg aaactgaaaa gactgactcc gtaacagatt ctggaccaac
 cttcaactat
 3541 cttcttgata tgcccccttg gtatttaacc aaggaaaaga aagatgaact
 ctgcaggcta
 3601 agaaatgaaa aagaacaaga gctggacaca ttaaaaagaa agagtccatc
 agatttgtgg
 3661 aaagaagact tggctacatt tattgaagaa ttggaggctg ttgaagccaa
 ggaaaaacaa
 3721 gatgaacaag tcggacttcc tgggaaaggg gggaaggcca aggggaaaaa
 aacacaaatg
 3781 gctgaagttt tgccctctcc gcgtggtcaa agagtcatc cacgaataac
 catagaaatg
 3841 aaagcagagg cagaaaagaa aaataaaaag aaaattaaga atgaaaatac
 tgaaggaagc
 3901 cctcaagaag atggtgtgga actagaaggc ctaaaacaaa gattagaaaa
 gaaacagaaa
 3961 agagaaccag gtacaaagac aaagaaacaa actacattgg catttaagcc
 aatcaaaaaa
 4021 ggaaagaaga gaaatccctg gtctgattca gaatcagata ggagcagtga
 cgaaagtaat
 4081 tttgatgtcc ctccacgaga aacagagcca cgagagagcag caacaaaaac
 aaaattcaca
 4141 atggatttgg attcagatga agatttctca gattttgatg aaaaaactga
 tgatgaagat
 4201 tttgtcccat cagatgctag tccacctaag accaaaactt ccccaaaact

```

tagtaacaaa
  4261 gaactgaaac cacagaaaag tgctcgtgtca gaccttgaag ctgatgatgt
taagggcagt
  4321 gtaccactgt cttcaagccc tcctgctaca catttcccag atgaaactga
aattacaaac
  4381 ccagttccta aaaagaatgt gacagtgaag aagacagcag caaaaagtca
gtcttccacc
  4441 tccactaccg gtgccaaaaa aagggtgtcc ccaaaaggaa ctaaaaggga
tccagctttg
  4501 aattctggtg tctctcaaaa gcctgatcct gccaaaacca agaatcgccg
caaaaggaag
  4561 ccatccactt ctgatgattc tgactctaata tttgagaaaa ttgtttcgaa
agcagtcaca
  4621 agcaagaaat ccaaggggga gagtgatgac ttccatatgg actttgactc
agctgtggct
  4681 cctcgggcaa aatctgtacg ggcaaagaaa cctataaagt acctggaaga
gtcagatgaa
  4741 gatgatctgt tttaaaatgt gaggcgatta ttttaagtaa ttatcttacc
aagccaaga
  4801 ctgggtttta agttacctga agctcttaac ttctctccct ctgaatttag
tttggggaag
  4861 gtgttttttag tacaagacat caaagtgaag taaagcccaa gtgttcttta
gctttttata
  4921 atactgtcta aatagtgacc atctcatggg cattgttttc ttctctgctt
tgtctgtggt
  4981 ttgagtctgc tttcttttgt ctttaaaacc tgatttttaa gttcttctga
actgtagaaa
  5041 tagctatctg atcacttcag cgtaaagcag tgtgtttatt aaccatccac
taagctaaaa
  5101 ctagagcagt ttgatttaaa agtgtcactc ttctctcttt tctactttca
gtagatatga
  5161 gatagagcat aattatctgt tttatcttag ttttatacat aatttaccat
cagatagaac
  5221 tttatggttc tagtacagat actctactac actcagcctc ttatgtgcca
agtttttctt
  5281 taagcaatga gaaattgctc atgttcttca tcttctcaaa tcatcagagg
ccgaagaaaa
  5341 acactttggc tgtgtctata acttgacaca gtcaatagaa tgaagaaaat
tagagtagtt
  5401 atgtgattat ttcagctctt gacctgtccc ctctggctgc ctctgagtct
gaatctccca
  5461 aagagagaaa ccaatttcta agaggactgg attgcagaag actcggggac
aacatttgat
  5521 ccaagatctt aaatgttata ttgataacca tgctcagcaa tgagctatta
gattcatttt
  5581 gggaaatctc cataatttca atttgtaaac tttgttaaga cctgtctaca
ttgttatatg
  5641 tgtgtgactt gagtaatggt atcaacgttt ttgtaaatat ttactatggt
tttctattag
  5701 ctaaattcca acaattttgt actttaataa aatgttctaa acattgcaac cca

```

//

```

3. CAMK2A: CAMK2A calcium/calmodulin-dependent protein kinase
II alpha [ Homo sapiens ]
Locus: NM_015981.3 (isoform 1)
AA /translation="MATITCTRFTEEYQLFEELGKGAFSVVRRCKVLAGQEYAAKII
NTKKLSARDHQKLEREARICRLKHPNIVRLHDSISEEGHHYLIFDLVTGGELFEDIV
AREYYSEADASHCIQQILEAVLHCHQMGMVVRDLKPENLLLASKLKGA AVKLADFGLA
IEVEGEQQAWFGFAGTPGYLSPEVLRKDPYKGPVDLWACGVILYILLVGYPFWDEDQ
HRLYQQIKAGAYDFPSPEWDVTPEAKDLINKMLTINPSKRITAAEALKHPWISHRST
VASCMPHRQETVDCLKKFNARRKLKGAILTTMLATRNFGSGKSGGNKSDGVKKRKS

```

SVQLMESSESTNTTIEDEDTKVRKQEI IKVTEQLIEAISNGDFESYTKMCDPGMTAFE
 PEALGNLVEGLDFHRFYFENLWSRNSKPVHTTILNPHIHLMGDESACIAYIRITQYLD
 AGGIPRTAQSEETRVWHRRDGKWQIVHFHRS GAPSVLPH

cDNA: 1 gggtgcatg gggacctgga tgctgacgaa ggctcgcgag gctgtgagca
 gccacagtgc
 61 cctgctcaga agccccgggc tcgtcagtc aaccggttct ctgtttgcac
 tcggcagcac
 121 gggcaggcaa gtggtcccta ggctcgggag cagagcagca gcgcctcagt
 cctggteccc
 181 cagtcccaag cctcacctgc ctgcccagcg ccaggatggc caccatcacc
 tgcacccgct
 241 tcacggaaga gtaccagctc ttcgaggaat tgggcaaggg agccttctcg
 gtggtgcgaa
 301 ggtgtgtgaa ggtgctggct ggccaggagt atgctgcaa gatcatcaac
 acaaagaagc
 361 tgtcagccag agaccatcag aagctggagc gtgaagcccg catctgccgc
 ctgctgaagc
 421 accccaacat cgtccgacta catgacagca tctcagagga gggacaccac
 tacctgatct
 481 tcgacctggt cactgggtggg gaactgtttg aagatatcgt ggcccgggag
 tattacagtg
 541 aggcggatgc cagtcactgt atccagcaga tcctggaggc tgtgtgtcac
 tgccaccaga
 601 tgggggtggt gcaccgggac ctgaagcctg agaatctgtt gctggcctcc
 aagctcaagg
 661 gtgccgcagt gaagctggca gactttggcc tggccataga ggtggagggg
 gagcagcagg
 721 catggtttgg gtttgcaggg actcctggat atctctcccc agaagtgtg
 cggaaggacc
 781 cgtacgggaa gcctgtggac ctgtgggctt gtgggggtcat cctgtacatc
 ctgctggttg
 841 ggtaccccc gttctgggat gaggaccagc accgcctgta ccagcagatc
 aaagccggcg
 901 cctatgattt cccatcgccg gaatgggaca ctgtcacccc ggaagccaag
 gatctgatca
 961 ataagatgct gaccattaac ccatccaaac gcatcacagc tgccgaagcc
 cttaagcacc
 1021 cctggatctc gcaccgctcc accgtggcat cctgcatgca cagacaggag
 accgtggact
 1081 gcctgaagaa gttcaatgcc aggaggaaac tgaagggagc cattctcacc
 acgatgctgg
 1141 ccaccaggaa cttctccgga ggggaagagtg ggggaaacaa gaagagcgat
 ggtgtgaaga
 1201 aaagaaagtc cagttccagc gttcagttaa tggaatctc agagagcacc
 aacaccacca
 1261 tcgaggatga agacacaaaa gtgcggaaac aggaattat aaaagtgaca
 gagcagctga
 1321 ttgaagccat aagcaatgga gattttgagt cctacacgaa gatgtgcgac
 cctggcatga
 1381 cagccttcga acctgaggcc ctggggaacc tggttgaggg cctggacttc
 catcgattct
 1441 attttgaaaa cctgtggtcc cggaacagca agcccgtagc caccaccatc
 ctgaateccc
 1501 acatccacct gatgggagac gagtcagcct gcatcgcta catccgcatc
 acgcagtacc
 1561 tggacgctgg cggcatccca cgcaccgccc agtcggagga gaccctgttc
 tggcaccgcc
 1621 gggatggcaa atggcagatc gtccacttcc acagatctgg ggcgcctcc
 gtctgcccc
 1681 actgagggac caggctgggg tcgctgcgtt gctgtgccgc agagatccac

tctgtccgtg
 1741 gagtggagct gctggttctc ccaggtggat tttgctggaa ttctcccatg
 tcatcacccc
 1801 accaccgtca cttctgtacc tgcatacaaga aaacctgctt gttcacaaaa
 gtcacgcaa
 1861 cttcagagcg aacggccaca tctccccacc tctaccccc accctctccc
 ctgccaggt
 1921 ggggcttctt caggcatggg tgtccacagc actggccccc tctccccagc
 ctcagctgct
 1981 gtccgcctga tctgtcttgg gctgtaggct agaatgcccg ggctggtgcc
 caccaggggc
 2041 tggggagaag gaggggtggc atgatgagga aggcagcatc cgtccgtccc
 tctcccagac
 2101 ctctcctctt ccagtgtccc cggggaaggg cagatgacac tcccttcccc
 ctaagccaac
 2161 cgcactgaag gagtggggag aagagcatac gccaggagcc tcctgcctca
 aagtgtctcc
 2221 ctaagtcttc ttctcctgtt gctgacctca ggggtggtctg acccttccct
 cgggtgtggg
 2281 gatgtggccc tctcaggtgc ccctacttgc tttctgcttc cttctggtga
 agtccacctc
 2341 caacattaac ctgcccaccc cccccctgc atccctggag aattccagct
 ttgtcgtatc
 2401 tcagagaggg aatctaattg tttttggggg gcaaaagaaa gcaacgttta
 ggtatcactt
 2461 ctacttggac cgcatacctt tttatagcca aatttctgtg tatttcgtaa
 atggatttgc
 2521 cgttaatgga tatttatgta ataactagac ttctcagatt attgtgagaa
 gggtcaggtt
 2581 ggaaggggtg taggaagagg ggtgaggggt agtttttttc tgttctagtt
 tttttttttt
 2641 tttttgtcat ctctgaggtg gaccttgtca cctgtggtta ttggggccaa
 ggtggactca
 2701 gctccgggga gaagggcctc tctgccattt cgggtcccaag gtgagctgac
 acaggcgttc
 2761 cttttgggac tgtggaagca tcagatgcca gcaactgactc aggaacagca
 agtcagggca
 2821 gagaggagga gggaggctgt caggatggaa atacctggac tttcttttgc
 ttccctcgca
 2881 aactggggtc ttctctaccg aacttcccag gatttcatct caccatatct
 gtgtgccgcc
 2941 cccagcacc cccaccacc tctggggggc ccgtgagcgt gtgtcttcat
 tgctctctc
 3001 cccttggcgt ctgatgacca cagcaaagca ctgggaattt ctactcttca
 tgctcatcc
 3061 tgcagcctcg ggttcgcatt ctctctttct tttctctttt ccctctttcc
 ctgggattga
 3121 ctctgagtgg aataccttgg cacatccact aggatctact gtctgcactg
 tttcttttgc
 3181 atgactttat acgcagtaag tatgttgaaa acaaacaaaa agaagaaaac
 actcaacaaa
 3241 accaatctac atgttttgga ctaaaaaaaa aaatagaggt tgtattctca
 gtgtccgact
 3301 cggaattatg ttgtgcctc tctgtgcttt tggcctctgt gtggccgtgt
 tttgccagca
 3361 tgagatactg tccctctctg aggatthtag gggaggaaga gccacgtccc
 cagggtattg
 3421 aggaggtccc ggtaccctcg accctctctg gtgttggttg gagcagaact
 ggtgaggtg
 3481 tttgatccga gatthttctga gctctcccca atcaccagct gtctgctggg
 ttcttttctc

```

3541 aagtcctgct gccaggccc aggtgagaca ggcaacgcca ggtctgcagg
ccaggagaga
3601 tgctgcccag gcctcctggg ttccaagctg gtccatcact ggcctctgtc
cttggcagag
3661 accttgctgc ccaggcccag gggcaggctc ttggcctgcc ccaggcccag
agggttccc
3721 agtaaggccc agtgatccca ttatcccagg ggcaaaacca cctgtcccct
tttgagctgc
3781 cagttcccta cagccatccc cagtcaaggg tgagggtgtg gccttcacca
ggggtctgtg
3841 taattaccga gcaaggctct agctcttctt cagcctcagt tccctcattg
gttaaaaggg
3901 ttctttgttc ccatccagcc gatgaaggag caaacgtctg gctatgtgaa
gcctaattta
3961 cctgcaggaa ctggcaggga tagtcactgg ctggactcct gtttacttct
agacctgggc
4021 aggtccatc ccctccccc cctgccctg attcccctcg tcggtgcctg
tcaactgett
4081 ttcagcagtg gactgcaggg gaaagagcag tgatttgggg tgagttagct
tcaattccca
4141 gctctgacca gacttgctgt gtgacctgg gcaagttcct ttccctcttt
ggagcttggg
4201 ttccctgcc gaggaactg agctggagga gcctgaggtc ctgcctttca
ttggctgaca
4261 cacctcctgt cactgtgtc actctccaag tgccagagaa gtggaggcag
atcgctaccc
4321 caggctgaga tggtcccccac tgtgaaggcc acgcctgtgg gtgggcagcc
acctggtgcc
4381 accacagggc accagggatg atcctgatgt ggcaggcagg ggagactcac
agaaaaatct
4441 gccagagcc taccctcacc agacaaactc tgtgtcctc caaacatcc
tttagatgca
4501 aaataataat aataataata ataaataaat aaataaaaat ccaaaccxaa
gtcaaaacct
4561 tggctccagc atgaaaacac gtttacagga aagtgttctc ctgggtttgt
gccaccatg
4621 gtgcgaatcc tgaccaagg cctcctgtct cccttcaaag ggagaccctt
ttgggggatg
4681 agtttgccag actcccctg ctggtttctt tgttactatt tgtttgggtt
tttgttttag
4741 ttcttttttt tttctttttc ttttttaaaa atatgtggct gtgaacttga
atgaacactg
4801 ctcaaacttt ctgctattgg gggggggcggg tgggatggga agaaggggcg
tttgttttat
4861 tcttggtgtt ttcagtgcaa taaatagcta caaacttctg tgcaaaaaaa
aaaaaaa
//
LOCUS      NM_171825      (isoform 2)
AA /translation="MATITCTRFTEEYQLFEELGKGAFSVVRRCKVLAGQFEYAAKII
NTKKLSARDHQKLEREARICRLKHPNIVRLHDSISEEGHHYLIFDLVTGGELFEDIV
AREYYSEADASHCIQQILEAVLHCHQMGGVVRDLKPENLLLASKLKGA AVKLADFLA
IEVEGEQQA WFGFAGTPGYLSPEVLRKDPYGKPVDLWACGVILYILLVGYPFWDEDQ
HRLYQQIKAGAYDFSPWDVTPEAKDLINKMLTINPSKRITAAEALKHPWISHRST
VASCMRHRETVDCLKKFNARRKLKGA ILTTLATRNFGSGKSGGNKSDGVKESSEST
NTTIEDEDTKVRKQEIIKVTEQLIEAISNGDFESYTKMCDPGMTAFEPEALGNLVEGL
DFHRFYFENLWSRNSKPVHTTILNPHIHLMGDESACIAYIRITQYLDAGGIPRTAQSE
ETRVWHRDGGKWQIVHFHRSGAPSVLPH

```

```

cDNA: 1 ggttgccatg gggacctgga tgctgacgaa ggctcgcgag gctgtgagca
gccacagtgc
61 cctgctcaga agccccgggc tcgtcagtc aaccggttct ctgtttgcac

```

tcggcagcac
 121 gggcaggcaa gtggtcccta ggttcgggag cagagcagca gcgcctcagt
 cctggteccc
 181 cagtcccaag cctcacctgc ctgccagcgc ccaggatggc caccatcacc
 tgcacccgct
 241 tcacggaaga gtaccagctc ttcgaggaat tgggcaaggg agccttctcg
 gtggtgcgaa
 301 ggtgtgtgaa ggtgctggct ggccaggagt atgtgccaa gatcatcaac
 acaaagaagc
 361 tgtcagccag agaccatcag aagctggagc gtgaagcccg catctgccgc
 ctgctgaagc
 421 accccaacat cgtccgacta catgacagca tctcagagga gggacaccac
 tacctgatct
 481 tcgacctggt cactggtggg gaactgtttg aagatatcgt ggcccgggag
 tattacagtg
 541 aggcggatgc cagtcaactgt atccagcaga tcctggaggc tgtgctgcac
 tgccaccaga
 601 tgggggtggt gcaccgggac ctgaagcctg agaatctgtt gctggcctcc
 aagctcaagg
 661 gtgccgcagt gaagctggca gactttggcc tggccataga ggtggagggg
 gagcagcagg
 721 catggtttgg gtttgcaggg actcctggat atctctcccc agaagtgtctg
 cggaaggacc
 781 cgtacgggaa gcctgtggac ctgtgggctt gtggggtcac cctgtacatc
 ctgctggttg
 841 ggtaccccc gttctgggat gaggaccagc accgcctgta ccagcagatc
 aaagccggcg
 901 cctatgattt cccatcgccg gaatgggaca ctgtcaccac ggaagccaag
 gatctgatca
 961 ataagatgct gaccattaac ccatccaaac gcatacacgc tgccgaagcc
 cttaaagcac
 1021 cctggatctc gcaccgctcc accgtggcat cctgcatgca cagacaggag
 accgtggact
 1081 gcctgaagaa gttcaatgcc aggaggaaac tgaaggaggc cattctcacc
 acgatgctgg
 1141 ccaccaggaa cttctccgga gggaagagtg ggggaaacaa gaagagcgat
 ggtgtgaagg
 1201 aatcctcaga gagcaccac accaccatcg aggatgaaga caccaaagtg
 cggaacagg
 1261 aaattataaa agtgacagag cagctgattg aagccataag caatggagat
 tttgagtct
 1321 acacgaagat gtgcgacctt ggcatgacag ccttcgaacc tgaggccctg
 gggaacctgg
 1381 ttgagggcct ggacttccat cgattctatt ttgaaaacct gtggtcccgg
 aacagcaagc
 1441 ccgtgcacac caccatctct aatccccaca tccacctgat gggcgacgag
 tcagcctgca
 1501 tcgcctacat ccgcatcacg cagtacctgg acgctggcgg catcccacgc
 accgcccagt
 1561 cggaggagac ccgtgtctgg caccgccggg atggcaaatg gcagatcgtc
 cacttcaca
 1621 gatctggggc gccctccgtc ctgcccact gagggaccag gctggggtcg
 ctgctgttgc
 1681 gtgccgcaga gatccactct gtccgtggag tggagctgct ggttctccca
 ggtggatttt
 1741 gctggaattc tcccatgtca tcacccacc accgtcactt ctgtacctgc
 atcaagaaaa
 1801 cctgcttgtt cacaaaagtc atcgcaactt cagagcgaac ggccacatct
 cccacactct
 1861 cacccccacc ctctccctg ccaggctggg gcttctcag gcatgggtgt
 ccacagcact

1921 ggccccctct cccagcctc agctgctgtc cgctgatct gtcttgggct
 gtaggctaga
 1981 atgcccgggc tgggtgccac caggggctgg ggagaaggag ggggtggcatg
 atgaggaagg
 2041 cagcatccgt ccgtccctct ccagacctc tcctcttcca gtgtccccgg
 ggaagggcag
 2101 atgacactcc ctcccccta agccaaccgc actgaaggag tggggagaag
 agcatacgcc
 2161 aggagcctcc tgctcaaag tgctcccta agtcttcttc ctctgtgtct
 gacctcaggg
 2221 tgggtctgacc ctccctcgg tgtgggggat gtggccctct cagggtcccc
 tacttgcttt
 2281 ctgcttcctt ctggtgaagt ccacctcaa cattaacctg cccacccac
 ccccgctc
 2341 cctggagaat tccagctttg tcgtatctca gagagggaat ctaattgttt
 ttggggggca
 2401 aaagaaagca acgtttaggt atcacttcta ctggaccgc atgccttttt
 atagccaaat
 2461 ttctgtgtat ttcgtaaagt gatttcgcgt taatggatat ttatgtaata
 actagacttc
 2521 tcagattatt gtgagaaggg tcaggttgga aggggtgtag gaagaggggt
 gaggggtagt
 2581 tttttctgt tctagttttt tttttttttt ttgtcatctc tgaggtggac
 cttgtcacct
 2641 gtggttattg gggccaagggt ggactcagct ccggggagaa gggcctctct
 gccatttcgg
 2701 tccaagggtg agctgacaca ggcgttcctt ttgggactgt ggaagcatca
 gatgccagca
 2761 ctgactcagg aacagcaagt cagggcagag aggaggaggg aggctgtcag
 gatggaaata
 2821 cctggacttt tctttgcttc cctcgcaaac tggggctctc tctaccgaac
 ttcccaggat
 2881 ttcactctac catatctgtg tgccgcccc agcaccccc acccacctct
 ggggggccc
 2941 tgagcgtgtg tcttcattgc ctctctccc ttggcgtctg atgaccacag
 caaagcactg
 3001 ggaatttcta ctcttcatgc ctcatcctgc agcctcgggt tcgcattctc
 tctttctttt
 3061 cctctttccc tctttccctg ggattgactc tgagtggaaat acctggcac
 atccactagg
 3121 atctactgtc tgcaactgtt tctttgcatg actttatacg cagtaagtat
 gttgaaaaca
 3181 aacaaaaaga agaaaacact caacaaaacc aatctacatg ttttgacta
 aaaaaaaaa
 3241 tagaggttgt attctcagtg tccgactcgg aattatgttg ctgcctctct
 gtgcttttgg
 3301 cctctgtgtg gccgtgtttt gccagcatga gatactgtcc cctctggagg
 attttagggg
 3361 aggaagagcc acgtccccag ggattggagg aggetccggt acctcgacc
 ctctggtg
 3421 ttggttgag cagaactggt gaggatgtt gatccgagat tttctgagct
 ctccccaatc
 3481 accagctgtc tgctgggttc tttctcaag tcctgctgcc caggcccagg
 tgagacaggc
 3541 aacgccaggt ctgcaggcca ggagagatgc tgcccaggcc tcctggttcc
 caagctggtc
 3601 catcactggc ctctgtcctt ggcagagacc ttgctgcca ggcccagggg
 caggetcttg
 3661 gcctgcccc ggcccagagg gcttcccagt aaggcccagt gatccatta
 tcccagggc
 3721 aaaaccacct gtcccccttt gagctgccag ttccctacag ccatccccag


```

tcaaggtga
3781 ggggtgtggcc ttcaccaggg gctgctgtaa ttaccgagca aggtctgagc
tcttcttcag
3841 cctcagttcc ctcatagggtt aaaaggggttc tttgttccca tccagccgat
gaaggagcaa
3901 acgtctggct atgtgaagcc taatttacct gcaggaactg gcagggatag
tactggctg
3961 gactcctgtt tacttctaga cctggtcagg ctccatcccc tccccacct
gccccgtatt
4021 cccctcgtcg gtgcctgtca actgcttttc agcagtggac tgcaggggaa
agagcagtga
4081 tttgggggtga gtaggcttca attcccagct ctgaccagac ttgctgtgtg
accttgggca
4141 agttcctttc cctcttttga gcttggtttc cctgccagag gaaactgagc
tggaggagcc
4201 tgaggctctg cctttcattg gctgacacac ctctgtcca ctgtgtcact
ctccaagtgc
4261 cagagaagtg gaggcagatc gctaccccag gctgagatgg cccccactgt
gaaggccacg
4321 cctgtgggtg ggcagccacc tgggtgccacc acagggcacc agggatgatc
ctgatgtggc
4381 aggcagggga gactcacaga aaaatctgcc cagagcctac ctcaccaga
caaactctgt
4441 gctcctccaa aacatccttt agatgcaaaa taataataat aataataata
aataaataaa
4501 taaaaatcca aacccaagtc aaaaccttgg ctccagcatg aaaacacgtt
tacaggaaag
4561 tgttctcctg ggtttgtgcc caccatgggtg cgaatcctga cccaaggcct
cctgtctccc
4621 ttcaaaggga gacccttttg ggggatgagt ttgccagact ccccgctctg
gtttctttgt
4681 tactatttgt ttggggtttt gttttagttc tttttttttt tcttttcttt
tttaaaaata
4741 tgtggctgtg aacttgaatg aacactgtc aaactttctg ctattggggg
gggcgggtgg
4801 gatgggaaga aggggcgttt gttttattct tgggtgtttc agtgcaataa
atagctacaa
4861 acttctgtgc aaaaaaaaaa aaaaa
//
4. CDK1: CDK1 cyclin-dependent kinase 1 [ Homo sapiens ]
LOCUS NM_001170406 (isoform 4)
AA/translation="MEDYTKIEKIGEGTYGVVYKGRHKTTGQVVAMKKIRLESEEEGV
PSTAIRESISLLKELRHPNIVSLQDVLMDLSRLYLIFEFLSMDLKKYLD SIPPGQYMDS
SLVKVKA

```

```

cDNA:1 agccgccctt tcctctttct ttgcgctct agccaccgga gaaggcctgc
ccagcgtagc
61 tgggctctga ttggctgctt tgaaagtcta cgggctaccc gattgtgaa
tccggggccc
121 tttagcgcg atctaccata cccattgact aactatggaa gattatacca
aaatagagaa
181 aattggagaa ggtacctatg gagttgtgta taagggtaga cacaaaacta
caggtcaagt
241 ggtagccatg aaaaaaatca gactagaaag tgaagaggaa ggggttccta
gtactgcaat
301 tcgggaaatt tctctattaa aggaacttcg tcatccaaat atagtcagtc
ttcaggatgt
361 gcttatgcag gattccaggt tatatctcat ctttgagttt ctttccatgg
atctgaagaa
421 atacttggat tctatccctc ctggtcagta catggattct tcacttgta
aggtaaaagc

```

481 ttaactaatt ttattaatat ttatgcactg tggatataaa gggactatat
 atagaagtcc
 541 ctgcattttg tgggaatatg cttggaaaaa gtgttagaat aagaaaaagt
 atttcatttt
 601 tctccctcat ggtagttta tacaggttag agatacccat gttattacca
 gatagtgttt
 661 ctagtaagta aaaattagtg cctgagataa catagaactg gtaggtattg
 ttggaagcta
 721 gggtagtctg gtctttcttt ggctgtcaga tacatgtaa acaaagtaat
 gaaagcctag
 781 ggcagagtgg tgggtgtagg tgttttattc cagttttgaa catgttttgg
 tcaatttatt
 841 gtagacattt attatatttc aggtaaatta taaaattgta tagttttaag
 tactgaagta
 901 tataaaagt tcttattctt gcaccagttc taccaaacca ctctgcagag
 gtagcgctgt
 961 tagttttatt tgtaatctta cacttgtagt tatgttcact ttgtatgtat
 ataaagattt
 1021 ttttttttac acaaggtgga cttatttgca tatgtatata tacatatatt
 cccttttttg
 1081 tgtaaaacat tatcaagacg tagatctacc tatgtctatt tacatttttg
 atataattaa
 1141 accacttcca tattgatgaa catttaaatt atttccaac ttggttattg
 ttgctcttat
 1201 taacagtact gcaactgaatg tccttataga ttttatctt cgtatgcaac
 tttataggat
 1261 aaatttttag aatgggaatg atggattgaa gatgtttatt tacattttga
 tagatattgc
 1321 cggttgcccc ctaaaaaact tntagcaatt tactcttaaa tactcatggt
 gtgtaataact
 1381 tattgtttta gtacatcatt gccaaaactt ggttttatca atctgttaac
 tatgtgaaaa
 1441 aggcataatta agattgtttt aattttatat ttcatgacaa tttaacactt
 catatttagc
 1501 tattataaac cgcctatatt ttcgttagga tacgttcttt aacaatcttg
 catgactttt
 1561 ggactttctg cttttatgtc ttgcttaagt ctctctcact caaagatcga
 atgtattaga
 1621 ataatacatg tcagtatttt tctggtagtt ttagtaagtc ctgtcttcca
 cacatacttt
 1681 ttttgtctta aattctgtat taagatttat tttgacttaa aaactgggat
 acagattctg
 1741 ctttatcttt ttcc

//

LOCUS NM_001786 (isoform 1)
 AA /translation="MEDYTKIEKIGEGTYGVVYKGRHKTTGQVVAMKKIRLESEEEGV
 PSTAIREISLLKELRHPNIVSLQDVLMDQSRLLYLIFEFLSMDLKKYLDSSIPGQYMDS
 SLVKSYLEYQILQGIVFCHSRRVLHRDLKPQNLLIDDKGTIKLADFGFLARAFGIPIRVY
 THEVVTWYRSPEVLLGSARYSTPVDIWSIGTIFAELATKKPLFHGDSEIDQLFRIFR
 ALGTPNNEVWPEVESLQDYKNTPKWKPGSLASHVKNLDENGLDLLSKMLIYDPAKRI
 SGKMALNHPYFNDLDNQIKKM

cDNA: 1 agcgcgggtga gtttgaaaact gctcgcactt ggcttcaaag ctggctcttg
 gaaattgagc
 61 ggagagcgac gcggttggtg tagctgccgc tgcggccgcc gcggaataat
 aagccgggat
 121 ctaccatacc cattgactaa ctatggaaga ttataccaaa atagagaaaa
 ttggagaagg
 181 tacctatgga gttgtgtata agggtagaca caaaactaca ggtcaagtgg
 tagccatgaa

```

241 aaaaatcaga ctagaaagtg aagaggaagg ggttcctagt actgcaattc
gggaaatttc
301 tctattaaag gaacttcgtc atccaaatat agtcagtctt caggatgtgc
ttatgcagga
361 ttccaggtta tatctcatct ttgagtttct ttccatggat ctgaagaaat
acttgattc
421 tatccctcct ggtcagtaca tggattcttc acttgттаag agttatttat
accaaatect
481 acaggggatt gtgttttgtc actctagaag agttcttcac agagacttaa
aacctcaaaa
541 tctcttgatt gatgacaaag gaacaattaa actggctgat tttggccttg
ccagagcttt
601 tggaatacct atcagagtat atacacatga ggtagtaaca ctctggtaca
gatctccaga
661 agtattgctg gggtcagctc gttactcaac tccagttgac atttgagta
taggcacat
721 atttgctgaa ctagcaacta agaaaccact tttccatggg gattcagaaa
ttgatcaact
781 cttcaggatt ttcagagctt tgggcactcc caataatgaa gtgtggccag
aagtggaatc
841 tttacaggac tataagaata ctttcccaa atggaaacca ggaagcctag
catcccatgt
901 caaaaacttg gatgaaaatg gcttgatttt gctctcgaaa atgttaatct
atgatccagc
961 caaacgaatt tctggcaaaa tggcactgaa tcatccatat ttaatgatt
tggaacatca
1021 gattaagaag atgtagcttt ctgacaaaaa gtttccatat gttatatcaa
cagatagttg
1081 tgtttttatt gttaactctt gtctattttt gtcttatata ttttctttg
ttatcaaact
1141 tcagctgtac ttogtcttct aatttcaaaa atataactta aaaatgtaaa
tattctatat
1201 gaattttaa ataatctctgt aaatgtgtgt aggtctcact gtaacaacta
tttgttacta
1261 taataaaaact ataattattga tgtcaggaat caggaaaaaa tttgagttgg
cttaaatcat
1321 ctcagtcctt atggcagttt ttttttcttg tagttggaac tactaaaatt
taggaaaatg
1381 ctaagttcaa gtttcgtaat gctttgaagt atttttatgc tctgaatggt
taaatgttct
1441 catcagtttc ttgccatggt gttaactata caacctggct aaagatgaat
atttttctac
1501 tggatattta atttttgacc taaatgttta agcattcgga atgagaaaac
tatacagatt
1561 tgagaaatga tgctaaattt ataggagttt tcagtaactt aaaaagctaa
catgagagca
1621 tgccaaaatt tgctaagtct taciaagatc aagggtctgc cgcaacaggg
aagaacagtt
1681 ttgaaaattt atgaactatc ttatttttag gtaggttttg aaagcttttt
gtctaagtga
1741 attcttatgc cttggtcaga gtaataactg aaggagttgc ttatcttggc
tttcgagtct
1801 gagtttaaaa ctacacattt tgacatagtg tttattagca gccatctaaa
aaggtcttaa
1861 tgtatattta actaaaatta ctagcttttg gaattaaact gtttaacaaa
taaaaaaaaa
1921 aaa
//

```

LOCUS NM_033379 (isoform 2)
AA /translation="MEDYTKIEKIGEGTYGVVYKGRHKTTGQVVAMKKIRLESEEEGV"

PSTAIRESISLLKELRHPNIVSLQDVLQMDSRLYLIFEFLSMDLKKYLDSSIPGQYMDS
 SLVKVVTWYRSPEVLLGSARYSTPVDIWSIGTIFAELATKKPLFHGDSEIDQLFRIF
 RALGTPNNEVWPEVESLQDYKNTFPKWKPGSLASHVKNLDENGLDLLSKMLIYDPAKR
 ISGKMALNHPYFNDLDNQIKKM

cDNA: 1 agcgcggtga gtttgaaact gctcgcaact ggcttcaaag ctggctcttg
 gaaattgagc
 61 ggagagcgac gcggttggtg tagctgccgc tgcggccgcc gcggaataat
 aagccgggat
 121 ctaccatacc cattgactaa ctatggaaga ttataccaaa atagagaaaa
 ttggagaagg
 181 tacctatgga gttgtgtata agggtagaca caaaactaca ggtcaagtgg
 tagccatgaa
 241 aaaaatcaga ctagaaagtg aagaggaagg ggttcctagt actgcaattc
 gggaaatttc
 301 tctattaaag gaacttcgtc atccaaatat agtcagtctt caggatgtgc
 ttatgcagga
 361 ttccaggtta tatctcatct ttgagtttct ttccatggat ctgaagaaat
 acttggaattc
 421 tatccctcct ggtcagtaca tggattcttc acttggttaag gtagtaaac
 tctggtacag
 481 atctccagaa gtattgctgg ggtcagctcg ttactcaact ccagttgaca
 tttggagtat
 541 aggcaccata tttgctgaac tagcaactaa gaaaccactt ttccatgggg
 attcagaaat
 601 tgatcaactc ttcaggattt tcagagcttt gggcactccc aataatgaag
 tgtggccaga
 661 agtggaaatct ttacaggact ataagaatac atttcccaa tggaaccag
 gaagcctagc
 721 atcccatgtc aaaaacttgg atgaaaatgg cttggatttg ctctcgaaaa
 tggttaatcta
 781 tgatccagcc aaacgaattt ctggcaaaat ggcactgaat catccatatt
 ttaatgattt
 841 ggacaatcag attaagaaga tgtagctttc tgacaaaaag tttccatatg
 ttatatcaac
 901 agatagttgt gtttttattg ttaactcttg tctatTTTTg tcttatatat
 atttctttgt
 961 tatcaaaact cagctgtact tcgtcttcta atttcaaaaa tataacttaa
 aaatgtaaat
 1021 attctatatg aatttaaata taattctgta aatgtgtgta ggtctcactg
 taacaactat
 1081 ttgttactat aataaaacta taatattgat gtcaggaatc agggaaaaat
 ttgagttggc
 1141 ttaaatcatc tcagtcctta tggcagtttt attttctgt agttggaact
 actaaaattt
 1201 agggaaatgc taagttcaag tttcgtaatg ctttgaagta tttttatgct
 ctgaatgttt
 1261 aaatgttctc atcagtttct tgccatgttg ttaactatac aacctggcta
 aagatgaata
 1321 tttttctact ggtattttta tttttgacct aaatgtttta gcattcggaa
 tgagaaaact
 1381 atacagattt gagaaatgat gctaaattta taggagtttt cagtaactta
 aaaagctaac
 1441 atgagagcat gccaaaattt gctaagtctt acaaagatca agggctgtcc
 gcaacaggga
 1501 agaacagttt tgaaaattta tgaactatct ttttttagg taggttttga
 aagctttttg
 1561 tctaagtga ttcttatgcc ttggtcagag taataactga aggagttgct
 tatcttggct
 1621 ttcgagtctg agtttaaaac tacacatttt gacatagtgt ttattagcag
 ccatctaaaa

1681 aggcctctaata gtatatatttaa ctaaaattac tagctttggg aattaaactg
 ttttaacaaat
 1741 aaaaaaaaaa aa
 //

5. CLTCL1: CLTCL1 clathrin, heavy chain-like 1 [Homo sapiens]

LOCUS NM_001835 (isoform 2)
 AA /translation="MAQILPVRFQEHFQLQNLGINPANIGFSTLTMESDKFICIREKV
 GEQAQVTIIDMSDPMAPIRRPISAESAIMNPASKVIALKAGKTLQIFNIEMSKMKAH
 TMAEEVIFWKWVSVNTVALVTETAVYHWSMEGDSQPMKMFDRHTSLVGCQVIHYRTDE
 YQKWLLLVGISAQQNRVVGAMQLYSVDRKVSQPIEGHAAFAEFKMEGNAKPATLFCF
 AVRNPITGGKLHIEVGQPAAGNQPFVKKAVDVFPPPEAQNDFPVMQIGAKHGVYILI
 TKYGYLHLYDLESGVCICMNRISADTIFVTAPHKPTSGIIGVNKKGQVLSVCVEEDNI
 VNYATNVLQNPDLGLRLAVRSNLAGAEKLFVRKFNTLFAQGSYAEAAKVAASAPKGIL
 RTRETVQKFQSIQAQSGQASPLLQYFGILLDQGLNKLKESLELCHLVLQQGRKQLLEK
 WLKEDKLECSEELGDLVKTTPMLALSVYLRANVPSKVIQCFAETGQFQKIVLYAKKV
 GYTPDWIFLLRGVMKISPEQGLQFSRMLVQDEEPLANISQIVDIFMENSLIQQCTSF
 LDALKNNRPAEGLLQTWLLEMNLVHAPQVADAILGNKMFTHYDRAHIAQLCEKAGLLQ
 QALEHYTDLYDIKRAVVHHTLLNPEWLVNFFGSLSVEDSVECLHAMLNANIRQNLQLC
 VQVASKYHEQLGTQALVELFESFKSYKGLFYFLGSIVNFSQDPDVHLKYIQAACKTGQ
 IKEVERICRESSCYNPERVKNFLKEAKLTDQLPLIIVCDRFGFVHDLVLYLYRNLRQ
 YIEIYVQKVNPSRTPAVIGGLLDVDCSEEVIKHLIMAVRGQFSTDELVAEVEKRNRLK
 LLLPWLESQIQEGCEEPATHNALAKIYIDSNNSPECFLRENAYYDSSVVGRYCEKRD
 HLACVAYERGQCDLELIKVCNENSLFKSEARYLVCRKDPELWAHVLEETNPSSRQLID
 QVVQTALSETRDPEEISVTVKAFMTADLPNELIELLEKIVLDNSVSEHRNLQNLIL
 TAIKADRTRVMEYISRLDNYDALDIASIAVSSALYEEAFVTFHKFDMNASAIQVLEH
 IGNLDRAVEFAERCNEPAVWSQLAQALQKDLVKEAINSIRGDDPSSYLEVVQSASR
 SNNWEDLVKFLQMARKKGRESYIETELIFALAKTSRVSELEDFINGPNNAHIQVQDR
 CYEEGMYEAAKLLYSNVSNFARLASTLVHLGEYQAAVDNSRKASSTRTWKEVCFACMD
 GQEFRFAQLCGLHIVIHADLEELMCYYQDRGYFEELIILLLEAALGLERAHMGMTL
 AILYSKFKPKQKMLEHLELFWSRVNIPKVLRAAEQAHWAELVFLYDKYEEYDNAVLT
 MSHPTAEWKEGQFKDIIITKANVELCYRALQFYLDYKPLLINDLLVLSPLRDHTWT
 VSFSSKAGQLPLVKPYLRSVQSHNNKSVNEALNHLTTEEDYQDAMQHAESRDAELA
 QKLLQWFLEEGKRECFAACLFCTCYDLLRPDMVLELAWRHNLDLAMPYFIQVMREYLSK
 VDKLDALESRLKQEEHVTEPAPLVDFDFGHE

cDNA: 1 accggtcagc ccgcgcgagg ggtcggcggt cattcctgcc gctgccgcgcg
 ccgccgcgca
 61 ggtcccgcac cagccatggc gcagatcctc cctgttcgct ttcaggagca
 cttccagctc
 121 caaaccttg gaattaatcc agctaacatt ggattcagca cactgaccat
 ggaatctgac
 181 aagttcatat gtatccgaga gaaagttggt gagcaggcac aggtcacgat
 cattgacatg
 241 agtgacccaa tggtccgat ccgacggcct atctctgcag agagtgccat
 catgaatcca
 301 gcctctaagg tgatagctct gaaagctggg aagacacttc agatctttaa
 tattgagatg
 361 aagagtaaaa tgaaggctca tactatggca gaagaagtga ttttctggaa
 atgggtttct
 421 gtgaacactg ttgccttggt gaccgagacc gcggtctacc actggagcat
 ggaaggtgac
 481 tcccagccca tgaagatggt tgatagacat accagtctgg tgggctgcc
 ggtgattcac
 541 taccggactg atgagtacca gaagtggctg ctgctcgtag gcctctcggc
 tcagcaaaac
 601 cgtgtggttg gagcaatgca gctctactct gtggatagga aggtttcaca
 acccatagaa
 661 ggccatgctg cggtttttgc agagttcaag atggagggga atgccaaagcc
 tgccaccctt

721 ttctgctttg ctgtacgtaa tcccacagga ggcaagttgc acatcattga
 agttggacag
 781 cctgcagcgg gaaaccaacc ttttgtaaag aaagcagtag atgtgttttt
 tcctccagag
 841 gcacagaatg attttccagt ggctatgcag attggagcta aacatggtgt
 tatttacttg
 901 atcacaaagt atggctatct tcactgtac gacctagagt ctggcgtgtg
 catctgcatg
 961 aaccgtatta gtgctgacac aatatttgtc actgctccac acaaaccaac
 ctctggaatt
 1021 attggtgtca aaaaaaggg acaggtactg tcagtttgtg ttgaggaaga
 taacattgtg
 1081 aattatgcaa ccaacgtgct tcagaatcca gaccttggtc tgcgtttggc
 cgttcgtagt
 1141 aacctggctg gggcagagaa gttgtttgtg agaaaattca ataccctctt
 tgcacagggc
 1201 agctatgctg aagccgcaa agttgcagcg tctgcaccaa agggaatcct
 gcgtaccaga
 1261 gagacgttcc agaaattcca gagtataccc gctcagtctg gccaggtctc
 tccattgctg
 1321 cagtacttct gaatcctgct cgaccagggt cagctcaata aacttgaatc
 cttagaactt
 1381 tgccatctgg ttcttcagca ggggcgtaag caactcctag agaagtggct
 gaaagaagat
 1441 aagctggagt gctcagagga gctcggagac ttggtcaaaa cactgaccc
 catgctcgct
 1501 ctgagtgtgt accttcgggc aaatgtgcca agcaaagtga tccagtgttt
 tgcagaaaca
 1561 ggccaattcc agaaaattgt gctctatgcc aaaaaggttg ggtacacccc
 agactggatc
 1621 tttctgctga ggggtgtaat gaagatcagt ccggaacagg gcctgcagtt
 ttctcgaatg
 1681 ctagtgcagg acgaggagcc gctggccaac attagccaga ttgtggacat
 tttcatggaa
 1741 aacagtttaa ttcagcagtg tacttccttc ttattggatg cttgaagaa
 taatcgccca
 1801 gctgaggggac tcctgcagac atggctgttg gagatgaacc ttgttcatgc
 acccaggtt
 1861 gcagatgcca tccttggaat taaaatgttt actcattacg accgggcccc
 cattgcccag
 1921 ctctgtgaga aggcaggcct cctgcagcaa gcaactggagc actacaccga
 cctctatgac
 1981 atcaagaggg ctgtggtcca cactcacctc ctcaatcccg agtggettgt
 caatttcttt
 2041 ggctccttat cggtggagga ttctgtggag tgtctgcatg ccatgctgtc
 tgctaacatc
 2101 agacagaacc ttcagctgtg tgtgcaggtg gcctctaagt accacgagca
 gctgggcacg
 2161 caggccctgg tggagctctt tgaatccttc aagagttaca aaggcctctt
 ctacttctg
 2221 ggctcaatcg tgaacttcag ccaagacca gatgtgcac tgaaatacat
 tcaggctgce
 2281 tgtaagacag ggcagatcaa ggaggtggag aggatatgcc gagagagcag
 ctgctacaac
 2341 ccagagcgtg tgaagaactt cctgaaggag gccaagctca cagaccagct
 tcccctcacc
 2401 atcgtgtgtg atcgttttgg ctttgtccat gaccttgtcc tatatttata
 ccgcaacaac
 2461 ctgcagaggt acattgagat ctacgtgcag aaggtcaacc ctagccggac
 ccagctgtg
 2521 attggagggc tgcttgatgt ggattgttct gaggaagtga ttaaactctt

aatcatggca
 2581 gtgagaggac agttctctac tgatgagttg gtggctgaag tagaaaaaag
 aaataggtct
 2641 aagctgctgc ttccctggct ggagtcaccag attcaggaag gctgtgagga
 gcctgccact
 2701 cacaatgcac tggctaaaat ctacatcgac agcaacaaca gccccgagtg
 cttcctgaga
 2761 gagaatgcct actatgacag cagcgtggtg ggccgctact gtgagaagcg
 agacccccat
 2821 ctggcctgtg ttgcctatga gcggggggcag tgtgaccttg agctcatcaa
 ggtgtgcaat
 2881 gagaattctc tgttcaaaag cgaggcccg c tacctggtat gcagaaagga
 tccggagctc
 2941 tgggctcacg tccttgagga gaccaacca tccaggagac agctaattga
 ccaggtggta
 3001 cagacagcat tgtcagaaac acgggatcct gaagagattt cggtcactgt
 caaagccttt
 3061 atgacagccg acctgcctaa tgaactgatt gaactgctgg agaagatagt
 tctggataac
 3121 tctgtcttca gcgagcacag gaatctacag aatctgttga tcctgactgc
 catcaaggca
 3181 gaccgcacac gggtcatgga gtacatcagc cgccctggaca actatgacgc
 actggacatc
 3241 gcgagcatcg ctgtcagcag cgcactgtat gaggaggcct tcaccgtttt
 ccacaagttt
 3301 gatatgaatg cctcagcaat ccaggtcctg atcgagcaca ttggaaacct
 ggaccgggca
 3361 tatgagtttg cggagagatg caatgagcct gctgtgtgga gtcagctggc
 ccaagcccag
 3421 ctccagaaag atttggtgaa ggaagccatc aactcctata tcagagggga
 cgacccttcc
 3481 tcttacctgg aagttgttca gtcagccagc aggagcaaca actgggagga
 tctagttaaa
 3541 tttctgcaga tggccaggaa aaagggccgt gagtcctata tagagactga
 acttattttt
 3601 gccttggtta aaaccagccg tgtttctgag ctagaagatt ttattaatgg
 acccaacaat
 3661 gccacatcc agcaggttgg agaccgctgt tacgaggagg gaatgtacga
 ggctgccaa
 3721 ctgctctata gcaatgtttc taactttgcc cgccctggctt ccacctgggt
 tcacctcggt
 3781 gagtatcagg cagcagtgga caacagccgc aaggccagca gcaccggac
 gtggaaggag
 3841 gtgtgctttg cctgcatgga tggacaagag ttccgcttcg cacagctgtg
 tggctttcac
 3901 atcgctcatc atgcagatga gctggaggag ctgatgtgct attaccagga
 tcgtggtac
 3961 tttgaggagc tgatcttgct gttggaagcg gccctgggccc tggagcgggc
 ccacatgggc
 4021 atgttccactg agctggccat cctctactcc aaattcaagc cacagaagat
 gctggagcat
 4081 ctggagcttt tctggctccg tgtcaacatc ccaaaggtgc tgagggtgc
 agagcaggca
 4141 cacctgtggg ctgagctggt gttcctctat gacaagtacg aggagtatga
 caatgctgtg
 4201 ctacccatga tgagccaccc cactgaggcc tgggaaggagg gtcagttaa
 ggacatcatt
 4261 accaaggttg ccaacgtcga gctctgttac agagccctgc agttctatatt
 ggattacaaa
 4321 ccaactgctca tcaatgacct gctgctggtg ctttcacccc ggctggacca
 cacctggaca

4381 gtcagtttct tttcaaaggc aggtcagctg cccctggtga agccttacct
 gcggtcagtc
 4441 cagagccaca acaacaagag tgtgaatgag gcactcaacc acctgctgac
 agaggaggag
 4501 gactatcagg atgccatgca gcatgctgca gagtcgcggg atgctgagct
 ggcccagaag
 4561 ttgctgcagt ggttcctgga ggaaggcaag agggagtgtc tcgcagcttg
 tctcttcacc
 4621 tgctatgacc tgcttcgccc agacatggtg cttgagctgg cctggaggca
 caacctcgtg
 4681 gacttggcca tgccctactt catccaggtg atgagggagt acctgagcaa
 ggtggacaaa
 4741 ctggatgcct tggagagtct gcgcaagcaa gaggagcatg tgacagagcc
 tgccccctctc
 4801 gtgtttgatt ttgatgggca tgaatgagac ccagctgatt gcactaagcc
 ctgccgtggg
 4861 cccagcccct gccagcttcc cctatggata tgccctctgt cccaacttcg
 ccagctcca
 4921 atgtacaact tccgcgtgta gtgggcgttg tcaccacca cctacctgc
 agagttacta
 4981 acttctccaa ggagcatgtc actccagcag cacaggggac gcaatgggag
 gcagggacac
 5041 ctggacaata tttatTTTTG ctgaaacca atgacggcaa cctctgagcc
 atcccagagc
 5101 ctggggaggc cagggtagag gctgacggcg caagaccagc ttagccgac
 aacagagact
 5161 ggactgtggg cctcctctgt ggagccaggc ctctcctctg ggcgctccg
 actggtctgga
 5221 gctgccccct ccaggccagt ttgaagacta catgaacacg tctgttttg
 aggtaccgga
 5281 cctcataaaa ggactctcag cctcttgga atcataaata ttaaagtcgg
 tttatccagg
 5341 caaaaaaaaa aaaaaaaaaa aaaaaaaaa a

//

LOCUS NM_007098 (isoform 1)
 AA /translation="MAQILPVRFQEHFQLQNLGINPANIGFSTLTMESDKFICIREKV
 GEQAQVTIIDMSDPMAPIRRPISAESAIMNPASKVIALKAGKTLQIFNIEMKSKMAH
 TMAEEVIFWKWVSVNTVALVTETAVYHWSMEGDSQPMKMFDRHTSLVGCQVIHYRTDE
 YQKWLVLVGISAQQNRVVGAMQLYSVDRKVSQPIEGHAAFAEFKMEGNAPATLFCF
 AVRNPITGGKLHIIEVGQPAAGNQPFVKKAVDVFFPPEAQNDFPVAMQIGAKHGVYILI
 TKYGYLHLYDLESGVCICMNRISADTIFVTAPHKPTSGIIGVNKKGQVLSVCVEEDNI
 VNYATNVLQNPDLGLRLAVRSNLAGAELFVRKFNTLFAQGSYAEAAKVAASAPKGL
 RTRETQVQKFQSIQAQSGQASPLLQYFGILLDQGLNKLESLELCHLVLLQGRKQLLEK
 WLKEDKLECSEELGDLVKTTDPMLALSVYLRANVPSKVIQCFAETGQFQKIVLYAKKV
 GYTPDWIFLLRGVMKISPEQGLQFSRMLVQDEEPLANISQIVDIFMENSLIQQCTSFL
 LDALKNNRPAEGLLQTWLLEMNLVHAPQVADAILGNKMFTHYDRAHIAQLCEKAGLLQ
 QALEHYTDLYDIKRAVVHTHLLNPEWLVNFFGSLSVEDSVECLHAMLSANIRQLQLC
 VQVASKYHEQLGTQALVELFESFKSYKGLFYFLGSIVNFSQDPDVHLKYIQAACKTGQ
 IKEVERICRESSCYNPERVKNFLKEAKLTDQLPLIIVCDRFGFVHDLVLYLYRNNLQR
 YIEIYVQKVNPSRTPAVIGLLLDVDCSEEVIKHLIMAVRGQFSTDELVAEVEKRNRLK
 LLLPWLESQIQEGCEEPATHNALAKIYIDSNNSPECFLRENAYDSSVVGRYCEKRD
 HLACVAYERGQCDELELIKVCNENSLFKSEARYLVCRKDPPELWAHVLEETNPSRRQLID
 QVVQTALSETRDPEEISVTVKAFMTADLPNELIELLEKIVLDNSVFSEHRNLQNLIL
 TAIKADRTRVMEYISRLDNYDALDIASIAVSSALYEEAFTVFHKFDMNASAIQVLEH
 IGNLDRAVEFAERCNEPAVWSQLAQAQLQKDLVKEAINSYIRGDDPSSYLEVVQSASR
 SNNWEDLVKFLQMARKKGRESYIETELIFALAKTSRVSELEDFINGPNNAHIQQVGDR
 CYEEGMYEAAKLLYSNVSNFARLASTLVHLGEYQAAVDNSRKASSTRTWKEVCFACMD
 GQEFRFAQLCGLHIVIHADLEELMCYYQDRGYFEELILLEAALGLERAHMGFMTEL
 AILYSKFKPQKMLEHLELFWSRVNIPKVLRAAEQHLWAELVFLYDKYEEYDNNAVLT
 MSHPTEAWKEGQFKDIIITKVANVELCYRALQFYLDYKPLINDLLLVLSRDLHTWTV

SFFSKAGQLPLVKPYLRSVQSHNNKSVNEALNHLLTEEDYQGLRASIDAYDNFDNIS
 LAQQLEKHQLMEFRCAAYLYKGNWWAQSVELCKDHLKDYKDAMQHAESRDAELAQK
 LLQWFLEEGKRECFACLFTCYDLLRPDMVLELAWRHNLDLAMPYFIQVMREYLSKV
 DKLDALESLRKQEEHVTEPAPLVFDFDGHE

cDNA: 1 accggtcagc ccgcgcgagg ggtcggcggtt cattcctgcc gctgccgccg
 ccgccgccga
 61 ggtcccgcac cagccatggc gcagatcctc cctgttcgct ttcaggagca
 cttccagctc
 121 caaaaccttg gaattaatcc agctaacatt ggattcagca cactgaccat
 ggaatctgac
 181 aagttcatat gtatccgaga gaaagttggt gagcaggcac aggtcacgat
 cattgacatg
 241 agtgacccaa tggtccgat cgcacggcct atctctgcag agagtgccat
 catgaatcca
 301 gcctctaagg tgatagctct gaaagctggg aagacacttc agatctttaa
 tattgagatg
 361 aagagtaaaa tgaaggetca tactatggca gaagaagtga tttctggaa
 atgggtttct
 421 gtgaacactg ttgccttgggt gaccgagacc gcggtctacc actggagcat
 ggaaggtgac
 481 tcccagccca tgaagatggt tgatagacat accagtctgg tgggctgcca
 ggtgattcac
 541 taccggactg atgagtacca gaagtggctg ctgctcgtag gcatctcggc
 tcagcaaaac
 601 cgtgtggttg gagcaatgca gctctactct gtggatagga aggtttcaca
 acccatagaa
 661 ggccatgctg cggtttttgc agagttcaag atggagggga atgccaaagcc
 tgccaccctt
 721 ttctgctttg ctgtacgtaa tcccacagga ggcaagttgc acatcattga
 agttggacag
 781 cctgcagcgg gaaaccaacc ttttgtaaag aaagcagtag atgtgttttt
 tcctccagag
 841 gcacagaatg attttccagt ggctatgcag attggagcta aacatgggtg
 tattttacttg
 901 atcacaaagt atggctatct tcctctgtac gacctagagt ctggcggtg
 catctgcatg
 961 aaccgtatta gtgctgacac aatatttgtc actgctccac acaaaccaac
 ctctggaatt
 1021 attggtgtca aaaaaaggg acaggtactg tcagtttgtg ttgaggaaga
 taacattgtg
 1081 aattatgcaa ccaacgtgct tcagaatcca gaccttggc tcggtttggc
 cgttcgtagt
 1141 aacctggctg gggcagagaa gttgtttgtg agaaaattca atacctctt
 tgcacagggc
 1201 agctatgctg aagccgccaa agttgcagcg tctgcaccaa agggaatcct
 gcgtaccaga
 1261 gagacggtcc agaaaattcca gagtataccc gctcagctctg gccaggttc
 tccattgctg
 1321 cagtacttcg gaatcctgct cgaccagggg cagctcaata aacttgaatc
 cttagaactt
 1381 tgccatctgg ttcttcagca ggggcgtaag caactcctag agaagtggct
 gaaagaagat
 1441 aagctggagt gctcagagga gctcggagac ttggtcaaaa ccactgaccc
 catgctcgct
 1501 ctgagtgtgt accttcgggc aaatgtgcca agcaaagtga tccagtgttt
 tgcagaaaca
 1561 ggccaattcc agaaaattgt gctctatgcc aaaaagggtt ggtacacccc
 agactggatc
 1621 tttctgctga ggggtgtaat gaagatcagt ccggaacagg gcctgcagtt
 ttctcgaatg

1681 ctagtgcagg acgaggagcc gctggccaac attagccaga ttgtggacat
 tttcatggaa
 1741 aacagttaa ttcagcagtg tacttccttc ttattggatg ccttgaagaa
 taatcgccca
 1801 gctgagggac tcctgcagac atggctgttg gagatgaacc ttgttcatgc
 accccaggtt
 1861 gcagatgcc tccctggaaa taaaatgttt actcattacg accgggcccc
 cattgcccag
 1921 ctctgtgaga aggcaggcct cctgcagcaa gcaactggagc actacaccga
 cctctatgac
 1981 atcaagaggg ctgtgggtcca cactcacctc ctcaatcccg agtggcttgt
 caatttcttt
 2041 ggctccttat cgggtggagga ttctgtggag tgtctgcatg ccatgctgtc
 tgctaacatc
 2101 agacagaacc ttcagctgtg tgtgcaggtg gcctctaagt accacgagca
 gctgggcacg
 2161 caggccctgg tggagctctt tgaatccttc aagagttaca aaggcctctt
 ctacttctg
 2221 ggctcaatcg tgaacttcag ccaagaccca gatgtgcac tgaatacat
 tcaggctgcc
 2281 tgtaagacag ggcagatcaa ggaggtggag aggatatgcc gagagagcag
 ctgctacaac
 2341 ccagagcgtg tgaagaactt cctgaaggag gccaaagctca cagaccagct
 tcccccatc
 2401 atcgtgtgtg atcgttttgg ctttgtccat gacctgtcc tatatttata
 ccgcaacaac
 2461 ctgcagaggt acattgagat ctacgtgcag aaggtcaacc ctagccggac
 ccagctgtg
 2521 attggagggc tgcttgatgt ggattgttct gaggaagtga ttaaactt
 aatcatggca
 2581 gtgagaggac agttctctac tgatgagttg gtggctgaag tagaaaaag
 aaataggctc
 2641 aagctgctgc ttccctggct ggagtcccag attcaggaag gctgtgagga
 gcctgccact
 2701 cacaatgcac tggctaaaaat ctacatcgac agcaacaaca gccccgagtg
 cttctgaga
 2761 gagaatgcct actatgacag cagcgtggtg ggccgctact gtgagaagcg
 agaccccat
 2821 ctggcctgtg ttgcctatga gcgggggcag tgtgaccttg agctcatcaa
 ggtgtgcaat
 2881 gagaattctc tgttcaaaag cgaggcccg cacctggtat gcagaaagga
 tccggagctc
 2941 tgggctcacg tccttgagga gaccaacca tccaggagac agctaattga
 ccaggtggta
 3001 cagacagcat tgtcagaaac acgggatcct gaagagattt cggtcactgt
 caaagccttt
 3061 atgacagccg acctgcctaa tgaactgatt gaactgctgg agaagatagt
 tctggataac
 3121 tctgtcttca gcgagcacag gaatctacag aatctgttga tcctgactgc
 catcaaggca
 3181 gaccgcacac gggcatgga gtacatcagc cgctggaca actatgacgc
 actggacatc
 3241 gcgagcatcg ctgtcagcag cgcactgtat gaggaggcct tcaccgtttt
 ccacaagttt
 3301 gatatgaatg cctcagcaat ccaggtcctg atcgagcaca ttggaaacct
 ggaccgggca
 3361 tatgagtttg cggagagatg caatgagcct gctgtgtgga gtcagctggc
 ccaagcccag
 3421 ctccagaaag atttggtgaa ggaagccatc aactcctata tcagagggga
 cgacccttc
 3481 tcttacctgg aagttgttca gtcagccagc aggagcaaca actgggagga

tctagttaaa
 3541 tttctgcaga tggccaggaa aaagggccgt gagtcctata tagagactga
 acttattttt
 3601 gccttggtta aaaccagccg tgtttctgag ctagaagatt ttattaatgg
 acccaacaat
 3661 gcccacatcc agcaggttgg agaccgctgt tacgaggagg gaatgtacga
 ggctgccaag
 3721 ctgctctata gcaatgtttc taactttgcc cgcttggtt ccaccttggg
 tcacctgggt
 3781 gagtatcagg cagcagtggg caacagccgc aaggccagca gacccgggac
 gtggaaggag
 3841 gtgtgctttg cctgcatgga tggacaagag ttccgcttcg cacagctgtg
 tggctttcac
 3901 atcgtcattc atgcagatga gctggaggag ctgatgtgct attaccagga
 tcgtggctac
 3961 tttgaggagc tgatcttgct gttggaagcg gccctggggc tggagcgggc
 ccacatgggc
 4021 atgttcaactg agctggccat cctctactcc aaattcaagc cacagaagat
 gctggagcat
 4081 ctggagcttt tctgggtccc tgtcaacatc ccaaaggtgc tgagggtgc
 agagcaggca
 4141 cacctgtggg ctgagctggg gttcctctat gacaagtacg aggagtatga
 caatgctgtg
 4201 ctcaccatga tgagccacc cactgaggcc tgggaaggagg gtcagttcaa
 ggacatcatt
 4261 accaaggttg ccaacgtcga gctctgttac agagccctgc agttctatct
 ggattacaaa
 4321 ccaactgctca tcaatgacct gctgctgggtg ctttcacccc ggctggacca
 cacctggaca
 4381 gtcagtttct tttcaaaggc aggtcagctg ccctgggtga agccttacct
 gcggtcagtc
 4441 cagagccaca acaacaagag tgtgaatgag gcaactcaacc acctgctgac
 agaggaggag
 4501 gactatcagg gcttaagggc atctatcgat gcctatgaca actttgacaa
 catcagcctg
 4561 gctcagcagc tggagaagca tcagctgatg gagttcaggt gcattgcggc
 ctatctgtac
 4621 aagggcaata actggtgggc ccagagcgtg gagctctgca agaaggatca
 tctctacaag
 4681 gatgccatgc agcatgctgc agagtcgcgg gatgctgagc tggccagaa
 gttgctgcag
 4741 tggttcctgg aggaaggcaa gagggagtgc ttgcagctt gtctcttcac
 ctgctatgac
 4801 ctgcttcgcc cagacatggg gcttgagctg gcctggaggc acaacctcgt
 ggacttggcc
 4861 atgccctact tcatccaggt gatgaggagg tacctgagca aggtggacaa
 actggatgcc
 4921 ttggagagtc tgcgcaagca agaggagcat gtgacagagc ctgcccctct
 cgtgtttgat
 4981 tttgatgggc atgaatgaga ccagctgat tgcactaagc cctgccgtgg
 gccagcccc
 5041 tgccagcttc ccctatggat atgcctctgc tcccaacttc gccagcctcc
 aatgtacaac
 5101 ttccgcgtgt agtgggcgtt gtcaccaccc acctacctg cagagttact
 aacttctcca
 5161 aggagcatgt cactccagca gcacagggga cgcaatggga ggcagggaca
 cctggacaat
 5221 atttattttt gctgaaaccc aatgacggca acctctgagc catcccagag
 cctggggagg
 5281 ccagggtaga ggctgacggc gcaagaccag ctttagccga caacagagac
 tggactgtgg

5341 gccctcctgc tggagccagg ccttcctcct gggcgccctcc gactggctgg
agctgcccc
5401 tccaggccag tttgaagact acatgaacac gtcttgtttg gaggtaccgg
acctcataaa
5461 aggactctca gcctcttggc aatcataaat attaaagtcg gtttatccag
gcaaaaaaaaa
5521 aaaaaaaaaa aaaaaaaaaa aa
//

6. EIF4G1: EIF4G1 eukaryotic translation initiation factor 4
gamma, 1 [Homo sapiens]
LOCUS NM_001194946 (isoform 6)
AA /translation="MNKAPQSTGPPAPSPGLPQPAFPFGQTAPVVFSTPQATQMNT
SQPRQGGFRSLQHFYPSRAQPPSSAASRVQSAAPARPGPAAHVYPAGSQVMMIPISQIS
YPASQGAYYIPGQGRSTYVVPTQQYPVQPGAPGFYPGASPTFEGTYAGAYYPAQGVQQ
FPTGVAPAPVLMNQPPQIAPKRERKTIRIRDPNQGGKDITEEIMSGARTASTPTPPQT
GGGLEPQANGETPQVAVIVRPDDRSQGAI IADRLPGLPGPEHSPSESQSSSPSTPSPS
PVLEPGSEPNLAVLSIPGDMTTIQMSVEESTPISRETGEPYRLSPEPTPLAEP ILEV
EVTLSKVPPESEFSSSPLQAPTPLASHTVEIHEPNGMVPSEDLEPEVESSPELAPPPA
CPSESPVPIAPTAQPEELLNGAPSPPAVDLSPVSEPEEQAKEVTASMAPPTIPSATPA
TAPSATSPAQEEEEEEEEEEEGEAGEAGEAESEKGGEEELLPESTPIPANLSQNLEA
AAATQVAVSVPKRRRIKELNKKEAVGDLDDAFKEANPAVPEVENQPPAGSNPGPESE
GSGVPPRPPEADETWDSEKDKIHNAENIQPGEQKYEYKSDQWKPLNLEEKRYDREFL
LGFQFIFASMQKPEGLPHISDVVLDKANKTPLRPLDPTRLQGINCGPDFTPSFANLGR
TTLSTRGPPRGGPGGELPRGPAGLGPRRSQQGPRKEPRKIIATVLMTEDIKLNKAEKA
WKPSKRTAADKDRGEEDADGSKTQDLFRRVRSILNKLTPQMFQQLMKQVTQLAIDTE
ERLKGVIDLIFEKAISEPNFVSAYANMCRCLMALKVPTTEKPTVTNFRKLLNRCQK
EFEKDKDDDEVFEKKQKEMDEAATAEERGLKEELEEARDIARRRSLGNIKF IGELFK
LKMLTEAIMHDCVVKLLKNHDEESLECLCRLLTTIGKDLDFEAKAPRMDQYFNQMEKI
IKEKKTSSRIRFMLQDVLDRGSNWVPRRGDQGPKTIDQIHKEAEEMEHREHIKVQQL
MAKGS DKRRGGPPGPPISRGLPLVDDGGWNTVPISKSGSRPIDTSRLTKITKPGSIDSN
NQLFAPGGRLSWGKGSSGGSGAKPSDAASEAARPATSTLNRFSAQQAVPTESDNR
VVQRSSLSRERGEKAGDRGDRLERSEGGDRGDRLDARTPATKRSFSKEVEERSRER
PSQPEGLRKAASLTEDRDRGRDAVKREAAALPPVSP LKAALSEEELEKSKAIIEEY
LH LNDMKEAVQCVQELASPSLLFIFVRHGVSTLERSAIAREHMQQLLHQLLCAGHLSTA
QYYQGLYEILELAEDMEIDIPHVWLYLAELVTPILQEGGVPMGELFREITKPLRPLGK
AASLLEILGLLCKSMGPKKVGTLWREAGLSWKEFLPEGQDIGAFVAEQKVEYTLGEE
SEAPGQRALPSEELNRQLEKLLKEGSSNQRFVDWIEANLSEQQIVSNTLVRLMTAVC
YSAIIFETPLRVDVAVLKARAKLLQKYLCDQEKELQALYALQALVVTLEQPPNLLRMF
FDALYDEDVVKEDAFYSWESSKDPAEQQGKGVALKSVTAFFKWLREAEESDHN

cDNA: 1 cggcggcgca gatcgcccg cgcggtccg cccctgcgc cggtcacgtg
ggggcgccgg
61 ctgcgcctgc ggagaagcgg tggccgccga gcgggatctg tgcggggagc
cggaatggt
121 tgtggactac gtctgtgcgg ctgcgtggg ctgcggccgc cgactgaag
gagactgaag
181 gccctcgat gccagaacc tgtaggccgc accgtggact tgttctaat
cgagggggtg
241 ctggggggac cctgatgtgg caccaaatga aatgaacaaa gctccacagt
ccacaggccc
301 cccaccgcc ccatccccg gactcccaca gccagcggtt ccccggggc
agacagcgcc
361 ggtggtgttc agtacgccac aagcgacaca aatgaacacg cttctcagc
cccgccagg
421 aggattcagg tctctgcagc attctaccc tagccgggccc cagccccga
gcagtgcagc
481 ctcccagtg cagagtgcag cccctgcccg cctgggccc gctgcccatg
tctaccctgc
541 tggatcccaa gtaatgatga tccctccca gatctctac ccagcctccc
agggggccta

601 ctacatccct ggacaggggc gttccacata cgttgtcccg acacagcagt
 accctgtgca
 661 gccaggagcc ccaggcttct atccagggtgc aagccctaca gaatttggga
 cctacgctgg
 721 cgctactat ccagcccaag ggggtgcagca gtttccact ggcgtggccc
 ccgccccagt
 781 tttgatgaac cagccacccc agattgctcc caagaggag cgtaagacga
 tccgaattcg
 841 agatccaaac caaggaggaa aggatatcac agaggagatc atgtctgggg
 cccgcaactgc
 901 ctccacaccc acccctcccc agacgggagg cgggtctggag cctcaagcta
 atgggggagac
 961 gccccagggt gctgtcattg tccggccaga tgaccgggtca caggagacaa
 tcattgctga
 1021 ccggccaggg ctgcctggcc cagagcatag cccttcagaa tcccagcctt
 cgtcgcccttc
 1081 tccgacccca tcaccatccc cagtcttggga accgggggtct gagcctaatac
 tcgcagtcct
 1141 ctctattcct ggggacacta tgacaactat acaaatgtct gtagaagaat
 caacccccat
 1201 ctcccgtgaa actggggagc catatcgctt ctctccagaa cccactcctc
 tcgccgaacc
 1261 catactggaa gtagaagtga cacttagcaa accggttcca gaatctgagt
 tttcttccag
 1321 tctctccag gctcccacc ctttggcatc tcacacagtg gaaattcatg
 agcctaattgg
 1381 catggtccca tctgaagatc tggaaccaga ggtggagtca agcccagagc
 ttgctcctcc
 1441 ccagcttgc cctccgaat ccctgtgcc cattgctcca actgcccac
 ctgaggaact
 1501 gctcaacgga gccccctgc caccagctgt ggacttaagc ccagtcagtg
 agccagagga
 1561 gcaggccaag gaggtgacag catcaatggc gccccccacc atcccctctg
 ctactccagc
 1621 tacggctcct tcagctactt cccagctca ggaggaggaa atggaagaag
 aagaagaaga
 1681 ggaagaagga gaagcaggag aagcaggaga agctgagagt gagaaaggag
 gagaggaact
 1741 gctcccccca gagagtaccc ctattccagc caacttgtct cagaatttgg
 aggcagcagc
 1801 agccactcaa gtggcagtat ctgtgccaaa gaggagacgg aaaattaagg
 agctaaataa
 1861 gaaggaggt gttggagacc ttctggatgc cttaaggag gcgaaccggg
 cagtaccaga
 1921 ggtggaaaat cagcctcctg caggcagcaa tccaggccca gagtctgagg
 gcagtgggtg
 1981 gccccacgt cctgaggaag cagatgagac ctgggactca aaggaagaca
 aaattcaca
 2041 tgctgagaac atccagccc gggaaacagaa gtatgaatat aagtcatatc
 agtggaagcc
 2101 tctaaaccta gaggagaaaa aacgttacga ccgtgagttc ctgcttggtt
 ttcagttcat
 2161 ctttgccagt atgcagaagc cagagggatt gccacatata agtgacgtgg
 tgctggacaa
 2221 ggccaataaa acaccactgc ggccactgga tcccactaga ctacaaggca
 taaattgtgg
 2281 ccagacttc actccatcct ttgccaacct tggccggaca acccttagca
 cccgtgggccc
 2341 cccaaggggt gggccagggt gggagctgcc ccgtgggccc gctggccctgg
 gacccggcg
 2401 ctctcagcag ggaccccgaa aagaaccacg caagatcatt gccacagtgt

taatgaccga
 2461 agatataaaa ctgaacaaag cagagaaagc ctggaaaccc agcagcaagc
 ggacggcggc
 2521 tgataaggat cgaggggaag aagatgctga tggcagcaaa acccaggacc
 tattccgcag
 2581 ggtgcgctcc atcctgaata aactgacacc ccagatgttc cagcagctga
 tgaagcaagt
 2641 gacgcagctg gccatcgaca ccgaggaacg cctcaaaggg gtcattgacc
 tcatttttga
 2701 gaaggccatt tcagagccca acttctctgt ggctatgcc aacatgtgcc
 gctgcctcat
 2761 ggcgctgaaa gtgcccacta cggaaaagcc aacagtgact gtgaacttcc
 gaaagctggt
 2821 gttgaatcga tgtcagaagg agtttgagaa agacaaagat gatgatgagg
 tttttgagaa
 2881 gaagcaaaaa gagatggatg aagctgctac ggcagaggaa cgaggacgcc
 tgaaggaaga
 2941 gctggaagag gctcgggaca tagcccggcg gcgctcttta gggaatatca
 agttttattgg
 3001 agagttgttc aaactgaaga tgttaacaga ggcaataatg catgactgtg
 tggtc aaact
 3061 gcttaagaac catgatgaag agtcccttga gtgcctttgt cgtctgctca
 ccaccattgg
 3121 caaagacctg gactttgaaa aagccaagcc ccgaatggat cagtatttca
 accagatgga
 3181 aaaaatcatt aaagaaaaga agacgtcatc ccgcatccgc tttatgctgc
 aggacgtgct
 3241 ggatctgcga gggagcaatt gggtgccacg ccgaggggat cagggtccca
 agaccattga
 3301 ccagatccat aaggaggctg agatggaaga acatcgagag cacatcaaag
 tgcagcagct
 3361 catggccaag ggcagtgaca agcgtcgggg cggtcctcca ggccctccca
 tcagccgtgg
 3421 acttcccctt gtggatgatg gtggctggaa cacagttccc atcagcaaag
 gtagccgccc
 3481 cattgacacc tcacgactca ccaagatcac caagcctggc tccatcgatt
 ctaacaacca
 3541 gctcttttga cctggagggc gactgagctg gggcaagggc agcagcggag
 gctcaggagc
 3601 caagccctca gacgcagcat cagaagctgc tcgcccagct actagtactt
 tgaatcgctt
 3661 ctacgccctt caacaagcgg taccacaga aagcacagat aatagacgtg
 tgggtgcagag
 3721 gagtagcttg agccgagaac gaggcgagaa agctggagac cgaggagacc
 gcctagagcg
 3781 gagtgaacgg ggaggggacc gtggggaccg gcttgatcgt gcgcggacac
 ctgctaccaa
 3841 gcggagcttc agcaaggaag tggaggagcg gagtagagaa cggccctccc
 agcctgaggg
 3901 gctgcgcaag gcagctagcc tcacggagga tcgggaccgt gggcgggatg
 ccgtgaagcg
 3961 agaagctgcc ctacccccag tgagccccct gaaggcggct ctctctgagg
 aggagttaga
 4021 gaagaaatcc aaggetatca ttgaggaata tctccatctc aatgacatga
 aagaggcagt
 4081 ccagtgcgtg caggagctgg cctcaccctc cttgctcttc atctttgtac
 ggcattggtg
 4141 cgagtctacg ctggagcgca gtgccattgc tcgtgagcat atggggcagc
 tgctgcacca
 4201 gctgctctgt gctgggcacg tgtctactgc tcagtactac caagggttgt
 atgaaatctt

4261 ggaattggct gaggacatgg aaattgacat cccccacgtg tggctctacc
 tagcggaact
 4321 ggtaacaccc attctgcagg aaggtggggg gcccatgggg gagctgttca
 gggagattac
 4381 aaagcctctg agaccgttgg gcaaagctgc ttccctgttg ctggagatcc
 tgggcctcct
 4441 gtgcaaaagc atgggtccta aaaaggtggg gacgctgtgg cgagaagccg
 ggcttagctg
 4501 gaaggaattt ctacctgaag gccaggacat tgggtgattc gtcgctgaac
 agaaggtgga
 4561 gtataccctg ggagaggagt cggaagcccc tggccagagg gcactcccct
 ccgaggagct
 4621 gaacaggcag ctggagaagc tgctgaagga gggcagcagt aaccagcggg
 tgttcgactg
 4681 gatagaggcc aacctgagtg agcagcagat agtatccaac acgttagttc
 gagccctcat
 4741 gacggctgtc tgctattctg caattatttt tgagactccc ctccgagtgg
 acgttgagct
 4801 gctgaaagcg cgagcgaagc tgctgcagaa atacctgtgt gacgagcaga
 aggagctaca
 4861 ggcgctctac gccctccagg ccctttagt gaccttagaa cagcctccca
 acctgctgcg
 4921 gatgttcttt gacgcactgt atgacgagga cgtggtgaag gaggatgcct
 tctacagttg
 4981 ggagagtagc aaggaccccg ctgagcagca gggcaagggt gtggccctta
 aatctgtcac
 5041 agccttcttc aagtggctcc gtgaagcaga ggaggagtct gaccacaact
 gagggctggt
 5101 ggggccgggg acctggagcc ccatggacac acagatggcc cggctagccg
 cctggactgc
 5161 agggggggcg cagcagcggc ggtggcagtg ggtgcctgta gtgtgatgtg
 tctgaactaa
 5221 taaagtggct gaagaggcag gatggcttgg ggctgcctgg gccccctcc
 aggatgccgc
 5281 caggtgtccc tctctcccc ctggggcaca gagatatatt atatataaag
 tcttgaaatt
 5341 tgggtgtgtc tgggggtggg aggggcacca acgctgccc ctggggctct
 tttttttatt
 5401 ttctgaaaat cactctcggg actgccgtcc tcgctgctgg gggcatatgc
 cccagccct
 5461 gtaccacccc tgctgttgcc tgggcagggg gaaggggggg cacggtgcct
 gtaattatta
 5521 aacatgaatt caattaagct caaaaaaaaa aaaaaaaaa
 //

LOCUS NM_004953 (isoform 4)
 AA /translation="MSGARTASTPTPPQTGGGLEPQANGETPQVAVIVRPDDRSQGA
 IADRLPGPEHSPSESQPSSPSTPSPSPVLEPGSEPNLAVLSIPGDTMTTIQMSVE
 ESTPISRETGEPLYRLSPEPTPLAEP ILEVETLSKVPPESEFSSSPLQAPTPLASHTV
 EIHEPNGMVPSEDLPEVESSPELAPPPACPSESVPPIAPTAQPELLNGAPSPPAVD
 LSPVSEPEEQAKEVTASMAPPTIPSATPATAPSATSPAQEEEMEEEEEEGEAGEAG
 EAESKGGEEELLPESTPIPANLSQNLEAAAATQVAVSVPKRRRIKELNKKEAVGDL
 LDFAKEANPAVPEVENQPPAGSNPGPESESGVPPRPPEADETWDSKEDIHNAENIQ
 PGEQKYEYKSDQWKPLNLEKKRYDREFLLGFQFIFASMQKPEGLPHISDVVLKANK
 TPLRPLDPTRLQGINCGPDFTPSFANLGRITLSTRGPPRGGPGGELPRGPQAGLGPRR
 SQQGPRKEPRKI IATVLMTEDIKLNKAEKAWKPSSKRTAADKDRGEEDADGSKTQDLF
 RRVRSILNKLTPQMFQQLMKQVTQLAIDTEERLKGVIDLIFEKAISEPNFSVAYANMC
 RCLMAKLVPTTEKPTVTNFRKLLNRCQKEFEKDKDDDEVFEKKQKEMDEAATAEER
 GRLKEELEEARDIARRSLGNIKFIFELFKLKMTEAIMHDCVVKLLKNHDEESLECL
 CRLTTIGKDLDFEKAKPRMDQYFNQMEKI IKEKKTSSRIRFMLQDVLDRGSNWVPR
 RGDQGPKITDQIHKEAEMEEHREHIKVQQLMAKGS DKRRGGPPGPPISRGLPLVDDGG

WNTVPISKGSRPIDTSRLTKITKPGSIDSNQLFAPGGRLSWGKGSSGGSGAKPSDAA
 SEARPATSTLNRFSAQQAVPTSTDNRRVVRSSLSRERGEKAGDRGDRLESERG
 GDRGDRLEDRARTPATKRSFSKEVEERSRERPSQPEGLRKAASLTEDRDRGRDAVKREA
 ALPPVSPLKAALSEEELEKKSKAIEEYLHLNDMKEAVQCVQELASPSLLFIFVRHGV
 ESTLERSAIAREHMGQLLHQLLCAGHLSTAQYYQGLYEILELAEDMEIDIPHVWLYLA
 ELVTPILQEGGVPMGELFREITKPLRPLGKAASLLLEILGLLCKSMGPKKVGTLWREA
 GLSWKEFLPEGQDIGAFVAEQKVEYTLGEESEAPGQRALPSEELNRQLEKLLKEGSSN
 QRVFDWIEANLSEQQIVSNTLVRLMTAVCYSIAIFETPLRVDVAVLKARAKLLQKYL
 CDEQKELQALYALQALVVTLEQPPNLLRMFFDALYDEDVVKEDAFYSWESSKDPAEQQ
 KGKVALKSVTAFFKWLREAEESDHN"

cDNA: 1 tctagatggg ggtcctgggc ccaggggtgt gcagccactg acttggggac
 tgctggtggg

61 gtagggatga gggagggagg ggcattgtga tgtacagggc tgctctgtga
 gatcaagggt

121 ctcttaaggg tgggagctgg ggcagggact acgagagcag ccagatgggc
 tgaaagtgga

181 actcaagggg tttctggcac ctacctacct gcttcccgct ggggggtggg
 gagttggccc

241 agagtcttaa gattggggca ggggtggagag gtgggctctt cctgcttccc
 actcatctta

301 tagctttctt tccccagatc cgaattcgag atccaaacca aggaggaaag
 gatatacacag

361 aggagatcat gtctggggcc cgcactgcct ccacacccac ccctccccag
 acgggaggcg

421 gtctggagcc tcaagctaata ggggagacgc ccaggttgc tgtcattgtc
 cggccagatg

481 accggtcaca gggagcaata attgctgacc ggccagggtc gcttgccca
 gagcatagcc

541 cttcagaata ccagccttcg tcgccttctc cgaccccatc accatcccca
 gtcttggaac

601 cggggtctga gcctaatactc gcagtcctct ctattcctgg ggacactatg
 acaactatac

661 aaatgtctgt agaagaatca acccccatct cccgtgaaac tggggagcca
 tatcgctct

721 ctccagaacc cactcctctc gccgaacca tactggaagt agaagtgaca
 cttagcaaac

781 cggttccaga atctgagttt tcttcagtc ctctccaggc tcccaccct
 ttggcatctc

841 acacagtga aattcatgag cctaattggca tgggtccatc tgaagatctg
 gaaccagagg

901 tggagtcaag ccagagctt gtcctcccc cagcttgccc ctccgaatcc
 cctgtgcca

961 ttgctccaac tgcccaacct gaggaactgc tcaacggagc ccctcgcca
 ccagctgtgg

1021 acttaagccc agtcagtga ccagaggagc aggccaagga ggtgacagca
 tcaatggcgc

1081 cccccaccat ccctctgct actccageta cggtccttc agctacttcc
 ccagctcagg

1141 aggaggaaat ggaagaagaa gaagaagagg aagaaggaga agcaggagaa
 gcaggagaag

1201 ctgagagtga gaaaggagga gaggaactgc tccccccaga gagtaccct
 attccagcca

1261 acttgtctca gaatttggag gcagcagcag ccactcaagt ggcagtatct
 gtgccaaga

1321 ggagacggaa aattaaggag cttaaataaga aggaggctgt tggagacctt
 ctggatgct

1381 tcaaggaggc gaaccoggca gtaccagagg tggaaaatca gcctcctgca
 ggcagcaatc

1441 caggcccaga gtctgagggc agtggtgtgc cccacgtcc tgaggaagca
 gatgagacct

1501 gggactcaaa ggaagacaaa attcacaatg ctgagaacat ccagcccggg

gaacagaagt
 1561 atgaatataa gtcagatcag tggaagcctc taaacctaga ggagaaaaaa
 cgttacgacc
 1621 gtgagttcct gcttggtttt cagttcatct ttgccagtat gcagaagcca
 gagggattgc
 1681 cacatatcag tgacgtggtg ctggacaagg ccaataaaac accactgcgg
 ccactggatc
 1741 ccactagact acaaggcata aattgtggcc cagacttcac tccatccttt
 gccaaccttg
 1801 gccggacaac ccttagcacc cgtggggccc caaggggtgg gccaggtggg
 gagctgcccc
 1861 gtggggcgca ggctggcctg ggaccccggc gctctcagca gggaccccg
 aaagaaccac
 1921 gcaagatcat tgccacagtg ttaatgaccg aagatataaa actgaacaaa
 gcagagaaag
 1981 cctggaaacc cagcagcaag cggacggcgg ctgataagga tcgaggggaa
 gaagatgctg
 2041 atggcagcaa aaccaggac ctattccgca ggggtgcgctc catcctgaat
 aaactgacac
 2101 ccagatggtt ccagcagctg atgaagcaag tgacgcagct ggccatcgac
 accgaggaac
 2161 gcctcaaagg ggtcattgac ctcatTTTTg agaaggccat ttcagagccc
 aacttctctg
 2221 tggcctatgc caacatgtgc cgctgcctca tggcgctgaa agtgcccact
 acggaaaagc
 2281 caacagtgc tgtgaacttc cgaaagctgt tgttgaatcg atgtcagaag
 gagtttgaga
 2341 aagacaaaga tgatgatgag gtttttgaga agaagcaaaa agagatggat
 gaagctgcta
 2401 cggcagagga acgaggacgc ctgaaggaag agctggaaga ggctcgggac
 atagcccggc
 2461 ggcgctcttt agggaaatgc aagtttattg gagagtgttt caaactgaag
 atgttaacag
 2521 aggcaataat gcatgactgt gtggtcaaac tgcttaagaa ccatgatgaa
 gagtcccttg
 2581 agtgcccttg tcgtctgctc accaccattg gcaaagacct ggactttgaa
 aaagccaagc
 2641 cccgaatgga tcagtatttc aaccagatgg aaaaaatcat taaagaaaag
 aagacgtcat
 2701 cccgcacccg ctttatgctg caggacgtgc tggatctgcg agggagcaat
 tgggtgccac
 2761 gccgagggga tcagggtccc aagaccattg accagatcca taaggaggct
 gagatggaag
 2821 aacatcgaga gcacatcaaa gtgcagcagc tcatggccaa gggcagtgc
 aagcgtcggg
 2881 gcggtcctcc aggcctctcc atcagccgtg gacttcccct tgtggatgat
 ggtggctgga
 2941 acacagttcc catcagcaaa ggtagccgcc ccattgacac ctcacgactc
 accaagatca
 3001 ccaagcctgg ctccatcgat tctaacaacc agctctttgc acctggaggg
 cgactgagct
 3061 ggggcaaggg cagcagcgga ggctcaggag ccaagccctc agacgcagca
 tcagaagctg
 3121 ctgccccagc tactagtact ttgaatcgct tctcagccct tcaacaagcg
 gtacccacag
 3181 aaagcacaga taatagacgt gtggtgcaga ggagtagctt gagccgagaa
 cgaggcgaga
 3241 aagctggaga ccgaggagac cgctagagc ggagtgaacg gggaggggac
 cgtggggacc
 3301 ggcttgatcg tgcgcgga cctgctacca agcggagctt cagcaaggaa
 gtggaggagc

```

3361 ggagtagaga acggccctcc cagcctgagg ggctgcgcaa ggcagctagc
ctcacggagg
3421 atcgggaccg tgggcgggat gccgtgaagc gagaagctgc cctaccccca
gtgagccccc
3481 tgaaggcggc tctctctgag gaggagttag agaagaaatc caaggctatc
attgaggaat
3541 atctccatct caatgacatg aaagaggcag tccagtgcgt gcaggagctg
gcctcaccct
3601 ccttgctctt catctttgta cggcatgggtg tcgagtctac gctggagcgc
agtgccattg
3661 ctctgtagca tatggggcag ctgctgcacc agctgctctg tgctgggcat
ctgtctactg
3721 ctcagtacta ccaaggggtt tatgaaatct tggaattggc tgaggacatg
gaaattgaca
3781 tccccacgt gtggctctac ctagecggaac tggtaacacc cattctgcag
gaaggtgggg
3841 tgcccatggg ggagctgttc agggagatta caaagcctct gagaccgttg
ggcaaagctg
3901 cttccctgtt gctggagatc ctgggcctcc tgtgcaaaag catgggtcct
aaaaggttg
3961 ggacgctgtg gcgagaagcc gggcttagct ggaaggaatt tctacctgaa
ggccaggaca
4021 ttggtgcatt cgctcgtgaa cagaaggtgg agtataccct gggagaggag
tcggaagccc
4081 ctggccagag ggcactcccc tccgaggagc tgaacaggca gctggagaag
ctgctgaagg
4141 agggcagcag taaccagcgg gtgttcgact ggatagaggc caacctgagt
gagcagcaga
4201 tagtatccaa cacgttagtt cgagccctca tgacggctgt ctgctattct
gcaattatct
4261 ttgagactcc cctccgagtg gacgttgacg tgctgaaagc gcgagcgaag
ctgctgcaga
4321 aatacctgtg tgacgagcag aaggagctac aggcgtctca cgccctccag
gcccttgtag
4381 tgacctaga acagcctccc aacctgctgc ggatgttctt tgacgcactg
tatgacgagg
4441 acgtggtgaa ggaggatgcc ttctacagtt gggagagtag caaggacccc
gctgagcagc
4501 agggcaaggg tgtggccctt aaatctgtca cagccttctt caagtggctc
cgtgaagcag
4561 aggaggagtc tgaccacaac tgagggtctgg tggggccggg gacctggagc
cccatggaca
4621 cacagatggc ccggctagcc gcctggactg cagggggggc gcagcagcgg
cgggtggcagt
4681 ggggtgcctgt agtgtgatgt gtctgaacta ataaagtggc tgaagaggca
ggatggcttg
4741 gggctgcctg ggccccctc caggatgccg ccagggtgtc ctctcctccc
cctggggcac
4801 agagatatat tatatataaa gtcttgaaat ttggtgtgtc ttgggggtggg
gaggggcacc
4861 aacgcctgcc cctggggctc ttttttttat tttctgaaaa tcaactctcg
gactgccgtc
4921 ctctgtgctg ggggcataatg cccagcccc tgtaccacce ctgctgttgc
ctgggcaggg
4981 ggaagggggg gcacggtgcc tgtaattatt aaacatgaat tcaattaagc
tcaaaaaaaaa
5041 aaaaaaaaaa
//
LOCUS          NM_182917                      (isoform 1)
AA /translation="MNKAPQSTGPPAPSPGLPQPAFPPGQTAPVVFSTPQATQMNT
SQPRQHFYPSRAQPPSSAASRVQSAAPARPGPAAHVYPAGSQVMMIPSQISYPASQGA

```

YYIPGQGRSTYVVPQTQQYFVQPGAPGFYPGASPTFEGTYAGAYYPAQGVQQFPTGVAP
 APVLMNQPPQIAPKRERKTIIRDPNQGGKDITEEIMSGARTASTPTPPQTGGGLEPQ
 ANGETPQVAVIVRPDDRSQGAIIADRPGLPGPEHSPSESQPSSSPTPSPSPVLEPGS
 EPNLAVLSIPGDTMTTIQMSVEESTPISRETGEPYRLSPEPTPLAEPILEVEVTLSPK
 VPESFSSSPLQAPTPLASHTVEIHEPNGMVPSEDLPEVESSPELAPPPACPSSESPV
 PIAPTAQPEELNGAPSPPAVDLSPVSEPEEQAKEVTASMAPPTIPSATPATAPSATS
 PAQEEEEEEEEEEGEAGEAGEAESEKGGEE LLPPESTPIPANLSQNLEAAAAATQVA
 VSVPKRRRKIKELNKKEAVGDLDAFKEANPAVPEVENQPPAGSNPGPESESGVPPR
 PEEADETWDSKEDIHNAENIQPGEQKYEYKSDQWKPLNLEEKRYDREFLLGFQFIF
 ASMQKPEGLPHISDVVLDKANKTPLRPLDPTRLQGINCGPDTFSPFANLGRITTLSTRG
 PPRGGPGGELPRGPQAGLGPRRSQQGPRKEPRKIATVLMTEDIKLNKAEKAWKPSSK
 RTAADKDRGEEDADGSKTQDLFRRVRSILNKLTQMFQQLMKQVTQLAIDTEERLKG
 IDLIFEKAISEPNFSVAYANMCRCMLALKVPTTEKPTVTNFRKLLNRCQKEFEKDK
 DDDEVFEKKQKEMDEAATAEERGRLEKEELEARDIARRRSLGNIKFIGELFKLKMTE
 AIMHDCVVKLLKNHDEESLECLCRLLTTIGKDLDFEAKAPRMDQYFNQMEKIIKEKKT
 SSRIRFMLQDVLDLRGSNWVPRRGDQGPKTIDQIHKEAEMEEHREHIKVQQLMAKGS
 KRRGGPPGPPISRGLPLVDDGGWNTVPISKGSRPIDTSRLTKITKPGSIDSNNQLFAP
 GGRLSWGKSGSGGSAKPSDAASEAARPATSTLNRFSAQQAVPTTESTDNRRVVQRSS
 LSRERGEKAGDRGDRLEERSERGGDRGDRLDARTPATKRSFSKEVEERSRERPSQPEG
 LRKAASLTEDRDRGRDAVKREAAALPPVSPLKAALSEEELEKKSKAIIIEYLHLNDMKE
 AVQCVQELASPSLLFIFVRHGVSTLERSAIAREHMGQLLHQLLCAGHLSTAQYYQGL
 YEILELAEDMEIDIPHVWLYLAELVTPILQEGGVPMGELFREITKPLRPLGKAASLLL
 EILGLLCKSMGPKKVGTLWREAGLSWKEFLPEGQDIGAFVAEQKVEYTLGEESEAPGQ
 RALPSEELNRQLEKLLKEGSSNQRFVDWIEANLSEQQIVSNTLVRLMTAVCYSAIF
 ETPLRVDVAVLKARAKLLQKYLCDQKELQALYALQALVVTLEQPPNLLRMFFDALYD
 EDVVKEDAFYSWESSKDPAEQQGKGVALKSVTAFFKWLREAEESDHN

cDNA: 1 tcacttgccct gaaaccggct cctcgacggc cgccgcccgc ctggcctttt
 agggcctgac
 61 tcccgcctt cctggcctac actcctgggc ggccggcaggc ctagcttctg
 gccagtgcg
 121 gggtccccgc cgccaggcgt atcctgtgtg cccctgggac aggcccgaa
 ccggtgtccc
 181 cgggtggggg gtggggacgc cacggccgaa gcagctagct ccgttcgtga
 tccgggagcc
 241 tgggtgccagc gagacctgga atttcgggtc tgggtgggtc ggggccccgc
 ggagccaggt
 301 tgataccctc acctcccaac cccaggccct cggatgcccga gaacctgtag
 gccgcaccgt
 361 ggacttgctt ttaatcgagg ggggtgctggg gggaccctga tgtggcacca
 aatgaaatga
 421 acaaagctcc acagtccaca ggccccccac ccgccccatc ccccggaatc
 ccacagccag
 481 cggtttcccc ggggcagaca gcgcgggtgg tgttcagtag gccacaagcg
 acacaaatga
 541 acacgccttc tcagccccgc cagcacttct accctagccg ggcccagccc
 ccgagcagtg
 601 cagcctcccc agtgcagagt gcagccctg ccgcacctgg cccagctgcc
 catgtctacc
 661 ctgctggatc ccaagtaatg atgatccctt cccagatctc ctaccagcc
 tcccagggg
 721 cctactacat ccctggacag gggcggtcca catacggtgt ccgacacag
 cagtagcctg
 781 tgcagccagg agccccaggc ttctatccag gtgcaagccc tacagaatgt
 gggacctacg
 841 ctggcgccca ctatccagcc caaggggtgc agcagtttcc cactggcgtg
 gccccgcgc
 901 cagttttgat gaaccagcca cccagattg ctccaagag ggagcgtaag
 acgatccgaa
 961 ttcagatcc aaaccaagga ggaaaggata tcacagagga gatcatgtct
 ggggcccga

1021 ctgcctccac acccaccct cccagacgg gaggcgtct ggagcctcaa
 gctaatgggg
 1081 agacgcccc ggttgctgtc attgtccggc cagatgaccg gtcacaggga
 gcaatcattg
 1141 ctgaccggcc agggctgctt ggcccagagc atagcccttc agaatcccag
 ccttcgtcgc
 1201 cttctccgac cccatcacca tccccagtct tggaaacggg gtctgagcct
 aatctcgcag
 1261 tcctctctat tcctggggac actatgacaa ctatacaaat gtctgtagaa
 gaatcaaccc
 1321 ccatctccc tgaaactggg gagccatata gcctctctcc agaaccact
 cctctcgcg
 1381 aaccatact ggaagtagaa gtgacactta gcaaaccggg tccagaatct
 gagttttctt
 1441 ccagtcctct ccaggtctcc acccctttgg catctcacac agtggaatt
 catgagccta
 1501 atggcatggt cccatctgaa gatctggaac cagaggtgga gtcaagccca
 gagcttgctc
 1561 ctccccagc ttgcccctcc gaatcccctg tgcccattgc tccaactgcc
 caacctgagg
 1621 aactgctcaa cggagccccc tcgccaccag ctgtggactt aagcccagtc
 agtgagccag
 1681 aggagcaggc caaggagggtg acagcatcaa tggcgccccc caccatcccc
 tctgctactc
 1741 cagctacggc tccttcagct acttccccag ctcaggagga ggaaatggaa
 gaagaagaag
 1801 aagaggaaga aggagaagca ggagaagcag gagaagctga gagtgagaaa
 ggaggagagg
 1861 aactgctccc ccagagagt acccctattc cagccaactt gtctcagaat
 ttggaggcag
 1921 cagcagccac tcaagtggca gtatctgtgc caaagaggag acggaaaatt
 aaggagctaa
 1981 ataagaagga ggctgttgga gaccttctgg atgccttcaa ggaggcgaac
 ccggcagtac
 2041 cagaggtgga aaatcagcct cctgcaggca gcaatccagg ccagagtct
 gagggcagtg
 2101 gtgtgcccc acgtcctgag gaagcagatg agacctggga ctcaaaggaa
 gacaaaattc
 2161 acaatgctga gaacatccag cccggggaac agaagtatga atataagtca
 gatcagtgga
 2221 agcctctaaa cctagaggag aaaaaacgtt acgaccgtga gttcctgctt
 ggttttcagt
 2281 tcatctttgc cagtatgcag aagccagagg gattgccaca tatcagtgac
 gtggtgctgg
 2341 acaaggccaa taaaacacca ctgcggccac tggatccac tagactacaa
 ggcataaatt
 2401 gtggcccaga ctactcca tcctttgcca accttggccg gacaaccctt
 agcacccgtg
 2461 ggcccccaag ggggtgggcca ggtggggagc tgccccgtgg gccgcaggct
 ggcttgggac
 2521 cccggcgctc tcagcaggga ccccgaaaag aaccacgcaa gatcattgcc
 acagtgttaa
 2581 tgaccgaaga tataaaactg aacaaagcag agaaagcctg gaaaccagc
 agcaagcgga
 2641 cggcggtga taaggatcga ggggaagaag atgctgatgg cagcaaaacc
 caggacctat
 2701 tccgcagggt gcgctccatc ctgaataaac tgacaccca gatgttccag
 cagctgatga
 2761 agcaagtgc gcagctggcc atcgacaccg aggaacgcct caaaggggtc
 attgacctca
 2821 tttttgagaa ggccatttca gagcccaact tctctgtggc ctatgccaac

atgtgccgct
 2881 gcctcatggc gctgaaagtg cccactacgg aaaagccaac agtgactgtg
 aacttccgaa
 2941 agctgttggt gaatcgatgt cagaaggagt ttgagaaaga caaagatgat
 gatgagggtt
 3001 ttgagaagaa gcaaaaagag atggatgaag ctgctacggc agaggaacga
 ggacgcctga
 3061 aggaagagct ggaagaggct cgggacatag cccggcggcg ctctttaggg
 aatatcaagt
 3121 ttattggaga gttgttcaaa ctgaagatgt taacagaggc aataatgcat
 gactgtgtgg
 3181 tcaaactgct taagaacat gatgaagagt cccttgagtg cctttgtcgt
 ctgctcacca
 3241 ccattggcaa agacctggac ttgaaaaag ccaagccccg aatggatcag
 tatttcaacc
 3301 agatggaaaa aatcattaaa gaaaagaaga cgatcatccg catccgcttt
 atgctgcagg
 3361 acgtgctgga tctgcgaggg agcaattggg tgccacggcg aggggatcag
 ggtcccaaga
 3421 ccattgacca gatccataag gaggtgaga tggagaaca tcgagagcac
 atcaaagtgc
 3481 agcagctcat ggccaagggc agtgacaagc gtcggggcgg tcctccaggc
 cctcccatca
 3541 gccgtggact tccccttgtg gatgatggtg gctggaacac agttcccatc
 agcaaaggta
 3601 gccgccccat tgacacctca cgactcacca agatcaccaa gcctggctcc
 atcgattcta
 3661 acaaccagct ctttgcacct ggagggcgac tgagctgggg caagggcagc
 agcggaggct
 3721 caggagccaa gccctcagac gcagcatcag aagctgctcg ccagctact
 agtactttga
 3781 atcgcttctc agcccttcaa caagcggtag ccacagaaag cacagataat
 agacgtgtgg
 3841 tgcagaggag tagcttgagc cgagaacgag gcgagaaagc tggagaccga
 ggagaccgcc
 3901 tagagcggag tgaacgggga ggggaccgtg gggaaccggc tgatcggtcg
 cggacacctg
 3961 ctaccaagcg gagcttcagc aagggaagtg aggagcggag tagagaacgg
 ccctcccage
 4021 ctgaggggct gcgcaaggca gctagcctca cggaggatcg ggaccgtggg
 cgggatgccg
 4081 tgaagcgaga agctgcccta cccccagtga gccccctgaa ggcggtctc
 tctgaggagg
 4141 agttagagaa gaaatccaag gctatcattg aggaatatct ccatctcaat
 gacatgaaag
 4201 aggcagtcca gtgcgtgcag gagctggcct caccctcctt gctcttcac
 tttgtacggc
 4261 atgggtgtcg gtctacgctg gagcgcagtg ccattgctcg tgagcatatg
 gggcagctgc
 4321 tgcaccagct gctctgtgct gggcatctgt ctactgctca gtactaccaa
 gggttgtatg
 4381 aaatcttgga attggctgag gacatggaaa ttgacatccc ccacgtgtgg
 ctctacctag
 4441 cggaactggt aacacccatt ctgcaggaag gtgggggtgcc catgggggag
 ctgttcaggg
 4501 agattacaaa gcctctgaga ccgttgggca aagctgcttc cctgttgcgtg
 gagatcctgg
 4561 gcctcctgtg caaaagcatg ggtcctaaaa aggtggggac gctgtggcga
 gaagccgggc
 4621 ttagctggaa ggaatttcta cctgaaggcc aggacattgg tgcatctgctc
 gctgaacaga

4681 aggtggagta taccctggga gaggagtcgg aagccctgg ccagagggca
 ctccctccg
 4741 aggagctgaa caggcagctg gagaagctgc tgaaggaggg cagcagtaac
 cagcgggtgt
 4801 tcgactggat agaggccaac ctgagtgagc agcagatagt atccaacacg
 ttagttcgag
 4861 ccctcatgac ggctgtctgc tattctgcaa ttatttttga gactccctc
 cgagtggacg
 4921 ttgcagtgtc gaaagcgga gcgaagctgc tgcagaaata cctgtgtgac
 gagcagaagg
 4981 agctacaggc gctctacgcc ctccaggccc ttgtagtac cttagaacag
 cctcccaacc
 5041 tgctgcggat gttctttgac gcactgtatg acgaggacgt ggtgaaggag
 gatgccttct
 5101 acagttggga gagtagcaag gaccccgctg agcagcaggg caaggggtgtg
 gcccttaaat
 5161 ctgtcacagc cttcttcaag tggctccgtg aagcagagga ggagtctgac
 cacaactgag
 5221 ggctgggtggg gccggggacc tggagcccca tggacacaca gatggcccg
 ctagccgcct
 5281 ggactgcagg ggggcggcag cagcggcggg ggcagtgggt gcctgtagt
 tgatgtgtct
 5341 gaactaataa agtggctgaa gaggcaggat ggcttggggc tgctggggc
 cccctccagg
 5401 atgccgccag gtgtccctct cctccccctg gggcacagag atatattata
 tataaagtct
 5461 tgaaatttgg tgtgtcttgg ggtggggagg ggcaccaacg cctgccctg
 gggctctttt
 5521 ttttattttc tgaaaatcac tctcgggact gccgtcctcg ctgctggggg
 catatgcccc
 5581 agccctgtga ccacccctgc tgttgctgg gcagggggaa gggggggcac
 ggtgctgtga
 5641 attattaaac atgaattcaa ttaagctcaa aaaaaaaaaa aaaaaa
 //

LOCUS NM_198241 (isoform 5)
 AA /translation="MNKAPQSTGPPAPSPGLPQPAFPPGQTAPVVFSTPQATQMNT
 SQPRQHFYPSRAQPPSSAASRVQSAAPARPGPAAHVYPAGSQVMMIPSQISYPASQGA
 YYIPGQGRSTYVPTQQYPVQPGAPGFYPGASPTFEGTYAGAYPAQGVQQFPTGVAP
 APVLMNQPPQIAPKRERKTIIRDPNQGKDIITEIMSGARTASTPTPPQTGGGLEPQ
 ANGETPQVAVIVRPDDRSQGAIIADRPGLPGPEHSPSESQFSSPSPTSPSPVLEPGS
 EPNLAVALSIPGDTMTTIQMSVEESTPISRETGEPYRLSPEPTPLAEPILEVEVTLSP
 VPSEFSSSPLQAPTPLASHTVEIHEPNGMVPSEDLPEVESSPELAPPPACSPSPV
 PIAPTAQPEELLNGAPSPPAVDLSPVSEPEEQAKEVTASMAPPTIPSATPATAPSATS
 PAQEEEMEEEEEEGEAGEAGEAESEKGGEE LLPPESTPIPANLSQNLEAAAATQVA
 VSVPKRRRKIKELNKKEAVGDLLDAFKEANPAVPEVENQPPAGSNPGPESESGVPPR
 PEEADETWDSKEDIHNAENIQPGEQKYEYKSDQWKPLNLEEKRYDREFLLGFQFIF
 ASMQKPEGLPHISDVVLDKANKTPLRPLDPTLQGINCGPDFTPSFANLGRITLSTRG
 PPRGGPGGELPRGPAGLGPRRSQQGPRKEPRKIIATVLMTEDIKLNKA EKAWKPSSKR
 TAADKDRGEEDADGSKTQDLFRVRVRSILNKLTQMFPQQLMKQVTQLAIDTEERLKGVI
 DLIFEKAISEPNFSVAYANMCRCLMALKVPTTEKPTVTNFRKLLNRCQKEFEKDKD
 DDEVFEKKQKEMDEAATAEERGLKEELEEARDIARRRSLGNIKF IGELFKLMLTEA
 IMHDCVVKLLKNHDEESLECLCRLTTIGKDLDFEKAKPRMDQYFNQMEKIIKEKKT
 SRIRFMLQDVLDRGSNWVPRRGDQGPKTIDQIHKEAEME E HREHIKVQQLMAKGS
 DKRRGGPPGPPISRGLPLVDDGGWNTVPISKGSRPIDTSRLTKITKPGSIDSNQ
 LFAFGRLSWGKGSSGGSGAKPSDAASEAARPATSTLNRFSA LQQAVPTES
 TDNRRVVQRSSLSRERGEKAGDRGDRRLERSERGGDRGDRLD RARTPATKRSFS
 KEVEERSRERPSQPEGLRKAASLTEDRDRGDAVKREAA LPVSP
 LKAALSEEELEKKS KAIIEEYHLHNDMKEAVQCVQELASPSLLFIFVRHGV
 ESTLERSAIAREHMGQLLHQLLCAGHLSTAQYYQGLYEILELAEDMEIDIPH
 VWLYLAELVTPILQEGGVPMGELFREITKPLRPLGKAASLLLEILGLLCKSMG
 PKKVGTLWREAGLSWKEFLPEGQDIGAFVAEQKVEYTLGEESEAPGQR

ALPSEELNRQLEKLLKEGSSNQRFVDWIEANLSEQQIVSNTLVRLMTAVCYSAIIFE
 TPLRVDVAVLKARAKLLQKYLCDQKELQALYALQALVVLTLEQPPNLLRMFFDALYDE
 DVVKEDAFYSWESSKDPAEQQGKGVALKSVTAFFKWLREAEESDHN

cDNA: 1 cggcggcgca gatcgcccg cgcggtccg cccctgcgc cggtcacgtg
 gggcgcccg
 61 ctgcgcctgc ggagaagcgg tggccgccga gcgggatctg tgcggggagc
 cggaatggt
 121 tgtggactac gtctgtgcgg ctgcgtgggg ctcgcccgcg cggactgaag
 gagactgaag
 181 gccctcggat gcccagaacc tgtaggccgc accgtggact tgttcttaat
 cgaggggggtg
 241 ctgggggggac cctgatgtgg caccaaataa aatgaacaaa gctccacagt
 ccacaggccc
 301 cccaccgcgc ccattccccg gactcccaca gccagcggtt ccccggggc
 agacagcgcc
 361 ggtggtgttc agtacgccac aagcgacaca aatgaacacg ccttctcagc
 cccgccagca
 421 cttctaccct agccggggcc agcccccgag cagtgcagcc tcccgagtgc
 agagtgcagc
 481 ccctgccgcg cctggcccag ctgcccattg ctaccctgct ggatcccaag
 taatgatgat
 541 cccttcccag atctcctacc cagcctccca gggggcctac tacatccctg
 gacaggggcg
 601 ttccacatac gttgtccga cacagcagta ccctgtgcag ccaggagccc
 caggcttcta
 661 tccaggtgca agccctacag aatttgggac ctacgctggc gcctactatc
 cagcccaagg
 721 ggtgcagcag tttcccaactg gcgtggcccc cgcgccagtt ttgatgaacc
 agccacccca
 781 gattgctccc aagagggagc gtaagacgat ccgaattcga gatccaaacc
 aaggaggaaa
 841 ggatatacaca gaggagatca tgtctggggc ccgcactgcc tccacacca
 cccctccca
 901 gacgggaggc ggtctggagc ctcaagctaa tggggagacg cccaggttg
 ctgtcattgt
 961 ccggccagat gaccggctac agggagcaat cattgctgac cggccagggc
 tgcttgccc
 1021 agagcatagc ccttcagaat cccagccttc gtgccttct ccgacccat
 caccatcccc
 1081 agtcttgga cgggggtctg agcctaattc cgcagtcctc tctattcctg
 gggacactat
 1141 gacaactata caaatgtctg tagaagaatc aacccccatc tcccgtaaa
 ctggggagcc
 1201 atatcgctc tctccagaac cactcctct cgcgaaccc atactggaag
 tagaagtgac
 1261 acttagcaaa ccggttccag aatctgagtt ttcttccagt cctctccagg
 ctccccccc
 1321 tttggcatct cacacagtgg aaattcatga gcctaattgg atggtcccat
 ctgaagatct
 1381 ggaaccagag gtggagtcaa gccagagct tgcctctccc ccagcttgcc
 cctccgaatc
 1441 ccctgtgccc attgctccaa ctgcccacc tgagggaactg ctcaacggag
 cccctcgcc
 1501 accagctgtg gacttaagcc cagtcagtga gccagaggag caggccaagg
 aggtgacagc
 1561 atcaatggcg cccccacca tccccctgct tactccagct acggtcctt
 cagctacttc
 1621 cccagctcag gaggaggaaa tggaagaaga agaagaagag gaagaaggag
 aagcaggaga
 1681 agcaggagaa gctgagagtg agaaaggagg agaggaactg ctccccccag

agagtacccc
 1741 tattccagcc aacttgtctc agaatttga ggcagcagca gccactcaag
 tggcagtatc
 1801 tgtgccaaag aggagacgga aaattaagga gctaaataag aaggaggctg
 ttggagacct
 1861 tctggatgcc ttcaaggagg cgaaccggc agtaccagag gtggaaaatc
 agcctcctgc
 1921 aggcagcaat ccaggcccag agtctgaggg cagtgggtgtg cccccacgtc
 ctgaggaagc
 1981 agatgagacc tgggactcaa aggaagacaa aattcacaat gctgagaaca
 tccagcccgg
 2041 ggaacagaag tatgaatata agtcagatca gtggaagcct ctaaacctag
 aggagaaaaa
 2101 acgttacgac cgtgagttcc tgcttggttt tcagttcatc tttgccagta
 tgcagaagcc
 2161 agagggattg ccacatatca gtgacgtggt gctggacaag gccaatataa
 caccactgcg
 2221 gccactggat cccactagac tacaaggcat aaattgtggc ccagacttca
 ctccatcctt
 2281 tgccaacctt ggccggacaa cccttagcac ccgtggggccc ccaaggggtg
 ggccagggtg
 2341 ggagctgccc cgtggggcgg ctggcctggg accccggcgc tctcagcagg
 gaccccgaaa
 2401 agaaccacgc aagatcattg ccacagtgtt aatgaccgaa gatataaaac
 tgaacaaagc
 2461 agagaaagcc tggaaaccca gcagcaagcg gacggcggct gataaggatc
 gaggggaaga
 2521 agatgctgat ggcagcaaaa ccaggacct attccgcagg gtgcgctcca
 tcctgaataa
 2581 actgacaccc cagatgttcc agcagctgat gaagcaagtg acgcagctgg
 ccatcgacac
 2641 cgaggaacgc ctcaaagggg tcattgacct ctttttgag aaggccattt
 cagagcccaa
 2701 cttctctgtg gcctatgcca acatgtgccg ctgcctcatg gcgctgaaag
 tgcccactac
 2761 ggaaaagcca acagtgactg tgaacttccg aaagctgttg ttgaatcgat
 gtcagaagga
 2821 gtttgagaaa gacaaagatg atgatgaggt ttttgagaag aagcaaaaag
 agatggatga
 2881 agctgctacg gcagaggaac gaggacgcct gaaggaagag ctggaagagg
 ctcgggacat
 2941 agcccggcgg cgctctttag ggaatatcaa gtttattgga gagtgttca
 aactgaagat
 3001 gttaacagag gcaataatgc atgactgtgt ggtcaaactg cttagaacc
 atgatgaaga
 3061 gtcccttgag tgcccttgct gtctgtcac caccattggc aaagacctgg
 actttgaaaa
 3121 agccaagccc cgaatggatc agtatttcaa ccagatggaa aaaatcatta
 aagaaaagaa
 3181 gacgtcatcc cgcacccgct ttatgtgca ggacgtgctg gatctgcgag
 ggagcaattg
 3241 ggtgccacgc cgaggggatc aggggcccaa gaccattgac cagatccata
 aggaggctga
 3301 gatggaagaa catcgagagc acatcaaagt gcagcagctc atggccaagg
 gcagtgacaa
 3361 gcgtcggggc ggtcctccag gccctcccat cagccgtgga cttccccttg
 tggatgatgg
 3421 tggctggaac acagttccca tcagcaaagg tagccgcccc attgacacct
 cacgactcac
 3481 caagatcacc aagcctgggt ccatcgattc taacaaccag ctctttgcac
 ctggaggcgg

3541 actgagctgg ggcaagggca gcagcggagg ctgaggagcc aagccctcag
 acgcagcatc
 3601 agaagctgct cgcacagcta ctagtacttt gaatcgcttc tcagcccttc
 aacaagcggg
 3661 acccacagaa agcacagata atagacgtgt ggtgcagagg agtagcttga
 gccgagaacg
 3721 aggcgagaaa gctggagacc gaggagaccg cctagagcgg agtgaacggg
 gaggggaccg
 3781 tggggaccgg cttgatcgtg cgcggaacc tgctaccaag cggagcttca
 gcaaggaagt
 3841 ggaggagcgg agtagagaac ggccctccca gcctgagggg ctgcgcaagg
 cagctagcct
 3901 cacggaggat cgggaccgtg ggcgggatgc cgtgaagcga gaagctgccc
 taccctcagt
 3961 gagccccctg aaggcggctc tctctgagga ggagttagag aagaaatcca
 aggctatcat
 4021 tgaggaatat ctccatctca atgacatgaa agaggcagtc cagtgcgtgc
 aggagctggc
 4081 ctaccctcc ttgctcttca tctttgtacg gcatggtgtc gagtctacgc
 tggagcgcag
 4141 tgccattgct cgtgagcata tggggcagct gctgcaccag ctgctctgtg
 ctgggcatct
 4201 gtctactgct cagtactacc aagggttgta tgaaatcttg gaattggctg
 aggacatgga
 4261 aattgacatc cccacgtgt ggctctacct agcgggaactg gtaacacca
 ttctgcagga
 4321 aggtgggggtg cccatggggg agctgttcag ggagattaca aagcctctga
 gaccgttggg
 4381 caaagctgct tcctgtttgc tggagatcct gggcctcctg tgcaaaagca
 tgggtcctaa
 4441 aaaggtgggg acgctgtggc gagaagccgg gcttagctgg aaggaatttc
 tacctgaagg
 4501 ccaggacatt ggtgcattcg tcgctgaaca gaaggaggag tataccctgg
 gagaggagtc
 4561 ggaagccctt ggccagaggg cactccctc cgaggagctg aacaggcagc
 tggagaagct
 4621 gctgaaggag ggcagcagta accagcgggt gttcgactgg atagaggcca
 acctgagtga
 4681 gcagcagata gtatccaaca cgttagtctg agccctcatg acggctgtct
 gctattctgc
 4741 aattattttt gagactcccc tccgagtgga cgttgcagtg ctgaaagcgc
 gagcgaagct
 4801 gctgcagaaa tacctgtgtg acgagcagaa ggagctacag gcgctctacg
 ccctccagge
 4861 ccttgtagtg acctagaac agcctcccaa cctgctgagg atgttctttg
 acgcactgta
 4921 tgacgaggac gtggtgaagg aggatgcctt ctacagttgg gagagtagca
 aggacccgc
 4981 tgagcagcag ggcaaggggtg tggcccttaa atctgtcaca gccttcttca
 agtggctccg
 5041 tgaagcagag gaggagtctg accacaactg agggctggtg gggccgggga
 cctggagccc
 5101 catggacaca cagatggccc ggctagccgc ctggactgca ggggggcggc
 agcagcggcg
 5161 gtggcagtgg gtgcctgtag tgtgatgtgt ctgaactaat aaagtggctg
 aagaggcagg
 5221 atggcttggg gctgcctggg cccctccca ggatgccgc aggtgtccct
 ctccctcccc
 5281 tggggcacag agatatatta tatataaagt cttgaaattt ggtgtgtctt
 ggggtgggga
 5341 ggggcaccaa cgcctgcccc tggggtcctt ttttttattt tctgaaaatc

```

actctcggga
5401 ctgccgtcct cgctgctggg ggcataatgcc ccagccctg taccaccct
gctgttgct
5461 gggcagggg aagggggggc acggtgcctg taattattaa acatgaattc
aattaagctc
5521 aaaaaaaaa aaaaaaa
//

```

```

LOCUS      NM_198242                      (isoform 3)
AA /translation="MNQPPQIAPKRERKTIRIRDPNQGGKDITEEIMSGARTASTPTP
PQTGGGLEPQANGETPQVAVIVRPDDRSQGAI IADRPGLPGPEHSPSESQPSSPSPTP
SPSPVLEPGSEPNLAVLSIPGDTMTTIQMSVEESTPISRETGEPYRLSPEPTPLAEPI
LEVEVTLSKVPPESEFSSSPLQAPTPLASHTVEIHEPNGMVPSEDLEPEVESSPELAP
PPACPSESPVPIAPTAQPEELLNGAPSPPAVDLSPVSEPEEQAKEVTASMAPPTIPSA
TPATAPSATSPAQEEEMEEEEEEEEGEAGEAGEAESEKGGEEELLPESTPIPANLSQN
LEAAAAATQVAVSVPKRRRKIKELNKKAVGDLLDAFKEANPAVPEVENQPPAGSNPGP
ESEGSGVPPRPEEADETWDSKEDIHNAENIQPGEQKYEYKSDQWKPLNLEEKRYDR
EFLLGQFIFASMQKPEGLPHISDVLDKANKTPLRPLDPTRLQGINCGPDFTPSFAN
LGRTTLSTRGPPRGPGGELPRGPAGLGPGRSQGPRKEPRKI IATVLMTEIDIKLKA
EKAWKPSSKRTAADKDRGEEDADGSKTQDLFRRVRSILNKLTPQMFQQLMKQVTQLAI
DTEERLKGVIDLIFEKAISEPNF SVAYANMCRCLMALKVPTTEKPTVTVNFRKLLNLR
CQKEFEKDKDDDEVFEKKQKEMDEAATAEERGRLEKEELEARDIARRSLGNIKFIGE
LFKLKMLTEAIMHDCVVKLLKNHDEESLECLCRLLTTIGKDLDFEKAKPRMDQYFNQM
EKIIKEKKTSSRIRFMLQDVLDLRGSNWVPRRGDQGPKTIDQIHKEAEMEHEHREHIKV
QQLMAKGS DKRRGGPPGPPISRGLPLVDDGGWNTVPISKGSRPIDTSRLTKITKPGSI
DSNNQLFAPGGRLSWGKGSSGGSGAKPSDAASEAARPATSTLNRF SALQQAVPTESTD
NRRVVQRSSLSRERGEKAGDRGDRLERSEGGDRGDRLDARTPATKRSFSKEVEERS
RERPSQPEGLRKAASLTEDRDRGRDAVKREALPPVSPLKAALSEEELEKSKAIEE
YLHLNDMKEAVQCQVELASPSLLFIFVRHGVSTLERSAIAREHMGQLLHQLLCAGHL
STAQYYQGLYEILELAEDMEIDIPHVWLYLAELVTPILQEGGVPMGELFREITKPLRP
LGKAASLLEILGLLCKSMGPKKVGT LWREAGLSWKEFLPEQGQDIGAFVAEQKVEYTL
GESEAPGQRALPSEELNRQLEKLLKEGSSNQRFVDWIEANLSEQQIVSNTLVRLMT
AVCYSAIIFETPLRVDVAVLKARAKLLQKYLCDQKELQALYALQALVVTLEQPPNLL
RMFFDALYDEDVVKEDAFYSWESSKDPAEQQGKGVALKSVTAFFKWLREAEESDHN

```

```

cDNA: 1 cggcgccgca gatcgcccg cgcggtccg cccctgcgc cggtcacgtg
ggggcgccgg
61 ctgcgcctgc ggagaagcgg tggccgccga gcgggatctg tgcggggagc
cggaaatggt
121 tgtggactac gtctgtgcgg ctgcgtgggg ctcggcgcgc cggactgaag
gagactgaag
181 gggcggtcca catagcttgt cccgacacag cagtacctg tgcagccagg
agccccagge
241 ttctatccag gtgcaagccc tacagaattt gggacctacg ctggcgccca
ctatccagcc
301 caaggggtgc agcagtttcc cactggcgtg gccccgcgc cagttttgat
gaaccagcca
361 cccagattg tccccagag ggagcgtaag acgatccgaa ttcgagatcc
aaaccaagga
421 ggaaaggata tcacagagga gatcatgtct gggggccgca ctgcctccac
accaccct
481 cccagacgg gaggggtct ggagcctcaa gctaattggg agacgcccc
ggttgcgtgc
541 attgtccggc cagatgaccg gtcacaggga gcaatcattg ctgaccggcc
agggtgcct
601 ggcccagagc atagcccttc agaatcccag ccttcgtcgc cttctccgac
cccatcacca
661 tccccagtct tggaaccggg gtctgagcct aatctgcag tctctctat
tcctggggac
721 actatgaaa ctatacaaat gtctgtagaa gaatcaacc ccactcccg
tgaaactggg

```

781 gagccatata gcctctctcc agaaccact cctctcgccg aaccataact
 ggaagtagaa
 841 gtgacactta gcaaaccggg tccagaatct gagttttctt ccagtcctct
 ccaggctccc
 901 acccctttgg catctcacac agtggaatt catgagccta atggcatggg
 cccatctgaa
 961 gatctggaac cagagggtga gtcaagccca gagcttgctc ctccccagc
 ttgccccctc
 1021 gaatccccctg tgccattgct tccaactgcc caacctgagg aactgctcaa
 cggagccccc
 1081 tcgccaccag ctgtggactt aagcccagtc agtgagccag aggagcaggc
 caaggagggtg
 1141 acagcatcaa tggcgccccc caccatcccc tctgctactc cagctacggc
 tccttcagct
 1201 acttccccag ctccaggagga ggaaatggaa gaagaagaag aagaggaaga
 aggagaagca
 1261 ggagaagcag gagaagctga gaggtagaaa ggaggagagg aactgctccc
 ccagagaggt
 1321 acccctattc cagccaactt gtctcagaat ttggaggcag cagcagccac
 tcaagtggca
 1381 gtatctgtgc caaagaggag acggaaaatt aaggagctaa ataagaagga
 ggctgttgga
 1441 gaccttctgg atgccttcaa ggaggcgaac ccggcagtac cagagggtga
 aaatcagcct
 1501 cctgcaggca gcaatccagg ccagagctct gagggcagtg gtgtgcccc
 acgtcctgag
 1561 gaagcagatg agacctggga ctcaaaggaa gacaaaattc acaatgctga
 gaacatccag
 1621 cccggggaac agaagtatga atataagtca gatcagtgga agcctctaaa
 cctagaggag
 1681 aaaaaacgtt acgaccgtga gttcctgctt ggttttcagt tcatctttgc
 cagtatgcag
 1741 aagccagagg gattgccaca tatcagtgc gtggtgctgg acaaggccaa
 taaaacacca
 1801 ctgcggccac tggatccac tagactacaa ggcataaatt gtggcccaga
 cttcactcca
 1861 tcctttgcca accttggccg gacaaccctt agcaccctg ggcccccaag
 ggtgggcca
 1921 ggtggggagc tgccccgtgg gccggctggc ctgggacccc ggcgctctca
 gcagggaccc
 1981 cgaaaagaac cacgcaagat cattgccaca gtgttaatga ccgaagatat
 aaaactgaac
 2041 aaagcagaga aagcctggaa acccagcagc aagcggacgg cggctgataa
 ggatcgaggg
 2101 gaagaagatg ctgatggcag caaaaccag gacctattcc gcagggtgcg
 ctccatcctg
 2161 aataaactga cccccagat gttccagcag ctgatgaagc aagtgcgca
 gctggccatc
 2221 gacaccgagg aacgcctcaa aggggtcatt gacctattt ttgagaaggc
 catttcagag
 2281 cccaacttct ctgtggccta tgccaacatg tgccgctgcc tcatggcgct
 gaaagtgcc
 2341 actacggaaa agccaacagt gactgtgaac ttccgaaagc tgttgttgaa
 tcgatgtcag
 2401 aaggagtttg agaaagacaa agatgatgat gaggtttttg agaagaagca
 aaaagagatg
 2461 gatgaagctg ctacggcaga ggaacgagga cgctgaagg aagagctgga
 agaggctcgg
 2521 gacatagccc ggcggcgctc tttagggaat atcaagttta ttggagagtt
 gttcaactg
 2581 aagatgttaa cagaggcaat aatgcatgac tgtgtggtca aactgcttaa

gaaccatgat
 2641 gaagagtccc ttgagtgcct ttgtcgtctg ctcaccacca ttggcaaaga
 cctggacttt
 2701 gaaaaagcca agccccgaat ggatcagtat ttcaaccaga tggaaaaaat
 cattaagaa
 2761 aagaagacgt catcccgcat ccgctttatg ctgcaggacg tgetggatct
 gcgagggagc
 2821 aattgggtgc caccgagagg ggatcagggg cccaagacca ttgaccagat
 ccataaggag
 2881 gctgagatgg aagaacatcg agagcacatc aaagtgcagc agctcatggc
 caagggcagt
 2941 gacaagcgtc ggggcggtcc tccaggccct cccatcagcc gtggacttcc
 ccttgtggat
 3001 gatggtggct ggaacacagt tcccatcagc aaaggtagcc gccccattga
 cacctcacga
 3061 ctcaccaaga tcaccaagcc tggctccatc gattctaaca accagctctt
 tgcacctgga
 3121 gggcgactga gctggggcaa gggcagcagc ggaggetcag gagccaagcc
 ctcagacgca
 3181 gcatcagaag ctgctcgccc agctactagt actttgaatc gcttctcagc
 ccttcaacaa
 3241 gcggtaccca cagaaagcac agataataga cgtgtggtgc agaggagtag
 cttgagccga
 3301 gaacgaggcg agaaagctgg agaccgagga gaccgcctag agcggagtga
 acggggaggg
 3361 gaccgtgggg accggcttga tegtgcgcgg acacctgcta ccaagcggag
 cttcagcaag
 3421 gaagtggagg agcggagtag agaacggccc tcccagcctg aggggctgcg
 caaggcagct
 3481 agcctcacgg aggatcggga ccgtgggcgg gatgccgtga agcgagaagc
 tgccctaccc
 3541 ccagtgagcc ccctgaaggc ggctctctct gaggaggagt tagagaagaa
 atccaaggct
 3601 atcattgagg aatatctcca tctcaatgac atgaaagagg cagtccagtg
 cgtgcaggag
 3661 ctggcctcac cctccttget cttcatcttt gtacggcatg gtgtcgagtc
 tacgtggag
 3721 cgcagtgcc ttgctcgtga gcatatgggg cagctgctgc accagctgct
 ctgtgctggg
 3781 catctgtcta ctgctcagta ctaccaaggg ttgtatgaaa tcttgaatt
 ggctgaggac
 3841 atggaaattg acatcccca cgtgtggctc tacctagcgg aactggtaac
 acccattctg
 3901 caggaagggtg gggtgcccat gggggagctg ttcagggaga ttacaaagcc
 tctgagaccg
 3961 ttgggcaaag ctgcttccct gttgctggag atcctgggccc tctgtgcaa
 aagcatgggt
 4021 cctaaaaag tggggacgct gtggcgagaa gcogggctta gctggaagga
 atttctacct
 4081 gaaggccagg acattggtgc attcgtcgtc gaacagaagg tggagtatac
 cctgggagag
 4141 gagtcggaag cccctggcca gagggcactc ccctccgagg agctgaacag
 gcagctggag
 4201 aagctgctga aggagggcag cagtaaccag cgggtgttcg actggataga
 ggccaacctg
 4261 agtgagcagc agatagtatc caacacgtta gttcgagccc tcatgacggc
 tgtctgctat
 4321 tctgcaatta tttttgagac tccctccga gtggacgttg cagtgetgaa
 agcgcgagcg
 4381 aagctgctgc agaaatacct gtgtgacgag cagaaggagc tacaggcgct
 ctacgcctc

4441 caggcccttg tagtgacctt agaacagcct cccaacctgc tgcggatggt
 ctttgacgca
 4501 ctgtatgacg aggacgtggt gaaggaggat gccttctaca gttgggagag
 tagcaaggac
 4561 cccgctgagc agcagggcaa ggggtgtggcc cttaaactctg tcacagcctt
 cttcaagtgg
 4621 ctccgtgaag cagaggagga gtctgaccac aactgagggc tgggtggggcc
 ggggacctgg
 4681 agcccatg acacacagat ggcccggcta gccgcctgga ctgcaggggg
 gcggcagcag
 4741 cggcgggtggc agtgggtggt tgtagtgtga tgtgtctgaa ctaataaagt
 ggctgaagag
 4801 gcaggatggc ttggggctgc ctgggcccc ctccaggatg ccgccaggtg
 tccctctctt
 4861 cccctgggg cacagagata tattatatat aaagtcttga aatttggtgt
 gtcttgggg
 4921 ggggaggggc accaacgcct gccctgggg tccttttttt tattttctga
 aaatcactct
 4981 cgggactgcc gtcctcgctg ctgggggcat atgccccagc cctgtacca
 ccctgctgt
 5041 tgcctgggca gggggaagg ggggcacggt gcctgtaatt attaaacatg
 aattcaatta
 5101 agctcaaaaa aaaaaaaaaa aaa

//

LOCUS NM_198244 (isoform 2)
 AA /translation="MMIPSQISYPASQGAYYIPGQGRSTYVVPTQQYPVQPGAPGFYP
 GASPTFTGYAGAYYPAQGVQQFPTGVAPAPVLMNQPPQIAPKRERKTIRIRDPNQGG
 KDITEEIMSGARTASTPTTPQTGGGLEPQANGETPQVAVIVRPDDRSQGAIIADRPGL
 PGPEHSPSESQPSSPSTPSPSPVLEPGSEPNLAVLSIPGDTMTTIQMSVEESTPISR
 ETGEPYRLSPEPTPLAEPPILEVEVTLSPVPPESEFSSSPLQAPTPLASHTVEIHEPNG
 MVSPELEPEVESSPELAPPPACPSESPVPIAPTAQPEELLNGAPSPPAVDLSPVSEP
 EEQAKEVTASMAPPTIPSATPATAPSATSPAQEEEEEEEEEEGEAGEAGEAESEKG
 GEELLPESTPIPANLSQNLEAAAAATQVAVSVPKRRRKIKELNKKAEAVGDLDDAFKEA
 NPAVPEVENQPPAGSNPGPESESGVPPRPEEADETWDSKEDIHNAENIQGEQKYE
 YKSDQWKPLNLEKKRYDREFLLGFQFIFASMQKPEGLPHISDVVLDKANKTPLRPLD
 PTRLQGINCGPDFTPSFANLGRITLSTRGPPRGPGGELPRGPAGLGPRRSQGPRKE
 PRKIIATVLMTEIDIKLNKAEKAWKPSSKRTAADKDRGEEDADGSKTQDLFRVRVSI LN
 KLTPQMFQQLMKQVTQLAIDTEERLKGVIDLIFEKAISEPNFSVAYANMCRCLMALKV
 PTTEKPTVTNFRKLLNRCQKEFEKDKDDDEVFEKKQKEMDEAATAEERGLKEELE
 EARDIARRRSLGNIKFIGELFKLKLMLTEAIMHDCVVKLLKNHDEESLECLCRLLTTIG
 KDLDFEKAKPRMDQYFNQMEKIIKEKKTSSRIRFMLQDVLDLRGSNNVPRRGDQPKT
 IDQIHKEAEMEEHREHIKVQQLMAKGS DKRRGGPPGPPISRGLPLVDDGGWNTVPI SK
 GSRPIDTSRLTKITKPGSIDSNNQLFAPGGRLSWGKGSSGGSGAKPSDAASEARPAT
 STLNRFSALQQAVPTESDNRVVRSSLSRERGEKAGDRGRDLERSEGGDRGRDLR
 RARTPATKRSFSKEVEERSRERPSQPEGLRKAASLTEDRDRGRDAVKREAAALPPVSPL
 KAALSEEELEKKSKAII E EYLHLNDMKEAVQCVQELASPSLLFIFVRHGVESTLERSA
 IAREHMGQLLHQLLCAGHLSTAQYYQGLYEILELAEDMEIDIPHVWLYLAELVTPILQ
 EGGVPMGELFREITKPLRPLGKAASLLEILGLLCKSMGPKKVGT LWREAGLSWKEFL
 PEGQDIGAFVAEQKVEYTLGEESEAPGQRALPSEELNRQLEKLLKEGSSNQRFVDWIE
 ANLSEQQIVSNTLVRLMTAVCYSAIIFETPLRVDVAVLKARAKLLQKYL CDEQKELQ
 ALYALQALVVTLEQPPNLLRMFFDALYDEDVVKEDAFYSWESSKDPAEQQKGVALKS
 VTAFFKWLREAEESDHN

cDNA: 1 cggcgccgca gatcgcccg cgcggtccg cccctgcgc cggtcacgtg
 gggcgcccg
 61 ctgcgcctgc ggagaagcgg tggccgccga gcgggatctg tgcggggagc
 cggaaatggt
 121 tgtggactac gtctgtgagg ctgcgtgggg ctcgcccgcg cggactgaag
 gagactgaag
 181 cacttctacc ctgacgggg ccagccccc agcagtgcag cctcccgagt

gcagagtgca
 241 gcccttgccc gccctggccc agctgccc atgtaccctg ctggatccca
 agtaatgatg
 301 atcccttccc agatctccta cccagcctcc cagggggcct actacatccc
 tggacagggg
 361 cgttccacat acgttgctcc gacacagcag taccctgtgc agccaggagc
 cccaggcttc
 421 tatccagggtg caagccctac agaatttggg acctacgctg gcgcctacta
 tccagcccaa
 481 ggggtgcagc agtttccac tggcgtggcc cccgccccag ttttgatgaa
 ccagccaccc
 541 cagattgctc ccaagaggga gcgtaagacg atccgaattc gagatccaaa
 ccaaggagga
 601 aaggatatca cagaggagat catgtctggg gcccgactg cctccacacc
 caccctccc
 661 cagacgggag gcggtctgga gcctcaagct aatggggaga cgccccaggt
 tgctgtcatt
 721 gtccggccag atgaccggtc acaggagca atcattgctg accggccagg
 gctgcctggc
 781 ccagagcata gcccttcaga atcccagcct tcgtcgcctt ctccgacccc
 atcaccatcc
 841 ccagtcttgg aaccggggtc tgagccta atcgcagtc tctctattcc
 tggggacact
 901 atgacaacta taaaaatgtc tgtagaagaa tcaacccccca tctcccgatga
 aactggggag
 961 ccatatcgcc tctctccaga acccactcct ctgcgcgaac ccatactgga
 agtagaagtg
 1021 acacttagca aaccgggttc agaactctgag ttttcttcca gtctctcca
 ggctcccacc
 1081 cttttggcat ctacacacagt ggaaattcat gagccta atg gcatggctcc
 atctgaagat
 1141 ctggaaccag aggtggagtc aagcccagag ctgtctctc cccagcttg
 cccctccgaa
 1201 tcccctgtgc ccattgctcc aactgcccc cctgaggaac tgctcaacgg
 agccccctcg
 1261 ccaccagctg tggacttaag cccagtcagt gagccagagg agcaggccaa
 ggaggtgaca
 1321 gcatcaatgg cgccccccac catccctct gctactccag ctacggctcc
 ttcagctact
 1381 tccccagctc aggaggagga aatggaagaa gaagaagaag aggaagaagg
 agaagcagga
 1441 gaagcaggag aagctgagag tgagaaagga ggagaggaac tgctcccccc
 agagagtacc
 1501 cctattccag ccaacttgct tcagaatttg gaggcagcag cagccactca
 agtggcagta
 1561 tctgtgccaa agaggagacg gaaaattaag gagctaaata agaaggaggc
 tggtggagac
 1621 cttctggatg ctttcaagga ggccaacccg gcagtaccag aggtggaaaa
 tcagctctct
 1681 gcaggcagca atccaggccc agagtctgag ggcagtgggtg tgccccacg
 tcctgaggaa
 1741 gcagatgaga cctgggactc aaaggaagac aaaattcaca atgctgagaa
 catccagccc
 1801 ggggaacaga agtatgaata taagtccagat cagtggagc ctctaaacct
 agaggagaaa
 1861 aaacgttacg accgtgagtt cctgcttggg tttcagttca tctttgccag
 tatgcagaag
 1921 ccagagggat tgccacatat cagtgcagtg gtgctggaca aggccaaataa
 aacaccactg
 1981 cggccactgg atcccactag actacaaggc ataaattgtg gccagactt
 cactccatcc

2041 tttgcccaacc ttggccgggac aaccetttagc acccgtgggc ccccaagggg
 tgggccaggt
 2101 ggggagctgc cccgtgggccc ggctggcctg ggaccccggc gctctcagca
 gggaccccga
 2161 aaagaaccac gcaagatcat tgccacagtg ttaatgaccg aagatatataa
 actgaacaaa
 2221 gcagagaaag cctggaaacc cagcagcaag cggacggcgg ctgataagga
 tcgaggggaa
 2281 gaagatgctg atggcagcaa aaccaggac ctattccgca gggcgcgctc
 catcctgaat
 2341 aaactgacac cccagatggt ccagcagctg atgaagcaag tgacgcagct
 ggccatcgac
 2401 accgaggaac gcctcaaagg ggtcattgac ctcatTTTTg agaaggccat
 ttcagagccc
 2461 aacttctctg ttggcctatgc caacatgtgc cgctgcctca tggcgctgaa
 agtgcccact
 2521 acggaaaagc caacagtgc tgtgaacttc cgaaagctgt tgttgaatcg
 atgtcagaag
 2581 gagtttgaga aagacaaaga tgatgatgag gtttttgaga agaagcaaaa
 agagatggat
 2641 gaagctgcta cggcagagga acgaggacgc ctgaaggaag agctggaaga
 ggctcgggac
 2701 atagcccggc ggcgctcttt agggaatatc aagtttattg gagagtgtt
 caaactgaag
 2761 atgttaacag aggcaataat gcatgactgt gtggtcaaac tgcttaagaa
 ccatgatgaa
 2821 gagtccttg agtgcccttg tcgtctgctc accaccattg gcaaagacct
 ggactttgaa
 2881 aaagccaagc cccgaatgga tcagtatttc aaccagatgg aaaaaatcat
 taaagaaaag
 2941 aagacgtcat cccgcatccg ctttatgctg caggacgtgc tggatctgcg
 agggagcaat
 3001 tgggtgccac gccgagggga tcagggtccc aagaccattg accagatcca
 taaggaggct
 3061 gagatggaag aacatcgaga gcacatcaaa gtgcagcagc tcatggccaa
 gggcagtgc
 3121 aagcgtcggg gcggtcctcc aggcctccc atcagccgtg gacttcccct
 tgtggatgat
 3181 ggtggctgga acacagttcc catcagcaaa ggtagccgcc ccattgacac
 ctcacgactc
 3241 accaagatca ccaagcctgg ctccatcgat tctaacaacc agctctttgc
 acctggaggg
 3301 cgactgagct ggggcaaggc cagcagcggg ggctcaggag ccaagccctc
 agacgcagca
 3361 tcagaagctg ctgcgccagc tactagtact ttgaatcgct tctcagccct
 tcaacaagcg
 3421 gtaccacag aaagcacaga taatagacgt gtggtgcaga ggagtgcctt
 gagccgagaa
 3481 cgaggcgaga aagctggaga ccgaggagac cgccatagagc ggagtgaacg
 gggaggggac
 3541 cgtggggacc ggcttgatcg tgcgcggaca cctgctacca agcggagctt
 cagcaaggaa
 3601 gtggaggagc ggagttaga acggccctcc cagcctgagg ggctgcgcaa
 ggcagctagc
 3661 ctcacggagg atcgggaccg tgggcgggat gccgtgaagc gagaagctgc
 cctaccccca
 3721 gtgagccccc tgaaggcggc tctctctgag gaggagttag agaagaaatc
 caaggctatc
 3781 attgaggaat atctccatct caatgacatg aaagaggcag tccagtgcgt
 gcaggagctg
 3841 gcctcacct ccttgctctt catctttgta cggcatggtg tcgagtctac

```

gctggagcgc
 3901 agtgccattg ctctgtagca tatggggcag ctgctgcacc agctgctctg
tgctgggcat
 3961 ctgtctactg ctccagtacta ccaaggggtg tatgaaatct tggaattggc
tgaggacatg
 4021 gaaattgaca tccccacgt gtggctctac ctagcggaac tggtaacacc
cattctgcag
 4081 gaaggtgggg tgcccatggg ggagctgttc agggagatta caaagcctct
gagaccgttg
 4141 ggcaaagctg cttccctggt gctggagatc ctgggcctcc tgtgcaaaag
catgggtcct
 4201 aaaaaggtgg ggacgctgtg gcgagaagcc gggcttagct ggaaggaatt
tctacctgaa
 4261 ggccaggaca ttggtgcatt cgtcgtgaa cagaaggtgg agtataccct
gggagaggag
 4321 tcggaagccc ctggccagag ggcaactccc tccgaggagc tgaacaggca
gctggagaag
 4381 ctgctgaagg agggcagcag taaccagcgg gtgttcgact ggatagaggc
caacctgagt
 4441 gagcagcaga tagtatccaa cacgttagtt cgagccctca tgacggctgt
ctgctattct
 4501 gcaattatit ttgagactcc cctccgagtg gacgttgcag tgctgaaagc
gcgagcgaag
 4561 ctgctgcaga aatacctgtg tgacgagcag aaggagctac aggcgctcta
cgccctccag
 4621 gccctttagt tgaccttaga acagcctccc aacctgctgc ggatgttctt
tgacgcactg
 4681 tatgacgagg acgtggtgaa ggaggatgcc ttctacagtt gggagagtag
caaggacccc
 4741 gctgagcagc agggcaaggg tgtggccctt aaatctgtca cagccttctt
caagtggctc
 4801 cgtgaagcag aggaggagtc tgaccacaac tgaggggctgg tggggccggg
gacctggagc
 4861 cccatggaca cacagatggc ccggctagcc gcctggactg caggggggag
gcagcagcgg
 4921 cgggtggcagt ggggtgctgt agtgtgatgt gtctgaacta ataaagtggc
tgaagaggca
 4981 ggatggcttg gggctgcttg ggccccctc caggatgccg ccagggtgtc
ctctcctccc
 5041 cctggggcac agagatatat tatatataaa gtcttgaaat ttggtgtgtc
ttgggggtgg
 5101 gaggggcacc aacgcctgcc cctgggggtc ttttttttat tttctgaaaa
tcaactctcg
 5161 gactgccgtc ctgctgctg ggggcatatg cccagcccc tgtaccaccc
ctgctgttgc
 5221 ctgggcaggg ggaagggggg gcacggtgcc tgtaattatt aaacatgaat
tcaattaagc
 5281 tcaaaaaaaaa aaaaaaaaaa
//
7. ENO1: ENO1 enolase 1, (alpha) [ Homo sapiens ]
LOCUS NM_001428
AA /translation="MSILKIHAREIFDSRGNPTVEVDLFTSKGLFRAAVPSGASTGIY
EALRLDNDKTRYMGKGVSKAVEHINKTIAPALVSKKLVNTEQEKIDKLMIEMDGTEN
KSKFGANAILGVSLAVCKAGAVEKGVPLYRHIADLAGNSEVILPVPAFNVINGGSHAG
NKLAMQEFMILPVGAANFREAMRIGAEVYHNLKNVIKEKYGKDATNVGDEGGFAPNIL
ENKEGLELLKTAIGKAGYTDKVVIGMDVAASEFFRSGKYDLDFKSPDDPSRYISPDQL
ADLYKSFIKDYPVVSIEDPFDQDDWGAWQKFTASAGIQVVGDDLTVTNPKRIAKAVNE
KSCNCLLLKVNQIGSVTESLQACKLAQANGWGMVSHRSGETEDTFIADLVVGLCTGQ
IKTGAPCRSERLAKYNQLLRIEEEELGSKAKFAGRNFRNPLAK

```

cDNA: 1 gtggggcccc agagcgacgc tgagtgcgtg cgggactcgg agtacgtgac


```

ggagccccga
  61 gctctcatgc ccgccacgcc gccccgggcc atcccccgga gccccggctc
cgcacacccc
 121 agttcggttc accgggtccta tctggggcca gagtttcgcc cgcaccacta
cagggcgcgt
 181 ggggagtcgg ggccccccag atctgcccgc ctcaagtccg cgggacgtca
ccccctttc
 241 cacgctactg cagccgtcgc agtcccaccc ctttcgggga ggtgagggaa
tgagtgaagg
 301 ctctcccacg gaatggcgag gcggagctga gggggcgtgc cccggaggcg
ggaagtgggt
 361 ggggctcgcc ttagctaggg aggaagtcgg cgcggggcggc gcggacagta
tctgtgggta
 421 cccggagcac ggagatctcg ccggctttac gttcacctcg gtgtctgcag
caccctccgc
 481 ttctctctct aggcgacgag acccagtggc tagaagttca ccatgtctat
tctcaagatc
 541 catgccaggg agatctttga ctctcgcggg aatcccactg ttgaggttga
tctcttcacc
 601 tcaaaaggtc tcttcagagc tgctgtgccc agtgggtgctt caactgggtat
ctatgaggcc
 661 ctagagctcc gggacaatga taagactcgc tatatgggga aggggtgtctc
aaaggctggt
 721 gagcacatca ataaaactat tgcgcctgcc ctgggtagca agaaactgaa
cgtcacagaa
 781 caagagaaga ttgacaaaact gatgatcgag atggatggaa cagaaaataa
atctaagttt
 841 ggtgcgaacg ccattctggg ggtgtccctt gccgtctgca aagctgggtc
cgttgagaag
 901 ggggtccccc tgtaccgcca catcgctgac ttggctggca actctgaagt
catcctgcca
 961 gtcccggcgt tcaatgtcat caatggcggg tctcatgctg gcaacaagct
ggccatgcag
1021 gagttcatga tctcccaggt cgggtgcagca aacttcaggg aagccatgcg
cattggagca
1081 gaggtttacc acaacctgaa gaatgtcatc aaggagaaat atgggaaaga
tgccaccaat
1141 gtgggggatg aaggcggggt tgctcccaac atcctggaga ataaagaagg
cctggagctg
1201 ctgaagactg ctattgggaa agctggctac actgataagg tggatcatcg
catggacgta
1261 gcggcctccg agttcttcag gtctgggaag tatgacctgg acttcaagtc
tccgatgac
1321 cccagcaggt acatctcgcc tgaccagctg gctgacctgt acaagtcctt
catcaaggac
1381 taccagtggt tgtctatcga agatcccttt gaccaggatg actggggagc
ttggcagaag
1441 ttcacagcca gtgcaggaat ccaggtagtg ggggatgatc tcacagtgc
caacccaaag
1501 aggatcgcca aggccgtgaa cgagaagtcc tgcaactgcc tctgctcaa
agtcaaccag
1561 attggctccg tgaccagatc tcttcaggcg tgcaagctgg cccaggccaa
tggttggggc
1621 gtcagtgtgt ctcatcgctt gggggagact gaagatacct tcatcgctga
cctggttgtg
1681 gggctgtgca ctgggcagat caagactggg gccccttgcc gatctgagcg
cttggccaa
1741 tacaaccagc tctcagaat tgaagaggag ctgggcagca aggctaagtt
tgccggcagg
1801 aacttcagaa accccttggc caagtaagct gtgggcaggc aagcccttcg
gtcacctggt

```

```

1861 ggctacacag acccctcccc tcgtgtcagc tcaggcagct cgaggccccc
gaccaacact
1921 tgcaggggtc cctgctagtt agcgccccac cgccgtggag ttcgtaccgc
ttccttagaa
1981 cttctacaga agccaagctc cctggagccc tgttggcagc tctagctttg
cagtcgtgta
2041 attggcccaa gtcattgttt ttctcgctc actttccacc aagtgtctag
agtcattgtga
2101 gcctcgtgtc atctccgggg tggccacagg ctagatcccc ggtggttttg
tgctcaaaat
2161 aaaaagcctc agtgacctat gagaataaaa aaaaaaaaaa aaaa
//

```

```

8. FBL: FBL fibrillarin [ Homo sapiens ]
LOCUS NM_001436
AA /translation="MKPGFSPRGGGFGGRGGFGDRGGRGGRGGFGGGRGRGGGFRGRG
RGGGGGGGGGGGGGGGGGGFHSNGNRGRGRGGKRGNGSGKNVMVEPHRHEGVFICRGK
EDALVTKNLVPGESVYGEKRVSISEGDDKIEYRAWNPFRSKLAAA ILGGVDQIHKPG
AKVLYLGAASGTTVSHVSDIVGPDGLVYAVEFSHRSGRDLINLAKKRTNI IPVIEDAR
HPHKYRMLIAMVDVIFADVAQPDQTRIVALNAHTFLRNGGHFVIS IKANCIDSTASAE
AVFASEVKKMQQENMKPQEQLTLEPYERDHAVVGVYRPPPKVKN

```

```

cDNA: 1 gcgtcacgca gcgcacgtcg ccgcgcgcct gcgtctttt ccacgtgcga
aagccccgga
61 ctctgtggagt tgtgaacgcc gcggactccg gagccgcaca aaccagggtc
cgccatgaag
121 ccaggattca gtccccgtgg ggggtggcttt ggccggccgag ggggttttgg
tgaccgtggt
181 ggctcgtggag gccgaggggg ctttggcggg ggccgaggtc gaggcggagg
cttttagaggt
241 cgtggacgag gaggaggtgg aggcggcggc ggccggtggag gaggaggaag
aggtggtgga
301 ggcttccatt ctggtggcaa ccggggctcg ggtcggggag gaaaaagagg
aaaccagtcg
361 gggaagaatg tgatggtgga gccgcacccg catgagggtg tcttcatttg
tcgaggaaag
421 gaagatgcac tggtcaccaa gaacctggtc cctgggggaat cagtttatgg
agagaagaga
481 gtctcgattt cggaaggaga tgacaaaatt gagtaccgag cctggaaccc
cttccgctcc
541 aagctagcag cagcaatcct ggggtggtgtg gaccagatcc acatcaaacc
gggggctaag
601 gttctctacc tcggggctgc ctcgggcacc acggtctccc atgtctctga
catcggttgg
661 ccggatggtc tagtctatgc agtcaggtc tcccaccgct ctggccgtga
cctcattaac
721 ttggccaaga agaggaccaa catcattcct gtgatcgagg atgctcgaca
cccacacaaa
781 taccgcatgc tcatcgcaat ggtggatgtg atctttgctg atgtggccca
gccagaccag
841 acccgattg tggccctgaa tgcccacacc ttctgcgta atggaggaca
ctttgtgatt
901 tccattaagg ccaactgcat tgactccaca gcctcagccg aggcctgtgt
tgctccgaa
961 gtgaaaaaga tgcaacagga gaacatgaag ccgcaggagc agttgaccct
tgagccatat
1021 gaaagagacc atgccgtggt cgtgggagtg tacaggccac ccccaaggt
gaagaactga
1081 agttcagcgc tgtcaggatt gcgagagatg tgtgttgata ctgttcacg
tgtgtttttc
1141 tattaaaaga ctcatcgtc tccccaaaaa a

```

//

9. GSK3B: GSK3B glycogen synthase kinase 3 beta [Homo sapiens]

LOCUS NM_001146156 (isoform 2)

AA /translation="MSGRPRTTSFAESCKPVQQPSAFGSMKVS RDKGSKVTTVVATP
GQGPDRPQEVSYTDTKVIGNGSFGVVYQAKLCDSGELVAIKKVLQDKRFKNRELQIMR
KLDHCNIVRLRYFFYSSGEKKDEVYLNVLVDYVPETVYRVARHYSRAKQTLPIYVKL
YMYQLFRSLAYIHSFGICHRDIKPQNLLDPDTAVLKLCDFGSAKQLVRGEPNVSYIC
SRYYRAPELIFGATDYTSSIDVWSAGCVLAELLLGQPIFPGDSGVDQLVEIIKVLGTP
TREQIREMNPNYTEFKFPQIKAHPWTKVFRPRTPEAIALCSRLLEYTPARLTPLEA
CAHSFFDEL RDPNVKLPNGRDTPALFNFTTQELSSNPPLATILIPPHARIQAAASTPT
NATAASDANTGDRGQTNNAASASASNST

cDNA: 1 cgggcttggtg ccgcccgcgc cgccgcgcgc gcccgggcca agtgacaaaag
gaaggaagga
61 agcgaggagg agccggcccc gcagccgctg acagggctct gggctggggc
aaagcgcgga
121 cacttcctga gcgggcaccg agcagagccg aggggcggga gggcggccga
gctgttgccg
181 cggacggggg agggggcccc gagggacgga agcggttgcc gggttcccat
gtccccggcg
241 aatggggaac agtcgaggag ccgctgcctg gggctctgaag ggagctgcct
ccgccaccgc
301 catggccgct ggatccagcc gccgcctgca gctgctcctg gcgcaatgag
gagaggagcc
361 gccgccaccg ccaccgcccc cctctgactg actcgcgact ccgccgccct
ctagtctgcc
421 gggcccctgc cgtcagcccc ccgatcccc cggttgccg gagctgcagc
gtttcccgtc
481 gcatctccga gccacccctt cctccctctt cctccctcc taccatccc
cctttctctt
541 caagcgtgag actcgtgatc cttccgcgc ttccttctt cattgactcg
gaaaaaaaaat
601 ccccgaggaa aatataatat tcgaagtact ctttttcaat caagtatttg
cccccgtttc
661 acgtgataca ttttttttta ggatttgccc tctcttttct ctctcccag
gaaagggagg
721 ggaaagaatt gtattttttt ccaagtccta aatcatctat atgttaaata
tccgtgcga
781 tctgtcttga aggagaaata ttcgcttggt tttgtttttt atagtataca
aaaggagtga
841 aaagccaaga ggacgaagtc tttttctttt tcttctgtgg gagaacttaa
tgctgcattt
901 atcggttaacc taacacccca acataaagac aaaaggaaga aaaggaggaa
ggaaggaaaa
961 ggtgattcgc gaagagagtg atcatgtcag ggcgggccag aaccacctcc
tttgcggaga
1021 gctgcaagcc ggtgcagcag ccttcagctt ttggcagcat gaaagttagc
agagacaagg
1081 acggcagcaa ggtgacaaca gtggtggcaa ctctgggca ggtccagac
aggccacaag
1141 aagtcagcta tacagacact aaagtgattg gaaatggatc atttgggtgtg
gtatatcaag
1201 ccaaactttg tgattcagga gaactggtcg ccatcaagaa agtattgcag
gacaagagat
1261 ttaagaatcg agagctccag atcatgagaa agctagatca ctgtaacata
gtccgattgc
1321 gttatttctt ctactccagt ggtgagaaga aagatgaggt ctatcttaat
ctggtgctgg
1381 actatgttcc ggaaacagta tacagagttg ccagacacta tagtcgagcc

```

aaacagacgc
 1441 tccctgtgat ttatgtcaag ttgtatatgt atcagctggt ccgaagttaa
gcctatatcc
 1501 attccttttg aatctgccat cgggatatta aaccgcagaa cctcttggtg
gatcctgata
 1561 ctgctgtatt aaaactctgt gactttggaa gtgcaaagca gctggtccga
ggagaacca
 1621 atgtttcgta tatctgttct cggactata gggcaccaga gttgatcttt
ggagccactg
 1681 attatacctc tagtatagat gtatggtctg ctggctgtgt gttggctgag
ctgttactag
 1741 gacaaccaat atttccaggg gatagtgggtg tggatcagtt ggtagaaata
atcaagggtc
 1801 tgggaactcc aacaaggagg caaatcagag aaatgaacct aaactacaca
gaatttaa
 1861 tccctcaa
taaggcacat ccttggacta aggtcttccg accccgaact
ccaccggagg
 1921 caattgcact gtgtagccgt ctgctggagt atacaccaac tgccgacta
acaccactgg
 1981 aagcttggtc acattcattt tttgatgaat tacgggacct aaatgtcaaa
ctaccaaatg
 2041 ggcgagacac acctgcactc ttcaacttca ccactcaaga actgtcaagt
aatccacctc
 2101 tggctaccat ccttattcct cctcatgctc ggattcaagc agctgcttca
accccacaa
 2161 atgccacagc agcgtcagat gctaatactg gagaccgtgg acagaccaat
aatgctgctt
 2221 ctgcatcagc ttccaactcc acctgaacag tcccgagcag ccagctgcac
aggaaaaacc
 2281 accagttact tgagtgtcac tcagcaacac tggtcacgtt tggaaagaat
attaaaaaga
 2341 gaaaaaaatc ctgttcattt tagtgttcaa tttttttatt attattgttg
ttcttattta
 2401 accttgtaaa atatctataa atacaaacca atttcattgt attctcactt
tgagggagat
 2461 ccaggggggtg ggagggggtg tggggagggg gaaagcggag cactagaaca
tacaatctct
 2521 ctcccacgac aatctttttt tatta
aaagt ctgctgttgt atactttaa
aacaggactc
 2581 ctgcctcatg ccccttccac aaaagaagaa aacctttttc tgtgctgatg
ggtttttttg
 2641 aactttgttt tcttttaaag tctagtgtga gactttggta tagtgcacag
cttgaaattg
 2701 gttgggagct tagcagggtat aactcaacgg ggacttaa
aat gtcacttgta
aaattaatcc
 2761 atatcttcgg gtatttatag acttgccctt ggcatgttgg tggcagggtg
ggcagacaaa
 2821 gaaatgtgta tcattcgtaa cccagggagg tcaataaagt ttggaactct
acagggaaga
 2881 ttcttagtag atttgtaag gttttgtttt gctctcagtt agtgctagtg
atgtagaggc
 2941 ttgtacagga ggctgccaga ggggaagcag caagcaagac tcaggcacac
atgctctaca
 3001 ggtggctctt tgtttgctg accaaagt
tc tttgcaa
atc ttagcacagt
ttcaaactag
 3061 tgacctggga ggagatggaa ggggtgttga gcaggctgag ctagctgctg
agg
tcaaagg
 3121 ctgatgagcc cagaggaagg ggacagg
tca gggatacatc tcacca
ctgt
gaataagttt
 3181 gtccagattt ttttctaaag ttacttcct tggaaagata cacttgagag
gacattgtag

```

3241 ttaaataatg tgaactgtaa cagtcaccta ctggtttatt tttcatatTT
 ttttaattgaa
 3301 aattgagctt gcagaaatag ccacattcta cacatagttc taatttttaa
 tccaaatcta
 3361 gaatctgtat ttaatttggt ttttaacctc atgcttttta catttatTTA
 ttgatgcatg
 3421 tcagatggta gaaatattaa aaactacaca tcagaatgat acagtcactt
 atacctgctg
 3481 actttatagg aaagctgatg atataaatgt gtgtatatat gttatatata
 catatatTTA
 3541 atactgcctt tttttttgtc tacagtatca aaattgactg gttgaagcat
 gagaagaatg
 3601 tttccccac acccagttaa gagtttttgt gtctgttttc tttgtgtatc
 agtgaacgat
 3661 gttaagaatc agtctctctt tttgaagaaa aagcaatatt ccttggaag
 caaggagaat
 3721 tgaaggacta tgtttgccgt gaggaaatag attttcatga ctagtttggt
 ttatactTTT
 3781 aaggttgga tctatgtggg ccttatatac tctaaaatga actttagtca
 ccttggtgct
 3841 tatgggccat tacttgacct atgaatcttt aaggcacaat cagttgtact
 ttacattTTA
 3901 agatcacttg agtgatggcc gcctttccct cctaccgct cctccccac
 atgccttcca
 3961 aggttagctg gtaactgtag ggctgcagag ctgagcccat ggttgtgtgt
 aacttgccct
 4021 caccctctc attgccacct taggtcactt tatgggtctc gtctccaga
 gggttcggaa
 4081 gtggagtctg ttggcagccc tcctgcaggc cctagcacc tgctctgctc
 cttaactgtg
 4141 tgtgtgactc tccaagagag ttgtcctgcc tgctgaagtg aaccagtacc
 cagaaagaca
 4201 actgtgagcc atcttggttt tcactcgtg tttagctgag gtcttgggcc
 acaaaagggg
 4261 tttcaciaac ctctggatat atcagagttt atgagaaagg aaacatgctc
 agtcaaacca
 4321 aatcaaacia attgaatttt atgttttata aagtgttct gaaagctaag
 atttgaaaga
 4381 agtctgaaat caaagtatTT ggcagcataa ctcttaaag gtagtggcgt
 tgatagacca
 4441 ttttcagaca gaatttataa agaatctgaa aaggcaggtc tgtgatagag
 aatggacct
 4501 gcattcagat ccaactgcc agcaagcgtt tggatgcaga cactgctctg
 gacgtggat
 4561 actccccaga gtccataaaa atcagtgtt attttaggaa acaggttgcc
 ccccaact
 4621 ggggtaaaag aagagagaaa agtcacgctt ttctctcatt tcattgtgtg
 tgcattgtgtg
 4681 cgtgtgtgtg tgtgtgtgtg tgtgtgaga tgtgtgattt ttctttctca
 aggatcatgg
 4741 tgggatcaca gaactctttt atacaagtga gatccaggtc tctgaatatc
 tttttgtata
 4801 taataataat aaaaagctcc tcaccaaatt caagcttgta cattatatTT
 tctttctgtg
 4861 tttttaaat taagttttat tgttttgtat gtaaatatgt ggaccagga
 actgttatta
 4921 atgagcaaaa agttactgtt cagggcagtg attctgttta ataacagac
 aaaatgtaga
 4981 cgagcttttt aaagccatat agttttaact ctgtacagta ggtaccggcc
 tgtattattg
 5041 taacaataac tctagcaatg tatagtgtat ctatatagtt tggagtgcct

tcgcttccat
 5101 gtgttttttt ttttaatttg ttctttttta aattttaatt ggtttccttt
 atccatgtct
 5161 ccctgtccac cccctttccc tttgaaataa taactcactc ataacagtat
 ctttgccct
 5221 tccacagtta agtttcagtg ataccatact caggagtggg aagaggaaat
 catattcgta
 5281 atttcatttc gttgaagccc tgcctttgtt ttggttctga atgtctttcc
 tcctcggtag
 5341 cagtgaagacc ggtttcattt catacttagt ccattcaggg acttagtgta
 gcaccaggga
 5401 gccctagagc tggaggatat cgaatagatt aaattttgct cgtctcttcc
 acaagcccta
 5461 accatgggtc ttaaaaacag cagattctgg gagccttcca tgcctctctc
 ctctctctt
 5521 ttatctactt ccctcccaaa tgagagagtg acagagaatt gtttttttat
 aaatcgaagt
 5581 ttcttaatag tatcagggtt tgatacgtca gtggtctaaa atgctatagt
 gcaattacta
 5641 gcagttactg cacggagtgc caccgtgcca atagaggact gttgttttaa
 caagggaact
 5701 cttagcccat ttctccctc cggccatctc tacccttgct caatgaaata
 tcattttaat
 5761 ttcttttaaa aaaaatcagt ttaattctta ctgtgtgccc aacacgaagg
 ccttttttga
 5821 aagaaaaata gaatgttttg cctcaaagta gtccatataa aatgtcttga
 atagaagaaa
 5881 aaactaccaa accaaagggt actatttttg aaacatcgtg tgttcattcc
 agcaaggcag
 5941 aagactgcac cttctttcca gtgacatgct gtgtcatttt ttttaagtcc
 tcttaatttt
 6001 tagacacatt tttggtttat gttttaacaa tgtatgccta accagtcac
 ttgtctgcac
 6061 caatgcaaag gtttctgaga ggagtattct ctatccctgt ggatatgaag
 aactggcat
 6121 ttcatctatt tttcccttcc ctttttaaaag gatttaactt tggaatcttc
 caaaggaagt
 6181 ttggccaatg ccagatcccc aggaatttgg ggggttttct ttcttttcaa
 ctgaaattgt
 6241 atctgattcc tactgttcat gttagtgatc atctaatac agagccaaac
 acttttctcc
 6301 cctgtgtgga aaagtaggta tgctttacaa taaaatctgt cttttctggt
 agaaacctga
 6361 gccactgaaa ataaaagaga caactagaag cacagtagag tcccagactg
 agatctacct
 6421 ttgagaggct ttgaaagtaa tcctgggggt ttggattatt ttcacaaggg
 ttatgcggt
 6481 ttattcaagt ttgttgctcc gttttgcacc tctgcaataa aagcaaaatg
 acaaccagta
 6541 cataaggggt tagcttgaca aagtagactt ccttgtgtta atttttaagt
 ttttttttcc
 6601 ttaactatat ctgtctacag gcagatacag atagttgtat gaaaatctgc
 ttgcctgtaa
 6661 aatttgcatt tataaatgtg ttgccgatgg atcaattggg cctgtacaca
 taccaattag
 6721 cgtgaccact tccatcttaa aaacaaacct aaaaaacaaa atttattata
 tatatatata
 6781 tatatatata aaggactgtg gggtgtatac aaactattgc aaacacttgt
 gcaaactctgt
 6841 cttgatataa aggaaaagca aaatctgtat aacattatta ctacttgaat
 gcctctgtga

```

6901 ctgatttttt tttcatttta aatataaaact tttttgtgaa aagtatgctc
aatgtttttt
6961 ttccctttcc ccattccctt gtaaatacat tttgttctat gtgacttggt
ttggaaatag
7021 ttaactggta ctgtaatttg cattaaataa aaagtaggtt agcctggaaa
tgaaattaaa
7081 aaaaaaaaaa aaaaa
//
LOCUS          NM_002093                      (isoform 1)
AA/translation="MSGRPRTTSFAESCKPVQQPSAFGSMKVS RDKGSKVTTVVATP
GQGPDRPQEVSYTDTKVIGNGSFGVVYQAKLCDSGELVAIKKVLQDKRFKNRELQIMR
KLDHCNIVRLRYFFYSSGEKKDEVYLNVLVDYVPETVYRVARHYSRAKQTLPLVIYVKL
YMYQLFRSLAYIHSFGICHARDIKPQNLLDPDTAVLKLCDFGSAKQLVRGEPNVSYIC
SRYYRAPELIFGATDYTSSIDVWSAGCVLAELLGQPIFPGD SGVDQLVEIIKVLGTP
TREQIREMNPNYTEFKFPQIKAHPWTKDSSGTGHFTSGVRVFRPRTPEAIALCSRLL
EYTP TARLTPLECAHSFFDEL RDPNVKLPNGRDTPALFNFTTQELSSNPPLATILIP
PHARIQAAASTPTNATAASDANTGDRGQTNNNAASASASNST

```

```

cDNA:  1  cgggcttgtg  ccgcgcgcgc  cgcgcgcgc  gcccgggcca  agtgacaaaag
gaaggaagga
      61  agcgaggagg  agccggcccc  gcagcgcgtg  acagggctct  gggctggggc
aaagcgcgga
     121  cacttctga  gcgggcaccg  agcagagccg  aggggcggga  gggcggccga
gctgttgccg
     181  cggacggggg  agggggcccc  gagggacgga  agcgggtgcc  gggttcccat
gtccccggcg
     241  aatggggaac  agtcgaggag  ccgctgcctg  ggggtctgaag  ggagctgcct
ccgccaccgc
     301  catggccgct  ggatccagcc  gccgcctgca  gctgctcctg  gcgcaatgag
gagaggagcc
     361  gccgccaccg  ccaccgcccc  cctctgactg  actcgcgact  ccgcgcacct
ctagttcgcc
     421  gggccccctg  cgtcagcccg  ccgatcccg  cggttgccg  gagctgcagc
gtttcccgtc
     481  gcatctccga  gccaccccc  cctccctct  cctccctcc  taccatccc
cctttctctt
     541  caagcgtgag  actcgtgata  ctccgcgcg  ttccttctt  cattgactcg
gaaaaaaaaat
     601  ccccgaggaa  aatataatat  tcgaagtact  ctttttcaat  caagtatttg
cccccgtttc
     661  acgtgataca  tattttttta  ggatttgccc  tctcttttct  ctctcccag
gaaagggagg
     721  ggaaagaatt  gtatttttct  ccaagtccta  aatcatctat  atgttaaata
tccgtgcgga
     781  tctgtcttga  aggagaaata  tategcttgt  tttgtttttt  atagtataca
aaaggagtga
     841  aaagccaaga  ggacgaagtc  tttttctttt  tcttctgtgg  gagaacttaa
tgctgcattt
     901  atcgттаacc  taacaccccc  acataaagac  aaaaggaaga  aaaggaggaa
ggaaggaaaa
     961  ggtgattcgc  gaagagagtg  atcatgtcag  ggcgcccag  aaccacctcc
tttgcggaga
    1021  gctgcaagcc  ggtgcagcag  ccttcagctt  ttggcagcat  gaaagttagc
agagacaagg
    1081  acggcagcaa  ggtgacaaca  gtggtggcaa  ctctgggca  gggccagac
aggccacaag
    1141  aagtcagcta  tacagacact  aaagtgattg  gaaatggatc  atttggtgtg
gtatatcaag
    1201  ccaaactttg  tgattcagga  gaactggtcg  ccatcaagaa  agtattgcag
gacaagagat
    1261  ttaagaatcg  agagctccag  atcatgagaa  agctagatca  ctgtaacata

```

gtccgattgc
 1321 gttattttctt ctactccagt ggtgagaaga aagatgaggt ctatcttaat
 ctgggtgctgg
 1381 actatgttcc ggaaacagta tacagagttg ccagacacta tagtcgagcc
 aaacagacgc
 1441 tccctgtgat ttatgtcaag ttgtatatgt atcagctgtt ccgaagttaa
 gcctatatcc
 1501 attcctttgg aatctgccat cgggatatta aaccgcagaa cctcttggtg
 gatcctgata
 1561 ctgctgtatt aaaactctgt gactttggaa gtgcaaagca gctgggtccga
 ggagaacca
 1621 atgtttcgta tatctgttct cgggtactata gggcaccaga gttgatcttt
 ggagccactg
 1681 attatacctc tagtatagat gtatggtctg ctggctgtgt gttggctgag
 ctgttactag
 1741 gacaaccaat atttccaggg gatagtgggtg tggatcagtt ggtagaaata
 atcaagggtcc
 1801 tgggaactcc aacaaggagg caaatcagag aatatgaacc aaactacaca
 gaatttaaata
 1861 tccctcaaat taaggcacat ccttggacta aggattcgtc aggaacagga
 catttcacct
 1921 caggagtgcg ggtcttccga ccccgaaact caccggaggc aattgcactg
 tgtagccgtc
 1981 tgctggagta tacaccaact gcccgactaa caccactgga agcttgtgca
 cattcaatttt
 2041 ttgatgaatt acgggaccca aatgtcaaac taccaaatgg gcgagacaca
 cctgcactct
 2101 tcaacttcac cactcaagaa ctgtcaagta atccacctct ggctaccatc
 cttattcctc
 2161 ctcatgctcg gattcaagca gctgcttcaa cccccacaaa tgccacagca
 gcgtcagatg
 2221 ctaatactgg agaccgtgga cagaccaata atgctgcttc tgcacagct
 tccaactcca
 2281 cctgaacagt cccgagcagc cagctgcaca ggaaaaacca ccagttactt
 gagtgtcact
 2341 cagcaacact ggtcacgttt ggaaagaata ttaaaaagag aaaaaaatcc
 tgttcatttt
 2401 agtgttcaat ttttttatta ttattgttgt tcttatttaa ctttgtaaaa
 tatctataaa
 2461 taaaaaccaa tttcattgta ttctcacttt gagggagatc cagggggtgg
 gaggggttgt
 2521 ggggaggggg aaagcggagc actagaacat acaatctctc tcccacgaca
 atcttttttt
 2581 attaaaagtc tgctgttgta tactttaaaa acaggactcc tgccatgc
 cccttcaca
 2641 aaagaagaaa acctttttct gtgctgatgg gtttttttga actttgtttt
 cttttaagat
 2701 ctagtgtgag actttggtat agtgcacagc ttgaaattgg ttgggagctt
 agcagggtata
 2761 actcaacggg gacttaaatg tcacttgtaa aattaatcca tatcttcggg
 tatttataga
 2821 cttgcctttg gcatgttggt ggcagggtgtg gcagacaaag aaatgtgtat
 cattcgtaac
 2881 ccaggagagt caataaagtt tggaactcta caggggaagat tcttagtaga
 tttgttaagg
 2941 ttttgttttg ctctcagtta gtgctagtga tgtagaggct tgtacaggag
 gctgccagag
 3001 gggaagcagc aagcaagact caggcacaca tgctctacag gtggctcttt
 gtttgctga
 3061 ccaaagttct ttgcaaatct tagcacagtt tcaaactagt gacctgggag
 gagatggaag

3121 ggggtgttgag caggetgagc tagctgctga ggtcaaaggc tgatgagccc
 agaggaaggg
 3181 gacaggtcag ggatacatct caccactgtg aataagtttg tccagatttt
 tttctaaagt
 3241 tacttccctt ggaaagatac acttgagagg acattgtagt taaataatgt
 gaactgtaac
 3301 agtcatctac tggtttattt ttcataattt ttaattgaaa attgagcttg
 cagaaatagc
 3361 cacattctac acatagtctt aattttaaat ccaaacttag aatctgtatt
 taatttgttt
 3421 tttaacctca tgctttttac atttatttat tgatgcatgt cagatggtag
 aaatattaaa
 3481 aactacacat cagaatgata cagtcactta tacctgctga ctttatagga
 aagctgatga
 3541 tataaatgtg tgtatatatg ttatatatac atatattcaa tactgccttt
 ttttttgtct
 3601 acagtatcaa aattgactgg ttgaagcatg agaagaatgt ttccccaca
 ccagttaag
 3661 agtttttgtg tctgttttct ttgtgtatca gtgaacgatg ttaagaatca
 gtctctcttt
 3721 ttgaagaaaa agcaatatcc cttggaaagc aaggagaatt gaaggactat
 gtttgccgtg
 3781 aggaaataga ttttcatgac tagtttgttt tatactttta aggttggcat
 ctatgtgggc
 3841 cttatatact ctaaaatgaa ctttagtcac cttggtgctt atgggccatt
 acttgacctt
 3901 tgaatcttta aggcacaatc agttgtactt tacattttaa gatcacttga
 gtgatggccg
 3961 cttttccctc ctaccogctc cttccccaca tgcccttcaa ggtagctgg
 taactgtagg
 4021 gctgcagagc tgagcccatg gttgtgtgta acttgccctc accctcctca
 ttgccacctt
 4081 aggtcacttt atgggtctcg tcctccagag ggttcggaag tggagtctgt
 tggcagccct
 4141 cctgcaggcc ctagcaccct gtccctgctc ttaactgtgt gtgtgactct
 ccaagagagt
 4201 tgtcctgcct gctgaagtga accagtacct agaaagacaa ctgtgagcca
 tcttggtttt
 4261 cactcgctgt ttagctgagg tcttgggcca caaaaggggt ttcacaaacc
 tctggatata
 4321 tcagagttta tgagaaagga aacatgctca gtcaaacca atcaaacaaa
 ttgaatttta
 4381 tgttttataa agtgcttctg aaagctaaga tttgaaagaa gtctgaaatc
 aaagtatttg
 4441 gcagcataac tccttaaagg tagtggcgtt gatagaccat tttcagacag
 aatttataaa
 4501 gaatctgaaa aggcaggtct gtgatagaga aatggacctg cattcagatc
 caactgcca
 4561 gcaagcgttt ggatgcagac actgctctgg acgtgggtata ctccccagag
 tccataaaaa
 4621 tcagtgttta ttttaggaaa caggttgccc cccacaactg gggtaaaaga
 agagagaaaa
 4681 gtcacgcttt tctctcattt cattgtgtgt gcatgtgtgc gtgtgtgtgt
 gtgtgtgtgt
 4741 gtgctgagat gtgtgatttt tctttctcaa ggatcatggg gggatcacag
 aactctttta
 4801 tacaagttag atccaggtct ctgaatatct ttttgatat aataataata
 aaaagctcct
 4861 caccaaattc aagcttgtag attatatttt ctttctgtgt ttttaaattt
 aagttttatt
 4921 gttttgtatg taaatatgtg gaccagga ctgttattaa tgagcaaaaa

gttactgttc
 4981 agggcagtga ttctgtttta taatcagaca aaatgtagac gagcttttta
 aagccatata
 5041 gttttaactc tgtacagtag gtaccggcct gtattattgt aacaataact
 ctagcaatgt
 5101 atagtgtatc tatatagttt ggagtgcctt cgcttccatg tgtttttttt
 ttttaattgt
 5161 tcttttttaa attttaattg gtttccttta tccatgtctc cctgtccacc
 ccctttccct
 5221 ttgaaataat aactcactca taacagtatc tttgcccctt ccacagttaa
 gtttcagtga
 5281 taccatactc aggagtggga agaggaaatc atattcgtaa tttcatttcg
 ttgaagccct
 5341 gcctttgttt tggttctgaa tgtctttcct cctcggtagc agtgagaccg
 gtttcatttc
 5401 atacttagtc cattcagggga cttagtgtag caccagggag ccctagagct
 ggaggatata
 5461 gaatagatta aattttgtct gtctcttcca caagccctaa ccatgggtct
 taaaaacagc
 5521 agattctggg agccttccat gctctctctc tctcctcttt tatctacttc
 cctcccaaat
 5581 gagagagtga cagagaattg tttttttata aatcgaagtt tcttaatagt
 atcaggtttt
 5641 gatacgctcag tgggtctaaaa tgctatagtg caattactag cagttactgc
 acggagtgcc
 5701 accgtgccaa tagaggactg ttgttttaac aagggaactc ttagccatt
 tcctccctcc
 5761 cgccatctct acccttgctc aatgaaatat cattttaatt tcttttaaaa
 aaaatcagtt
 5821 taattcttac tgtgtgcccc acacgaaggc cttttttgaa agaaaaatag
 aatgttttgc
 5881 ctcaaagtag tccatataaa atgtcttgaa tagaagaaaa aactacaaaa
 ccaaaggtta
 5941 ctatttttga aacatcgtgt gttcattcca gcaaggcaga agactgcacc
 ttctttccag
 6001 tgacatgctg tgctattttt ttttaagtcct ctttaatttt agacacattt
 ttggtttatg
 6061 ttttaacaat gtatgcctaa ccagtcactt tgtctgcacc aatgcaaagg
 tttctgagag
 6121 gagtattctc tatccctgtg gatatgaaga cactggcatt tcatctattt
 ttccctttcc
 6181 tttttaaagg atttaacttt ggaatcttcc aaaggaagtt tggccaatgc
 cagatcccca
 6241 ggaatttggtt ggggttttctt tcttttcaac tgaaattgta tctgattcct
 actgttcattg
 6301 ttagtgatca tctaatacaca gagccaaaca cttttctccc ctgtgtggaa
 aagtaggtat
 6361 gctttacaat aaaatctgtc ttttctggta gaaacctgag ccaactgaaaa
 taaaagagac
 6421 aactagaagc acagtagagt cccagactga gatctacctt tgagaggctt
 tgaaagtaat
 6481 ccctgggggtt tggattattt tcacaagggt tatgccgttt tattcaagtt
 tgttgctccg
 6541 ttttgacctc ctgcaataaa agcaaaatga caaccagtac ataaggggtt
 agcttgacaa
 6601 agtagacttc cttgtgttaa tttttaagtt tttttttcct taactatata
 tgtctacagg
 6661 cagatacaga tagttgtatg aaaatctgct tgccgtgaaa atttgcatth
 ataaatgtgt
 6721 tgccgatgga tcaactgggc ctgtacacat accaatttagc gtgaccactt
 ccatcttaaa

```

6781 aacaaaccta aaaaacaaaa tttattatat atatatatat atatataataa
aggactgtgg
6841 gttgtataca aactattgca aacacttggtg caaatctgtc ttgatataaa
ggaaaagcaa
6901 aatctgtata acattattac tacttgaatg cctctgtgac tgattttttt
ttcatttttaa
6961 atataaacctt ttttgtgaaa agtatgctca atgttttttt tccctttccc
cattcccttg
7021 taaatacatt ttgttctatg tgacttggtt tggaaatagt taactggtac
tgtaatttgc
7081 attaaataaa aagtaggtta gcctggaaat gaaattaaaa aaaaaaaaaa aaaa
//

```

10. HDLBP: HDLBP high density lipoprotein binding protein [Homo sapiens]

LOCUS NM_001243900 (isoform b)

```

AA /translation="MHLAERDRWLFVATVMMHFVSIKSGFPGLCVGRSTMSSVAVLT
QESFAEHRSGLVPPQIKVATLNSEESDPPTYKDAFPPLPEKAACLESAQEPAGAWGN
KIRPIKASVITQVFHVPLEERKYKDMNQFGEQAKICLEIMQRTGAHLELSLAKDQG
LSIMVSGKLDVAMKARKDIVARLQTQASATVAIPKEHHRFVIGKNGEKLQDLELKTAT
KIQIPRPDDPSNQIKITGTKEGIEKARHEVLLISAEQDKRAVERLEVEKAFHPFIAGP
YNRLVGEIMQETGTRINIPPPSVNRTEIVFTGEKEQLAQAVARIKKIYEEKANSFTVS
SVAAPSWLHRFIIIGKKGQNLAKITQMPKVHIEFTEGEDKITLEGPTEDVNVAQEQIE
GMVKDLINRMDYVEINIDHKFHRHLIGKSGANINRIKDQYKVSVRIPDSEKSNLIRI
EGDPQGVQQAQKRELLELASRMENERTKDLEIEQRFHRTIIGQKGERIREIRDKFPEVI
INFPDPAQKSDIVQLRGPKNVEVEKCTKYMQKMVADLVENSYSISVPIFKQFHKNIIIGK
GGANIKKIREESNTKIDLPAENSNSSETIIITGKRANCEAARSRLSIQKDLANIAEVE
VSIPAKLHNSLIGTKGRLIRSIMEECGGVHIFPVEGSGSDTVVIRGPSSDVEKAKKQ
LLHLAAEEKQTKSFTVDIRAKPEYHKFLIGKGGKIRKVRDSTGARVIFPAAEDKDQDL
ITIIIGKEDAVREAQKELEALIQNLNDNVEDSMLVDPKHHRHFVIRRGQVLREIAEYEG
GVMVSFPRSGTQSDKVTLKAKDCVEAAKKRIQEIIEDLEAQVTLCAIPQKFHRSVM
GPKGSRIQITRDFSVQIKFPDREENAVHSTEPVVQENGDEAGEGREAKDCDPSPRR
CDIIIIISGRKEKCEAAKEALEALVPVTIEVEVPFDLHRYVIGQKSGIRKMMDEFEVN
IHVPAPQLQSDIIAITGLAANLDRAKAGLLERVKELQAEQEDRALRSFKLSVTVDPKY
HPKIIIGRKGAIVITQIRLEHDVNIQFPDKDDGNQPDQITITGYEKNTEAARDAILRIV
GELEQMVSEDVPLDHRVHARIIGARGKAIRKIMDEFKVDIRFPQSGAPDPNCVTVTGL
PENVEEAIDHILNLEEEYLADVVDSEALQVYMKPPAHEEAKAPSRGFVVRDAPWTASS
SEKAPDMSSSEEFPSFGAQVAPKTLPWGPKR

```

cDNA: 1 ggagcgtccc ggcttctccc ggcggggggg cgagtaagcc agcggcagga
ccagcgggcg

61 ggggcccacg aaaaaagctg gcaggctgac agaggcggcc tcaggacgga
ccttctggct

121 actgaccgtt ttgctgctac cacttataac cacctgggta agtcgagatt
tgagggtggt

181 ttagtttggg gcctggatgc accttcgaga gagagaccgc tggctttttg
tagcaactgt

241 catgatgcat tttgtaagca ttaagagtgg ttttcccgga ttgtgtgtag
gtgtgagatc

301 aaccatgagt tccgttgacg ttttgaccca agagagtttt gctgaacacc
gaagtgggct

361 ggttccgcaa caaatcaaag ttgccactct aaattcagaa gaggagagcg
accctccaac

421 ctacaaggat gccttccttc cacttcctga gaaagctgct tgcttgaaaa
gtgcccagga

481 acccgctgga gcctggggga acaagatccg acccatcaag gcttctgtca
tcactcaggt

541 gttccatgta cccctggagg agagaaaata caaggatatg aaccagtttg
gagaaggtga

601 acaagcaaaa atctgccttg agatcatgca gagaactggt gctcacttgg
agctgtcttt

661 ggccaaagac caaggcctct ccatcatggt gtcaggaaag ctggatgctg
 tcatgaaagc
 721 tcggaaggac attgttgcta gactgcagac tcaggcctca gcaactgttg
 ccattcccaa
 781 agaacaccat cgctttgtta ttggcaaaaa ttgagagaaa ctgcaagact
 tggagctaaa
 841 aactgcaacc aaaatccaga tcccacgccc agatgacccc agcaatcaga
 tcaagatcac
 901 tggcaccaaa gagggcatcg agaaagctcg ccatgaagtc ttactcatct
 ctgccgagca
 961 ggacaaacgt gctgtggaga ggctagaagt agaaaaggca ttccaccctt
 tcatcgctgg
 1021 gccgtataat agactggttg gcgagatcat gcaggagaca ggcacgcgca
 tcaacatccc
 1081 cccaccacgc gtgaaccgga cagagattgt cttcactgga gagaaggaac
 agttggctca
 1141 ggctgtggct cgcataaaga agatttatga ggagaaggcc aatagcttca
 ccgtctcttc
 1201 tgtcgccgcc ccttcctggc ttcaccgttt catcattggc aagaaagggc
 agaacctggc
 1261 caaaatcact cagcagatgc caaagggtca catcgagtgc acagagggcg
 aagacaagat
 1321 caccctggag ggccctacag aggatgtcaa tgtggcccag gaacagatag
 aaggcatggt
 1381 caaagatttg attaacggga tggactatgt ggagatcaac atcgaccaca
 agttccacag
 1441 gcacctcatt gggaagagcg gtgccaacat aaacagaatc aaagaccagt
 acaaggtgtc
 1501 cgtgcgcatc cctcctgaca gtgagaagag caatttgatc cgcacgagg
 gggacccaca
 1561 gggcggtgcag caggccaagc gagagctgct ggagcttgca tctcgcatgg
 aaaatgagcg
 1621 taccaaggat ctaatcattg agcaaagatt tcacgcaca atcattgggc
 agaagggtga
 1681 acggatccgt gaaattcgtg acaaattccc agaggtcac attaaactttc
 cagaccacgc
 1741 acaaaaaagt gacattgtcc agctcagagg acctaagaat gaggtggaaa
 aatgcacaaa
 1801 atacatgcag aagatggtgg cagatctggt ggaaaatagc tattcaattt
 ctgttccgat
 1861 cttcaaacag tttcacaaga atatcattgg gaaaggaggc gcaaacatta
 aaaagattcg
 1921 tgaagaaagc aacacccaaa tcgaccttc agcagagaat agcaattcag
 agaccattat
 1981 catcacaggc aagcgagcca actgcgaagc tgcccgagc aggattctgt
 ctattcagaa
 2041 agacctggcc aacatagccg aggtagaggt ctccatccct gccaaagctgc
 acaactccct
 2101 cattggcacc aagggcgctc tgatccgctc catcatggag gagtgcggcg
 ggtccacat
 2161 tcactttccc gtggaagggt caggaagcga caccgttggt atcaggggcc
 cttcctcgga
 2221 tgtggagaag gccaaagaagc agctcctgca tctggcgag gagaagcaaa
 ccaagagttt
 2281 cactgttgac atccgcgcca agccagaata ccacaaattc ctcatcgga
 agggggggcg
 2341 caaaattcgc aagggtgcgc acagcactgg agcacgtgtc atcttccctg
 cggtgagga
 2401 caaggaccag gacctgatca ccatcattgg aaaggaggac gccgtccgag
 aggcacagaa
 2461 ggagctggag gccttgatcc aaaacctgga taatgtggtg gaagactcca

tgctggtgga
 2521 cccaagcac caccgccact tcgtcatccg cagaggccag gtcttgcggg
 agattgctga
 2581 agagtatggc ggggtgatgg tcagcttccc acgctctggc acacagagcg
 acaaagtcac
 2641 cctcaagggc gccaaggact gtgtggaggc agccaagaaa cgcattcagg
 agatcattga
 2701 ggacctggaa gctcaggatga cattagaatg tgctataccc cagaaattcc
 atcgatctgt
 2761 catgggcccc aaagggttcca gaatccagca gattactcgg gatttcagtg
 ttcaaattaa
 2821 attcccagac agagaggaga acgcagttca cagtacagag ccagttgtcc
 aggagaatgg
 2881 ggacgaagct ggggagggga gagaggctaa agattgtgac cccggctctc
 caaggagggtg
 2941 tgacatcatc atcatctctg gccggaaaga aaagtgtgag gctgccaagg
 aagctctgga
 3001 ggcattggtt cctgtcacca ttgaagtaga ggtgcccttt gaccttcacc
 gttacgttat
 3061 tgggcagaaa ggaagtggga tccgcaagat gatggatgag tttgagggtga
 acatacatgt
 3121 cccggcacct gagctgcagt ctgacatcat cgccatcacg ggctcgtctg
 caaatttga
 3181 cccggccaag gctggactgc tggagcgtgt gaaggagcta caggccgagc
 aggaggaccg
 3241 ggctttaagg agttttaagc tgagtgtcac tgtagacccc aaataccatc
 ccaagattat
 3301 cgggagaaa ggggcagtaa ttacccaaat ccggttggag catgacgtga
 acatccagtt
 3361 tcctgataag gacgatggga accagcccca ggaccaaatt accatcacag
 ggtacgaaaa
 3421 gaacacagaa gctgccaggg atgctatact gagaattgtg ggtgaacttg
 agcagatggt
 3481 ttctgaggac gtcccgtctg accaccgctg tcacgcccgc atcattggtg
 cccgcggcaa
 3541 agccattcgc aaaatcatgg acgaattcaa ggtggacatt cgcttcccac
 agagcggagc
 3601 cccagacccc aactgcgtca ctgtgacggg gctcccagag aatgtggagg
 aagccatcga
 3661 ccacatctc aatctggagg aggaatacct agctgacgtg gtggacagtg
 aggcgtctga
 3721 ggtatacatg aaacccccag cacacgaaga ggccaaggca ccttcagag
 gctttgtggt
 3781 gcgggacgca ccctggaccg ccagcagcag tgagaaggct cctgacatga
 gcagctctga
 3841 ggaatttccc agctttgggg ctgaggtggc tcccagacc ctcccttggg
 gccccaaacg
 3901 ataatgatca aaaagaacag aaccctctcc agcctgctga cccaaacca
 accacacaat
 3961 ggtttgtctc aatctgacct agcggctgga ccctccgtaa attgttgacg
 ctcttcccc
 4021 ttcccagagt cccgcaggga gcctagcgcc tggtgtgtg tgcgccgct
 cctccaggcc
 4081 tggcctgccc cgctcaggac ctgctccact gtttaacact aaaccaaggt
 catgagcatt
 4141 cgtgctaaga taacagactc cagctcctgg tccacccggc atgtcagtca
 gcaactctggc
 4201 cttcatcacg agagctccgc agcgtggct aggatccac ttctgtgtc
 atgacctcag
 4261 gaaataaacg tccttgactt tataaaagcc aaacgtttgc cctcttcctt
 tcccacctcc

4321 ctectgccag tttcccttgg tccagacagt cctgtttgtg gagtgcaatc
 agcctcctcc
 4381 agctgccaga gcgcctcage acaggtgtca ggggtgcaagg aagacctggc
 aatggacagc
 4441 aggaggcagg ttcttgagagc tgggggggtga cctgagaggc agaggggtgac
 gggttctcag
 4501 gcagtcctga ttttacctgc cgtgggggtct gaaagcacca aggggtccctg
 cccctacctc
 4561 cactgccaga ccctcagcct gaggtctggt gagtggagcc tggaggcaag
 gtggtaggca
 4621 ccatctgggt cccctgtggc cgtcacagtg tctgctgtga ttgagatgcg
 cacaggttgg
 4681 gggaggtagg gccttacgct tgtcctcagt gggggcagtt tgccttagat
 gacagctggg
 4741 ctctttctca caccacctgc agccctccc tgccctgcc ctagctgctg
 tgtgttcagt
 4801 tgccttcttt ctacctcage cggcgtggag tggctctctgt gcagttagtg
 ccacccca
 4861 caccgctctc ttgattgaga tgtttctggt ggttatgggt ttcccggtga
 gctgggggtg
 4921 ggcgcctgt acctaagctg gaggtggcg ctctccctca gcacaggtgg
 gtcagtggcc
 4981 agcaggccca tctggagtgg gagtgggcac ttccaccccg cccacaggcc
 atccggtgt
 5041 gcaggccagc ccctaggagc aggtcccggt tgactggcag tttcacggt
 ctagggccga
 5101 gacgatggca tggggcctag agcatgaggt agagcagaat gcagaccagc
 ccgctggatg
 5161 ccgagagacc ctgctctccg agggaggcat ctgtgtcatg ctgtgagggc
 tgaggacggg
 5221 gccctagtct ctggttttct ggtcttaaca tccttatctg tgtccgccac
 ggaggtgact
 5281 gagctgctag cgagttgtcc tgtcccaggt acttgagttt tggaaaagct
 gactcacgcc
 5341 catccatctc acagcccttc cctggggaca gtgccttcg ccttgacacc
 tcactctcag
 5401 ttgaataact caagcttgggt catcttcaga ctgaattct tgagtagacc
 cagacggctt
 5461 agcccaagtc tagttgcage tgccctggca agtccccatt tgctcaggca
 gccctgaatg
 5521 ggcctgttta caggaatggt aaattgggat tggaaggaat atagcttcca
 gcttcataagg
 5581 ctagggtgac cacggcttag gaaacaggga aagaaagcaa ggcccttttc
 ctgcctttcc
 5641 cgggatctgt ctactccacc tccacggggg aggccagtgg ggaagggtg
 tcacctcttc
 5701 cccatctgca tgagttctgg aactctgtcc tgttggctgc ttgcttccag
 ctcccccaa
 5761 tctccatcgc agcgggttcc tctgtcttt tctacagtgt cataaaacat
 cctgccccta
 5821 cctctccca aaggtcaatt ttaattctca ccaagttttg cacatctctg
 tatgtcgtt
 5881 gatgtcttag acgcgagccc tttcctaaac tgttcagcgc tctcttttcc
 tttgggtggt
 5941 tgttgcaagg gtgatgacat gactgtcccc aggcctgtct ccctgaagcg
 tctgtgctgt
 6001 caggacagcc ctgggcagag atgaggcagg ggtgaggcgt gcgtgtgctt
 ttctccttg
 6061 ttggatgtct tccatatcat ctgtttccat agctacaatc catcccttgg
 ccttaacttt
 6121 ggaatttgga gattatatgc aaacatgtgt aaaggctcat gaatatggat

gacactggaa
 6181 ttttataaat tctaaaataa aacccgaaac cagatgtagc atgctggggac
 tcatttttgaa
 6241 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa a
 //

LOCUS NM_005336 (isoform a)
 AA /translation="MSSVAVLTQESFAEHRSGLVPPQQIKVATLNSEESDPPTYKDAF
 PPLPEKAACLESAQEPAGAWGNKIRPIKASVITQVFHVPLEERKYKDMNQFGEQEQA
 ICLEIMQRTGAHLELSLAKDQGLSIMVSGKLDVAMKARKDIVARLQTQASATVAIPKE
 HHRFVIGKNGEKLQDLELKTATKIQIPRPDDPSNQIKITGTKEGIEKARHEVLLISAE
 QDKRAVERLEVEKAFHPFIAGPYNRLVGEIMQETGTRINIPPSVNRTEIVFTGEKEQ
 LAQAVARIKKIYEEKKKKTTTIAVEVKKSQHKYVIGPKGNSLQEILERTGVSVEIPPS
 DSISETVILRGEPEKLGQALTEVYAKANSFTVSSVAAPSWLHRFIIGKKGQNLAKITQ
 QMPKVHIEFTGEDKITLEGPTEDVNVAQEQIEGMVKDLINRMDYVEINIDHKFHRHL
 IGKSGANINRIKDQYKVSVRIPPDSEKSNLIRIEGDPQGVQQAQKRELLELASRMENER
 TKDLIIIEQRFHRTIIGQKGERIREIRDKFPEVIINFPDPAQKSDIVQLRGPKNEVEKC
 TKYMQKMDVADLVENSYSISVPIFKQFHKNIIIGKGGANIKKIREESNTKIDLPANSENS
 ETIIITGKRANCEAARSRLSIQKDLANIAEVEVSIPAKLHNSLIGTKGRLIRSIMEE
 CGGVHIIHFPVEGSGSDTVVIRGPSSDVEKAKKQLLHLAEEKQTKSFTVDIRAKPEYHK
 FLIGKGGGKIRKVRDSTGARVIFPAEDKDQDLITIIGKEDAVREAQKELEALIQNLD
 NVVEDSMLVDPKHHRHFVIRRGQVLRERIAEEYGGVMVSFPRSGTQSDKVTLKGAKDCV
 EAAKKRIQEIIEDLEAQVTLECAIPQKFHRSVMGPKGSRIQQITRDFSVQIKFPDREE
 NAVHSTEPVVQENGDEAGEGREAKDCDPSPRCDIIISGRKEKCEAAKEALEALVP
 VTIEVEVPFDLHRVYIGQKSGGIRKMMDEFEVNIHVPAPQLQSDIIAITGLAANLDRA
 KAGLLERVKELQAEQEDRALRSFKLSVTVDPKYHPKIIIGRKGAVITQIRLEHDVNIQF
 PDKDDGNQPDQITITGYEKNTEAARDAILRIVGELEQMVEDVPLDHRVHARIIGAR
 GKAIKIMDEFKVDIRFPQSGAPDPNCVTVTGLPENVEEAIDHILNLEEEYLADVDS
 EALQVYMKPPAHEEAKAPSRGFVVRDAPWTASSSEKAPDMSSEEFPSFGAQVAPKTL
 PWGPKR

cDNA: 1 atagaggctg ggggtggggg gggaggtcaa gcgtagcctc ttctccttta
 ccaagatggc
 61 ggcttgctcc tgtttcgcca cagttcctac cttatgagct cggttttctt
 atgcttataa
 121 gagtgggaaca gcaaaagctg gcaggctgac agaggcgggc tcaggacgga
 ccttctggct
 181 actgaccgtt ttgctgtggt tttcccgat tgtgtgtagg tgtgagatca
 accatgagtt
 241 ccgttgccagt tttgacccaa gagagttttg ctgaacaccg aagtgggctg
 gttccgcaac
 301 aaatcaaagt tgccactcta aattcagaag aggagagcga ccctccaacc
 tacaaggatg
 361 ccttcctcc acttcctgag aaagctgctt gcctggaaag tgcccaggaa
 cccgctggag
 421 cctgggggaa caagatccga cccatcaagg cttctgtcat cactcagggtg
 ttccatgtac
 481 ccctggagga gagaaaatac aaggatatga accagtttgg agaaggtgaa
 caagcaaaaa
 541 tctgccttga gatcatgcag agaactggtg ctcacttgga gctgtctttg
 gccaaagacc
 601 aaggcctctc catcatggtg tcaggaaagc tggatgctgt catgaaagct
 cggaaggaca
 661 ttgttgctag actgcagact caggcctcag caactgttgc cattcccaaa
 gaacaccatc
 721 gctttgttat tggcaaaaat ggagagaaac tgcaagactt ggagctaaaa
 actgcaacca
 781 aaatccagat cccacgcccc gatgaccca gcaatcagat caagatcact
 ggcaccaaag
 841 agggcatcga gaaagctcg catgaagtct tactcatctc tgccgagcag
 gacaaacgtg

901 ctgtggagag gctagaagta gaaaaggcat tccacccctt catcgctggg
 ccgtataata
 961 gactgggttg cgagatcatg caggagacag gcacgcgcac caacatcccc
 ccaccagcg
 1021 tgaaccggac agagattgtc ttcactggag agaaggaaca gttggctcag
 gctgtggctc
 1081 gcatcaagaa gatttatgag gagaagaaaa agaagactac aaccattgca
 gtggaagtga
 1141 agaaatccca acacaagtat gtcattgggc ccaagggcaa ttcattgcag
 gagatccttg
 1201 agagaactgg agtttccgtt gagatccac cctcagacag catctctgag
 actgtaatac
 1261 ttcgaggcga acctgaaaag ttaggtcagg cggtgactga agtctatgcc
 aaggccaata
 1321 gcttcaccgt ctccctctgt gccgcccctt cctggcttca ccgtttcatc
 attggcaaga
 1381 aagggcagaa cctggccaaa atcactcagc agatgccaaa gggtcacatc
 gagttcacag
 1441 agggcgaaga caagatcacc ctggagggcc ctacagagga tgtcaatgtg
 gccaggaac
 1501 agatagaagg catggtcaaa gatttgatta accggatgga ctatgtggag
 atcaacatcg
 1561 accacaagtt ccacaggcac ctcatggga agagcgggtgc caacataaac
 agaatcaaag
 1621 accagtacaa ggtgtccgtg cgcacccctc ctgacagtga gaagagcaat
 ttgatccgca
 1681 tcgaggggga cccacagggc gtgcagcagg ccaagcgaga gctgctggag
 cttgcatctc
 1741 gcatggaaaa tgagcgtacc aaggatctaa tcattgagca aagatttcat
 cgcacaatca
 1801 ttgggcagaa ggggtgaacgg atccgtgaaa ttcgtgacaa attcccagag
 gtcatcatta
 1861 actttccaga cccagcacia aaaagtgaca ttgtccagct cagaggacct
 aagaatgagg
 1921 tggaaaaatg cacaaaatac atgcagaaga tgggtggcaga tctggtggaa
 aatagctatt
 1981 caatttctgt tccgatcttc aaacagtttc acaagaatat cattgggaaa
 ggaggcgcaa
 2041 acattaaaaa gattcgtgaa gaaagcaaca ccaaatcga cctccagca
 gagaatagca
 2101 attcagagac cattatcatc acaggcaagc gagccaactg cgaagctgcc
 cggagcagga
 2161 ttctgtctat tcagaaagac ctggccaaca tagccgaggt agaggtctcc
 atccctgcca
 2221 agctgcacia ctccctcatt ggcaccaagg gccgtctgat ccgtccatc
 atggaggagt
 2281 gcggcggggt ccacattcac tttcccgtag aaggttcagg aagcgacacc
 gttgttatca
 2341 ggggcccttc ctcgatgtg gagaaggcca agaagcagct cctgcatctg
 gcggaggaga
 2401 agcaaaccac gagtttctact gttgacatcc gcgccaagcc agaataccac
 aaattcctca
 2461 tcggcaaggg gggcggaaca attcgcaagg tcgcgacag cactggagca
 cgtgtcatct
 2521 tcctgcggc tgaggacaag gaccaggacc tgatcaccat cattggaaag
 gaggacgcg
 2581 tccgagaggc acagaaggag ctggaggcct tgatccaaaa cctggataat
 gtggtggaag
 2641 actccatgct ggtggacccc aagcaccacc gccacttcgt catccgcaga
 ggccaggtct
 2701 tgccggagat tgctgaagag tatggcgggg tgatggtcag cttcccacgc

tctggcacac
 2761 agagcgacaa agtcaccctc aaggcgcca aggactgtgt ggaggcagcc
 aagaaacgca
 2821 ttcaggagat cattgaggac ctggaagctc aggtgacatt agaattgtgt
 ataccccaga
 2881 aattccatcg atctgtcatg ggccccaaag gttccagaat ccagcagatt
 actcgggatt
 2941 tcagtgttca aattaaattc ccagacagag aggagaacgc agttcacagt
 acagagccag
 3001 ttgtccagga gaatggggac gaagctgggg aggggagaga ggctaaagat
 tgtgacccc
 3061 gctctccaag gaggtgtgac atcatcatca tctctggccg gaaagaaaag
 tgtgaggctg
 3121 ccaaggaagc tctggaggca ttggttcctg tcaccattga agtagaggtg
 ccctttgacc
 3181 ttcaccgtta cgttattggg cagaaaggaa gtgggatccg caagatgatg
 gatgagtttg
 3241 aggtgaacat acatgtcccg gcacctgagc tgcagtctga catcatcgcc
 atcacgggcc
 3301 tcgctgcaaa tttggaccgg gccaaaggctg gactgctgga gcgtgtgaag
 gagctacagg
 3361 ccgagcagga ggaccgggct ttaaggagtt ttaagctgag tgtcactgta
 gaccccaaat
 3421 accatcccaa gattatcggg agaaaggggg cagtaattac ccaaaccggg
 ttggagcatg
 3481 acgtgaacat ccagtttctt gataaggacg atgggaacca gcccaggac
 caaattacca
 3541 tcacagggtg cgaaaagaac acagaagctg ccagggatgc tatactgaga
 attgtgggtg
 3601 aacttgagca gatggtttct gaggacgtcc cgctggacca ccgcgttcac
 gcccgcatca
 3661 ttggtgcccg cggcaaagcc attcgcaaaa tcatggacga attcaagggtg
 gacattcgt
 3721 tcccacagag cggagcccca gaccccaact gcgtcactgt gacggggctc
 ccagagaatg
 3781 tggaggaagc catcgaccac atcctcaatc tggaggagga atacctagct
 gacgtggtgg
 3841 acagtgaggc gctgcaggta tacatgaaac cccagcaca cgaagaggcc
 aaggcacctt
 3901 ccagaggctt tgtggtgagg gacgcacctt ggaccgccag cagcagtgag
 aaggctcctg
 3961 acatgagcag ctctgaggaa tttcccagct ttggggctca ggtggctccc
 aagaccctcc
 4021 cttggggccc caaacgataa tgatcaaaaa gaacagaacc ctctccagcc
 tgctgaccca
 4081 aacccaacca cacaatgggtt tgtctcaatc tgaccacagc gctggaccct
 ccgtaaattg
 4141 ttgacgctct tcccccttcc cgaggctccg caggagacct agcgctggc
 tgtgtgtgag
 4201 gccgtcctc caggcctggc cgtgcccgtc caggacctgc tccactgttt
 aacactaaac
 4261 caaggatcat agcattcgtg ctaagataac agactccagc tctgtgtcca
 cccggcatgt
 4321 cagtcagcac tctggccttc atcacgagag ctccgcagcc gtggctagga
 ttccacttcc
 4381 tgtgtcatga cctcaggaaa taaacgtcct tgactttata aaagccaaac
 gtttgccctc
 4441 ttcccttccc acctccctcc tgccagtctt ccttgggtcca gacagtcctg
 tttgtggagt
 4501 gcaatcagcc tctccagct gccagagcgc ctcagcacag gtgtcagggt
 gcaaggaaga

4561 cctggcaatg gacagcagga ggcaggttcc tggagctggg gggtagcctg
 agaggcagag
 4621 ggtgacgggt tctcaggcag tcttgatttt acctgccgtg gggctctgaaa
 gcaccaaggg
 4681 tccctgcccc tacctccact gccagaccct cagcctgagg tctggtgagt
 ggagcctgga
 4741 ggcaagggtg taggcaccat ctgggtcccc tgtggccgtc acagtgtctg
 ctgtgattga
 4801 gatgcgcaca ggttggggga ggtagggcct tacgcttgtc ctcagtgggg
 gcagtttgcc
 4861 ttagatgaca gctgggctct tcttcacacc acctgcagcc cctccctgcc
 cctgccctag
 4921 ctgctgtgtg ttcagttgcc ttctttctac ctcagccggc gtggagtggg
 ctctgtgcag
 4981 ttagtgccac cccacacacc cgtctcttga ttgagatgtt tctggtgggt
 atgggtttcc
 5041 cgtggagctg ggggtgggag cctgttacct aagctggagg ctggcgctct
 ccctcagcac
 5101 aggtgggtca gtggccagca ggcccatctg gagtgggagt gggcacttcc
 accccgcca
 5161 caggccatcc ggctgtgcag gccagcccct aggagcaggt cccgggtgac
 tggcagtttt
 5221 cagggtctag ggccgagacg atggcatggg gcctagagca tgaggtagag
 cagaatgcag
 5281 accacgccg tggatgccga gagaccctgc tctccgaggg aggcactctgt
 gtcactgtgt
 5341 gagggctgag gacggggccc tagtctctgg tttcttggtc ttaacatcct
 tatctgtgtc
 5401 cgccacggag gtgactgagc tgctagcgag ttgtcctgtc ccaggtactt
 gagttttgga
 5461 aaagctgact cagcggccatc catctcacag cccttccctg gggacagtgc
 cttccgcctt
 5521 gacacctcac tctcagttga ataactcaag cttgggtcatc ttcagactcg
 aattcttgag
 5581 tagaccaga cggcttagcc caagtctagt tgcagctgcc tcggcaagtc
 cccatttgct
 5641 caggcagccc tgaatgggccc tgtttacagg aatggtaaat tgggattgga
 aggaatatag
 5701 cttccagctt cataggctag ggtgaccacg gcttaggaaa cagggaaga
 aagcaaggcc
 5761 cttttcctgc ctttccggg atctgtctac tccacctcca cgggggaggc
 cagtgggaa
 5821 gggctgtcac ctcttcccca tctgcatgag ttctggaact ctgtcctgtt
 ggctgcttgc
 5881 ttccagctcc ccccaatctc catcgcagcg ggttccctct gtcttttcta
 cagtgtcata
 5941 aaacatcctg ccctaccct ctcccaaagg tcaattttta ttctaccaa
 gttttgcaca
 6001 tctctgtatg tcgcttgatg tcttagacgc gagcccttct ctaaactgtt
 cagcgtctc
 6061 ttttcctttg ggtggttgtt gcaaggggtg tgacatgact gtccccaggc
 ctgtctccct
 6121 gaagcgtctg tgctgtcagg acagccctgg gcagagatga ggcaggggtg
 aggcgtgcgt
 6181 gtgcttttcc tcttggttg atgtcttcca tatcatctgt ttccatagct
 acaatccatc
 6241 ccttggcctt aactttggaa tttggagatt atatgcaaac atgtgtaaag
 gctcatgaat
 6301 atggatgaca ctggaatttt ataaattcta aaataaaacc cgaaaccaga
 ttagcatgc
 6361 tgggactcat tttgaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa

aaaaaaaaa
6421 aaaaaaa
//

LOCUS NM_203346 (isoform a, transcript
variant 2)
AA /translation="MSSVAVLTQESFAEHRSGLVPPQQIKVATLNSEESDPPTYKDAF
PPLPEKAACLES AQEPAGAWGNKIRPIKASVITQVFHVPLEERKYKDMNQFGEGEQAK
ICLEIMQRTGAHLELSLAKDQGLSIMVSGKLDV MKARKDIVARLQTQASATVAIPKE
HHRFVIGKNGEKLQDLELKTATKIQIPRPDDPSNQIKITGTKEGIEKARHEVLLISAE
QDKRAVERLEVEKAFHPFIAGPYNRLVGEIMQETGTRINIPPPSVNRTEIVFTGEKEQ
LAQAVARIKKIYEEKKKKTTTIAVEVKKSQHKYVIGPKGNSLQEILERTGVSVEIPPS
DSISETVILRGEPEKLQALTEVYAKANSFTVSSVAAPSWLHRFIIGKKGQNLAKITQ
QMPKVHIEFTEGEDKITLEGPTEDVNVAQE QIEGMVKDLINRMDYVEINIDHKFHRHL
IGKSGANINRIKDQYKVSVRIPDSEKSNLIRIEGDPQGVQQAKRELLELASRMENER
TKDLIIIEQRFHRTIIGQKGERIREIRDKFPEVIINFPDPAQKSDIVQLRGPKNEVEKC
TKYMQKMDVADLVENSYSISVPIFKQFHKNIIGKGGANIKKIREESNTKIDLPAENSNS
ETIIITGKRANCEAARSRLSIQKDLANIAEVEVSIPAKLHNSLIGTKGRLIRSIMEE
CGGVHIIHFPVEGSGSDTVVIRGPSSDVEKAKKQLLHLAEKQTKSFTVDIRAKPEYHK
FLIGKGGGKIRKVRDSTGARVIFPAAEDKDQDLITIIGKEDAVREAQKEALEALIQNLD
NVVEDSMLVDPKHHRHFVIRRGQVLR EIAEEYGGVMVSFPRSGTQSDKVT LKGAKDCV
EAAKKRIQEIIEDLEAQVTLECAIPQKFHRSVMGPKGSRIQQITRDFSVQIKFPDREE
NAVHSTEPVQENGDEAGEGREAKDCDGPSPRRCDIIISGRKEKCEAAKEALEALVP
VTIEVEVPFDLHRYVIGQKSGGIRKMMDEFEVNIHVPAPELQSDIIAITGLAANLDRA
KAGLLERVKELQAEQEDRALRSFKLSVTVDPKYHPKIIIGRKGAVITQIRLEHDVNIQF
PDKDDGNQPQDQITITGYEKNTEAARDAILRIVGELEQMVSEDVPLDHRVHARIIGAR
GKAIRKIMDEFKVDIRFPQSGAPDPNCVTVTGLPENVEEAIDHILNLEEEYLADVDS
EALQVYMKPPAHEEAKAPSRGFVVRDAPWTASSEKAPDMSSEEFPSFGAQVAPKTL
PWGPKR

cDNA: 1 ggagcgtccc ggcttctccc ggcggggggg cgagtaagcc agcggcagga
ccagcgggcg
61 ggggcccacg acaaaagctg gcaggctgac agaggcggcc tcaggacgga
ccttctgget
121 actgaccgtt ttgctgtggt tttcccgat tgtgtgtagg tgtgagatca
accatgagtt
181 ccgttgacgt tttgacccaa gagagttttg ctgaacaccg aagtgggctg
gttccgcaac
241 aaatcaaagt tgccactcta aattcagaag aggagagcga ccctccaacc
tacaaggatg
301 ccttcctcc acttcctgag aaagetgctt gcctggaaag tgcccaggaa
cccgttgag
361 cctgggggaa caagatccga cccatcaagg cttctgtcat cactcaggtg
ttccatgtac
421 ccctggagga gaaaaatac aaggatatga accagtttg agaagtgaa
caagcaaaaa
481 tctgccttga gatcatgcag agaactggtg ctcaacttga gctgtctttg
gccaaagacc
541 aaggcctctc catcatggtg tcaggaaagc tggatgctgt catgaaagct
cggaaggaca
601 ttgttgctag actgcagact caggcctcag caactgttgc cattcccaaa
gaacaccatc
661 gctttgttat tggcaaaaat ggagagaaac tgcaagactt ggagctaaaa
actgcaacca
721 aaatccagat ccacgcccc gatgaccca gcaatcagat caagatcact
ggcaccaaaag
781 agggcatcga gaaagctcg catgaagtct tactcatctc tgccgagcag
gacaaacgtg
841 ctgtggagag gctagaagta gaaaaggcat tccaccctt catcgctggg
ccgtataata
901 gactggttgg cgagatcatg caggagacag gcacgcgat caacatcccc

ccaccacg
 961 tgaaccggac agagattgtc ttactggag agaaggaaca gttggctcag
 gctgtggtc
 1021 gcatcaagaa gatttatgag gagaagaaaa agaagactac aaccattgca
 gtggaagtga
 1081 agaaatccca acacaagtat gtcattgggc ccaagggcaa ttcattgcag
 gagatccttg
 1141 agagaactgg agtttccgtt gagatccac cctcagacag catctctgag
 actgtaatac
 1201 ttcgaggcga acctgaaaag ttaggtcagg cggtgactga agtctatgcc
 aaggccaata
 1261 gcttcacgt ctctctgtc gccgcccctt cctggettca ccgtttcatc
 attggcaaga
 1321 aagggcagaa cctggccaaa atcactcagc agatgccaaa ggttcacatc
 gagttcacag
 1381 agggcgaaga caagatcacc ctggagggcc ctacagagga tgtcaatgtg
 gccaggaac
 1441 agatagaagg catggtcaaa gatttgatta accggatgga ctatgtggag
 atcaacatcg
 1501 accacaagtt ccacaggcac ctcatggga agagcgggtgc caacataaac
 agaatacaag
 1561 accagtacaa ggtgtccgtg cgcacccctc ctgacagtga gaagagcaat
 ttgatccga
 1621 tcgaggggga cccacagggc gtgcagcagg ccaagcgaga gctgctggag
 cttgcatctc
 1681 gcatggaaaa tgagcgtacc aaggatctaa tcattgagca aagatttcat
 cgcacaatca
 1741 ttgggcagaa ggggtgaacgg atccgtgaaa ttcgtgacaa attcccagag
 gtcattatta
 1801 actttccaga cccagcacia aaaagtgaca ttgtccagct cagaggacct
 aagaatgagg
 1861 tggaaaaatg cacaaaatac atgcagaaga tgggtggcaga tctggtggaa
 aatagctatt
 1921 caatttctgt tccgatcttc aaacagtttc acaagaatat cattgggaaa
 ggaggcgcaa
 1981 acattaaaaa gattcgtgaa gaaagcaaca ccaaaatcga cctccagca
 gagaatagca
 2041 attcagagac cattatcatc acaggcaagc gagccaactg cgaagctgcc
 cggagcagga
 2101 ttctgtctat tcagaaagac ctggccaaca tagccgaggt agaggtctcc
 atccctgcca
 2161 agctgcacia ctccctcatt ggcaccaagg gccgtctgat ccgctccatc
 atggaggagt
 2221 gcggcggggc ccacattcac tttcccggtg aagggttcagg aagcgacacc
 gttgttatca
 2281 ggggcccttc ctcgatgtg gagaaggcca agaagcagct cctgcatctg
 gcggaggaga
 2341 agcaaaccac gagtttctact gttgacatcc gcgccaagcc agaataccac
 aaattcctca
 2401 tcggcaaggg gggcgccaaa attcgcaagg tgcgcgacag cactggagca
 cgtgtcatct
 2461 tccctgcggc tgaggacaag gaccaggacc tgatcaccat cattggaaag
 gaggacgcg
 2521 tccgagaggc acagaaggag ctggaggcct tgatccaaaa cctggataat
 gtggtggaag
 2581 actccatgct ggtggacccc aagcaccacc gccacttcgt catccgcaga
 ggccaggctc
 2641 tgcgggagat tctgaagag tatggcgggg tgatggtcag cttcccacgc
 tctggcacac
 2701 agagcgacaa agtcacccctc aaggcgcca aggactgtgt ggaggcagcc
 aagaaacgca

2761 ttcaggagat cattgaggac ctggaagctc aggtgacatt agaattgtgct
 ataccccaga
 2821 aattccatcg atctgtcatg ggccccaaag gttccagaat ccagcagatt
 actcgggatt
 2881 tcagtgttca aattaaattc ccagacagag aggagaacgc agttcacagt
 acagagccag
 2941 ttgtccagga gaatggggac gaagctgggg aggggagaga ggctaaagat
 tgtgaccccg
 3001 gctctccaag gaggtgtgac atcatcatca tctctggccg gaaagaaaag
 tgtgaggctg
 3061 ccaaggaagc tctggaggca ttggttcctg tcaccattga agtagagggtg
 ccctttgacc
 3121 ttcaccgtta cgttattggg cagaaaggaa gtgggatccg caagatgatg
 gatgagtttg
 3181 aggtgaacat acatgtcccg gcacctgagc tgcagtctga catcatcgcc
 atcacgggac
 3241 tcgctgcaaa tttggaccgg gccaaaggctg gactgctgga gcgtgtgaag
 gagctacagg
 3301 ccgagcagga ggaccgggct ttaaggagtt ttaagctgag tgtcactgta
 gaccccaaat
 3361 accatcccaa gattatcggg agaaaggggg cagtaattac ccaaatccgg
 ttggagcatg
 3421 acgtgaacat ccagtttctt gataaggacg atgggaacca gcccaggac
 caaattacca
 3481 tcacagggtg cgaaaagaac acagaagctg ccagggatgc tatactgaga
 attgtgggtg
 3541 aacttgagca gatggtttct gaggacgtcc cgctggacca ccgcgttcac
 gcccgcatca
 3601 ttggtgcccg cggcaaagcc attcgcaaaa tcatggacga attcaagggtg
 gacattcgct
 3661 tcccacagag cggagcccca gaccccaact gcgtcactgt gacggggctc
 ccagagaatg
 3721 tggaggaagc catcgaccac atcctcaatc tggaggagga atacctagct
 gacgtggtgg
 3781 acagtgaggc gctgcaggta tacatgaaac ccccagcaca cgaagaggcc
 aaggcacctt
 3841 ccagaggctt tgtggtgctg gacgcaccct ggaccgccag cagcagttag
 aaggctcctg
 3901 acatgagcag ctctgaggaa tttcccagct ttggggctca ggtggctccc
 aagaccctcc
 3961 cttggggccc caaacgataa tgatcaaaaa gaacagaacc ctctccagcc
 tgctgacca
 4021 aacccaacca cacaatgggtt tgtctcaatc tgaccagcg gctggaccct
 ccgtaaattg
 4081 ttgacgtctt tcccccttc cgaggtcccg caggagacct agcgctggc
 tgtgtgtgctg
 4141 gccgctctc caggcctggc cgtgcccgt caggacctgc tccactgttt
 aacactaaac
 4201 caaggtcatg agcattcgtg ctaagataac agactccagc tcttggtcca
 cccggcatgt
 4261 cagtcagcac tctggccttc atcacgagag ctccgcagcc gtggctagga
 ttccacttcc
 4321 tgtgtcatga cctcaggaaa taaacgtcct tgactttata aaagccaaac
 gtttgccctc
 4381 ttcttttccc acctccctcc tgccagtttc ccttggtcca gacagtctg
 tttgtggagt
 4441 gcaatcagcc tctccagct gccagagcgc ctcagcacag gtgtcagggt
 gcaaggaaga
 4501 cctggcaatg gacagcagga ggcaggttcc tggagctggg gggtagcctg
 agaggcagag
 4561 ggtgacgggt tctcaggcag tctgattttt acctgccgtg gggctgaaa

gcaccaaggg
 4621 tccctgcccc tacctccact gccagaccct cagcctgagg tctggtgagt
 ggagcctgga
 4681 ggcaaggtgg taggcaccat ctgggtcccc tgtggccgtc acagtgtctg
 ctgtgattga
 4741 gatgcgcaca ggttggggga ggtagggcct tacgcttgtc ctcaagtggg
 gcagtttgcc
 4801 ttagatgaca gctgggctct tcttcacacc acctgcagcc cctccctgcc
 cctgccctag
 4861 ctgctgtgtg ttcagttgcc ttctttctac ctcaagccggc gtggagtgg
 ctctgtgcag
 4921 ttagtgccac cccacacacc cgtctcttga ttgagatgtt tctggtgggt
 atgggtttcc
 4981 cgtggagctg ggggtgggag cgtgtacct aagctggagg ctggcgctct
 ccctcagcac
 5041 aggtgggtca gtggccagca ggcccatctg gagtgggagt gggcacttcc
 accccgcccc
 5101 caggccatcc ggctgtgcag gccagcccct aggagcaggt cccgggtgac
 tggcagtttt
 5161 cacggtctag ggccgagacg atggcatggg gcctagagca tgaggtagag
 cagaatgcag
 5221 accacgccgc tggatgccga gagaccctgc tctccgaggg aggcctctgt
 gtcattgtgt
 5281 gagggctgag gacggggccc tagtctctgg tttcttggtc ttaacatcct
 tatctgtgtc
 5341 cgccacggag gtgactgagc tgctagcgag ttgtcctgtc ccaggtactt
 gagttttgga
 5401 aaagctgact cacgcccac catctcacag cccttccctg gggacagtgc
 cttccgcctt
 5461 gacacctcac tctcagttga ataactcaag cttgggtcac ttcagactcg
 aattcttgag
 5521 tagaccaga cggttagacc caagtctagt tgcagctgcc tcggcaagtc
 cccatttgct
 5581 caggcagccc tgaatgggac tgtttacagg aatggtaa atgggattgga
 aggaatatag
 5641 cttccagctt cataggctag ggtgaccacg gcttaggaaa cagggaaga
 aagcaaggcc
 5701 cttttcctgc ctttccggg atctgtctac tccacctcca cgggggaggc
 cagtggggaa
 5761 gggctgtcac ctcttcccc tctgcatgag ttctggaact ctgtcctgtt
 ggctgcttgc
 5821 ttccagctcc cccaatctc catcgcagcg ggttcctcct gtcttttcta
 cagtgtcata
 5881 aaacatcctg cccctaccct ctcccaaagg tcaattttta ttctaccaa
 gttttgcaca
 5941 tctctgtatg tcgcttgatg tcttagacgc gagccctttc ctaaactgtt
 cagcgtctc
 6001 ttttcctttg ggtggttgtt gcaaggggtga tgacatgact gtccccaggc
 ctgtctccct
 6061 gaagcgtctg tgctgtcagg acagccctgg gcagagatga ggcaggggtg
 aggcgtgcgt
 6121 gtgcttttcc tccttggttg atgtcttcca tatcatctgt ttccatagct
 acaatccatc
 6181 ccttggcctt aactttggaa tttggagatt atatgcaa acatgtgtaa
 gctcatgaat
 6241 atggatgaca ctggaatttt ataaattcta aaataaaacc cgaaaccaga
 tgtagcatgc
 6301 tgggactcat tttgaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
 aaaaaaaaaa
 6361 aaaaaa

```
//
11. HIST1H2BA: HIST1H2BA histone cluster 1, H2ba [ Homo sapiens
]
LOCUS NM_170610
AA /translation="MPEVSSKGATISKKGFKKAVVKTQKKEGKKRKRTRKESYSIYIY
KVLKQVHPDTGISSKAMSIMNSFVTDIFERIASEASRLAHYSKRSTISSREIQTAVRL
LLPGELAKHAVSEGTKAVTKYTSSK
```

```
cDNA: 1 atgccggagg tgtcatctaa aggtgctacc atttccaaga agggctttaa
gaaagctgtc
61 gttaagaccc agaaaaagga aggcaaaaag cgcaagagga cccgtaagga
gagttattct
121 atttacatct acaaagtgtc aaagcaggtc catccggaca ctggcatctc
ttcgaaagct
181 atgagcatta tgaattcctt cgtcactgat atctttgagc gtatagcgag
cgaggcatca
241 cgtttggtc actacagcaa gcgctccacc atttcttcca gagagattca
gacagcagtg
301 cgcttgctac tgccgggaga gctggctaaa catgctgtgt ctgagggcac
caaggctgtc
361 actaagtaca ccagctccaa gtaagcctgc taagtaaacg tcatttctaa
cccaaaggct
421 cttttcagag ccactta
//
```

```
12. HMGB2: HMGB2 high mobility group box 2 [ Homo sapiens ]
LOCUS NM_001130688 (isoform 2)
AA /translation="MGKGDPNKPRGKMSSYAFFVQTCREEHKKKHPDSSVNFAEFSKK
CSERWKTMSAKEKSKFEDMAKSDKARYDREMKNYVPPKGDKKGKKKDPNAPKRPPSAF
FLFCSEHRPKIKSEHPGLSIGDTAKKLGEMWSEQSAKDKQPYEQKAAKLKEYEKDIA
AYRAKGKSEAGKKGPRPTGSKKKNPEDEEEEEEEEEDEEEEEDEDEE
```

```
cDNA: 1 aaaccagttc acgccggagc cccgtgaggg aagcgtctcc gttgggtccg
gccgctctgc
61 gggactctga ggaaaagctc gcaccaggca agaataccct ccaataccct
cgggtggacg
121 cggatctgtc aacatgggta aaggagaccc caacaagccg cggggcaaaa
tgtctctgta
181 cgccttcttc gtgcagacct gccgggaaga gcacaagaag aaacacccgg
actcttccgt
241 caatttcgcg gaattctcca agaagtgttc ggagagatgg aagaccatgt
ctgcaaagga
301 gaagtccaag tttgaagata tggcaaaaag tgacaaagct cgctatgaca
gggagatgaa
361 aaattacgtt cctcccaaag gtgataagaa ggggaagaaa aaggacccca
atgctcctaa
421 aaggccacca totgccttct tcctgttttg ctctgaacat cgcccaaga
tcaaaagtga
481 acacctggc ctatccattg gggatactgc aaagaaattg ggtgaaatgt
ggtctgagca
541 gtcagccaaa gataaacaac catatgaaca gaaagcagct aagctaaagg
agaaatatga
601 aaaggatatt gctgcatatc gtgccaaggg caaaagtga gaggaaaga
agggccctgg
661 caggccaaca ggctcaaaga agaagaacga accagaagat gaggaggagg
aggaggaaga
721 agaagatgaa gatgaggagg aagaggatga agatgaagaa taaatggcta
tcctttaatg
781 atgcgtgtgg aatgtgtgtg tgtgctcagg caattatfff gctaagaatg
tgaattcaag
841 tgcagctcaa tactagcttc agtataaaaa ctgtacagat tttgtatag
```

```

ctgataagat
  901 tctctgtaga gaaaatactt ttaaaaaatg caggttgtag ctttttgatg
ggctactcat
  961 acagttagat tttacagctt ctgatgttga atgttcctaa atatttaatg
gttttttttaa
 1021 tttcttgtgt atggtagcac agcaaaactg taggaattag tatcaatagt
aaattttggg
 1081 ttttttagga tgttgcattht cgttttttta aaaaaaattt tgtaataaaa
ttatgtatat
 1141 tatttctatt gtctttgtct taatatgcta agttaatttt cactttaaaa
aagccatttg
 1201 aagaccagag ctatgttgat ttttttcggt atttctgcct agtagttctt
agacacagtt
 1261 gacctagtaa aatgtttgag aattaaaacc aaacatgctc atatttgcaa
aatgttcttt
 1321 aaaagttaca tgttgaactc agtgaacttt ataagaattt atgcagtttt
acagaacggt
 1381 aagttttgta cttgacgttt ctgtttatta gctaaattgt tcctcaggtg
tgtgtatata
 1441 tatatacata tatatatata tatatat

```

//

```

LOCUS          NM_001130689                (isoform 3)
AA /translation="MGKGDPNKPRGKMSSYAFFVQTCREEHKKKHPDSSVNFAEFSKK
CSERWKMTSAKEKSKFEDMAKSDKARYDREMKNYVPPKGDKKGKKKDPNAPKRPPSAF
FLFCSEHRPKIKSEHPGLSIGDTAKKLGEMWSEQSAKDKQPYEQKAAKLKEKYEKDIA
AYRAKGKSEAGKKGPGRPTGSKKKNEPEDEEEEEEEEEDEDEEEEEDEDEE

```

```

cDNA: 1 ggatttgggc ggaagcgga gccccgccag cccccgccct ggcagctgag
ggctccgcgc
  61 cgaccctccg gcttcccctc tccccctcgc gccccgtagc gtggacgcgg
atctgtcaac
 121 atgggttaaag gagaccccaa caagccgcgc ggcaaaatgt cctcgtagc
cttcttcgtg
 181 cagacctgcc ggaagagca caagaagaaa caccgcgact cttccgtcaa
tttcgaggaa
 241 ttctccaaga agtgttcgga gagatggaag accatgtctg caaaggagaa
gtcgaagttt
 301 gaagatatgg caaaaagtga caaagctcgc tatgacaggg agatgaaaaa
ttacgttcct
 361 cccaaagggtg ataagaaggg gaagaaaaag gaccccaatg ctctaaaaag
gccaccatct
 421 gccttcttcc tgttttgctc tgaacatcgc ccaaagatca aaagtgaaca
ccctggccta
 481 tccattgggg atactgcaaa gaaattgggt gaaatgtggt ctgagcagtc
agccaaagat
 541 aaacaaccat atgaacagaa agcagctaag ctaaaggaga aatatgaaaa
ggatatgtgt
 601 gcatatcgtg ccaagggcaa aagtgaagca ggaaagaagg gcctggcag
gccaacaggc
 661 tcaaagaaga agaacgaacc agaagatgag gaggaggagg aggaagaaga
agatgaagat
 721 gaggaggaag aggatgaaga tgaagaataa atggctatcc tttaatgatg
cgtgtggaat
 781 gtgtgtgtgt gctcaggcaa ttattttgct aagaatgtga attcaagtgc
agctcaatac
 841 tagcttcagt ataaaaactg tacagatttt tgtatagctg ataagattct
ctgtagagaa
 901 aatactttta aaaaatgcag gttgtagctt tttgatgggc tactcataca
gttagatttt
 961 acagcttctg atgttgaatg ttctaaata tttaatggtt tttttaattt

```



```

cttgtgtatg
1021 gtagcacagc aaacttgttag gaattagtagt caatagtaaa ttttgggttt
tttaggatgt
1081 tgcatttcgt ttttttaaaa aaaattttgt aataaaatta tgtatattat
ttctattgtc
1141 tttgtcttaa tatgctaagt taattttcac tttaaaaaag ccatttgaag
accagagcta
1201 tgttgatttt tttcgggtatt tctgcctagt agttcttaga cacagttgac
ctagtaaaat
1261 gtttgagaat taaaacccaa catgctcata tttgcaaaat gttcttttaa
agttacatgt
1321 tgaactcagt gaactttata agaatttatg cagttttaca gaacgttaag
ttttgtactt
1381 gacgtttctg tttattagct aaattgttcc tcaggtgtgt gtatatatat
atacatatat
1441 atatatatat atat

//
LOCUS          NM_002129                      (isoform 1)
AA /translation="MGKGDPNKPRGKMSSYAFFVQTCREEHKKKHPDSSVNFAEFSKK
CSERWKTMSAKEKSKFEDMAKSDKARYDREMKNYVPPKGDKKGKKKDPNAPKRPPSAF
FLFCSEHRPKIKSEHPGLSIGDTAKKLGEMWSEQSAKDKQPYEQKAAKLKEYEKDIA
AYRAKGKSEAGKKGPGRPTGSKKKNEPEDEEEEEEEDEDEEEDEDEE
cDNA:  1 ggggatgtgg cccgtggcct agctcgtcaa gttgccgtgg cgcggagaac
tctgcaaaac
      61 aagaggtcga ggattgcgtt agagataaac cagttcacgc cggagccccg
tgagggaagc
     121 gtctccgttg ggtccggccg ctctgcggga ctctgaggaa aagctcgcac
caggtggacg
     181 cggatctgtc aacatgggta aaggagaccc caacaagccg cggggcaaaa
tgtcctcgta
     241 cgccttcttc gtgcagacct gccgggaaga gcacaagaag aaacacccgg
actcttcggt
     301 caatttcgcg gaattctcca agaagtgttc ggagagatgg aagaccatgt
ctgcaaagga
     361 gaagtcgaag tttgaagata tggcaaaaag tgacaaagct cgctatgaca
gggagatgaa
     421 aaattacgtt cctcccaaag gtgataagaa ggggaagaaa aaggacccca
atgctcctaa
     481 aaggccacca tctgccttct tcctgttttg ctctgaacat cgcccaaaga
tcaaaagtga
     541 acaccctggc ctatccattg gggatactgc aaagaaattg ggtgaaatgt
ggtctgagca
     601 gtcagccaaa gataaacaac catatgaaca gaaagcagct aagctaaagg
agaaatatga
     661 aaaggatatt gctgcatact gtgccaaagg caaaagtga gcaggaaaga
agggccctgg
     721 caggccaaca ggctcaaaga agaagaacga accagaagat gaggaggagg
aggaggaaga
     781 agaagatgaa gatgaggagg aagaggatga agatgaagaa taaatggcta
tcctttaatg
     841 atgcgtgtgg aatgtgtgtg tgtgctcagg caattatfff gctaagaatg
tgaattcaag
     901 tgcagctcaa tactagcttc agtataaaaa ctgtacagat ttttgtatag
ctgataagat
     961 tctctgtaga gaaaataact ttaaaaaatg caggttgtag ctttttgatg
ggctactcat
    1021 acagttagat tttacagctt ctgatgttga atgttcctaa atatttaagt
gtttttttaa
    1081 tttcttgtgt atggtagcac agcaaacttg taggaattag tatcaatagt

```

```

aaattttggg
1141 ttttttagga tgttgcattt cgttttttta aaaaaaattt tgtaataaaa
ttatgtatat
1201 tatttctatt gtctttgtct taatatgcta agttaatttt cactttaaaa
aagccatttg
1261 aagaccagag ctatgttgat ttttttcggt atttctgcct agtagttctt
agacacagtt
1321 gacctagtaa aatgtttgag aattaaaacc aaacatgctc atatttgcaa
aatgttcttt
1381 aaaagttaca tgttgaactc agtgaacttt ataagaattt atgcagtttt
acagaacggt
1441 aagttttgta cttgacgttt ctgtttatta gctaaattgt tcctcaggtg
tgtgtatata
1501 tatatacata tatatatata tatatat

```

//

13. HNRNPK: HNRNPK heterogeneous nuclear ribonucleoprotein K [Homo sapiens]

LOCUS NM_002140 (isoform a variant 1)
AA/translation="METEQPEETFPNTETNGEFGKRPAEDMEEEQAFKRSRNTDEMVE
LRILLQSKNAGAVIGKGGKNIKALRTDYNASVSPDSSGPERILSISADIETIGEILK
KIIPTLEEGLQLPSPTATSQPLLESDAVECLNYQHYKGSDFDCELRLLIHQSLAGGII
GVKGAKIKELRENTQTTIKLFQECCPHSTDRVVLIGGKPDVRVVECIKIILDLISESPI
KGRAQPYDPNIFYDETYDYGFTMMFDDRGRPVGFPMRGRGGFDRMPGRRGGRMPPTS
RRDYDDMSPRRGPPPPPPGRGGRGGSRRNLPLPPPPPPRGDL MAYDRRGRPGDRYD
GMVGFSADETWDS AIDTWSPSEWQ MAYEPQGGSGYDYSYAGGRGSYDGLGGPIITTQV
TIPKDLAGSIIGKGGQRIKQIRHESGASIKIDEPLEGSEDRIITITGTQDQIQNAQYL
LQNSVKQYADVEGF

```

cDNA: 1 ccctagccgc ccctcccccc agctagttag tgccgcgaacg agaaaggagg
agggcgcctcc
61 aggcgacagc actgcagacg ccattatcct ctgtttctct gctgcaccga
cctcgacgtc
121 ttgcctgtgt ccacttggt cgcgccctat aggcactgac agcactgggg
tgtcagttgt
181 tgggtccgacc cagaacgctt cagttctgct ctgcaaggat atataataac
tgattggtgt
241 gcccgtttaa taaaagaata tggaaactga acagccagaa gaaaccttcc
ctaactactga
301 aaccaatggt gaatttggt aacgcctgac agaagatatg gaagaggaac
aagcatttaa
361 aagatctaga aacactgatg agatggttga attacgcatt ctgcttcaga
gcaagaatgc
421 tggggcagtg attggaaaag gaggcaagaa tattaaggct ctccgtacag
actacaatgc
481 cagtgtttca gtcccagaca gcagtggccc cgagcgcata ttgagtatca
gtgctgatat
541 tgaaacaatt ggagaaatcc tgaagaaaat catccctacc ttggaaggag
gcctgcagtt
601 gccatcacc actgcaacca gccagctccc gctcgaatct gatgctgtgg
aatgcttaaa
661 ttaccaacac tataaaggaa gtgactttga ctgcgagttg aggcgtgtga
ttcatcagag
721 tctagcagga ggaattattg ggggtcaaagg tgctaaaatc aaagaacttc
gagagaacac
781 tcaaaccacc atcaagcttt tccaggaatg ctgtcctcat tccactgaca
gagttgttct
841 tattggagga aaacccgata ggggtttaga gtgcataaag atcatccttg
atcttatatc
901 tgagtctccc atcaaaggac gtgcacagcc ttatgatccc aatttttacg
atgaaaccta

```

961 tgattatggt gggttttaciaa tgatgtttga tgaccgtcgc ggacgcccag
 tgggattttcc
 1021 catgcgggga agaggttggt ttgacagaat gcctcctggt cggggtgggc
 gtcccatgcc
 1081 tccatctaga agagattatg atgatatgag ccctcgtcga ggaccacctc
 cccctcctcc
 1141 cggacgaggc ggccggggtg gtagcagagc tcggaatctt cctcttcctc
 caccaccacc
 1201 acctagaggg ggagacctca tggcctatga cagaagaggg agacctggag
 accgttacga
 1261 cggcatgggt gggttcagtg ctgatgaaac ttgggactct gcaatagata
 catggagccc
 1321 atcagaatgg cagatggctt atgaaccaca ggggtggctcc ggatatgatt
 attcctatgc
 1381 aggggggtcgt ggctcatatg gtgatcttgg tggacctatt attactacac
 aagtaactat
 1441 tcccaaagat ttggctggat ctattattgg caaagggtgg cagcggatta
 aacaaatccg
 1501 tcatgagtcg ggagcttcga tcaaaattga tgagccttta gaaggatccg
 aagatcggat
 1561 cattaccatt acaggaacac aggaccagat acagaatgca cagtatttgc
 tgcagaacag
 1621 tgtgaagcag tatgcagatg ttgaaggatt ctaatgcaag atattttttc
 ttttttatag
 1681 tgtgaagcag tattctggaa agtttttcta agactagtga agaactgaag
 gagtcctgca
 1741 tctttttttt tttatctgct tctgttttaa aagccaacat tctctgctt
 cataggtggt
 1801 ctgcatttga ggtgtagtga aatctttgct gttcaccaga tgtaatgttt
 tagttcctta
 1861 caaacagggt tggggggggg aagggcgtgc aaaaactaac attgaaattt
 tgaaacagca
 1921 gcagagttag tggattttat ttttcgttat tgttggtggg ttaaaaaatt
 ccccccattg
 1981 aattattgtg aacaccttgc tttgtggtca ctgtaacatt tggggggtgg
 gacaggagg
 2041 aaaagtaaca atagtccaca tgtccctggc atctgttcag agcagtgtgc
 agaattgta
 2101 gctcttttgt aagaaacgtt ttatgatttt taaaataaat ttagtgaacc
 tatttttggg
 2161 ggtcattttt tttttaagac agtcatttta aaatgggtggc tgaattttcc
 aaccacccc
 2221 caaactaac actaagttta attttcagct cctctgttgg acatataagt
 gcatctcttg
 2281 ttggacatag gcaaaataac ttggcaaaact tagttctggg gatttcttga
 tggtttgga
 2341 gtctattgct gggaagaaat tccatcatat atattcatgc ttataataag
 ctggggattt
 2401 tttgtttggt tttgcaaatg cttgccccta cttttcaaca attttctatg
 ttagttgtga
 2461 agaactaagg tggggagcag tactacaagt tgagtaatgg tatgagtata
 taccagaatt
 2521 ctgattggca gcaagtttta ttaatcagaa taacacttgg ttatggaagt
 gactaatgct
 2581 gaaaaaattg attattttta ttagataatt tctcacctat agacttaaac
 tgtcaatttg
 2641 ctctagtgtc ttattagtta aactttgtaa aatatatata tacttgtttt
 tccattgtat
 2701 gcaaatgaa agaaaaagat gtaccatttc tctgttgtat gttggattat
 gtaggaaatg
 2761 tttgtgtaca attcaaaaaa aaaaaagatg aaaaaagttc ctgtggatgt

```

tttgtgtagt
  2821 atcttggcat ttgtattgat agttaaaatt cacttccaaa taaataaaac
acccatgatg
  2881 ctagatttga tgtgtgcccc atttgaacaa ggggttgattg acacctgtaa
aatttgttga
  2941 aacgttcctc ttaaaaggaa atatagtaat cttatgtaaa aaaaaaaaaa aaaa
//
LOCUS          NM_031262                      (isoform 3 variant 3)
AA/translation="METEQPEETFPNTETNGEFGKRP AEDMEEEQAFKRSRNTDEMVE
LRILLQSKNAGAVIGKGGKNIKALRTDYNASVSPDSSGPERILSISADIETIGEILK
KIIP TLEEG LQLP SPTATS QLP LESDAVECLNYQHYKGSDFDCELRLLIHQSLAGGII
GVKGAKIKELRENTQTTIKLFQECCPHSTDRVVLIGGKPD RV ECIKIILDLIS ESPI
KGRAQPYDPNFYDETYDYGGFTMMFDDRGRPVGFPMRGRGGFDRMP PGRGGRMP PPS
RRDYDDMSPRRGPPPPPPGRGGRGGSRRNLPLPPPPPPRGDL MAYDRRGRPGDRYD
GMVGFSADETWDSAIDTWSPSEWQ MAYEPQGGSGYDYSYAGGRGSYGD LGGP IITQV
TIPKDLAGSIIGKGGQRIKQIRHESGASIKIDEPLEGSEDRIITITGTQDQIQNAQYL
LQNSVKQYSGKFF

```

```

cDNA:  1 ccctagccgc ccctcccccc agctagttag tgcgcgaaacg agaaaggagg
agggcgctcc
      61 aggcgacagc actgcagacg ccattatcct ctgtttctct gctgcaccga
cctcgacgtc
     121 ttgcctgtgt cccacttggt cgcggcctat aggtactgc agcactgggg
tgtcagttgt
     181 tgggccgacc cagaacgctt cagttctgct ctgcaaggat atataataac
tgattggtgt
     241 gcccgtttaa taaaagaata tggaaactga acagccagaa gaaaccttcc
ctaactactga
     301 aaccaatggt gaatttggt aacgccctgc agaagatatg gaagaggaaac
aagcatttaa
     361 aagatctaga aacactgatg agatggttga attacgcatt ctgcttcaga
gcaagaatgc
     421 tggggcagtg attggaaaag gaggcaagaa tattaaggct ctccgtacag
actacaatgc
     481 cagtgtttca gtcccagaca gcagtggccc cgagcgcata ttgagtatca
gtgctgatat
     541 tgaaacaatt ggagaaattc tgaagaaaat catccctacc ttggaaggag
gcctgcagtt
     601 gccatcacc actgcaacca gccagctccc gctogaatct gatgctgtgg
aatgcttaaa
     661 ttaccaacac tataaaggaa gtgactttga ctgcgagttg aggctgttga
ttcatcagag
     721 tctagcagga ggaattattg ggggtcaaag tgctaaaatc aaagaacttc
gagagaacac
     781 tcaaacacc atcaagcttt tccaggaatg ctgtcctcat tccactgaca
gagttgttct
     841 tattggagga aaaccogata gggttgtaga gtgcataaag atcatccttg
atcttatatc
     901 tgagtctccc atcaaaggac gtgcacagcc ttatgatccc aatttttacg
atgaaaccta
     961 tgattatggt ggttttacia tgatgtttga tgaccgtcgc ggacgcccag
tgggatttcc
    1021 catgcgggga agagggtggt ttgacagaat gcctcctggg cggggtgggc
gtcccatgcc
    1081 tccatctaga agagattatg atgatatgag ccctcgtcga ggaccacctc
ccctcctcc
    1141 cggacgaggc ggccgggggtg gtagcagagc tcggaatctt cctcttctc
caccaccacc
    1201 acctagaggg ggagacctca tggcctatga cagaagaggg agacctggag
accgttacga
    1261 cggcatggtt ggtttcagtg ctgatgaaac ttgggactct gcaatagata

```

```

catggagccc
1321 atcagaatgg cagatggcctt atgaaccaca ggggtggctcc ggatatgatt
attcctatgc
1381 aggggggtcgt ggctcatatg gtgatcttgg tggacctatt attactacac
aagtaactat
1441 tcccaaagat ttggctggat ctattattgg caaagggtgg cagcggatta
aacaatccg
1501 tcatgagtcg ggagcttcga tcaaaattga tgagccttta gaaggatccg
aagatcggat
1561 cattaccatt acaggaacac aggaccagat acagaatgca cagtatttgc
tgcagaacag
1621 tgtgaagcag tattctggaa agtttttcta agactagtga agaactgaag
gagtcctgca
1681 tctttttttt tttatctgct tctgttttaa aagccaacat tcctctgctt
cataggtggt
1741 ctgcatttga ggtgtagtga aatctttgct gttcaccaga tgtaatgttt
tagttcctta
1801 caaacagggg tggggggggg aagggcgtgc aaaaactaac attgaaattt
tgaaacagca
1861 gcagagtga ggtattttat ttttcgttat tgttggtggg ttaaaaaatt
cccccatgt
1921 aattattgtg aacaccttgc tttgtggtca ctgtaacatt tggggggtgg
gacagggagg
1981 aaaagtaaca atagtccaca tgtccctggc atctgttcag agcagtgtgc
agaatgtaat
2041 gctcttttgt aagaaacggt ttatgatttt taaaataaat ttagtgaacc
tatttttggg
2101 ggtcattttt tttttaagac agtcatttta aaatgggtggc tgaatttccc
aaccacccc
2161 caaactaaac actaagttta attttcagct cctctgttgg acatataagt
gcatctcttg
2221 ttggacatag gcaaaataac ttggcaaaact tagttctggg gatttcttga
tggtttggaa
2281 gtctattgct ggaagaaat tccatcatc atattcatgc ttataataag
ctgggggattt
2341 tttgtttgtt tttgcaaag cttgcccta cttttcaaca attttctatg
ttagttgtga
2401 agaactaagg tggggagcag tactacaagt tgagtaatgg tatgagtata
taccagaatt
2461 ctgattggca gcaagtttta ttaatcagaa taacacttgg ttatggaagt
gactaatgct
2521 gaaaaaattg attattttta ttagataatt tctcacctat agacttaaac
tgtcaatttg
2581 ctctagtgtc ttattagtta aactttgtaa aatatatata tacttgtttt
tccattgtat
2641 gcaaatgaa agaaaaagat gtaccatttc tctgttgtat gttggattat
gtaggaaatg
2701 tttgtgtaca attcaaaaaa aaaaaagatg aaaaaagttc ctgtggatgt
tttgtgtagt
2761 atcttggcat ttgtattgat agttaaaatt cacttccaaa taaataaaac
acccatgatg
2821 ctagatttga tgtgtgcccg atttgaacaa gggttgattg acacctgtaa
aatgtgtga
2881 aacgttcctc ttaaaaggaa atatagtaat cttatgtaaa aaaaaaaaaa aaaaa
//

```

```

LOCUS      NM_031263                      (isoform a variant 2)
AA /translation="METEQPEETFPNTETNGEFGKRPADMEEEQAFKRSRNTDEMVE
LRILLQSKNAGAVIGKGGKNIKALRTDYNASVSPDSSGPERILSISADIETIGEILK
KIIPITLEEGLQLPSPTATSQPLESDAVECLNYQHYKGSDFDCELRLLIHQSLAGGII
GVKGAKIKELRENTQTIKLFQECCPHSTDRVVLIGGKPDRVVECIKIILDILIESPI

```

KGRAQPYDPNFYDETYDYGFTMMFDDRRGRPVGFPMRGRGGFDRMPPGRGGRPMPPS
 RRDYDDMSPRRGPPPPPPGRGGRGGSRRNLPLPPPPPPRGDL MAYDRRGRPGDRYD
 GMVGFSADETWDS AIDTWSPSEWQMA YEPQGGSGYDYSYAGGRGSYGD LGGP IITQV
 TIPKDLAGSIIGKGGQRIKQIRHESGASIKIDEPLEGSEDRIITITGTQDQIQNAQYL
 LQNSVKQYADVEGF

cDNA: 1 tagggcgcgga cggcgggggag gacgcgagaa ggcgggggag gggagcctgc
 gctcgttttc
 61 tgtctagctc cgaccggctg aggcggcgcg gcagcggagg gacggcagtc
 tcgcgcggct
 121 actgcagcac tggggtgtca gttgttggtc cgaccagaa cgcttcagtt
 ctgctctgca
 181 aggatatata ataactgatt ggtgtgcccg ttaataaaaa gaatatggaa
 actgaacagc
 241 cagaagaaac cttccctaac actgaaacca atggtgaatt tggtaaacgc
 cctgcagaag
 301 atatggaaga ggaacaagca tttaaaagat ctagaaacac tgatgagatg
 gttgaattac
 361 gcattctgct tcagagcaag aatgctgggg cagtgtattg aaaaggaggc
 aagaatatta
 421 aggctctccg tacagactac aatgccagtg tttcagtccc agacagcagt
 ggccccgagc
 481 gcatattgag tatcagtgtc gatattgaaa caattggaga aattctgaag
 aaaatcatcc
 541 ctaccttga agagggcctg cagttgccat caccactgc aaccagccag
 ctcccgtctg
 601 aatctgatgc tgtggaatgc ttaaattacc aacactataa aggaagtgc
 tttgactgag
 661 agttgaggct gttgattcat cagagtctag caggaggaat tattggggtc
 aaaggtgcta
 721 aaatcaaaga acttcgagag aacactcaaa ccaccatcaa gcttttccag
 gaatgctgtc
 781 ctcatccac tgacagagtt gttcttattg gaggaaaacc cgatagggtt
 gtagagtgc
 841 taaagatcat ccttgatctt atatctgagt ctcccatcaa aggacgtgca
 cagccttatg
 901 atcccaattt ttacgatgaa acctatgatt atggtgggtt tacaatgatg
 tttgatgacc
 961 gtcgcggacg ccagtgagg tttcccatgc ggggaagagg tggttttgac
 agaatgcctc
 1021 ctggtcgggg tgggcgtccc atgcctccat ctagaagaga ttatgatgat
 atgagccctc
 1081 gtcgaggacc acctccccct cctcccgac gaggcggccg ggggtgtagc
 agagctcgga
 1141 atcttctct tctccacca ccaccaccta gagggggaga cctcatggcc
 tatgacagaa
 1201 gagggagacc tggagaccgt tacgacggca tggttgggtt cagtgtgat
 gaaacttggg
 1261 actctgcaat agatacatgg agcccatcag aatggcagat ggcttatgaa
 ccacagggtg
 1321 gctccgata tgattattcc tatgcagggg gtcgtggctc atatggtgat
 cttggtggac
 1381 ctattattac tacacaagta actattccca aagatttggc tggatctatt
 attggcaaag
 1441 gtggtcagcg gattaaacaa atccgtcatg agtcgggagc ttcgatcaaa
 attgatgagc
 1501 ctttagaagg atccgaagat cggatcatta ccattacagg aacacaggac
 cagatacaga
 1561 atgcacagta tttgctgcag aacagtgtga agcagtatgc agatgttgaa
 ggattcta
 1621 gcaagatatt ttttcttttt tatagtgtga agcagtattc tggaaagttt

```

ttctaagact
  1681 agtgaagaac tgaaggagtc ctgcatcttt ttttttttat ctgcttctgt
ttaaaaagcc
  1741 aacattcctc tgcttcatag gtgttctgca tttgaggtgt agtgaaatct
ttgctgttca
  1801 ccagatgtaa tgttttagtt ccttacaaac agggttgggg gggggaaggg
cgtgcaaaaa
  1861 ctaacattga aattttgaaa cagcagcaga gtgagtggat tttatttttc
gttattgttg
  1921 gtggttttaa aaattccccc catgtaatta ttgtgaacac cttgctttgt
ggtcactgta
  1981 acatttgggg ggtgggacag ggaggaaaag taacaatagt ccacatgtcc
ctggcatctg
  2041 ttcagagcag tgtgcagaat gtaatgctct tttgtaagaa acgttttatg
atttttaaaa
  2101 taaatttagt gaacctattt ttggtggtca tttttttttt aagacagtca
ttttaaaatg
  2161 gtggctgaat ttcccaaccc acccccaaac taaacactaa gtttaatttt
cagctcctct
  2221 gttggacata taagtgcac tcttggttga cataggcaaa ataacttggc
aaacttagtt
  2281 ctggtgattt cttgatgggt tggaagtcta ttgctgggaa gaaattccat
catacatatt
  2341 catgcttata ataagctggg gattttttgt ttgtttttgc aaatgcttgc
ccctactttt
  2401 caacaatttt ctatgttagt tgtgaagaac taagggtggg agcagtacta
caagttgagt
  2461 aatggtatga gtatatacca gaattctgat tggcagcaag ttttattaat
cagaataaca
  2521 cttggttatg gaagtgacta atgctgaaaa aattgattat ttttattaga
taatttctca
  2581 cctatagact taaactgtca atttgcctca gtgtcttatt agttaaaactt
tgtaaaatat
  2641 atatatactt gtttttccat tgtatgcaaa ttgaaagaaa aagatgtacc
atttctctgt
  2701 tgtatgttgg attatgtagg aaatgtttgt gtacaattca aaaaaaaaaa
agatgaaaaa
  2761 agttcctgtg gatgttttgt gtagtatctt ggcatttgta ttgatagtta
aaattcactt
  2821 ccaaataaat aaaacaccca tgatgctaga tttgatgtgt gcccgatttg
aacaagggtt
  2881 gattgacacc tgtaaaattt gttgaaacgt tcctcttaaa aggaaatata
gtaatcttat
  2941 gtaaaaaaaaa aaaaaaaaaa

```

//

14. HNRPD L: HNRPD L heterogeneous nuclear ribonucleoprotein D-like [Homo sapiens]

LOCUS NM_001207000

(isoform B)

AA/translation="MEVPPRLSHVPPPLFPSAPATLASRSLSHWRPRPRQLAPLLPS

LAPSSARQGARRAQRHVTAQQPSRLAGGAAIKGGRRRRPDLFRRHFKSSSIQRSAAAA

AATRTARQHPPADSSVTMEDMNEYSNIEEFAEGSKINASKNQDDGKMF IGGLSWDTS

KKDLTEYLSRFGEVVDCTIKTDPVTGRSRGFGFVLFKDAASVDKVLELKEHKLDGKLI

DPKRAKALKGKEPPKKVFVGGGLSPDTSEEQIKEYFGAFGEIENIELPMDTKTNERRGF

CFITYTDEEPVKKLLSRYHQIGSGKCEIKVAQPKEVYRQQQQQKGGRGAAAGGRGG

TRGRGRGQQSTYGKASRGGGNHQNNYQPY

cDNA: 1 gaggcgcgcg ggggcccggg cttegcccgga tcagcccggg aggccccgcc
gcgcccctt

61 ggcccgcgcg ccggtggtca cagtggaaga ggcccgcgcg ctgcgctgcc
cggaggagcc

121 gtcgcgcgcc cgttctctgt tcggttggtt cctgccagct cgaggacaaa
 acacgcgtgc
 181 gcgcggcggg cgagcgcgct cgccgcctca gtcgccagcg ccggggcgag
 tccgcctttt
 241 tccggagcag actggcgcg gtgctagtcg gtagcagcg ccgccgcagc
 ggctccgcac
 301 tggcgaaccg agggcagaaa aaggcgggtg tgacggcttt ttggtaggag
 tgggctggac
 361 cggacgccag agacaaaggc tccaaggca agagggactg tggcctgcg
 tcggtctgc
 421 tcgggactgc tgaccccagg aatttacgcc cttcgtttt tctcttctga
 ttcttctctt
 481 ctcccaagcc cgcgtccct cagcgtggc ctctctcct gccgggaggg
 ccgcatgga
 541 ggtcccgccc aggttttccc atgtgccgc gccattgttc cctccgctc
 ccgtacttt
 601 agcctccgc agcctctccc attggcgcc gcggccgcg cggcagctag
 cccgctcct
 661 ccttcgctc gctcccagct ccgcccgca gggggcgcg cgggccagc
 gccacgtcac
 721 cgcccagcag ccctccgat tggcgggcg ggcggtata aaggaggggc
 gcaggcggg
 781 cccgatctc ttccgcgcg attttaaata cagctccata caacgtccg
 ccgccgtgc
 841 tgccgcgacc cggactgcgc gccagcacc cctgcgcg agctccgtca
 ctatggagga
 901 tatgaacgag tacagcaata tagaggaatt cgcagaggga tccaagatca
 acgcgagcaa
 961 gaatcagcag gatgacggta aaatgtttat tggaggcttg agctgggata
 caagcaaaaa
 1021 agatctgaca gagtacttgt ctcgatttgg ggaagttgta gactgcacaa
 ttaaaacaga
 1081 tccagtcact gggagatcaa gaggatttgg atttgtgctt ttcaaagatg
 ctgctagtgt
 1141 tgataagggt ttggaactga aagaacacaa actggatggc aaattgatag
 atcccaaaag
 1201 ggccaaagct ttaaaaggga aagaacctcc caaaaagggt tttgtgggtg
 gattgagccc
 1261 ggatacttct gaagaacaaa ttaaagaata ttttgagacc tttggagaga
 ttgaaaatat
 1321 tgaacttccc atggatacaa aaacaaatga aagaagagga ttttgtttta
 tcacatatac
 1381 tgatgaagag ccagtaaaaa aattgttaga aagcagatac catcaaattg
 gttctgggaa
 1441 gtgtgaaatc aaagttgcac aaccacaaaga ggtatatagg cagcaacagc
 aacaacaaaa
 1501 aggtggaaga ggtgctgcag ctggtggacg aggtggtacg aggggtcgtg
 gccgaggcca
 1561 acagagcact tatggcaagg catctcgagg ggggtggcaat caccaaaaca
 attaccagcc
 1621 atactaaagg agaacattgg agaaaacagg aggagatggt aaagtaaccc
 atcttgcagg
 1681 acgacattga agattggtct tctgttgatc taagatgatt atttgtaaa
 agactttcta
 1741 gtgtacaaga caccattgtg tccaactgta tatagctgcc aattagtttt
 ctttgttttt
 1801 actttgtcct ttgctatctg tgttatgact caatgtggat ttgtttatac
 acattttatt
 1861 tgtatcattt catgttaaac ctcaataaaa tgcttcctta tgtgattgct
 tttctgcgtc
 1921 aggtactaca tagctctgta aaaaatgtaa tttaaaataa gcaataatta

aggcacagtt
 1981 gattttgtag agtattgggc catacagaga aactgtgggc ctttataaat
 agccagccag
 2041 cgtcaccctc ttctccaatt tgtagggtga ttttatgctc ttaaggcttc
 atcttctccc
 2101 tgtaactgag atttctacca cacctttgaa caatgttctt tcccttctgg
 ttatctgaag
 2161 actgtcctga aaggaagaca taagtgttgt gattagtaga agctttctag
 tagaccatat
 2221 ttcttctgga ttgtaataaa attgttagta gctcctttta ctttgttcct
 gtctctggaa
 2281 agccattttt gaattgctga ttactttggc tttaatcagt ggtcacctag
 aaaaagcttt
 2341 gtaatcataa cacaatgagt aattcttgat aaaagttcag atacaaaagg
 agcactgtaa
 2401 aactggtagg agctatgggt taagagcatt ggaagtagtt acaactcaag
 gattttggta
 2461 gaaaggtatg agtttggctg aaaaattaaa atagtggcaa aataagattt
 agttgtgttt
 2521 tctcagagcc gccacaagat tgaacaaaat gttttctgtt tgggcatcct
 gaggaagttg
 2581 tattagctgt taatgctctg tgagtttaga aaaagtcttg atagtaaatc
 tagtttttga
 2641 cacagtgcac gaactaagta gttaaatatt tacatattca gaaaggaata
 gtggaaaagg
 2701 tatcttggtt atgacaaagt cattacaaat gtgactaagt cattacaaat
 gtgactgagt
 2761 cattacagtg gacctctgg gtgcattgaa aagaatccgt tttatatcca
 ggtttcagag
 2821 gacctggaat aataaaaagc tttggatttt gcattcagtg tagttggatt
 ttgggacctt
 2881 ggectcagtg ttatttactg ggattggcat acgtgttcac aggcagagta
 gttgatctca
 2941 cacaacgggt gatctcaca aactggtaag tttcttatgc tcatgagccc
 tccctttttt
 3001 tttttaattt ggtgcctgca actttcttaa caatgattct acttctggg
 ctatcacatt
 3061 ataatgctct tggcctcttt tttgctgctg ttttgctatt cttaaactta
 ggccaagtac
 3121 caatgttggc tgttagaagg gattctgttc attcaacatg caactttagg
 gaatggaagt
 3181 aagttcattt ttaagttgtg ttgtcagtag gtgcggtgtc tagggtagtg
 aatcctgtaa
 3241 gttcaaattt atgattaggt gacgagttga cattgagatt gtcttttcc
 ctgatcaaaa
 3301 aatgaataaa gcctttttta acaaaatcca aacttttaat caagtcttga
 tatgtatgac
 3361 tgagaaaaaa tacactacat cttagagatga ttgagatgtt ttgcaaagaa
 ttgaaggggg
 3421 agtgagaatt ggtttttctt gcaggggctt tgaactctag atttgggctt
 tgaactctag
 3481 atttaattca gatttcaggg tctatcagtt caccaactga tgcaaatttg
 aacagatact
 3541 ctaaggctaa gtgtcctagg ttggatgaac tgaagctact atcaagatct
 cgttcccaag
 3601 gattaattta gaacaaagta attggacaag tttattgggg aggggataga
 aatgaattct
 3661 aaagtaccta taacaaatac tctgtgtatg ttttttacct cgtattttgcc
 ttttacattg
 3721 tttagaccaa attctgtgtg atgttatcct cggaagagg atagaaatta
 attctaaagt

3781 acctataaca aatgctcggt ttgtatatgt ttttatacat cgtattttgcc
 ttttgcattg
 3841 ttcagaccaa attctgtgtg atgttatcct aacaaaacac cttagtaatt
 tcttttggtta
 3901 acatgttaat ctgtaatctc actttttataa gatgaggact attaaaatga
 gatgtctgtt
 3961 gggatgctaa aaaaaaaaaa aaaaaa

//

LOCUS NM_031372 (isoform a)
 AA /translation="MEVPPRLSHVPPPLFSPAPATLASRSLSHWRPRPPRQLAPLLPS
 LAPSSARQGARRAQRHVTAQQPSRLAGGAAIKGGRRRRPDLFRRHFKSSSIQRSAAAA
 AATRTARQHPPADSSVTMEDMNEYSNIEEFAEGSKINASKNQDDGKMFIGGLSWDTS
 KKDLTEYLSRFGFVVDCTIKTDPVTGRSRGFGFVLFKDAASVDKVLELKEHKLDGKLI
 DPKRAKALKGKEPPKKVFVGGGLSPDTSEEQIKEYFGAFGEIENIELPMDTKTNERRGF
 CFITYTDEEPVKKLLESRYHQIGSGKCEIKVAQPKEVYRQQQQQKGGRGAAAGRGG
 TRGRGRGQQGNWNQGFNNYDQGYGNYSAYGGDQNYSGYGGYDYGYNIGNYGYGQG
 YADYSGQQSTYGKASRGGGNHQNNYQPY

cDNA: 1 gaggccgcgc ggggcccggg cttcggccga tcagcccggg aggccccgcc
 gcgccccctt
 61 ggcccgcgcg cccgtgggtca cagtggaaga ggcccgcgcg ctgcgtgcc
 cggaggagcc
 121 gtccgcgcgc cgcttctgt tcggtggtt cctgccagct cgaggacaaa
 acacgcgtgc
 181 gcgcggcggg cgagcgcgt cgccgcctca gtccgcagcg ccgggcgcag
 tccgcctttt
 241 tccggagcag actggccgcg gtgctagtcg gtagcagcgg ccgccgcagc
 ggctccgcac
 301 tggcgaaacc agggcagaaa aaggcggggt tgacggcttt ttggtaggag
 tgggctggac
 361 cggacgccag agacaaaggc tccaagga agagggactg tggccctgcg
 tcggtctgtc
 421 tcgggactgc tgaccccagg aatttacgcc ccttcgtttt tctcttctga
 ttcttctctt
 481 ctcccaagcc cgcgtccct caccgtggc ctctctctt gccgggaggg
 ccgcgatgga
 541 ggtcccgccc aggetttccc atgtgccgc gccattgttc ccctccgctc
 ccgctacttt
 601 agcctccgc agcctctccc attggcggcc gcggccgcgc cggcagctag
 ccccgctcct
 661 cccttcgctc gctcccagct ccgccggca gggggcgcgc cgggccagc
 gccacgtcac
 721 cggccagcag ccctcccgat tggcgggcgc ggccgctata aaggaggggc
 gcaggcggcg
 781 cccgatctc ttccgcgcgc attttaaatc cagctccata caacgtccg
 ccgcgcgtgc
 841 tgccgcgacc cggactgcgc gccagcacc ccctgccgac agctccgtca
 ctatggagga
 901 tatgaacgag tacagcaata tagaggaatt cgcagaggga tccaagatca
 acgcgagcaa
 961 gaatcagcag gatgacggta aaatgtttat tggaggcttg agctgggata
 caagcaaaaa
 1021 agatctgaca gactacttgt ctcgatttgg ggaagttgta gactgcacaa
 ttaaaacaga
 1081 tccagtcact gggagatcaa gaggatttgg atttgtgctt ttcaaagatg
 ctgctagtgt
 1141 tgataaggtt ttggaactga aagaacacaa actggatggc aaattgatag
 atcccaaaag
 1201 ggccaaagct ttaaaaggga aagaacctcc caaaaagggt tttgtgggtg
 gattgagccc

1261 ggatacttct gaagaacaaa ttaaagaata ttttggagcc tttggagaga
 ttgaaaatat
 1321 tgaacttccc atggatacaa aaacaaatga aagaagagga ttttgtttta
 tcacatatat
 1381 tgatgaagag ccagtaaaaa aattgttaga aagcagatac catcaaattg
 gttctgggaa
 1441 gtgtgaaatc aaagttgcac aacccaaaga ggtatatagg cagcaacagc
 aacaacaaaa
 1501 aggtggaaga ggtgctgcag ctggtggacg aggtggtacg aggggtcgtg
 gccgaggtca
 1561 gggccaaaac tggaaccaag gatttaataa ctattatgat caaggatatg
 gaaattacaa
 1621 tagtgcctat ggtggtgatc aaaactatag tggctatggc ggatatgatt
 atactgggta
 1681 taactatggg aactatggat atggacaggg atatgcagac tacagtggcc
 aacagagcac
 1741 ttatggcaag gcatctcgag ggggtggcaa tcacccaaac aattaccagc
 cataactaaag
 1801 gagaacattg gagaaaacag gaggagatgt taaagtaacc catcttgcag
 gacgacattg
 1861 aagattggtc ttctgttgat ctaagatgat tattttgtaa aagactttct
 agtgtacaag
 1921 acaccattgt gtccaactgt atatagctgc caattagttt tctttgtttt
 tactttgtcc
 1981 tttgctatct gtgttatgac tcaatgtgga tttgtttata cacattttat
 ttgtatcatt
 2041 tcatgttaaa cctcaataa atgcttcctt atgtgattgc tttctgcgt
 caggtactac
 2101 atagctctgt aaaaaatgta atttaaaata agcaataatt aaggcacagt
 tgattttgta
 2161 gagtattggt ccatacagag aaactgtggt cctttataaa tagccagcca
 gcgtcacct
 2221 cttctccaat ttgtagggtg attttatgct ctttaaggctt catcttctcc
 ctgtaactga
 2281 gatttctacc acacctttga acaatgttct ttcccttctg gttatctgaa
 gactgtcctg
 2341 aaaggaagac ataagtgttg tgattagtag aagctttcta gtagaccata
 tttcttctgg
 2401 attgtaataa aattgttagt agctcctttt actttgttcc tgtctctgga
 aagccatttt
 2461 tgaattgctg attactttgg cttaaatcag tggtcaccta gaaaaagctt
 tgtaatcata
 2521 acacaatgag taattcttga taaaagttca gatacaaaag gagcactgta
 aaactggtag
 2581 gagctatggt ttaagagcat tggaagtagt tacaactcaa ggattttggt
 agaaaggat
 2641 gagtttggtc gaaaaattaa aatagtggca aaataagatt tagttgtggt
 ttctcagagc
 2701 cgccacaaga ttgaacaaaa tgttttctgt ttgggcatcc tgaggaagtt
 gtattagctg
 2761 ttaatgctct gtgagtttag aaaaagtctt gatagtaa atagtttttg
 acacagtgc
 2821 tgaactaagt agttaaatat ttacatatcc agaaaggaat agtggaaaag
 gtatcttggg
 2881 tatgacaaag tcattacaaa tgtgactaag tcattacaaa tgtgactgag
 tcattacagt
 2941 ggaccctctg ggtgcattga aaagaatccg ttttatatcc aggtttcaga
 ggacctggaa
 3001 taataaaaag ctttggattt tgcattcagt gtagttggat tttgggacct
 tggcctcagt
 3061 gttatttact gggattggca tacgtgttca caggcagagt agttgatctc

```

acacaacggg
  3121 tgatctcaca aaactggtaa gtttcttatg ctcatgagcc ctcccttttt
ttttttaatt
  3181 tgggtgcctgc aactttctta acaatgattc tacttcctgg gctatcacat
tataatgctc
  3241 ttggcctctt ttttgctgct gttttgctat tcttaaactt aggccaagta
ccaatggttg
  3301 ctgttagaag ggattctggt cattcaacat gcaactttag ggaatggaag
taagttcatt
  3361 tttaagttgt gttgtcagta ggtgcggtgt ctagggtagt gaatcctgta
agttcaaatt
  3421 tatgattagg tgacgagttg acattgagat tgtccttttc cctgatcaaa
aatgaataa
  3481 agccttttta aacaaaatcc aaacttttaa tcaagtcttg atatgtatga
ctgagaaaaa
  3541 atacactaca tctagagatg attgagatgt tttgcaaaga attgaagggg
gagtgagaat
  3601 tgggtttttct tgcaggggct ttgaacteta gatttgggct ttgaacteta
gatttaattc
  3661 agatttcagg gtctatcagt tcaccaactg atgcaaattt gaacagatac
tctaaggcta
  3721 agtgtcctag gttggatgaa ctgaagctac tatcaagatc tcgttcccaa
ggattaattt
  3781 agaacaaagt aattggacaa gtttattggg gaggggatag aaatgaattc
taaagtacct
  3841 ataacaaata ctctgtgtat gttttttaca tcgtatttgc cttttacatt
gttttagacca
  3901 aattctgtgt gatgttatcc tcgggaagag gatagaaatt aattctaaag
tacctataac
  3961 aaatgctcgg tttgtatatg tttttataca tcgtatttgc cttttgcatt
gttcagacca
  4021 aattctgtgt gatgttatcc taacaaaaca ccttagtaat ttctttgggt
aacatgttaa
  4081 tctgtaatct cacttttata agatgaggac tattaaaatg agatgtctgt
tgggatgcta
  4141 aaaaaaaaaa aaaaaaa
//

```

15. HSPA9: HSPA9 heat shock 70kDa protein 9 (mortalin) [Homo sapiens]

LOCUS NM_004134

AA /translation="MISASRAAAARLVGAAASRGPTAARHQDSWNGLSHEAFRLVSRR
DYASEAIKGAVVGIDLGTTNSCVAVMEGKQAKVLENAEGARTTPSVVAFADGERLVG
MPAKRQAVTNPNNTFYATKRLIGRRYDDPEVQKDIKNVFFKIVRASNGDAWVEAHGKL
YSPSQIGAFVLMKMKETAENYLGHTAKNAVITVPAYFNDSQRQATKDAGQISGLNVLR
VINEPTAAALAYGLDKSEDKVIAVYDLGGGTFDISILEIQGVFEVKSTNGDTFLGGE
DFDQALLRHIVKEFKRETGVDLTKDNMALQRVREAAEKAKCELSSTVQTDINLPYLT
DSSGPKHLNMKLTRAQFEGIVTDLIRRTIAPCQKAMQDAEVSKSDIGEVILVGGMTRM
PKVQQTVDLFGRAVSKAVNPDEAVAIGAAIQGGVLAGDVTDLVLLDVTPLSLGIETL
GGVFTKLINRNTTIPTKKSQVFSTAADGQTQVEIKVCQGEREMAGDNKLLGQFTLIGI
PPAPRGVPQIEVTFDIDANGIVHVSADKGTGREQQIVIQSSGGLSKDDIENMVKNAE
KYAEDRRKKERVEAVNMAEGIIHDTETKMEEFKDQLPADECNKLKEEISKMRELLAR
KDSETGENIRQAASSLQQASLKLKFEMAYKKMASEREGSGSGSGTGEQKEDQKEEKQ

```

cDNA:  1 ttctctccct ggactctttc tgagctcaga gccgcgcgag ccgggacagg
agggcagget
      61 ttctccaacc atcatgctgc ggagcatatt acctgtacgc cctggctccg
ggagcggcag
     121 tcgagtatcc tctggtcagg cggcgcgggc ggcgccctcag cggaagagcg
ggcctctggg
     181 ccgcagtgac caacccccgc cctcacccc acgtggttg aggtttccag

```

```

aagcgtgcc
  241 gccaccgcat cgcgcagctc tttgccgtcg gagcgttgt ttgctgcctc
gtactcctcc
  301 atttatccgc catgataagt gccagccgag ctgcagcagc ccgtctcgtg
ggcgcgcgag
  361 cctcccgggg ccctacggcc gcccgccacc aggatagctg gaatggcctt
agtcattgagg
  421 ctttttagact tgtttcaagg cgggattatg catcagaagc aatcaaggga
gcagttgttg
  481 gtattgattt gggactacc aactcctgcg tggcagttat ggaaggtaaa
caagcaaagg
  541 tgctggagaa tgccgaaggt gccagaacca ccccttcagt tgtggccttt
acagcagatg
  601 gtgagcgact tgttggaatg cgggccaagc gacaggctgt caccaacca
aacaatacat
  661 tttatgctac caagcgtctc attggccggc gatatgatga tcctgaagta
cagaaagaca
  721 ttaaaaatgt tccctttaa attgtccgtg cctccaatgg tgatgcctgg
gttgaggctc
  781 atgggaaatt gtattctccg agtcagattg gagcatttgt gttgatgaag
atgaaagaga
  841 ctgcagaaaa ttacttgggg cacacagcaa aaaatgctgt gatcacagtc
ccagcttatt
  901 tcaatgactc gcagagacag gccactaaag atgctggcca gatattctga
ctgaatgtgc
  961 ttcgggtgat taatgagccc acagctgctg ctcttgcta tggctagac
aaatcagaag
 1021 acaaagtcac tgctgtatat gatttaggtg gtggaacttt tgatatttct
atcctggaaa
 1081 ttcagaaagg agtatttgag gtgaaatcca caaatgggga taccttctta
ggtggggaag
 1141 actttgacca ggccttgcta cggcacattg tgaaggagtt caagagagag
acagggttg
 1201 atttgactaa agacaacatg gcacttcaga gggtagggga agctgctgaa
aaggctaaat
 1261 gtgaactctc ctcatctgtg cagactgaca tcaatttgcc ctattctaca
atggattctt
 1321 ctggacccaa gcatttgaat atgaagtga cccgtgctca atttgaaggg
attgtcactg
 1381 atctaatacag aaggactatc gctccatgcc aaaaagctat gcaagatgca
gaagtcagca
 1441 agagtacatc aggagaagtg attcttgtgg gtggcatgac taggatgccc
aaggttcagc
 1501 agactgtaca ggatcttttt ggcagagccc caagtaaagc tgtcaatcct
gatgaggctg
 1561 tggccattgg agctgccatt caggagagtg tgttggccgg cgatgtcacg
gatgtgctgc
 1621 tccttgatgt cactccctg tctctgggta ttgaaactct aggaggtgtc
tttaccaaac
 1681 ttattaatag gaataccact attccaacca agaagagcca ggtattctct
actgccgtg
 1741 atgggtcaaac gcaagtggaa attaaagtgt gtcagggtga aagagagatg
gctggagaca
 1801 acaaactcct tggacagttt actttgattg gaattccacc agcccctcgt
ggagtctctc
 1861 agattgaagt tacatttgac attgatgcca atgggatagt acatgtttct
gctaaagata
 1921 aaggcacagg acgtgagcag cagattgtaa tccagtcttc tgggtggatta
agcaaagatg
 1981 atattgaaaa tatggttaaa aatgcagaga aatatgctga agaagaccgg
cgaaagaagg

```

2041 aacgagttga agcagttaat atggctgaag gaatcattca cgacacagaa
 accaagatgg
 2101 aagaattcaa ggaccaatta cctgctgatg agtgcaacaa gctgaaagaa
 gagatttcca
 2161 aaatgagggg gctcctggct agaaaagaca gcgaaacagg agaaaatatt
 agacaggcag
 2221 catcctctct tcagcaggca tctactgaagc tgttcgaaat ggcatacaaa
 aagatggcat
 2281 ctgagcgaga aggctctgga agttctggca ctggggaaca aaaggaagat
 caaaaggagg
 2341 aaaaacagta ataatagcag aaattttgaa gccagaagga caacatatga
 agcttaggag
 2401 tgaagagact tcctgagcag aaatgggcga acttcagtct ttttactgtg
 tttttgcagt
 2461 attctatata taatttcctt aatttgtaaa tttagtacc attagctagt
 gatcatttaa
 2521 tggacagtga ttctaacagt ataaagttca caatattcta tgtccctagc
 ctgtcatttt
 2581 tcagctgcat gtaaaaggag gtaggatgaa ttgatcatta taaagattta
 actattttat
 2641 gctgaagtga ccatattttc aaggggtgaa accatctcgc acacagcaat
 gaaggtagtc
 2701 atccatagac ttgaaatgag accacatatg gggatgagat ctttctagtt
 agcctagtac
 2761 tgctgtactg gcctgtatgt acatggggtc cttcaactga ggcttgcaa
 gtcaagctgg
 2821 ctgtgccatg tttgtagatg gggcagagga atctagaaca atgggaaact
 tagctattta
 2881 tattaggtac agctattaaa acaaggtagg aatgaggcta gaccttaac
 ttccctaagg
 2941 catacttttc tagctacett ctgccctgtg tctggcacct acatcettga
 tgattgttct
 3001 cttaccatt ctggaatttt tttttttta aataaatata gaaagcatct
 tgatctcttg
 3061 tttgtgaggg gtgatgccct gagatttagc ttcaagaata tgccatggct
 catgcttccc
 3121 atatttccca aagagggaaa tacaggattt gctaacactg gttaaaaaatg
 caaattcaag
 3181 atttggaagg gctgttataa tgaaataatg agcagtatca gcatgtgcaa
 atcttgtttg
 3241 aaggatttta ttttctcccc ttagaccttt ggtacattta gaatcttgaa
 agtttctaga
 3301 tctctaacat gaaagtttct agatctctaa catgaaagtt ttagatctc
 taacatgaaa
 3361 accaaggtgg ctattttcag gttgctttca gctccaagta gaaataacca
 gaattggctt
 3421 acattaaaga aactgcatct agaaataagt cctaagatac tatttctatg
 gctcaaaaat
 3481 aaaaggaacc cagatttctt tcccta

//

16. MAP2K2: MAP2K2 mitogen-activated protein kinase kinase 2 [Homo sapiens]

LOCUS NM_030662

AA /translation="MLARRKPVLPALTINPTIAEGPSPTSEGASEANLVDLQKKLEEL
 ELDEQQKKRLEAFLTQKAKVGELKDDDFERISELGAGNGGVVTKVQHRPSGLIMARKL
 IHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLK
 EAKRIPEEILGKVSIAVLRGLAYLREKHQIMHRDVKPSNILVNSRGEIKLCDFGVSGQ
 LIDSMANSFVGTRSYMAPERLQGTHYSVQSDIWSMGLSLVELAVGRYPPIPPDAKELE
 AIFGRPVVDGEEGEPHSISPRPRPPGRPVSGHGMDSRPAMAFELLDYIVNEPPPKLP
 NGVFTPDFQEFVNKCLIKNPAERADLKMLTNHTFIKRSEVEEVDFAGWLCKTLRLNQP

GTPTRTAV

cDNA: 1 cccctgcctc tgggactcgg gctgcggcgt cagccttctt cgggcctcgg
 cagcggtagc
 61 ggctcgctcg cctcagcccc agcgcacctc ggctacctc ggcccaggcc
 cgcagcgccg
 121 cccgccctcg gccgccccga cgccggcctg ggccgcggcc gcagccccgg
 gctcgcgtag
 181 gcgccgaccg ctcccgcccc gccccctatg ggccccggct agaggcgccg
 ccgccgcggg
 241 cccgcggagc cccgatgctg gcccgaggga agccggtgct gccggcgctc
 accatcaacc
 301 ctaccatcgc cgaggggccca tccccacca gcgagggcgc ctccgaggca
 aacctggtgg
 361 acctgcagaa gaagctggag gagctggaac ttgacgagca gcagaagaag
 cggtcggaag
 421 cctttctcac ccagaaagcc aaggctcggc aactcaaaga cgatgacttc
 gaaaggatct
 481 cagagctggg cgccgggcaac ggccgggtgg tcaccaaagt ccagcacaga
 ccctcgggcc
 541 tcatcatggc caggaagctg atccacctg agatcaagcc ggccatccgg
 aaccagatca
 601 tccgcgagct gcaggctctg cacgaatgca actcgccgta catcgtgggc
 ttctacgggg
 661 ccttctacag tgacggggag atcagcattt gcatggaaca catggacggc
 ggctccctgg
 721 accaggtgct gaaagaggcc aagaggattc ccgaggagat cctggggaaa
 gtcagcatcg
 781 cggttctccg gggcttggcg tacctccgag agaagcacca gatcatgcac
 cgagatgtga
 841 agccctccaa catcctcgtg aactctagag gggagatcaa gctgtgtgac
 ttccgggtga
 901 gcggccagct catcgactcc atggccaact ccttcgtggg cagcgctcc
 tacatggctc
 961 cggagcgggt gcagggcaca cattactcgg tgcagtcgga catctggagc
 atgggcctgt
 1021 ccctggtgga gctggcgcgc ggaaggtacc ccatacccc gcccgacgcc
 aaagagctgg
 1081 aggccatctt tggccggccc gtggtcgacg gggaagaagg agagcctcac
 agcatctcgc
 1141 ctcggccgag gccccccggg cgccccgtca gcggtcacgg gatggatagc
 cggcctgcca
 1201 tggccatctt tgaactcctg gactatattg tgaacgagcc acctcctaag
 ctgccccacg
 1261 gtgtgttcac ccccgacttc caggagtgtg tcaataaatg cctcatcaag
 aaccagcgg
 1321 agcgggcgga cctgaagatg ctacacaaacc acaccttcac caagcggctc
 gaggtggaag
 1381 aagtggattt tgccggctgg ttgtgtaaaa ccctgcggct gaaccagccc
 ggcacaccca
 1441 cgcgcaccgc cgtgtgacag tggccgggct ccctgcgtcc cgctggtgac
 ctgcccaccg
 1501 tcctgtcca tgccccgcc ttccagctga ggacaggctg gcgcctccac
 ccacctcct
 1561 gcctcacccc tgcggagagc accgtggcgg ggcgacagcg catgcaggaa
 cgggggtctc
 1621 ctctcctgcc cgtcctggcc ggggtgcctc tggggacggg cgacgtgct
 gtgtgtggtc
 1681 tcagaggctc tgcttcctta ggttacaaaa caaacaggg agagaaaaag
 caaaaaaaa
 1741 aaaaaaaaaa aaaaaaaaaa

//

17. LDHA: LDHA lactate dehydrogenase A [Homo sapiens]
 LOCUS NM_001135239 (isoform 2)
 AA/translation="MATLKDQLIYNLLKEEQTPQNKITVVGVGAVGMACAISILMKDL
 ADELALVDVIEDKLGEMMDLQHGSFLRTPKIVSGKVDILTYVAWKISGFPKNRVIG
 SGCNLD SARFRYLMGERLGVHPLSCHGWVLGEHGDSSVPVWSGMNVAGVSLKTLHPDL
 GTDKDKEQWKEVHKQVVESAYEVIKLGKGYTSAIGLSVADLAESIMKNLRRVHPVSTM
 IKGLYGIKDDVFLSVPCILGQNGISDLVKVTLTSEEEARLKKSADTLWGIQKELQF

cDNA: 1 gtctgccggt cggttgtctg gctgcgcgcg ccacccgggc ctctccagtg
 ccccgccctgg
 61 ctccggcatcc acccccagcc cgactcacac gtgggttccc gcacgtccgc
 cgcccccccc
 121 cgctgacgtc agcatagctg ttccacttaa ggcccctccc gcgcccagct
 cagagtgtctg
 181 cagccgctgc cgccgattcc ggatctcatt gccacgcgcc cccgacgacc
 gcccgacgtg
 241 cattcccgat tccttttgggt tccaagtcca atatggcaac tctaaaggat
 cagctgattt
 301 ataatcttct aaaggaagaa cagaccccc agaataagat tacagttggt
 ggggttgggtg
 361 ctgttggcat ggctgtgcc atcagtatct taatgaagga cttggcagat
 gaacttgctc
 421 ttgttgatgt catcgaagac aaattgaagg gagagatgat ggatctccaa
 catggcagcc
 481 ttttccttag aacaccaaag attgtctctg gcaaagtgga tatcttgacc
 tacgtggctt
 541 ggaagataag tggttttccc aaaaaccgtg ttattggaag cggttgcaat
 ctggattcag
 601 cccgattccg ttacctaatg ggggaaaggc tgggagttca cccattaagc
 tgtcatgggt
 661 gggtccttgg ggaacatgga gattccagtg tgctgtatg gagtggaatg
 aatgttgctg
 721 gtgtctctct gaagactctg caccagatt tagggactga taaagataag
 gaacagtgga
 781 aagaggttca caagcagggtg gttgagagt cttatgaggt gatcaaactc
 aaaggctaca
 841 catcctgggc tattggactc tctgtagcag atttggcaga gagtataatg
 aagaatctta
 901 ggccgggtgca cccagtttcc accatgatta agggctctta cggaataaag
 gatgatgtct
 961 tccttagtgt tccttgcaat ttgggacaga atggaatctc agaccttggtg
 aagggtgactc
 1021 tgacttctga ggaagaggcc cgtttgaaga agagtgcaga tacactttgg
 gggatccaaa
 1081 aggagctgca attttaaagt cttctgatgt catatcattt cactgtctag
 gctacaacag
 1141 gattctaggt ggagggtgtg catgttgtcc tttttatctg atctgtgatt
 aaagcagtaa
 1201 tattttaaga tggactggga aaaacatcaa ctctgaagt tagaaataag
 aatggtttgt
 1261 aaaatccaca gctatatact gatgctggat ggtattaatc ttgtgtagtc
 ttcaactggt
 1321 tagtgtgaaa tagttctgcc acctctgacg caccactgcc aatgctgtac
 gtactgcatt
 1381 tgccccctga gccagggtgga tgtttaccgt gtgttatata acttctggc
 tccttcactg
 1441 aacatgccta gtccaacatt ttttccaggt gagtcacatc ctgggatcca
 gtgtataaat
 1501 ccaatatcat gtcttggtgca taattcttcc aaaggatctt attttgtgaa


```

ctatatcagt
1561 agtgtacatt accatataat gtaaaaagat ctacatacaa acaatgcaac
caactatcca
1621 agtggttatac caactaaaac cccaataaaa ccttgaacag tgactacttt
ggttaattca
1681 ttatattaag atataaagtc ataaagctgc tagttattat attaatttgg
aaatattagg
1741 ctattcttgg gcaaccctgc aacgattttt tctaacaggg atattattga
ctaatagcag
1801 aggatgtaat agtcaactga gttgtattgg taccacttcc attgtaagtc
ccaaggtatt
1861 atatatttga taataatgct aatcataatt ggaaagtaac attctatatg
taaagtataa
1921 atttatttgc caactgaata taggcaatga tagtgtgtca ctatagggaa
cacagatttt
1981 tgagatcttg tcctctggaa gctggtaaca attaaaaaca atcttaaggc
agggaaaaaa
2041 aaaaaaaaaa aa

//
LOCUS      NM_001165414                      (isoform 3)
AA/translation="MGEPSGGYTYTQTSIFLFHAKIPFGSKSNMATLKDQLIYNLLKE
EQTPQNKITVVGAVGMACAISILMKDLADELALVDVIEDKLKGEMMDLQHGSFLFR
TPKIVSGKDYNVTANSKLVIIITAGARQQEGESRLNLVQRNVNIFKFIIPNVVKYSPNC
KLLIVSNPVDILTIVAWKISGFPKNRVIGSGCNLDSARFRYLMGERLGVHPLSCHGWV
LGEHGDSSVPVWSGMNVAGVSLKTLHPDLGTDKDKEQWKEVHKQVVESAYEVIKLGKY
TSWAIGLSVADLAESIMKNLRRVHPVSTMIKGLYGIKDDVFLSVPCILGQNGISDLVK
VTLTSEEEARLKKSadTLWGIQKELQF

cDNA:  1 ttgggcgggg cgtaaaagcc gggcggtcgg aggaccagc aattagtctg
atttcgccc
61 acctttccga gcgggaagga gagccacaaa gcgcgcagtc gcgcggatca
ccgcaggctc
121 ctgtgccttg ggcttgagct ttgtggcagt taatggcttt tctgcacgta
tctctggtgt
181 ttacttgaga agcctggctg tgtccttget gtaggagccg gagtagctca
gagtgatctt
241 gtctgaggaa aggccagccc cacttggggg taataaaccg cgatgggtga
accctcagga
301 ggctatactt acacccaaac gtcgatattc cttttccacg ctaagattcc
ttttggttcc
361 aagtccaata tggcaactct aaaggatcag ctgatttata atcttctaaa
ggaagaacag
421 acccccaga ataagattac agttgttggg gttggtgctg ttggcatggc
ctgtgccatc
481 agtatcttaa tgaaggactt ggcagatgaa cttgctcttg ttgatgtcat
cgaagacaaa
541 ttgaaggagg agatgatgga tctccaacat ggcagccttt tccttagaac
accaaagatt
601 gtctctggca aagactataa tgtaactgca aactccaagc tggtcattat
cacggctggg
661 gcacgtcagc aagagggaga aagccgtctt aatttgggtcc agcgtaacgt
gaacatcttt
721 aaattcatca ttccaatgt tgtaaaatac agcccgaaact gcaagttgct
tattgtttca
781 aatccagtgg atatcttgac ctacgtggct tggaagataa gtggttttcc
caaaaaccgt
841 gttattggaa gcggttgcaa tctggattca gcccgattcc gttacetaat
gggggaaagg
901 ctgggagttc acccatgaag ctgtcatggg tgggtccttg gggaacatgg
agattccagt

```

```

    961 gtgcctgtat ggagtggaat gaatgttgc ggtgtctctc tgaagactct
gcaccagat
    1021 ttagggactg ataaagataa ggaacagtgg aaagagggtc acaagcaggt
ggttgagagt
    1081 gcttatgagg tgatcaaact caaaggctac acatcctggg ctattggact
ctctgtagca
    1141 gatttggcag agagtataat gaagaatctt aggggggtgc acccagtttc
caccatgatt
    1201 aagggtcttt acggaataaa ggatgatgtc ttccttagtg ttccttgcac
tttgggacag
    1261 aatggaatct cagaccttgt gaagggtgact ctgacttctg aggaagaggg
ccgtttgaag
    1321 aagagtgcag atacactttg ggggatccaa aaggagctgc aattttaaag
tcttctgatg
    1381 tcatatcatt tcaactgtct ggctacaaca ggattctagg tggaggttgt
gcatgttgtc
    1441 ctttttatct gatctgtgat taaagcagta atattttaag atggactggg
aaaaacatca
    1501 actcctgaag ttagaaataa gaatggtttg taaaatccac agctatatcc
tgatgctgga
    1561 tggattaat cttgtgtagt cttcaactgg ttagtgtgaa atagttctgc
cacctctgac
    1621 gcaccactgc caatgctgta cgtactgcat ttgcccttg agccaggtgg
atgtttaccg
    1681 tgtgttatat aacttctgg ctccttcaact gaacatgcct agtccaacat
tttttcccag
    1741 tgagtcacat cctgggatcc agtgtataaa tccaatatca tgtcttgtgc
ataattcttc
    1801 caaaggatct tattttgtga actatatcag tagtgtacat taccatataa
tgtaaaaaga
    1861 tctacatata aacaatgcaa ccaactatcc aagtgttata ccaactaaaa
cccccaataa
    1921 accttgaaca gtgactactt tggttaattc attatattaa gatataaagt
cataaagctg
    1981 ctagtattata tattaatttg gaaatattag gctattcttg ggcaaccctg
caacgatttt
    2041 ttctaacagg gatattattg actaatagca gaggatgtaa tagtcaactg
agttgtattg
    2101 gtaccacttc cattgtaagt cccaaagtat tatatatattg ataataatgc
taatcataat
    2161 tggaaagtaa cattctatat gtaaagttaa aattttattg ccaactgaat
ataggcaatg
    2221 atagtgtgtc actataggga acacagattt ttgagatctt gtccctctgga
agctggtaac
    2281 aattaataaac aatcttaagg cagggaataa aaaaaaaaaa aaa

```

//

```

LOCUS      NM_001165415                      (isoform 4)
AA/translation="MATLKDQLIYNLLKEEQTPQNKITVVGVGAVGMACAISILMKDL
ADELALVDVIEDKLKGEMMDLQHGSLFLRTPKIVSGKDYNVTANSKLVIITAGARQQE
GESRLNLVQRNVNIFKFIIPNVVKYSPNCKLLIVSNPVDILTYVAVKISGFPKNRVIG
SGCNLDSARFRYLMGERLGVHPLSCHGWVLGEHGDSSVPVWSGMNVAGVSLKTLHPDL
GTDKDKEQWKECRYTLGDPKGAAILKSSDVISFHLGYNRILGGGCACCPFYLICD

```

```

cDNA:  1 gtctgccggt cggttgtctg gctgcgcgcg ccaccggggc ctctccagtg
ccccgcctgg
      61 ctcggcacac acccccagcc cgactcacac gtgggttccc gcacgtccgc
cgccccccc
     121 cgctgacgtc agcatagctg ttccacttaa ggccccctccc gcgcccagct
cagagtgtctg
     181 cagccgctgc cgccgattcc ggatctcatt gccacgcgcc cccgacgacc

```

```

gcccgacgtg
  241 cattccccgat tccttttgggt tccaagtcca atatggcaac tctaaaggat
cagctgattt
  301 ataatcttct aaaggaagaa cagaccccc agaataagat tacagttggt
ggggttgggtg
  361 ctgttggcat ggctgtgcc atcagtatct taatgaagga cttggcagat
gaacttgctc
  421 ttgttgatgt catcgaagac aaattgaagg gagagatgat ggatctccaa
catggcagcc
  481 ttttccttag aacaccaaag attgtctctg gcaaagacta taatgtaact
gcaaactcca
  541 agctggatcat tatcacggct ggggcacgtc agcaagagg agaaagccgt
cttaatttgg
  601 tccagcgtaa cgtgaacatc tttaaattca tcattcctaa tgttgtaaaa
tacagcccgga
  661 actgcaagtt gcttattggt tcaaatccag tggatatctt gacctacgtg
gcttggaaga
  721 taagtggttt tcccaaaaac cgtgttattg gaagcgggtt caatctggat
tcagcccgat
  781 tccgttacct aatgggggaa aggctgggag ttcacccatt aagctgtcat
gggtgggtcc
  841 ttggggaaca tggagattcc agtgtgcctg tatggagtgg aatgaatggt
gctggtgtct
  901 ctctgaagac tctgcacca gatttaggga ctgataaaga taaggaacag
tggaagagt
  961 gcagatacac tttgggggat ccaaaaggag ctgcaatttt aaagtcttct
gatgtcatat
 1021 catttcactg tctaggctac aacaggattc taggtggagg ttgtgcatgt
tgtccttttt
 1081 atctgatctg tgattaaagc agtaatat taaatggac tgggaaaaac
atcaactcct
 1141 gaagttagaa ataagaatgg tttgtaaaat ccacagctat atcctgatgc
tggatggtat
 1201 taatcttgtg tagtcttcaa ctggttagtg tgaaatagtt ctgccacctc
tgacgcacca
 1261 ctgccaatgc tgtacgtact gcatttgccc cttgagccag gtggatgttt
accgtgtgtt
 1321 atataacttc ctggctcctt cactgaacat gcctagtcca acattttttc
ccagtgaagtc
 1381 acatcctggg atccagtgt taaatccaat atcatgtctt gtgcataatt
cttccaaagg
 1441 atcttatttt gtgaactata tcagtagtgt acattaccat ataatgtaaa
aagatctaca
 1501 tacaacaact gcaaccaact atccaagtg tataccaact aaaaccccca
ataaaccttg
 1561 aacagtgact actttgggta attcattata ttaagatata aagtcataaa
gctgctagtt
 1621 attatattaa tttggaaata ttaggtatt cttgggcaac cctgcaacga
ttttttctaa
 1681 cagggatatt attgactaat agcagaggat gtaatagtca actgagttgt
attggtacca
 1741 cttccattgt aagtcccaaa gtattatata tttgataata atgctaata
taattggaaa
 1801 gtaacattct atatgtaaat gtaaaattta tttgccaact gaatataggc
aatgatagtg
 1861 tgtcactata gggaacacag atttttgaga tcttgtcctc tggaagctgg
taacaattaa
 1921 aaacaatctt aaggcaggga aaaaaaaaaa aaaaaaa
//

```

LOCUS

NM_001165416

(isoform 5)

AA/translation="MATLKDQLIYNLLKEEQTPQNKITVVGVGAVGMACAISILMKDL
 ADELALVDVIEDKLGEMMDLQHGSFLRTPKIVSGKDYNVTANSKLVIITAGARQQE
 GESRLNLVQRNVNIFKFIIPNVVKYSPNCKLLIVSNPVDILTYVAWKISGFPKNRVIG
 SGCNLDSARFRYLMGERLGVHPLSCHGWVLGEHGDSSVPVWSGMNVAGVSLKTLHPDL
 GTDKDKEQWKEVHKQVVERVFTE

cDNA: 1 gtctgccggt cggttgtctg gctgcgcgcg ccacccgggc ctctccagtg
 ccccgccctgg
 61 ctcgccatcc acccccagcc cgactcacac gtgggttccc gcacgtccgc
 cgcccccccc
 121 cgctgacgtc agcatagctg ttccacttaa ggcccctccc gcgcccagct
 cagagtgtctg
 181 cagccgctgc cgccgattcc ggatctcatt gccacgcgcc cccgacgacc
 gcccgacgtg
 241 cattcccgat tccttttggg tccaagtcca atatggcaac tctaaaggat
 cagctgattt
 301 ataatcttct aaaggaagaa cagaccccc agaataagat tacagttggt
 ggggttgggtg
 361 ctgttgccat ggctgtgcc atcagtatct taatgaagga cttggcagat
 gaacttgctc
 421 ttgttgatgt catcgaagac aaattgaagg gagagatgat ggatctccaa
 catggcagcc
 481 ttttccttag aacaccaaag attgtctctg gcaaagacta taatgtaact
 gcaaactcca
 541 agctggcat tatcacggct ggggcacgtc agcaagaggg agaaagccgt
 cttaatttgg
 601 tccagcgtaa cgtgaacatc tttaaattca tcattcctaa tgttgtaaaa
 tacagcccga
 661 actgcaagtt gcttattggt tcaaaccag tggatatctt gacctacgtg
 gcttggaaga
 721 taagtgggtt tccccaaac cgtgttattg gaagcgggtg caatctggat
 tcagcccgat
 781 tccgttacct aatgggggaa aggtgggag ttcaccatt aagctgtcat
 ggggtgggtcc
 841 ttggggaaca tggagattcc agtgtgcctg tatggagtgg aatgaatggt
 gctggtgtct
 901 ctctgaagac tctgcaccca gatttaggga ctgataaaga taaggaacag
 tggaaagagg
 961 ttcacaagca ggtggttgag agggctctta cggaataaag gatgatgtct
 tccttagtgt
 1021 tccttgcatc ttgggacaga atggaatctc agacctgtg aaggtgactc
 tgacttctga
 1081 ggaagaggcc cgtttgaaga agagtgcaga tacactttgg gggatccaaa
 aggagctgca
 1141 attttaaagt cttctgatgt catatcattt cactgtctag gctacaacag
 gattctaggt
 1201 ggaggttgtg catgttgtcc tttttatctg atctgtgatt aaagcagtaa
 tattttaaga
 1261 tggactggga aaaacatcaa ctctgaagt tagaaataag aatggtttgt
 aaaatccaca
 1321 gctatatcct gatgctggat ggtattaatc ttgtgtagtc ttcaactggt
 tagtgtgaaa
 1381 tagttctgcc acctctgacg caccactgcc aatgctgtac gtactgcatt
 tgccccctga
 1441 gccaggtgga tgtttaccgt gtgttatata acttctggc tccttcactg
 aacatgcta
 1501 gtccaacatt tttcccagtg gagtcacatc ctgggatcca gtgtataaat
 ccaatatcat
 1561 gtcttggtgca taattcttcc aaaggatctt attttgtgaa ctatatcagt
 agtgtacatt
 1621 accatataat gtaaaaagat ctacatacaa acaatgcaac caactatcca

```

agtgttatac
1681 caactaaaac cccaataaaa ccttgaacag tgactacttt ggtaattca
ttatattaag
1741 atataaagtc ataaagctgc tagttattat attaatttgg aaatattagg
ctattcttgg
1801 gcaaccctgc aacgattttt tctaacaggg atattattga ctaatagcag
aggatgtaat
1861 agtcaactga gttgtattgg taccacttcc attgtaagtc ccaaagtatt
atataattga
1921 taataatgct aatcataatt ggaaagtaac attctatatg taaatgtaaa
atttatttgc
1981 caactgaata taggcaatga tagtgtgtca ctataggga cacagatttt
tgagatcttg
2041 tcctctggaa gctggtaaca attaaaaaca atcttaaggc agggaaaaaa
aaaaaaaaa
2101 aa

```

//

```

LOCUS          NM_005566                      (isoform 1)
AA/translation="MATLKDQLIYNLLKEEQTPQNKITVVGVGAVGMACAISILMKDL
ADELALVDVIEDKLKGEMMDLQHGSFLRTPKIVSGKDYNVTANSKLVIITAGARQQE
GESRLNLVQRNVNIFKFIIPNVVKYSPNCKLLIVSNPVDILTYVAWKISGFKNRVIG
SGCNLDSARFRYLMGERLGVHPLSCHGWVLGEHGDSSVPVWSGMNVAGVSLKTLHPDL
GTDKDKEQWKEVHKQVVEYAYEVIKLGYTSSWAGLSVADLAESIMKNLRRVHPVSTM
IKGLYGIKDDVFLSVPCILGQNGISDLVKVTLTSEEEARLKKSADTLWGIQKELQF

```

```

cDNA:  1 gtctgceggg cggttgtctg gctgcgcgcg ccacccgggc ctctccagtg
ccccgcctgg
61 ctcgccatcc acccccagcc cgactcacac gtgggttccc gcacgtccgc
cgccccccc
121 cgctgacgtc agcatagctg ttccacttaa ggcccctccc gcgccagct
cagagtgtctg
181 cagccgtgc cgccgattcc ggatctcatt gccacgcgcc cccgacgacc
gcccgacgtg
241 cattcccgat tccttttggg tccaagtcca atatggcaac tctaaaggat
cagctgattt
301 ataatcttct aaaggaagaa cagacccccc agaataagat tacagttggt
ggggttggtg
361 ctgttgcat ggccgtgtgc atcagtatct taatgaagga cttggcagat
gaacttgctc
421 ttgttgatgt catcgaagac aaattgaagg gagagatgat ggatctcaa
catggcagcc
481 ttttccttag aacaccaaag attgtctctg gcaaagacta taatgtaact
gcaaactcca
541 agctggatcat tatcagcgtt ggggcacgtc agcaagaggg agaaagccgt
cttaatttgg
601 tccagcgtaa cgtgaacatc tttaaattca tcattcctaa tggtgtaaaa
tacagccga
661 actgcaagtt gcttattggt tcaaaccag tggatatctt gacctacgtg
gcttgaaga
721 taagtgttt tccaaaaaac cgtgttattg gaagcgggtg caatctggat
tcagcccgat
781 tccgttacct aatgggggaa aggtggggag ttcaccatt aagctgtcat
gggtgggtcc
841 ttggggaaca tggagattcc agtgtgcctg tatggagtgg aatgaatgtt
gctggtgtct
901 ctctgaagac tctgcacca gatttaggga ctgataaaga taaggaaacag
tggaaagagg
961 ttcacaagca ggtggttgag agtgcttatg aggtgatcaa actcaaaggc
tacacatcct
1021 gggctatttg actctctgta gcagatttgg cagagagtat aatgaagaat

```

cttaggcggg
 1081 tgcacccagt ttccaccatg attaagggtc tttacggaat aaaggatgat
 gtcttcctta
 1141 gtgttccttg cattttggga cagaatggaa tctcagacct tgtgaagggtg
 actctgactt
 1201 ctgaggaaga ggcccgtttg aagaagagtg cagatacact ttgggggatc
 caaaaggagc
 1261 tgcaatttta aagtcttctg atgtcatatc atttcactgt ctaggctaca
 acaggattct
 1321 aggtggaggt tgtgcatggt gtccttttta tctgatctgt gattaaagca
 gtaatatctt
 1381 aagatggact gggaaaaaca tcaactcctg aagttagaaa taagaatggt
 ttgtaaaatc
 1441 cacagctata tcctgatgct ggatggtatt aatcttgtgt agtcttcaac
 tggttagtgt
 1501 gaaatagttc tgccacctct gacgcaccac tgccaatgct gtacgtactg
 catttgcccc
 1561 ttgagccagg tggatgttta ccgtgtgtta tataacttcc tggctccttc
 actgaacatg
 1621 cctagtccaa ctttttttcc cagtgagtca catcctggga tccagtgtat
 aaatccaata
 1681 tcatgtcttg tgcataatcc ttccaaagga tcttattttg tgaactatat
 cagtagtgta
 1741 cattaccata taatgtaaaa agatctacat acaaacaatg caaccaacta
 tccaagtgtt
 1801 ataccaacta aaacccccaa taaaccttga acagtgacta ctttgggtta
 ttcattatat
 1861 taagatataa agtcataaag ctgctagtta ttatattaat ttggaaatat
 taggctatcc
 1921 ttgggcaacc ctgcaacgat tttttctaac agggatatta ttgactaata
 gcagaggatg
 1981 taatagtcaa ctgagttgta ttggtaccac ttccattgta agtcccaaag
 tattatatat
 2041 ttgataataa tgctaatacat aattggaaaag taacattcta tatgtaaag
 taaaatttat
 2101 ttgccaaactg aatataggca atgatagtgt gtcactatag ggaacacaga
 tttttgagat
 2161 cttgtcctct ggaagctggg aacaattaaa aacaatctta aggcagggaa
 aaaaaaaaaa
 2221 aaaaaa

//

18. MAP4: MAP4 microtubule-associated protein 4 [Homo sapiens]

LOCUS NM_001134364 (isoform 4)
 AA/translation="MADLSLADALTEPSPDIEGEIKRDFIATLEAEAFDDVVGETVGK
 TDYIPLLDVDEKTGNSESKKKPCSETSQIEDTPSSKPTLLANGGHGVEGSDTTGSPTE
 FLEEKMAQEYPNSQNPEDTNFCFQPEQVVDPIQTDPFKMYHDDDLADLVFPSSATA
 DTSIFAGQNDPLKDSYGMSPCNTAVVPQGSVEALNSPHSESFVSPEAVAEPQPTAV
 PLELAKEIEMASEERPPAQALEIMMGLKTTDMAPSKETEMALAKDMALATKTEVALAK
 DMESPTKLDVTLAKDMQPSMESDMALVKDMELPTEKEVALVKDVRWPTETDVSACKNV
 VLPTEVEVAPAKDVTLKKETERASPIKMDLAPSKDMGPPKENKKETERASPIKMDLAP
 SKDMGPPKENKIVPAKDLVLLSEIEVAQANDIISSTEISSAEKVALSSETEVALARDM
 TLPPETNVILTKDKALPLEAEVAPVKDMAQLPETEIAPAKDVAPSTVKEVGLLKDMSP
 LSETEMALGKDVTPPETEVVLIKNVCLPPEMEVALTEDQVPALKTEAPLAKDGVLT
 ANNVTAPKDVPLSETEATPVPIKDMEDIAQTQKGISEDHLESLQDVGQSAAPTFMIS
 PETVTGTGKKCSLPAEEDSVLEKLGERKPCNSQPSELSSSETSGIARPEEGRPVVSGTG
 NDITTPPNKELPPSPEKKTKPLATTQPAKTSTSKAKTQPTSLPKQPAPTTIGLNNKKP
 MSLASGLVPAAPPKRPASARPSILPSKDVKPKPIADAKAPEKRASPSKPASAPASR
 SGSKSTQTVAKTTTAAVASTGPSSRSPSTLLPKKPTAIKTEGKPAEVKKMTAKSVPA
 DLSRPKSTSTSSMKKTTTLSGTAPAGVVPSPRVKATPMPSPSTTPFIDKKPTSAPKS

STTPRLSRLATNTSAPDLKNVRSKVGSTENIKHQPGGGRAKVEKKTEAAATTRKPESN
 AVTKTAGPIASAQKQFAGKVQIVSKVSYSHIQSKCGSKDNIKHVPGGGNVQIQNKKV
 DISKVSSKCGSKANIKHKPGGGDVKIESQKLNFKKAQAKVGSLDNVGHLPPAGGAVKI
 ETYRLTFRANARARTDHGADIVSRPPHFPGGPNSSGSRVLGPLSRAVH

cDNA: 1 aggccccacc cgctggtggc cgggtccgcg tgtgcgccga ctctcgact
 ctctcgctc
 61 cgggcgccca gactctgaga gagagcgacg gccatcatag aacagcgaag
 gcagtcgac
 121 ggctgcggt ccgcttcggc attcgcaggc cgcaggcggg aggctagagc
 cccagggcg
 181 acctcgcccc aaccgcccgc ggctcgggca gctctgcaga gacgtcgtgg
 cggcaggggc
 241 agcaccatt ggtccgccac agcctccgc cctccccctc gccacgetta
 ttggccggag
 301 cggcggcgct cgcgggtag gcggtggcgg cgtccctccc ttgcgcggc
 cctcaagagg
 361 cgacgaggaa gcggccgct cctgcgccc cgcctccg gctagctcgc
 tggtcccg
 421 ctctccga cgtctctac ctctcacgg ctcttccgg cgtctctctg
 gctcccttct
 481 gccccagctc cgtctcggcg gcggcgggca gttgcagtgg tgcagaatgg
 ctgacctcag
 541 tcttgcatg gcattaacag aacctctcc agacattgag ggagagataa
 agcgggactt
 601 cattgccaca ctagaggcag aggccttga tgatgttggt ggagaaactg
 ttggaaaaac
 661 agactatatt cctctcttg atgttgatga gaaaaccggg aactcagagt
 caaagaagaa
 721 accgtgctca gaaactagcc agattgaaga tactccatct tctaaaccaa
 cactcctage
 781 caatggtggt catggagtag aaggagcga tactacaggg tctccaactg
 aattccttga
 841 agagaaaatg gcctaccagg aatacccaa tagccagaac tggccagaag
 ataccaactt
 901 ttgtttccaa cctgagcaag tggctgatcc tatccagact gatcccttta
 agatgtacca
 961 tgatgatgac ctggcagatt tggctcttcc ctccagtgcg acagctgata
 cttcaatatt
 1021 tgcaggacaa aatgatccct tgaaagacag ttacgggtatg tctccctgca
 acacagctgt
 1081 tgtacctcag ggggtggtctg tggaagcctt aaactctcca cactcagagt
 cctttgttcc
 1141 cccagaggct gttgcagaac ctctcagcc aacggcagtt cccttagagc
 tagccaagga
 1201 gatagaaatg gcatacagaag agaggccacc agcacaagca ttggaaataa
 tgatgggact
 1261 gaagactact gacatggcac catctaaaga aacagagatg gccctcgcca
 aggacatggc
 1321 actagctaca aaaaccgagg tggcattggc taaagatatg gaatcaccca
 ccaaattaga
 1381 tgtgacactg gccaaaggaca tgcagccatc catggaatca gatatggccc
 tagtcaagga
 1441 catggaacta cccacagaaa aagaagtggc cctgggttaag gatgtcagat
 ggcccacaga
 1501 aacagatgta tcttcagcca agaattgtgt actgccaca gaaacagagg
 tagccccagc
 1561 caaggatgtg acactgttga aagaaacaga gagggcatct cctataaaaa
 tggacttagc
 1621 cccttccaag gacatgggac caccctaaaga aaacaagaaa gaaacagaga
 gggcatctcc

1681 tataaaaatg gacttggctc cttccaagga catgggacca cccaaagaaa
 acaagatagt
 1741 ccagccaag gatttgggtat tactctcaga aatagaggtg gcacaggcta
 atgacattat
 1801 atcatccaca gaaatatact ctgctgagaa ggtggctttg tcctcagaaa
 cagaggtagc
 1861 cctggccagg gacatgacac tgcccccgga aaccaacgtg atcttgacca
 aggataaagc
 1921 actaccttta gaagcagagg tggccccagt caaggacatg gctcaactcc
 cagaaacaga
 1981 aatagccccg gccaggatg tggtccgctc cacagtaaaa gaagtgggct
 tgttgaagga
 2041 catgtctcca ctatcagaaa cagaaatggc tctgggcaag gatgtgactc
 cacctccaga
 2101 aacagaagta gttctcatca agaacgtatg tctgcctcca gaaatggagg
 tggccctgac
 2161 tgaggatcag gtcccagccc tcaaaacaga agcaccctg gctaaggatg
 gggttctgac
 2221 cctggccaac aatgtgactc cagccaaaga tgttccacca ctctcagaaa
 cagaggcaac
 2281 accagttcca attaaagaca tggaaattgc acaaacacaa aaaggaataa
 gtgaggattc
 2341 ccatttagaa tctctgcagg atgtggggca gtcagctgca cctactttca
 tgatttcacc
 2401 agaaaccgtc acaggaacgg ggaaaaagtg cagcttgccg gccgaggagg
 attctgtgtt
 2461 agaaaaacta ggggaaagga aaccatgcaa cagtcaacct tctgagcttt
 cttcagagac
 2521 ctcaggaata gccaggccag aagaaggaag gcctgtggtg agtgggacag
 gaaatgacat
 2581 caccacccca ccgaacaagg agctcccacc aagcccagag aagaaaacaa
 agcctttggc
 2641 caccactcaa cctgcaaaga cttcaacatc gaaagccaaa acacagccca
 cttctctccc
 2701 taagcagcca gctcccacca ccattggtgg gttgaataaa aaacccatga
 gccttgcttc
 2761 aggcttagtg ccagctgccc cacccaaacg ccctgccgct gcctctgcca
 ggccttccat
 2821 cttaccttca aaagacgtga agccaaagcc cattgcagat gcaaaggctc
 ctgagaagcg
 2881 ggcctcacca tccaagccag cttctgcccc agcctccaga tctgggtcca
 agagcactca
 2941 gactgttgca aaaaccacaa cagctgctgc tgttgectca actggcccaa
 gcagtaggag
 3001 cccctccacg ctctgcccc aagaagccac tgccattaag actgagggaa
 aacctgcaga
 3061 agtcaagaag atgactgcaa agtctgtacc agctgacttg agtcgcccaa
 agagcacctc
 3121 caccagttcc atgaagaaaa ccaccactct cagtgggaca gccccgctg
 caggggtggt
 3181 tcccagccga gtcaaggcca caccatgcc ctcccggccc tccacaactc
 ctttcataga
 3241 caagaagccc acctcggcc aaccagctc caccaccccc cggctcagcc
 gcctggccac
 3301 caatacttct gctcctgate tgaagaatgt ccgctccaag gttggctcca
 cggaaaacat
 3361 caagcatcag cctggaggag gccgggccaa agtagagaaa aaaacagagg
 cagctgctac
 3421 aaccgaaag cctgaatcta atgcagtcac taaaacagcc ggccaattg
 caagtgcaca
 3481 gaaacaacct gcggggaaag tccagatagt ctccaaaaaa gtgagctaca

gccatattca
 3541 gtccaagtgt ggttccaagg acaatattaa gcatgtccct ggaggtggta
 atgttcagat
 3601 tcagaacaag aaagtggaca tctctaaggt ctctccaag tgtgggtcta
 aggctaacat
 3661 caagcacaag cctggtggag gagatgtcaa gattgaaagt cagaagttga
 acttcaagga
 3721 gaaggccag gccaaagtgg gatccctcga taatgtgggc cacctacctg
 caggaggtgc
 3781 tgtgaagatt gagacctaca ggctgacgtt ccgggcaaatt gccaggcccc
 gcaccgacca
 3841 cggggccgac attgtctccc gccccccaca ctccctggc ggccccaaact
 cgggctcccc
 3901 ggtccttggc cccctttccc gggctgtcca ctagaccagt gagcgcttgg
 gcgccgtgct
 3961 gggcagcccg ctaggtctgc ctccctcct gctttgcgtg cccggggcag
 cagcagccct
 4021 gccccacacc tcctctcact cccagcctg ggcccatctc cctgctttgg
 tcttgcccca
 4081 tcaactgcgc actgctccgt ggaggaggtt gggaggggggt tggggtggtt
 gaggctaagt
 4141 tgggatctag gagaggagaa ccagattcta tcctcatctt tttttggttc
 tttgtccaa
 4201 acccaaaaga aactgacatg cctcccttc tccttgatc tacctggagg
 gaagagtggg
 4261 ggtggattcc gagtggtgac aggacgtga ccgtggagct taagccactg
 cctctccctc
 4321 tgggtcccaca aatggggcgc cccctccc catgcaggtg gtgtcgggcc
 cttcttgctg
 4381 ccctgcccc agttgggggt cagtgtgcc tgtcccatg cttaacatac
 ccgcctagct
 4441 gctgtcacat tttcttgtt ttgtcctttt attttttct aataacctaa
 aaactggcaa
 4501 aatagttctg caggttgaag ccatgtctac atgaaagtcc tcagtaagtg
 ttagagggaa
 4561 cagggcggag atatccttat gccacccccg ctggaggatg tgggcagctt
 agggccctgg
 4621 aggcggtgcg gcagggaaga ggggtgcaga ggctgtggct ggtgagccgg
 tcaggcacac
 4681 aaggggccct tggagcgtgg actggttgg tttgccattt tgttgtgtgt
 atgtgtctt
 4741 tcttttctaa ccaagaggct ggttttggca tctctgtccc attccctggg
 atctggtgg
 4801 cagccctagg ataaaaagcc agggctggag aacaagaaag ggccaggaga
 tggaaattct
 4861 tcaggccggc acccacacc taggacatgt aagccctcat gtccaaggga
 gcctcatgca
 4921 gatagtagga aatcaggtct ggaaatttaa aaataaaagg catgagacta
 aggctatctg
 4981 ctcccttat gccctgactg gagaggggag ggaggagagg caaggccac
 agagggcac
 5041 ccagctaggc cttgggatgg ctgcagtga gagaaatccc gggaactgta
 ttgacacaaa
 5101 gattcttatt gcacttgtat tttttgtatt aaagtttgca tggtttctaa
 taaaggattc
 5161 aaacataagt ttgtagtga atggcctggg agattccaag ggcttctctg
 gagggggatt
 5221 ggctgcagt tagatttgc tctgaggagg ctgcccaga cttggcctcc
 tcatgcccc
 5281 tcctgacctc tgcccttctc tggctcctgg atccctggag aaggtagggg
 tcttgacctc

5341 agtttagatt tgatctccat gtgcagggag gctgtcctgg gcctgacagg
 tcctccccct
 5401 ttctgaggtg gcagtgcctt gtggaggttt gacaccatgt ccctagetcc
 ccaagcacac
 5461 accaggaaac tgcaggggct cacggaggaa gtgctgcctg ggccaggggg
 accagctttc
 5521 ctccgtagag accatgtgca gaacacttct gctgtgcaa gaacatgagg
 gagccagtgt
 5581 tttgtcagca ggaagaaagg gcctgctggg atgaaagtgg gaaggaaaca
 gggttgcgta
 5641 gtcaggagac acctcagggg caacagcaca ggcccagagt acctgctgcc
 tccactgcgt
 5701 ctgtcctggg gtcattgagga tgctgaggtt gacgacaggt tccaggctct
 ttactcctt
 5761 tggccaaagg ttgggggtag gtggcccaag tggcgtgctc tctaggtaga
 caacaggagt
 5821 ggtcagagtt ccctcaaagg atcctccact ccagagcacc tgagaaggcc
 gggaccagag
 5881 gccctgtgtg atgtgtactc cgcagctgtt tgggggtggga catttctgta
 cttctcgatt
 5941 tgcttatggc tcagccatta cctgtgtcag tccatgattc tgttgtaaca
 gttttaagag
 6001 taaataaata aagctgcctg atgtcccatc acgcagaaaa aaaaaa

//

LOCUS NM_002375 (isoform 1)
 AA /translation="MADLSLADALTEPSPDIEGEIKRDFIATLEAEAFDDVVGETVGK
 TDYIPLLDVDEKTGNSESKKKPCSETSIQIEDTPSSKPTLLANGGHGVEGSDTTGSPTE
 FLEEKMAYQEYPNSQNWPEDTNFCFQPEQVVDPIQTDPFKMYHDDDLADLVFPSSATA
 DTSIFAGQNDPLKDSYGMSPCNTAVVPQGWVSVEALNSPHSESFVSPEAVAEPPTAV
 PLELAKEIEMASEERPPAQALEIMMGLKTTDMAPSKETEMALAKDMALATKTEVALAK
 DMESPTKLDVTLAKDMQPSMESDMALVKDMELPTEKEVALVKDVRWPTETDVSSAKNV
 VLPTETEVAPAKDVTLLKETERASPIKMDLAPSKDMGPPKENKKETERASPIKMDLAP
 SKDMGPPKENKIVPAKDLVLLSEIEVAQANDIISSTEISSAEKVALSSETEVALARDM
 TLPPETNVILTKDKALPLEAEVAPVKDMAQLPETEIAPAKDVPSTVKEVGLLKDMSP
 LSETEMALGKDVTPPETEVVLIKNVCLPPEMEVALTEDQVPALKTEAPLAKDGVLT
 ANNVTAPKDVPLSETATPVPIKMEIAQTQKGISEDHLESQDVGQSAAPTSMIS
 PETVTGTGKKCSLPAEEDSVLEKLGERKPCNSQPSELSSSETSGIARPEEGRPVVSGTG
 NDITTPPNKELPPSPEKKTPLATTQPAKTSTSKAKTQPTSLPKQPAPTTIGGLNKKP
 MSLASGLVPAAPPKRPASARPSILPSKDVKPKPIADAKAPEKRASPSKPASAPASR
 SGSKSTQTVAKTTTAAAVASTGPPSSRSPSTLLPKKPTAIKTEGKPAEVKKMTAKSVPA
 DLSRPKSTSTSSMKTTTSGTAPAAGVVPSPRVKATPMPSPRPSTTPFIDKKPTSAPKS
 STTPRLSRLATNTSAPDLKNVRSKVGSTENIKHQPGGGRKVEKKTEAAATTRKPESN
 AVTKTAGPIASAQKQAPAGKVQIVSKKVSYSHIQSKCGSKDNKHPVGGGNVQIQNKKV
 DISKVSSKCGSKANIKHKPGGGDVKIESQKLNFKKAQAKVGS LDNVGHLPPAGGAVKT
 EGGGSEAPLCPGPPAGEEPAISEAAPEAGAPTSASGLNGHPTLSGGGDQREAQTLDSQ
 IQETSI

cDNA: 1 aggccccacc cgctgggtggc ccggtccgcg tgtgcgccga ctctcgcaact
 ctctctgctc
 61 cgggcgccca gactctgaga gagagcgacg gccatcatag aacagcgaag
 gcagtcgate
 121 ggctgcgggt ccgcttcggc attcgcaggc cgcaggcggg aggctagagc
 cccagggcgc
 181 acctcgcccc aaccgcccgc ggctcgggca gctctgcaga gacgtcgtgg
 cggcagggce
 241 agcaccatt ggtccgccac agccctccgc cctccccctc gccacgetta
 ttggccggag
 301 cggcggcgct cgccgggtag gcggtggcgg cgteccctcc ttgcgccggc
 cctcaagagg
 361 cgacgaggaa gcggccgcct cctgcgccc cgccctccg gctagctcgc

tggetcccgg
 421 ctctctccga cgtctcttac ctctctcacgg ctcttcccgg cgctctcctg
 gctcccttct
 481 gccccagctc cgtctcggcg gcggcgggca gttgcagtgg tgcagaatgg
 ctgacctcag
 541 tcttgcatgat gcattaacag aacctctcc agacattgag ggagagataa
 agcgggactt
 601 cattgccaca ctagaggcag aggcctttga tgatgttgtg ggagaaactg
 ttggaaaaac
 661 agactatatt cctctcttg atgttgatga gaaaaccggg aactcagagt
 caaagaagaa
 721 accgtgctca gaaactagcc agattgaaga tactccatct tctaaaccaa
 cactcctagc
 781 caatgggtgg catggagtag aaggagcgga tactacaggg tctccaactg
 aattccttga
 841 agagaaaatg gcctaccagg aatacccaa tagccagaac tggccagaag
 ataccaactt
 901 ttgtttccaa cctgagcaag tggctgatcc tatccagact gatcccttta
 agatgtacca
 961 tgatgatgac ctggcagatt tggcttttcc ctccagtgcg acagctgata
 cttcaatatt
 1021 tgcaggacaa aatgatccct tgaaagacag ttacgggatg tctccctgca
 acacagctgt
 1081 tgtacctcag ggggtgtctg tggaagcctt aaactctcca cactcagagt
 cctttgttcc
 1141 cccagaggct gttgcagaac ctctcagcc aacggcagtt cccttagagc
 tagccaagga
 1201 gatagaaatg gcatacagaag agaggccacc agcacaagca ttggaaataa
 tgatgggact
 1261 gaagactact gacatggcac catctaaaga aacagagatg gccctcgcca
 aggacatggc
 1321 actagctaca aaaaccgagg tggcattggc taaagatatg gaatcaccca
 ccaaattaga
 1381 tgtgacactg gccaaaggaca tgcagccatc catggaatca gatatggccc
 tagtcaagga
 1441 catggaacta cccacagaaa aagaagtggc cctgggttaag gatgtcagat
 ggcccacaga
 1501 aacagatgta tottcagcca agaattgtgt actgcccaca gaaacagagg
 tagccccage
 1561 caaggatgtg aactgtttga aagaaacaga gagggcatct cctataaaaa
 tggacttagc
 1621 cctttccaag gacatgggac caccacaaga aaacaagaaa gaaacagaga
 gggcatctcc
 1681 tataaaaaatg gacttggctc cttccaagga catgggacca cccaaagaaa
 acaagatagt
 1741 cccagccaag gatttggat tactctcaga aatagagggtg gcacaggcta
 atgacattat
 1801 atcatccaca gaaatatcct ctgctgagaa ggtggctttg tctcagaaa
 cagaggtagc
 1861 cctggccagg gacatgacac tgcccccgga aaccaactg atcttgacca
 aggataaagc
 1921 actaccttta gaagcagagg tggccccagt caaggacatg gctcaactcc
 cagaaacaga
 1981 aatagccccg gccaaaggatg tggctccgtc cacagtaaaa gaagtgggct
 tgttgaagga
 2041 catgtctcca ctatcagaaa cagaaatggc tctgggcaag gatgtgactc
 cacctccaga
 2101 aacagaagta gttctcatca agaactgatg tctgcctcca gaaatggagg
 tggcctgac
 2161 tgaggatcag gtcccagccc tcaaaacaga agcaccctg gctaaggatg
 gggttctgac

2221 cctggccaac aatgtgactc cagccaaaga tgttccacca ctctcagaaa
 cagaggcaac
 2281 accagttcca attaaagaca tggaaattgc acaaacacaa aaaggaataa
 gtgaggatc
 2341 ccatttagaa tctctgcagg atgtggggca gtcagctgca cctactttca
 tgatttcacc
 2401 agaaaccgtc acaggaacgg ggaaaaagtg cagcttgccg gccgaggagg
 attctgtgtt
 2461 agaaaaacta ggggaaagga aaccatgcaa cagtcaacct tctgagcttt
 cttcagagac
 2521 ctgaggaata gccaggccag aagaaggaag gcctgtggtg agtgggacag
 gaaatgacat
 2581 caccacccca ccgaacaagg agctcccacc aagcccagag aagaaaacaa
 agcctttggc
 2641 caccactcaa cctgcaaaga cttcaacatc gaaagccaaa acacagccca
 cttctctccc
 2701 taagcagcca gctcccacca ccattggtgg gttgaataaa aaacccatga
 gccttgcttc
 2761 aggettagtg ccagctgccc cacccaaagc ccctgccgtc gcctctgcca
 ggcttccat
 2821 cttaccttca aaagacgtga agccaaagcc cattgcagat gcaaaggctc
 ctgagaagcg
 2881 ggcttcacca tccaagccag cttctgcccc agcctccaga tctgggtcca
 agagcactca
 2941 gactgttgca aaaaccacaa cagctgctgc tgttgctca actggcccaa
 gcagtaggag
 3001 cccctccacg ctctgcccc agaagcccac tgccattaag actgagggaa
 aacctgcaga
 3061 agtcaagaag atgactgcaa agtctgtacc agctgacttg agtcgcccaa
 agagcacctc
 3121 caccagttcc atgaagaaaa ccaccactct cagtgggaca gccccgctg
 caggggtggt
 3181 tcccagccga gtcaaggcca caccatgcc ctcccgccc tccacaactc
 ctttcataga
 3241 caagaagccc acctcggcca aaccagctc caccacccc cggtcagcc
 gcctggccac
 3301 caatacttct gctcctgac tgaagaatgt ccgctccaag gttggctcca
 cggaaaacat
 3361 caagcatcag cctggaggag gccgggcca agtagagaaa aaaacagagg
 cagctgctac
 3421 aaccgaaag cctgaatcta atgcagtcac taaaacagcc ggccaattg
 caagtgcaca
 3481 gaaacaacct gcggggaaag tccagatagt ctccaaaaa gtgagctaca
 gccatattca
 3541 gtccaagtgt ggttccaagg acaatattaa gcatgtccct ggaggtggta
 atgttcagat
 3601 tcagaacaag aaagtggaca tctctaaggt ctctccaag tgtgggtcta
 aggctaacat
 3661 caagcacaag cctggtggag gagatgtcaa gattgaaagt cagaagttga
 acttcaagga
 3721 gaaggccag gccaaagtgg gatccctcga taatgtgggc cacctacctg
 caggaggtgc
 3781 tgtgaagact gagggcgggtg gcagcgaggc tcctctgtgt ccgggtcccc
 ctgctgggga
 3841 ggagccggcc atctctgagg cagcgccctga agctggcgcc cccacttcag
 ccagtggcct
 3901 caatggccac cccacctgt caggggggtg tgaccaaagg gagggccaga
 ccttgacag
 3961 ccagatccag gagacaagca tctaattgat acattctggt ctctcttcc
 gtctccccg
 4021 tgttcccctc ttgtctcccc tgttcccctc tcccttccct cctcccatgt

cactgcagat
 4081 tgagacctac aggctgacgt tccgggcaaa tgccagggcc cgcaccgacc
 acggggccga
 4141 cattgtctcc cgccccccac acttccctgg cgcccccaac tcgggtctcc
 gggtccttgg
 4201 ccccccttcc cgggctgtcc actagaccag tgagcgcttg ggcgccgtgc
 tgggcagccc
 4261 gctaggctcg ccttccctcc tgctttgcgt gcccggggca gcagcagccc
 tgccccacac
 4321 ctctctctac tccccagcct gggcccatct ccttgctttg gtcttgcccc
 atcactgcgc
 4381 cactgctccg tggaggaggt tgggaggggg ttgggggtgg tgaggctaag
 ttgggatcta
 4441 ggagaggaga accagattct atctctatct ttttttgggt ctttggcca
 aacccaaaag
 4501 aaactgacat gccctccctt ctccctggat ctacctggag ggaagagtgg
 aggtggattc
 4561 cgagtgggtga caggacgctg accgtggagc ttaagccact gcctctccct
 ctggtccac
 4621 aaatgggcgc cccccctcc ccatgcaggt ggtgtcgggc ccttcttgc
 gccctgcccc
 4681 aagttggggg tcagtgtgc ctgtcccat gcttaacata cccgcctagc
 tgctgtcaca
 4741 ttttcttgt tttgtcctt ttttttttc taataacctt aaaactggca
 aaatagttct
 4801 gcaggttgaa gccatgtcta catgaaagtc ctacagtaagt gttagaggga
 acagggcgga
 4861 gatatcctta tgccaccccc gctggaggat gtgggcagct tagggccctg
 gaggcggtgc
 4921 ggcagggaag aggggtgcag aggctgtggc tggtagaccg gtcaggcaca
 caaggggccc
 4981 ttggagcgtg gactggttgg ttttgccatt ttgttgtgtg tatgtgtctt
 ttcttttcta
 5041 accaagaggc tggttttggc atctctgtcc cattccctgg gatctggtgg
 tcagccctag
 5101 gataaaaagc cagggtctga gaacaagaaa gggccaggag atggaattcc
 ttcaggccgg
 5161 caccacacac ctaggacatg taagccctca tgtccaaggg agcctcatgc
 agatagtagg
 5221 aaatcaggtc tggaaattta aaaataaaaag gcatgagact aaggctatct
 gcttccctta
 5281 tgccctgact ggagagggga gggaggagag gcaaggcca cagagggcat
 cccagctagg
 5341 ccttgggatg gctgcagtga ggagaaatcc cggaactgt attgacacaa
 agattcttat
 5401 tgcacttgta ttttttgtat taaagtttgc atggtttcta ataaaggatt
 caaacataag
 5461 tttgtagtga aatggcctgg gagattccaa gggcttctct ggagggggat
 tggctgcagt
 5521 gtagatttgc ctctgaggag gctgccccag acttggcctc ctcatgcccc
 ctctgacct
 5581 ctgcccttct ctggtcctgg catccctgga gaaggtaggg gtcttgacct
 aagtttagat
 5641 ttgatctcca tgtgcaggga ggctgtcctg ggctgacag gtcttcccc
 tttctgaggt
 5701 agcagtgcct tgtggagggt tgacaccatg tccctagctc cccaagcaca
 caccaggaaa
 5761 ctgcaggggc tcacggagga agtgcctgcct gggccagggg gaccagcttt
 cctccgtaga
 5821 gaccatgtgc agaacacttc tgctgtgcca agaacatgag ggagccagtg
 ttttgtcagc

5881 aggaagaaaag ggccctgctgg gatgaaagtg ggaaggaaaac aggggttgctg
 agtcaggaga
 5941 cacctcaggg gcaacagcac aggccagag tacctgctgc ctccactgcg
 tctgtcctgg
 6001 ggtcatgagg atgctgaggt tgacgacagg ttccagggtcc tttcactcct
 ttggccaaag
 6061 gttgggggta ggtggcccaa gtggcgtgct ctctaggtag acaacaggag
 tggtcagagt
 6121 tccctcaaag gatcctccac tccagagcac ctgagaaggc cgggaccaga
 ggccctgtgt
 6181 gatgtgtact ccgcagctgt ttgggggtggg acatttctgt acttctcgat
 ttgcttatgg
 6241 ctacgccatt acctgtgtca gtccatgatt ctgttgtaac agttttaaga
 gtaaataaat
 6301 aaagctgcct gatgtcccat cagcagaaa aaaaaaa

//

LOCUS NM_030885 (isoform 3)
 AA/translation="MADLSLADALTEPSPDIEGEIKRDFIATLEAEAFDDVVGETV GK
 TDYIPLLDVDEKTGNSESKKKPCSETS QIEDTPSSKPTLLANGGHGVEGSDTTEA

cDNA: 1 aggccccacc cgctgggtggc ccggtccgcg tgtgcgccga ctctcgcaact
 ctctctgctc
 61 cgggcgccca gactctgaga gagagcgacg gccatcatag aacagcgaag
 gcagtcgac
 121 ggctgctggg ccgcttcggc attcgcaggc cgcaggcggg aggctagagc
 ccccaggcgc
 181 acctcgcccc aaccgcccgc ggctcgggca gctctgcaga gacgtcgtgg
 cggcagggcc
 241 agcacccatt ggtccgccac agccctccgc cctccccctc gccacgctta
 ttggccggag
 301 cggcggcgct cgccgggtag gcggtggcgg cgctccctcc ttgcgccggc
 cctcaagagg
 361 cgacgaggaa gcggccgcct ccctgcgcc cgcctcccg gctagctcgc
 tggctcccg
 421 ctctctccga cgtctctac ctctcacgg ctcttccgg cgtctctctg
 gctcccttct
 481 gccccagctc cgtctcggcg gcggcgggca gttgcagtgg tgcagaatgg
 ctgacctcag
 541 tcttgcatg gcattaacag aaccatctcc agacattgag ggagagataa
 agcgggactt
 601 cattgccaca ctagaggcag aggcctttga tgatgttgtg ggagaaactg
 ttggaaaaac
 661 agactatatt cctctcctgg atgttgatga gaaaaccggg aactcagagt
 caaagaagaa
 721 accgtgctca gaaactagcc agattgaaga tactccatct tctaaaccaa
 cactcctagc
 781 caatgggtgt catggagtag aaggagcga tactacagaa gcctagcgtg
 tctctcaaca
 841 ctggggctgc tgcaacacca gaccagtgat ctttcttaag catcggtata
 cttctaaaac
 901 cttcagcatt ttgcagagct ttgcttttca ttctggaca tgatgtagaa
 gaaactgagg
 961 gtagttcttc ggggcctatt tctgctgatg cctgagcaaa caacctgctt
 cctcttgtgc
 1021 tctgcagggt ttgatggagc ctcatctccc tttgtgaaca caaagtgcaa
 aatgaattct
 1081 ttttaatttt agtaattttt acaaaggtta tctaatgtct tttatttctt
 gttttcttta
 1141 tgattttatc atttgattca ttctcacatt ttttctctt aaatatattt
 agttgacctt

1201 tttccttttg ttttcaaagt ttcaacatga atcagaatag tgtaacacca
 aatgagaaca
 1261 tgtgttttca taaaggggtt gaggccacca gtactgcagc gaatttcctt
 ttcttctccc
 1321 tctccttcc ttctctgagc ttgcttttag ggaagggtta tcttacaggc
 tacctatggt
 1381 tctctccacc ttactaaaat ctaaataatg atagatattt taagttttta
 aattgagtag
 1441 ttctgagtaa tcctagaata tttttccaaa ttaaataatc ctttattatt
 tgcaagttgg
 1501 gccaaatttt tttttttttg gagacggact cttacaatc taagattggt
 tcaacaggac
 1561 tttcttattc ccattcctaa ttttttcaaa ctaattgctt aaatctagaa
 ccagttgaga
 1621 ttagtactgt acaatggtat gctttgattg tatttataga aatataacat
 aaaacatgga
 1681 ccatgttttg aaatcttaga ggaattctgg tttaaaatct gaaatacttt
 aaagttttct
 1741 atccttttac tgattatgca gcttcttata acccccaagg tacagattat
 ttcagcttaa
 1801 aagaaataat tggcaccatg ttctgagaaa gattttgaga tatacattgt
 tttttgtttt
 1861 tgagacaggg tctcactctt gcctaggctg gagtgcggtg gcgcgatctt
 ggcttactgc
 1921 accctctgcc tcccagggtc aagtgggtct cctgcctcag cctcccaagt
 agctgggatt
 1981 ataggtgtgc gccaccacac cagctaattt ttgtattttt agtagagacg
 gggttttact
 2041 ttgttggtcc ggctgggtct gaactcctga tctcaagtga tccaccgcc
 ttggccaccc
 2101 aaagtgtctg gattacaggt gtgagacact gtgcctggcc agatatacat
 tgttttagat
 2161 cccctgatac agaactactt ttgagatggt aagattagaa tatcatgaaa
 gtttaaactg
 2221 aatccttgca gcgacttccg gaatttagga agcattccct cttctacagg
 ggtctggtca
 2281 caagggtctg attctctgac aaaaatttct tctatggatt ctggacagaa
 gacacttgag
 2341 ggtgatattt tttaaaggaa agaggttatg cttatcttct tagcagttga
 taaaatatta
 2401 aaactctctt gccatagaga atacaccatc aaagaaaaca caaccctttc
 cctttggtgt
 2461 acagttattt attaatgga ttttgggtt tctttcgcca gggatctttt
 caaaactggt
 2521 agtagttatt tttaaaaatc atgtttgaca tctttctatt gctcgttaacc
 agtccctgta
 2581 gctgtctaag ttatgggtgg agaagcctgg gtatgacttt ccgttgtgta
 cactcacact
 2641 tcatgattga cttttattta ttcttttatt tccatttggt tatgettatt
 tttgtttgaa
 2701 atttgttttt ttcaaataatg tttccttttt gaacttacag aattgttgaa
 attttctact
 2761 aacagccagc taaaatttgg tatatgtag ctctatctgt ttcacttgga
 cgtttcattt
 2821 tgaaagaaag aaattttatg tttcacatat agttttatac aaagtagcca
 gtcccataat
 2881 gaaatgctgt attgccatag tggtcacacc caagtgggtc agtatctcaa
 tggtaggga
 2941 gccagactgg tcagggtctg tttgttgaaa tgtgatgatt ttcatatgcc
 ttctttctct
 3001 ttctctctct cttttttttt ccttttttgg cccaatgttg aagatgtaga

```

actttgtttt
  3061 taaataatgt ttttataatt tcattcgtat acctaagttt gtattttttg
tgacttttga
  3121 cttcaacagt ttgtatatgt ggacttctaa tgtgattact gtactaaata
aattccacta
  3181 ataaacatct tacattaaca ccttaaaaaa aaaaaaaaaa aaaa

//
19.  MAPK1: MAPK1 mitogen-activated protein kinase 1 [ Homo
      sapiens ]
      LOCUS      NM_002745                      (isoform 1)
      AA/translation="MAAAAAAGAGPEMVRGQVFDVGPRYTNLASYIGEGAYGMVCSAYD
      NVNKVRVAIKKISPFHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVY
      IVQDLMETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLNTT
      CDLKICDFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCIL
      AEMLSNRPFIIPGKHLYLDQLNHILGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWN
      RLFPNADSKALDLLDKMLTFNPHKRIEVEQALAHYPYEQYYDPSDEPIAEAPFKFDME
      LDDLPKEKLKELIFEETARFQPGYRS

cDNA:  1 gcccctccct ccgcccgcgc gccggccgcg ccgtcagttc ggcaggcagg
caggcaatcg
      61 gtccgagtgg ctgtcggttc ttcagctctc ccgctcggcg tcttccttcc
tcctcccggg
      121 cagcgtcggc ggctgcaccg gcggcgccgc agtccttcgc ggaggggcga
caagagctga
      181 gcggcgcccg ccgagcgtcg agctcagcgc ggcgaggcg gcggcgcccc
ggcagccaac
      241 atggcgccgc gcggcgccgc gggcgccggc ccggagatgg tccgcgggca
ggtgttcgac
      301 gtggggccgc gctacaccaa cctctcgtac atcggcgagg gcgcctacgg
catggtgtgc
      361 tctgcttatg ataatgtcaa caaagttcga gtagctatca agaaaatcag
cccctttgag
      421 caccagacct actgccagag aacctgagg gagataaaaa tcttactgcg
cttcagacat
      481 gagaacatca ttggaatcaa tgacattatt cgagcaccaa ccatcgagca
aatgaaagat
      541 gtatatatag tacaggacct catggaaaca gatctttaca agctcttgaa
gacacaacac
      601 ctacagcaatg accatatctg ctattttctc taccagatcc tcagaggggt
aaaatatatc
      661 cattcagcta acgttctgca ccgtgacctc aagccttcca acctgctgct
caacaccacc
      721 tgtgatctca agatctgtga ctttggcctg gcccggtgtg cagatccaga
ccatgatcac
      781 acagggttcc tgacagaata tgtggccaca cgttggtaca gggctccaga
aattatgttg
      841 aattccaagg gctacaccaa gtccattgat atttggctct taggctgcat
tctggcagaa
      901 atgctttcta acaggcccat ctttccaggg aagcattatc ttgaccagct
gaaccacatt
      961 ttgggtattc ttggatcccc atcacaagaa gacctgaatt gtataataaa
tttaaaagct
      1021 aggaactatt tgctttctct tccacacaaa aataaggtgc catggaacag
gctgttccca
      1081 aatgctgact ccaaagctct ggacttattg gacaaaatgt tgacattcaa
cccacacaag
      1141 aggattgaag tagaacaggc tctggcccac ccatatctgg agcagtatta
cgacccgagt
      1201 gacgagccca tcgccgaagc accattcaag ttcgacatgg aattggatga
cttgccctaag

```


1261 gaaaagctca aagaactaat ttttgaagag actgctagat tccagccagg
 atacagatct
 1321 taaatttgctc aggacaaggg ctgagaggac tggacgtgct cagacatcgg
 tgttcttctt
 1381 cccagttctt gacccctggg cctgtctcca gcccgctctg gcttatccac
 tttgactcct
 1441 ttgagccgtt tggaggggcg gtttctggta gttgtggctt ttatgctttc
 aaagaatttc
 1501 ttcagtccag agaattcctc ctggcagccc tgtgtgtgtc acccattggg
 gacctgcggc
 1561 agtatgtact tcagtgcacc tactgcttac tgttgcttta gtcactaatt
 gctttctggg
 1621 ttgaaagatg cagtggttcc tccctctcct gaatcctttt ctacatgatg
 ccctgctgac
 1681 catgcagccg caccagagag agattcttcc ccaattggct ctagtcaactg
 gcatctcact
 1741 ttatgatagg gaaggctact acctagggca ctttaagtca gtgacagccc
 cttatttgca
 1801 cttcaccttt tgaccataac tgtttcccca gagcaggagc ttgtggaaat
 accttggctg
 1861 atgttgacgc ctgcagcaag tgcttccgct tccggaatcc ttggggagca
 cttgtccacg
 1921 tcttttctca tatcatggta gtcactaaca tatataaggt atgtgctatt
 ggcccagctt
 1981 ttagaaaatg cagtcatctt tctaaataaa aaggaagtac tgcaccagc
 agtgtcactc
 2041 tgtagttact gtggtcactt gtaccatata gaggtgtaac acttgtcaag
 aagcgttatg
 2101 tgcagtactt aatgtttgta agacttaca aaaaagattt aaagtggcag
 cttcactcga
 2161 catttggtga gagaagtaca aaggttgcag tgctgagctg tgggcggttt
 ctggggatgt
 2221 cccaggggtg aactccacat gctgggtgcat atacgccctt gagctacttc
 aaatgtgggt
 2281 gtttcagtaa ccacgttcca tgctgagga tttagcagag aggaacactg
 cgtctttaa
 2341 tgagaaagta tacaattctt tttccttcta cagcatgtca gcatctcaag
 ttcatttttc
 2401 aacctacagt ataacaattt gtaataaagc ctccaggagc tcatgacgtg
 aagcactggt
 2461 ctgtcctcaa gtactcaaat atttctgata ctgctgagtc agactgtcag
 aaaaagctag
 2521 cactaaactg tgtttggagc tctatccata ttttactgat ctctttaagt
 atttgctcct
 2581 gccactgtgt actgtggagt tgactcgggtg ttctgtccca gtgcgggtgcc
 tcctcttgac
 2641 tccccactg ctctctgtgg tgagaaattt gccttggtca ataattactg
 taccctcgca
 2701 tgactgttac agctttctgt gcagagatga ctgtccaagt gccacatgcc
 tacgattgaa
 2761 atgaaaactc tattgttacc tctgagttgt gttccacgga aaatgctatc
 cagcagatca
 2821 tttagaaaaa ataattctat ttttagcttt tcatttctca gctgtccttt
 tttcttggtt
 2881 gatttttgac agcaatggag aatgggttat ataaagactg cctgctaata
 tgaacagaaa
 2941 tgcatttgta attcatgaaa ataaatgtac atcttctatc ttcacattca
 tgtaagatt
 3001 cagtgttgct ttcctctgga tcagcgtgtc tgaatggaca gtcaggttca
 gggtgtgctg
 3061 aacacagaaa tgctcacagg cctcactttg ccgccaggc actggcccag

cacttggatt
 3121 tacataagat gagttagaaa ggtacttctg tagggtcctt tttacctctg
 ctcggcagag
 3181 aatcgatgct gtcattgttcc tttattcaca atcttaggtc tcaaatatc
 tgtcaaacc
 3241 taacaaagaa gccccgacat ctgaggttgg attccctggg tctctctaaa
 gagggcctgc
 3301 ccttgtgccc cagaggtgct gctgggcaca gccaagagtt gggaagggcc
 gccccacagt
 3361 acgcagtcct caccacccag cccaggggtgc tcacgctcac cactcctgtg
 gctgaggaag
 3421 gatagctggc tcattcctcg aaaacagacc cacatctcta ttcttgccct
 gaaatacgcg
 3481 cttttcactt gcgtgctcag agctgccgtc tgaaggcca cacagcattg
 acgggacaca
 3541 gaaatgtgac tgttaccgga taacactgat tagtcagttt tcatttataa
 aaaagcattg
 3601 acagttttat tactcttgtt tctttttaaa tggaaagtta ctattataag
 gttaatttgg
 3661 agtcctcttc taaatagaaa accatatacct tggctactaa catctggaga
 ctgtgagctc
 3721 cttcccatc cccttcctgg tactgtggag tcagattggc atgaaaccac
 taacttcatt
 3781 ctagaatcat tgtagccata agttgtgtgc tttttattaa tcatgccaaa
 cataatgtaa
 3841 ctgggcagag aatggtccta accaaggtag ctatgaaaag cgctagctat
 catgtgtagt
 3901 agatgcatca ttttggtctt tcttacattt gtaaaaatgt acagattagg
 tcactttaat
 3961 tcatattagt gacacggaac agcacctcca ctatttgtat gttcaaataa
 gctttcagac
 4021 taatagettt tttggtgtct aaaatgtaag caaaaaattc ctgctgaaac
 attccagtc
 4081 tttcatttag tataaaagaa atactgaaca agccagtggg atggaattga
 aagaactaat
 4141 catgaggact ctgtcctgac acaggtcctc aaagctagca gagatacgca
 gacattgtgg
 4201 catctgggta gaagaatact gtattgtgtg tgcagtgcac agtgtgtggt
 gtgtgcacac
 4261 tcattccttc tgctcttggg cacaggcagt ggggtgtagag gtaaccagta
 gctttgagaa
 4321 gctacatgta gctcaccagt ggttttctct aaggaatcac aaaagtaaac
 taccacaacca
 4381 catgccacgt aatatttcag ccattcagag gaaactgtt tctctttatt
 tgcttatatg
 4441 ttaatatggt ttttaaattg gtaactttta tatagtatgg taacagtatg
 ttaatacaca
 4501 catacatag cacacatgct ttgggtcctt ccataatact tttatatttg
 taaatcaatg
 4561 ttttgagaca atcccaagtt taagggaat atttttgtaa atgtaatggt
 tttgaaaatc
 4621 tgagcaatcc ttttgcttat acatttttaa agcatttgtg ctttaaaatt
 gttatgctgg
 4681 tgtttgaaac atgatactcc tgtggtgcag atgagaagct ataacagtga
 atatgtggtt
 4741 tctcttacgt catccacctt gacatgatgg gtcagaaaca aatggaaatc
 cagagcaagt
 4801 cctccagggt tgcaccagggt ttacctaaag cttgttgccct tttcttgtgc
 tgtttatgcg
 4861 tgtagagcac tcaagaaagt tctgaaactg ctttgtatct gctttgtact
 gttggtgcct

4921 tcttgggtatt gtacccccaaa attctgcata gattatttag tataatggta
 agttaaaaaa
 4981 tgttaaagga agatttttatt aagaatctga atgtttattc attatatgtt
 tacaatttaa
 5041 cattaacatt tatttgtggt atttgtgatt tggttaatct gtataaaaaat
 tgtaagtaga
 5101 aagggtttata tttcatctta attcttttga tgttgtaaac gtacttttta
 aaagatggat
 5161 tatttgaatg tttatggcac ctgacttgta aaaaaaaaaa actacaaaaa
 aatccttaga
 5221 atcattaaat tgtgtccctg tattacaaa ataacacagc accgtgcatg
 tatagtttaa
 5281 ttgcagtttc atctgtgaaa acgtgaaatt gtctagtcct tcgttatggt
 ccccgatgt
 5341 cttccagatt tgctctgcat gtggtaactt gtgttagggc tgtgagctgt
 tcctcgagtt
 5401 gaatggggat gtcagtgtct ctaggggtct ccagggtggt cttcagacct
 tcacctgtgg
 5461 gggggggggg aggcgggtgcc cagcccatc tcctcatcct cctgaacttc
 tgcaacccca
 5521 ctgctgggca gacatcctgg gcaaccctt tttcagagc aagaagtcatt
 aaagatagga
 5581 tttcttggac atttggttct tatcaatatt gggcattatg taatgactta
 tttacaaaac
 5641 aaagatactg gaaaatgttt tggatgtggt gttatggaaa gagcacaggc
 cttggacca
 5701 tccagctggg ttcagaacta cccctgctt ataaactggg ctggtgtggt
 gccagtcatt
 5761 ctgcgtctct gctttcttcc tctgcttcag actgtcagct gtaaagtggg
 agcaatatta
 5821 cttgccttgt atatggtaaa gattataaaa atacatttca actgttcagc
 atagtacttc
 5881 aaagcaagta ctcagtaaatt agcaagtctt tttaaa

//

LOCUS NM_138957 (isoform 2)
 AA/translation="MAAAAAAGAGPEMVRGQVFDVGPRYTNL SYIGEGAYGMVCSAYD
 NVNKVRVAIKKISPFHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVY
 IVQDLMETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTT
 CDLKICDFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCIL
 AEMLSNRPIFPKHYLDQLNHILGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWN
 RLFPNADSKALDLDKMLTFNPHKRIEVEQALAHPPYLEQYYDPSEPIAEAPFKFDME
 LDDLPEKELKELIFEETARFQPGYRS

cDNA: 1 gccctccct ccgcccgcgc gccggcccgc ccgtcagtc ggcaggcagg
 caggcaatcg
 61 gtccgagtgg ctgtcggctc ttcagctctc ccgtcggcg tcttccttcc
 tcctcccggg
 121 cagcgtcggc ggctgcaccg gcggcgggcg agtcctcg ggagggcgga
 caagagctga
 181 gcggcgggcg ccgagcgtcg agctcagcgc ggcgaggcg gcggcgggcc
 ggcagccaac
 241 atggcgggcg cgcgggcggc gggcgcgggc ccggagatgg tccgcgggca
 ggtgttcgac
 301 gtggggcgcg gctacaccaa cctctcgtac atcggcgagg gcgcctacgg
 catggtgtgc
 361 tctgcttatg ataattgtcaa caaagttcga gtagctatca agaaaaatcag
 cccctttgag
 421 caccagacct actgccagag aacctgagg gagataaaaa tcttactgcg
 cttcagacat
 481 gagaacatca ttggaatcaa tgacattatt cgagcaccaa ccatcgagca

aatgaaagat
 541 gtatatatag tacaggacct catggaaaca gatctttaca agctcttgaa
 gacacaacac
 601 ctcagcaatg accatatctg ctattttctc taccagatcc tcagagggtt
 aaaatatatc
 661 cattcagcta acgttctgca ccgtgacctc aagccttcca acctgctgct
 caacaccacc
 721 tgtgatctca agatctgtga ctttggcctg gcccggtgtg cagatccaga
 ccatgatcac
 781 acagggttcc tgacagaata tgtggccaca cgttggtaca gggctccaga
 aattatgttg
 841 aattccaagg gctacaccaa gtccattgat atttggctctg taggctgcat
 tctggcagaa
 901 atgctttcta acaggcccat ctttccaggg aagcattatc ttgaccagct
 gaaccacatt
 961 ttgggtattc ttggatcccc atcacaagaa gacctgaatt gtataataaa
 tttaaaagct
 1021 aggaactatt tgctttctct tccacacaaa aataaggtgc catggaacag
 gctgttccca
 1081 aatgctgact ccaaagctct ggacttattg gacaaaatgt tgacattcaa
 cccacacaag
 1141 aggattgaag tagaacaggc tctggcccac ccatatctgg agcagtatta
 cgacccgagt
 1201 gacgagccca tcgccgaagc accattcaag ttcgacatgg aattggatga
 cttgcctaag
 1261 gaaaagctca aagaactaat ttttgaagag actgctagat tccagccagg
 atacagatct
 1321 taaatttgct aggtacctgg agtttaatac agtgagctct agcaagggag
 gcgctgcctt
 1381 ttgtttctag aatattatgt tcctcaaggt ccattatctt gtattctttt
 ccaagctcct
 1441 tattggaagg tattttttta aatttagaat taaaaattat ttagaaagtt
 acatataaa

//

20. MARCKS: MARCKS myristoylated alanine-rich protein kinase C
 substrate [Homo sapiens]

LOCUS NM_002356

AA/translation="MGAQFSKTAAKGEAAAERPGEAAVASSPSKANGQENGHVKNVD
 ASPAAESGAKEELQANGSAPAADKEEPAAAGSGAASPSAAEKGEPAAPAAPEAGASP
 VEKEAPAEGEAAEPGSPTAAEGEASASSTSSPKAEDGATPSPNETPKKKKKRFSF
 KKSFKLSGFSFKKNKKEAGEGGEAEAPAAEGGKDEAAGGAAAAAEAGAASGEQAAAP
 GEEAAAGEEGAAGGDPQEAKPQEAAVAPEKPPASDETKAAEEPSKVEEKKAEFEAGASA
 AACEAPSAAGPGAPPEQEAPAEPEAAAAASSACAAPSQEAQPECSPEAPPAEAAE

cDNA: 1 cttgggcgtt ggaccccgca tcttattagc aaccagggag atttctccat
 tttcctcttg
 61 tctacagtgc ggctacaaat ctgggatttt tttattactt cttttttttt
 cgaactacac
 121 ttgggctcct ttttttgtgc tcgacttttc cacccttttt cctccctcc
 tgtgctgctg
 181 ctttttgatc tcttcgacta aaattttttt atccggagtg tatttaatcg
 gttctgttct
 241 gtctcttcca ccacccccac cccctccct ccggtgtgtg tgccgctgcc
 gctgttgccg
 301 ccgcccgtgc tgetgctcgc cccgtcgtta caccaaccgc aggcctcttg
 tttccctctt
 361 tggatctggt gagtttcttt gttgaagaag ccagcatggg tgcccagttc
 tccaagaccg
 421 cagcgaaggg agaagccgcc gcggagaggc ctggggaggc ggctgtggcc
 tcgtgcctt

481 ccaaagcgaa cggacaggag aatggccacg tgaaggtaaa cggcgacgct
 tcgcccgcgg
 541 ccgccgagtc gggcgccaag gaggagctgc aggccaacgg cagcgccccg
 gccgccgaca
 601 aggaggagcc cgcggccgcc gggagcgggg cggcgctgcc ctccgcggcc
 gagaaaggtg
 661 agccggccgc cgcgctgcc cccgaggccg gggccagccc ggtagagaag
 gaggcccccg
 721 cggaaggcga ggctgccgag cccggctcgc ccacggccgc ggagggagag
 gccgcgtcgg
 781 ccgcctcctc gacttcttcg cccaaggccg aggacggggc cacgccctcg
 ccagcaacg
 841 agaccccgaa aaaaaaaaaaag aagcgctttt cttcaagaa gtctttcaag
 ctgagcggct
 901 tctccttcaa gaagaacaag aaggaggctg gagaaggcgg tgaggctgag
 gcgcccgtg
 961 ccgaaggcgg caaggacgag gccgccgggg gcgcagctgc ggccgccgcc
 gaggcggggg
 1021 cggcctccgg ggagcaggca gcggcgccgg gcgaggaggc ggcagcgggc
 gaggaggggg
 1081 cggcgggtgg cgaccgcgag gaggccaagc cccaggaggc cgctgtcgcg
 ccagagaagc
 1141 cgcccgccag cgacgagacc aaggccgccg aggagcccag caaggtggag
 gagaaaaagg
 1201 ccgaggaggc cggggccagc gccgcgcct gcgaggcccc ctccgccgcc
 gggcccggcg
 1261 cgcccccgga gcaggaggca gccccgcgg aggagcccgc ggccgccgca
 gcctcgtcag
 1321 cctgcgcagc ccctcacag gaggcccagc ccgagtgcag tccagaagcc
 cccccagcgg
 1381 aggcggcaga gtaaaagagc aagcttttgt gagataatcg aagaactttt
 ctcccccggt
 1441 tgtttgttgg agtggtgcc ggtactggtt ttggagaact tgtctacaac
 cagggtattga
 1501 ttttaaagat gtcttttttt attttacttt tttttaagca ccaaattttg
 ttgttttttt
 1561 tttttctccc ctccccacag atcccatctc aaatcattct gttaaccacc
 attccaacag
 1621 gtcgaggaga gcttaaacac cttcttcctc tgccctggtt ctcttttatt
 ttttattttt
 1681 tcgcatcagt attaatgttt ttgcatactt tgcactttta ttcaaaagtg
 taaactttct
 1741 ttgtcaatct atggacatgc ccataatga aggagatggg tgggtcaaaa
 agggatatca
 1801 aatgaagtga taggggtcac aatggggaaa ttgaagtggg gcataacatt
 gccaaaatag
 1861 tgtgccacta gaaatggtgt aaaggctgtc tttttttttt ttttttaaag
 aaaagttatt
 1921 accatgtatt ttgtgaggca ggtttacaac actacaagtc ttgagttaag
 aaggaaagag
 1981 gaaaaaagaa aaaacaccaa taccagatt taaaaaaaaa aaaacgatca
 tagtccttagg
 2041 agttcattta aaccatagga acttttctact tatctcatgt tagctgtacc
 agtcagtgat
 2101 taagtagaac tacaagttgt ataggcttta ttgtttattg ctggtttatg
 accttaataa
 2161 agtgtaatta tgtattacca gcagggtgtt ttttaactgtg actattgtat
 aaaaacaaat
 2221 cttgatatcc agaagcacat gaagtttgca actttccacc ctgcccattt
 ttgtaaaact
 2281 gcagtcactt tggacctttt aaaacacaaa ttttaaactc aaccaagctg

tgataagtgg
 2341 aatgggttact gtttatactg tggtatgttt ttgattacag cagataaatgc
 tttcttttcc
 2401 agtcgtcttt gagaataaag gaaaaaaaaa tcttcagatg caatgggttt
 gtgtagcatc
 2461 ttgtctatca tgttttgtaa atactggaga agctttgacc aatttgactt
 agagatggaa
 2521 tgtaactttg cttacaaaaa ttgctattaa actcctgctt aagggtgttct
 aattttctgt
 2581 gagcacacta aaagcgaaaa ataaatgtga ataaaatgta caaatgtgtt
 gtgttttttt
 2641 atgttctaata aatactgaga cttctaggtc ttaggttaat ttttaggaag
 atcttgcatg
 2701 ccatcaggag taaattttat tgtggttctt aatctgaagt tttcaagctc
 tgaaattcat
 2761 aatccgcagt gtcagattac gtagaggaag atcttacaac attccatgtc
 aaatctgtta
 2821 ccattttattg gcatttagtt ttcatttaag aattgaacat aattattttt
 attgtagcta
 2881 tatagcatgt cagattaaat catttacaac aaaaggggtg tgaacctaa
 actatttaaa
 2941 tgtcttatga gaaaatttca taaagccatt ctcttgatc tccaggtccag
 aaacaaattt
 3001 taaactgagt gagagtctat agaatccata ctgcagatgg gtcatgaaat
 gtgaccaaatt
 3061 gtgtttcaaa aattgatggg gtattacctg ctattgtaat tgcttagtgc
 ttggctaatt
 3121 tccaaattat tgcataatat gttctacctt aagaaaacag gtttatgtaa
 caagtaattg
 3181 gtgttgaaatg gatgatgtca gttcatgggc ctttagcata gttttaagca
 tcattttttt
 3241 tttttttttt gaaagtgtgt tagcatcttg ttactcaaag gataagacag
 acaataatac
 3301 ttcactgaat attaaataac tttactagtt tacctcctct gctctttgcc
 acccgataac
 3361 tggatatctt ttccttcaaa ggaccctaaa ctgattgaaa ttttagatat
 gtatcaaaaa
 3421 cattatttca tttaatgcac atctgttttg ctgtttttga gcagtgtgca
 gtttaggggt
 3481 catgataaat cattgaacca catgtgtaac aactgaatgc caaatcttaa
 actcattaga
 3541 aaaataacaa attaggtttt gacacgcatt ctttaattgga ataattggatc
 aaaaatagtg
 3601 gttcatgacc ttaccaaaca cccttgctac taataaaatc aaataacact
 tagaagggtg
 3661 tgtattttta gttaggggtt cttgatcttg gaggatgttt gaaagttaaa
 aattgaattt
 3721 ggtaacccaa ggactgattt atgggtcttt cctatcttaa ccaacgtttt
 cttagttacc
 3781 tagatggcca agtacagtgc ctggtatgta gtaagactca gtaaaaaagt
 ggatttttaa
 3841 aaataactcc caaagtgaat agtcaaaaat cctgttagca aactgttata
 tattgctaag
 3901 tttgttcttt taacagctgg aatttattaa gatgcattat tttgatttta
 ttcactgcct
 3961 aaaacacttt ggggtggtatt gatggagtgt gtggattttc ctccaagtga
 ttaaatgaaa
 4021 tttgacgtat cttttcatcc aaagttttgt acatcatgtt ttctaacgga
 aaaaaatggt
 4081 aatatggctt ttttgtatta ctaaaaatag ctttgagatt aaggaaaaat
 aaataactct

```

4141 tgtacagttc agtattgtct attaaatctg tattggcagt atgtataatg
gcatttgctg
4201 tggttacaaa atacttcctc tgggttataa taatcatttg atccaattcc
tattgcttgt
4261 aaaataaagt tttaccagtt gatataatca aaaaaaaaaa aaaa

```

```
//
```

```

21. NME1: NME1 NME/NM23 nucleoside diphosphate kinase 1 [ Homo
sapiens ]
LOCUS NM_000269 (isoform b)
AA/translation="MANCERTFIAIKPDGVQRGLVGEIIKRFEQKGFRVLGLKFMQAS
EDLLKEHYVDLKDPRFFAGLVKYMHS GPVVMVWEGLNVVKTGRVMLGETNPADSKPG
TIRGDFCIQVGRNIIHGSDSVESAEKEIGLWFHPEELVDYTSCAQNWIYE

```

```

cDNA: 1 gcagaagcgt tccgtgcgtg caagtgctgc gaaccacgtg ggtccccgggc
gcgttttcggg
61 tgctggcggc tgcagccgga gttcaaacct aagcagctgg aaggaaccat
ggccaactgt
121 gagcgtaacct tcattgcgat caaaccagat ggggtccagc ggggtcttgt
gggagagatt
181 atcaagcggt ttgagcagaa aggattccgc cttgttggtc tgaaattcat
gcaagcttcc
241 gaagatcttc tcaaggaaca ctacgttgac ctgaaggacc gtccattctt
tgccggcctg
301 gtgaaataca tgcactcagg gccggtagtt gccatggtct gggaggggct
gaatgtgggtg
361 aagacgggcc gagtcagtct cggggagacc aacctgcag actccaagcc
tgggaccatc
421 cgtggagact tctgcataca agttggcagg aacattatac atggcagtg
ttctgtggag
481 agtgcagaga aggagatcgg cttgtggttt caccctgagg aactggtaga
ttacacgagc
541 tgtgctcaga actggatcta tgaatgacag gagggcagac cacattgctt
ttcacatcca
601 tttccctcc ttcccatggg cagaggacca ggctgtagga aatctagtta
tttacaggaa
661 cttcatcata atttgagggg aagctcttgg agctgtgagt tctccctgta
cagtgttacc
721 atccccgacc atctgattaa aatgcttcct cccagcatag gattcattga
gttggttact
781 tcatattgtt gcattgcttt tttttccttc t
//

```

```

LOCUS NM_198175 (isoform 1)
AA/translation="MVLLSTLGIVFQGE GPPISCDTGTMANCERTFIAIKPDGVQRG
LVGEIIKRFEQKGFRVLGLKFMQASEDLLKEHYVDLKDPRFFAGLVKYMHS GPVVMV
WEGLNVVKTGRVMLGETNPADSKPGTIRGDFCIQVGRNIIHGSDSVESAEKEIGLWFH
PEELVDYTSCAQNWIYE

```

```

cDNA: 1 gcagaagcgt tccgtgcgtg caagtgctgc gaaccacgtg ggtccccgggc
gcgttttcggg
61 tgctggcggc tgcagccgga gttcaaacct aagcagctgg aagggccctg
tggttaggta
121 ccatagagtc tctacacagg actaagtcag cctgggtgtg aggggaggca
gacacacaaa
181 cagaaaattg gactacagtg ctaagatgct gtaagaagag gttactaaa
ggacaggaag
241 atggggccaa gagatgggtg tactgtctac tttagggatc gtctttcaag
gcgaggggcc
301 tcctatctca agctgtgata caggaaccat ggccaactgt gagcgtaacct
tcattgcgat
361 caaaccagat ggggtccagc ggggtcttgt gggagagatt atcaagcggt

```

```

ttgagcagaa
  421 aggattccgc cttgttggtc tgaaattcat gcaagcttcc gaagatcttc
tcaaggaaca
  481 ctacgttgac ctgaaggacc gtccattctt tgccggcctg gtgaaatata
tgcaactcagg
  541 gccggtagtt gccatggtct gggaggggct gaatgtggtg aagacgggcc
gagtcattgct
  601 cggggagacc aacctgcag actccaagcc tgggaccatc cgtggagact
tctgcataca
  661 agttggcagg aacattatac atggcagtga ttctgtggag agtgcagaga
aggagatcgg
  721 cttgtggttt cacctgagg aactggtaga ttacacgagc tgtgtcaga
actggatcta
  781 tgaatgacag gagggcagac cacattgctt ttcacatcca tttccctcc
ttcccatggg
  841 cagaggacca ggctgtagga aatctagtta ttacaggaa cttcatcata
atctggaggg
  901 aagctcttgg agctgtgagt tctccctgta cagtgttacc atccccgacc
atctgattaa
  961 aatgcttctc cccagcatag gattcattga gttggttact tcatattggt
gcattgcttt
 1021 ttttctcttc t

```

//

```

22. NME2: NME2 NME/NM23 nucleoside diphosphate kinase 2 [ Homo
sapiens ]
LOCUS NM_001018137 (isoform a variant 2)
AA/translation="MANLERTFIAIKPDGVQRGLVGEIIKRFEQKGFRLVAMKFLRAS
EEHLKQHYIDLKDRPFFPGLVKYMNSGPVAMVWEGLNVVKTGRVMLGETNPADSKPG
TIRGDFCIQVGRNIIHGSDSVKSAEKEISLWFKPEELVDYKSCAHDWVYE

```

```

cDNA: 1 atctcagggc agtaccactg ctgtgcggct gtcagtcagt gctgcaggcg
ccgagaggag
  61 gggcttgtga ccgccccagg gaagctgggc atcaccaaag ggagcttggt
tgccagggac
 121 actgcaagta ggaagtgtct acaggtcgat gacaggccta atctctatga
cagggtctag
 181 actttcctca ggggtccagg ggcacactca ggggtgaactg gaaaactcga
ccgcacttta
 241 gtgccaggac catggccaac ctggagcgca ccttcacgc catcaagccg
gacggcgtgc
 301 agcgcgccct ggtgggcgag atcatcaagc gcttcgagca gaagggattc
cgctctgtgg
 361 ccatgaagtt cctccgggcc tctgaagaac acctgaagca gcaactacatt
gacctgaaag
 421 accgaccatt ctccctggg ctggtgaagt acatgaactc agggccggtt
gtggccatgg
 481 tctgggaggg gctgaacgtg gtgaagacag gccgagtgat gcttggggag
accaatccag
 541 cagattcaaa gccaggcacc attcgtgggg acttctgcat tcaggttggc
aggaacatca
 601 ttcattggcag tgattcagta aaaagtgtg aaaaagaaat cagcctatgg
tttaagcctg
 661 aagaactggt tgactacaag tcttgtgctc atgactgggt ctatgaataa
gaggtggaca
 721 caacagcagt ctccctcagc acggcgtggt gtgtccctgg acacagctct
tcattccatt
 781 gacttagagg caacaggatt gatcattctt ttatagagca tatttgccaa
taaagctttt
 841 ggaagccgga aaaaaaaaaa aaaaaaa

```



```

//
LOCUS          NM_001018138                      (isoform a variant 3)
AA/translation="MANLERTFIAIKPDGVQRGLVGEIIKRFEQKGFRLVAMKFLRAS
EEHLKQHYIDLKDRPFFPGLVKYMNSGPVAMVWEGLNVVKTGRVMLGETNPADSKPG
TIRGDFCIQVGRNIIHGSDSVKSAEKEISLWFKPEELVDYKSCAHDWVYE

cDNA:   1 gcggccgcgc gtggtggggg aggagggacc ggccggcgccc acgtggcctc
cgcgggcccc
      61 gccagagcct gcgcccgggc cctgaccgca cctctcgccc cgcaggacca
tgcccaacct
     121 ggagcgcacc ttcacgcca tcaagccgga cggcgtgcag cgcggcctgg
tgggcgagat
     181 catcaagcgc ttcgagcaga agggattccg cctcgtggcc atgaagtcc
tccgggecte
     241 tgaagaacac ctgaagcagc actacattga cctgaaagac cgaccattct
tccttgggct
     301 ggtgaagtac atgaactcag ggccggttgt ggccatggtc tgggaggggc
tgaacgtggt
     361 gaagacaggc cgagtgatgc ttggggagac caatccagca gattcaaagc
caggcaccat
     421 tcgtggggac ttctgcattc aggttggcag gaacatcatt catggcagtg
attcagtaaa
     481 aagtgtctgaa aaagaaatca gcctatggtt taagcctgaa gaactggttg
actacaagtc
     541 ttgtgctcat gactgggtct atgaataaga ggtggacaca acagcagtct
ccttcagcac
     601 ggcgtggtgt gtccctggac acagctcttc attccattga cttagaggca
acaggattga
     661 tcattctttt atagagcata ttgccaata aagcttttgg aagccggaaa
aaaaaaaaaa
     721 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa
//
LOCUS          NM_001018139                      (isoform a variant 4)
AA/translation="MANLERTFIAIKPDGVQRGLVGEIIKRFEQKGFRLVAMKFLRAS
EEHLKQHYIDLKDRPFFPGLVKYMNSGPVAMVWEGLNVVKTGRVMLGETNPADSKPG
TIRGDFCIQVGRNIIHGSDSVKSAEKEISLWFKPEELVDYKSCAHDWVYE

cDNA:   1 aggcggtggg ggcgcacccc ctggcgactc ctcccgttcc ctcttcgct
tgcgctgcgg
      61 caggaccatg gccaacctgg agcgcacett catcgccatc aagccggacg
gcgtgcagcg
     121 cggcctggtg ggcgagatca tcaagcgctt cgagcagaag ggattccgcc
tcgtggccat
     181 gaagttcctc cgggcctctg aagaacacct gaagcagcac tacattgacc
tgaaagaccg
     241 accattcttc cctgggctgg tgaagtacat gaactcaggg ccggttggtg
ccatggtctg
     301 ggaggggctg aacgtggtga agacaggccg agtgatgctt ggggagacca
atccagcaga
     361 ttcaaagcca ggcaccattc gtggggactt ctgcattcag gttggcagga
acatcattca
     421 tggcagtgat tcagtaaaaa gtgctgaaaa agaaatcagc ctatggttta
agcctgaaga
     481 actggttgac tacaagtctt gtgctcatga ctgggtctat gaataagagg
tggacacaac
     541 agcagtctcc ttcagcacgg cgtggtgtgt ccctggacac agctcttcat
tccattgact
     601 tagaggcaac aggattgatc attcttttat agagcatatt tgccaataaa
gcttttggaa
     661 gccggaaaaa aaaaaaaaaa aa
//

```

LOCUS NM_001198682 (isoform b variant 5)
 AA/translation="MANLERTFIAIKPDGVQRGLVGEIIKRFEQKGFRLVAMKFLRAS
 EEHLKQHYIDLKDRPFFPGLVKYMNSGPVAMEHHSWQ

cDNA: 1 tgcctggcga gggcgcgccc cggtctggcg tggacactgt tctccggccg
 cgtcgggccc
 61 ggcggggtggg gcgttcctgc gggttggcg gctgggccct ccgggggtgtg
 gccacccgc
 121 gctccgccct gcgcccctcc tccgccgcg gctccgggt gtggtggtcg
 caccagctct
 181 ctgctctccc agcgcagcgc cgccgcccg cccctccagc ttcccggaacc
 atggccaacc
 241 tggagcgcac cttcatcgcc atcaagccgg acggcgtgca gcgcggcctg
 gtgggcgaga
 301 tcatcaagcg cttcgagcag aagggtattcc gcctcgtggc catgaagtcc
 ctccgggccc
 361 ctgaagaaca cctgaagcag cactacattg acctgaaaga ccgaccattc
 ttccctgggc
 421 tgggtgaagta catgaactca gggccggttg tggccatgga acatcattca
 tggcagtgat
 481 tcagtaaaaa gtgctgaaaa agaaatcagc ctatggttta agcctgaaga
 actggttgac
 541 tacaagtctt gtgctcatga ctgggtctat gaataagagg tggacacaac
 agcagtctcc
 601 ttcagcacgg cgtggtgtgt ccctggacac agctcttcat tccattgact
 tagaggcaac
 661 aggattgatc attcttttat agagcatatt tgccaataaa gcttttggaa
 gccggaaaaa
 721 aaaaaaaaaa aaa

//
 LOCUS NM_002512 (isoform a variant 1)
 AA/translation="MANLERTFIAIKPDGVQRGLVGEIIKRFEQKGFRLVAMKFLRAS
 EEHLKQHYIDLKDRPFFPGLVKYMNSGPVAMVWEGLNVVKTGRVMLGETNPADSKPG
 TIRGDFCIQVGRNIIHGSDSVKSAEKEISLWFKPEELVDYKSCAHDWVYE

cDNA: 1 tgcctggcga gggcgcgccc cggtctggcg tggacactgt tctccggccg
 cgtcgggccc
 61 ggcggggtggg gcgttcctgc gggttggcg gctgggccct ccgggggtgtg
 gccacccgc
 121 gctccgccct gcgcccctcc tccgccgcg gctccgggt gtggtggtcg
 caccagctct
 181 ctgctctccc agcgcagcgc cgccgcccg cccctccagc ttcccggaacc
 atggccaacc
 241 tggagcgcac cttcatcgcc atcaagccgg acggcgtgca gcgcggcctg
 gtgggcgaga
 301 tcatcaagcg cttcgagcag aagggtattcc gcctcgtggc catgaagtcc
 ctccgggccc
 361 ctgaagaaca cctgaagcag cactacattg acctgaaaga ccgaccattc
 ttccctgggc
 421 tgggtgaagta catgaactca gggccggttg tggccatggt ctgggagggg
 ctgaacgtgg
 481 tgaagacagg ccgagtgatg cttggggaga ccaatccagc agattcaaag
 ccaggcacca
 541 ttcgtgggga cttctgcatt cagggttgga ggaacatcat tcatggcagt
 gattcagtaa
 601 aaagtgtctga aaaagaaatc agcctatggt ttaagcctga agaactggtt
 gactacaagt
 661 cttgtgctca tgactgggtc tatgaataag aggtggacac aacagcagtc
 tccttcagca

721 cggcgtggtg tgtccctgga cacagctctt cattccattg acttagagggc
aacaggattg
781 atcattcttt tatagagcat atttgccaat aaagcttttg gaagccggaa
aaaaaaaaa
841 aaaaaa

//

23. PGK1: PGK1 phosphoglycerate kinase 1 [Homo sapiens]
LOCUS NM_000291
AA/translation="MSLSNKLTLDKLDVKGRVVMRVDFNVPMKNNQITNNQRIKAAV
PSIKFCLDNGAKSVVLMShLGRPDGVMPDKYSLEPVAVELKSLLGKDVFLKDCVGP
EVEKACANPAAGSVILLENLRFHVEEEGKGKDASGNKVKAEPAKIEAFRASLSKLGDV
YVNDAFGTAHRAHSSMVGVNLPQKAGGFLMKKELNYFAKALESPPERPFLAILGGAKVA
DKIQLINNMLDKVNEMIIGGGMAFTFLKVLNNMEIGTSLFDEEGAKIVKDLMSKAEKN
GVKITLPVDFVTADKFDENAKTGQATVASGIPAGWMGLDCGPESKKYAEAVTRAKQI
VWNGPVGVFEWEAFARGTKALMDEVVKATSRGCITIIGGGDTATCCAKWNTEDKVSHV
STGGGASLELLEGGKVLPGVDALSNI

cDNA: 1 gagagcagcg gccgggaagg ggcggtgcgg gaggcgggggt gtggggcggt
agtgtgggcc
61 ctgttcctgc ccgcgcggtg ttccgcattc tgcaagcctc cggagcgcac
gtcggcagtc
121 ggctccctcg ttgaccgaat caccgacctc tctccccagc tgtattttcca
aaatgtcgct
181 ttctaacaag ctgacgctgg acaagctgga cgttaaaggg aagcgggtcg
ttatgagagt
241 cgacttcaat gttcctatga agaacaacca gataacaaac aaccagagga
ttaaggctgc
301 tgtcccaagc atcaaattct gcttggacaa tggagccaag tccgtagtcc
ttatgagcca
361 cctaggccgg cctgatggtg tgcccatgcc tgacaagtac tccttagagc
cagttgctgt
421 agaactcaaa tctctgctgg gcaaggatgt tctgttcttg aaggactgtg
taggcccaga
481 agtggagaaa gcctgtgcca acccagctgc tgggtctgtc atcctgctgg
agaacctccg
541 ctttcatgtg gaggaagaag ggaagggaaa agatgcttct gggaacaagg
ttaaagccga
601 gccagccaaa atagaagctt tccgagcttc actttccaag ctaggggatg
tctatgtcaa
661 tgatgctttt ggcactgctc acagagccca cagctccatg gtaggagtca
atctgccaca
721 gaaggctggt gggtttttga tgaagaagga gctgaactac tttgcaaagg
ccttggagag
781 ccagagcgca cccttctgg ccctcctggg cggagctaaa gttgcagaca
agatccagct
841 catcaataat atgctggaca aagtcaatga gatgattatt ggtggtggaa
tggcttttac
901 cttccttaag gtgctcaaca acatggagat tggcacttct ctgtttgatg
aagagggagc
961 caagattgtc aaagacctaa tgtccaaagc tgagaagaat ggtgtgaaga
ttaccttgcc
1021 tgttgacttt gtcactgctg acaagtttga tgagaatgcc aagactggcc
aagccactgt
1081 ggcttctggtg atacctgctg gctggatggg cttggactgt ggtcctgaaa
gcagcaagaa
1141 gtatgctgag gctgtcactc gggctaagca gattgtgtgg aatggtcctg
tgggggtatt
1201 tgaatgggaa gcttttgccc ggggaaccaa agctctcatg gatgaggtgg
tgaaagccac
1261 ttctaggggc tgcataacca tcataggtgg tggagacact gccacttgct

```

gtgccaaatg
  1321 gaacacggag gataaagtca gccatgtgag cactgggggt ggtgccagtt
tggagctcct
  1381 ggaaggtaaa gtccttcctg ggggtggatgc tctcagcaat atttagtact
ttcctgcctt
  1441 ttagttcctg tgcacagccc ctaagtcaac ttagcatttt ctgcatctcc
acttggcatt
  1501 agctaaaacc ttccatgtca agattcagct agtggccaag agatgcagtg
ccaggaaccc
  1561 ttaaacagtt gcacagcatc tcagctcatc ttcactgcac cctgggatttg
catacattct
  1621 tcaagatccc atttgaattt tttagtgtact aaaccattgt gcattctaga
gtgcatatat
  1681 ttatatatttg cctgttaaaa agaaagtgag cagtgttagc ttagttctct
tttgatgtag
  1741 gttattatga ttagctttgt cactgtttca ctactcagca tggaaacaag
atgaaattcc
  1801 atttgtaggt agtgagacaa aattgatgat ccattaagta aacaataaaa
gtgtccattg
  1861 aaaccgtgat tttttttttt ttcctgtcat actttgttag gaagggtag
aatagaatct
  1921 tgaggaacgg atcagatgtc tatattgttg aatgcaagaa gtggggcagc
agcagtggag
  1981 agatgggaca attagataaa tgtccattct ttatcaaggg cctactttat
ggcagacatt
  2041 gtgctagtgc ttttattcta acttttattt ttatcagtta cacatgatca
taatttaaaa
  2101 agtcaaggct tataacaaaa aagccccagc ccatttctcc cattcaagat
tcccactccc
  2161 cagaggtgac cactttcaac tcttgagttt ttcaggtata tacctccatg
tttctaagta
  2221 atatgcttat attgttcaact tctttttttt ttatttttta aagaaatcta
tttcatacca
  2281 tggaggaagg ctctgttcca catatatttc cacttcttca ttctctcggt
atagttttgt
  2341 cacaattata gattagatca aaagtctaca taactaatac agctgagcta
tgtagtatgc
  2401 tatgattaa tttacttatg taaaaaaaaa aaaaaaaaaa

```

//

```

24. PGK2: PGK2 phosphoglycerate kinase 2 [ Homo sapiens ]
LOCUS NM_138733
AA/translation="MSLSKKLTLDKLDVRGKRIVMRVDFNVPMMKNQITNNQRIKASI
PSIKYCLDNGAKAVVLSHLGRPDGVPMPDKYSLAPVAVELKSLLGKDVFLKDCVGA
EVEKACANPAPGSVILLENLRFHVEEGKGQDPSGKKIKAEPDKIEAFRASLSKLGDV
YVNDAFGTAHRAHSSMVGVLPHKASGFLMKKELDYFAKALENPVRPFLAILGGAKVA
DKIQLIKNMLDKVNEMIIGGGMAYTFLKVLNNMEIGASLFDEEGAKIVKDIMAKAQKN
GVRITFPVDFVTGDKFDENAQVGKATVASGISPGWMGLDCGPESNKNHAQVVAQARLI
VWNGPLGVFEWDAFAKGTKALMDEIVKATSKGCITVIGGGDTATCCAkwntEDKVSHV
STGGGASLELLEGGKILPGVEALSNM

```

```

cDNA: 1 aacagtggcc gttgtgctgg agacagtgag gagaagaaag gggcgggaca
agggcaaagg
  61 cgttagaagt caccaccgac ccagcccctc aacagcaagt tggttcttca
gcattaagat
  121 ccaggtgtca gcctatgtct ttatattgtc aagatgtctc tttctaagaa
gttgacttta
  181 gacaaaactgg atgtagaggg gaagcgagtc atcatgagag tagacttcaa
tggtcccatg
  241 aagaagaacc agattacaaa caaccagagg atcaaggctt ccatccaag
catcaagtac

```

```

301 tgcttgga ca atggagccaa ggcagtagtt cttatgagtc atctaggtcg
gcctgatggt
361 gttcccatgc ctgacaaata ttccttagca cctgttgctg ttgagctcaa
atccttgctg
421 ggcaaggatg ttctgttctt gaaggactgt gtaggcgcag aagtggagaa
agcctgtgcc
481 aaccagctc ctgggttcagt catcctgctg gagaacctgc gctttcatgt
ggaggaagaa
541 gggaagggcc aagatccctc tggaaagaag attaaagctg agccagataa
aatagaagcc
601 ttccgagcat cactttccaa gctaggggac gtctatgtca atgatgcttt
tggcactgca
661 caccgcgctc atagtcccat ggtgggagtg aatctgcccc ataaagcatc
cggattcttg
721 atgaagaagg aactagatta ctttgctaaa gccttgga aa acccagtga
accctttctg
781 gctatacttg gtggagccaa agtggcagac aagatccaac ttatcaaaaa
tatgctggac
841 aaagtcaatg agatgattat tgggtgtgga atggcttata cttccttaa
ggtactcaac
901 aacatggaga ttggtgcttc cctgtttgat gaagaggag ccaagatcgt
taaagatata
961 atggccaaag cacaaaagaa tgggtgtaagg attacttttc ctgttgattt
tggtactggg
1021 gacaagtttg acgagaacgc tcagggttga aaagccactg tagcatctgg
catatctcct
1081 ggctggatgg gtttggactg tggctcctgag agcaacaaga atcatgctca
agttgtggct
1141 caagcaaggc taattgtttg gaatgggccg ttaggagtat ttgaatggga
tgcccttgct
1201 aagggaacca aagccctcat ggatgaaatt gtgaaagcca cttccaaggg
ctgcatact
1261 gttatagggg gtggagacac tgctacttgc tgtgccaaat ggaacactga
agataaagtc
1321 agccatgtca gcaactggagg cggtgccagt ctagagcttc tggaaggtaa
aatccttctc
1381 ggagtagagg ccctcagcaa catgtagtta atatagtgtt acttccttct
gtttctgtc
1441 catggccctt aagtcagctt aatgctttta catctcgatg tgacttttgt
taaaatctac
1501 tctagatca agacctatgt aatggacaag cagcaggcca tcaggaactc
ttaatatcag
1561 cacagcaatt cattttagtt tggtcacgca tttgctgtt caagttctca
tttgaacttc
1621 accattgtgc tatctagggg ggacatatc ttaagttgcc tattaagaa
agtgaactga
1681 agaaactgaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa a

```

//

25. RAB7A: RAB7A RAB7A, member RAS oncogene family [Homo sapiens]

LOCUS NM_004637

AA/translation="MTSRKKVLLKVIILGDSGVGKTSMLNQYVNKKFSNQYKATIGAD
FLTKEVMVDDRLVTMQIWDTAGQERFQSLGVAFYRGADCCVLVFDVTAPNTFKTLD
SWRDEFLIQASPRDPENFFVVLGNKIDLENRQVATKRAQAWCYSKNNIPYFETSAKEAI
NVEQAFQTIARNALKQETEVELYNEFPEPIKLDKNDRAKASAESCSC

cDNA: 1 acttccgctc ggggcggcgg cgggtggcggg agtgggagcg ggctggagt
cttgccata
61 aagcctgagg cggcggcagc ggcggagttg gcggttgga gagctcggga
gagttccctg

```

121 gaaccagaac ttggaccttc tcgcttctgt cctccgttta gtctcctcct
cggcgggagc
181 cctcgcgacg cgcccggccc ggagccccc ggcgagcggc cgcgtttgaa
ggatgacctc
241 taggaagaaa gtgttgctga aggttatcat cctgggagat tctggagtcg
ggaagacatc
301 actcatgaac cagtatgtga ataagaaatt cagcaatcag tacaaaagcca
caataggagc
361 tgactttctg accaaggagg tgatggtgga tgacaggcta gtcacaatgc
agatatggga
421 cacagcagga caggaacggt tccagtctct cgggtgtggc ttctacagag
gtgcagactg
481 ctgcgttctg gtatttgatg tgactgcccc caacacattc aaaaccctag
atagctggag
541 agatgagttt ctcatccagg ccagtccccg agatcctgaa aacttcccat
ttgttgtgtt
601 gggaaacaag attgacctcg aaaacagaca agtggccaca aagcgggcac
aggcctggtg
661 ctacagcaaa aacaacattc cctactttga gaccagtgcc aaggaggcca
tcaacgtgga
721 gcaggcgctc cagacgattg cacggaatgc acttaagcag gaaacggagg
tgagagctgta
781 caacgaattt cctgaacctt tcaaactgga caagaatgac cgggccaaagg
cctcggcaga
841 aagctgcagt tgctgagggg gcagtgagag ttgagcacag agtccttcac
aaaccaagaa
901 cacacgtagg ccttcaacac aattcccctc tcctcttcca aacaaaacat
acattgatct
961 ctacacatcca gctgcaaaaa gaaaaccca tcaaacacag ttacacccca
catatctctc
1021 acacacacac acacacgcac acacacacac acagatctga cgtaatcaaa
ctccagccct
1081 tgcccgtgat ggctccttgg ggtctgcctg cccaccaca tgagcccgcg
agtatggcag
1141 caggacaagc cagcgggtgga agtcattctg atatggagtt ggcattggaa
gcttattctt
1201 tttgttcact ggagagagag agaactgttt acagttaatc tgtgtctaata
tatctgattt
1261 tttttattgg tcttgtggtc tttttacccc ccttttcccc tccctccttg
aaggctaccc
1321 cttgggaagg ctggtgcccc atgccccatt acaggctcac acccagctctg
atcaggctga
1381 gttttgtatg tatctatctg ttaatgcttg ttacttttaa ctaatcagat
ctttttacag
1441 tatccattta ttatgtaatg cttcttagaa aagaatctta tagtacatgt
taatatatgc
1501 aaccaattaa aatgtataaa ttagtgtaag aaattcttgg attatgtggt
taagtcctgt
1561 aatgcaggcc tgtaagggtg agggttgaac cctgtttgga ttgcagagtg
ttactcagaa
1621 ttgggaaatc cagctagcgg cagtattctg tacagtagac acaagaatta
tgtacgcctt
1681 ttatcaaaga cttaagagcc aaaaagcttt tcatctctcc agggggaaaa
ctgtctagtt
1741 cccttctgtg tctaaatttt ccaaaacggt gatttgcata atacagtggg
atgtgcaatg
1801 gataaattgc cgttatttca aaaattaaaa ttctcatttt ctttcttttt
tttccccct
1861 gctccacact tcaaaactcc cgttagatca gcattctact acaagagtga
aaggaaaacc
1921 ctaacagatc tgtcctagtg attttacctt tgttctagaa ggcgctcctt

```

```

tcagggttgt
  1981 ggtattctta ggtagcgga gctttttcct cttttcccca cccatctccc
caatattgcc
  2041 cattattaat taacctcttt ctttggttgg aacctggca gttctgctcc
cttcctagga
  2101 tctgcccctg cattgtagct tgcttaacgg agcacttctc ctttttccaa
aggtctacat
  2161 tctagggtgt gggctgagtt cttctgtaaa gagatgaacg caatgccaat
aaaattgaac
  2221 aagaacaatg ataaaaaaaa
//

26. RPL17: RPL17 ribosomal protein L17 [ Homo sapiens ]
LOCUS NM_000985 (isoform A variant 1)
AA/translation="MVRYSLDPENPTKSCSRGSNLRVHFKNTRETAQAIGMHIRKA
TKYLDVTLQKQCVFRRYNGGVGRCAQAKQWGTQGRWPKKSAEFLHMLKNAESNA
ELKGLDVDSLVIIEHIQVNKAPKMRRRTYRAHGRINPYMSSPCHIEMLTEKEQIVPKP
EEEVAQKKKISQKKLKKQKLMARE

cDNA: 1 cctgcctcct cagatctcgt ttcttcggct acgaatctcg cgagaagtca
agttctcatg
  61 agttctccca aaatccaccg ctcttcctct ttccctaagc agcctgaggg
ttgactggat
  121 tggtgaggcc cgtgtggcta cttctgtgga agcagtgtctg tagttactgg
aagataaaaag
  181 ggaaagcaag cccttggtgg gggaaagtat ggctgcatg atggcatttc
ttaggacacc
  241 tttggattaa taatgaaaac aactactctc tgagcagctg ttcgaatcat
ctgatattta
  301 tactgaatga gttactgtaa gtacgtattg acagaattac actgtacttt
cctctaggtg
  361 atctgtgaaa atggttcgct attcacttga cccggagaac cccacgaaat
catgcaaatc
  421 aagaggttcc aatcttcgtg ttcactttaa gaacactcgt gaaactgctc
aggccatcaa
  481 gggtatgcat atacgaaaag ccacgaagta tctgaaagat gtcactttac
agaaacagtg
  541 tgtaccattc cgacgttaca atggtggagt tggcaggtgt gcgcaggcca
agcaatgggg
  601 ctggacacaa ggtcgggtggc ccaaaaagag tgctgaattt ttgctgcaca
tgcttaaaaa
  661 cgcagagagt aatgctgaac ttaagggttt agatgtagat tctctggtca
ttgagcatat
  721 ccaagtgaac aaagcaccta agatgcgccg ccggacctac agagctcatg
gtcggattaa
  781 ccatacatg agctctccct gccacattga gatgacctt acggaaaagg
aacagattgt
  841 tcctaaacca gaagaggagg ttgcccagaa gaaaaagata tcccagaaga
aactgaagaa
  901 acaaaaactt atggcacggg agtaaatcca gcattaaaat aaatgtaatt
aaaaggaaaa
  961 gaaaaaaaaa aaaaaaaaaa aaaaa
//

LOCUS NM_001035006 (isoform a variant 2)
AA/translation="MVRYSLDPENPTKSCSRGSNLRVHFKNTRETAQAIGMHIRKA
TKYLDVTLQKQCVFRRYNGGVGRCAQAKQWGTQGRWPKKSAEFLHMLKNAESNA
ELKGLDVDSLVIIEHIQVNKAPKMRRRTYRAHGRINPYMSSPCHIEMLTEKEQIVPKP
EEEVAQKKKISQKKLKKQKLMARE

cDNA: 1 cctgcctcct cagatctcgt ttcttcggct acgaatctcg cgagaagtca

```

```

agtttctcatg
  61 agtttctccca aaatccaccg ctcttctctt ttccctaagc agcctgaggt
gatctgtgaa
 121 aatgggttcgc tattcacttg acccgagaa cccacgaaa tcatgcaaat
caagagggttc
 181 caatcttcgt gttcacttta agaactcgc tgaaactgct caggccatca
agggtatgca
 241 tatacgaaaa gccacgaagt atctgaaaga tgtcacttta cagaaacagt
gtgtaccatt
 301 cgcacgttac aatgggtggag ttggcaggtg tgcgcaggcc aagcaatggg
gctggacaca
 361 aggtcgggtg cccaaaaaga gtgctgaatt ttgctgcac atgcttaaaa
acgcagagag
 421 taatgctgaa ctttaagggt tagatgtaga ttctctggtc attgagcata
tccaagttaa
 481 caaagcacct aagatgcgcc gccggacct cagagctcat ggtcggatta
acccatacat
 541 gagctctccc tgccacattg agatgatcct tacggaaaag gaacagattg
ttcctaaacc
 601 agaagaggag gttgccaga agaaaaagat atcccagaag aaactgaaga
aacaaaaact
 661 tatggcacgg gagtaaattc agcattaaaa taaatgtaat taaaaggaaa
agaaaaaaa
 721 aaaaaaaaaa aaaaaa
//

```

LOCUS NM_001199340 (isoform a variant 3)
AA/translation="MVRYSLDPENPTKSKSRGSNLRVHFKNTRETAQAIGMHIRKA
TKYLKDVTLQKQCVFRRYNGGVGRCAQAKQWGTQGRWPKKSAEFLHMLKNAESNA
ELKGLDVDSLVIHQVNKAPKMRRTYRAHGRINPYMSSPCHIEMILTEKEQIVPKP
EEEVAQKKKISQKKLKKQKLMARE

```

cDNA:  1 cctgcctcct cagatctcgt ttcttcggct acgaatctcg cgagaagtca
agtttctcatg
  61 agtttctccca aaatccaccg ctcttctctt ttccctaagc agcctgaggg
ttgactggat
 121 tgggtgaggcc cgtgtggcta cttctgtgga agcagtgcgt tagttactgg
aagataaaaag
 181 ggaaagcaag cccttgggtg gggaaagtga tctgtgaaaa tgggtcgcga
ttcacttgac
 241 cgggagaacc ccacgaaatc atgcaaatca agagggtcca atcttcgtgt
tcactttaag
 301 aacactcgtg aaactgctca ggccatcaag ggtatgcata tacgaaaagc
cacgaagtat
 361 ctgaaagatg tcactttaca gaaacagtgt gtaccattcc gacgttacaa
tggtggagtt
 421 ggcagggtgt cgcaggccaa gcaatggggc tggacacaag gtcggtggcc
caaaaagagt
 481 gctgaatttt tgctgcacat gcttaaaaaa gcagagagta atgctgaact
taagggttta
 541 gatgtagatt ctctggatc tgagcatatc caagtgaaca aagcacctaa
gatgcgcgcg
 601 cggacctaca gagctcatgg tcggattaac ccatacatga gctctccctg
ccacattgag
 661 atgaccccta cggaaaagga acagattgtt cctaaaccag aagaggaggt
tgcccagaag
 721 aaaaagatat ccagaagaa actgaagaaa caaaaactta tggcacggga
gtaaattcag
 781 cattaaaata aatgtaatta aaaggaaaag aaaaaaaaaa aaaaaaaaaa aaaa
//

```


LOCUS NM_001199341 (isoform a variant 4)
 AA/translation="MVRYSLDPENPTKSCSRGSNLRVHFKNTRETAQAIGMHIRKA
 TKYLKDVT LQKQCVFRRYNGGVGRCAQAKQWGTQGRWPKKSAEFLHMLKNAESNA
 ELKGLDVDSLVIIEHIQVNKAPKMRRRTYRAHGRINPYMSSPCHIEMLTEKEQIVPKP
 EEEVAQKKKISQKKLKKQKLMARE

cDNA: 1 gcctgaggtg agtggtttctc ctgcgttgct ccgagggccc aatcctcctg
 ccatcgccgc
 61 catcctggct tcggggggcgc cggcctccag gcccccgga ggagaaactcc
 tagggctact
 121 aaatcctcgc tggaggcggt ggcttcttat gcgggaggac gtggcgagg
 gcctgacttt
 181 gggagccggg gtcagtcggc ctctgaggtg atctgtgaaa atggttcgct
 attcattga
 241 cccggagaac cccacgaaat catgcaaatac aagagggttc aatcttcgtg
 ttcactttta
 301 gaacactcgt gaaactgctc aggccatcaa gggatatgcat atacgaaaag
 ccacgaagta
 361 tctgaaagat gtcactttac agaaacagtg tgtaccattc cgacgttaca
 atggtggagt
 421 tggcaggtgt gcgcaggcca agcaatgggg ctggacacaa ggtcggtggc
 ccaaaaagag
 481 tgctgaattt ttgctgcaca tgcttaaaaa cgcagagagt aatgctgaac
 ttaagggttt
 541 agatgtagat tctctggtca ttgagcatat ccaagtgaac aaagcaccta
 agatgcgcgc
 601 ccggacctac agagctcatg gtcggattaa ccatacatg agctctccct
 gccacattga
 661 gatgatcctt acggaaaagg aacagattgt tcctaaacca gaagaggagg
 ttgcccagaa
 721 gaaaaagata tcccagaaga aactgaagaa acaaaaaactt atggcacggg
 agtaaattca
 781 gcattaaaat aaatgtaatt aaaaggaaaa gaaaaaaaaa aaaaaaaaaa aaaaa
 //

LOCUS NM_001199342 (isoform A variant 5)
 AA/translation="MVRYSLDPENPTKSCSRGSNLRVHFKNTRETAQAIGMHIRKA
 TKYLKDVT LQKQCVFRRYNGGVGRCAQAKQWGTQGRWPKKSAEFLHMLKNAESNA
 ELKGLDVDSLVIIEHIQVNKAPKMRRRTYRAHGRINPYMSSPCHIEMLTEKEQIVPKP
 EEEVAQKKKISQKKLKKQKLMARE

cDNA: 1 gcctgaggtg agtggtttctc ctgcgttgct ccgagggccc aatcctcctg
 ccatcgccgc
 61 catcctggct tcggggggcgc cggcctccag gcccccgga ggagaaactcc
 tagggctact
 121 aaatcctcgc tggaggcggt ggcttcttat gcgggaggac gtggcgagg
 gcctgacttt
 181 gggagccggg gtcagtcggc ctctgagggt tgactggatt ggtgaggccc
 gtgtggctac
 241 ttctgtggaa gcagtgtgt agttactgga agataaaagg gaaagcaagc
 ccttggtggg
 301 ggaaagtgat ctgtgaaaat ggttcgctat tcacttgacc cggagaaccc
 cacgaaatca
 361 tgcaaatcaa gaggttccaa tcttcgtgtt cactttaaga aactcgtga
 aactgctcag
 421 gccatcaagg gtatgcatac acgaaaagcc acgaagtatc tgaaagatgt
 cactttacag
 481 aaacagtgtg taccattccg acgttacaat ggtggagttg gcaggtgtgc
 gcaggccaag
 541 caatggggct ggacacaagg tcggtggccc aaaaagagtg ctgaattttt
 gctgcacatg

```

        601 cttaaaaacg cagagagtaa tgctgaactt aagggttttag atgtagattc
tctggtcatt
        661 gagcatatcc aagtgaacaa agcacctaag atgcgcgcgc ggacctacag
agctcatggt
        721 cggattaacc catacatgag ctctccctgc cacattgaga tgatccttac
ggaaaaggaa
        781 cagattgttc ctaaaccaga agaggaggtt gcccagaaga aaaagatatac
ccagaagaaa
        841 ctgaagaaac aaaaacttat ggcacgggag taaattcagc attaaaataa
atgtaattaa
        901 aaggaaaaga aaaaaaaaaa aaaaaaaaaa aaa
//

```

```

LOCUS      NM_001199343      (isoform a variant 6)
AA/translation="MVRYSLDPENPTKCKSRGSNLRVHFKNTRETAQAIGMHIRKA
TKYLDVTLQKQCVFRRYNGGVGRCAQAKQWGTQGRWPKKSAEFLHMLKNAESNA
ELKGLDVDSLVIIEHIQVNKAPKMRRRTYRAHGRINPYMSSPCHIEMLTEKEQIVPKP
EEEVAQKKKISQKKLKKQKLMARE

```

```

cDNA:      1 gcctgaggtg agtggtttctc ctgcgttgct ccgagggccc aatcctcctg
ccatcgccgc
        61 catcctggct tcgggggggc cgccctccag gccccggga ggagaactcc
tagggtact
        121 aaatcctcgc tggaggcggt ggttcttat gcgggaggac gtggcgagg
gcctgacttt
        181 gggagccggg ggttgactgg attggtgagg ccctgtggc tacttctgtg
gaagcagtgc
        241 tgtagttact ggaagataaa agggaaagca agcccttggg gggggaaagt
gatctgtgaa
        301 aatggttcgc tttcacttg acccgagaga cccacgaaa tcatgcaaat
caagagggtc
        361 caatcttcgt gttcacttta agaactcgc tgaaactgct caggccatca
agggtatgca
        421 tatacgaaaa gccacgaagt atctgaaaga tgtaacttta cagaaacagt
gtgtaccatt
        481 ccgacgttac aatggtggag ttggcaggtg tgcgcaggcc aagcaatggg
gctggacaca
        541 aggtcgggtg cccaaaaaga gtgctgaatt tttgctgcac atgcttaaaa
acgcagagag
        601 taatgctgaa cttagggtt tagatgtaga ttctctggtc attgagcata
tccaagtgaa
        661 caaagcacct aagatgcgc gcccgacct cagagctcat ggtcggatta
accatacat
        721 gagctctccc tgccacattg agatgacct tacggaaaag gaacagattg
ttcctaaacc
        781 agaagaggag gttgccaga agaaaaagat atcccagaag aaactgaaga
aacaaaaact
        841 tatggcacgg gagtaaattc agcattaaaa taaatgtaat taaaaggaaa
agaaaaaaaa
        901 aaaaaaaaaa aaaaaa
//

```

```

LOCUS      NM_001199344      (isoform a variant 7)
AA/translation="MVRYSLDPENPTKCKSRGSNLRVHFKNTRETAQAIGMHIRKA
TKYLDVTLQKQCVFRRYNGGVGRCAQAKQWGTQGRWPKKSAEFLHMLKNAESNA
ELKGLDVDSLVIIEHIQVNKAPKMRRRTYRAHGRINPYMSSPCHIEMLTEKEQIVPKP
EEEVAQKKKISQKKLKKQKLMARE

```

```

cDNA:      1 gcctgaggtg agtggtttctc ctgcgttgct ccgagggccc aatcctcctg
ccatcgccgc
        61 catcctggct tcgggggggc cgccctccag gccccggga ggagaactcc

```

```

tagggctact
  121 aaatcctcgc tggaggcggt ggcttcttat gcgggaggac gtggcggagg
gcctgacttt
  181 gggagccggg gtgatctgtg aaaatgggtc gctattcact tgacccggag
aaccacga
  241 aatcatgcaa atcaagaggt tccaatcttc gtgttcactt taagaacact
cgtgaaactg
  301 ctcaggccat caagggtatg catatacgaa aagccacgaa gtatctgaaa
gatgtcactt
  361 tacagaaaca gtgtgtacca ttccgacgtt acaatgggtg agttggcagg
tgtgcgcagg
  421 ccaagcaatg gggctggaca caaggtcggt ggcccaaaaa gagtgtgaa
tttttgcgtc
  481 acatgcttaa aaacgcagag agtaatgctg aacttaaggg tttagatgta
gattctctgg
  541 tcattgagca tatccaagtg aacaaagcac ctaagatgcg ccgccggacc
tacagagctc
  601 atggtcggat taaccctaac atgagctctc cctgccacat tgagatgatc
cttacgaaa
  661 aggaacagat tgttcctaaa ccagaagagg aggttgccca gaagaaaaag
atatcccaga
  721 agaaactgaa gaaacaaaaa cttatggcac gggagtaa at tcagcattaa
aataaatgta
  781 attaaaagga aaagaaaaaa aaaaaaaaaa aaaaaaa

```

//

```

LOCUS      NM_001199345                      (isoform b variant 8)
AA/translation="MHIRKATKYLKDVTLQKQCVFRRYNGGVGRCAQAKQWGTQGR
WPKKSAEFLHMLKNAESNAELKGLDVSIVIEHIQVKNKAPKMRRRTYRAHGRINPYM
SSPCHIEMLTEKEQIVPKPEEEVAQKKKISQKKLKKQKLMARE

```

```

cDNA:  1 cctgcctcct cagatctcgt ttcttcggct acgaatctcg cgagaagtca
agttctcatg
   61 agttctccca aaatccaccg ctcttcctct ttccctaagc agcctgaggt
gatctgtgaa
  121 aatggttcgc tattcacttg acccgagagaa cccacgaaa taacactcgt
gaaactgctc
  181 aggccatcaa gggtatgcat atacgaaaag ccacgaagta tctgaaagat
gtcactttac
  241 agaaacagtg tgtaccattc cgacgttaca atgggtggagt tggcaggtgt
gcgcaggcca
  301 agcaatgggg ctggacacaa ggtcgggtggc ccaaaaagag tgctgaat
ttgctgcaca
  361 tgcttaaaaa cgcagagagt aatgctgaac ttaagggttt agatgtagat
tctctggtca
  421 ttgagcatat ccaagtgaac aaagcaccta agatgcgccg ccggacctac
agagctcatg
  481 gtcggattaa ccatacatg agctctccct gccacattga gatgacott
acggaaaagg
  541 aacagattgt tcctaaacca gaagaggagg ttgccagaa gaaaaagata
tcccagaaga
  601 aactgaagaa acaaaaactt atggcacggg agtaaatca gcattaaat
aatgtaatt
  661 aaaaggaaaa gaaaaaaaaa aaaaaaaaaa aaaaa

```

//

```

27.  RPL28: RPL28 ribosomal protein L28 [ Homo sapiens ]
LOCUS      NM_000991                      (isoform 2)
AA/translation="MSAHLQWMVVRNCSSFLIKRNKQTYSTEPNNLKARNSEFRYNGLI
HRKTVGVEPAADGKGVVVVVKRRSGQRKPATSYVRTTINKNARATLSSIRHMIRKNKY
RPDLRMAAIRRASAILRSQKPVVMVKRTRPTKSS

```

```

cDNA:  1  ctctttccgt  ctcaggctgc  cgctgcgaag  ggagccgccg  ccatgtctgc
      gcattctgcaa
      61  tggatggtcg  tgcggaactg  ctccagtttc  ctgatcaaga  ggaataagca
      gacctacagc
      121 actgagccca  ataacttgaa  ggcccgcaat  tccttccgct  acaacggact
      gattcacgc
      181 aagactgtgg  gcgtggagcc  ggagccgac  ggcaaagggt  tcgtggtggt
      cattaagcgg
      241 agatccggcc  agcgggaagc  tgccacctcc  tatgtgcgga  ccaccatcaa
      caagaatgct
      301 cgcgccacgc  tcagcagcat  cagacacatg  atccgcaaga  acaagtaccg
      ccccgacctg
      361 cgcattggcag  ccatccgcag  ggccagcgcc  atcctgcgca  gccagaagcc
      tgtgatggtg
      421 aagaggaagc  ggaccgcgcc  caccaagagc  tcctgagccc  cctgccccca
      gagcaataaa
      481 gtcagctggc  tttctcacct  gcctcgactg  ggctccctt  tttgaaacgc
      tctggggagc
      541 tctggccctg  tgtgttgtca  ttcaggccat  gtcataaaaa  ctctgcatgt
      caccttgtec
      601 atctggaggt  gatgtcaatg  gctggccatg  caggaggggt  ggggtagctg
      ccttgteect
      661 ggtgagggca  agggtcactg  tcttcacaga  aaaagtttgc  tgacttgatga
      ttgagacctc
      721 ctgtcccatt  gtgagggtgc  ctgaagaatc  ccagctgggg  cagtggcttc
      cattcagaag
      781 aagaaaggcc  ttttctagcc  cagaagggtg  caggctgagg  gctgggccct
      gggccctggt
      841 gctgtagcac  gggttgggga  cttgggggtg  tcccagacc  tgggggacga
      cagacatcac
      901 gggaggaaga  tgagatgact  tttgcatcca  gggagtgggt  gcagccacat
      ttggagggga
      961 tgggctttac  ttgatgcaac  ctcatctctg  agatgggcaa  cttggtgggt
      ggtggcttat
      1021 aactgtaagg  gagatggcag  cccagggta  cagccagcag  gcattgagca
      gccttagcat
      1081 tgtcccccta  ctcccgctct  ccagggtgtc  ccatccctcc  cctgtctctt
      tgagctggct
      1141 cttgtcactt  aggtctcact  tcagtggccg  ctctggggcc  acctgtcac
      ccaagctttc
      1201 ctgattgccc  agccctcttg  tttcctttgg  cctgtttgct  ccctagtgtt
      tattacagct
      1261 tgtgaggcca  ggagtttgag  accatcctag  gcaacataat  gagacaccgt
      ctctaaaata
      1321 aaattagctg  ggtgtggtgg  tgcaccgcct  gtggtcccag  ctctcagag
      gttgagtaga
      1381 ggctgaggtg  agcggagcac  ttgagccaag  agtatgaggc  tgcagtgagc
      ccatgagccc
      1441 caccactaca  ctccagcctg  gaagacacca  tgacacacag  tgaggcctgg
      atggggaaag
      1501 agtcctgctg  ttgatctcca  catgtttcct  gggcacctaa  ctctgtcagc
      cactgccagg
      1561 gaccaaggat  ccagcatcca  tggcaccctc  ggttcttgcc  atcctggggg
      acccgattca
      1621 aagaaggact  ctgctccctg  tctgagacca  ccccgggtc  tgactgagag
      taaggggact
      1681 gtcagggcct  cgacttgcca  ttggttgggg  tcgtacgggg  ctgggagccc
      tgcgttttga
      1741 ggcagaccac  tgcccttccg  acctcagtc  tgtctgctcc  agtcttgccc
      agctcgaagg

```

1801 agagcagatc tgaccaattg ccagcccctg tctgctgtga attaccatct
 cctttgtcct
 1861 tcccttagtt gggctctatta gctcagattg agaggtgttg ccttaaaact
 gagttgggtg
 1921 acttggtacc tgetcaggac ccccgcaact gtcccaatcc cactcaggcc
 cacctccagc
 1981 tggcctcact ccgctggtga cttcgtacct gctcaggagc cccactgtc
 ccagtccac
 2041 tcaggcccat ctctggctgg cctcactgcg ctgggactcc gccttcataa
 ggagagctca
 2101 ctgctcacgt tagtagatgg ccccttctcg tgaggcctct cccctggcac
 ctgcttcagt
 2161 tgtcctccac agcactgatt tgcagccac aagctggcag gtttatctgt
 ctcatgtttg
 2221 tcttgtgctg gtgggcaagg ggtttgtcta gcacaccagc atataatgag
 atgcttgatg
 2281 aatggtgcat attgaatgta taaagccac cggctctgag agtttgctca
 ctggagactt
 2341 tctggagatg gagtctcgct ctgttgccca ggctggcgag tgcaatggcg
 cgatcttggc
 2401 tcaactgcagc ctccacctcc tgggttcaag cgattctcct gcctcagcct
 cccgagtagc
 2461 tgggattaca ggtgggtgtc accacacca gctcagtatt gtatttttag
 cagagatggg
 2521 gtttcacat tttgccagg ctggtttgga actcctgact tcaaattacc
 cacctgcctc
 2581 agcctccaa agtgetggca ttacaggcgc tcgaggcttt ctgatgtggc
 tgctgtgct
 2641 cagaaggcct tgtccttaac cacctccttg cctgccctgg aggcctgtgc
 ctctaggccc
 2701 caccctctgt ggagtcctgc tggctttctc catccctatc tgaatcctcc
 ctgctgtgtg
 2761 gcctcccctg gtctcatccg taacacagcc cagcttagtg ggcctctgtt
 cctgcgggtg
 2821 gccagcctgt ctgtgtggct gggctgggga ggccacgtct ggtatctgaa
 tgctatcggg
 2881 gggttgggtg ggaggaacca ggagagggct ggagggaggg agatggtctc
 agccccacag
 2941 agtttgagct cctcagtgtg ctgagcaaac gtggagacac catttcctc
 ctctagacct
 3001 catcttgag agagagatgt tggatggggc catctattcc agctttattc
 acacaaatca
 3061 tgtctgttgg cctggaaatt ggaaaaccag ttaaaccaaa aacatgatat
 taagaaaaca
 3121 ggcaggetca ccatagtaaa aatgetgaaa gccaaagaca aaattgggag
 aacaaaagaa
 3181 aagcgtcttg tcacatacag aaggctcctg ataaagttag tagctgccct
 catcagaaac
 3241 caggcccagc cagtggggac acatccagag tgetgaaaga acctccccca
 ggtcactcta
 3301 tccccagag tgatgcccg cagcattccc agctcagggc taatggttca
 cggaagccag
 3361 gaatcaaact gcctgggttc cagtcccagc tctgccagtt atgccagct
 gtggggactt
 3421 gggcagctcg tttagtagca ccgtgcctca gtttcccata tgtaaaaggc
 cattttgagt
 3481 gcctttcaca gccctgcata aggcagggtg ctcagtgttc actgetgtct
 ctccagctct
 3541 tagtccagta gctgcatggg gactgagcgt agggcgacc ctggaaggct
 gccaaagcca
 3601 aagttgtgca gagcgtggg gactccagac tccccacagc agcagagact

```

cgggactgag
 3661 gcacacctctg ttacacaggac atgctggcat ctactgggtc agggctctgc
tgctcggtgg
 3721 ctgtgcaacc ttgggcaagt tcctcaacct ctctgtgtct tcgtaccctc
atctgtaaca
 3781 tgcgtgtcga tagaccctac tactcagggt tgatgagaag attaaatgtg
caaaacctgc
 3841 ttgactgtgc ccacaaatcc tgattgtagg aataaattaa tgacttttta
taaataatattt
 3901 gatcagatgg actcatgac acagatgtct tcacatgcct atgactaatt
tgtacacaaa
 3961 ctaatgctcg tgtttcccaa gcacctggaa gacatgccag atccatgtgc
agtaatgcct
 4021 ggtggctcca ggtctgcccc gccgtcctgt ggggctgtga gctttcccag
cctcctgccc
 4081 gtgtttgtga atatcattct gtcctcagct gcatttccag cccaggetgt
ttggcgctgc
 4141 ccaggaatgg tatcaattcc cctgtttctc ttgtagccag ttactagaat
aaaatcatct
 4201 actttaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaa
//

```

```

LOCUS          NM_001136134                (isoform 1)
AA/translation="MSAHLQWMVVRNCSSFLIKRNKQTYSTEPNNLKARNsFRYNGLI
HRKTVGVEPAADGKGVVVVIKRRSGQRKPATS YVRTTINKNARATLSSIRHMI RKNKY
RPDLRMVSWGLGIRLGETGQCCGEGPPTTGCNMGWRGMDSCFQPTPHTQHWPRGRLVE
CMG

```

```

cDNA:  1 ctctttccgt ctcaggctgc cgctgcgaag ggagccgccg ccatgtctgc
gcacctgcaa
  61 tggatggtcg tgcggaactg ctccagtttc ctgatcaaga ggaataagca
gacctacagc
 121 actgagccca ataacttgaa ggcccgcaat tccttccgct acaacggact
gattcacgcg
 181 aagactgtgg gcgtggagcc ggcagccgac ggcaaagggt tcgtggtggt
cattaagcgg
 241 agatccggcc agcggaagcc tgccacctcc tatgtgcgga ccaccatcaa
caagaatgct
 301 cgcgccacgc tcagcagcat cagacacatg atccgcaaga acaagtaccg
ccccgacctg
 361 cgcattggtga gctgggggtt ggggatcagg cttggggaga ctggccagtg
ctgtggggaa
 421 gggcctccca ctactggttg caatatgggc tggagaggga tggattcttg
ctttcagcct
 481 actccccaca cccagcattg gcctaggggg cggtttgtgg agtgtatggg
ctgagccttg
 541 ctctgtctcc ccgccccag gcagccatcc gcagggccag cgccatcctg
cgcagccaga
 601 agcctgtgat ggtgaagagg aagcggaccc gccccaccaa gagtcctga
gccccctgcc
 661 ccagagcaa taaagtcagc tggttttctc acctgcctcg actgggcctc
cctttttgaa
 721 acgctctggg gagctctggc cctgtgtgtt gtcattcagg ccatgtcatc
aaaactctgc
 781 atgtcacctt gtccatctgg aggtgatgtc aatggctggc catgcaggag
gggtggggta
 841 gctgccttgt ccctggtgag ggcaagggtc actgtcttca cagaaaaagt
ttgtgactt
 901 gtgattgaga cctactgtcc cattgtgagg tggcctgaag aatcccagct
ggggcagtg
 961 cttccattca gaagaagaaa ggctttttct agcccagaag ggtgcaggct

```

gagggctggg
 1021 ccctggggccc tgggtgctgta gcacggtttg gggacttggg gtgttcccaa
 gacctggggg
 1081 acgacagaca tcacgggagg aagatgagat gacttttgca tccagggagt
 ggggtgcagcc
 1141 acatttgag gggatgggct ttacttgatg caacctcatc tctgagatgg
 gcaacttggg
 1201 ggggtgggtggc ttataactgt aaggggagatg gcagccccag ggtacagcca
 gcaggcattg
 1261 agcagcetta gcattgtccc cctactcccg tctccaggt gtcccatcc
 ctcccctgtc
 1321 tctttgagct ggctcttgtc acttaggtct catctcagt ggcgtcctg
 ggccaccctg
 1381 tcaccaagc tttcctgatt gccagccct ctgttttct ttggcctgtt
 tgctccctag
 1441 tgtttattac agcttgtgag gccaggagt tgagaccatc ctaggcaaca
 taatgagaca
 1501 ccgtctctaa aataaaatta gctgggtgtg gtgggtgcacc gcctgtggtc
 ccagctcttc
 1561 agaggttgag tagaggctga ggtgagcga gcacttgagc caagagtatg
 aggctgcagt
 1621 gagcccatga gccccaccac tacactccag cctggaagac accatgacac
 acagtgagge
 1681 ctggatgggg aaagagtcct gctgttgatc ctacatgtt tctgggcac
 ctaactctgt
 1741 cagccactgc cagggaacca ggatccagca tccatggcac ccctggttcc
 tgccatcctg
 1801 gggtagccga ttcaaagaag gactctgtc cctgtctgag accacccccg
 gctctgactg
 1861 agagtaaggg gactgtcagg gcctcgactt gccattgggt ggggtcgtac
 ggggctggga
 1921 gccctgcgtt ttgaggcaga ccaactgccct tccgacctca gtctgtctg
 ctccagtcct
 1981 gccagctcg aaggagagca gatctgacca ctgtccagcc cctgtctgct
 gtgaattacc
 2041 atttcctttg tcttccctt agttgggtct attagctcag attgagaggt
 gttgccttaa
 2101 aactgagttg ggtgacttgg tacctgtcga ggaccccccg cactgtccca
 atcccactca
 2161 ggcccacctc cagctggcct cactccgctg gtgacttcgt acctgtcag
 gagccccac
 2221 tgtccagtc ccactcagge ccatctctgg ctggcctcac tgcgtggga
 ctccgccttc
 2281 ataaggagag ctcaactgtc acgttagtag atggccctt ctctgaggc
 ctctccctg
 2341 gcacctgctt cagttgtcct ccacagcact gatttgcagc ccacaagctg
 gcaggtttat
 2401 ctgtctcatg tttgtcttgt gctgggtggc aaggggtttg tctagcacac
 cagcatataa
 2461 tgagatgctt gatgaatggg gcatattgaa tgtataaagc ccaccggtcc
 tgagagtttg
 2521 ctcaactggag actttctgga gatggagtct cgctctgttg ccaggtctgg
 cgagtgcaat
 2581 ggcgcgatct tggtcactg cagcctccac ctctgggtt caagcgatc
 tctgcctca
 2641 gcctcccag tagctgggat tacaggtggg tgtcaccaca ccagctcag
 tattgtattt
 2701 ttagcagaga tggggtttca ccattttgcc caggtgggtt tggaactcct
 gacttcaaat
 2761 taccacctg cctcagctc ccaaagtgt ggcattacag gcgctcgagg
 ctttctgatg

2821 tggctgctgc tgtcagaag gccttgtcct taaccacctc cttgcctgcc
 ctggaggctt
 2881 gtgcctctag gccccacccc ctgtggagtc ctgctggctt tctccatccc
 tatctgaatc
 2941 ctccctgctg tgtggcctcc cctggtctca tccgtaacac agcccagctt
 agtgggctc
 3001 tgttcctgcg ggtggccagc ctgtctgtgt ggctgggctg gggaggccac
 gtctggatc
 3061 tgaatgctat cggtgggttg gggaggagga accaggagag ggctggaggg
 agggagatgg
 3121 tctcagcccc acagagtttg gagtcctcag tgtgctgagc aaacgtggag
 acaccatttc
 3181 cctcctctag acctcatctt ggagagagag atgttgatg gggccatcta
 ttccagcttt
 3241 attcacacaa atcatgtctg ttggcctgga aattggaaaa ccagttaaac
 caaaaacatg
 3301 atattaagaa aacaggcagg ctcccatag taaaaatgct gaaagccaaa
 gacaaaattg
 3361 ggagaacaaa agaaaagcgt cttgtcacat acagaaggtc cctgataaag
 ttagtagctg
 3421 ccctcatcag aaaccaggcc caggcagtgg ggacacatcc agagtgtga
 aagaacctcc
 3481 cccaggtcat cctatcccca agagtgatgc ccggcagcat tcccagctca
 gggctaattg
 3541 ttcacggaag ccaggaatca aactgcctgg gtccagtc cagctctgcc
 agttatgcc
 3601 agctgtgggg acttgggcag ctcgtttagt agcaccgtgc ctgagtttc
 catatgtaaa
 3661 aggccatttt gagtgccttt cacagccctg cataaggcag gtgtctcagt
 gttcactgct
 3721 gtctctccag ctcttagtcc agtagctgca tggtagagtga gcgtagggcg
 caccctggaa
 3781 ggctgccaag cccaaagttg tgcagagcgc tggggactcc agactcccca
 cagcagcaga
 3841 gactcgggac tgaggcatcc tctgttcaca ggacatgctg gcatctactg
 ggtcagggt
 3901 ctgctgctcg gtggctgtgc aaccttgggc aagttcctca acctctctgt
 gtcttcgtac
 3961 cctcatctgt aacatgcgtg tcgatagacc ctactactca gggttgatga
 gaagattaaa
 4021 tgtgcaaaac ctgcttgact gtgcccacaa atcctgattg taggaataaa
 ttaatgactt
 4081 tttataaata ttttgatcag atggactcat gatcacagat gtcttcacat
 gcctatgact
 4141 aatttgtaca caaactaatg ctcggttttc ccaagcacct ggaagacatg
 ccagatccat
 4201 gtgcagtaat gcctgggtggc tccaggtctg ccccgccgtc ctgtggggct
 gtgagctttc
 4261 ccagcctcct gcccggtgtt gtgaatatca ttctgtctc agctgcattt
 ccagcccagg
 4321 ctgtttggcg ctgcccagga atggtatcaa ttccctgtt tctctttag
 ccagttacta
 4381 gaataaaatc atctacttta aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
 aaaaaaaaaa
 //

LOCUS NM_001136135 (isoform 3)
 AA/translation="MSAHLQWMVVRNCSSFLIKRNKQTYSTEPNNLKARNSEFRYNGLI
 HRKTVGVEPAADGKGVVVIKRRSGQRKPATSYVRTTINKNARATLSSIRHMIRKNKY
 RPDLRMDMLASTGSGLCSSVAVQPWASSSTSLCLRTLICNMRVDRPYSGLMRRLNVQ
 NLLDCAHKS


```

cDNA: 1 ctctttccgt ctcaggtcgc cgctgcgaag ggagccgccg ccatgtctgc
gcatctgcaa
    61 tggatggtcg tgcggaactg ctccagtttc ctgatcaaga ggaataagca
gacctacagc
    121 actgagccca ataacttgaa ggcccgcaat tccttccgct acaacggact
gattcacgcg
    181 aagactgtgg gcgtggagcc ggcagccgac ggcaaagggtg tcgtggtggt
cattaagcgg
    241 agatccggcc agcgggaagcc tgccacctcc tatgtgcgga ccaccatcaa
caagaatgct
    301 cgcgccacgc tcagcagcat cagacacatg atccgcaaga acaagtaccg
ccccgacctg
    361 cgcattggaca tgcctggcatc tactgggtca gggtctctgct gctcgggtggc
tgtgcaacct
    421 tgggcaagtt cctcaacctc tctgtgtctt cgtacctca tctgtaacat
gcgtgtcgat
    481 agaccctact actcagggtt gatgagaaga tttaatgtgc aaaacctgct
tgactgtgcc
    541 cacaaatcct gattgtagga ataaattaat gactttttat aaatattttg
atcagatgga
    601 ctcatgatca cagatgtctt cacatgccta tgactaattt gtacacaaac
taatgctcgt
    661 gtttcccaag cacctggaag acatgccaga tccatgtgca gtaatgcctg
gtggctccag
    721 gtctgccccg ccgtcctgtg gggctgtgag ctttccagc ctctgccccg
tgtttgtgaa
    781 tatcattctg tcctcagctg catttccagc ccaggctgtt tggcgtgcc
caggaatggt
    841 atcaattccc ctgtttctct tgtagccagt tactagaata aaatcatcta
ctttaaaaaa
    901 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa

```

//

```

LOCUS      NM_001136136                      (isoform 4)
AA/translation="MSAHLQWMVVRNCSSFLIKRNKQTYSTEPNNLKARNSEFRYNGLI
HRKTVGVEPAADGKGVVVVIKRRSGEFCLVWARERPLSRVWEL

```

```

cDNA: 1 ctctttccgt ctcaggtcgc cgctgcgaag ggagccgccg ccatgtctgc
gcatctgcaa
    61 tggatggtcg tgcggaactg ctccagtttc ctgatcaaga ggaataagca
gacctacagc
    121 actgagccca ataacttgaa ggcccgcaat tccttccgct acaacggact
gattcacgcg
    181 aagactgtgg gcgtggagcc ggcagccgac ggcaaagggtg tcgtggtggt
cattaagcgg
    241 agatccgggt agttttgtct ggtttgggac agagagcggc ccctttcccg
ggtctgggag
    301 ctgtgatttt ttactgtcag gcaggaagag cggttaactgc catcgcggcg
ggcatccctg
    361 gcgccagggt gttggtctgg gtaccggctt ccctctcggc cgacttgtca
gctctgtgag
    421 ccgcgcgcgt ctgagcccggt gtctcacct gtaaagtgga gaaatgaaaa
aggacctgaa
    481 cttcctcggt ggttggtgag agttaaggca cggggttgat gttttcagat
gaaattctca
    541 aagcaagtca gggtaggggat ggatggtttc atcccacagg tgggaagatt gagg
//

```

```

LOCUS      NM_001136137                      (isoform 5)
AA/translation="MSAHLQWMVVRNCSSFLIKRNKQTYSTEPNNLKARNSEFRYNGLI

```

HRKTVGVEPAADGKGVVVVIKRRSE

```

cDNA:      1 ctctttccgt ctcaggtcgc cgctgcgaag ggagccgccg ccatgtctgc
gcatctgcaa
      61 tggatggtcg tgcggaactg ctccagtttc ctgatcaaga ggaataagca
gacctacagc
      121 actgagccca ataacttgaa ggcccgcaat tccttccgct acaacggact
gattcacccg
      181 aagactgtgg gcgtggagcc ggcagccgac ggcaaagggtg tcgtgggtgg
cattaagcgg
      241 agatccgagt gagtttttct caggtccttg attggaactg ctcagagacc
aagggtcctt
      301 ttactcagtg gcagcaacaa acgcagtctg ttggctagtg atcctcctgt
ctcagggaca
      361 cgtagtccag ggagcagcca attgcttggc acttggggac cccgttctgg
ggagtctga
      421 aagctttcac ctcttggatt gccgaatata tgggtggccc ttctagact
aagggactgg
      481 cctgagttag gctgggcctc tcagccaagc tgatgttgaa ccactgctgt
gggatgggc
      541 ctggggttcc tgggaagctg ttcataacca ttgccaggag cgtgggtct
ggctggacct
      601 ggatcagatc ctaactgaag cggcagcttt ctggcatgag aaaggagtgt
tttcatggtg
      661 gacagaattg ggctatgagt gt
//

```

```

28.  RPS5: RPS5 ribosomal protein S5 [ Homo sapiens ]
LOCUS      NM_001009
AA/translation="MTEWETAAPAVAETPDIKLFGKWSTDDVQINDISLQDYIAVKEK
YAKYLPHSAGRYAAKFRKAQCPIVERLTNSMMMHGRNNGKKLMTVRIVKHAFEIIHL
LTGENPLQVLVNAI INSGPREDSTRIGRAGTVRRQAVDVSPLRRVNQAIWLLCTGARE
AAFRNIKTIAECLADELINAAGSSNSYAIKKKDELERVAKSNR

```

```

cDNA:      1 ctcttctgt ctgtaccagg gcggcgctg gtctacgccg agtgacagag
acgtccagge
      61 tgtgttctca ggatgaccga gtgggagaca gcagcaccag cgggtggcaga
gacccagac
      121 atcaagctct ttgggaagtg gagcaccgat gatgtgcaga tcaatgacat
ttccctgcag
      181 gattacattg cagtgaagga gaagtatgcc aagtacctgc ctcacagtgc
agggcggtat
      241 gccgcaaac gcttcogcaa agctcagtgt cccattgtgg agcgctcac
taactccatg
      301 atgatgcacg gccgcaacaa cggcaagaag ctcatgactg tgcgcacgtg
caagcatgcc
      361 ttccagatca tacacctgct cacaggcgag aacctctgc aggtcctgg
gaacgccatc
      421 atcaacagtg gtccccggga ggactccaca cgcattgggc gcgcggggac
tgtgagacga
      481 caggctgtgg atgtgtcccc cctgcgccgt gtgaaccagg ccatctggct
gctgtgcaca
      541 ggcgtcgtg aggtgcctt ccggaacatt aagaccattg ctgagtgcct
ggcagatgag
      601 ctcatcaatg ctgccaaagg ctctcgaaac tcctatgcca ttaagaagaa
ggacgagctg
      661 gagcgtgtgg ccaagtccaa ccgctgattt tcccagctgc tgcccaataa
acctgtctgc
      721 cctttggggc agtcccagcc aaaaaaaaaa aaaaa
//

```

29. RPS6: RPS6 ribosomal protein S6 [Homo sapiens]
 LOCUS NM_001010
 AA/translation="MKLNISFPATGCQKLEVDDERKLRTFYEKRMATEVAADALGEE
 WKGYVVRISGGNDKQGFPKQGVLTGHRVRLLLSKGHSCYRPRRTGERKRKSVRGCI
 DANLSVLNLVIVKKGEKDIPGLTDTTVPRRLGPKRASRIRKLFNLSKEDDVRQYVVRK
 PLNKEGKKPRTKAPKIQRLVTPRVLQHKRRRIALKKQRTKKNKKEAAEYAKLLAKRMK
 EAKEKRQEQIAKRRRLSSLRASTSKSESSQK

cDNA: 1 cctcttttcc gtggcgccctc ggaggcggtc agctgcttca agatgaagct
 gaacatctcc
 61 ttcccagcca ctggctgcc aaaactcatt gaagtggacg atgaacgcaa
 acttcgtact
 121 ttctatgaga agcgtatggc cacagaagtt gctgctgacg ctctgggtga
 agaatggaag
 181 ggttatgtgg tccgaatcag tgggtgggaac gacaaacaag gtttcccat
 gaagcagggg
 241 gtcttgacct atggccgtgt ccgcctgcta ctgagtaagg ggcattcctg
 ttacagacca
 301 aggagaactg gagaaagaaa gagaaaatca gttcgtgggt gcattgtgga
 tgcaaactctg
 361 agcgtttctca acttggttat tgtaaaaaa ggagagaagg atattcctgg
 actgactgat
 421 actacagtgc ctgcgcgcct gggcccaaaa agagctagca gaatccgcaa
 acttttcaat
 481 ctctctaaag aagatgatgt ccgccagtat gttgtaagaa agcccttaa
 taaagaagg
 541 aagaaaccta ggaccaaagc acccaagatt cagcgtcttg ttactccacg
 tgtcctgcag
 601 cacaaacggc ggcgtattgc tctgaagaag cagcgtacca agaaaaataa
 agaagaggct
 661 gcagaatatg ctaaactttt ggccaagaga atgaaggagg ctaaggagaa
 gcgccaggaa
 721 caaattgcga agagacgcag actttcctct ctgcgagctt ctacttctaa
 gtctgaatcc
 781 agtcagaaat aagatttttt gagtaacaaa taaataagat cagactctg

//

30. SLTM: SLTM SAFB-like, transcription modulator [Homo sapiens]
 LOCUS NM_001013843 (isoform b)
 AA/translation="MAAATGAVAASAASGQAEGKKITDLRVIDLKSELKRRNLDITGV
 KTVLISRLKQAIIEEGDPDNIELTVSTDTPNKKPTKGGKKEADELSGDASVEDDA
 FIKDCELENQEAHEQDGNDELKDEEFGENEEENVHSELLSAEENKRAHELIAEGI
 EDIEKEDIESQEIEAQEGEDDTFLTAQDGEENEKEGSLAEADHTAHEEMEHTTVK
 EAEDDNISVTIQAEDAITLDFDGDLLLETGKNVKITDSEASKPKDGQDAIAQSPEKES
 KDYEMNANHKGKEDCVKGDPEKEARESSKKAESGDKEKDTLKKGPSSTGASGQAK
 SSSKESKDSKTSKDDKGSTSTSGSSGSSSTKNIWVSGLSSNTKAADLKNLFGKYGKV
 LSAKVVTNARSPGAKCYGIVTMSSSTEVSRCIAHLHRTHELHGQLISVEKVKGDP
 SKKE MKKENDEKSSSRSSGDKNTSDRSSKTQASVKKEKRSEKSEKESKDTKKIEGKDE
 KNDNGASGQTSESIKKSEEKKRISKSPPGHMVILDQTKGDHCRPSRRGRYEKIHGRSK
 EKERASLDKKRDKYRKEILPFEKMKEQRLREHLVRFERLRRAMELRRRREIAERER
 RERERIRIIREREERERLQREERERLEIERQKLERERMERERLERERIRIEQERRKEAE
 RIAREREELRRQQQLRYEQEKRNSLKRPRDVRHRRDDPYWSENKKLSLDTDARFGHG
 SDYSRQQRNFNDFHRRERGRFPSSAVQSSSFERRDRFVGQSEGKKARPTARREDPSF
 ERYPKNFSDSRNEPPPPRNELRESDRREVRGERDERRTVI IHDRPDITHPRHPREAG
 PNPSRPTSWKSEGSMTDKRETRVERPERSGREVSGHVSVRGAPPNGRSSASGYGSREG
 DRGVITDRGGGSHYPEERHVVERHGRDTSGRKEWHGPPSQGPSYHDTRRMGDGRAG
 AGMITQHSSNASPINRIVQISGNSMPPRGSGSGFKPKGPPRRF

cDNA: 1 gcggccgccc aggcctgggt ggaagttggc gctgctgccg ccgcctgca
 gccactcgc

```

        61  tgccctcgga  gcgcgtgct  cttctaagat  ggctgccgct  accggtgcgg
tggcagcctc
       121  ggccgcctcg  ggtcaggcgg  aaggtaaaaa  gatcaccgat  ctgcgggtca
tcgatctgaa
       181  gtccgagctg  aagcggcgga  acttagacat  caccggagtc  aagaccgtgc
tcatctcccg
       241  actcaagcag  gctattgaag  aggaaggagg  cgatccagat  aatattgaat
taactgtttc
       301  aactgatact  ccaaacaaga  aaccaactaa  aggcaaaggt  aaaaaacatg
aagcagatga
       361  gttgagtgga  gatgcttctg  tggaagatga  tgcttttata  aaggactgtg
aattggagaa
       421  tcaagaggca  catgagcaag  atggaaatga  tgaactaaag  gactctgaag
aatttggtga
       481  aaatgaagaa  gaaaatgtgc  attccaagga  gttactctct  gcagaagaaa
acaagagagc
       541  tcatgaatta  atagaggcag  aaggaataga  agatatagaa  aaagaggaca
tcgaaagtca
       601  ggaaattgaa  gctcaagaag  gtgaagatga  tacctttcta  acagcccaag
atggtgagga
       661  agaagaaaat  gagaaagaag  ggagcctagc  tgaggctgat  cacacagctc
atgaagagat
       721  ggaagctcat  acgactgtga  aagaagctga  ggatgacaac  atctcgggtc
caatccaggc
       781  tgaagatgcc  atcactctgg  attttgatgg  tgatgacctc  ctagaaacag
gtaaaaatgt
       841  gaaaattaca  gattctgaag  caagtaagcc  aaaagatggg  caggacgcca
ttgcacagag
       901  cccggagaag  gaaagcaagg  attatgagat  gaatgcgaac  cataaagatg
gtaagaagga
       961  agactgcgtg  aagggtgacc  ctgtcgagaa  ggaagccaga  gaaagttcta
agaaagcaga
      1021  atctggagac  aaagaaaagg  atactttgaa  gaaagggccc  tcgtctactg
gggcctctgg
      1081  tcaagcaaag  agctcttcaa  aggaatctaa  agacagcaag  acatcatcta
aagatgacaa
      1141  aggaagtaca  agtagtacta  gtggtagcag  tggaagctca  actaaaaata
tctgggttag
      1201  tggactttca  tctaatacca  aagctgctga  tttgaagaac  ctctttggca
aatatggaaa
      1261  ggttctgagt  gcaaaagtag  ttacaaatgc  tcgaagtcct  ggggcaaaat
gctatggcat
      1321  tgtaactatg  tcttcaagca  cagagggtgc  cagggtgtatt  gcacatcttc
atcgcaactga
      1381  gctgcatgga  cagctgattt  ctgttgaaaa  agtaaaaggt  gatccctcta
agaaagaaat
      1441  gaagaaagaa  aatgatgaaa  agagtagttc  aagaagttct  ggagataaaa
aaaatacgag
      1501  tgatagaagt  agcaagacac  aagcctctgt  caaaaaagaa  gagaaaagat
cgtctgagaa
      1561  atctgaaaaa  aaagaaagca  aggatactaa  gaaaatagaa  ggtaaagatg
agaagaatga
      1621  taatggagca  agtggccaaa  catcagaatc  gattaaaaaa  agtgaagaaa
agaagcgaat
      1681  aagttccaag  agtccaggac  atatggtaat  actagaccaa  actaaaggag
atcattgtag
      1741  accatcaaga  agaggaagat  atgagaaaat  tcatggaaga  agtaaggaaa
aggagagagc
      1801  tagtctagat  aaaaaaagag  ataaagacta  cagaaggaaa  gagatcttgc
cttttgaaaa
      1861  gatgaaggaa  caaaggttga  gagaacatth  agttcgtttt  gaaaggctgc

```

gacgagcaat
 1921 ggaacttcga agacgaagag agattgcaga gagagagcgt cgagagcgag
 aacgcatttag
 1981 aataattcgt gaacgggaag aacgggaacg cttacagaga gagagagagc
 gcctagaaat
 2041 tgaaaggcaa aaactagaga gagagagaat ggaacgcgaa cgcttgaaaa
 gggaacgcat
 2101 tcgtattgaa caggaacgtc gtaaggaagc tgaacggatt gctcgagaaa
 gagaggaact
 2161 cagaaggcaa caacagcagc ttcgttatga acaagaaaaa aggaattcct
 tgaaacgccc
 2221 acgtgatgta gatcataggg gagatgatcc ttactggagc gagaataaaa
 agttgtctct
 2281 agatacagat gcacgatttg gccatggatc cgactactct cgccaacaga
 acagatttaa
 2341 tgactttgat caccgagaga ggggcaggtt tcctgagagt tcagcagtac
 agtcttcac
 2401 ttttgaaagg cgggatcgct ttgttgggtca aagtgagggg aaaaaagcac
 gacctactgc
 2461 acgaaggga gatccaagct tcgaaagata tccccaaaaa ttcagtgcact
 ccagaagaaa
 2521 tgagcctcca ccaccaagaa atgaacttag agaatcagac aggcgagaag
 tacgagggga
 2581 gcgagacgaa aggagaacgg tgattattca tgacaggcct gatatcactc
 atcctagaca
 2641 tcctcgagag gcaggggcca atccttcag acccaccagc tggaaaagtg
 aaggaagcat
 2701 gtccactgac aaacgggaaa caagagttga aaggccagaa cgatctggga
 gagaagtatc
 2761 agggcacagt gtgagaggcg ctccccctgg gaatcgtagc agcgcttcgg
 ggtacgggag
 2821 cagagaggga gacagaggag tcatcacaga ccgaggaggt ggatcacagc
 actatcctga
 2881 ggagcgacat gtggttgaac gccatggacg ggacacaagc ggaccaagga
 aagagtggca
 2941 tgggtccacc tctcaagggc ctagctatca tgatacgagg cgaatgggtg
 acggccgggc
 3001 aggagcaggc atgataaccc aacattcaag taacgcatcc ccaattaata
 gaattgtaca
 3061 aatcagtggc aattccatgc caagaggaag tggtccgga ttttaagccat
 ttaagggtgg
 3121 acctccgca cgattctgaa aatgagctct ctgccaaggt ttttaagataa
 tttattgaaa
 3181 tctcctgtaa actttacttg actacttatg aagaggacct ctgacttgct
 tgagagttct
 3241 gtcagacttt tctttttaaa aatttaacat gattgctttt ctcaattttg
 gagaagatgt
 3301 ttaaatagtt ctgttgtaac ttttaatagt tttgtgtatc attcaacttt
 ttttcttgca
 3361 gcaccgaggc acatttgaaa agatggaatt gaagtcgttt tgtttaacgc
 tgtgtgaata
 3421 taaagagtag tttgcagctg tgtggtagtg gtttaatttg cagccttagc
 tctgtggtgt
 3481 ctggctctag agttaacttct ttttaccag cattttcagc ctccattttg
 aaggctgtct
 3541 acacttaaga agtcttagct gtctaatttt tagagaataa gattgttcat
 tgcattttctg
 3601 agtattatgt aacctatttt tgcagaaggt actgttacat taagtgcac
 tgtgtatcct
 3661 ggtttaaaaa aatgtaatct tttttgaaat aaaccttcat attctgtata
 gttgctaaag

3721 tgttgagaac ctttttaatt gtaaaatgag aaccgatttt cagtttagtg
 tagcagcaca
 3781 cttgttcagg tttgcatggt atgaaaccaa atagattcat gaaaccttgg
 ccatgagggt
 3841 tgtttcacia ggttcttaga ccgagttgtg caggtaagt cacttttagg
 taatctgcac
 3901 tgtttgtttg atggataaat tccatctctg ggaattgtgt gggattaat
 gtttccatgt
 3961 tcccaactat gttgagaagt ggaaaaaac ccaggttcta gatgggtgaa
 tcagttgggt
 4021 tttgtaaata cttgtatgtg gggaagacat tgttgtcttt ttgtgaaat
 aaaaatccac
 4081 acctggaagt gtaaaaaaaaa aaaaaaaaaa

//

LOCUS NM_024755 (isoform a)
 AA/translation="MAAATGAVAASAASGQAEGKKITDLRVIDLKSELKRRNLDITGV
 KTVLISRLKQAIEEEGGDPDNIELTVSTDTPNKKPTKKGKKHEADELSGDASVEDDA
 FIKDCELENQEAHEQDGNDELKDSEEFGENEEENVHSELLSAEENKRAHELIEAEGI
 EDIEKEDIESQEIEAQEGEDDTFLTAQDGEENEKDIAGSGDGTQEVSKPLPSEGL
 AEADHTAHEEMEAHTTVKEAEDDNISVTIQAEDAITLDFDGDLLLETGKNVKITDSEA
 SKPKDQDAIAQSPEKESKDYEMNANHKGKEDCVKGPVEKEARESSKKAESGDKE
 KDTLKKGPSSTGASGQAKSSSKESKDSKTSSKDDKGSTSSSTSGSSGSSTKNIWVSL
 SNTKAADLKNLFGKYGKVLAKVVTNARSPGAKCYGIVTMSSSTEVSRCIAHLHRT
 ELHGQLISVEKVGDPSSKKEMKKENDEKSSSRSSGDKKNTSDRSSKTQASVKKEEKS
 SEKESKSDTKKIEGKDEKNDNGASGQTSESIKKSEEKKRISSKSPGHMVILDQTKG
 DHCPRSRGRYEKIHGRSKEKERASLDKKRDKDYRKEILPFKMKEQRLREHLVRFER
 LRRAMELRRRREIAERERRERERIRIREREERERLQREERERLEIERQKLERERMERE
 RLERERIRIEQERRKEAERIAEREREELRRQQQLRYEQEKRNSLKRPRVDHRRDDPY
 WSENKKLSLDTDARFHHGSDYSRQQNRNFDFHREGRFPESAVQSSSFERRDRFVG
 QSEGKKARPTARREDPSFERYPKNFSDSRRNEPPPPRNLRESDRREVRGERDERTV
 I IHDRPDITHPRHPREAGPNPSRPTSWKSEGSMSDCKRETRVERPERSGREVS
 GHSVRGAPPGNRSSASGYGSREGDRGVIDRGGGSQHYPEERHVVERHGRDTS
 GPRKEWHGPPSQGPSYHDTRRMGDGRAGAMITQHSSNASPINRIVQISGNSMPRGSGSGFKPFKGGP
 PRRF

cDNA: 1 gggcgccgaggcctgggt ggaagttggc gctgctgccg ccgcctgca
 gccactcgc
 61 tgccctcgga gcgcgctgct cttctaagat ggctgccgct accggtgagg
 tggcagcctc
 121 ggccgcctcg ggtcaggcgg aaggtaaaaa gatcaccgat ctgcgggtca
 tcgatctgaa
 181 gtccgagctg aagcggcgga acttagacat caccggagtc aagaccgtgc
 tcatctcccg
 241 actcaagcag gctattgaag aggaaggagg cgatccagat aatattgaat
 taactgtttc
 301 aactgatact ccaaacaaga aaccaactaa aggcaaagggt aaaaaacatg
 aagcagatga
 361 gttgagtgga gatgcttctg tggaagatga tgcttttata aaggactgtg
 aattggagaa
 421 tcaagaggca catgagcaag atggaaatga tgaactaaag gactctgaag
 aatttggtga
 481 aaatgaagaa gaaaatgtgc attccaagga gttactctct gcagaagaaa
 acaagagagc
 541 tcatgaatta atagaggcag aaggaataga agatatagaa aaagaggaca
 tcgaaagtca
 601 ggaaattgaa gctcaagaag gtgaagatga tacctttcta acagcccaag
 atggtgagga
 661 agaagaaaat gagaaagata tagcaggttc tggatgatgg acacaagaag
 tatctaaacc
 721 tcttccttca gaaggagacc tagctgaggc tgatcacaca gctcatgaag

agatggaagc
 781 tcatacgact gtgaaagaag ctgaggatga caacatctcg gtcacaatcc
 aggctgaaga
 841 tgccatcact ctggattttg atggatgatga cctcctagaa acaggtaaaa
 atgtgaaaat
 901 tacagattct gaagcaagta agccaaaaga tgggcaggac gccattgcac
 agagcccgga
 961 gaaggaaagc aaggattatg agatgaatgc gaaccataaa gatggtaaga
 aggaagactg
 1021 cgtgaagggg gacctgtcg agaaggaagc cagagaaagt tctaagaaag
 cagaatctgg
 1081 agacaaagaa aaggatactt tgaagaaagg gccctcgtct actggggcct
 ctgggtcaagc
 1141 aaagagctct tcaaaggaat ctaaagacag caagacatca tctaaagatg
 acaaaggaag
 1201 tacaagtagt actagtggta gcagtggaag ctcaactaaa aatatctggg
 ttagtggact
 1261 ttcattctaat accaaagctg ctgatttgaa gaacctcttt ggcaaataatg
 gaaaggttct
 1321 gagtgcaaaa gtagttacaa atgctcgaag tcctggggca aaatgctatg
 gcattgtaac
 1381 tatgtcttca agcacagagg tgtccagggtg tattgcacat cttcatcgca
 ctgagctgca
 1441 tggacagctg atttctgttg aaaaagtaaa aggtgatccc tctaagaaag
 aatgaagaa
 1501 agaaaatgat gaaaagagta gttcaagaag ttctggagat aaaaaaata
 cgagtgatag
 1561 aagtagcaag acacaagcct ctgtcaaaaa agaagagaaa agatcgctcg
 agaaatctga
 1621 aaaaaaagaa agcaaggata ctaagaaaat agaaggtaaa gatgagaaga
 atgataatgg
 1681 agcaagtggc caaacatcag aatcgattaa aaaaagtga gaaaagaagc
 gaataagttc
 1741 caagagtcca ggacatatgg taataactaga ccaaactaaa ggagatcatt
 gtagaccatc
 1801 aagaagagga agatatgaga aaattcatgg aagaagtaag gaaaaggaga
 gagctagtct
 1861 agataaaaaa agagataaag actacagaag gaaagagatc ttgccttttg
 aaaagatgaa
 1921 ggaacaaagg ttgagagAAC atttagttcg ttttgaaagg ctgcgacgag
 caatggaact
 1981 tcgaagacga agagagattg cagagagaga gcgtcgagag cgagaacgca
 ttagaataat
 2041 tcgtgaacgg gaagaacggg aacgcttaca gagagagaga gagcgctag
 aaattgaaag
 2101 gcaaaaacta gagagagaga gaatggaacg cgaacgcttg gaaagggaac
 gcattcgtat
 2161 tgaacaggaa cgtcgtaagg aagctgaacg gattgctcga gaaagagagg
 aactcagaag
 2221 gcaacaacag cagcttcggt atgaacaaga aaaaaggaat tccttgaaac
 gccacgtga
 2281 tgtagatcat aggcgagatg atccttactg gagcgagaat aaaaagttgt
 ctctagatac
 2341 agatgcacga tttggccatg gatccgacta ctctcgccaa cagaacagat
 ttaatgactt
 2401 tgatcacgca gagaggggca ggtttcctga gagttcagca gtacagtctt
 catcttttga
 2461 aaggcgggat cgctttgttg gtcaaagtga ggggaaaaaa gcacgaccta
 ctgcacgaag
 2521 ggaagatcca agcttcgaaa gatatcccaa aaatttcagt gactccagaa
 gaaatgagcc

```

2581 tccaccacca agaaatgaac ttagagaatc agacaggcga gaagtacgag
gggagcgaga
2641 cgaaaggaga acggtgatta ttcattgacag gcctgatata actcatccta
gacatcctcg
2701 agaggcaggg cccaatcctt ccagaccac cagctggaaa agtgaaggaa
gcatgtccac
2761 tgacaaacgg gaaacaagag ttgaaaggcc agaacgatct gggagagaag
tatcagggca
2821 cagtgtgaga ggcgtcccc ctgggaatcg tagcagcgct tcggggtacg
ggagcagaga
2881 gggagacaga ggagtcattca cagaccgagg aggtggatca cagcactatc
ctgaggagcg
2941 acatgtggtt gaacgccatg gacgggacac aagcggacca aggaaagagt
ggcatggtcc
3001 accctctcaa ggcctagct atcatgatac gaggcgaatg ggtgacggcc
gggcaggagc
3061 aggcatgata acccaacatt caagtaacgc atccccaatt aatagaattg
tacaatcag
3121 tggcaattcc atgccaaagag gaagtggctc cggatttaag ccatttaagg
gtggacctcc
3181 ggcagcattc tgaaaatgag ctctctgcca aggttttaag ataatttatt
gaaatctcct
3241 gtaaaacttta cttgactact tatgaagagg acctctgact tgcttgagag
ttctgtcaga
3301 cttttctttt taaaaattta acatgattgc ttttctcaat tttggagaag
atgttttaaat
3361 agttctgttg taacttttaa tagttttgtg tatcattcaa cttttttct
tgcagcaccg
3421 aggcacattt gaaaagatgg aattgaagtc gttttgttta acgctgtgtg
aatataaaga
3481 gtagtttgca gctgtgtggt agtggtttaa tttgcagcct tagctctgtg
gtgtctggct
3541 ctagagttac ttctttttac caagcatttt cagcctccat tttgaaggct
gtctacactt
3601 aagaagtctt agctgtctaa tttttagaga ataagattgt tcattgcatt
tctgagtatt
3661 atgtaaccta tttttgcaga aggtactgtt acattaagtg catctgtgta
tcctggttta
3721 aaaaaatgta atcttttttg aaataaacct tcatattctg tatagttgct
aaagtgttga
3781 gaaccttttt aattgtaaaa tgagaaccga ttttcagttt agtgtagcag
cacacttggt
3841 caggtttgca tggatatgaa ccaaatagat tcatgaaacc ttggccatga
ggtttgtttc
3901 acaaggttct tagaccgagt tgtgcaggta agtgcacttt taggtaatct
gcactgtttg
3961 tttgatggat aaattccatc tctgggaatt gtgtgggtat taatgtttcc
atgttccaa
4021 ctatgttgag aagtggaaaa aaaccaggt tctagatggg tgaatcagtt
gggttttgta
4081 aatacttgta tgtggggaag acattgttgt ctttttgta aaataaaaat
ccacacctgg
4141 aagtgtaaaa aaaaaaaaaa aaaa
//

```

31. TMED4: TMED4 transmembrane emp24 protein transport domain
containing 4 [Homo sapiens]
LOCUS NM_182547
AA/translation="MAGVGAGPLRAMGRQALLLLALCATGAQGLYFHIGETEKRCFIE
EIPDETMVIGNYRTQMWDKQKEVFLPSTPGLGMHVEVKDPDGKVVLRSQYGEGRFTF
TSHTPGDHQICLHSNSTRMELFAGGKLRVHLDIQGEHANNYPEIAAKDKLTEQLRA

RQLLDQVEQIQKEQDYQRYREERFRLTSESTNQRLVWWSIAQTVILILTGIWQMRHLK
SFFEAKKLV

cDNA: 1 ggcgcttagg ggctgaggcg cgatggcagg tgctggggct gggcctctgc
gggcgatggg
61 ggggcaggcc ctgctgcttc tcgcgctgtg cgccacaggc gccaggggc
tctacttcca
121 catcggcgag accgagaagc gctgtttcat cgaggaaatc cccgacgaga
ccatgggcat
181 cggcaactat cgtaccacaga tgtgggataa gcagaaggag gtcttcctgc
cctcgacccc
241 tggcctgggc atgcacgtgg aagtgaagga ccccgacggc aagggtgtgc
tgtcccggca
301 gtacggctcg gagggcgct tcacgttcac ctcccacacg cccggtgacc
atcaaactcg
361 tctgcactcc aattctacca ggatggctct ctctgctggg ggcaaaactgc
gtgtgcatct
421 cgacatccag gttggggagc atgccaacaa ctacctgag attgctgcaa
aagataagct
481 gacggagcta cagctccgcg cccgccagtt gcttgatcag gtggaacaga
ttcagaagga
541 gcaggattac caaaggatct gtgaagagcg ctccgactg acgagcgaga
gcaccaacca
601 gagggtccta tgggtgggtcca ttgctcagac tgtcatectc atcctcactg
gcatctggca
661 gatgcgtcac ctcaagagct tctttgaggc caagaagctg gtgtagtgcc
ctctttgtat
721 gacccttcct ttttacctca tttatttggg actttcccca cacagtcctt
tatccgctg
781 gatttttagg gaaaaaatg aaaaagaata agtcacattg gttccatggc
cacaaacat
841 tcagatcagc cacttgctga cctggttct taaggacaca tgacattagt
ccaatctttc
901 aaaatcttgt cttagggctt gtgaggaatc agaactaacc caggactcag
tcctgcttct
961 ttgacctga gtgattttcc tctgttttcc actaaataag caaatgaaaa
ctctctccat
1021 taataaaaaa aaaaaaaa aaaaaa
//

32. TNRCBA: ADRBK1 adrenergic, beta, receptor kinase 1 [Homo
sapiens]

LOCUS NM_001619

AA/translation="MADLEAVLADVSYLMAMEKSKATPAARASKKILLPEPSIRSVMQ
KYLEDRGEVTFEKIFSQKLGyllFRDFCLNHLEEARPLVEFYEEIKKYEKLETEEERV
ARSREIFDSYIMKELLACSHPFSSKATEHVQGHGKKQVPPDLFPYIEEICQNLRGD
VFQKFIESDKFTRFCQWKNVELNIHLTMNDFSVHRIIGRGGFGEVYGCRKADTGKMYA
MKCLDKKRIKMKQGETLALNERIMLSLVSTGDCPFIVCMSYAFHTPDKLSFILDLMNG
GDLHYHLSQHGVFSEADMRFYAAEIIILGLEHMHNRFFVYRDLKPANILLDEHGHVRIS
DLGLACDFSKKKPHASVGTGHYMAPEVLQGVAYDSSADWFSLGCMFLKLLRGHSPFR
QHKTDKKHEIDRMTLTMAVELPDSFSPELRSLEGLLQRDVNRRLGCLGRGAQEVKES
PFFRSLDWQMVFLQKYPPPLIPPRGEVNAADAFDIGSFDEEDTKGIKLLDSDQELYRN
FPLTISERWQQEAETVFDITINAETDRLEARKKAKNKQLGHEEDYALGKDCIMHGYS
KMGNPFLTQWQRRYFYLFPNRLEWRGEGEAPQSLTMEETQISVEETQIKERKCLLLKI
RGGKQF ILQCSDPELVQWKELRDAYREAQQLVQRVPMKNKPRSPVELSKVPLVQ
RGSANGL

cDNA: 1 cgggcgcgcg ggcggcgggc ggcggcggcg cccgactgca gtcccgcgcg
gagcgagcg
61 cgagccgggg ccgggcccga gccggcgcca tggggcgggc ccgcctgtga
gcggcgggca

121 ggggagccgc gggcgccgag cagggccagg cgggaggcgt cggcgcccga
 gggcgagcga
 181 gccgcggccg ggccggggccg agcgccgagc gagcaggagc ggcggcggcg
 gcggcgggcg
 241 cgggaggagg cagcgccgcc gccaaagtgg cggacctgga ggcggtgctg
 gccgacgtga
 301 gctacctgat ggccatggag aagagcaagg ccacgccggc cgcgcgcgcc
 agcaagaaga
 361 tcctgctgcc cgagcccagc atccgcagtg tcatgcagaa gtacctggag
 gaccggggcg
 421 aggtgacctt tgagaagatc ttttcccaga agctggggta cctgctcttc
 cgagacttct
 481 gcctgaacca cctggaggag gccaggccct tgggtggaatt ctatgaggag
 atcaagaagt
 541 acgagaagct ggagacggag gaggagcgtg tggcccgcag ccgggagatc
 ttcgactcat
 601 acatcatgaa ggagctgctg gcctgctcgc atcccttctc gaagagtgcc
 actgagcatg
 661 tccaaggcca cctggggaag aagcaggtgc ctccggatct cttccagcca
 tacatcgaag
 721 agatttgtca aaacctccga ggggacgtgt tccagaaatt cattgagagc
 gataagttca
 781 cacggttttg ccagtggaag aatgtggagc tcaacatcca cctgaccatg
 aatgacttca
 841 gcgtgcatcg catcattggg cgcgggggct ttggcgaggc ctatgggtgc
 cggaaggctg
 901 acacaggcaa gatgtacgcc atgaagtgcc tggacaaaaa gcgcatcaag
 atgaagcagg
 961 gggagaccct ggccctgaac gagcgcatca tgcctctcgt cgtcagcact
 ggggactgcc
 1021 cattcattgt ctgcatgtca tacgcgttcc acacgccaga caagctcagc
 ttcacctctg
 1081 acctcatgaa cgggtggggac ctgcactacc acctctcca gcacggggtc
 ttctcagagg
 1141 ctgacatgcg cttctatgcg gccgagatca tcctgggcct ggagcacatg
 cacaaccgct
 1201 tcgtggtcta ccgggacctg aagccagcca acatccttct ggacgagcat
 ggccacgtgc
 1261 ggatctcgga cctgggcctg gcctgtgact tctccaagaa gaagccccat
 gccagcgtgg
 1321 gcacccacgg gtacatggct ccggaggtcc tgcagaaggg cgtggcctac
 gacagcagtg
 1381 ccgactggtt ctctctgggg tgcattgctt tcaagttgct gcgggggcac
 agcccccttc
 1441 ggcagcacia gaccaaagac aagcatgaga tcgaccgcat gacgctgacg
 atggccgtgg
 1501 agctgcccga ctcccttctc cctgaactac gctccctgct ggaggggttg
 ctgcagaggg
 1561 atgtcaaccg gagattgggc tgccctgggccc gaggggctca ggaggtgaaa
 gagagcccct
 1621 ttttccgctc cctggactgg cagatggtct tcttgcagaa gtaccctccc
 ccgctgatcc
 1681 cccacgagg ggaggtgaac ggggccgacg ccttcgacat tggctccttc
 gatgaggagg
 1741 acacaaaagg aatcaagtta ctggacagtg atcaggagct ctaccgcaac
 ttccccctca
 1801 ccatctcgga gcggtggcag caggaggtgg cagagactgt cttcgacacc
 atcaacgctg
 1861 agacagaccg gctggaggct cgcaagaaag ccaagaacaa gcagctgggc
 catgaggaag
 1921 actacgcctt gggcaaggac tgcattcatg atggctacat gtccaagatg

```

ggcaaccct
  1981 tcttgaccca gtggcagcgg cggacttct acctgttccc caaccgcctc
gagtggcggg
  2041 gcgagggcga ggccccgcag agcctgctga ccatggagga gatccagtcg
gtggaggaga
  2101 cgcagatcaa ggagcgcaag tgcttctcc tcaagatccg cggtgggaaa
cagttcattt
  2161 tgcagtgcga tagcgacct gagctggtgc agtggagaa ggagctgcgc
gacgcctacc
  2221 gcgaggccca gcagctggtg cagcgggtgc ccaagatgaa gaacaagccg
cgctcgcccg
  2281 tgggtggagct gagcaagggt ccgctggtcc agcgcggcag tgccaacggc
ctctgaccgg
  2341 cccaccggcc ttttataaac ctctaattta ttttgtcgaa tttttattat
ttgttttccc
  2401 gccaaagcga aaaggtttta ttttgtaatt attgtgattt cccgtggccc
cagcctggcc
  2461 cagctcccc gggagggggc cgcttgctc ggctcctgct gcaccaaccc
agccgctgcc
  2521 cggcgccctc tgtcctgact tcaggggctg cccgctccca gtgtcttct
gtgggggaag
  2581 agcacagccc tcccgccct tcccgaggg atgatgccac accaagctgt
gccaccctgg
  2641 gctctgtggg ctgcaactctg tgcccatggg cactgctggg tggcccatcc
ccctcacca
  2701 ggggcaggca cagcacaggg atccgacttg aattttccca ctgcaccccc
tcctgctgca
  2761 gaggggcagg ccctgcaactg tcctgctcca cagtgttggc gagaggaggg
gccggttgc
  2821 tccctggccc tcaaggcctc ccacagtgc tcgggctcct gtgcccttat
tcaggaaaag
  2881 cctctgtgct actggtgcc tccaactcca ctccctgac actgcggggc
ttggctgaga
  2941 gagtggcatt ggcagcagg gctgctacc tccctgctgt cccctcttgc
cccaaccccc
  3001 agcacccggg ctgagggacc acagcaaggc acctgcagg tgggccatac
tggcctcgcc
  3061 tggcctgagg tctcctgat gctgggctgg gtgcgacccc atctgcccag
gacggggcgg
  3121 gccaggtggg cgggcagcac agcaaggagg ctggctgggg cctatcagtg
tgcccccat
  3181 cctggcccat cagtgtacc cggcccaggc tggccagccc cacagcccac
gtcctgtcag
  3241 tgccgcggcc tcgcccacc catgcccct cgtgccagtc gcgtgcctg
tgtggtgtcg
  3301 cgccttctcc ccccgggggc tgggttggcg caccctccc tccgctctac
tcattccccg
  3361 gggcgtttct ttgcgattt ttgaatgtga ttttaaagag tgaaaaatga
gactatgcgt
  3421 ttttataaaa aatggtgcct gattaaaaaa aaaaaaaaaa aaaaaaaaaa
aaaaaaaa
//

```

```

33. TUBB: TUBB tubulin, beta class I [ Homo sapiens ]
LOCUS NM_178014
AA/translation="MREIVHIQAGQCGNQIGAKFEVISDEHGIDPTGTYHGSDQL
DRISVYYNEATGGKYVPRAILVDLEPGTMDSVRSFGQIFRPDNFVFGQSGAGNNWA
KGHYTEGAELVDSVLDVVRKEAESCDCLQGFQLTHSLGGGTGSGMGTLISKIREEYP
DRIMNTFSVVPSPKVS DTVVEPYNATLSVHQLVENTDETYCIDNEALYDICFRTLKLT
TPTYGDLNHLVSATMSGVITCLRFPQNLADLRKLAVNMVFPRLHFFMPGFAPLTSR
GSQQYRALTVPELTQQVFDAKNMMAACDPRHGRYLTVAAVFRGRMSMKEVDEQMLNVQ

```

NKNSSYFVEWIPNNVKTAVCDIPPRGLKMAVTFIGNSTAIQELFKRISEQFTAMFRRK
 AFLHWYTGEGMDEMEFTEAESNMNDLVSEYQQYQDATAEEEEEDFGEEAEEEE

cDNA: 1 gcacctcgct gctccagcct ctggggcgca ttccaacctt ccagcctgcg
 acctgcgag
 61 aaaaaaaatt acttattttt ttgccccata cataccttga ggcgagcaaa
 aaaattaaat
 121 tttaaccatg agggaaatcg tgcacatcca ggctggtcag tgtggcaacc
 agatcggtgc
 181 caagttctgg gaggtgatca gtgatgaaca tggcatcgac cccaccggca
 cctaccacgg
 241 ggacagcgac ctgcagctgg accgcatctc tgtgtactac aatgaagcca
 caggtggcaa
 301 atatgttctt cgtgccatcc tgggtgatct agaacctggg accatggact
 ctgttcgctc
 361 aggtcctttt ggccagatct ttagaccaga caactttgta tttggtcagt
 ctggggcgagg
 421 taacaactgg gccaaaggcc actacacaga gggcgccgag ctggttgatt
 ctgtcctgga
 481 tgtggtacgg aaggaggcag agagctgtga ctgcctgcag ggcttccagc
 tgacccactc
 541 actgggcggg ggcacaggct ctggaatggg cactctcctt atcagcaaga
 tccgagaaga
 601 ataccctgat cgcacatga ataccttcag tgtggtgcct tcacccaaag
 tgtctgacac
 661 cgtggtcgag ccctacaatg ccaccctctc cgtccatcag ttggtagaga
 atactgatga
 721 gacctattgc attgacaacg aggccctcta tgatatctgc ttccgcactc
 tgaagctgac
 781 cacaccaacc tacggggatc tgaaccacct tgtctcagcc accatgagtg
 gtgtcaccac
 841 ctgcctccgt ttccctggcc agctcaatgc tgacctccgc aagttggcag
 tcaacatggg
 901 ccccttccca cgtctccatt tctttatgcc tggttttgcc cctctacca
 gccgtggaag
 961 ccagcagtat cgagctctca cagtgccgga actcaccag caggtcttcg
 atgccaagaa
 1021 catgatggct gcctgtgacc cccgccacgg ccgatacctc accgtggctg
 ctgtcttcgg
 1081 tggtcggatg tccatgaagg aggtcgatga gcagatgctt aacgtgcaga
 acaagaacag
 1141 cagctacttt gtggaatgga tccccaacaa tgtcaagaca gccgtctgtg
 acatcccacc
 1201 tcgtggcctc aagatggcag tcaccttcac tggcaatagc acagccatcc
 aggagctctt
 1261 caagcgcac tcggagcagt tcaactgccat gttccgcccg aaggccttcc
 tccactggta
 1321 cacaggcgag ggcattggac agatggagtt caccgaggct gagagcaaca
 tgaacgacct
 1381 cgtctctgag tatcagcagt accaggatgc caccgcagaa gaggaggagg
 atttcggtga
 1441 ggaggccgaa gaggaggcct aaggcagagc ccccatcacc tcaggcttct
 cagttccctt
 1501 agccgtctta ctcaactgcc cttttcctct cctcagaat ttgtgtttgc
 tgctctatc
 1561 ttgttttttg tttttcttct tggggggggg ctagaacagt gcctggcaca
 tagtaggcgc
 1621 tcaataaata cttgtttgtt gaatgtctcc tctctcttct cactctggga
 aacctaggtt
 1681 tctgccattc tgggtgacct tgtatttctt tctggtgccc attccatttg
 tccagttaat

```

1741 acttcctctt aaaaatctcc aagaagctgg gtctccagat ccattttaga
accaaccagg
1801 tgctgaaaac acatgtagat aatggccatc atcctaagcc caaagtagaa
aatggtagaa
1861 ggtagtggtt agaagtcact atataaggaa ggggatggga tttccattc
taaaagtttt
1921 ggagaggga atccaggcta ttaaagtcac taaatttcta agtatgtcca
tttcccatct
1981 cagcttcaag ggaggtgtca gcagtattat ctccactttc aatctccctc
caagctctac
2041 tctggaggag tctgtccac tctgtcaagt ggaatccttc ctttccaac
tctacctccc
2101 tcaactcagct ctttccctt gatcagagaa agggatcaag ggggttggga
ggggggaaag
2161 agaccagcct tggtcctaa gcctccagaa acgtcttctt aatccccacc
ttttcttact
2221 cccaaaaaag aatgaacacc cctgactctg gagtgggtga tactgccaca
tcagtgtttg
2281 agtcagtcct cagaggagag gggaaccctc ctccatcttt ttgcaacat
ctcatttctt
2341 ctttttgctg ttgcttcccc cctcacacac ttggttttgt tctatcctac
atttgagatt
2401 tctattttat gttgaacttg ctgctttttt tcatattgaa aagatgacat
cgcccaaga
2461 gccaaaaata aatgggaatt gaaaaaaaaa aaaaaaaaaa aaaaaaaaaa

```

//

```

34. UBE21: UBE2I ubiquitin-conjugating enzyme E2I [ Homo
sapiens ]
LOCUS NM_003345 (variant 1)
AA/translation="MSGIALSRLAQERKAWRKDHPFGFVAVPTKNPDGTMNLMNWECA
IPGKKGTPWEGGLFKLRMLFKDDYPSSPPKCKFEPPLFHPNVYPSGTVCLSILEEDKD
WRPAITIKQILLGIQELLNEPNIQDPAQAEAYTIYCQNRVEYEKRVRAQAKKFAPS

```

```

cDNA: 1 gccgcgcgca gggctctcgg agctgctctg gctgcgcgcg gagcgggctc
cggagggaag
61 tcccgagaca aagggaagcg ccgcgcgcgc cgcgcgcgcg ggtcctccac
ctgtccgcta
121 cgctcgccgg ggctgcggcc gcccgaggga ctttgaacat gtcggggatc
gccctcagca
181 gactcgccca ggagaggaaa gcatggagga aagaccacc atttggtttc
gtggctgtcc
241 caacaaaaaa tcccgatggc acgatgaacc tcatgaactg ggagtgcgcc
attccaggaa
301 agaaagggac tccgtgggaa ggaggcttgt ttaaactacg gatgcttttc
aaagatgatt
361 atccatcttc gccacaaaa tgtaaattcg aaccaccatt atttcaccg
aatgtgtacc
421 cttcggggac agtgtgcctg tccatcttag aggaggacaa ggactggagg
ccagccatca
481 caatcaaaca gatcctatta ggaatacagg aacttctaaa tgaacaaat
atccaagacc
541 cagctcaagc agaggcctac acgatttact gccaaaacag agtggagtac
gagaaaaggg
601 tccgagcaca agccaagaag ttgcgccct cataagcagc gaccttgagg
catcgtcaaa
661 aggaagggat tggtttgga agaacttgtt tacaacattt ttgcaaactc
aaagttgctc
721 cataaatga ctagtcacct ggggggggtg ggcgggcgcc atcttcatt
gccgcgcgg
781 gtgtgcggtc tcgattcgct gaattgccg tttcataca gggctctctc

```

cttcggtctt
 841 ttgtattttt gattgttatg taaaactcgc ttttatttta atattgatgt
 cagtatttca
 901 actgctgtaa aattataaac ttttataactt gggtaagtcc cccaggggcg
 agttcctcgc
 961 tctgggatgc aggcattgctt ctcaccgtgc agagctgcac ttggcctcag
 ctggctgtat
 1021 ggaaatgcac cctccctcct gccgctcctc tctagaacct tctagaacct
 gggctgtgct
 1081 gcttttgagc ctcagacccc aggtcagcat ctcggttctg cgccacttcc
 tttgtgttta
 1141 tatggcgttt tgtctgtgtt gctgtttaga gtaaataaac tgtttatata
 aaggttttgg
 1201 ttgcattatt atcattgaaa gtgagaggag ggggcctccc agtgcccggc
 cctccccacc
 1261 cacctgcagc cccaccgcgg gccaggacca ggctctccat ctgcttcgga
 tgcacgcagg
 1321 ctgtgaggct ctgtcttgcc ctggatcttt gtaaacaggg ctgtgtacaa
 agtgetgctg
 1381 aggtttctgt gctccccgca tctgcgggct gtagagcgtt gggcagctaa
 gatctgcata
 1441 ggtcgggatt ggcattcgaga ccctggcaac tgcaccggtg ccagctgtct
 tggggggcac
 1501 aaggccaggt ccagaccagg gctgggggct gcctgaggac tcctatccgg
 gcagcctgct
 1561 ggcggggggtt cccctcttca gtggccaggt cacagggatg gagctgcgct
 gtgcataggg
 1621 tgccacctca ggtgtctgtc ctttgtgtcc tcaggaggca gccttgctac
 caccgtggc
 1681 aaacgccagg tgctttttct gggagagccc acagccgtgg ccctccaggg
 cttccccgac
 1741 ccttagcgcc aggtagaggg ccctgggcag cctgtgtctg gaattcttgc
 tcctgaggcc
 1801 acctgagtgt ggtctgtcct ggggaggctg tgcgcctcag cagccgtcct
 gacgtgagc
 1861 cctctgcaaa ggttggggcg gccaggcctc ttggggctgc ctgagccact
 gcaggaagtg
 1921 gcctggctgg gaagttgggt gccggtcacc tcccagcagg aaggcacagt
 ggacagagat
 1981 gggaagccct gggggacaca gcccggtgct cccagccctc caacctctgg
 ctcccaaccc
 2041 agtctcccca tcctagcgag cttggccctc ctcagtttgc tttcaagcct
 tggggctgga
 2101 gctggccctg ctgccctggc acccccgggt ggctggagct gggctcccgt
 ggcccaagtg
 2161 cagggtccca agagggcagg gcggggctcc ccaaaggagc aaagaatgca
 gggagggcgg
 2221 tccagggccc tgggaagggg agctcggcac cctccaggtc cgtgtgggac
 tccagccgt
 2281 gttggctggg aatcgagtt agaggtgact tccaaaggcc ccccgagccg
 gcagtgcctc
 2341 ccaccacccc tccagcgact ctgcggtgcc agtgccttgt tggttttcc
 ggctacgcac
 2401 cctgcagtca ctgagctctc ggtctgacgt ctgatgtttg tggtttgtt
 ataacacggg
 2461 gccttacctg gggaattcag ctggtttgaa tatttgtagc ccgtcccag
 aatgtcttat
 2521 tttgtaatga ctgaactaca tttagtaata gttacacatg tatatggtta
 atacatatgg
 2581 aaattcaata tattttgtag ttaacgtatt ctgaagtaac ggatgtttct
 cgccaatcgt

```

2641 agtgacttca gctaacgaaa tgttcttttg tagtaccacg gtccctcggcc
taacgaagga
2701 cgtgaacctt gtaagaggag agctctgaaa cgcggtcacc tttgtttagt
ggaaggga
2761 gtgtgttccc ggcattgagg gctcgggaat tagtaaagaa ttgtgggcaa
tggattaacc
2821 actgtatcta agaattccacc attaaagcat ttgcacagac aaaaaaaaaa a

```

//

```

LOCUS          NM_194259                      (variant 2)
AA/translation="MSGIALSRLAQERKAWRKDHPFGFVAVPTKNPDGTMNLMNWECA
IPGKKGTPWEGGLFKLRMLFKDDYPSSPPKCKFEPPLFHPNVYPSGTVCLSILEDKD
WRPAITIKQILLGIQELLNEPNIQDPAQAEAYTIYCQNRVEYEKRVRAQAKKFAPS

```

```

cDNA:  1  gccgcgccca  gggtcctcgg  agctgctctg  gctgcgcgcg  gagcgggctc
cgagagggaag
      61  tcccagagaca  aagggaagcg  ccgccgccgc  cgcccgcctc  ggtcctccac
ctgtccgcta
     121  cgctcgccgg  ggcctgcggcc  gcccgaggct  gccctgagga  tctgtgtttg
gtgaaaagga
     181  gccaaattca  cctgcagggc  aggcggtctt  agcagcttca  gaagcctggg
gccctggcga
     241  cactggacct  gccttggett  ctttgatccc  aaccccaccc  ccgattttctg
ctctgctgac
     301  tggggaagtc  atcgtgccac  ccagaacctg  agtgcggggc  tctcagagct
ccttcgtccg
     361  tgggtctgcc  ggggaactggg  ctttgtctcc  ctaacgagtg  ccagggaactt
tgaacatgtc
     421  ggggatcgcc  ctcagcagac  tcgcccagga  gaggaaagca  tggaggaaag
accaccatt
     481  tggtttcgtg  gctgtcccaa  caaaaaatcc  cgatggcacg  atgaacctca
tgaactggga
     541  gtgcgccatt  ccaggaaaga  aagggactcc  gtgggaagga  ggcttgttta
aactacggat
     601  gcttttcaaa  gatgattatc  catcttcgcc  accaaaatgt  aaattcgaac
caccattatt
     661  tcaccggaat  gtgtaccctt  cggggacagt  gtgcctgtcc  atcttagagg
aggacaagga
     721  ctggaggcca  gccatcacia  tcaaacagat  cctattagga  atacaggaac
ttctaaatga
     781  accaaatata  caagaccagc  ctcaagcaga  ggcttacacg  atttactgcc
aaaacagagt
     841  ggagtagcag  aaaagggtcc  gagcacaagc  caagaagttt  gcgccctcat
aagcagcgac
     901  cttgtggcat  cgtcaaaagg  aagggtattg  tttggcaaga  acttggtttac
aacatttttg
     961  caaatctaaa  gttgctccat  acaatgacta  gtcacctggg  ggggttgggc
gggcgccatc
    1021  ttccattgcc  gccgcgggtg  tgcgggtctc  attcgttgaa  ttgcccgttt
ccatacaggg
    1081  tctcttcctt  cggctctttg  tatttttgat  tgttatgtaa  aactcgcttt
tattttaata
    1141  ttgatgtcag  tatttcaact  gctgtaaaat  tataaacttt  tatactggg
taagtcccc
    1201  aggggcgagt  tcctcgctct  gggatgcagg  catgcttctc  accgtgcaga
gctgcacttg
    1261  gcctcagctg  gctgtatgga  aatgcacctc  ccctcctgcc  gtcctctct
agaaccttct
    1321  agaactggg  ctgtgtgtgt  tttgagctc  agacccagc  tcagcatctc
ggttctgcgc
    1381  cacttccttt  gtgtttatat  ggcgttttgt  ctgtgttgct  gtttagagta

```

```

aataaactgt
 1441 ttatataaag gttttggttg cattattatc attgaaagtg agaggaggcg
gcctcccagt
 1501 gcccggccct cccacccac ctgcagcccc acccggggcc aggaccaggc
tctccatctg
 1561 cttcggatgc acgcaggctg tgaggctctg tcttgccctg gatctttgta
aacagggctg
 1621 tgtacaaagt gctgctgagg tttctgtgct ccccgcatct gcgggctgta
gagcgtggg
 1681 cagctaagat ctgcataggt cgggattggc atcgagacct tggcaactgc
accggtgcca
 1741 gctgtcttgg gggccacaag gccaggcca gaccagggct gggggctgcc
tgaggactcc
 1801 tatccgggca gcctgctggc gggggttccc ctcttcagtg gccaggtcac
agggatggag
 1861 ctgcgctgtg catagggcgc cacctcagggt gtctgtccct tgtgtccctc
ggaggcagcc
 1921 ttgctaccac ccgtggcaaa cgccaggcgc tttttctggg agagcccaca
gccgtggccc
 1981 tccagggctt ccccgacct tagcgccagg tagagggccc tgggcagcct
gtgtctggaa
 2041 ttcttcgtcc tgaggccacc tgagtgtggt ctgtcctggg gaggctgtgc
gcctcagcag
 2101 ccgtcctgac gctgagccct ctgcaaaggt tgggcgggcc aggcctcttg
gggctgectg
 2161 agccactgca ggaagtggcc tggctgggaa gttgggtgcc ggtcacctcc
cagcaggaag
 2221 gcacagtgga cagagatggg aagccctggg ggacacagcc cgggtgctccc
agccctccaa
 2281 cctctggctc ccaaccagct ctcccatcc tagcgagctt ggccctctc
agtttcgttt
 2341 caagcettgg ggttgagct ggccctgctg ccctggcacc ccccggtggc
tgagctggg
 2401 tccccgtggc ccaagtgcag ggtcccaaga gggcagggcg gggctcccca
aaggagcaaa
 2461 gaatgcaggg agggcggtcc agggccctgg gaaggggagc tcggcaccct
ccaggtccgt
 2521 gtgggactcc agccgctggt ggctgggaat cgaagttaga ggtgacttcc
aaaggccccc
 2581 cgagccggca gtgcccccca ccacctcc agcgactctg cggtgccagt
gccttgttgg
 2641 cttttccggc tacgcacct gcagtcactg agctctcggt ctgacgtctg
atgtttgtgg
 2701 tttgtttata acacggggcc ttacctgggg aattcagctg gtttgaatat
ttgtagcccg
 2761 ctcccagaat gtcttatttt gtaatgactg aactacattt agtaatagtt
acacatgtat
 2821 atggttaata catatggaaa ttcaatatat tttgtagtta acgtattctg
aagtaacgga
 2881 tgtttctcgc caatcgtagt gacttcagct aacgaaatgt tctttttag
taccacggtc
 2941 ctcggcctaa cgaaggacgt gaaccttgta agaggagagc tctgaaacgc
ggtcaccttt
 3001 gtttagtgga agggaaagtg tgttcccggc atgagggtgcc tcggaattag
taaagaattg
 3061 tgggcaatgg attaaccact gtatctaaga atccaccatt aaagcatttg
cacagacaaa
 3121 aaaaaaaa
//

```

LOCUS

NM_194260

(variant 3)

AA/translation="MSGIALSRLAQERKAWRKDHPFGFVAVPTKNPDGTMNLMNWECA
IPGKKGTPWEGGLFKLRMLFKDDYPSSPPKCKFEPPLFHPNVYPSGTVCLSILEEDKD
WRPAITIKQILLGIQELLNEPNIQDPAQAEAYTIYCQNRVEYEKRVRAQAKKFAPS

cDNA: 1 aactcgcggg agcgtcaccg tctcgcgacg cttcagagga tccttaggcc
tcagtgggtct
61 ttgacccccg gccccaggac ctgaccccaa ggaaacctcc gggacctgtg
gctggagagg
121 tgaccgccag gcatccgggg agcctttgga gatctcggct tcctttttcc
cccgtgtctt
181 gccggcggtg cctcgggtgg acgcgggcag cccgaagggg agtttacaga
cgctccctca
241 catcggggac gcggtctcct taagggcgga ctttgaacat gtcggggatc
gccctcagca
301 gactcgccca ggagaggaaa gcatggagga aagaccacc atttggtttc
gtggctgtcc
361 caacaaaaaa tcccgatggc acgatgaacc tcatgaactg ggagtgcgcc
attccaggaa
421 agaaagggac tccgtgggaa ggaggttgtt ttaaactacg gatgcttttc
aaagatgatt
481 atccatcttc gccacaaaaa tgtaaattcg aaccaccatt atttcaccg
aatgtgtacc
541 cttcggggac agtgtgcctg tccatcttag aggaggacaa ggactggagg
ccagccatca
601 caatcaaaca gatcctatta ggaatacagg aacttctaaa tgaacaaat
atccaagacc
661 cagctcaagc agaggcctac acgatttact gccaaaacag agtggagtac
gagaaaaggg
721 tccgagcaca agccaagaag tttgcgcct cataagcagc gaccttgtgg
catcgtcaaa
781 aggaagggat tggtttgga agaacttgtt tacaacattt ttgcaaact
aaagttgtc
841 cataaatga ctagtcacct ggggggggtg ggcgggcgcc atcttcatt
gccgcgcgg
901 gtgtgcggtc tcgattcgct gaattgcccg tttccataca gggctctctc
cttcggtctt
961 ttgtattttt gattgttatg taaaactcgc ttttatttta atattgatgt
cagtatttca
1021 actgctgtaa aattataaac ttttatactt gggtaagtcc cccaggggag
agttcctcgc
1081 tctgggatgc aggcattgct ctcaccgtgc agagctgcac ttggcctcag
ctggctgtat
1141 ggaaatgcac cctccctcct gccgctcctc tctagaacct tctagaacct
gggctgtgct
1201 gcttttgagc ctcagacccc aggtcagcat ctcggttctg cgccacttcc
tttgtgttta
1261 tatggcgttt tgtctgtgtt gctgtttaga gtaaataaac tgtttatata
aaggttttgg
1321 ttgcattatt atcattgaaa gtgagaggag gcggcctccc agtgcccggc
cctccccacc
1381 cacctgcagc cccaccgcgg gccaggacca ggctctccat ctgcttcgga
tgcacgcagg
1441 ctgtgaggct ctgtcttgcc ctggatcttt gtaaacaggg ctgtgtacaa
agtgetgtg
1501 aggtttctgt gctccccgca tctgcgggct gtagagcgct gggcagctaa
gatctgcata
1561 ggtcgggatt ggcacogaga ccctggcaac tgcaccggtg ccagctgtct
tgggggccac
1621 aaggccaggt ccagaccagg gctgggggct gcctgaggac tcctatccgg
gcagcctgct
1681 ggcggggggt cccctcttca gtggccaggt cacagggatg gagctgcgct

```

gtgcataggg
  1741 tgccacctca ggtgtctgtc ccttgtgtcc tcaggaggca gccttgctac
caccctgtggc
  1801 aaacgccagg tgctttttct gggagagccc acagccgtgg ccctccaggg
cttccccgac
  1861 ccttagcgcc aggtagaggg ccctgggcag cctgtgtctg gaattcttcg
tcctgagggc
  1921 acctgagtgt ggtctgtcct ggggaggtg tgcgcctcag cagccgtcct
gacgtgagc
  1981 cctctgcaaa ggttggggccg gccaggcctc ttggggctgc ctgagccact
gcaggaagtg
  2041 gcctggctgg gaagttgggt gccggtcacc tcccagcagg aaggcacagt
ggacagagat
  2101 gggaagccct gggggacaca gcccggtgct cccagccctc caacctctgg
ctcccaacc
  2161 agtctcccca tcttagcgag cttggccctc ctcagtttcg tttcaagcct
tggggctgga
  2221 gctggccctg ctgccctggc acccccgggt ggtggagct ggggtcccgt
ggcccaagtg
  2281 cagggtccca agagggcagg gcggggctcc ccaaaggagc aaagaatgca
gggagggcgg
  2341 tccagggccc tgggaagggg agctcggcac cctccaggtc cgtgtgggac
tccagccgt
  2401 gttggtggg aatcgaagtt agaggtgact tccaaaggcc ccccgagccg
gcagtgcctc
  2461 ccaccacccc tccagcgact ctgcggtgcc agtgccttgt tggcttttcc
ggctacgcac
  2521 cctgcagtca ctgagctctc ggtctgacgt ctgatgtttg tggtttgttt
ataacacggg
  2581 gccttacctg gggaattcag ctggtttgaa tatttgtagc ccgtcccag
aatgtcttat
  2641 tttgtaatga ctgaactaca tttagtaata gttacacatg tatatggtta
atacatatgg
  2701 aaattcaata tattttgtag ttaacgtatt ctgaagtaac ggatgtttct
cgccaatcgt
  2761 agtgacttca gctaacgaaa tgttcttttg tagtaccacg gtctcggcc
taacgaagga
  2821 cgtgaacctt gtaagaggag agctctgaaa cgcggtcacc tttgtttagt
ggaagggaaa
  2881 gtgtgttccc ggcattgagg gcctcggaat tagtaaagaa ttgtgggcaa
tggattaacc
  2941 actgtatcta agaattccacc attaaagcat ttgcacagac aaaaaaaaaa a
//

```

```

LOCUS          NM_194261                      (variant 4)
AA/translation="MSGIALSRLAQERKAWRKDHPFGFVAVPTKNPDGTMNLMNWECA
IPGKKGTPWEGGLFKLRMLFKDDYPSSPPKCKFEPPLFHPNVYPSGTVCLSILEEDKD
WRPAITIKQILLGIQELLNEPNIQDPAQAEAYTIYCQNRVEYEKRVRAQAKKFAPS

```

```

cDNA:  1 aactcgcggg agcgtcaccg tcttgcgacg cttcagagga tccttaggcc
tcagtggctc
      61 ttgacccccg gccccaggac ctgaccccaa ggaaacctcc gggacctgtg
gctggagagg
     121 gactttgaac atgtcgggga tcgccctcag cagactcgcc caggagagga
aagcatggag
     181 gaaagaccac ccatttggtt tcgtggctgt cccaacaaaa aatcccgatg
gcacgatgaa
     241 cctcatgaac tgggagtgcg ccattccagg aaagaaaggg actccgtggg
aaggaggctt
     301 gtttaacta cggatgcttt tcaaagatga ttatccatct tcgccaccaa
aatgtaaatt

```

```

361 cgaaccacca ttatttcacc cgaatgtgta cccttcgggg acagtgtgcc
tgtccatctt
421 agaggaggac aaggactgga ggccagccat cacaatcaaa cagatcctat
taggaataca
481 ggaacttcta aatgaaccaa atatccaaga ccagctcaa gcagaggcct
acacgattta
541 ctgccaaaac agagtggagt acgagaaaag ggtccgagca caagccaaga
agtttgcgcc
601 ctcataagca gcgaccttgt ggcatcgtca aaaggaaggg attggtttgg
caagaacttg
661 tttaacaacat ttttgcaaat ctaaagtgtc tccatacaat gactagtcac
ctgggggggt
721 tgggcgggcg ccatcttcca ttgccgccgc ggggtgtgagg tctcgattcg
ctgaattgcc
781 cgtttccata cagggctctc tccttcggtc ttttgtatct ttgattgtta
tgtaaaactc
841 gcttttattt taatattgat gtcagtatct caactgctgt aaaattataa
acttttatac
901 ttgggtaagt cccccagggg cgagttcctc gctctgggat gcaggcatgc
ttctcaccgt
961 gcagagctgc acttggcctc agctggctgt atggaaatgc accctccctc
ctgccgctcc
1021 tctctagaac cttctagaac ctgggctgtg ctgcttttga gcctcagacc
ccaggtcagc
1081 atctcggttc tgcgccactt cctttgtgtt tatatggcgt tttgtctgtg
ttgctgttta
1141 gagtaaataa actgtttata taaaggtttt gggtgcatta ttatcattga
aagtgagagg
1201 aggcggcctc ccagtgcctg gccctcccca cccacctgca gccccaccgc
gggccaggac
1261 caggctctcc atctgcttcg gatgcacgca ggctgtgagg ctctgtcttg
ccctggatct
1321 ttgtaaacag ggctgtgtac aaagtgtgtc tgaggtttct gtgctccccg
catctgcggg
1381 ctgtagagcg ctgggcagct aagatctgca taggtcggga ttggcatcga
gaccttgga
1441 actgcaccgg tgccagctgt cttggggggc acaaggccag gtccagacca
gggctggggg
1501 ctgcctgagg actcctatcc gggcagcctg ctggcggggg tccccctctt
cagtggccag
1561 gtcacaggga tggagctgcg ctgtgcatag ggtgccacct cagggtgtctg
tccttgtgt
1621 cctcaggagg cagccttget accaccctg gcaaacgcca ggtgcttttt
ctgggagagc
1681 ccacagccgt ggccctccag ggcttccccg acccttagcg ccaggtagag
ggccctgggc
1741 agcctgtgtc tgggaattctt cgtcctgagg ccacctgagt gtggtctgtc
ctggggaggg
1801 tgtgcgcctc agcagccgtc ctgacgtga gccctctgca aaggttgggc
cggccaggcc
1861 tcttggggct gctgagcca ctgcaggaag tggcctggct gggaagttgg
gtgccggtea
1921 cctcccagca ggaaggcaca gtggacagag atgggaagcc ctgggggaca
cagcccgggtg
1981 ctcccagccc tccaacctct ggctcccaac ccagtctccc catcctagcg
agcttgccc
2041 tctcagttt cgtttcaagc cttggggctg gagctggccc tgctgcctg
gcaccccccg
2101 gtggctggag ctgggtcccc gtggcccaag tgcagggtcc caagagggca
gggcggggt
2161 ccccaaagga gcaaagaatg cagggagggc ggtccagggc cctgggaagg

```

```
ggagctcggc
  2221 accctccagg tccgtgtggg actccagccg ctggtggctg ggaatcgaag
ttagaggtga
  2281 cttccaaagg cccccgagc cggcagtgcc ccccaccacc cctccagcga
ctctgcggtg
  2341 ccagtgcctt gttggctttt ccggctacgc accctgcagt cactgagctc
tcggtctgac
  2401 gtctgatgtt tgtggtttgt ttataacacg gggccttacc tggggaattc
agctggtttg
  2461 aatatttgta gcccgctccc agaatgtctt attttgtaat gactgaacta
catttagtaa
  2521 tagttacaca tgtatatggg taatacatat ggaaattcaa tatattttgt
agttaacgta
  2581 ttctgaagta acggatgttt ctgcccaatc gtagtgactt cagctaacga
aatgttcttt
  2641 tgtagtacca cggtcctcgg cctaacgaag gacgtgaacc ttgtaagagg
agagctctga
  2701 aacgcggtca cttttgttta gtggaaggga aagtgtgttc ccggcatgag
gtgcctcgga
  2761 attagtaaag aattgtgggc aatggattaa ccactgtatc taagaatcca
ccattaaage
  2821 atttgcacag acaaaaaaaaa aaa
//
```

CLAIMS

1. A method for identifying a modulator of a biological system, the method comprising:
 - establishing a model for the biological system, using cells associated with the biological system, to represents a characteristic aspect of the biological system;
 - obtaining a first data set from the model, wherein the first data set represents global proteomic changes in the cells associated with the biological system;
 - obtaining a second data set from the model, wherein the second data set represents one or more functional activities or cellular responses of the cells associated with the biological system, wherein said one or more functional activities or cellular responses of the cells comprises global enzymatic activity and/or an effect of the global enzyme activity on the enzyme metabolites or substrates in the cells associated with the biological system;
 - generating a consensus causal relationship network among the global proteomic changes and the one or more functional activities or cellular responses based solely on the first and second data sets using a programmed computing device, wherein the generation of the consensus causal relationship network is not based on any known biological relationships other than the first and second data sets; and
 - identifying, from the consensus causal relationship network, a causal relationship unique in the biological system, wherein at least one enzyme associated with the unique causal relationship is identified as a modulator of the biological system.
2. The method of claim 1, wherein the first data set further represents lipidomic data characterizing the cells associated with the biological system.
3. The method of claim 2, wherein the consensus causal relationship network is generated among the global proteomic changes, lipidomic data, and the one or more functional activities or cellular responses of the cells, wherein said one or more functional activities or cellular responses of the cells comprises global enzymatic activity and/or the effect of the global enzymatic activity on at least one enzyme metabolite or substrate.

4. The method of claim 1, wherein the first data set further represents one or more of lipidomic, metabolomic, transcriptomic, genomic and SNP data characterizing the cells associated with the biological system.
5. The method of claim 1, wherein the first data set further represents two or more of lipidomic, metabolomic, transcriptomic, genomic and SNP data characterizing the cells associated with the biological system.
6. The method of claims 4 or 5, wherein the consensus causal relationship network is generated among the global proteomic changes, the one or more of lipidomic, metabolomic, transcriptomic, genomic, and SNP data, and the one or more functional activities or cellular responses of the cells, wherein said one or more functional activities or cellular responses of the cells comprises global enzymatic activity and/or the effect of the global enzymatic activity on at least one enzyme metabolite or substrate.
7. The method of any one of claims 1-6, wherein the global enzyme activity comprises global kinase activity.
8. The method of any one of claims 1-7, wherein the effect of the global enzyme activity on the enzyme metabolites or substrates comprises the phospho proteome of the cells.
9. The method of any one of claims 1-8, wherein the second data set representing one or more functional activities or cellular responses of the cell further comprises one or more of bioenergetics, cell proliferation, apoptosis, organellar function, cell migration, tube formation, chemotaxis, extracellular matrix degradation, sprouting, and a genotype-phenotype associate actualized by functional models selected from ATP, ROS, OXPHOS, and Seahorse assays.
10. The method of claim 1-8, wherein the consensus causal relationship network is generated among the global proteomic changes, the one or more of lipidomic, metabolomic, transcriptomic, genomic, and SNP data, and the one or more functional activities or cellular responses of the cells, wherein said one or more functional activities or cellular responses of the cells comprises global enzymatic activity and/or the effect of the global enzymatic activity on at least one enzyme metabolite or substrate and further comprises one or more of bioenergetics, cell proliferation, apoptosis, organellar

function, cell migration, tube formation, chemotaxis, extracellular matrix degradation, sprouting, and a genotype-phenotype associate actualized by functional models selected from ATP, ROS, OXPHOS, and Seahorse assays.

11. The method of any one of claims 1-10, wherein the model of the biological system comprises an *in vitro* culture of cells associated with the biological system, optionally further comprising a matching *in vitro* culture of control cells.

12. The method of claim 11, wherein the *in vitro* culture of the cells is subject to an environmental perturbation, and the *in vitro* culture of the matching control cells is identical cells not subject to the environmental perturbation.

13. The method of claim 12, wherein the environmental perturbation comprises one or more of contact with a bioactive agent, a change in culture condition, introduction of a genetic modification / mutation, and introduction of a vehicle that causes a genetic modification / mutation.

14. The method of claim 13, wherein the environmental perturbation comprises contacting the cells with an enzymatic activity inhibitor.

15. The method of claim 14, wherein the enzymatic activity inhibitor is a kinase inhibitor.

16. The method of claim 13, wherein the environmental perturbation comprises contacting the cells with CoQ10.

17. The method of claim 14, wherein the environmental perturbation further comprises contacting the cells with CoQ10.

18. The method of claim 1, wherein the generating step is carried out by an artificial intelligence (AI) -based informatics platform.

19. The method of claim 18, wherein the AI-based informatics platform receives all data input from the first and second data sets without applying a statistical cut-off point.

20. The method of claim 1, wherein the consensus causal relationship network established in the generating step is further refined to a simulation causal relationship

network, before the identifying step, by *in silico* simulation based on input data, to provide a confidence level of prediction for one or more causal relationships within the consensus causal relationship network.

21. The method of claim 11, wherein the unique causal relationship is identified as part of a differential causal relationship network that is uniquely present in cells associated with the biological system, and absent in the matching control cells.

22. The method of claim 12, wherein the unique causal relationship is identified as part of a differential causal relationship network that is uniquely present in cells subject to the environmental perturbation, and absent in the matching control cells.

23. The method of any one of claims 1 to 22, wherein the unique causal relationship identified is a relationship between at least one pair selected from the group consisting of expression of a gene and level of a lipid; expression of a gene and level of a transcript; expression of a gene and level of a metabolite; expression of a first gene and expression of a second gene; expression of a gene and presence of a SNP; expression of a gene and a functional activity; level of a lipid and level of a transcript; level of a lipid and level of a metabolite; level of a first lipid and level of a second lipid; level of a lipid and presence of a SNP; level of a lipid and a functional activity; level of a first transcript and level of a second transcript; level of a transcript and level of a metabolite; level of a transcript and presence of a SNP; level of a first transcript and level of a functional activity; level of a first metabolite and level of a second metabolite; level of a metabolite and presence of a SNP; level of a metabolite and a functional activity; presence of a first SNP and presence of a second SNP; and presence of a SNP and a functional activity.

24. The method of any one of claims 1 to 23, wherein the unique causal relationship identified is a relationship between at least a level of a lipid, expression of a gene, and one or more functional activities wherein the functional activity is a global kinase activity.

25. A method for identifying a modulator of a disease process, the method comprising:

establishing a model for the disease process, using disease related cells, to represents a characteristic aspect of the disease process;

obtaining a first data set from the model, wherein the first data set represents global proteomic changes in the disease related cells;

obtaining a second data set from the model, wherein the second data set represents one or more functional activities or cellular responses of the cells associated with the biological system, wherein said one or more functional activities or cellular responses of the cells comprises global enzyme activity and/or an effect of the global enzyme activity on the enzyme metabolites or substrates in the disease related cells;

generating a consensus causal relationship network among the global proteomic changes and the one or more functional activities or cellular responses of the cells based solely on the first and second data sets using a programmed computing device, wherein the generation of the consensus causal relationship network is not based on any known biological relationships other than the first and second data sets; and

identifying, from the consensus causal relationship network, a causal relationship unique in the disease process, wherein at least one enzyme associated with the unique causal relationship is identified as a modulator of the disease process.

26. The method of claim 25, wherein the first data set further represents lipidomic data characterizing the cells associated with the biological system.

27. The method of claim 26, wherein the consensus causal relationship network is generated among the global proteomic changes, lipidomic data, and the one or more functional activities or cellular responses of the cells, wherein said one or more functional activities or cellular responses of the cells comprises global enzymatic activity and/or an effect of the global enzyme activity on the enzyme metabolites or substrates in the disease related cells.

28. The method of claim 25, wherein the first data set further represents one or more of lipidomic, metabolomic, transcriptomic, genomic and SNP data characterizing the cells associated with the biological system.

29. The method of claim 28, wherein the first data set further represents two or more of lipidomic, metabolomic, transcriptomic, genomic and SNP data characterizing the cells associated with the biological system.

30. The method of claim 28 or 29, wherein the consensus causal relationship network is generated among the global proteomic changes, the one or more of lipidomic, metabolomic, transcriptomic, genomic and SNP data, and the one or more functional activities or cellular responses of the cells, wherein said one or more functional activities or cellular responses of the cells comprises global enzymatic activity and/or the effect of the global enzymatic activity on at least one enzyme metabolite or substrate in the disease related cells.

31. The method of any one of claims 25 to 30, wherein the global enzyme activity comprises global kinase activity, and wherein the effect of the global enzyme activity on the enzyme metabolites or substrates comprises the phospho proteome of the cells.

32. The method of any one of claims 25 to 31, wherein the second data set representing one or more functional activities or cellular responses of the cell further comprises one or more of bioenergetics, cell proliferation, apoptosis, organellar function, cell migration, tube formation, chemotaxis, extracellular matrix degradation, sprouting, and a genotype-phenotype associate actualized by functional models selected from ATP, ROS, OXPHOS, and Seahorse assays.

33. The method of claim 32, wherein the consensus causal relationship network is generated among the global proteomic changes, the one or more of lipidomic, metabolomic, transcriptomic, genomic and SNP data, and the one or more functional activities or cellular responses of the cells, wherein said one or more functional activities or cellular responses of the cells comprises one or more of bioenergetics, cell proliferation, apoptosis, organellar function, cell migration, tube formation, chemotaxis, extracellular matrix degradation, sprouting, and a genotype-phenotype associate actualized by functional models selected from ATP, ROS, OXPHOS, and Seahorse assays.

34. The method of any of claims 25 to 33, wherein the disease process is cancer, diabetes, obesity, cardiovascular disease, age related macular degeneration, diabetic retinopathy, or inflammatory disease.
35. The method of any of claims 25 to 33, wherein the disease process comprises angiogenesis.
36. The method of any of claims 25 to 33, wherein the disease process comprises hepatocellular carcinoma, lung cancer, breast cancer, prostate cancer, melanoma, carcinoma, sarcoma, lymphoma, leukemia, squamous cell carcinoma, colorectal cancer, pancreatic cancer, thyroid cancer, endometrial cancer, bladder cancer, kidney cancer, a solid tumor, leukemia, non-Hodgkin lymphoma, or a drug-resistant cancer.
37. The method of any of claims 25 to 33, wherein the disease model comprises an *in vitro* culture of disease cells, optionally further comprising a matching *in vitro* culture of control or normal cells.
38. The method of claim 37, wherein the *in vitro* culture of the disease cells is subject to an environmental perturbation, and the *in vitro* culture of the matching control cells is identical disease cells not subject to the environmental perturbation.
39. The method of claim 38, wherein the environmental perturbation comprises one or more of contact with a bioactive agent, a change in culture condition, introduction of a genetic modification / mutation, and introduction of a vehicle that causes a genetic modification / mutation.
40. The method of claim 39, wherein the environmental perturbation comprises contacting the cells with an enzymatic activity inhibitor.
41. The method of claim 40, wherein the enzymatic activity inhibitor is a kinase inhibitor.
42. The method of claim 39, wherein the environmental perturbation comprises contacting the cells with CoQ10.

43. The method of claim 25, wherein the characteristic aspect of the disease process comprises a hypoxia condition, a hyperglycemic condition, a lactic acid rich culture condition, or combinations thereof.

44. The method of claim 25, wherein the generating step is carried out by an artificial intelligence (AI) -based informatics platform.

45. The method of claim 25, wherein the AI-based informatics platform receives all data input from the first and second data sets without applying a statistical cut-off point.

46. The method of claim 25, wherein the consensus causal relationship network established in the generating step is further refined to a simulation causal relationship network, before the identifying step, by *in silico* simulation based on input data, to provide a confidence level of prediction for one or more causal relationships within the consensus causal relationship network.

47. The method of claim 37, wherein the unique causal relationship is identified as part of a differential causal relationship network that is uniquely present in model of disease cells, and absent in the matching control cells.

48. The method of claim 38, wherein the unique causal relationship is identified as part of a differential causal relationship network that is uniquely present in cells subject to environmental perturbation, and absent in the matching control cells.

49. A method for identifying a modulator of a biological system, the method comprising:

establishing a model for the biological system, using cells associated with the biological system, to represent a characteristic aspect of the biological system ;

obtaining a first data set from the model, wherein the first data set represents global proteomic changes in the cells and one or more of lipidomic, metabolomic, transcriptomic, genomic, and SNP data characterizing the cells associated with the biological system;

obtaining a second data set from the model, wherein the second data set represents one or more functional activities or cellular responses of the cells associated

with the biological system, wherein said one or more functional activities or cellular responses of the cells comprises global kinase activity and/or an effect of the global kinase activity on the kinase metabolites or substrates in the cells associated with the biological system;

generating a consensus causal relationship network among the global proteomic changes, the one or more of lipidomic, metabolomic, transcriptomic, genomic, and SNP data, and the one or more functional activities or cellular responses based solely on the first and second data sets using a programmed computing device, wherein the generation of the consensus causal relationship network is not based on any known biological relationships other than the first and second data sets; and

identifying, from the consensus causal relationship network, a causal relationship unique in the biological system, wherein at least one kinase associated with the unique causal relationship is identified as a modulator of the biological system.

50. A method for treating, alleviating a symptom of, inhibiting progression of, preventing, diagnosing, or prognosing a disease in a mammalian subject, the method comprising:

administering to the mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a biologically active substance that affects the modulator identified by any one of claims 1-48, thereby treating, alleviating a symptom of, inhibiting progression of, preventing, diagnosing, or prognosing the disease.

51. A method of diagnosing or prognosing a disease in a mammalian subject, the method comprising:

determining an expression or activity level, in a biological sample obtained from the subject, of one or more modulators identified by any one of claims 1-48; and

comparing the level in the subject with the level of expression or activity of the one or more modulators in a control sample,

wherein a difference between the level in the subject and the level of expression or activity of the one or more modulators in the control sample is an indication that the

subject is afflicted with a disease, or predisposed to developing a disease, or responding favorably to a therapy for a disease, thereby diagnosing or prognosing the disease in the mammalian subject.

52. A method of identifying a therapeutic compound for treating, alleviating a symptom of, inhibiting progression of, or preventing a disease in a mammalian subject, the method comprising:

contacting a biological sample from a mammalian subject with a test compound;

determining the level of expression, in the biological sample, of one or more modulators identified by any one of claims 1-48;

comparing the level of expression of the one or more modulators in the biological sample with a control sample not contacted by the test compound; and

selecting the test compound that modulates the level of expression of the one or more modulators in the biological sample,

thereby identifying a therapeutic compound for treating, alleviating a symptom of, inhibiting progression of, or preventing a disease in a mammalian subject.

53. A method for treating, alleviating a symptom of, inhibiting progression of, or preventing a disease in a mammalian subject, the method comprising:

administering to the mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising the therapeutic compound of claim 52, thereby treating, alleviating a symptom of, inhibiting progression of, or preventing the disease.

54. A method for treating, alleviating a symptom of, inhibiting progression of, or preventing a disease in a mammalian subject, the method comprising:

administering to the mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a biologically active substance that affects expression or activity of any one or more of TCOF1, TOP2A, CAMK2A, CDK1, CLTCL1, EIF4G1, ENO1, FBL, GSK3B, HDLBP, HIST1H2BA, HMGB2, HNRNPK,

HNRPDL, HSPA9, MAP2K2, LDHA, MAP4, MAPK1, MARCKS, NME1, NME2, PGK1, PGK2, RAB7A, RPL17, RPL28, RPS5, RPS6, SLTM, TMED4, TNRCBA, TUBB, and UBE21,

thereby treating, alleviating a symptom of, inhibiting progression of, or preventing the disease.

55. The method of claim 54, wherein the disease is hepatocellular carcinoma.

56. A method of diagnosing or prognosing a disease in a mammalian subject, the method comprising:

determining an expression or activity level, in a biological sample obtained from the subject, of any one or more proteins of TCOF1, TOP2A, CAMK2A, CDK1, CLTCL1, EIF4G1, ENO1, FBL, GSK3B, HDLBP, HIST1H2BA, HMGB2, HNRNPK, HNRPDL, HSPA9, MAP2K2, LDHA, MAP4, MAPK1, MARCKS, NME1, NME2, PGK1, PGK2, RAB7A, RPL17, RPL28, RPS5, RPS6, SLTM, TMED4, TNRCBA, TUBB, and UBE21; and

comparing the level in the subject with the level of expression or activity of the one or more proteins in a control sample,

wherein a difference between the level in the subject and the level of expression or activity of the one or more proteins in the control sample is an indication that the subject is afflicted with a disease, or predisposed to developing a disease, or responding favorably to a therapy for a disease, thereby diagnosing or prognosing the disease in the mammalian subject.

57. The method of claim 56, wherein the disease is hepatocellular carcinoma.

58. A method of identifying a therapeutic compound for treating, alleviating a symptom of, inhibiting progression of, or preventing a disease in a mammalian subject, the method comprising:

contacting a biological sample from a mammalian subject with a test compound;

determining the level of expression, in the biological sample, of any one or more proteins of TCOF1, TOP2A, CAMK2A, CDK1, CLTCL1, EIF4G1, ENO1, FBL, GSK3B, HDLBP, HIST1H2BA, HMGB2, HNRNPK, HNRPDL, HSPA9, MAP2K2, LDHA, MAP4, MAPK1, MARCKS, NME1, NME2, PGK1, PGK2, RAB7A, RPL17, RPL28, RPS5, RPS6, SLTM, TMED4, TNRCBA, TUBB, and UBE21;

comparing the level of expression of the one or more proteins in the biological sample with a control sample not contacted by the test compound; and

selecting the test compound that modulates the level of expression of the one or more proteins in the biological sample,

thereby identifying a therapeutic compound for treating, alleviating a symptom of, inhibiting progression of, or preventing a disease in a mammalian subject.

59. The method of claim 58, wherein the disease is hepatocellular carcinoma.

60. A method for treating, alleviating a symptom of, inhibiting progression of, or preventing a disease in a mammalian subject, the method comprising:

administering to the mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising the therapeutic compound of claim 58, thereby treating, alleviating a symptom of, inhibiting progression of, or preventing the disease.

61. A method for identifying a modulator of angiogenesis, said method comprising:

(1) establishing a model for angiogenesis, using cells associated with angiogenesis, to represents a characteristic aspect of angiogenesis;

(2) obtaining a first data set from the model for angiogenesis, wherein the first data set represents one or more of genomic data, lipidomic data, proteomic data, metabolomic data, transcriptomic data, and single nucleotide polymorphism (SNP) data characterizing the cells associated with angiogenesis;

(3) obtaining a second data set from the model for angiogenesis, wherein the second data set represents one or more functional activities or cellular responses of the

cells associated with angiogenesis;

(4) generating a consensus causal relationship network among the one or more of genomic data, lipidomic data, proteomic data, metabolic data, transcriptomic data, and single nucleotide polymorphism (SNP) data characterizing the cells associated with angiogenesis, and the one or more functional activities or cellular responses of the cells associated with angiogenesis based solely on the first data set and the second data set using a programmed computing device, wherein the generation of the consensus causal relationship network is not based on any known biological relationships other than the first data set and the second data set;

(5) identifying, from the consensus causal relationship network, a causal relationship unique in angiogenesis, wherein a gene, lipid, protein, metabolite, transcript, or SNP associated with the unique causal relationship is identified as a modulator of angiogenesis.

62. A method for identifying a modulator of angiogenesis, said method comprising:

(1) establishing a model for angiogenesis, using cells associated with angiogenesis, to represents a characteristic aspect of angiogenesis;

(2) obtaining a first data set from the model for angiogenesis, wherein the first data set represents lipidomic data;

(3) obtaining a second data set from the model for angiogenesis, wherein the second data set represents one or more functional activities or a cellular responses of the cells associated with angiogenesis;

(4) generating a consensus causal relationship network among the lipidomics data and the one or more functional activities or cellular responses based solely on the first data set and the second data set using a programmed computing device, wherein the generation of the consensus causal relationship network is not based on any known biological relationships other than the first data set and the second data set;

(5) identifying, from the consensus causal relationship network, a causal relationship unique in angiogenesis, wherein a lipid associated with the unique causal relationship is identified as a modulator of angiogenesis.

63. The method of claim 61 or 62, wherein the second data set representing one or more functional activities or cellular responses of the cells associated with angiogenesis comprises global enzymatic activity and/or an effect of the global enzymatic activity on the enzyme metabolites or substrates in the cells associated with angiogenesis.

64. A method for identifying a modulator of angiogenesis, said method comprising:

(1) establishing a model for angiogenesis, using cells associated with angiogenesis, to represent a characteristic aspect of angiogenesis;

(2) obtaining a first data set from the model for angiogenesis, wherein the first data set represents one or more of genomic data, lipidomic data, proteomic data, metabolic data, transcriptomic data, and single nucleotide polymorphism (SNP) data characterizing the cells associated with angiogenesis;

(3) obtaining a second data set from the model for angiogenesis, wherein the second data set represents one or more functional activities or cellular responses of the cells associated with angiogenesis, wherein the one or more functional activities or cellular responses comprises global enzymatic activity and/or an effect of the global enzymatic activity on the enzyme metabolites or substrates in the cells associated with angiogenesis;

(4) generating a consensus causal relationship network among the one or more of genomic data, lipidomic data, proteomic data, metabolic data, transcriptomic data, and single nucleotide polymorphism (SNP) data characterizing the cells associated with angiogenesis and the one or more functional activities or cellular responses of the cells associated with angiogenesis based solely on the first data set and the second data set using a programmed computing device, wherein the generation of the consensus causal relationship network is not based on any known biological relationships other than the first data set and the second data set;

(5) identifying, from the consensus causal relationship network, a causal relationship unique in angiogenesis, wherein an enzyme associated with the unique causal relationship is identified as a modulator of angiogenesis.

65. The method of claim 63 or 64, wherein the global enzyme activity comprises global kinase activity and an effect of the global enzymatic activity on the enzyme metabolites or substrates in the cells associated with angiogenesis comprises the phosphoproteome of the cell.
66. The method of claim 63 or 64, wherein the global enzyme activity comprises global protease activity.
67. The method of any one of claims 61 to 66, wherein the modulator stimulates or promotes angiogenesis.
68. The method of any one of claims 61 to 66, wherein the modulator inhibits angiogenesis.
69. The method of any one of claims 61 to 68, wherein the model for angiogenesis comprising cells associated with angiogenesis is selected from the group consisting of an *in vitro* cell culture angiogenesis model, rat aorta microvessel model, newborn mouse retina model, chick chorioallantoic membrane (CAM) model, corneal angiogenic growth factor pocket model, subcutaneous sponge angiogenic growth factor implantation model, MATRIGEL® angiogenic growth factor implantation model, and tumor implantation model; and wherein the model of angiogenesis optionally further comprises a matching control model of angiogenesis comprising control cells.
70. The method of claim 69, wherein the *in vitro* culture angiogenesis model is selected from the group consisting of MATRIGEL® tube formation assay, migration assay, Boyden chamber assay, scratch assay.
71. The method of claim 69 or 70, wherein the cells associated with angiogenesis in the *in vitro* culture model are human endothelial vessel cells (HUVEC).
72. The method of claim 69, wherein the angiogenic growth factor in the corneal angiogenic growth factor pocket model, subcutaneous sponge angiogenic growth factor implantation model, or MATRIGEL® angiogenic growth factor implantation model is selected from the group consisting of FGF-2 and VEGF.
73. The method of claim 69, wherein the cells in the model of angiogenesis are subject to an environmental perturbation, and the cells in the matching model of

angiogenesis are identical cells not subject to the environmental perturbation.

74. The method of claim 73, wherein the environmental perturbation comprises one or more of a contact with an agent, a change in culture condition, an introduced genetic modification or mutation, a vehicle that causes a genetic modification or mutation, and induction of ischemia.

75. The method of claim 74, wherein the agent is a pro-angiogenic agent or an anti-angiogenic agent.

76. The method of claim 75, wherein the pro-angiogenic agent is selected from the group consisting of FGF-2 and VEGF.

77. The method of claim 75, wherein the anti-angiogenic agent is selected from the group consisting of VEGF inhibitors, integrin antagonists, angiostatin, endostatin, tumstatin, Avastin, sorafenib, sunitinib, pazopanib, and everolimus, soluble VEGF-receptor, angiopoietin 2, thrombospondin1, thrombospondin 2, vasostatin, calreticulin, prothrombin (kringle domain-2), antithrombin III fragment, vascular endothelial growth inhibitor (VEGI), Secreted Protein Acidic and Rich in Cysteine (SPARC) and a SPARC peptide corresponding to the follistatin domain of the protein (FS-E), and coenzyme Q10.

78. The method of claim 74, wherein the agent is an enzymatic activity inhibitor.

79. The method of claim 74, wherein the agent is a kinase activity inhibitor.

80. The method of claim 61 or 64, wherein the first data set comprises protein and/or mRNA expression levels of a plurality of genes in the genomic data set.

81. The method of claim 61 or 64, wherein the first data set comprises two or more of genomic data, lipidomic data, proteomic data, metabolic data, transcriptomic data, and single nucleotide polymorphism (SNP) data.

82. The method of claim 61 or 64, wherein the first data set comprises three or more of genomic data, lipidomic data, proteomic data, metabolic data, transcriptomic data, and single nucleotide polymorphism (SNP) data.

83. The method of any one of claims 61 to 64, wherein the second data set representing one or more functional activities or a cellular responses of the cells associated with angiogenesis further comprises one or more of bioenergetics, cell proliferation, apoptosis, organellar function, cell migration, tube formation, enzyme activity, chemotaxis, extracellular matrix degradation, sprouting, and a genotype-phenotype association actualized by functional models selected from ATP, ROS, OXPHOS, and Seahorse assays.
84. The method of claim 83, wherein the enzyme activity is kinase activity.
85. The method of claim 83, wherein the enzyme activity is protease activity.
86. The method of any one of claims 61 to 64, wherein step (4) is carried out by an artificial intelligence (AI) -based informatics platform.
87. The method of claim 86, wherein the AI-based informatics platform comprises REFS(TM).
88. The method of claim 86, wherein the AI-based informatics platform receives all data input from the first data set and the second data set without applying a statistical cut-off point.
89. The method of any one of claims 61 to 64, wherein the consensus causal relationship network established in step (4) is further refined to a simulation causal relationship network, before step (5), by *in silico* simulation based on input data, to provide a confidence level of prediction for one or more causal relationships within the consensus causal relationship network.
90. The method of any one of claims 61 to 64, wherein the unique causal relationship is identified as part of a differential causal relationship network that is uniquely present in cells, and absent in the matching control cells.
91. The method of any one of claims 61 to 90, wherein the unique causal relationship identified is a relationship between at least one pair selected from the group consisting of expression of a gene and level of a lipid; expression of a gene and level of a transcript; expression of a gene and level of a metabolite; expression of a first gene and expression of a second gene; expression of a gene and presence of a SNP; expression of

a gene and a functional activity; level of a lipid and level of a transcript; level of a lipid and level of a metabolite; level of a first lipid and level of a second lipid; level of a lipid and presence of a SNP; level of a lipid and a functional activity; level of a first transcript and level of a second transcript; level of a transcript and level of a metabolite; level of a transcript and presence of a SNP; level of a first transcript and level of a functional activity; level of a first metabolite and level of a second metabolite; level of a metabolite and presence of a SNP; level of a metabolite and a functional activity; presence of a first SNP and presence of a second SNP; and presence of a SNP and a functional activity.

92. The method of claim 91, wherein the functional activity is selected from the group consisting of bioenergetics, cell proliferation, apoptosis, organellar function, cell migration, tube formation, enzyme activity, chemotaxis, extracellular matrix degradation, and sprouting, , and a genotype-phenotype association actualized by functional models selected from ATP, ROS, OXPHOS, and Seahorse assays.

93. The method of claim 91 or 92, wherein the functional activity is kinase activity.

94. The method of claim 91 or 92, wherein the functional activity is protease activity.

95. The method of any one of claims 61 to 93, wherein the unique causal relationship identified is a relationship between at least a level of a lipid, expression of a gene, and one or more functional activities wherein the functional activity is a kinase activity.

96. The method of any one of claims 61 to 95, further comprising validating the identified unique causal relationship in angiogenesis.

97. A method for providing a model for angiogenesis for use in a platform method, comprising:

establishing a model for angiogenesis, using cells associated with angiogenesis, to represent a characteristic aspect of angiogenesis, wherein the model for angiogenesis is useful for generating data sets used in the platform method;

thereby providing a model for angiogenesis for use in a platform method.

98. A method for obtaining a first data set and second data set from a model for angiogenesis for use in a platform method, comprising:

(1) obtaining a first data set from the model for angiogenesis for use in a platform method, wherein the model for angiogenesis comprises cells associated with angiogenesis, and wherein the first data set represents one or more of genomic data, lipidomic data, proteomic data, metabolic data, transcriptomic data, and single nucleotide polymorphism (SNP) data characterizing the cells associated with angiogenesis;

(2) obtaining a second data set from the model for angiogenesis for use in the platform method, wherein the second data set represents one or more functional activities or cellular responses of the cells associated with angiogenesis;

thereby obtaining a first data set and second data set from the model for angiogenesis for use in a platform method.

99. A method for identifying a modulator of angiogenesis, said method comprising:

(1) generating a consensus causal relationship network among a first data set and second data set obtained from a model for angiogenesis, wherein the model comprises cells associated with angiogenesis, and wherein the first data set represents one or more of genomic data, lipidomic data, proteomic data, metabolic data, transcriptomic data, and single nucleotide polymorphism (SNP) data characterizing the cells associated with angiogenesis; and the second data set represents one or more functional activities or cellular responses of the cells associated with angiogenesis, using a programmed computing device, wherein the generation of the consensus causal relationship network is not based on any known biological relationships other than the first data set and the second data set;

(2) identifying, from the consensus causal relationship network, a causal relationship unique in angiogenesis, wherein at least one of a gene, a lipid, a protein, a metabolite, a transcript, or a SNP associated with the unique causal relationship is identified as a modulator of angiogenesis;

thereby identifying a modulator of angiogenesis.

100. A method for identifying a modulator of angiogenesis, said method comprising:

- (1) providing a consensus causal relationship network generated from a model for angiogenesis;
- (2) identifying, from the consensus causal relationship network, a causal relationship unique in angiogenesis, wherein at least one of a gene, a lipid, a protein, a metabolite, a transcript, or a SNP associated with the unique causal relationship is identified as a modulator of angiogenesis;

thereby identifying a modulator of angiogenesis.

101. The method of claim 90, wherein the consensus causal relationship network is generated among a first data set and second data set obtained from the model for angiogenesis, wherein the model comprises cells associated with angiogenesis, and wherein the first data set represents one or more of genomic data, lipidomic data, proteomic data, metabolic data, transcriptomic data, and single nucleotide polymorphism (SNP) data characterizing the cells associated with angiogenesis; and

the second data set represents one or more functional activities or cellular responses of the cells associated with angiogenesis, using a programmed computing device, wherein the generation of the consensus causal relationship network is not based on any known biological relationships other than the first data set and the second data set.

102. The method of any one of claims 97 to 101, wherein the model for angiogenesis is selected from the group consisting of *in vitro* cell culture angiogenesis model, rat aorta microvessel model, newborn mouse retina model, chick chorioallantoic membrane (CAM) model, corneal angiogenic growth factor pocket model, subcutaneous sponge angiogenic growth factor implantation model, MATRIGEL® angiogenic growth factor implantation model, and tumor implantation model; and wherein the model of angiogenesis optionally further comprises a matching control model of angiogenesis comprising control cells.

103. The method of any one of claims 97 to 102, wherein the first data set comprises lipidomics data.

104. The method of any one of claims 97 to 103, wherein the second data set representing one or more functional activities or cellular responses of the cells associated with angiogenesis comprises global enzymatic activity, and/or an effect of the global enzymatic activity on the enzyme metabolites or substrates in the cells associated with angiogenesis.

105. The method of claim 104, wherein the second data set comprises kinase activity or protease activity.

106. The method of any one of claims 97 to 103, wherein the second data set representing one or more functional activities or cellular responses of the cells associated with angiogenesis comprises one or more of bioenergetics profiling, cell proliferation, apoptosis, organellar function, cell migration, tube formation, kinase activity, and protease activity; and a genotype-phenotype association actualized by functional models selected from ATP, ROS, OXPHOS, and Seahorse assays.

107. The method of any one of claims 61 to 106, wherein the angiogenesis is related to a disease state.

108. A method for modulating angiogenesis in a mammalian subject, the method comprising:

administering to the mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a biologically active substance that affects the modulator identified by any one of claims 61-107, thereby modulating angiogenesis.

109. A method of detecting modulated angiogenesis in a mammalian subject, the method comprising:

determining a level, activity, or presence, in a biological sample obtained from the subject, of one or more modulators identified by any one of claims 61-107; and

comparing the level, activity, or presence in the subject with the level, activity, or presence of the one or more modulators in a control sample,

wherein a difference between the level, activity, or presence in the subject and the level, activity, or presence of the one or more modulators in the control sample is an

indication that angiogenesis is modulated in the mammalian subject.

110. A method of identifying a therapeutic compound for modulating angiogenesis in a mammalian subject, the method comprising:

contacting a biological sample from a mammalian subject with a test compound;

determining the level, activity or presence, in the biological sample, of one or more modulators identified by any one of claims 61-107;

comparing the level, activity, or presence of the one or more modulators in the biological sample with a control sample not contacted by the test compound; and

selecting the test compound that modulates the level, activity, or presence of the one or more modulators in the biological sample,

thereby identifying a therapeutic compound for modulating angiogenesis in a mammalian subject.

111. A method for modulating angiogenesis in a mammalian subject, the method comprising:

administering to the mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising the therapeutic compound of claim 110, thereby treating, alleviating a symptom of, inhibiting progression of, preventing, diagnosing, or prognosing the disease.